<SEC-DOCUMENT>0001564590-20-054893.txt : 20201123
<SEC-HEADER>0001564590-20-054893.hdr.sgml : 20201123
<ACCEPTANCE-DATETIME>20201123163431
ACCESSION NUMBER:		0001564590-20-054893
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201123
DATE AS OF CHANGE:		20201123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		201338073

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arwr-10k_20200930.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-11-23T21:13:03.2633166+00:00 -->
<!-- Version            : 5.0.1.569 -->
<!-- Package ID         : 998add94503b4928937c39d61a9ae7d1 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:arwr="http://www.arrowheadresearch.com/20200930" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
arwr-10k_20200930.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000879407_20191001_20200930">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0000879407_20191001_20200930">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0000879407_20191001_20200930">0000879407</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0000879407_20191001_20200930">--09-30</ix:nonNumeric>
			<ix:nonNumeric id="F_000409" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000411" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000414" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000416" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000417" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20200930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000418" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20200930">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000429" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000430" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000431" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20180101_20181231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0000879407_20200930" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0000879407_20190930" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000105" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20191001_20200930">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000106" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20181001_20190930">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000107" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20171001_20180930">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000632" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000879407_20191001_20200930" decimals="INF">0.004</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000633" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000879407_20181001_20190930" decimals="INF">0.0150</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000634" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0000879407_20171001_20180930" decimals="INF">0.0205</ix:nonFraction>
			<ix:nonNumeric id="F_000642" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000879407_20191001_20200930">P6Y3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000643" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000879407_20181001_20190930">P6Y3M</ix:nonNumeric>
			<ix:nonNumeric id="F_000644" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0000879407_20171001_20180930">P6Y3M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000635" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000879407_20191001_20200930" decimals="INF">0.018</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000636" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000879407_20181001_20190930" decimals="INF">0.0311</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000637" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0000879407_20171001_20180930" decimals="INF">0.0299</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000640" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0000879407_20191001_20200930" decimals="2">0.90</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000641" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0000879407_20191001_20200930" decimals="2">0.92</ix:nonFraction>
			<ix:nonNumeric id="F_000749" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20191001_20191231">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000750" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20200101_20200331">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000751" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20200401_20200630">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000752" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20200701_20200930">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000773" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20181001_20181231">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000774" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20190101_20190331">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000775" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20190401_20190630">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000776" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0000879407_20190701_20190930">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="arwr-20200930.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000879407_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_20201116">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-16</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20171001_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20170930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20170930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171001_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171001_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-10-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-10-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-10-03</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arwrTarget">
				<xbrli:measure>arwr:Target</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseCollaborationAndStockPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-09-27</xbrli:startDate>
					<xbrli:endDate>2016-09-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20160928">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-09-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-06</xbrli:startDate>
					<xbrli:endDate>2020-10-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-06</xbrli:startDate>
					<xbrli:endDate>2020-10-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-06</xbrli:startDate>
					<xbrli:endDate>2020-10-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20191201_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMaximumMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMinimumMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMaximumMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-09-27</xbrli:startDate>
					<xbrli:endDate>2016-09-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arwrAgreement">
				<xbrli:measure>arwr:Agreement</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160928">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-09-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arwrObligation">
				<xbrli:measure>arwr:Obligation</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-03</xbrli:startDate>
					<xbrli:endDate>2018-10-03</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROJNJ1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROJNJ1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROJNJ1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-07</xbrli:startDate>
					<xbrli:endDate>2020-10-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMinimumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-07</xbrli:startDate>
					<xbrli:endDate>2020-10-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-07</xbrli:startDate>
					<xbrli:endDate>2020-10-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arwrBundle">
				<xbrli:measure>arwr:Bundle</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneYearMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneYearMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:MarketableSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="arwr:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="arwr:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="arwr:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="arwr:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191201_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_us-gaapTypeOfArrangementAxis_arwrAROENacAndAROHIF2CandidatesMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20171001_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-01</xbrli:startDate>
					<xbrli:endDate>2019-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_arwrOption">
				<xbrli:measure>arwr:Option</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160101_20160131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-01-01</xbrli:startDate>
					<xbrli:endDate>2016-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20190131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200501_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-01</xbrli:startDate>
					<xbrli:endDate>2020-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HalozymeIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SubleaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HalozymeIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SubleaseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171001_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20171001_20180930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2018-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionsUpToThreePercentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20191001_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionNextTwoPercentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20191001_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-10-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20200701_20200930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20181001_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-10-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20190401_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-01</xbrli:startDate>
					<xbrli:endDate>2019-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_20190701_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-07-01</xbrli:startDate>
					<xbrli:endDate>2019-09-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-10-23</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023_20201023">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-10-23</xbrli:startDate>
					<xbrli:endDate>2020-10-23</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="border-top:none 0pt;padding-top:0pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;border-top:Double 2.25pt;padding-top:1pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, DC 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000879407_20191001_20200930">10-K</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One) </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000031" name="dei:DocumentAnnualReport" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000879407_20191001_20200930" format="ixt:datemonthdayyearen">September&#160;30, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0000879407_20191001_20200930">2020</ix:nonNumeric></ix:nonNumeric>. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:DocumentTransitionReport" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number <ix:nonNumeric id="F_000021" name="dei:EntityFileNumber" contextRef="C_0000879407_20191001_20200930">001-38042</ix:nonNumeric> </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:14.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0000879407_20191001_20200930">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:0.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:49.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000879407_20191001_20200930">46-0408024</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State of incorporation)</p></td>
<td valign="bottom" style="width:0.84%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityAddressAddressLine1" contextRef="C_0000879407_20191001_20200930">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric id="F_000025" name="dei:EntityAddressAddressLine2" contextRef="C_0000879407_20191001_20200930">Suite 700</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000026" name="dei:EntityAddressCityOrTown" contextRef="C_0000879407_20191001_20200930">Pasadena</ix:nonNumeric>, <ix:nonNumeric id="F_000027" name="dei:EntityAddressStateOrProvince" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric id="F_000028" name="dei:EntityAddressPostalZipCode" contextRef="C_0000879407_20191001_20200930">91105</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000029" name="dei:CityAreaCode" contextRef="C_0000879407_20191001_20200930">626</ix:nonNumeric>) <ix:nonNumeric id="F_000030" name="dei:LocalPhoneNumber" contextRef="C_0000879407_20191001_20200930">304-3400</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address and telephone number of principal executive offices) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered under Section&#160;12(b) of the Exchange Act: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:36.64%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:25.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:37.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom" style="width:36.64%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000879407_20191001_20200930">Common Stock, $0.001 par value</ix:nonNumeric></p></td>
<td valign="bottom" style="width:25.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0000879407_20191001_20200930">ARWR</ix:nonNumeric></p></td>
<td valign="bottom" style="width:37.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:SecurityExchangeName" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Exchange Act: None </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<ix:nonNumeric id="F_000009" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0000879407_20191001_20200930">Yes</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;No&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by a check mark if the registrant is not required to file reports pursuant to Section&#160;13 or 15(d)&#160;of the Act.&#160;Yes&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;<ix:nonNumeric id="F_000011" name="dei:EntityVoluntaryFilers" contextRef="C_0000879407_20191001_20200930">No</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric id="F_000010" name="dei:EntityCurrentReportingStatus" contextRef="C_0000879407_20191001_20200930">Yes</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;No&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T <span style="color:#000000;">(&#167; 232.405 of this chapter) </span>during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric id="F_000018" name="dei:EntityInteractiveDataCurrent" contextRef="C_0000879407_20191001_20200930">Yes</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;No&#160;<span style="font-family:'Times New Roman';"><span style="font-size:9pt;font-family:'Times New Roman'">&#9744;</span></span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:24.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityFilerCategory" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:entityfilercategoryen">Large&#160;accelerated&#160;filer</ix:nonNumeric>&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:18.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:23.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated&#160;filer&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:30.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;Reporting&#160;Company <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntitySmallBusiness" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
</tr>
<tr>
<td valign="top" style="width:24.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000014" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:18.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:23.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
<td valign="bottom" style="width:0.76%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:30.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;Yes&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:EntityShellCompany" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;No&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of issuer&#8217;s voting and non-voting outstanding Common Stock held by non-affiliates was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000017" name="dei:EntityPublicFloat" contextRef="C_0000879407_20200331" decimals="-8" scale="9">2.9</ix:nonFraction> billion based upon the closing stock price of issuer&#8217;s Common Stock on March&#160;31, 2020. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding Common Stock have been excluded in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of November 16, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000016" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0000879407_20201116" decimals="INF" format="ixt:numdotdecimal">102,756,771</ix:nonFraction> shares of the issuer&#8217;s Common Stock were issued and outstanding. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-bottom:0pt;margin-top:4pt;border-bottom:Double 2.25pt;padding-bottom:1pt;text-indent:5%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0000879407_20191001_20200930">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#8217;s 2021 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-top:4pt;border-top:none 0pt;padding-top:0pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="border-top:none 0pt;padding-top:0pt;text-align:center;margin-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;I</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:87.26%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM&#160;</span>1<span style="font-size:7.5pt;">.</span></p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">B</span><span style="font-size:7.5pt;text-decoration:underline;">USINESS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7.5pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;1A.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item1A_RiskFactors"><span style="text-decoration:underline;">R</span><span style="font-size:7.5pt;text-decoration:underline;">ISK</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">ACTORS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;1B.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item1B_UnresolvedStaffComments"><span style="text-decoration:underline;">U</span><span style="font-size:7.5pt;text-decoration:underline;">NRESOLVED</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">TAFF</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">OMMENTS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;2.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item2_Properties"><span style="text-decoration:underline;">P</span><span style="font-size:7.5pt;text-decoration:underline;">ROPERTIES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;3.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item3_LegalProceedings"><span style="text-decoration:underline;">L</span><span style="font-size:7.5pt;text-decoration:underline;">EGAL</span><span style="text-decoration:underline;"> P</span><span style="font-size:7.5pt;text-decoration:underline;">ROCEEDINGS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;4.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item4_MineSafetyDisclosures"><span style="text-decoration:underline;">M</span><span style="font-size:7.5pt;text-decoration:underline;">INE</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">AFETY</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ISCLOSURES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:87.26%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;5.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item5_MarketForRegistrants"><span style="text-decoration:underline;">M</span><span style="font-size:7.5pt;text-decoration:underline;">ARKET</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">FOR</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">THE</span><span style="text-decoration:underline;"> R</span><span style="font-size:7.5pt;text-decoration:underline;">EGISTRANT</span><span style="text-decoration:underline;">&#8217;</span><span style="font-size:7.5pt;text-decoration:underline;">S</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">OMMON</span><span style="text-decoration:underline;"> E</span><span style="font-size:7.5pt;text-decoration:underline;">QUITY</span><span style="text-decoration:underline;">, R</span><span style="font-size:7.5pt;text-decoration:underline;">ELATED</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">TOCKHOLDER</span><span style="text-decoration:underline;"> M</span><span style="font-size:7.5pt;text-decoration:underline;">ATTERS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> I</span><span style="font-size:7.5pt;text-decoration:underline;">SSUER</span><span style="text-decoration:underline;"> P</span><span style="font-size:7.5pt;text-decoration:underline;">URCHASES</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">OF</span><span style="text-decoration:underline;"> E</span><span style="font-size:7.5pt;text-decoration:underline;">QUITY</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">ECURITIES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;6.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item6_SelectedFinancial"><span style="text-decoration:underline;">S</span><span style="font-size:7.5pt;text-decoration:underline;">ELECTED</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">INANCIAL</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ATA</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;7.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item7_MDA"><span style="text-decoration:underline;">M</span><span style="font-size:7.5pt;text-decoration:underline;">ANAGEMENT</span><span style="text-decoration:underline;">&#8217;</span><span style="font-size:7.5pt;text-decoration:underline;">S</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ISCUSSION</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> A</span><span style="font-size:7.5pt;text-decoration:underline;">NALYSIS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">OF</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">INANCIAL</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">ONDITION</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> R</span><span style="font-size:7.5pt;text-decoration:underline;">ESULTS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">OF</span><span style="text-decoration:underline;"> O</span><span style="font-size:7.5pt;text-decoration:underline;">PERATIONS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;7A.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item7A_QuantitativeAndQualitative"><span style="text-decoration:underline;">Q</span><span style="font-size:7.5pt;text-decoration:underline;">UANTITATIVE</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> Q</span><span style="font-size:7.5pt;text-decoration:underline;">UALITATIVE</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ISCLOSURES</span><span style="text-decoration:underline;"> A</span><span style="font-size:7.5pt;text-decoration:underline;">BOUT</span><span style="text-decoration:underline;"> M</span><span style="font-size:7.5pt;text-decoration:underline;">ARKET</span><span style="text-decoration:underline;"> R</span><span style="font-size:7.5pt;text-decoration:underline;">ISK</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;8.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item8_FinancialStatementsAndSuppData"><span style="text-decoration:underline;">F</span><span style="font-size:7.5pt;text-decoration:underline;">INANCIAL</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">TATEMENTS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">UPPLEMENTARY</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ATA</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;9.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item9_ChangesInAndDisagreements"><span style="text-decoration:underline;">C</span><span style="font-size:7.5pt;text-decoration:underline;">HANGES</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">IN</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ISAGREEMENTS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">WITH</span><span style="text-decoration:underline;"> A</span><span style="font-size:7.5pt;text-decoration:underline;">CCOUNTANTS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">ON</span><span style="text-decoration:underline;"> A</span><span style="font-size:7.5pt;text-decoration:underline;">CCOUNTING</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">INANCIAL</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">ISCLOSURE</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;9A.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item9A_ControlsAndProcedures"><span style="text-decoration:underline;">C</span><span style="font-size:7.5pt;text-decoration:underline;">ONTROLS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> P</span><span style="font-size:7.5pt;text-decoration:underline;">ROCEDURES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;9B.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item9B_OtherInformation"><span style="text-decoration:underline;">O</span><span style="font-size:7.5pt;text-decoration:underline;">THER</span><span style="text-decoration:underline;"> I</span><span style="font-size:7.5pt;text-decoration:underline;">NFORMATION</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:87.26%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;10.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item10_DirectorsExecutives"><span style="text-decoration:underline;">D</span><span style="font-size:7.5pt;text-decoration:underline;">IRECTORS</span><span style="text-decoration:underline;">, E</span><span style="font-size:7.5pt;text-decoration:underline;">XECUTIVE</span><span style="text-decoration:underline;"> O</span><span style="font-size:7.5pt;text-decoration:underline;">FFICERS</span><span style="text-decoration:underline;">, </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">ORPORATE</span><span style="text-decoration:underline;"> G</span><span style="font-size:7.5pt;text-decoration:underline;">OVERNANCE</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;11.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item11_ExecutiveCompensation"><span style="text-decoration:underline;">E</span><span style="font-size:7.5pt;text-decoration:underline;">XECUTIVE</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">OMPENSATION</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;12.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item12_SecurityOwnership"><span style="text-decoration:underline;">S</span><span style="font-size:7.5pt;text-decoration:underline;">ECURITY</span><span style="text-decoration:underline;"> O</span><span style="font-size:7.5pt;text-decoration:underline;">WNERSHIP</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">OF</span><span style="text-decoration:underline;"> C</span><span style="font-size:7.5pt;text-decoration:underline;">ERTAIN</span><span style="text-decoration:underline;"> B</span><span style="font-size:7.5pt;text-decoration:underline;">ENEFICIAL</span><span style="text-decoration:underline;"> O</span><span style="font-size:7.5pt;text-decoration:underline;">WNERS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> M</span><span style="font-size:7.5pt;text-decoration:underline;">ANAGEMENT</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> R</span><span style="font-size:7.5pt;text-decoration:underline;">ELATED</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">TOCKHOLDERS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;13.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item13_CertainRelationships"><span style="text-decoration:underline;">C</span><span style="font-size:7.5pt;text-decoration:underline;">ERTAIN</span><span style="text-decoration:underline;"> R</span><span style="font-size:7.5pt;text-decoration:underline;">ELATIONSHIPS</span><span style="text-decoration:underline;">, R</span><span style="font-size:7.5pt;text-decoration:underline;">ELATED</span><span style="text-decoration:underline;"> T</span><span style="font-size:7.5pt;text-decoration:underline;">RANSACTIONS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> D</span><span style="font-size:7.5pt;text-decoration:underline;">IRECTORS</span><span style="text-decoration:underline;"> I</span><span style="font-size:7.5pt;text-decoration:underline;">NDEPENDENCE</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;14.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item14_PrincipalAccountantFees"><span style="text-decoration:underline;">P</span><span style="font-size:7.5pt;text-decoration:underline;">RINCIPAL</span><span style="text-decoration:underline;"> A</span><span style="font-size:7.5pt;text-decoration:underline;">CCOUNTANT</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">EES</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">ERVICES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:87.26%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:87.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I<span style="font-size:7.5pt;">TEM</span>&#160;15.</p></td>
<td valign="bottom" style="width:0.64%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:87.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Item15_Exhibits"><span style="text-decoration:underline;">E</span><span style="font-size:7.5pt;text-decoration:underline;">XHIBITS</span><span style="text-decoration:underline;"> </span><span style="font-size:7.5pt;text-decoration:underline;">AND</span><span style="text-decoration:underline;"> F</span><span style="font-size:7.5pt;text-decoration:underline;">INANCIAL</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">TATEMENT</span><span style="text-decoration:underline;"> S</span><span style="font-size:7.5pt;text-decoration:underline;">CHEDULES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="3" valign="middle" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:95.7%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Signature"><span style="text-decoration:underline;">SIGNATURE</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="3" valign="middle" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="middle" style="width:4.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="width:95.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#IndexToFinancialStatementsAndSchedules"><span style="text-decoration:underline;">INDEX TO FINANCIAL STATEMENTS AND SCHEDULES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.06%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:3.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORWARD-LOOKING STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933 and Section&#160;21E of the Securities Exchange Act of 1934, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Annual Report on Form 10-K except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; or &#8220;continue&#8221; or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control. As such, our actual results may differ significantly from those expressed in any forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item&#160;1 (Business) and Item&#160;1A (Risk Factors) of Part I and Item&#160;7 (Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations) of Part II of this Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART I </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;" id="NotesToConsolidatedFinanStatements">Unless otherwise noted, (1)&#160;the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation and its Subsidiaries, (2)&#160;the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3)&#160;the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;), and Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), (4)&#160;the term &#8220;Common Stock&#8221; refers to Arrowhead&#8217;s Common Stock, (5) the term &#8220;Preferred Stock&#8221; refers to Arrowhead&#8217;s Preferred Stock&#160;&#160;and (6) the term &#8220;Stockholder(s)&#8221; refers to the holders of Arrowhead Common Stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_BUSINESS">ITEM&#160;1.<span style="margin-left:14pt;">B</span>USINESS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Description of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220; RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pipeline Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of our RNAi technologies enables us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is leading the field in bringing the promise of RNAi to address diseases outside of the liver, and our pipeline now includes disease targets in the liver, lung, and solid tumors.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gei541vqjlbv000001.jpg" title="" alt="" style="width:623px;height:474px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-AAT</span><span style="font-size:12pt;font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-AAT is the Company&#8217;s second generation subcutaneously administered RNAi therapeutic being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency (AATD), which is a rare genetic disorder that severely damages the liver and lungs of affected individuals. ARO-AAT is designed to reduce production of the mutant Z-AAT protein by silencing the AAT gene in order to prevent accumulation of Z-AAT in the liver, allow clearance of the accumulated Z-AAT protein, prevent repeated cycles of cellular damage, and possibly prevent or even reverse the progression of liver fibrosis. In October 2020, Arrowhead signed an agreement with the Takeda Pharmaceuticals U.S.A., Inc. to co-develop and co-commercialize ARO-AAT, pending completion of review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead is currently investigating ARO-AAT in two clinical studies:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">SEQUOIA (AROAAT2001), which is a multi-center, multi-dose, placebo-controlled, adaptive Phase 2/3 study to evaluate the safety, efficacy and tolerability of ARO-AAT, administered subcutaneously to patients with alpha-1 antitrypsin deficiency.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">AROAAT2002, which is a pilot open-label, multi-dose, Phase 2 study to assess changes in a novel histological activity scale in response to ARO-AAT over time in patients with alpha-1 antitrypsin deficiency associated liver disease.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Goal of ARO-AAT Treatment</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The goal of ARO-AAT treatment is prevention and potential reversal of Z-AAT accumulation-related liver injury and fibrosis. Reduction of inflammatory Z-AAT protein, which has been clearly defined as the cause of progressive liver disease in AATD patients, is important as it is expected to halt the progression of liver disease and allow fibrotic tissue repair.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alpha-1 Antitrypsin Deficiency (AATD)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AATD is a genetic disorder associated with liver disease in children and adults, and pulmonary disease in adults. AAT is a circulating glycoprotein protease inhibitor that is primarily synthesized and secreted by liver hepatocytes. Its physiologic function is the inhibition of neutrophil proteases to protect healthy lung tissues during inflammation and prevent tissue damage. The most common disease variant, the Z mutant, has a single amino acid substitution that results in improper folding of the protein.&#160;&#160;The mutant protein cannot be effectively secreted and accumulates in globules in the hepatocytes. This triggers continuous hepatocyte injury, leading to fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Current Treatments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individuals with the homozygous PiZZ genotype have severe deficiency of functional AAT leading to pulmonary disease and hepatocyte injury and liver disease. Lung disease in this patient population is frequently treated with AAT augmentation therapy. However, augmentation therapy does nothing to treat liver disease, and there is no specific therapy for hepatic manifestations. There is a significant unmet need as liver transplant, with its attendant morbidity and mortality, is currently the only available cure.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-AAT in Normal Adult Volunteers</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin Levels in Normal Adult Volunteers</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03362242</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Assessment of Changes in a Novel Histological Activity Scale in Response to ARO-AAT</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Pilot Open Label, Multi-dose, Phase 2 Study to Assess Changes in a Novel Histological Activity Scale in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03946449 </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Safety, Tolerability and Effect on Liver Histologic Parameters of ARO-AAT (SEQUOIA)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency (AATD)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03945292</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-APOC3<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and a key regulator of triglyceride metabolism. We believe that knocking down the hepatic </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead is currently investigating ARO-A</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">POC3</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a Phase 1/2 clinical trial</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hypertriglyceridemia</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Elevated triglyceride levels are an independent risk factor for cardiovascular disease. Severely elevated triglycerides (often over 2,000 mg/dL) in patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder, can result in potentially fatal acute pancreatitis.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients with Familial Chylomicronemia Syndrome (FCS)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-APOC3 in Adult Healthy Volunteers as Well as in Severely Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03783377</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-ANG3</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-ANG3 is designed to reduce production of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum and liver triglyceride and has genetic validation as a novel target for cardiovascular disease. Arrowhead is currently investigating ARO-ANG3 in a Phase 1/2 clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dyslipidemia and Hypertriglyceridemia </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dyslipidemia and hypertriglyceridemia are risk factors for atherosclerotic coronary heart disease and cardiovascular events.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1 Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-ANG3 in Adult Healthy Volunteers and in Dyslipidemic Patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03747224</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-HSD<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-HSD is designed to reduce production of HSD17B13, a hydroxysteroid dehydrogenase involved in the metabolism of hormones, fatty acids and bile acids. Published human genetic data indicate that a loss of function mutation in HSD17B13 provides strong protection against nonalcoholic steatohepatitis (NASH) cirrhosis and alcoholic hepatitis and cirrhosis. Arrowhead is currently investigating ARO-HSD in a Phase 1/2 clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nonalcoholic steatohepatitis</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a buildup of fat in the liver. This can cause scarring of the liver and in advanced cases can lead to cirrhosis.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1/2a Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of ARO-HSD in Normal Healthy Volunteers as Well as in Patients With NASH or Suspected NASH</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04202354</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-ENaC<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-ENaC is designed to reduce production of the epithelial sodium channel alpha subunit (&#945;ENaC) in the airways of the lung. In cystic fibrosis patients, increased ENaC activity contributes to airway dehydration and reduced mucociliary transport. Arrowhead is currently investigating ARO-ENaC in a Phase 1/2 clinical trial.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cystic Fibrosis</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cystic fibrosis (CF) is a rare disease caused by a genetic mutation that leads to mucus buildup in the lungs and pancreas. In CF lung disease, patients can have difficulty breathing and experience frequent and persistent lung infections.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients With Cystic Fibrosis</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04375514</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-Lung2</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-Lung2 is being developed against an undisclosed target as a potential treatment for chronic obstructive pulmonary disorder (COPD). Arrowhead intends to file a clinical trial application at the end of 2020 to begin a Phase 1/2 clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-COV</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-COV is being developed to address the current novel coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-HIF2</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-HIF2 is being developed for the treatment of clear cell renal cell carcinoma (ccRCC). ARO-HIF2 is designed to inhibit the production of HIF-2&#945;, which has been linked to tumor progression and metastasis in ccRCC. Arrowhead believes it is an important target for intervention because over 90% of ccRCC tumors express a mutant form of the Von Hippel-Landau protein that is unable to degrade HIF-2&#945;, leading to its accumulation during tumor hypoxia and promoting tumor growth. Arrowhead is currently investigating ARO-HIF2 in a Phase 1b clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renal Cell Carcinoma</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Renal Cell Carcinoma (&#8220;RCC&#8221;) is a type of kidney cancer that originates in the cells that line the small tubes that filter waste material from the blood. RCC is the most common type of kidney cancer accounting for more than 90% of cases with approximately 50,000 diagnoses in the United States each year.&#160;&#160;Unfortunately, patients with advanced stages of RCC have a 5-year survival rate of only 12-25%. Surgical resection is the mainstay of current treatment while chemotherapy and radiation have not been successful at prolonging survival. The treatment options for patients with metastatic disease are extremely limited.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1b Adaptive Dose-Finding Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04169711</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Partnered Programs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Janssen Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead entered into a license agreement in October 2018 with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;), part of the Janssen Pharmaceutical Companies of Johnson &#38; Johnson, to develop and commercialize ARO-HBV. In addition, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three additional RNAi therapeutics against new targets to be selected by Janssen.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the license agreement, Arrowhead received $175 million as an upfront payment. Separately, Johnson &#38; Johnson Innovation &#8211; JJDC, Inc. (JJDC) made a $75.0 million equity investment in Arrowhead at a price of $23.00 per share of Arrowhead Common Stock.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead is eligible to receive up to approximately $1.6 billion in milestone payments under the license agreement. Arrowhead is also eligible to receive approximately $1.9 billion in option and milestone payments for the collaboration and option agreement related to up to three additional targets. Arrowhead is further eligible to receive tiered royalties up to mid-teens under the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license agreement and up to low teens under the collaboration and option agreement on product sales.</span><span style="font-size:12pt;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since signing the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">license </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreement, Arrowhead has received $50</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in developmental milestone payments from Janssen.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">JNJ-3989 (also referred to as JNJ-73763989 and formerly referred to as ARO-HBV)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">JNJ-3989 is being developed in collaboration with Janssen as a potential therapy for patients with chronic hepatitis B infection, when used in combination with other therapeutic modalities. JNJ-3989 is a subcutaneous, RNAi therapy candidate which is designed to silence all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogues act. The company believes this, especially the elimination of hepatitis B surface antigen (HBsAg), may allow the body&#8217;s natural immune defenses to clear the virus and potentially lead to a functional cure. JNJ-3989 (ARO-HBV) is currently being investigated in multiple Phase 2 clinical trials being conducted by Janssen. The phase 1/2a study and its preceding studies were conducted by Arrowhead. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03365947</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ-73763989 in Healthy Japanese Adult Participants</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Double-blind, Placebo-controlled, Randomized, Parallel, Single Dose Study to Investigate Pharmacokinetics, Safety, and Tolerability of JNJ-73763989 in Healthy Japanese Adult Participants</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04002752</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection (REEF-1)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2b, Multicenter, Double-blind, Active-controlled, Randomized Study to Investigate the Efficacy and Safety of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03982186</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Randomized, Double Blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04129554</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ-73763989 in Healthy Chinese Adult Participants</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Randomized, Open-Label, Parallel, Single Dose Study to Investigate Pharmacokinetics, Safety, and Tolerability of JNJ-73763989 in Healthy Chinese Adult Participants</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04586439</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1, Single-Dose, Open-Label, Parallel-Group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of JNJ-73763989</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04208386</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus (REEF-D)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study With Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04535544</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">tudy Name: </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">A Study of JNJ-73763989 + JNJ-56136379 + Nucleos(t)Ide Analog (NA) Regimen With or Without Pegylated Interferon Alpha-2a (PegIFN-&#945;2a) in Treatment-Naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection and Normal Alanine Aminotransferase (ALT)</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Response-guided Treatment With JNJ-73763989 + JNJ-56136379 + Nucleos(t)Ide Analog Regimen With or Without Pegylated Interferon Alpha-2a in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection and Normal ALT</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04439539</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (INSIGHT)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04585789</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 are being developed against undisclosed liver-expressed targets as part of Arrowhead&#8217;s research collaboration and option agreement with Janssen.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amgen Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amgen Inc. (&#8220;Amgen&#8221;) acquired a worldwide, exclusive license in September 2016 to develop and commercialize Olpasiran (previously referred to as AMG 890 or ARO-LPA). Under the terms of the agreements taken together for Olpasiran and ARO-AMG1, the Company received $35.0 million in upfront payments and $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and the Company was eligible to receive up to $617.0 million in option payments and development, regulatory and sales milestone payments. The Company remains eligible to receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments under the Olpasiran (ARO-LPA) agreement.&#160;&#160;Since signing the agreements, Arrowhead has received $30.0 million in developmental milestone payments from Amgen.&#160;&#160;The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran (AMG 890, ARO-LPA) agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Olpasiran (formerly AMG 890 and ARO-LPA)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Olpasiran is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. Amgen started a Phase 2 clinical study in July 2020 evaluating the efficacy, safety, and tolerability of Olpasiran in subjects with elevated levels of lipoprotein(a), triggering a $20 million milestone payment to Arrowhead. Amgen also reported Phase 1 clinical results at the American Heart Association Scientific Sessions conference in November 2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Trials</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT03626662</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Study Name: Randomized Study to Evaluate Efficacy, Safety, and Tolerability of AMG 890 in Subjects With Elevated Lipoprotein(a)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of AMG 890 (a GalNAc-conjugated Small Interfering RNA [siRNA]) in Subjects With Elevated Lipoprotein(a)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ClinicalTrials.gov Identifier: NCT04270760</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RNA Interference &#38; the Benefits of RNAi Therapeutics</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Small molecule and antibody drugs have proven effective at inhibiting certain cell surface, intracellular, and extracellular targets. However, other drug targets have proven difficult to inhibit with traditional drug-based and biologic therapeutics. Developing effective drugs for these targets would have the potential to address large underserved markets for the treatment of many diseases. Using the ability to specifically silence any gene, RNAi therapeutics may be able to address previously &#8220;undruggable&#8221; targets, unlocking the market potential of such targets. </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gei541vqjlbv000002.jpg" title="" alt="" style="width:507px;height:339px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This figure depicts the mechanism by which gene silencing occurs. Double stranded RNAi triggers are introduced into a cell and get loaded into the RNA-induced silencing complex, (</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RISC</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">). The strands are then separated, leaving an active RISC/RNAi trigger complex. This complex can then pair with and degrade the complementary messenger RNAs (</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mRNA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) and stop the production of the target proteins. RNAi is a catalytic process, so each RNAi trigger can degrade mRNA hundreds of times, which results in a relatively long duration of effect for RNAi therapeutics.</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Key Advantages of RNAi as a Therapeutic Modality</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Silences the expression of disease associated genes&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Potential to address any target in the transcriptome including previously "undruggable" targets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Rapid lead identification&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">High specificity&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Opportunity to use multiple RNA sequences in one drug product for synergistic silencing of related targets&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">RNAi therapeutics are uniquely suited for personalized medicine through target and cell specific delivery and gene knockdown.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Targeted RNAi Molecule (TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>) Platform</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead&#8217;s Targeted RNAi Molecule (TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. Targeting has been core to Arrowhead&#8217;s development philosophy and the TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform builds on more than a decade of work on actively targeted drug delivery vehicles. Arrowhead scientists have discovered ways to progressively &#8220;TRiM&#8221; away extraneous features and chemistries and retain optimal pharmacologic activity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform comprises a highly potent RNA trigger identified using Arrowhead&#8217;s proprietary trigger selection rules and algorithms with the following components optimized, as needed, for each drug candidate: a high affinity targeting ligand&#59; various linker and chemistries&#59; structures that enhance pharmacokinetics&#59; and highly potent RNAi triggers with sequence specific stabilization chemistries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therapeutics developed with the TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform offer several advantages: simplified manufacturing and reduced costs&#59; multiple routes of administration&#59; and potential for improved safety because there are less metabolites from smaller molecules, thereby reducing the risk of intracellular buildup. At Arrowhead, we also believe that for RNAi to reach its true potential, it must target organs outside the liver. Arrowhead is leading this expansion with the TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform, which has shown the potential to reach multiple tissues, including liver, lung, tumor, muscle and others.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gei541vqjlbv000003.jpg" title="" alt="" style="width:623px;height:438px;" /><span style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">RNA Chemistries</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The structure and chemistries of the oligonucleotide molecules used to trigger the RNAi mechanism can be tailored for optimal activity. Arrowhead&#8217;s broad portfolio of RNA trigger structures and chemistries, including some proprietary structures, enable the company to optimize each drug candidate on a target-by-target basis and utilize the combination of structure and chemical modifications that yield the most potent RNAi trigger.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a component of the TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform, Arrowhead&#8217;s design philosophy for RNA chemical modifications is to start with a structurally simple molecule and add only selective modification and stabilization chemistries as necessary to achieve the desired level of target knockdown and duration of effect. The conceptual framework for the stabilization strategy starts with a more sophisticated RNAi trigger screening and selection process that identifies potent sequences rapidly in locations that others may miss. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Facility </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead&#8217;s research and development operations are primarily located in Madison, Wisconsin, and San Diego, California. Substantially all of the Company&#8217;s assets are located either in these facilities or in our corporate headquarters in Pasadena. A summary of our research and development resources is provided below:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">192 R&#38;D personnel as of September 30, 2020&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">State-of-the-art laboratories consisting of 121,000 total sq. ft.&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Complete small animal facilities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Primate colony housed at the Wisconsin National Primate Research Center, an affiliate of the University of Wisconsin&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">In-house histopathology capabilities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Animal models for cardio metabolic, viral, lung, and oncologic diseases&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Animal efficacy and safety assessment&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">In-house drug manufacturing capabilities to produce GMP material&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Polymer, peptide, oligonucleotide and small molecule synthesis and analytics capabilities (HPLC, NMR, MS, etc.)&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;">Polymer, peptide and oligonucleotide PK, biodistribution, clearance methodologies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Conventional and confocal microscopy, flow cytometry, Luminex platform, qRT-PCR and clinical chemistry analytics.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual Property and Key Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company controls approximately 398 issued patents (including 250 directed to RNAi trigger molecules&#59; 35 directed to targeting groups or targeting compounds&#59; and 5 for hydrodynamic gene delivery), including European validations, and approximately 548 currently pending patent applications worldwide from 57 different patent families. The Company&#8217;s patent applications have been filed throughout the world, including, in the United States, Argentina, ARIPO (Africa Regional Intellectual Property Organization), Australia, Brazil, Canada, Chile, China, Eurasian Patent Organization, Europe, GCC (Gulf Cooperation Council), Hong Kong, Israel, India, Indonesia, Iraq, Jordan, Japan, Republic of Korea, Lebanon, Mexico, New Zealand, OAPI (African Intellectual Property Organization), Peru, Philippines, Russian Federation, Saudi Arabia, Singapore, Thailand, Taiwan, Uruguay, Venezuela, Vietnam, and South Africa.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RNAi Triggers</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company owns issued patents or has filed patent applications directed to RNAi trigger molecules, which serve as the foundation of Arrowhead&#8217;s TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform, and are targeted to reduce expression of various gene targets, including the following: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.54%;width:80.46%;">
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Patent Group</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Year(s) of Expiration*</p></td>
</tr>
<tr>
<td colspan="2" valign="top" style="background-color:#EEECE1;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:100%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RNAi Triggers Gene Target</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HBV </p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2032, 2036, 2037</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AAT</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2035, 2038</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LPA</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2036</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Factor 12</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2036, 2038</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-bottom:solid 0.75pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIF2&#945;</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-bottom:solid 0.75pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2034, 2036, 2040</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RRM2</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">APOC3</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2035, 2038</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ANGPTL3</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2038</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HSD17B13</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2039</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#945;-ENaC </p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028, 2038</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#946;-ENaC</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#946;-Catenin</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2033</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cx43</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2029</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HCV</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIF1A</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HRH1</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HSF1</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2030, 2032</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FRP-1</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KRAS</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2033</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PDtype4</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PI4Kinase</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SYK</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TNF-&#945;</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2027, 2028</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Assuming issuance of any pending patent applications.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delivery Technologies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The delivery technology-related patents and patent applications, which include components used in Arrowhead&#8217;s TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform, have been filed and/or issued in various jurisdictions worldwide including the United States, Argentina, Australia, Brazil, Canada, China, Eurasian Patent Organization, Europe (including validations in France, Germany, Italy, Spain, Switzerland, United Kingdom), GCC (Gulf Cooperation Council), Israel, India, Japan, Lebanon, Mexico, New Zealand, Philippines, Russia, South Korea, Singapore, Taiwan, Uruguay, and South Africa. The Company also controls a number of patents directed to hydrodynamic nucleic acid delivery, which issued in the United States, Australia and Europe (validated in Austria, Belgium, Switzerland, Germany, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denmark, Spain, Finland, France, the United Kingdom, Hungary, Ireland, Italy, Netherlands and Sweden).&#160;&#160;The approximate year of expiration for each of these various groups of patents are set forth below:&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:4.54%;width:80.46%;">
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Patent Group</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:-7.2pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Estimated Year(s) of Expiration*</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="top" style="background-color:#EEECE1;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Targeting ligands and other RNAi delivery technologies</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:0%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeting groups <span style="font-style:italic;">(</span>Galactose derivative trimer-PK<span style="font-style:italic;">)</span></p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2031</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeting groups (&#945;v&#946;3 integrin)</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2034, 2039, 2039</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeting groups (&#945;v&#946;6 integrin)</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2037, 2038</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Targeting groups (Galactose derivative ligands)</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2037, 2037</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RNAi agent design (5&#8242;-phosphate mimic)</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2037</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Physiologically labile linkers</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2036</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biologically cleavable linkers</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2036</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trialkyne linkers</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2039</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Transferrin targeting</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LDLR targeting</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peptide targeting (CPP-Arg) </p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2028</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Peptide targeting (YM3-10H)</p></td>
<td valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2032</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="top" style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:11.5pt;">
<td colspan="2" valign="top" style="background-color:#EEECE1;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Hydrodynamic delivery</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second iteration</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
</tr>
<tr style="height:11.5pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:58.8%; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third iteration</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:41.1%; border-bottom:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:24.5pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Assuming issuance of any pending patent applications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RNAi and drug delivery patent landscapes are complex and rapidly evolving. As such, we may need to obtain additional patent licenses prior to commercialization of our candidates. You should review the factors identified in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Non-Exclusively Licensed Patent Rights obtained from Roche</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 21, 2011, Arrowhead acquired the RNAi therapeutics business of Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche Ltd. (collectively, &#8220;Roche&#8221;).&#160;&#160;The acquisition provided us with two primary sources of value:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Broad freedom to operate with respect to key patents directed to the primary RNAi-trigger formats: canonical, UNA, meroduplex, and dicer substrate structures&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">A large team of scientists experienced in RNAi and oligonucleotide delivery. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to this acquisition, Roche assigned to Arrowhead its entire rights under certain licenses including: the License and Collaboration Agreement between Roche and Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;) dated July 8, 2007 (the &#8220;Alnylam License&#8221;)&#59; the Non-Exclusive Patent License Agreement between Roche and MDRNA, Inc. dated February 12, 2009 (&#8220;MDRNA License&#8221;)&#59; and the Non-Exclusive License Agreement between Roche and City of Hope dated September 19, 2011 (the &#8220;COH License&#8221;) (collectively the &#8220;RNAi Licenses&#8221;).&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The RNAi Licenses include licenses to patents related to modifications of double-stranded oligonucleotides, including modifications to the base, sugar, or internucleoside linkage, nucleotide mimetics, and end modifications, which do not abolish the RNAi activity of the double-stranded oligonucleotides.&#160;&#160;Also included are patents relating to modified double-stranded oligonucleotides, such as meroduplexes described in U.S. Patent No. 9,074,205 assigned to Marina Biotech (f/k/a MDRNA, Inc.), as well as U.S. Patent Nos. 8,314,227, 9,051,570, and 9,303,260 related to unlocked nucleotide analogs (&#8220;UNA&#8221;). The UNA patents were assigned by Marina Biotech to Arcturus Therapeutics, Inc., but remain part of the MDRNA License.&#160;&#160;The RNAi Licenses further include patents related to dicer substrates and uses of the double-stranded oligonucleotides that function through the mechanism of RNA interference, such as described in City of Hope&#8217;s U.S. Patent Nos. 8,084,599, 8,658,356, 8,691,786, 8,796,444, 8,809,515, and 9,518,262.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2012 License to Alnylam</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for licenses obtained from Alnylam to certain RNAi intellectual property, in January 2012, we granted Alnylam a worldwide non-exclusive, sublicensable royalty-bearing license under our broad and target-specific DPC intellectual property rights to research, develop and commercialize RNAi-based products against a single undisclosed target in combination with DPC technology. Under the license to Alnylam, Alnylam may be obligated to pay us development and sales milestone payments of up to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the low double-digit millions of dollars for each licensed product that progresses through clinical trials, receives marketing approval and is the subject of a first commercial sale.&#160;&#160;Additionally, Alnylam may be obligated to pay us low single-digit percentage royalties on sales of such products.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of Assets from Novartis</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 3, 2015, the Company entered into an Asset Purchase and Exclusive License Agreement (the &#8220;RNAi Purchase Agreement&#8221;) with Novartis pursuant to which the Company acquired Novartis&#8217; RNAi assets and rights thereunder. Pursuant to the RNAi Purchase Agreement, the Company acquired or was granted a license to certain patents and patent applications owned or controlled by Novartis related to RNAi therapeutics, was assigned Novartis&#8217;s rights under a license from Alnylam (the &#8220;Alnylam-Novartis License&#8221;) and acquired a license to certain additional Novartis assets (the &#8220;Licensed Novartis Assets&#8221;).&#160;&#160;The patents acquired from Novartis include multiple patent families covering delivery technologies and RNAi-trigger design rules and modifications.&#160;&#160;The Licensed Novartis Assets include an exclusive, worldwide right and license, solely in the RNAi field, with the right to grant sublicenses through multiple tiers under or with respect to certain patent rights and know how relating to delivery technologies and RNAi-trigger design rules and modifications.&#160;&#160;Under the assigned Alnylam-Novartis License, the Company acquired a worldwide, royalty-bearing, exclusive license with limited sublicensing rights to existing and future Alnylam intellectual property (including intellectual property that came under Alnylam&#8217;s control on or before March 31, 2016), excluding intellectual property concerning delivery technology, to research, develop and commercialize 30 undisclosed gene targets. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cardiovascular Collaboration and License Agreements with Amgen</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 28, 2016, the Company entered into two Collaboration and License agreements and a Common Stock Purchase Agreement with Amgen. Under the First Collaboration and License Agreement, Amgen received an option to a worldwide, exclusive license to ARO-AMG1<sub style="font-size:85%; vertical-align:bottom">,</sub> an RNAi therapy for an undisclosed genetically validated cardiovascular target. Under the Second Collaboration and License agreement, Amgen received a worldwide, exclusive license to Arrowhead&#8217;s novel, RNAi AMG 890 (ARO-LPA) program, now referred to as Olpasiran. The Olpasiran RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35 million in upfront payments and $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock.&#160;&#160;The Company was eligible to receive up to $617.0 million in option payments and development, regulatory and sales milestone payments.&#160;&#160;In August 2018, the Company received a $10.0 million milestone payment from Amgen following the administration of the first dose of Olpasiran in a phase 1 clinical study.&#160;&#160;In July 2020, the Company received a $20.0 million milestone payment from Amgen following the initiation of a Phase 2 clinical study of Olpasiran.&#160;&#160;The Company remains eligible to receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments under the Olpasiran agreement.&#160;&#160;The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran agreement.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, Arrowhead delivered to Amgen a candidate that met or exceeded the activity and safety requirements stipulated in the ARO-AMG1 collaboration agreement. The option period expired on August 7, 2019 and Amgen advised Arrowhead that it did not intend to exercise its option.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.67%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License and Research Collaboration Agreements with Janssen Pharmaceuticals, Inc.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 3, 2018, the Company entered into a License Agreement (&#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (&#8220;Janssen Collaboration Agreement&#8221;) with Janssen.&#160;&#160;<span style="color:#000000;">The Company also entered into a Stock Purchase Agreement (&#8220;JJDC Stock Purchase Agreement&#8221;) with JJDC.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Janssen License Agreement, Janssen received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), Janssen is wholly responsible for further clinical development and commercialization of JNJ-3989 (ARO-HBV).<span style="color:#000000;">&#160;&#160;</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Janssen Collaboration Agreement, Janssen will be able to select up to three new targets against which the Company will develop clinical candidates. These candidates are subject to certain restrictions and do not include candidates that were already in the Company&#8217;s pipeline. The Company will perform discovery, optimization and preclinical development on selected targets, entirely funded by Janssen, which on its own or in combination with Janssen development work, is sufficient to allow the filing of a U.S. Investigational New Drug application or equivalent, at which time Janssen will have the option to take an exclusive license to the Company&#8217;s intellectual property rights covering that compound. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned compound.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreements taken together, the Company has received (i) $175</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million as an upfront payment, (ii) $75</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in the form of an equity investment by </span><span style="Background-color:#FFFFFF;">JJDC</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the Company&#8217;s common stock at a price of $23.00 per share,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (iii) two developmental milestone payments of $25 million each for clinical study programs achieved,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and may receive (i</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">v)</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and (v) up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement. </span><span style="color:#000000;">The Company is further eligible to receive tiered royalties up to </span><span style="color:#000000;">mid-teens</span><span style="color:#000000;"> under the Janssen License agreement and up to low teens under the Janssen Collaboration Agreement on product sales.&#160;&#160;</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">License and Research Collaboration Agreements with Takeda Pharmaceuticals U.S.A., Inc.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 7, 2020, the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda Pharmaceuticals U.S.A., Inc.&#160;&#160;(&#8220;Takeda&#8221;).&#160;&#160;Under the Takeda License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with the Company eligible to receive tiered royalties of 20% to 25% on net sales.&#160;&#160;The Company will receive $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities in the United States, at the federal, state, and local levels, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs and biologic products.&#160;&#160;All of our foreseeable product candidates are expected to be regulated as drugs. The processes for obtaining regulatory approval in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of our products and our R&#38;D activities and require the expenditure of substantial time and financial resources.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Review and Approval of Drugs in the United States<span style="font-weight:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA and other government entities regulate drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), the Public Health Service Act, and the regulations promulgated under those statutes, as well as other federal and state statutes and regulations. Failure to comply with applicable legal and regulatory requirements in the United States at any time during the product development process, approval process, or after approval, may subject us to a variety of administrative or judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, withdrawal of approvals, delay or suspension of clinical trials, issuance of warning letters and other types of regulatory letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil monetary penalties, refusals of or debarment from government contracts, exclusion from the federal healthcare programs, restitution, disgorgement of profits, civil or criminal investigations by the FDA, U.S. Department of Justice, State Attorneys General, and/or other agencies, False Claims Act suits and/or other litigation, and/or criminal prosecutions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An applicant seeking approval to market and distribute a new drug in the United States must typically undertake the following:<span style="font-size:12pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)&#160;completion of pre-clinical laboratory tests, animal studies, and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) regulations&#59; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)&#160;submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;) for human clinical testing, which must become effective without FDA objection before human clinical trials may begin&#59; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)&#160;approval by an independent institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated&#59; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)&#160;performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s current good clinical practice (&#8220;cGCP&#8221;) regulations, to establish the safety and effectiveness of the proposed drug product for each indication for which approval is sought&#59; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)&#160;preparation and submission to the FDA of a New Drug Application (&#8220;NDA&#8221;)&#59;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)&#160;satisfactory review of the NDA by an FDA advisory committee, where appropriate or if applicable,</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7)&#160;satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug product, and the active pharmaceutical ingredient or ingredients thereof, are produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;) regulations and to assure that the facilities, methods, and controls are adequate to ensure the product&#8217;s identity, strength, quality, and purity&#59; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8)&#160;payment of user fees, as applicable, and securing FDA approval of the NDA&#59; and</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9)&#160;compliance with any post-approval requirements, such as any Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) or post-approval studies required by the FDA. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical Studies and an IND<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies can include <span style="font-style:italic;">in vitro </span>and animal studies to assess the potential for adverse events and, in some cases, to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Other studies include laboratory evaluation of the purity, stability and physical form of the manufactured drug substance or active pharmaceutical ingredient and the physical properties, stability and reproducibility of the formulated drug or drug product. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some preclinical testing, such as longer-term toxicity testing, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following commencement of a clinical trial under an IND, the FDA may place a clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Human Clinical Studies in Support of an NDA<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on its ClinicalTrials.gov website. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 3: The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites in late-stage clinical trials to assure compliance with cGCP and the integrity of the clinical data submitted. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Submission of an NDA to the FDA<span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee, currently $2.876 million for fiscal year 2021, for applications requiring clinical data, and the sponsor of an approved NDA is also subject to an annual program fee, currently $336,432 for fiscal year 2021.&#160;&#160;These fees are adjusted annually.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under certain circumstances, the FDA will waive the application fee for the first human drug application that a small business, defined as a company with less than 500 employees, including employees of affiliates, submits for review. An affiliate is defined as a business entity that has a relationship with a second business entity if one business entity controls, or has the power to control, the other business entity, or a third-party controls, or has the power to control, both entities.&#160;&#160;In addition, an application to market a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA also may require submission of a REMS plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s Decision on an NDA</span><span style="font-style:normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. After approval, the FDA may seek to prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. Some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety and effectiveness of drug products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a drug for this type of disease or condition will be recovered from sales in the U.S. for that drug. Orphan drug designation entitles the applicant to incentives such as grant funding towards clinical study costs, tax advantages, and waivers of FDA user fees.&#160;&#160;Orphan drug designation must be requested before submitting an NDA, and both the drug and the disease or condition must meet certain criteria specified in the Orphan Drug Act and FDA&#8217;s implementing regulations at 21 C.F.R. Part 316.&#160;&#160;The granting of an orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval.&#160;&#160;Safety and effectiveness of a drug must be established through adequate and well-controlled studies.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other application to market the same drug for the same indication, except in very limited circumstances, for seven years.&#160;&#160;Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Expedited Review and Accelerated Approval Programs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of NDAs.&#160;&#160;For example, Fast Track Designation may be granted to a drug intended for treatment of a serious or life-threatening disease or condition and data demonstrate its potential to address unmet medical needs for the disease or condition.&#160;&#160;The key benefits of Fast Track Designation are the eligibility for priority review, rolling review (submission of portions of an application before the complete marketing application is submitted), and accelerated approval, if relevant criteria are met.&#160;&#160;The FDA may grant the NDA a priority review designation, which sets the target date for FDA action on the application at six months after the FDA accepts the application for filing.&#160;&#160;Priority review is granted where there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may approve an NDA under the accelerated approval program if the drug treats a serious condition, provides a meaningful advantage over available therapies, and demonstrates an effect on either (1) a surrogate endpoint that is reasonably likely to predict clinical benefit, or (2) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ongoing studies after marketing approval are generally required to verify the drug&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Food and Drug Administration Safety and Innovation Act of 2012 (&#8220;FDASIA&#8221;) established the Breakthrough Therapy designation.&#160;&#160;A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as breakthrough therapy, FDA will provide more intensive guidance on the drug development program and expedite its review. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Requirements<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events or problems with manufacturing processes of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information&#59; imposition of post-market studies or clinical trials to assess new safety risks&#59; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">fines, warning letters or holds on post-approval clinical trials&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of products&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Abbreviated New Drug Applications for Generic Drugs<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 1984, with passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the &#8220;Hatch-Waxman Amendments&#8221;) amending the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (&#8220;ANDA&#8221;) to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the reference listed drug, or RLD. To reference that information, however, the ANDA applicant must demonstrate, and the FDA must conclude, that the generic drug does, in fact, perform in the same way as the RLD it purports to copy. Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the generic drug do not show a significant difference from the rate and extent of absorption of the RLD.&#8221;&#160;&#160;Upon approval of an ANDA, the FDA indicates that the generic product is &#8220;therapeutically equivalent&#8221; to the RLD and it assigns a therapeutic equivalence rating to the approved generic drug in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider the therapeutic equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of a therapeutic equivalence rating often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of nonpatent exclusivity for the RLD has expired. The FDCA provides a period of five years of data exclusivity for new drug containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Hatch-Waxman Patent Certification and the 30 Month Stay<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, the applicant must certify with respect to each patent that: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the required patent information has not been filed&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the listed patent has expired&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration&#59; or </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the listed patent is invalid, unenforceable or will not be infringed by the new product. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that a Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Studies and Exclusivity</span><span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With the enactment of FDASIA, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied&#59; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot accept or approve another application. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Patent Term Restoration and Extension<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments. Those Amendments permit a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of a NDA, plus the time between the submission date of a NDA and ultimate approval. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Legislative Developments </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 21st Century Cures Act (the &#8220;Cures Act&#8221;), which was signed into law in December 2016, includes provisions to accelerate the development and delivery of new treatments.&#160;&#160;For example, the Cures Act requires the FDA to establish a program to evaluate the potential use of real world evidence to help to support the approval of a new indication for an approved drug and to help to support or satisfy post-approval study requirements, to issue guidance on adaptive and novel clinical trial designs for new drugs, and to establish a process for qualifying drug development tools used to support FDA approval for marketing or investigational use of a drug. The Cures Act also permits the FDA to rely on qualified data summaries to support the approval of a supplemental application for an already approved drug.&#160;&#160;The FDA is in the process of implementing the Cures Act requirements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Review and Approval of Drug Products in the European Union</span><span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any <span style="color:#000000;">pharmaceutical</span> product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions governing, among other things, research and development, testing, manufacturing, quality control, safety, efficacy,&#160;&#160;clinical trials, marketing authorization, packaging, storage, record keeping, reporting, export and import, advertising and other promotional practices involving <span style="color:#000000;">pharmaceutical</span> products, as well as commercial sales, distribution and post-approval monitoring and reporting of our products. Whether or not it obtains FDA approval for a <span style="color:#000000;">pharmaceutical</span> product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the <span style="color:#000000;">pharmaceutical</span> product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Drug and Biologic Development Process</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the EU Clinical Trial Directive 2001/20/EC (&#8220;Clinical Trials Directive&#8221;), a system for the approval of clinical trials in the European Union has been implemented through national legislation of the EU Member States. Under this system, before a clinical trial can be initiated, an applicant must obtain approval  in each EU Member State in which the clinical trial is to be conducted by two separate entities: The National Competent Authority (&#8220;NCA&#8221;), and one or more Ethics Committees. The NCA of the EU Member States in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU Member State before the commencement of the trial. Any substantial changes to trial protocol or other information submitted with the clinical trial applications must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU Member State where they occur. Clinical trial applications (&#8220;CTAs&#8221;) must also be accompanied by an investigational <span style="color:#000000;">pharmaceutical</span> product dossier with supporting information prescribed by the corresponding national laws of the Member States and further detailed in applicable guidance documents. However, the EU Member States have transposed and applied the provisions of the Clinical Trials Directive in a manner that is not always uniform. This has led to variations in the rules governing the conduct of clinical trials in the individual EU Member States. The EU has, therefore, adopted Regulation (EU) No 536/2014 (&#8220;Clinical Trials Regulation&#8221;). The Clinical Trials Regulation, which will replace the Clinical Trials Directive, introduces a complete overhaul of the existing regulation of clinical trials for pharmaceutical products in the EU, including a new coordinated procedure for authorization of clinical trials that is reminiscent of the mutual recognition procedure for marketing authorization of pharmaceutical products, and increased obligations on sponsors to publish clinical trial results. The coming into effect of the Clinical Trials Regulation has been postponed several times due to technical difficulties with the underlying IT systems that are still ongoing. Currently it is expected to come into force not before December 2021. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new Clinical Trials Regulation seeks to simplify and streamline the approval of clinical trials in the European Union, in particular through a harmonized electronic submission and assessment process for clinical trials conducted in multiple EU Member States. For example, the sponsor will submit a single application for approval of a clinical trial via the clinical trials information system. As part of the application process, the sponsor shall propose a reporting EU Member State, which will coordinate the validation and evaluation of the application. The reporting EU Member State shall consult and coordinate with the other concerned EU Member States. If an application is rejected, it can be amended and resubmitted through the EU portal. If an approval is issued, the sponsor can start the clinical trial in all concerned EU Member States. However, a concerned EU Member State can in limited circumstances declare an &#8220;opt-out&#8221; from an approval. In such a case, the clinical trial cannot be conducted in that EU Member State. The Clinical Trials Regulation also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU database. Information stored in the EU database will be made publicly available subject to transparency rules. </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">National laws, regulations, and the applicable Good Clinical Practice and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines on Good Clinical Practice (&#8220;GCP&#8221;).</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the development of a pharmaceutical product, the European Medicines Agency (&#8220;EMA&#8221;) and national regulators within the EU provide the opportunity for dialogue and guidance on the development program.&#160;&#160;At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party (&#8220;SAWP&#8221;). A fee is incurred with each scientific advice procedure. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU, pediatric data or an approved Pediatric Investigation Plan (&#8220;PIP&#8221;), or deferral or waiver, must be approved by the EMA, prior to submission of a MAA to the EMA or to the competent authorities of the EU Member States&#59; an application has to include </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results of studies as described in an approved PIP, unless the pharmaceutical product is exempt because of a deferral or waiver. In most EU Member States, companies are also required to have an approved PIP before enrolling pediatric patients in a clinical trial.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Authorization Procedures </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the EU and in Iceland, Norway and Liechtenstein (together the European Economic Area or &#8220;EEA&#8221;), pharmaceutical products may only be placed on the market after obtaining a Marketing Authorization (&#8220;MA&#8221;). To obtain an MA of a drug under European Union regulatory systems, an applicant can submit an MAA through, amongst others, a centralized or decentralized procedure. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU Member States and, after national implementing decisions, the three additional member states of the European Economic Area. The centralized procedure is compulsory for specific <span style="color:#000000;">pharmaceutical</span> products, including for medicines produced by certain biotechnological processes, products designated as orphan <span style="color:#000000;">pharmaceutical</span> products, advanced therapy <span style="color:#000000;">pharmaceutical</span> products and <span style="color:#000000;">pharmaceutical</span> products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For <span style="color:#000000;">pharmaceutical</span> products containing a new active substance not yet authorized in the European Economic Area before May 20, 2004 and indicated for the treatment of other diseases, <span style="color:#000000;">pharmaceutical</span> products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a marketing authorization through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a marketing authorization through the centralized procedure. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more. Accelerated evaluation might be granted by the CHMP in exceptional cases when a <span style="color:#000000;">pharmaceutical</span> product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. On request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. However, the European Commission has final authority for granting the MA within 67 days after receipt of the CHMP opinion. Although the United Kingdom has left the European Union on January 31, 2020, the relevant EU laws on marketing authorization procedures and other pharmaceutical laws still apply until the end of the transition period, which is currently expected to last until the end of 2020. Further changes may be forthcoming in the scope of the centralized approval procedure as the terms of the future relationship are still being negotiated between the United Kingdom and the European Union.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decentralized procedure permits companies to file identical MA applications for a pharmaceutical product to the competent authorities in various EU Member States simultaneously if such pharmaceutical product has not received marketing approval in any EU Member State before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The decentralized procedure provides for approval by one or more other, or concerned, EU Member States of an assessment of an application performed by one-member state designated by the applicant, known as the reference EU Member State. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference EU Member State and concerned EU Member States. The reference EU Member State prepares a draft assessment report and drafts of the related materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference EU Member State&#8217;s assessment report and related materials, each concerned EU Member State must decide whether to approve the assessment report and related materials. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a Member State cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the European Commission, whose decision is binding on all EU Member States. </p>
<p style="margin-top:6pt;text-align:justify;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;), describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the MA. RMPs and Periodic Safety Update Reports (&#8220;PSURs&#8221;) are routinely available to third parties requesting access, subject to limited redactions.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketing Authorizations have an initial duration of five years. After these five years, the authorization may be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the European Commission or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Data and Market Exclusivity in the European Union<span style="font-style:normal;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the E</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uropean Union</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received an MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, new chemical entities qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. The overall ten-year period </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">can</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The data exclusivity period begins on the date of the product&#8217;s first MA in the European Union. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant pre-clinical or clinical studies were carried out in relation to the new indication. Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial chance was authorized).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a compound is considered to be a new chemical entity and the sponsor is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the drug if such company can complete a full MAA with a complete database of pharmaceutical test, preclinical tests and clinical trials and obtain marketing approval of its pharmaceutical product. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Development</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, companies developing a new <span style="color:#000000;">pharmaceutical</span> product are obligated to study their product in children and must therefore agree on a PIP with the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;). These companies must conduct pediatric clinical trials in accordance with that PIP, unless a waiver applies, <span style="font-style:italic;">e.g.</span> because the relevant disease or condition occurs only in adults. The marketing authorization application for the <span style="color:#000000;">pharmaceutical</span> product must include the results of pediatric clinical trials conducted in accordance with the PIP, unless a waiver applies, or a deferral has been granted, in which case the pediatric clinical trials must be completed at a later date. <span style="color:#000000;">Pharmaceutical</span> products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan <span style="color:#000000;">pharmaceutical</span> products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similar to the United States, both marketing authorization holders and manufacturers of <span style="color:#000000;">pharmaceutical</span> products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory authorities of the EU Member States. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of <span style="color:#000000;">pharmaceutical</span> products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the EU Member State laws implementing Directive 2001/83/EC on <span style="color:#000000;">pharmaceutical</span> products for human use and other core legislation relating to pharmaceutical products, and other EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of <span style="color:#000000;">pharmaceutical</span> products and marketing of such products, both before and after grant of marketing authorization, manufacturing of <span style="color:#000000;">pharmaceutical</span> products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The holder of an EU marketing authorization for a <span style="color:#000000;">pharmaceutical</span> product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of <span style="color:#000000;">pharmaceutical</span> products.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These pharmacovigilance rules can impose on holders of marketing authorizations the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. Marketing authorization holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of PSURs in relation to </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products for which they hold marketing authorizations The EMA reviews PSURs for </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> products authorized through the centralized procedure. If the EMA has concerns that the risk-benefit profile of a product has varied, it can adopt an opinion advising that the existing marketing authorization for the product be suspended, withdrawn or varied. The Agency can advise that the marketing authorization holder be obliged to conduct post-authorization Phase 4 safety studies. The EMA opinion is submitted to the European Commission for its consideration. If the Commission agrees with the opinion, it can adopt a decision varying the existing marketing authorization. Failure by the marketing authorization holder to fulfill the obligations for which the European Commission&#8217;s decision provides can undermine the on-going validity of the marketing authorization. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the marketing authorization for the <span style="color:#000000;">pharmaceutical</span> product or imposition of financial penalties or other enforcement measures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Advertising and Promotion</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The advertising and promotion of our products is also subject to EU laws concerning promotion of <span style="color:#000000;">pharmaceutical</span> products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU Member States may apply to the advertising and promotion of <span style="color:#000000;">pharmaceutical</span> products and may differ from one country to another. These laws require that promotional materials and advertising in relation to <span style="color:#000000;">pharmaceutical</span> products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the <span style="color:#000000;">pharmaceutical</span> product. It forms an intrinsic and integral part of the marketing authorization granted for the <span style="color:#000000;">pharmaceutical</span> product. Promotion of a <span style="color:#000000;">pharmaceutical</span> product that does not comply with the SmPC is considered to constitute off-label promotion. The off-label promotion of <span style="color:#000000;">pharmaceutical</span> products is prohibited in the European Union. The applicable laws at the EU level and in the individual EU Member States also prohibit the direct-to-consumer advertising of prescription-only <span style="color:#000000;">pharmaceutical</span> products. Violations of the rules governing the promotion of <span style="color:#000000;">pharmaceutical</span> products in the European Union could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pricing and Reimbursement Environment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a <span style="color:#000000;">pharmaceutical</span> product obtains a marketing authorization in the European Union, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. The EU Member States are free to restrict the range of <span style="color:#000000;">pharmaceutical</span> products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of <span style="color:#000000;">pharmaceutical</span> products for human use. An EU Member State may approve a specific price or level of reimbursement for the <span style="color:#000000;">pharmaceutical</span> product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the <span style="color:#000000;">pharmaceutical</span> product on the market, including volume-based arrangements, caps and reference pricing mechanisms.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our product candidates, if any, to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, <span style="color:#000000;">pharmaceutical</span> products launched in the European Union do not follow price structures of the United States and generally published and actual prices tend to be significantly lower. Publication of discounts by third party payers or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The so-called health technology assessment (&#8220;HTA&#8221;) of <span style="color:#000000;">pharmaceutical</span> products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including France, Germany, Ireland, Italy and Sweden. The HTA process, which is governed by the national laws of these countries, is the procedure according to which the assessment of the public health impact, therapeutic impact, and the economic and societal impact of use of a given <span style="color:#000000;">pharmaceutical</span> product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual <span style="color:#000000;">pharmaceutical</span> products as well as their potential implications for the healthcare system. Those elements of <span style="color:#000000;">pharmaceutical</span> products are compared with other treatment options available on the market. The outcome of HTA regarding specific <span style="color:#000000;">pharmaceutical</span> products will often influence the pricing and reimbursement status granted to <span style="color:#000000;">pharmaceutical</span> products by the regulatory authorities of individual EU Member States. A negative HTA of one of our products by a leading and recognized HTA body could not only undermine our ability to obtain reimbursement for such product in the EU Member </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State in which such negative assessment was issued, but also in other EU Member States. For example, EU Member States that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">have not yet developed HTA mechanisms could rely to some extent on the HTA performed in other countries with a developed HTA framework, when adopting decisions concerning the pricing and reimbursement of a specific </span><span style="color:#000000;">pharmaceutical</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 31, 2018, the European Commission adopted a proposal for a regulation on health technology assessment. This legislative proposal is intended to boost cooperation among EU Member States in assessing health technologies, including new <span style="color:#000000;">pharmaceutical</span> products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The proposal provides that EU Member States will be able to use common HTA tools, methodologies and procedures across the European Union, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU Member States will continue to be responsible for assessing non-clinical (<span style="font-style:italic;">e.g.</span>, economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. The European Commission has stated that the role of the draft HTA regulation is not to influence pricing and reimbursement decisions in the individual EU Member States, but there can be no assurance that the draft HTA regulation will not have effects on pricing and reimbursement decisions if and when the draft HTA regulation comes into force.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain reimbursement or pricing approval in some countries, including the EU Member States, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care. There can be no assurance that any country will allow favorable pricing, reimbursement and market access conditions for any of our products, or that we will be feasible to conduct additional cost-effectiveness studies, if required.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain of the EU Member States, <span style="color:#000000;">pharmaceutical</span> products that are designated as orphan <span style="color:#000000;">pharmaceutical</span> products may be exempted or waived from having to provide certain clinical, cost-effectiveness and other economic data in connection with their filings for pricing/reimbursement approval. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">European Data Laws</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The collection and use of personal health data and other personal information in the European Union is governed by the provisions of the GDPR, which came into force in May 2018 and related implementing laws in individual EU Member States. In addition, following the United Kingdom&#8217;s formal departure from the European Union on January 31, 2020, the United Kingdom entered a transition period until December 31, 2020, during which time the GDPR will remain applicable to the United Kingdom. At the end of the transition period, there is uncertainty regarding the future relationship between the United Kingdom and the European Union in relation to data protection. Once the United Kingdom leaves the European Union and the transition period has expired, the United Kingdom will become a &#8220;third country&#8221; for the purposes of data protection law. A &#8220;third country&#8221; is a country other than the EU Member States and the three additional European Economic Area countries (Norway, Iceland and Liechtenstein) that have adopted a national law implementing the GDPR. Under the GDPR, personal data can only be transferred to third countries in compliance with specific conditions for cross-border data transfers. Appropriate safeguards are required to enable transfers of personal data from the EU and EEA Member States. This status has a number of significant practical consequences, in particular for international data transfers, competent supervisory authorities and enforcement of the GDPR. The GDPR increased responsibility and liability in relation to personal data that we process. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR imposes a number of strict obligations and restrictions on the ability to process (processing includes collection, analysis and transfer of) personal data, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification of data processing obligations to the national data protection authorities and the security and confidentiality of the personal data. The GDPR also prohibits the transfer of personal data to countries outside of the European Union that are not considered by the European Commission to provide an adequate level of data protection, except if the data controller meets very specific requirements. These countries include the United States, and following the end of the transition period, it may include the United Kingdom if no adequacy decision is given prior to this. Following the Schrems II decision of the Court of Justice of the European Union on July 16, 2020, there is uncertainty as to the general permissibility of international data transfers under the GDPR. In light of the implications of this decision we may face difficulties regarding the transfer of personal data from the European Union to third countries. The European Data Protection Board has adopted draft recommendations for data controllers and processors who export personal data to third countries regarding supplementary measures to ensure compliance with the GDPR when transferring personal data outside of the European Union. These recommendations were submitted to public consultation until November 30, 2020, however it is unclear when and in which form these recommendations will be published in final form.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU&#160;Member States and the United Kingdom may result in significant monetary fines, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and in certain cases their directors and officers as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU Member States and the United Kingdom may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the European Union and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the United Kingdom. Guidance developed at both EU level and at the national level in individual EU Member States and the United Kingdom concerning implementation and compliance practices are often updated or otherwise revised.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is, moreover, a growing trend towards required public disclosure of clinical trial data in the European Union which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation, EMA disclosure initiatives and voluntary commitments by industry. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the Clinical Trials Regulation and the General Data Protection Regulation, further adds to the complexity that we face with regard to data protection regulation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.52%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Promotional Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU Member States. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of <span style="color:#000000;">pharmaceutical</span> products is prohibited in the European Union. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU Member States. One example is the UK Bribery Act 2010. This Act applies to any company incorporated in or &#8220;carrying on business&#8221; in the United Kingdom, irrespective of where in the world the alleged bribery activity occurs. Violation of these laws could result in substantial fines and imprisonment. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.52%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:1.87%;text-indent:2.67%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Legislation Regarding Marketing, Authorization and Pricing of Pharmaceutical Products in the European Union</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:6pt;text-indent:5.25%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other core legislation relating to the marketing, authorization and pricing of pharmaceutical products in the European Union includes the following:&#160;&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Directive 2001/83/EC, establishing the requirements and procedures governing the marketing authorization for medicinal products for human use, as well as the rules for the constant supervision of products following authorization.&#160;&#160;This Directive has been amended several times, most recently by Directive 2012/26/EU regarding pharmacovigilance, and the Falsified Medicines Directive 2011/62/EU.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Regulation (EC) 726/2004, as amended, establishing procedures for the authorization, supervision and pharmacovigilance of medicinal products for human and veterinary use and establishing the EMA.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Regulation (EC) 469/2009, establishing the requirements necessary to obtain a Supplementary Protection Certificate, which extends the period of patent protection applicable to medicinal products at the EU-level.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Directive 89/105/EEC, ensuring the transparency of measures taken by the European Union member states to set the prices and reimbursements of medicinal products. Specifically, while each member state has competence over the pricing and reimbursement of medicines for human use, they must also comply with this Directive, which establishes procedures to ensure that member state decisions and policies do not obstruct trade in medicinal products. The European Commission proposed to repeal and replace Directive 89/105/EEC, but this proposal was withdrawn in 2015.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Directive 2003/94/EC, laying down the principles of good manufacturing practice in respect of medicinal products and investigational medicinal products for human use </span><span style="font-family:Times New Roman;color:#000000;">(the "GMP Directive")</span><span style="font-family:Times New Roman;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;color:#000000;">Directive 2005/28/EC of April 8, 2005, laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorization of the manufacturing or importation of such products" (the "GCP Directive").</span><span style="font-size:11pt;font-family:Times New Roman;">&#160;&#160;</span></p></td></tr></table></div>
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:3.94%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">New Legislation and Regulations</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:3.94%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, legislation is drafted, introduced and passed in the European Union, its member states and other states of Europe that could significantly change the statutory provisions governing the testing, approval, manufacturing, marketing, coverage and reimbursement of pharmaceutical products. In addition to new legislation, pharmaceutical regulations and policies are often revised or interpreted by the EMA and national agencies in ways that may significantly affect our business and our products.&#160;&#160;&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following the United Kingdom&#8217;s formal departure from the European Union on January 31, 2020, the United Kingdom entered a transition period until December 31, 2020, during which time EU pharmaceutical laws will remain applicable to the United Kingdom as if it remained an EU Member State. After the transition period, however, changes may be forthcoming depending on the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terms of the United Kingdom and European Union&#8217;s future relationship that are negotiated</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> if any.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the date of this filing, we cannot predict the regulatory implications of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the United Kingdom&#8217;s departure from the European Union</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the (i) enforcement of EU </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmaceutical </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">law</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the UK before </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020 </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(which might be less stringent)&#59; and / or (ii) the UK regime on market authorizations</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> following the transition period</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pharmaceutical Coverage, Pricing and Reimbursement<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as, in the United States, Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor&#8217;s decision to provide coverage for a drug product does not necessarily imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on our investment in product development. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider a product to be cost effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, risk sharing, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals. As a result, the marketability of any product which receives regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In particular, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Even if favorable coverage and reimbursement status is attained for one or more products that receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements for any of our products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Healthcare Laws and Regulations<span style="font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with healthcare providers, physicians, third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arrangements and relationships through which we market, sell and distribute products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal healthcare Anti-Kickback Statute prohibits, among other things, persons from soliciting, offering, receiving or providing any remuneration (in cash or in kind), directly or indirectly, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any item, facility or service for which payment may be made in whole or in part under a federal healthcare program such as Medicare and Medicaid&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="color:#000000;font-family:Times New Roman;">the federal&#160;Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) prohibits, among other things, U.S. corporations and persons acting on their behalf from offering, promising, authorizing or making payments to any foreign government official (including certain healthcare professionals in many countries), political party, or political candidate in an attempt to obtain or retain business or otherwise seek preferential treatment abroad&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal False Claims Act, which may be enforced by the U.S. Department of Justice or private whistleblowers to bring civil actions (qui tam actions) on behalf of the federal government, imposes civil penalties, as well as liability for treble damages and for attorneys&#8217; fees and costs, on individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, making a false statement material to a false or fraudulent claim, or improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the Department of Health and Human Services&#8217; Civil Monetary Penalties authorities, which imposes administrative sanctions for, among other things, presenting or causing to be presented false claims for government payment and providing remuneration to government health program beneficiaries to influence them to order or receive healthcare items or services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes criminal and civil liability for, among other conduct, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also imposes criminal and civil liability and penalties on those who violate requirements, including mandatory contractual terms, intended to safeguard the privacy, security, transmission and use of individually identifiable health information&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal false statements statute relating to healthcare matters prohibits falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the federal Physician Payment Sunshine Act requires manufacturers of drugs (among other products) to report to the Centers for Medicare and Medicaid Services within the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals, as well as physician ownership and investment interests in the reporting manufacturers&#59;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">similar state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">certain state laws require pharmaceutical companies to comply with voluntary compliance guidelines promulgated by a pharmaceutical industry association and relevant compliance guidance issues by HHS Office of Inspector General&#59; bar drug manufacturers from offering or providing certain types of payments or gifts to physicians and other health care providers&#59; and/or require disclosure of gifts or payments to physicians and other healthcare providers. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various state and foreign laws also govern the privacy and security of health information in some circumstances&#59; many of these laws differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Certain Financial Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial information required in this Item 1 is included in Part II, Item 6 and Part IV, Item&#160;15 of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Human Capital Management</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Arrowhead Employees</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, Arrowhead employed 232 fulltime employees at three facilities in the US, including Pasadena, CA, Madison, WI and San Diego, CA.&#160;&#160;During FY2020, we grew our capabilities across the three sites by adding 98 new employees.&#160;&#160;The new employees were hired to support and extend our clinical and preclinical pipeline, with hires in commercial, clinical development </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and operations, research, manufacturing, and general and administrative functions. In FY2020, we added a site in San Diego to increase our access to the large talent pool of academic and industry experienced personnel in the area. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc. Employees by Geography</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Number of Employees as of September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Site</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pasadena, CA</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Madison, WI</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, CA</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">232</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to add additional employees in FY2021 with a focus on expanding our inhouse manufacturing capacity, as well as increasing expertise and bandwidth in clinical and preclinical research and development.&#160;&#160;The Company continually evaluates the business need and opportunity and balances in house expertise and capacity with outsourced expertise and capacity.&#160;&#160;Currently, we outsource substantial clinical trial work to clinical research organizations and certain drug manufacturing to contract manufacturers.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug development is a complex endeavor which requires deep expertise and experience across a broad array of disciplines.&#160;&#160;Pharmaceutical companies both large and small compete for a limited number qualified applicants to fill specialized positions.&#160;&#160;To attract qualified applicants to the Company, Arrowhead offers a total rewards package consisting of base salary and cash target bonus targeting the 50<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> to 75<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> percentile of market based on geography, a comprehensive benefit package and equity compensation for every employee.&#160;&#160;Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility.&#160;&#160;Actual bonus payout is based on performance.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A large majority of Arrowhead&#8217;s employees have obtained advanced degrees in their professions.&#160;&#160;Arrowhead supports our employees&#8217; further development with individualized development plans, mentoring, coaching, group training, conference attendance and financial support including tuition reimbursement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Response to COVID-19</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning in March 2020, Arrowhead has supported our employees and government efforts to curb the COVID-19 pandemic through a multifaceted communication, infrastructure, and behavior modification and enforcement effort:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Establishing clear and regular COVID-19 policies, safety protocols, and updates to all employees&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Decreasing density and increasing physical distancing in workspaces for employees working onsite by scheduling adjustments and adding work from home flexibility&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Adjusting attendance policies to encourage those who are sick to stay home&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Increasing cleaning protocols across all locations&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Providing additional personal protective equipment and cleaning supplies&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Implementing protocols to address actual and suspected COVID-19 cases and potential exposure&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Prohibiting all domestic and international non-essential travel for all employees&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:8pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">Requiring masks to be worn in all locations.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we established a childcare subsidy fund to support employees who incurred additional expenses related to the loss of in person schooling and childcare.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Corporate Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead was originally incorporated in South Dakota in 1989 and was reincorporated in Delaware in 2000. In April 2016, Arrowhead changed its name from Arrowhead Research Corporation to Arrowhead Pharmaceuticals, Inc. The Company&#8217;s principal executive offices are located at 177 E. Colorado Blvd, Suite 700, Pasadena, California 91105, and its telephone number is (626)&#160;304-3400. We also operate research and development facilities in Madison, Wisconsin and San Diego, California. </p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investor Information</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our website address is <span style="text-decoration:underline;color:#000000;">http://www.arrowheadpharmaceuticals.com.</span>&#160;&#160;Our reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, including our annual reports on Form 10-K, our quarterly reports on Form 10-Q and our current reports on Form 8-K, and amendments to those reports, are accessible through our website, free of charge, as soon as reasonably practicable after these reports are filed electronically with, or otherwise furnished to, the SEC. These SEC reports can be accessed through the &#8220;Investors&#8221; section of our website. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding Arrowhead and other issuers that file electronically with the SEC. The SEC&#8217;s Internet website address is </span><span style="text-decoration:underline;color:#000000;">http://www.sec.gov</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:10.27%;text-indent:-10.27%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item1A_RiskFactors"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">RISK F</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ACTORS </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should carefully consider the risks discussed below and all of the other information contained in this report in evaluating us and an investment in our securities. If any of the following risks and uncertainties should occur, they could have a material adverse effect on our business, financial condition or results of operations. In that case, the trading price of our Common Stock could decline. Many of the following risks and uncertainties may be exacerbated by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. Additionally, we note that we have accrued net losses annually since inception given the stage of our drug development. We urge you to consider our likelihood of success and prospects in light of the risks, expenses and difficulties frequently encountered by entities at similar stages of development. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Risks Related to Our Discovery, Development, and Commercialization of Medicines</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our results of operations and financial condition may be adversely affected by the novel coronavirus (COVID-19) pandemic and other public health epidemics.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business and its operations, including but not limited to our research and development activities and our supply chain, could be adversely affected by health epidemics in regions where we have business operations, and such health epidemics could cause significant disruption in the operations of third parties upon whom we rely. In December 2019, a novel strain of coronavirus, SARS-CoV-2, causing a disease referred to as COVID-19, was reported to have surfaced in Wuhan, China. In response to public health directives and orders related to COVID-19, we have implemented work-from-home policies for substantially all of our employees to the extent work can be performed effectively at home. The effects of executive and similar government orders, shelter-in-place orders and our work-from-home policies may negatively impact our productivity, disrupt our business, increase our expenses, including costs associated with preventive and precautionary measures that we, companies with which we conduct business, and governments are taking, and delay our clinical trials and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, results of operations and financial condition.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarantines, shelter-in-place, executive and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases, have impacted and may continue to impact personnel at our business partners in the United States and other countries, or our access to raw materials for our research and development facility discovery efforts, which would disrupt our supply chain.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our clinical trials have been and may continue to be affected by the COVID-19 pandemic. For example, during fiscal year 2020, we temporarily paused enrollment in our two ARO-AAT studies: SEQUOIA and the ARO-AAT 2002 study but resumed the process of screening and enrolling patients during the year ended September 30, 2020. During the pause in enrollment, patients already enrolled in these studies continued to be dosed per protocol and continued to come in for their follow up visits. Additional delays have occurred in the Company&#8217;s earlier stage programs, but we do not expect a material impact to any program&#8217;s anticipated timelines. Several of the Company&#8217;s other clinical candidates are in the start-up stage (ARO-HSD, ARO-HIF2 and ARO-ENaC), during which significant clinical costs will continue to be incurred.&#160;&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters in Pasadena, California have continued to operate with limited impact, other than for enhanced safety measures, including work from home policies. However, the Company cannot predict the impact of the progression of COVID-19 will have on future financial results due to a variety of factors including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees, and ultimately the length of the COVID-19 pandemic. If COVID-19 continues to spread in the United States and elsewhere, we may experience additional disruptions that could severely impact our business, preclinical studies and clinical trials, including:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">delays in receiving authorization from local regulatory authorities to initiate any planned clinical trials&#59;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">delays or difficulties in enrolling patients in our clinical trials&#59;</span><span style="color:#000000;font-family:Times New Roman;">&#160;&#160;</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;"></span>&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials&#59;</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:7pt;">changes in local regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether&#59;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">diversion of healthcare resources away from the conduct of clinical trials, including the&#160;diversion of hospitals serving as our clinical trial sites and hospital staff supporting the&#160;conduct of our clinical trials&#59;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">interruption of key clinical trial activities, such as clinical trial site monitoring and data entry and verification, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;">and study procedures, the occurrence of which could affect the completeness and integrity of clinical trial data and, as a result, the determine the outcomes of the trial&#59;</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events&#59;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">risk that participants enrolled in our clinical trials will not be able to travel to our clinical trial sites as a result of quarantines or other restrictions resulting from COVID-19&#59;</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">risk that participants enrolled in our clinical trials will not be able to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services&#59;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">interruptions or delays in preclinical studies due to restricted or limited operations at our research and development laboratory facilities&#59;</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees&#59;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59;</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:13.5pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">refusal of the FDA to accept data from clinical trials in affected geographies&#59; and</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span><span style="color:#000000;font-family:Times New Roman;margin-left:17pt;">interruption or delays to our clinical activities.</span></p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by COVID-19, and the duration of such impact, may be difficult to assess or predict, the widespread pandemic has resulted in significant disruption of global financial markets, which could reduce our ability to access capital and negatively affect our future liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 and related government orders and restrictions could materially affect our business and the value of our common stock.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar public health emergency is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems, or the global economy as a whole. However, any one or a combination of these events could have an adverse effect on our results of operations and financial condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">There are substantial risks inherent in attempting to commercialize our new drugs, and, as a result, we may not be able to successfully develop products for commercial use. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development efforts involve therapeutics based on RNA interference and our delivery systems, which are largely unproven technologies. Our scientists and engineers are working on developing technology in the early stages. However, such technology&#8217;s commercial feasibility and acceptance are unknown. Scientific research and development requires significant amounts of capital and takes a long time to reach commercial viability if it can be achieved at all. To date, our research and development projects have not produced commercially viable drugs and may never do so. During the research and development process, we may experience technological barriers that we may be unable to overcome. Further, certain underlying premises in our development programs are not proven.&#160;&#160;For instance, the reduction of the production of mutant alpha-1 antitrypsin in the liver may not lead to a reduction of globules in the liver, and even if it leads to a reduction in such globules, this may not lead to other beneficial hepatic changes.&#160;&#160;It is also unknown at this time what changes in the liver may be required to gain regulatory approval and/or favorable reimbursement for a drug that reduces the production of mutant alpha-1 antitrypsin in the liver.&#160;&#160;Similar uncertainties and risks exist that are specific to each of our development programs.&#160;&#160;Because of these and similar uncertainties, it is possible that no commercial products will be successfully developed. If we are unable to successfully develop commercial products, we will be unable to generate revenue or build a sustainable or profitable business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">There can be no assurance that our product candidates will obtain regulatory approval. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The sale of human therapeutic products in the United States and foreign jurisdictions is subject to extensive and time consuming regulatory approval which requires, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">controlled research and human clinical testing&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">establishment of the safety and efficacy of the product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">government review and approval of a submission containing manufacturing, pre-clinical and clinical data&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">adherence to cGMP regulations during production and storage.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product candidates we currently have under development will require significant development, pre-clinical and clinical testing and investment of significant funds to gain regulatory approval before they can be commercialized. The results of our research </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and human clinical testing of our products may not meet regulatory requirements.&#160;&#160;Some of our product candidates, if approved, will require the completion of post-market studies. There can be no assurance that any of our products will be further developed and approved. The process of completing clinical testing and obtaining required approvals will take a number of years and require the use of substantial resources. Further, there can be no assurance that product candidates employing a new technology will be shown to be safe and effective in clinical trials or receive applicable regulatory approvals. If we fail to obtain regulatory approvals for any or all of our products, we will not be able to market such product and our operations may be adversely affected. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If testing of a particular product candidate does not yield successful results, then we will be unable to commercialize that product candidate. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We must demonstrate our product candidates&#8217; safety and efficacy in humans through extensive clinical testing. Our research and development programs are at an early stage of development. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of any products, including the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">the results of pre-clinical studies may be inconclusive, or they may not be indicative of results that will be obtained in human clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">safety and efficacy results attained in early human clinical trials may not be indicative of results that are obtained in later clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">after reviewing test results, we may abandon projects that we might previously have believed to be promising&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">we or our regulators may suspend or terminate clinical trials because the participating subjects or patients are being exposed to unacceptable health risks&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">our product candidates may not have the desired effects or may include undesirable side effects or other characteristics that preclude regulatory approval or limit their commercial use if approved.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Topline data may not accurately reflect the complete results of a particular study or trial. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may publicly disclose topline or interim data from time to time, which is based on a preliminary analysis of then-available efficacy and safety data such as the data reported from the AROAAT2002, AROANG31001, and AROAPOC31001 clinical studies which are based on preliminary analysis of key efficacy and safety data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or drug and our company in general. In addition, the information we may publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from a future analysis of results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">It may take us longer than we project to complete clinical trials, and we may not be able to complete them at all. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although for planning purposes, we project the commencement, continuation and completion of our clinical trials, a number of factors, including scheduling conflicts with participating clinicians and clinical institutions, and difficulties in identifying or enrolling patients who meet trial eligibility criteria, may cause significant delays. Enrollment of clinical trials may be particularly difficult in orphan diseases or limited-sized patient populations.&#160;&#160;The FDA or other regulatory bodies may require additional, longer or broader clinical trials to establish safety and effectiveness, notwithstanding guidance the Company may have received from those bodies during clinical trial planning and execution.&#160;&#160;Further, the cost for conducting clinical trials is significant and if our cash resources become limited we may not be able to commence, continue, and/or complete our clinical trials.&#160;&#160;We may not commence or complete clinical trials involving any of our product candidates as projected or may not conduct them successfully. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fast Track designation for </span><span style="color:#000000;">ARO-AAT </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may not lead to a faster development or review process.</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been granted a Fast Track designation for <span style="color:#000000;">ARO-AAT </span>in the United States for the treatment of liver disease associated with AATD.&#160;&#160;Fast Track designation is intended to facilitate the development and expedite the review of new therapies to treat serious conditions with unmet medical needs by providing sponsors with the opportunity for frequent interactions with the FDA. Fast Track designation applies to the combination of the drug candidate and the specific indication for which it is being studied. Product candidates that receive Fast Track designation may receive more frequent interactions with the FDA regarding the product candidate&#8217;s development plan and clinical trials and may be eligible for the FDA&#8217;s Rolling Review. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite receiving Fast Track designation, ARO-AAT may not actually receive faster clinical development or regulatory review or approval any sooner than other product candidates that do not have such designation, or at all. Furthermore, such a designation does not increase the likelihood that ARO-AAT will receive marketing approval in the United States. The FDA may also withdraw Fast Track if it determines that ARO-AAT no longer meets the relevant criteria.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our product candidates are approved for commercialization, failure to comply with regulatory requirements or unanticipated problems with our products may result in various adverse actions such as the suspension or withdrawal of one or more of our products, closure of a facility or enforcement of substantial penalties or fines. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval to sell any of our product candidates is received, regulatory agencies will subject any marketed product(s), as well as the manufacturing facilities, to continual review and periodic inspection. If  previously unknown problems with a product or with regulatory requirements are discovered, such as adverse events of unanticipated severity or frequency, problems with a manufacturing process or laboratory facility, or failure to comply with applicable regulatory approval requirements, a regulatory agency may impose restrictions or penalties on that product or on us. Such restrictions or penalties may include, among other things: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">restrictions on the marketing or manufacturing of our products, the withdrawal of the product from the market, or product recalls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">warning letters or holds on clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">closure of the facility, enforcement of substantial fines, injunctions, or the imposition of civil or criminal penalties. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if our product candidates are approved for commercialization, future regulatory reviews or inspections may result in the suspension or withdrawal of one or more of our products, closure of a facility or enforcement of substantial fines. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval to sell any of our product candidates is received, regulatory agencies will subject any marketed product(s), as well as the manufacturing facilities, to continual review and periodic inspection. If previously unknown problems with a product or manufacturing and laboratory facility are discovered, or we fail to comply with applicable regulatory approval requirements, a regulatory agency may impose restrictions on that product or on us. The agency may require the withdrawal of the product from the market, closure of the facility or enforcement of substantial fines. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by clinical trial participants, consumers, health-care providers, pharmaceutical companies, or others selling our products. If we cannot successfully defend ourselves against these claims, we may incur substantial liabilities. Regardless of merit or eventual outcomes of such claims, product liability claims may result in: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.94%;">
<tr>
<td valign="top" style="width:3.32%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top" style="width:96.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">decreased demand for our product candidates&#59;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.94%;">
<tr>
<td valign="top" style="width:3.32%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top" style="width:96.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">impairment of our business reputation&#59;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.94%;">
<tr>
<td valign="top" style="width:3.32%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top" style="width:96.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">withdrawal of clinical trial participants&#59;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.94%;">
<tr>
<td valign="top" style="width:3.32%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top" style="width:96.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs of litigation&#59;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.94%;">
<tr>
<td valign="top" style="width:3.32%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top" style="width:96.66%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">substantial monetary awards to patients or other claimants&#59; and</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.94%;">
<tr>
<td valign="top" style="width:3.32%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top" style="width:96.68%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">loss of revenues.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
</td>
<td valign="top">
</td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
</td>
<td valign="top">
</td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our insurance coverage may not be sufficient to reimburse us for all expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of any approved drug candidate will depend in part on the availability of coverage and reimbursement from third-party payers such as government insurance programs, including Medicare and Medicaid, private health insurers, health maintenance organizations and other health care related organizations, who are increasingly challenging the price of medical products and services. Accordingly, coverage and reimbursement may be uncertain. Adoption of any drug by the medical community may be limited if third-party payers will not offer coverage. Additionally, significant uncertainty exists as to the reimbursement status of newly approved drugs. &#160;Cost control initiatives may decrease coverage and payment levels for any drug and, in turn, the price that we will be able to charge and/or the volume of our sales. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payers. Any denial of private or government payer coverage or inadequate reimbursement could harm our business and reduce our revenue. If we partner with third parties with respect to any of our product candidates, we may be reliant on that partner to obtain reimbursement from government and private payors for the drug, if approved, and any failure of that partner to establish adequate reimbursement could have a negative impact on our revenues and profitability. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, both the federal and state governments in the United States and foreign governments continue to propose and pass new legislation, regulations, and policies affecting coverage and reimbursement rates, which are designed to contain or reduce the cost of health care.&#160;&#160;Further federal and state proposals and healthcare reforms are likely, which could limit the prices that can be charged for the product candidates that we develop and may further limit our commercial opportunity. There may be future changes that result in reductions in potential coverage and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If future reimbursement for approved product candidates, if any, is substantially less than we project, or rebate obligations associated with them are substantially greater than we expect, our future net revenue and profitability could be materially diminished. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not enjoy the market exclusivity benefits of our orphan drug designations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.2%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we may obtain orphan designations in the treatment of certain diseases our products are intended to treat, the designation may not be applicable to any particular product we might get approved and that product may not be the first product to receive approval for that indication.&#160;&#160;Under the Orphan Drug Act, the first product with an orphan designation receives market exclusivity, which prohibits the FDA from approving the &#8220;same&#8221; drug for the same indication.&#160;&#160;The FDA has stated that drugs can be the &#8220;same&#8221; even when they are not identical but has not provided guidance with respect to how it will determine &#8220;sameness&#8221; for RNAi drugs.&#160;&#160;It is possible that another RNAi drug could be approved for the treatment of a disease one of our orphan products is intended to treat before our product is approved, which means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval until the first product&#8217;s orphan drug exclusivity period expires or we demonstrate, if we can, that our product is superior. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Further, orphan drug exclusivity can be lost if the FDA later determines that the request for designation was materially defective or if the applicant is unable to assure the availability of sufficient quantities of the drug to meet the needs of patients with the disease or condition for which the drug was designated.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our success depends on the attraction and retention of senior management and scientists with relevant expertise. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future success depends to a significant extent on the continued services of our key employees, including our senior scientific, technical and managerial personnel. We do not maintain key person life insurance for any of our executives and we do not maintain employment agreements with many senior employees. Competition for qualified employees in the pharmaceutical industry is high, and our ability to execute our strategy will depend in part on our ability to continue to attract and retain qualified scientists and management. If we are unable to find, hire and retain qualified individuals, we will have difficulty implementing our business plan in a timely manner, or at all. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Risks Related to Our Intellectual Property</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed rights to pending patents and have filed and expect to continue to file patent applications. Researchers sponsored by us may also file patent applications that we may need to license. Such patent applications may not be available for licensing or may not be economically feasible to license.&#160;&#160;Certain of our patents may not be granted or may not contain claims of the necessary breadth because, for example, prior patents exist.&#160;&#160;If a particular patent is not granted, the value of the invention described in the patent would be diminished. Further, even if these patents are granted, they may be difficult to enforce. Even if ultimately successful, efforts to enforce our patent rights could be expensive, distracting for management, cause our patents to be invalidated or held unenforceable, and thus frustrate commercialization of products. Even if patents are issued and are enforceable, others may develop similar, superior or parallel technologies to any technology developed by us and not infringe on our patents.&#160;&#160;Our technology </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may prove to infringe upon patents or rights owned by others. Patent prosecution and maintenance is expensive, and we may be forced to curtail prosecution or maintenance if our cash resources are limited. Thus, the patents held by or licensed to us may not afford us any meaningful competitive advantage. If we are unable to derive value from our licensed or owned intellectual property, the value of your investment may decline. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are party to technology license agreements with third parties that require us to satisfy obligations to keep them effective and, if these agreements are terminated, our technology and our business would be seriously and adversely affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to license agreements to incorporate third party proprietary technologies into our drug products under development. These license agreements require us to pay royalties and satisfy other conditions. If we fail to satisfy our obligations under these agreements, the terms of the licenses may be materially modified, such as by rendering currently exclusive licenses non-exclusive, or it may give our licensors the right to terminate their respective agreement with us, which could limit our ability to implement our current business plan and harm our business and financial condition. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our potential products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the intellectual property landscape in the fields in which we participate is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate without infringing on third party rights. However, if granted marketing approval, we are currently aware of certain patent rights held by third parties that, if found to be valid and enforceable, could be alleged to render one or more of our drug candidates infringing. If a claim should be brought and is successful, we may be required to pay substantial damages, be forced to abandon any affected drug candidates and/or seek a license from the patent holder. In addition, any patent infringement claims brought against us, whether or not successful, may cause us to incur significant expenses and divert the attention of our management and key personnel from other business concerns. These could negatively affect our results of operations and prospects. We cannot be certain that patents owned or licensed by us will not be challenged, potentially successfully, by others. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our customers, licensees, and other parties with whom we have business relationships and we may be required to indemnify those parties for any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of customers, licensees, and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, we may be unable to continue selling such products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We license patent rights from third-party owners and we rely on such owners to obtain, maintain and enforce the patents underlying such licenses. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. We also expect to enter into additional licenses to third-party intellectual property in the future. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success will depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents are issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our technology licensed from various third parties may be subject to retained rights. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, while the company undertakes efforts to protect its trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span><span style="color:#000000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to effectively secure first-tier technologies when competing against other companies or investors. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future success may require that we acquire patent rights and know-how to new or complimentary technologies. However, we compete with a substantial number of other companies that may also compete for technologies we desire. In addition, many venture capital firms and other institutional investors, as well as other pharmaceutical and biotech companies, invest in companies seeking to commercialize various types of emerging technologies. Many of these companies have greater financial, scientific and commercial resources than us. Therefore, we may not be able to secure the technologies we desire. Furthermore, should any commercial undertaking by us prove to be successful, there can be no assurance competitors with greater financial resources will not offer competitive products and/or technologies. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Risks Related to Our Business Model</span></p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business model assumes we will generate revenue by, among other activities, marketing or out-licensing the products we develop.&#160;&#160;Our drug candidates are in the early stages of development and because we have a short development history with both RNA interference and our delivery technologies, there is a limited amount of information about us upon which you can evaluate our business and prospects. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no approved drugs and thus have not begun to market or generate revenues from the commercialization of any products. We have only a limited history upon which one can evaluate our RNAi therapeutic business as our drug candidates are still at an early stage of development. Thus, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to execute our business plan, we will need to successfully: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Execute product development activities using unproven technologies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Build, maintain, and protect a strong intellectual property portfolio&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Demonstrate safety and efficacy of our drug candidates in multiple human clinical studies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Receive FDA approval and approval from similar foreign regulatory bodies&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Gain market acceptance for the development and commercialization of any drugs we develop&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Ensure our products are reimbursed by commercial and/or government payors at a rate that permits commercial viability&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Develop and maintain successful strategic relationships with suppliers, distributors, and commercial licensing partners&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Manage our spending and cash requirements as our expenses will increase in the near term if we add programs and additional preclinical and clinical trials&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Effectively market any products for which we obtain marketing approval.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unsuccessful in accomplishing these objectives, we may not be able to develop products, raise capital, expand our business or continue our operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may need to establish additional relationships with strategic and development partners to fully develop our drug candidates and market any approved products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over the past three years we have entered into license and collaboration agreements with Takeda, Janssen and Amgen. Our business strategy includes obtaining additional collaborations with other pharmaceutical and biotech companies to support the development of our RNAi therapeutics and other drug candidates. We do not possess all of the financial and development resources necessary to develop and commercialize products that may result from our technologies. Unless we expand our product development capacity and enhance our internal marketing capability, we may need to make appropriate arrangements with strategic partners to develop and commercialize any drug candidates that may be approved. We may not be able to attract such partners, and even if we are able to enter into such partnerships, the terms may be less favorable than anticipated. Further, entering into partnership agreements may limit our commercialization options and/or require us to share revenues and profits with our partners. If we do not find appropriate partners, or if our existing arrangements or future agreements are not successful, our ability to develop and commercialize products could be adversely affected. Even if we are able to find collaborative partners, the overall success of the development and commercialization of product candidates in those programs will depend largely on the efforts of other parties and will be beyond our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">control. In addition, in the event we pursue our commercialization strategy through collaboration or licenses to third parties, there are a variety of technical, business and legal risks, including: </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We may not be able to control the amount and timing of resources that our collaborators may be willing or able to devote to the development or commercialization of our drug candidates or to their marketing and distribution&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates or that result in costly litigation or arbitration that diverts our management&#8217;s resources.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any of the above events or other related events could impair our ability to generate revenues and harm our business and financial condition. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to generate milestone and royalty payments under our current and potential future licensing and collaboration agreements is substantially controlled by our partners, and as such, we will likely need other sources of financing to continue to develop our internal drug candidates.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For instance, under our licensing and collaboration agreements with Amgen, Janssen and Takeda, our partners substantially control clinical development and commercialization for all of the candidates discussed. To the extent that i) either of these partners interests in advancing these candidates or targets changes, ii) unforeseen scientific issues with the candidates arise or iii) the pace at which either moves the candidates through clinical trials toward commercialization slows, our ability to collect milestones and royalties may be significantly diminished.&#160;&#160;This would further cause us to rely upon other sources of financing to continue to develop our other internal drug candidates.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may lose a considerable amount of control over our intellectual property and may not receive anticipated revenues in strategic transactions, particularly where the consideration is contingent on the achievement of development or sales milestones. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business model has been to develop new technologies and to utilize the intellectual property created through the research and development process to develop commercially successful products. If the acquirers of our technologies fail to achieve performance milestones, we may not receive a significant portion of the total value of any sale, license or other strategic transaction. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need to achieve commercial acceptance of our drug candidates to generate revenues and achieve profitability. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our research and development efforts yield technologically feasible applications, we may not successfully develop commercial products. &#160;Drug development takes years of study in human clinical trials prior to regulatory approval, and, even if we are successful, it may not be on a timely basis. During our drug development period, superior competitive technologies may be introduced which could diminish or extinguish the potential commercial uses for our drug candidates. Additionally, the degree to which the medical community and consumers will adopt any product we develop is uncertain. The rate and degree of market acceptance of our products will depend on a number of factors, including the establishment and demonstration in the medical community of the clinical efficacy and safety of our products, their potential advantage over alternative treatments, and the costs to patients and third-party payors, including insurance companies and Medicare. Recent efforts in the United States and abroad to reduce overall healthcare spending has put significant pressure on the price of prescription drugs and certain companies have been publicly criticized for the relatively high cost of their therapies.&#160;&#160;These pressures may force us to sell any approved drugs at a lower price than we or analysts may anticipate or may result in lower levels of reimbursement and coverage from third parties.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict whether significant commercial market acceptance for our products, if approved, will ever develop, and we cannot reliably estimate the projected size of any such potential market. Our revenue growth and achievement of consistent profitability will depend substantially on our ability to introduce products that will be accepted by the medical community. If we are unable to cost-effectively achieve acceptance of our technology among the medical establishment and patients, or if the associated products do not achieve wide market acceptance, our business will be materially and adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on outside sources for various components and processes for our products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third parties for various components and processes for our product candidates. We may not be able to achieve multiple sourcing because there may be no acceptable second source, other companies may choose not to work with us, or the component or process sought may be so new that a second source does not exist or does not exist on acceptable terms. There may be a disruption or delay in the performance of our third-party contractors, suppliers or collaborators which is beyond our control. If such third parties are unable to satisfy their commitments to us, the development of our products would be adversely affected. Therefore, it is possible that our development plans will have to be slowed down or stopped completely at times due to our inability to obtain required raw materials, components, and outsourced processes at an acceptable cost, if at all, or to get a timely response from vendors. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have limited manufacturing capability and must rely on third-party manufacturers to manufacture our clinical supplies and commercial products, if and when approved, and if they fail to meet their obligations, the development and commercialization of our products could be adversely affected. &#160; </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited manufacturing capabilities and experience. Our drug candidates are composed of multiple components and require specialized formulations for which scale-up and manufacturing could be difficult. We have limited experience in such scale-up and manufacturing requiring us to depend on a limited number of third parties, who may not be able to deliver in a timely manner, or at all. In order to develop products, apply for regulatory approvals, and commercialize our products, we will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. Our internal GMP manufacturing capabilities are limited to small-scale production of material.&#160;&#160;There are a limited number of manufacturers that supply synthetic oligonucleotides. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our contract manufacturers to meet our delivery time requirements or provide adequate amounts of material to meet our needs. Included in these risks are synthesis and purification failures and contamination during the manufacturing process, which could result in unusable product and cause delays in our development process, as well as additional expense to us. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, our product candidates have not yet been manufactured for commercial use. If any of our product candidates become approved for commercial sale, we will need to establish either internal or third-party manufacturing capacity. Manufacturing partner requirements may require us to fund capital improvements, perhaps on behalf of third parties, to support the scale-up of manufacturing and related activities. We may not be able to establish scaled manufacturing capacity for an approved product in a timely or economic manner, if at all. If we or our third-party manufacturers are unable to provide commercial quantities of such an approved product, we will have to successfully transfer manufacturing technology to a different manufacturer. Engaging a new manufacturer for such an approved product could require us to conduct comparative studies or utilize other means to determine bioequivalence of the new and prior manufacturers&#8217; products, which could delay or prevent our ability to commercialize such an approved product. If we or any of these manufacturers is unable or unwilling to increase its manufacturing capacity or if we are unable to establish alternative arrangements on a timely basis or on acceptable terms, the development and commercialization of such an approved product may be delayed or there may be a shortage in supply. Any inability to manufacture our product candidates or future approved drugs in sufficient quantities when needed would seriously harm our business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers of our approved products, if any, must comply with cGMP requirements relating to methods, facilities and controls used in the manufacturing, processing and packaging of the product, which are intended to ensure that drug products are safe and that they consistently meet applicable requirements and specifications.&#160;&#160;These requirements include quality control, quality assurance, and the maintenance of records and documentation. Manufacturers of our approved products, if any, may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. These requirements are enforced by the FDA and other health authorities through periodic announced and unannounced inspections of manufacturing facilities.&#160;&#160;A failure to comply with these requirements or to provide adequate and timely corrective actions in response to deficiencies identified in an inspection may result in enforcement action, including warning letters, fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, plant shutdown, or the delay, withholding, or withdrawal of product approval. If the safety of any quantities supplied is compromised due to a manufacturer&#8217;s failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, which would seriously harm our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, the development of our products may be adversely affected. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We contract with certain third-parties to provide certain services, including site selection, enrollment, monitoring and data management services. We rely on these parties to carry out our clinical trials in compliance with GCP and other relevant requirements.&#160;&#160;Although we depend heavily on these parties, we do not control them and therefore we cannot be assured that these third-parties will adequately perform all of their contractual obligations to us. These third parties may face disruptions due to the COVID-19 pandemic that may affect our ability to initiate and complete our clinical studies.&#160;&#160;If our third-party service providers cannot adequately and timely fulfill their obligations to us, or if the quality and accuracy of our clinical trial data is compromised due to failure by such third parties to adhere to our protocols, GCP, or other regulatory requirements or if such third-parties otherwise fail to meet deadlines, our development plans may be delayed or terminated. Further, if clinical study results are compromised, then we may need to repeat the affected studies, which could result in significant additional costs and delays to us. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face competition from various entities including large pharmaceutical companies, small biotech companies, private companies, and research institutions.<span style="color:#000000;font-weight:normal;font-style:normal;">&#160;&#160;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many <span style="color:#000000;">of our competitors have greater financial resources and may have more experience in research and development, manufacturing, managing clinical trials and/or regulatory compliance than we do.&#160;&#160;Our competitors may compete with us for lead </span></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">clinical trial investigators, clinical trial site locations and patient enrollment.&#160;&#160;These competitors may also compete with us on recruiting scientific and management personnel.&#160;&#160;Because our products are in the early stages of development, along with many of the competing products, and given unpredictability inherent in drug development, it is difficult to predict which third parties may provide the most competition, and on what specific basis that competition may be based. </span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may have difficulty expanding our operations successfully as we evolve from a company primarily involved in discovery and pre-clinical testing into one that develops and commercializes drugs. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that as we increase the number of product candidates we are developing we will also need to expand our operations. This expected growth may place a strain on our administrative and operational infrastructure. As product candidates we develop enter and advance through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities for us. As our operations expand due to our development progress, we expect that we will need to manage additional relationships with various collaborators, suppliers, and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business and operations could suffer in the event of information technology system failures. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, ransomware and other cyber-attacks, human error, natural disasters, terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations and loss of intellectual property. For example, the loss of pre-clinical trial data or data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory filings and development efforts and significantly increase our costs. Further, cybersecurity breaches may allow hackers access to our preclinical compounds, strategies, discoveries, trade secrets, and/or other confidential information.&#160;&#160;To the extent that any disruption or security breach were to result in a loss of or damage to our data, or inappropriate disclosure of confidential, proprietary or private information, we could incur liability or regulatory penalties, including under laws and regulations governing the protection of health and other personally identifiable information, we could lose valuable trade secret rights, the development of our product candidates could be delayed, and we could suffer reputational damage and damage to key business relationships.&#160;&#160;The risk of a cyber-security breach or other informational technology disruption, particularly through cyber-attacks, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We have experienced cyber-security attacks in the past, which to date have not had a material impact on our operations or development programs&#59; however&#59; there is no assurance that such impacts will not be material in the future. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research, development and manufacturing activities involve the use of potentially harmful biological materials as well as materials, chemicals and various radioactive compounds that could be hazardous to human health and safety or the environment. We store most of these materials and various wastes resulting from their use at our facility in Madison, Wisconsin pending ultimate use and disposal. We cannot completely eliminate the risk of contamination, which could cause interruption to our research and development and manufacturing efforts, injury to our employees and others, environmental damage, and liabilities under federal, state and local law.&#160;&#160;In such an event, we may be held liable for any resulting damages, and any liability could exceed our resources. Although we carry insurance in amounts and types that we consider commercially reasonable, we do not have insurance coverage for losses relating to an interruption of our research, development or manufacturing efforts caused by contamination, and the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be affected. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If a natural or man-made disaster strikes our research and development facility or otherwise affects our business, it could delay our progress developing our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct research and development in facilities in Madison, Wisconsin and San Diego, California.&#160;&#160;The facilities and the equipment we use are costly to replace and require substantial lead time to repair or replace. Our facilities may be harmed by natural or man-made disasters, including, without limitation, earthquakes, floods, fires and acts of terrorism&#59; and if our facilities are affected by a disaster, our development efforts would be delayed.&#160;&#160;Significant delays in our development efforts could materially impact our ability to obtain regulatory approval and to commercialize our products.&#160;&#160;Any insurance we maintain against damage to our property and the disruption of our business due to disaster may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.&#160; In addition, our development activities could be harmed or delayed by a shutdown of the U.S. government, including the FDA.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Litigation claims may result in financial losses or harm our reputation and may divert management resources.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When the market price of a stock is volatile, holders of that stock have often initiated securities class action litigation against the company that issued the stock. We cannot predict with certainty the eventual outcome of such litigation, arbitration or third-party inquiry. We may not be successful in defending ourselves or asserting our rights in current or future lawsuits, investigations, or claims that have been or may be brought against us and, as a result, our business could be materially harmed. These lawsuits, arbitrations, investigations or claims may result in large judgments or settlements against us, any of which could have a negative effect on our financial performance and business. Additionally, lawsuits, arbitrations and investigations can be expensive to defend, whether or not the lawsuit, arbitration or investigation has merit, and the defense of these actions may divert the attention of our management and other resources that would otherwise be engaged in running our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Risks Related to Our Financial Condition </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses since our inception and we expect that our operating losses will continue for the foreseeable future as we continue our drug development and discovery efforts. To achieve profitability, we must, either directly or through licensing and/or partnering relationships, meet certain milestones, successfully develop and obtain regulatory approval for one or more drug candidates and effectively manufacture, market and sell any drugs we successfully develop. Even if we successfully commercialize drug candidates that receive regulatory approval, we may not be able to realize revenues at a level that would allow us to achieve or sustain profitability. Accordingly, we may never generate significant revenue and, even if we do generate significant revenue, we may never achieve consistent profitability. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will require substantial additional funds to complete our research and development activities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business currently does not generate the cash that is necessary to finance our operations. Subject to the success of the research and development programs of our company and our partners, and potential licensing or partnering transactions, we may need to raise additional capital to: <span style="font-size:1pt;">&#160;</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fund research and development infrastructure and activities relating to the development of our drug candidates, including pre-clinical and clinical trials and manufacturing to support these efforts&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fund a commercialization infrastructure and activities related to the sale, marketing, customer support, and distribution of our drug products if and when they become approved&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fund our general and administrative infrastructure and activities&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pursue business development opportunities for our technologies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Add to and protect our intellectual property&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Retain our management and technical staff.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital needs depend on many factors, including: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><span style="font-family:Times New Roman;">The scope, duration, and expenditures associated with our research and development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><span style="font-family:Times New Roman;">Regulatory requirements for our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><span style="font-family:Times New Roman;">The extent to which our research and development and clinical efforts are successful&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><span style="font-family:Times New Roman;">The outcome of potential partnering or licensing transactions, if any, and the extent to which our business development efforts result in the acquisition of new programs or technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><span style="font-family:Times New Roman;">Competing technological developments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><span style="font-family:Times New Roman;">Our intellectual property positions, if any, in our products&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-size:10pt;"><span style="font-family:Times New Roman;">The regulatory approval process and regulatory standards for our drug candidates.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to raise additional funds through public or private equity offerings, debt financings or additional strategic alliances and licensing arrangements in the future to continue our operations. We may not be able to obtain additional financing on terms favorable to us, if at all. General market conditions may make it very difficult for us to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities, further dilution to our stockholders will result, which may substantially dilute the value of your investment. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants that could limit our flexibility in conducting future business activities and, in the event of insolvency, would be paid before holders of equity securities </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received any distribution of corporate assets. In order to raise additional funds through alliance, joint venture or licensing arrangements, we may be required to relinquish rights to our technologies or drug candidates or grant licenses on terms that are not favorable to us. If adequate funds are not available, we may have to further delay, reduce or eliminate one or more of our planned activities. These actions would likely reduce the market price of our common stock.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our accruals.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be correct.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The investment of our cash, cash equivalents and fixed income marketable securities is subject to risks which may cause losses and affect the liquidity of these investments. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September&#160;30, 2020, we had $309.4 million in fixed income and equity marketable securities. These investments are primarily in corporate bonds and equity securities, but our investments may also include commercial paper, securities issued by the U.S. government obligations, certificates of deposit and money market funds meeting the criteria of our investment policy, which is focused on the preservation of our capital. These investments are subject to general credit, liquidity, and market and interest rate risks, particularly in the current economic environment. We may realize losses in the fair value of these investments or a complete loss of these investments, which would have a negative effect on our consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to utilize net operating loss carryforwards and other tax benefits may be limited. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have historically incurred net losses. Under the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation is generally allowed a deduction for net operating losses (NOLs) carried forward from a prior taxable year. Under that provision, we can carryforward our NOLs to offset our future taxable income, if any, until such NOLs are used or expire. As of September 30, 2020, we had federal, and state NOL carryforwards of approximately $473 million and $497 million, respectively. As a result of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (&#8220;CARES Act&#8221;) and legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (&#8220;2017 Tax Act&#8221;), NOLs arising before January 1, 2018, and NOLs arising after January 1, 2018, are subject to different rules.&#160;&#160;Under the CARES Act and 2017 Tax Act, federal NOLs incurred in 2018, 2019 and 2020 can generally be carried back five years, carried forward indefinitely and can offset 100% of future taxable income for tax years before January 1, 2021 and up to 80% of future taxable income for tax years after December 31, 2020.&#160;&#160;Any NOLs arising on or after January 1, 2021, cannot be carried back, can generally be carried forward indefinitely and can offset up to 80% of future taxable income. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law.  These NOL carryforwards could expire unused before offsetting potential future income tax liabilities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under Section 382 of the Code and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percent change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. It is possible that we have experienced an ownership change limitation. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.<span style="color:#000000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our <span style="color:#000000;">business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncomplianc</span>e. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each year we are required to evaluate our internal controls systems in order to allow management to report on and our Independent Registered Public Accounting Firm to attest to, our internal controls as required by Section 404 of the Sarbanes-Oxley Act. As a result, we continue to incur additional expenses and divert our management's time to comply with these regulations. In addition, if we cannot continue to comply with the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory authorities, such as the SEC, the Public Company Accounting Oversight Board (&#8220;PCAOB) or The Nasdaq Global Select Market. Any such action could adversely affect our financial results and the market price of our Common Stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We could be subject to additional tax liabilities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to U.S. federal, state, local and sales taxes in the United States and Australia. Significant judgment is required in evaluating our tax positions. During the ordinary course of business, there are many activities and transactions for which the ultimate tax determination is uncertain. In addition, our tax obligations and effective tax rates could be adversely affected by changes in the relevant tax, accounting and other laws, regulations, principles and interpretations, including those relating to income tax nexus, by recognizing tax losses or lower than anticipated earnings in jurisdictions where we have lower statutory rates and higher than anticipated earnings in jurisdictions where we have higher statutory rates, by changes in foreign currency exchange rates, or by changes in the valuation of our deferred tax assets and liabilities. We may be audited in various jurisdictions, and such jurisdictions may assess additional taxes, sales taxes and value-added taxes against us. Although we believe our tax estimates are reasonable, the final determination of any tax audits or litigation could be materially different from our historical tax provisions and accruals, which could have a material adverse effect on our operating results or cash flows in the period for which a determination is made.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Risks Related to Investment and Securities </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Board of Directors has the authority to issue shares of &#8220;blank check&#8221; preferred stock, which may make an acquisition of the Company by another company more difficult. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted and may in the future adopt certain measures that may have the effect of delaying, deferring or preventing a takeover or other change in control of the Company that a holder of our Common Stock might consider in its best interest.&#160;&#160;For example, our Board of Directors, without further action by our stockholders, currently has the authority to issue up to 5,000,000 shares of preferred stock and to fix the rights (including voting rights), preferences and privileges of these shares (&#8220;blank check&#8221; preferred). Such preferred stock may have rights, including economic rights, senior to our Common Stock. These factors could also reduce the price that certain investors might be willing to pay for shares of our Common Stock and result in the market price being lower than it would be without these provisions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We do not intend to declare cash dividends on our Common Stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not distribute cash to our stockholders unless and until we can develop sufficient funds from operations to meet our ongoing needs and implement our business plan. The time frame for that is unpredictable and investors should not expect dividends in the near future, if at all. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research reports about our business or if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our Common Stock can be influenced by the research and reports that industry or securities analysts publish about our business. Currently, coverage of our Company by industry and securities analysts is limited. Investors have many investment opportunities and may limit their investments to companies that receive greater coverage from analysts. If additional industry or securities analysts do not commence coverage of the Company, the trading price of our stock could be negatively impacted. If one or more of the analysts downgrade our stock or comment negatively on our prospects, our stock price may decline. If one or more of these analysts cease to cover our industry or us or fail to publish reports about the Company regularly, our Common Stock could lose visibility in the financial markets, which could also cause our stock price or trading volume to decline. Further, incorrect judgments, estimates or assumptions made by research analysts may adversely affect our stock price, particularly if subsequent performance falls below the levels that were projected by the research analyst(s), even if we did not set or endorse such expectations.&#160;&#160;Any of these events could cause further volatility in our stock price and could result in substantial declines in the value of our stock.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market for purchases and sales of our Common Stock may be limited, and the sale of a limited number of shares could cause the price to fall sharply. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although our Common Stock is listed for trading on the Nasdaq Global Select Market, at various times our securities are relatively thinly traded. Investor trading patterns could serve to exacerbate the volatility of the price of our stock. For example, mandatory sales of our Common Stock by institutional holders could be triggered if an investment in our Common Stock no longer satisfies their investment standards and guidelines. It may be difficult to sell shares of our Common Stock quickly without significantly depressing the value of the stock. Unless we are successful in developing continued investor interest in our stock, sales of our stock could result in major fluctuations in the price of the stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our Common Stock price has fluctuated significantly over the last several years and may continue to do so in the future, without regard to our results of operations and prospects. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we are early in the stage of our drug development, there are few objective metrics by which our progress may be measured. Consequently, we expect that the market price of our Common Stock will continue to fluctuate significantly. We may not continue to generate substantial revenue from the license or sale of our technology for several years, if at all. In the absence of product revenue as a measure of our operating performance, we anticipate that investors and market analysts will assess our performance by considering factors such as: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Announcements of developments related to our business&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our ability to enter into or extend investigation phase, development phase, commercialization phase and other agreements with new and/or existing partners&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Announcements regarding the status of any or all of our collaborations or products, including clinical trial results&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Market perception and/or investor sentiment regarding our technology&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Announcements of actions taken by regulatory authorities, such as the U.S. Food and Drug Administration&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Announcements regarding developments in the RNA interference or biotechnology fields in general&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Announcements regarding clinical trial results with our products or competitors&#8217; products&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Market perception and/or announcements regarding other companies developing products in the field of biotechnology generally or specifically RNA interference&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The issuance of competitive patents or disallowance or loss of our patent rights&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The addition or departure of key executives&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Variations in our operating results.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not have control over many of these factors but expect that they may influence our stock price. As a result, our stock price may be volatile and such volatility could result in the loss of all or part of your investment. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stockholder equity interest may be substantially diluted in any additional equity issuances. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our certificate of incorporation authorizes the issuance of 145,000,000 shares of Common Stock and 5,000,000 shares of Preferred Stock, on such terms and at such prices as our Board of Directors may determine. The following serves as a summary of share issuance activity during the fiscal year ended September 30, 2020:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">2,270,032 shares of Common Stock pursuant to the exercise of stock options and the vesting of restricted stock units.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">4,600,000 shares of Common Stock were issued as part of the December 2019 securities offering</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2020, we had 102,376,303 shares of Common Stock issued and outstanding. The issuance of additional securities in financing transactions by us or through the exercise of options or warrants will dilute the equity interests of our existing stockholders, perhaps substantially, and could result in dilution in the tangible net book value of a share of our Common Stock, depending upon the price and other terms on which the additional shares are issued. </p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Inherent in Our Industry</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Drug development is time consuming, expensive and risky. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on technology related to new and improved pharmaceutical candidates. Product candidates that appear promising in the early phases of development, such as in animal and early human clinical trials, often fail to reach the market for a number of reasons, such as: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Clinical trial results may be unacceptable, even though preclinical trial results were promising&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Inefficacy and/or harmful side effects in humans or animals&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The necessary regulatory bodies, such as the U.S. Food and Drug Administration, may not approve our potential product for the intended use, or at all&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"><span style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;"></span>&#9679;</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Manufacturing and distribution may be uneconomical.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, any positive pre-clinical results in animals for our pre-clinical programs may not be replicated in human clinical studies. These programs may be also found to be unsafe in humans, particularly at higher doses needed to achieve the desired levels of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">efficacy. Also, the positive safety results from single dose human clinical studies may not be replicated in other human studies, including multiple dose studies. Clinical and pre-clinical study results are frequently susceptible to varying interpretations by scientists, medical personnel, regulatory personnel, statisticians and others, which often delays, limits, or prevents further clinical development or regulatory approvals of potential products. Clinical trials can take many years to complete, including the process of study design, clinical site selection and the recruitment of patients. As a result, we can experience significant delays in completing clinical studies, which can increase the cost of developing a drug candidate and shorten the time that an approved product may be protected by patents. If our drug candidates are not successful in human clinical trials, we may be forced to curtail or abandon certain development programs. If we experience significant delays in commencing or completing our clinical studies, we could suffer from significant cost overruns, which could negatively affect our capital resources and our ability to complete these studies. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Throughout the world and particularly in the United States the healthcare system is under significant financial pressure to reduce costs.&#160;&#160;The price of pharmaceuticals has been a topic of considerable public discussion that could lead to price controls or other price-limiting strategies by payors that have the effect of lowering payment and reimbursement rates for drugs or otherwise making the commercialization of pharmaceuticals less profitable. These effects could reduce or eliminate our ability to return value to our shareholders.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory standards are promulgated by various government entities and are subject to change based on factors such as scientific developments, public perceptions of risk, and political forces.&#160; Because clinical trials often take years to complete, it is sometimes possible for standards that exist during the conception and initiation of a clinical trial to change before the clinical trial is completed or reviewed by government regulators.&#160; For example, we may initiate clinical trials that are designed to show benefits on relatively short-term endpoints, but ultimately be required to show benefits in longer-term outcome studies. While some government entities have safeguards intended to ensure standards agreed upon by sponsors and regulators at the outset of a clinical trial are applied during regulatory review processes, those safeguards generally permit regulators to apply more rigorous standards where regulators believe doing so is necessary.&#160; As such, there can be no assurance that regulatory standards that are appropriate at the outset of a clinical trial program will not become more rigorous during the regulatory approval process and could potentially result in a delayed approval or denial of marketing authorization.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1B.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item1B_UnresolvedStaffComments">UNRESOLVED STAFF COMMENTS </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 2.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item2_Properties">PROPERTIES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not own any real property. The following table summarizes the Company&#8217;s leased facilities as of September 30, 2020.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Office</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Space</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Monthly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Primary&#160;Use</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease&#160;Term</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pasadena, California</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,000&#160;sq.&#160;ft.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,736</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corp.&#160;Headqtrs.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April&#160;2027</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.5&#160;years</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Madison, Wisconsin</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,000&#160;sq.&#160;ft.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,315</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research&#160;Facility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;2031</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15&#160;years</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,000&#160;sq.&#160;ft</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research&#160;Facility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January&#160;2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3&#160;years</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;3.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item3_LegalProceedings">LEGAL PROCEEDINGS </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal Proceedings are set forth in our financial statement schedules in Part&#160;IV,&#160;Item 15 of this Annual Report and are incorporated herein by reference. See Note 7 &#8212; <span style="font-style:italic;">Commitments and Contingencies </span>of Notes to Consolidated Financial Statements of Part&#160;IV,&#160;Item 15. <span style="font-style:italic;">Exhibits and Financial Statement Schedules</span>.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;4.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item4_MineSafetyDisclosures">MINE SAFETY DISCLOSURES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART II </span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 5.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item5_MarketForRegistrants">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Common Stock is traded on The Nasdaq Global Select Market under the symbol &#8220;ARWR&#8221;. <span style="font-size:12pt;"> </span>At November 16, 2020, 102,756,771 shares of the Company&#8217;s Common Stock were issued and outstanding, and were owned by <span style="color:#000000;">106</span> stockholders of record, based on information provided by the Company&#8217;s transfer agent.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has never paid dividends on its Common Stock and does not anticipate that it will do so in the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance Under the Equity Compensation Plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The disclosure required under this item related to equity compensation plans is incorporated by reference from Item&#160;12 of Part III of this Annual Report on Form 10-K. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Sales of Unregistered Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All information under this Item has been previously reported on our Current Reports on Form 8-K. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Repurchases of Equity Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not repurchase any shares of our Common Stock during the quarter ended September 30, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.27%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Performance Graph</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing.&#160;&#160;The graph compares the cumulative 5-year total return to shareholders on our Common Stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. We selected the Nasdaq Biotechnology Index because we believe the index reflects the market conditions within the industry in which we primarily operate. The comparison of total return on investment, defined as the change in year-end stock price plus reinvested dividends, for each of the periods assumes that $100 was invested on September 30, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">201</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, in each of our Common Stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index, with investment weighted on the basis of market capitalization.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The comparisons in the following graph are based on historical data and are not intended to forecast the possible future performance of our Common Stock.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gei541vqjlbv000004.jpg" title="" alt="" style="width:719px;height:424px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:98.57%;">
<tr>
<td style="width:11.4%;"></td>
<td style="width:0.52%;"></td>
<td style="width:4.55%;"></td>
<td style="width:0.51%;"></td>
<td style="width:2.75%;"></td>
<td style="width:8.28%;"></td>
<td style="width:2.75%;"></td>
<td style="width:0.51%;"></td>
<td style="width:2.75%;"></td>
<td style="width:7.54%;"></td>
<td style="width:2.75%;"></td>
<td style="width:0.51%;"></td>
<td style="width:2.75%;"></td>
<td style="width:8.17%;"></td>
<td style="width:2.75%;"></td>
<td style="width:0.51%;"></td>
<td style="width:2.75%;"></td>
<td style="width:8.43%;"></td>
<td style="width:2.75%;"></td>
<td style="width:0.51%;"></td>
<td style="width:2.75%;"></td>
<td style="width:7.17%;"></td>
<td style="width:2.75%;"></td>
<td style="width:2.75%;"></td>
<td style="width:7.81%;"></td>
<td style="width:2.75%;"></td>
<td style="width:0.6%;"></td>
</tr>
<tr style="height:17.6pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$100 investment in stock or index</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ticker</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2015</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2016</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2017</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:26.75pt;">
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARWR</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127.60</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.17</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">332.81</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">489.24</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">747.57</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:26.75pt;">
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NASDAQ Biotechnology Index</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#94;NBI</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95.52</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110.22</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121.03</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98.69</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134.32</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:26.05pt;">
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NASDAQ Composite Index</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#94;IXIC</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114.97</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140.60</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">174.16</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173.14</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241.71</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CCECFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.06%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 6.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item6_SelectedFinancial"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SELECTED FINA</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NCIAL DATA </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following selected financial data has been derived from our audited consolidated financial statements and should be read in conjunction with the consolidated financial statements, the related notes thereto and the independent auditors&#8217; report thereon, and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; which are included elsewhere in this Form&#160;10-K and in previously filed Annual Reports on Form&#160;10-K of Arrowhead Pharmaceuticals, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="27" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended September 30</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">OPERATING SUMMARY</span></p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REVENUE</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">87,992,066</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">168,795,577</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16,142,321</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">31,407,709</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">158,333</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OPERATING EXPENSES</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,874,979</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,048,686</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,968,505</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,904,466</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,117,818</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,275,890</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,556,257</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,110,051</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,499,152</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,594,888</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment expense</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,050,817</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent consideration - fair value adjustments</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,862,464</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL OPERATING EXPENSES (a)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">181,150,869</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,604,943</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,078,556</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,403,618</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,901,059</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OPERATING INCOME (LOSS)</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(93,158,803</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">61,190,634</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(55,936,235</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(36,995,909</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(81,742,726</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NET INCOME (LOSS)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(84,553,226</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">67,974,849</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(54,450,478</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(34,380,295</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(81,723,002</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NET INCOME (LOSS) PER SHARE:</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) Per Share - Basic</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(0.84</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0.72</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(0.47</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1.34</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) Per Share - Diluted</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(0.84</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">0.69</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(0.47</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1.34</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding &#8211; basic</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,722,224</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,858,857</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,638,469</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,898,598</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,050,880</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding &#8211; diluted</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,722,224</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,607,815</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,638,469</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,898,598</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,050,880</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CASH DIVIDEND PAID PER SHARE OF COMMON STOCK</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="27" valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">FINANCIAL POSITION SUMMARY</span></p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CASH AND CASH EQUIVALENTS (b)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">143,582,667</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">221,804,128</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">30,133,213</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">24,838,567</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> $</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">85,366,448</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INVESTMENTS AND MARKETABLE SECURITIES</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">309,396,353</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">81,075,887</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">46,400,176</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">40,769,539</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.52%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TOTAL ASSETS (b)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">522,503,743</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">349,845,437</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">111,609,951</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">104,022,280</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">128,176,505</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OTHER LONG-TERM OBLIGATIONS</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20,043,178</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8,738,506</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4,003,999</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.1%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4,454,070</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7,508,452</p></td>
<td valign="middle" style="background-color:#D8EEFC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><span style="font-size:10pt;">The increase in our Total Operating Expenses during the year ended September 30, 2020 is primarily due to the expansion of our pipeline of clinical candidates.&#160;&#160;We expect research and development expenses to continue to increase as our other pipeline candidates progress. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><span style="font-size:10pt;">The Company&#8217;s Cash, Cash Equivalents, Marketable Securities, Short- and Long-Term Investments and Total Assets increased from September 30, 2019 to September 30, 2020 due primarily due to the December 2019 securities offering that generated $250.5 million in net cash.&#160;&#160;The offering cash inflows were partially offset by cash used in research and development expenditures.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item7_MDA"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MAN</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Business </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unless otherwise noted, (1)&#160;the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation, (2)&#160;the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3)&#160;the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;), and Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), (4)&#160;the term &#8220;Common Stock&#8221; refers to Arrowhead&#8217;s Common Stock, (5) the term &#8220;Preferred Stock&#8221; refers to Arrowhead&#8217;s Preferred Stock and (6) the term &#8220;Stockholder(s)&#8221; refers to the holders of Arrowhead Common Stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them.&#160;&#160;Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-LUNG2 as a candidate to treat chronic obstructive pulmonary disorder (&#8220;COPD&#8221;) and ARO-COV for treatment for the current novel coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.<span style="font-size:14pt;"> </span>ARO<span style="color:#000000;">-JNJ1, ARO-JNJ2 and ARO-JNJ3 are being developed for undisclosed liver-expressed targets under a collaboration agreement with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;).&#160;&#160;</span>ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) in October 2020. <span style="color:#000000;">ARO-HBV (JNJ-3989) for chronic hepatitis B virus was out-licensed to Janssen in October 2018.&#160;&#160;ARO-LPA (AMG 890)</span><span style="color:#000000;font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">&#160;</sub></span><span style="color:#000000;">for cardiovascular disease was out-licensed to Amgen Inc. (&#8220;Amgen&#8221;) in 2016.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead operates lab facilities in Madison, Wisconsin and San Diego, California, where the Company&#8217;s research and development activities, including the development of RNAi therapeutics, are based. The Company&#8217;s principal executive offices are located in Pasadena, California. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has focused its resources on therapeutics that exclusively utilize the Company&#8217;s Targeted RNAi Molecule (TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup>) platform technology. Therapeutics built on the TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> platform have demonstrated high levels of pharmacologic activity in multiple animal models spanning several therapeutic areas. TRiM<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> enabled therapeutics offer several potential advantages over prior generation and competing technologies, including: simplified manufacturing and reduced costs&#59; multiple routes of administration including subcutaneous injection and inhaled administration&#59; the ability to target multiple tissue types including liver, lung and tumors&#59; and the potential for improved safety and reduced risk of intracellular buildup, because there are less metabolites from smaller, simpler molecules.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal year 2020, the Company has continued to develop its pipeline and partnered candidates.&#160;&#160;Regarding the Company&#8217;s wholly-owned pipeline candidates, the Company dosed its first patients in three of its pipeline candidate studies: ARO-HSD1001, a phase 1/2 clinical study of ARO-HSD&#59; ARO-ENaC1001, a phase 1/2 clinical study of ARO-ENaC and ARO-HIF21001, a phase 1b study of ARO-HIF2. The Company also presented new clinical data on its two cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, at multiple medical meetings, including the European Society of Cardiology Congress and the American Heart Association Scientific Sessions.&#160;&#160;Finally, the Company is also progressing ARO-LUNG2 toward entering clinical trials and is continuing to perform discovery work to identify new candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s partnered candidates under its collaboration agreements also continue to progress.&#160;&#160;Janssen began dosing patients in a phase 2b triple combination study called REEF-1,&#160;designed to enroll up to 450 patients with chronic hepatitis B infection, and in connection with the start of this study Arrowhead earned a&#160;$25.0 million&#160;milestone payment under the License Agreement (&#8220;Janssen License Agreement&#8221;).&#160;&#160;The Company is currently performing discovery, optimization and preclinical research and development for ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3 for Janssen as part of the Research Collaboration and Option Agreement (&#8220;Janssen Collaboration Agreement&#8221;).&#160;&#160;Under the terms of the Janssen agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead common stock, two $25.0 million milestone payments and may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement.&#160;&#160;The Company is further eligible to receive tiered royalties up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement on product sales. The Company&#8217;s collaboration agreement with Amgen for Olpasiran (formerly referred to as AMG 890 or ARO-LPA), (the &#8220;Second Collaboration and License Agreement&#8221; or &#8220;Olpasiran Agreement&#8221;), continues to progress.&#160;&#160;In July 2020, Amgen initiated a Phase 2 clinical study, which resulted in a $20.0 million milestone payment to the Company. The Company has received $35.0 million in upfront payments, $21.5 million in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the form of an equity investment by Amgen in the Company&#8217;s Common Stock, $30</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in milestone payments, and may receive up to</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> an additional</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $400</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in remaining development, regulatory and sales milestone payments.&#160;&#160;The Company is eligible to receive up to&#160;low double-digit royalties for sales of products under the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Olpasiran</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement.&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7, 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company entered into a</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n Exclusive</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> License </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and Co-Funding </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement (</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda License </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement&#8221;) with </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;Under the </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda License</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Agreement, </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with the Company eligible to receive tiered royalties of 20 to 25% on net sales.&#160;&#160;The Company will receive $300</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognition for these collaboration agreements is discussed further in Note 2 Notes to Consolidated Financial Statements of Part IV, Item 15. <span style="font-style:italic;">Exhibits and Financial Statement Schedules</span>.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company continues to develop<span style="color:#000000;"> other clinical candidates for future clinical trials.&#160;</span>Clinical candidates are tested internally and through GLP toxicology studies at outside laboratories.&#160;&#160;Drug materials for such studies and clinical trials are either contracted to third-party manufactures or manufactured internally.&#160;&#160;The Company engages third-party contract research organizations (&#8220;CROs&#8221;) to manage clinical trials and works cooperatively with such organizations on all aspects of clinical trial management, including plan design, patient recruiting, and follow up.&#160;&#160;These outside costs, relating to the preparation for and administration of clinical trials, are referred to as &#8220;candidate costs.&#8221;&#160;&#160;If the clinical candidates progress through human testing, candidate costs will increase.&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is actively monitoring the COVID-19 pandemic.&#160;&#160;The financial results for the year ended September 30, 2020 were not significantly impacted by COVID-19.&#160;&#160;The Company had temporarily paused enrollment in its two ARO-AAT studies, SEQUOIA and the ARO-AAT 2002 study, but resumed the process of screening and enrolling patients during the year ended September 30, 2020.&#160;&#160;During the pause in enrollment, patients already enrolled in these studies continued to be dosed per protocol and continued to come in for their follow up visits. Additional delays have occurred in the Company&#8217;s earlier stage programs, but Company does not expect a material impact to any program&#8217;s anticipated timelines. Several of the Company&#8217;s other clinical candidates are in the start-up stage (ARO-HSD, ARO-HIF2 and ARO-ENaC), during which significant clinical costs will continue to be incurred. Additionally, the Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters in Pasadena, California have continued to operate with limited impact, other than for enhanced safety measures, including work from home policies. However, the Company cannot predict the impact of the progression of COVID-19 will have on future financial results due to a variety of factors including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees, and ultimately the length of the COVID-19 pandemic.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net losses were $84.6 million for the year ended September 30, 2020 as compared to net income of $68.0 million for the year ended September 30, 2019 and net losses of $54.5 million for the year ended September 30, 2018. Net losses per share &#8211; diluted were $0.84 for the year ended September 30, 2020 as compared to net income per share-diluted of $0.69 for the year ended September 30, 2019 and net losses per share-diluted of $0.65 for the year ended September 30, 2018. An increase in research and development and general and administrative expenses coupled with a decrease in revenue from the license and collaboration agreements with Janssen were the drivers of the increase in net losses and net losses per share for the year ended September 30, 2020, as discussed further below.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has strengthened its liquidity and financial position through upfront and milestone payments received under its collaboration agreements, as well as equity financings. <span style="color:#000000;">Under the terms of the Company&#8217;s agreements with Janssen taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead Common Stock, and two $25.0 million milestone payments.&#160;&#160;Under the terms of the Company&#8217;s agreements with Amgen, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock and $30.0 million in milestone payments.  </span><span style="Background-color:#FFFFFF;color:#000000;">T</span>he Company&#8217;s October 2020 licensing agreement with Takeda will result in a $300.0 million upfront payment expected to be collected in the first fiscal quarter of 2021. <span style="color:#000000;">Additionally, in December 2019, the Company completed a securities offering which generated approximately $250.5 million in net cash proceeds. </span>These cash proceeds secure the funding needed to continue to advance our pipeline candidates. The Company had $143.6 million of cash and cash equivalents, $85.0 million of marketable securities, $86.9 million in short-term investments, $137.5 million of long term investments and $522.5 million of total assets as of September 30, 2020, as compared to $221.8 million, $0, $36.9 million, $44.2 million and $349.8 million as of September 30, 2019, respectively. Based upon the Company&#8217;s current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund operations for at least the next twelve months. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management makes certain judgments and uses certain estimates and assumptions when applying accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) in the preparation of our Consolidated Financial Statements. We evaluate our estimates and judgments on an ongoing basis and base our estimates on historical experience and on assumptions that we believe to be reasonable under the circumstances. Our experience and assumptions form the basis for our judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may vary from what we anticipate and different assumptions or estimates about the future could change our reported results. We believe the following accounting policies are the most critical to us, in that they require our most difficult, subjective or complex judgments in the preparation of our consolidated financial statements. For further information, see&#160;<span style="font-style:italic;">Note 1, Organization and Significant Accounting Policies</span>, to our Consolidated Financial Statements, which outlines our application of significant accounting policies.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation&#8212;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#8217;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation and Use of Estimates&#8212;The <span style="color:#000000;">preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation</span>.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents&#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $1.8 million and $1.0&#160;&#160;restricted cash at September 30, 2020 and September 30, 2019, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#8217;s <span style="color:#000000;">lease for its corporate headquarters in Pasadena, California.&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk&#8212;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments&#8212;The Company may invest excess cash balances in short-term and long-term marketable debt securities and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in debt securities in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 320, Investments &#8211; Debt and Equity Securities, which requires debt securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2020, 2019 and 2018, all of the Company&#8217;s debt securities were classified as held-to-maturity. Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended September 30, 2020, the Company purchased shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#8217;s Consolidated Balance Sheet as &#8220;marketable securities&#8221; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss).  </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment&#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration&#8212;The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $0 at September 30, 2020 and September 30, 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212; <span style="color:#000000;">On October 1, 2018, the Company adopted FASB Topic 606 &#8211; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#8217;s adoption of the new revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#8217;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen and Takeda, and the analysis of the impact of this guidance on those agreements is discussed further in </span>Note 2 of Notes to Consolidated Financial Statements of Part IV, Item 15. <span style="font-style:italic;">Exhibits and Financial Statement Schedules</span><span style="color:#000000;">. &#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the new revenue standard, the Company performs the following five steps: (i) identify the contract&#59; (ii) identify the performance obligations&#59; (iii) determine the transaction price&#59; (iv) allocate the transaction price to the performance obligations in the contract&#59; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials&#59; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CTA</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) or a New Drug Application (</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NDA</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) in the United States&#59; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in our Consolidated Statement</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed&#160;&#160;are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the new revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the proportional performance method. Labor hours or costs incurred are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on the Company&#8217;s Consolidated Balance Sheets.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#8217;s current operating plan and, if the Company&#8217;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Doubtful Accounts&#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per Share&#8212;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees. During the years ended September 30, 2020, 2019 and 2018, the calculation of the effect of dilutive stock options and restricted stock units was 0 shares, 4,748,958 shares, and 0 shares, respectively. During the year ended September 30, 2020, the calculation of the effect of dilutive stock option and restricted stock units excluded all </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended September 30, 20</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the calculation of the effect of dilutive stock options and restricted stock units excluded 1,007,500 stock options and 11,500 restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2018, the calculation of the effect of dilutive stock option and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:2.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases - The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following data summarizes our results of operations for the following periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:87.5%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,992,066</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,795,577</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,142,321</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Income (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(93,158,803</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,190,634</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,936,235</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (loss)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(84,553,226</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,974,849</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,450,478</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.84</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.69</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.65</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.16%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decrease in revenue for the year ended September 30, 2020 compared to the year ended September 30, 2019 was driven by the timing of the recognition of the $252.6 million initial transaction price associated with our agreements with Janssen and JJDC as we achieved progress toward completing our performance obligation under those agreements. The increase in Net Losses during the year ended September 30, 2020 was driven by this decrease in Revenue and also increases in Research and Development and General and Administrative Expenses as our pipeline of clinical candidates has continued to increase.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue for the years ended September 30, 2020, 2019, and 2018 was $87,992,066, $168,795,577 and $16,142,321, respectively.&#160;&#160;Revenue in the current period is primarily related to the recognition of a portion of the $252.6 million initial transaction price associated with our agreements with Janssen and JJDC as we achieved progress towards completing our performance obligation under those agreements.&#160;&#160;In addition, revenue in the current period consisted of a $20 million milestone payment from Amgen for the initiation of phase 2 clinical study for AMG 890 (ARO-LPA).&#160;&#160;Revenue for the year ended September 30, 2019, was also primarily related to the recognition of a portion of the $252.6 million initial transaction price associated with our agreements with Janssen and JJDC.&#160;&#160;A higher proportion of performance activity was ongoing during the prior period than the current, which resulted in the higher revenue recognized in the prior period. Revenue for the year ended September 30, 2018, was primarily related to a $10 million milestone payment received from Amgen in August 2018, which was earned following the administration of the first does of AMG 890 (ARO-LPA). </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amgen Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;28, 2016, the Company entered into two collaboration and license agreements, and a common stock purchase Agreement with Amgen Inc., a Delaware corporation (&#8220;Amgen&#8221;). Under one of the license agreements (the &#8220;Second Collaboration and License Agreement&#8221; or &#8220;Olpasiran Agreement&#8221;), Amgen has received a worldwide, exclusive license to Arrowhead&#8217;s novel, RNAi Olpasiran program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the other collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement.&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement.&#160;&#160;Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study, which resulted in a $20.0 million milestone payment to the Company. During the years ended September 30, 2020, 2019 and 2018, the Company recognized $20.1 million, $0.3 million, and $16.1 million of Revenue associated with its agreements with Amgen, respectively.&#160;&#160;As of September 30, 2020, there were $0 million in contract assets recorded as accounts receivable and $0 contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Janssen Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 3, 2018, the Company entered into a License Agreement (&#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (&#8220;Janssen Collaboration Agreement&#8221;) with Janssen Pharmaceuticals, Inc.&#160;&#160;(&#8220;Janssen&#8221;) part of the Janssen Pharmaceutical Companies of Johnson &#38; Johnson.&#160;&#160;The Company also entered into a Stock Purchase Agreement (&#8220;JJDC Stock Purchase Agreement&#8221;) with Johnson &#38; Johnson Innovation-JJDC, Inc.&#160;&#160;(&#8220;JJDC&#8221;), a New Jersey corporation.&#160;&#160;Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potentially curative therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1 / 2 study of JNJ-3989 (ARO-HBV), Janssen is wholly responsible for clinical development and commercialization.&#160;&#160;Under the Janssen Collaboration Agreement, Janssen will be able to select three new targets against which Arrowhead will develop clinical candidates.&#160;&#160;These candidates are subject to certain restrictions and do not include candidates that already were in the Company&#8217;s pipeline.&#160;&#160;The Company will perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, is sufficient to allow the filing of a U.S. Investigational New Drug application or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned candidate.&#160;&#160;Under the terms of the agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead Common Stock, two $25.0 million milestone payments and may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement.&#160;&#160;<span style="color:#000000;">The Company is further eligible to receive tiered royalties up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement on product sales</span>.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated these agreements in accordance with the new revenue recognition requirements that became effective for the Company on October 1, 2018.&#160;&#160;The adoption of the new revenue standard did not have a material impact on the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">balances reported when evaluated under the superseded revenue standard.&#160;&#160;At the inception of these agreements, the Company has identified one distinct performance obligation.&#160;&#160;Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&#38;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of ARO-HBV drug product is completed and delivered to Janssen (the &#8220;Janssen R&#38;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Janssen R&#38;D </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ervices, and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and thus, one performance obligation.&#160;&#160;The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for this option will be accounted for if and when it is exercised. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the transaction price totaled approximately $252.6 million which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, the two $25 million milestone payments earned and estimated payments for reimbursable Janssen R&#38;D Services to be performed.&#160;&#160;The Company has allocated the total $252.6 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&#38;D Services.&#160;&#160;This revenue will be recognized using a proportional performance method (based on actual labor hours versus estimated total labor hours) beginning in October 2018 and ending as the Company&#8217;s efforts in overseeing the phase 1/2 clinical trial are completed.&#160;&#160;During the years ended September 30, 2020 and 2019, the Company recognized approximately $65.0 million and $167.5 million of Revenue associated with this performance obligation, respectively. As of September 30, 2020, there were $0 in contract assets recorded as accounts receivable and $19.3 million of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.&#160;&#160;The $19.3 million of current deferred revenue is driven by the upfront payment, the premium paid by JJDC for its equity investment in the Company, and the two $25.0 million milestone payments earned, net of revenue recognized to date.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has begun to conduct its discovery, optimization and preclinical research and development of ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3 under the Janssen Collaboration Agreement.&#160;&#160;All costs and labor hours spent by the Company will be entirely funded by Janssen.&#160; During the years ended September 30, 2020 and 2019, the Company recognized $2.9 million and $1.0 million of Revenue associated with these efforts, respectively. As of September 30, 2020, there were $0.8 million of cont<span style="color:#000000;">ract assets recorded as accounts </span>receivable and $0 of contract liabilities recorded as curren<span style="color:#000000;">t deferred revenue on the Company&#8217;s Consolidated Balance</span> Sheets.&#160; <span style="color:#000000;"> &#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. Certain reclassifications have been made to prior-period operating expense categories to conform to the current period presentation.&#160;&#160;For purposes of comparison, the amounts for the years ended September 30, 2020 and 2019 are shown in the tables below. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&#38;D expenses are related to the Company&#8217;s research and development efforts, and related program costs which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses.&#160;&#160;Internal costs primarily relate to operations at our research facilities in Madison, Wisconsin and San Diego, California, including facility costs and laboratory-related expenses. Salaries and stock compensation expense consist of salary, bonuses, payroll taxes and related benefits and stock compensation for our R&#38;D personnel.&#160;&#160;Depreciation and amortization expense relates to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depreciation on lab equipment and leasehold improvements at our research facilit</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;The following table provides details of research and development expenses for the periods indicated:</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(table below in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Salaries</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,300</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,502</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,798</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities related</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,136</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,649</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,487</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Candidate costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,638</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,062</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,576</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&#38;D discovery costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,192</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,901</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,291</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expense, excluding non-cash expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,266</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,114</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,152</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,277</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,515</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,762</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">363</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation/amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,332</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,420</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">912</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,875</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,049</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,826</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Salaries expense increased by $10,798,000 from $15,502,000 during the year ended September 30, 2019 to $26,300,000 during the current period. This increase is primarily due to an increase in R&#38;D headcount that has occurred as the Company has expanded its pipeline of candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities expense increased by $1,487,000 from $2,649,000 during the year ended September 30, 2019 to $4,136,000 during the current period. This category includes rental costs for our research and development facilities in Madison, Wisconsin and San Diego, California. This increase is primarily due the commencement of our sublease in San Diego, California in April 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Candidate costs increased by $13,576,000 from $47,062,000 during the year ended September 30, 2019 to $60,638,000 during the current period.&#160;&#160;This increase is primarily due to the progression of our pipeline candidates into and through clinical trials, which results in higher outsourced clinical trial, toxicity study and manufacturing costs.&#160;&#160;We anticipate these expenses to continue to increase as our pipeline of candidates grows and progresses to later phase clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">R&#38;D discovery costs increased by $8,291,000 from $7,901,000 during the year ended September 30, 2019 to $16,192,000 in the current period.&#160;&#160;This increase is due to the growth of our discovery efforts, including the addition of our research facility in San Diego.&#160;&#160;We anticipate this expense to continue to increase as we increase headcount to support our discovery efforts to identify new drug candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation expense, a non-cash expense, increased by $12,762,000 from $3,515,000 during the year ended September 30, 2019 to $16,277,000 during the current period.&#160;&#160;Stock compensation expense is based upon the valuation of stock options and restricted stock units granted to employees, directors, and certain consultants. Many variables affect the amount expensed, including the Company&#8217;s stock price on the date of the grant, as well as other assumptions. The increase in the expense is primarily due to the increased headcount discussed above and a mix of higher grant date fair values of awards amortizing during the periods due to the Company&#8217;s stock price at the time of the grants.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense, a non-cash expense, increased by $912,000 from $4,420,000 during the year ended September 30, 2019 to $5,332,000 during the current period. The majority of depreciation and amortization expense relates to depreciation on lab equipment and leasehold improvements at our Madison research facility.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">General&#160;&#38; Administrative Expenses </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides details of our general and administrative expenses for the periods indicated: </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(table below in thousands) </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Twelve</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Months</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">% of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase (Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Category</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.4%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Salaries</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,781</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,288</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,493</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional/outside services</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,342</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,605</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,737</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities related</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,203</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,434</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">769</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other G&#38;A</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,232</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,332</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">900</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total general &#38; administrative expense, excluding non-cash expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,558</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,659</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,899</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,106</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,878</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,228</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.26%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">205</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation/amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">611</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">592</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3116</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:31.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total general &#38; administrative expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,275</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,556</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,719</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Salaries expense increased by $3,493,000 from $8,288,000 during the year ended September 30, 2019 to $11,781,000 during the current period. The increase is primarily driven by annual merit increases, performance bonuses and increased headcount.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional/outside services include legal, accounting, consulting, patent expenses, business insurance expenses and other outside services retained by the Company. Professional/outside services expense increased by $1,737,000 from $5,605,000 during the year ended September 30, 2019 to $7,342,000 during the current period. The increases is primarily related to certain patent-related expenses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facilities-related expense increased by $769,000 from $1,434,000 during the year ended September 30, 2019 to $2,203,000 during the current period. This category primarily includes rental costs for our corporate headquarters in Pasadena, California.&#160;&#160;The increase in the expense is primarily related to costs incurred as we moved into our new corporate headquarters during the current period.&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other G&#38;A expense increased by $900,000 from $2,332,000 during the year ended September 30, 2019 to $3,232,000 during the current period. This category consists primarily of travel, communication and technology, office expenses, and franchise and property tax expenses.&#160;&#160;The increase in the expense was due to increased communication and technology and office expenses associated with our new corporate headquarters.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation expense, a non-cash expense, increased by $18,228,000 from $8,878,000 during the year ended September 30, 2019 to $27,106,000 during the current period.&#160;&#160;Stock compensation expense is based upon the valuation of stock options and restricted stock units granted to employees, directors, and certain consultants. Many variables affect the amount expensed, including the Company&#8217;s stock price on the date of the grant, as well as other assumptions. The increase in expense is primarily due to the timing of the achievement of certain performance-based awards in each period and a mix of higher grant date fair values of awards amortizing during the periods due to the Company&#8217;s stock price at the time of the grants. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense, a noncash expense, increased by $592,000 from $19,000 during the year ended September 30, 2019 to $611,000 during the current period. The increase is primarily related to amortization of leasehold improvements for our new corporate headquarters. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Income / Expense </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income / expense was income of $6,957,768 during the year ended September 30, 2019 compared to income of $8,607,977 during the current period. Interest income has increased in the current period as our investment holdings have grown.&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Cash Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has historically financed its operations through the sale of its equity securities. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020, the Company had cash on hand of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143.6</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million as compared to $221.8 million at September 30, 2019.&#160;&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ash invested in short-term fixed income securities</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and marketable securities</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was $</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171.9</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million at </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30, 2020, compared to $36.9 million at September 30, 2019. </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> C</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ash invested in long-term fixed income securities was $1</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37.5 </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">million at </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 30, 2020, compared to $44.2 million at September 30, 2019.&#160;&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also entered into an Open Market Sale Agreement (the &#8220;ATM&#8221; agreement), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s common stock through Jefferies LLC.&#160;&#160;As of the year ended September 30, 2020, no shares have been issued under the ATM agreement.&#160;&#160;</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes its current financial resources are sufficient to fund its operations through at least the next twelve months.</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of cash flows for the years ended September 30, 2020, 2019, and 2018 as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="8" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.32%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Years ended September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.98%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash Flow from:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,391,570</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,034,923</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,223,417</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(240,777,764</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,746,007</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,434,963</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">257,947,873</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,381,999</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,953,026</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(78,221,461</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,670,915</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,294,646</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of period</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,804,128</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,133,213</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,838,567</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.48%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,582,667</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,804,128</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,133,213</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended September 30, 2020, the Company used $95.4 million in cash from operating activities, which was primarily related to the ongoing expenses of the Company&#8217;s research and development programs and general and administrative expenses.&#160;&#160;Cash used in investing activities was $240.8 million, which was primarily related to the purchase of investments of $279.0 million and property and equipment of $12.0 million, partially offset by maturities of fixed-income securities of $50.1 million.&#160;&#160;Cash provided by financing activities of $257.9 million was driven by the securities financing in December 2019, which generated $250.5 million in net cash proceeds, as well as $7.5 million in cash received from stock option exercises. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During <span style="color:#000000;">the year ended September 30, 2019, the Company generated $173.0 million in cash from operating activities, which was primarily related to the $175.0 million upfront payment and the two $25.0 million milestone payments received from Janssen, and the premium JJDC paid on the Company&#8217;s common stock during the period.&#160;&#160;These inflows were partially offset by approximately $66.5 million of cash used for the ongoing expenses of the Company&#8217;s research and development programs and general and administrative expenses.&#160;&#160;Cash used in investing activities was $47.7 million, which was primarily related to purchases of fixed-income investments of $90.3 million partially offset by maturities of fixed-income investments of $54.5 million.&#160;&#160;Cash provided by financing activities of $66.4 million was driven by the equity investment the Company received from JJDC during the period</span>.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended September 30, 2018, the Company used $47.2 million in cash from operating activities, which was primarily related to $57.2 million used for the on-going expenses of its research and development programs and general and administrative expenses, offset by the $10 million milestone payment for the AMG 890 (ARO-LPA) Agreement with Amgen.&#160;&#160;Cash used in investing activities was $7.4 million, which was primarily related to maturities of fixed-income investments of $46.1 million offset by purchases of fixed-income securities of $52.1 million.&#160;&#160;Cash provided by financing activities of $60.0 million was driven by the $56.6 million of cash generated from the underwritten public offering in January 2018.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the table below, we set forth our enforceable and legally binding obligations and future commitments at September 30, 2020 for the categories shown, as well as obligations related to contracts in such categories that we are likely to continue. Some of the figures that we include in this table are based on management&#8217;s estimates and assumptions about these obligations, including their duration, the possibility of renewal, anticipated actions by third parties and other factors. Because these estimates and assumptions are necessarily subjective, the obligations we will actually pay in future periods may vary from those reflected in the table. The following </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">table does not include any future obligations that may be owed under existing license agreements, as the certainty of achieving the relevant milestones that would trigger these payments is currently unknown.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:56.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments due by Period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.06%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less&#160;than&#160;1 Year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1-3&#160;Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3-5&#160;Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More&#160;than &#160;5 Years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-Term Debt</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital Leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Leases</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,311,207</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,091,901</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,260,044</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,627,966</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,331,296</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unconditional Purchase Obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,965,922</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,176,232</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,789,690</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Long-Term Liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,277,129</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,268,133</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,049,734</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,627,966</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,331,296</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any off-balance sheet arrangements.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 7A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item7A_QuantitativeAndQualitative"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">QUANTITAT</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risk related to changes in interest rates, which could adversely affect the value of our interest rate-sensitive assets and liabilities.&#160;&#160;We do not hold any instruments for trading purposes and investment criteria are governed by the Company&#8217;s Investment Policy. As of September 30, 2020 and 2019, we had cash and cash equivalents of $143.6 million and $221.8 million, respectively, and short-term and long-term investments and marketable securities of $309.4 million and $81.1 million, respectively. At times, we have invested our cash reserves in corporate bonds typically with maturities of less than 3 years, and we have historically classified these investments as held-to-maturity.&#160;&#160;Due to the relatively short-term nature of the investments that we hold, we do not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to our investment portfolio.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item8_FinancialStatementsAndSuppData">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item is included in Item&#160;15 of this Annual Report on Form 10-K. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 9.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item9_ChangesInAndDisagreements">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 9A.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item9A_ControlsAndProcedures">CONTROLS AND PROCEDURES. </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Chief Executive Officer and our Chief Financial Officer, after evaluating our &#8220;disclosure controls and procedures&#8221; (as defined in Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Annual Report on Form 10-K (the &#8220;Evaluation Date&#8221;) have concluded that as of the Evaluation Date, our disclosure controls and procedures are effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and to ensure that information required to be disclosed by us in such reports is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, where appropriate, to allow timely decisions regarding required disclosure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No change in the Company&#8217;s internal controls over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act) occurred during the Company&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.12%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;). This process includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets&#59; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors&#59; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the internal control over financial reporting to future periods are subject to risk that the internal control may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.12%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Management&#8217;s Assessment of the Effectiveness of our Internal Control over Financial Reporting</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Management conducted an assessment of the effectiveness of the Company&#8217;s internal control over financial reporting based on the criteria set forth in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on the Company&#8217;s assessment, management has concluded that its internal control over financial reporting was effective as of September&#160;30, 2020&#160;to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. The Company&#8217;s </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">independent registered public accounting firm, Rose, Snyder and Jacobs LLP, has issued an audit report on the Company&#8217;s internal control over financial reporting, which appears in Item&#160;15 of this Form 10-K.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no change in our internal control over financial reporting that occurred during the fourth quarter of the year ended September&#160;30, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 9B.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item9B_OtherInformation">OTHER INFORMATION </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART III </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 10.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item10_DirectorsExecutives">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this Item will be incorporated by reference from our Definitive Proxy Statement to be filed for our 2021 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a Code of Ethics, as part of our Code of Corporate Conduct, that applies to all of our directors, officers and employees, including our principal executive, principal financial and principal accounting officers, or persons performing similar functions. Our Code of Ethics is posted on our website located at https://arrowheadpharma.com/code-corporate-conduct/. We intend to disclose future amendments to certain provisions of the Code of Ethics, and waivers of the Code of Ethics granted to executive officers and directors, on the website within four business days following the date of the amendment or waiver.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 11.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item11_ExecutiveCompensation">EXECUTIVE COMPENSATION</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this Item will be incorporated by reference from our Definitive Proxy Statement to be filed for our 2021 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2021.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 12.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item12_SecurityOwnership">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this Item will be incorporated by reference from our Definitive Proxy Statement to be filed for our 2021 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2021.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 13.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item13_CertainRelationships">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this Item will be incorporated by reference from our Definitive Proxy Statement to be filed for our 2021 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2021.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;14.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item14_PrincipalAccountantFees">PRINCIPAL ACCOUNTANT FEES AND SERVICES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information called for by this Item will be incorporated by reference from our Definitive Proxy Statement to be filed for our 2021 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 28, 2021.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART IV </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160; 15.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="Item15_Exhibits">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following documents are filed as part of this Annual Report on Form 10-K: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Index to Financial Statements and Schedule on page F-1. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statement Schedules. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Index to Financial Statements and Schedule on page F-1. All other schedules are omitted as the required information is not present or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the consolidated financial statements or notes thereto. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibits. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form 10-K: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.05pt;">
<td valign="bottom" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;Herein</p></td>
</tr>
<tr style="height:3pt;">
<td valign="bottom" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:2.8pt;">
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459020036812/arwr-ex11_467.htm"><span style="text-decoration:underline;">Open Market Sale Agreement, dated as of August 5, 2020, by and between Arrowhead Pharmaceuticals, Inc. and Jefferies LLC</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex21.htm"><span style="text-decoration:underline;">Stock and Asset Purchase Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 1.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K as Exhibit 2.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 5, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December&#160;20, 2011</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459015003902/arwr-ex21_20150331298.htm"><span style="text-decoration:underline;">Asset Purchase and Exclusive License Agreement between Arrowhead Research Corporation and Novartis Institutes for BioMedical Research, Inc., dated March 3, 2015&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 2.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">May 11, 2015</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of Arrowhead Research Corporation, a Delaware corporation, filed with the Secretary of State of the State of Delaware on April 5, 2016</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K as Exhibit 3.3</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 6, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex34.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc.</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K as Exhibit 3.4</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 6, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex41.htm"><span style="text-decoration:underline;">Form of Common Stock Certificate of Arrowhead Pharmaceuticals, Inc.</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K, as Exhibit 4.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 6, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312516751770/d278005dex42.htm"><span style="text-decoration:underline;">Form of Indenture</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registration Statement on Form S-3, as Exhibit 4.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 28, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312517092797/d319463dex41.htm"><span style="text-decoration:underline;">Rights Agreement dated as of March 21, 2017, between the Company and Computershare Trust Company, N.A., as rights agent, which includes as Exhibit B the Form of Rights Certificate</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K, as Exhibit 4.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 23, 2017</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex44_92.htm"><span style="text-decoration:underline;">Description of Registrant&#8217;s Securities</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 4.4</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 25, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312512009893/d275001ddef14a.htm"><span style="text-decoration:underline;">Arrowhead Research Corporation 2004 Equity Incentive Plan, as amended</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 14C, as Annex B</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 12, 2012</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312513481209/d647635ddef14a.htm"><span style="text-decoration:underline;">Arrowhead Research Corporation 2013 Incentive Plan</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schedule 14C, as Annex A</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 20, 2013</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312514048097/d675317dex101.htm"><span style="text-decoration:underline;">Form of Stock Option Agreement for use with the 2013 Incentive Plan</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 12, 2014</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312514048097/d675317dex102.htm"><span style="text-decoration:underline;">Form of Restricted Stock Unit Agreement for use with the 2013 Incentive Plan</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K, as Exhibit 10.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 12, 2014</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312506253375/dex1011.htm"><span style="text-decoration:underline;">Executive Incentive Plan, adopted December 12, 2006</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.11</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 14, 2006</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312508133616/dex101.htm"><span style="text-decoration:underline;">Employment Agreement between Arrowhead and Dr. Christopher Anzalone, dated June 11, 2008</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current Report on Form 8-K, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 13, 2008</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7**</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312509258134/dex108.htm"><span style="text-decoration:underline;">Amendment to Employment Agreement between Arrowhead and Dr. Christopher Anzalone, effective May 12, 2009</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.8</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 22, 2009</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex1033.htm"><span style="text-decoration:underline;">Non-Exclusive License Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.33</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 20, 2011</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.05pt;">
<td valign="bottom" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;Herein</p></td>
</tr>
<tr style="height:3pt;">
<td valign="bottom" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex1036.htm"><span style="text-decoration:underline;">Collaboration Agreement by and among Alnylam Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc., dated October&#160;29, 2009 &#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.36</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 20, 2011</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459014003557/arwr-ex10_20140630353.htm"><span style="text-decoration:underline;">License Agreement by and between Alnylam Pharmaceuticals, Inc., Arrowhead Research Corporation and Arrowhead Madison, Inc.&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 12, 2014</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459016012515/arwr-ex101_83.htm"><span style="text-decoration:underline;">Lease Agreement between University Research Park, Incorporated and Arrowhead Madison, Inc., dated January 8, 2016</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 9, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459016030217/arwr-ex1018_310.htm"><span style="text-decoration:underline;">First Collaboration and Licensing Agreement between Arrowhead Pharmaceuticals, Inc. and Amgen Inc., dated September 28, 2016&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.18</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">December 14, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459016030217/arwr-ex1019_309.htm"><span style="text-decoration:underline;">Second Collaboration and Licensing Agreement between Arrowhead Pharmaceuticals, Inc. and Amgen Inc., dated September 28, 2016&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.19</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">December 14, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000119312516776646/d272157dex101.htm"><span style="text-decoration:underline;">Common Stock Purchase Agreement between the Company and Amgen Inc., dated September 28, 2016</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amendment No. 1 to the Registration Statement on Form S-3, as Exhibit 10.1)</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 25, 2016</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex101_156.htm"><span style="text-decoration:underline;">License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated October 3, 2018&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 7, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex102_155.htm"><span style="text-decoration:underline;">Research Collaboration and Option Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated October 3, 2018&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 7, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex103_154.htm"><span style="text-decoration:underline;">Stock Purchase Agreement by and between Johnson &#38; Johnson Innovation-JJDC, Inc. and Arrowhead Pharmaceuticals, Inc., dated October 3, 2018</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.3</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 7, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex104_153.htm"><span style="text-decoration:underline;">Registration Rights Agreement by and between Arrowhead Pharmaceuticals, Inc. and Johnson &#38; Johnson Innovation-JJDC, Inc., dated October 3, 2018</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.4</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">February 7, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex1019_310.htm"><span style="text-decoration:underline;">Amendment No. 1 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated December 18, 2018&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.19</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 25, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex1020_311.htm"><span style="text-decoration:underline;">Amendment No. 2 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated February</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="text-decoration:underline;">4, 2019&#8224;</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.20</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 25, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex1021_309.htm"><span style="text-decoration:underline;">Amendment No. 1 to Research Collaboration and Option Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated November 14, 2019&#8224;</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Annual Report on Form 10-K, as Exhibit 10.21</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">November 25, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459019028760/arwr-ex101_67.htm"><span style="text-decoration:underline;">Office Lease by and between 177 Colorado Owner LLC and Arrowhead Pharmaceuticals, Inc., dated April 17, 2019</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">August 5, 2019</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex1023_125.htm"><span style="text-decoration:underline;">Amendment No. 1 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated October 22, 2018*+</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex1024_124.htm"><span style="text-decoration:underline;">Amendment No. 2 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 10, 2019*+</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex1025_123.htm"><span style="text-decoration:underline;">Amendment No. 3 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 11, 2019*+</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:12.05pt;">
<td valign="bottom" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td colspan="3" valign="bottom" style="width:35%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated&#160;by&#160;Reference&#160;Herein</p></td>
</tr>
<tr style="height:3pt;">
<td valign="bottom" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex1026_121.htm"><span style="text-decoration:underline;">Amendment No. 4 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated September 19, 2019 *+</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.28</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex1027_122.htm"><span style="text-decoration:underline;">Amendment No. 5 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated May 14, 2020*+</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/879407/000156459020022860/arwr-ex101_202.htm"><span style="text-decoration:underline;">Sublease Agreement by and between Halozyme, Inc. and Arrowhead Pharmaceuticals Inc. dated March 3, 2020</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Quarterly Report on Form 10-Q, as Exhibit 10.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:normal;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">May 7, 2020</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex21_669.htm"><span style="text-decoration:underline;">List of Subsidiaries*</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex23_668.htm"><span style="text-decoration:underline;">Consent of Independent Public Registered Accounting Firm*</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Signature"><span style="text-decoration:underline;">Power of Attorney (contained on signature page)</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex311_7.htm"><span style="text-decoration:underline;">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex312_10.htm"><span style="text-decoration:underline;">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex321_6.htm"><span style="text-decoration:underline;">Certification by Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002***</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="arwr-ex322_9.htm"><span style="text-decoration:underline;">Certification by Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002***</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Schema Document*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Calculation Linkbase Document*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Label Linkbase Document*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Presentation Linkbase Document*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;font-style:normal;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Definition Linkbase Document*</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2020, formatted in Inline XBRL (included as Exhibit 101)*</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:22%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="top" style="width:12%;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Filed herewith</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates compensation plan, contract or arrangement.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Furnished herewith</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Certain schedules and exhibits in this exhibit have been omitted in accordance with Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Signature"><span style="text-decoration:underline;">SIGN</span><span style="text-decoration:underline;">ATURE </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form&#160;10-K to be signed on its behalf by the undersigned, thereunto duly authorized, on this 20th day of November 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: November 20, 2020 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:right;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40.16%;">
<tr>
<td colspan="4" valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD PHARMACEUTICALS, INC.</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:2.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&#160;</p></td>
<td valign="bottom" style="width:89.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:2.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="bottom" style="width:89.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Christopher Anzalone</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:2.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="bottom" style="width:89.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Christopher Anzalone</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;text-align:left;">&#160;</p></td>
<td valign="top" style="width:2.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&#160;</p></td>
<td valign="bottom" style="width:89.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report on Form&#160;10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 1pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Christopher Anzalone</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer, President and</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 20, 2020</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Christopher Anzalone</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director (Principal Executive Officer)</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="color:#000000;">Kenneth A. Myszkowski</span></p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer (Principal</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 20, 2020</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kenneth A. Myszkowski</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial and Accounting Officer)</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/<span style="font-weight:bold;color:#000000;"> </span><span style="color:#000000;">Douglass Given</span></p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director, Chairman of the Board of Directors</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 20, 2020</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Douglass Given</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="color:#000000;">Mauro Ferrari</span></p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 20, 2020</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Mauro Ferrari</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="color:#000000;">Michael S. Perry</span></p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 20, 2020</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Michael S. Perry</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="color:#000000;">William Waddill</span></p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 20, 2020</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">William Waddill</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Marianne De Backer</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 20, 2020</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Marianne De Backer</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Adeoye Olukotun</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 20, 2020</p></td>
</tr>
<tr style="height:1.15pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Adeoye Olukotun</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:normal;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:3.8pt;">
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
<td valign="bottom" style="width:auto;">
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-weight:bold;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="IndexToFinancialStatementsAndSchedules"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO FINAN</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CIAL STATEMENTS AND SCHEDULE</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Reports of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Balance_Sheets"><span style="text-decoration:underline;">Consolidated Balance Sheets of Arrowhead Pharmaceuticals, Inc., September&#160;30, 2020 and 2019</span><span style="text-decoration:none;color:#auto;"></span></a></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Statements_of_Operations"><span style="text-decoration:underline;">Consolidated Statements of Operations and Comprehensive Income (Loss) of Arrowhead Pharmaceuticals, Inc. for the years ended September&#160;30, 2020, 2019 and 2018</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Statement_of_Stockholders"><span style="text-decoration:underline;">Consolidated Statement of Stockholders&#8217; Equity of Arrowhead Pharmaceuticals, Inc. for the years ended September 30, 2020, 2019, and 2018</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Statements_of_Cash_Flows"><span style="text-decoration:underline;">Consolidated Statements of Cash Flows of Arrowhead Pharmaceuticals, Inc. for the years ended September&#160;30, 2020, 2019 and 2018</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Notes_to_Consolidated"><span style="text-decoration:underline;">Notes to Consolidated Financial Statements of Arrowhead Pharmaceuticals, Inc.</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="width:1.66%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:4%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p></td>
<td valign="bottom" style="width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF INDEPENDENT REGIST</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ERED PUBLIC ACCOUNTING FIRM</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and<br />Stockholders of Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Arrowhead Pharmaceuticals, Inc. and Subsidiaries (the Company) as of September 30, 2020 and 2019, and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended September 30, 2020, and the related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2020 and 2019, and the results of its operations and its cash flows for each of the years in the three-year period ended September 30, 2020, in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of September 30, 2020, based on criteria established in <span style="font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated November 23, 2020, expressed an unqualified opinion.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matters</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition &#8211; Contract cost estimates</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Description of the Matter</span></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As discussed in Note 1 and Note 2 to the Consolidated Financial Statements, the Company earns its revenue through license and collaboration agreements. For performance obligations related to services that are required to be recognized over time, the Company generally measures its progress to completion using an input measure of total labor costs incurred divided by total labor costs expected to be incurred. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auditing revenue recognition is complex and highly judgmental due to the variability and uncertainty associated with the Company&#8217;s assessment of measure of progress. Changes in these estimates would have a significant effect on the amount of revenue recognized. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">How We Addressed the Matter in Our Audit</span></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls that address the risk of material misstatement of license and collaboration agreement revenue including those associated with cost to complete estimates. We tested controls over management&#8217;s process to collect, review, and approve the data used in assessing revenue recognized over time. </span></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="keyword">To test the measures of progress used for performance obligations related to services that are required to be recognized over time, our&#160;audit&#160;procedures included, among others, evaluating the appropriateness of the Company&#8217;s accounting policy for each type of arrangement, testing the identified measure of performance by reading contracts with customers, including all amendments, and reviewing the contract analyses prepared by management. We evaluated whether the selected measures of progress towards satisfaction of performance obligations were applied consistently. We also tested the completeness and accuracy of the underlying data used for the measure of progress by testing the underlying cost data and conducting interviews of project personnel. </p>
<p style="margin-top:24pt;text-align:left;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rose, Snyder &#38; Jacobs LLP</p>
<p style="margin-top:6pt;text-align:left;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2004.</p>
<p style="margin-top:6pt;text-align:left;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Encino, California</p>
<p style="margin-top:6pt;text-align:left;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 23, 2020</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-3</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and<br />Stockholders of Arrowhead Pharmaceuticals, Inc. </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on Internal Control over Financial Reporting</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited Arrowhead Pharmaceuticals, Inc. and Subsidiaries (the Company&#8217;s) internal control over financial reporting as of September 30, 2020, based on criteria established in <span style="font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of September 30, 2020, based on criteria established in <span style="font-style:italic;">Internal Control&#8212;Integrated Framework (2013)</span> issued by COSO.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets as of September 30, 2020 and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended September 30, 2020 and related notes, and our report dated November 23, 2020 expressed an unqualified opinion thereon.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Definition and Limitations of Internal Control over Financial Reporting</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company&#59; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company&#59; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rose, Snyder &#38; Jacobs LLP</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Encino, CA</p>
<p style="text-align:left;margin-top:6pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 23, 2020</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-4</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I_FINANCIAL_INFORMATION">PART I. FINANCIAL INFORMATION </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_FINANCIAL_STATEMENTS">FINANCIAL STATEMENTS </p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Balance_Sheets">Consolidated Balance Sheets </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CURRENT ASSETS</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">143,582,667</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">221,804,128</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">845,673</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">661,361</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">4,250,896</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:PrepaidExpenseCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">3,317,999</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current assets</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:OtherAssetsCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">1,781,691</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:OtherAssetsCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">2,563,435</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:MarketableSecuritiesCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">85,019,719</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short term investments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">86,889,751</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">36,899,894</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL CURRENT ASSETS</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:AssetsCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">322,370,397</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:AssetsCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">265,246,817</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">30,880,868</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">23,214,899</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">15,363,151</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">17,063,580</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long term investments</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">137,486,883</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">44,175,993</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">16,137,085</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">265,359</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">144,148</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TOTAL ASSETS</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:Assets" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">522,503,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:Assets" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">349,845,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CURRENT LIABILITIES</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AccountsPayableCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">6,828,909</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AccountsPayableCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">7,649,921</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">5,388,556</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">6,504,729</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll and benefits</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">8,060,854</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">4,955,887</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">1,094,777</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:DeferredRentCreditCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">173,952</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">19,291,075</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">77,769,629</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other current liabilities</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">17,262</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:OtherLiabilitiesCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">16,561</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL CURRENT LIABILITIES</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:LiabilitiesCurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">40,681,433</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:LiabilitiesCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">97,070,679</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LONG-TERM LIABILITIES</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, net of current portion</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">20,043,178</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent, net of current portion</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:DeferredRentCreditNoncurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">3,703,364</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">5,035,142</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL LONG-TERM LIABILITIES</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">20,043,178</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:LiabilitiesNoncurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">8,738,506</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 7)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000077">&#160;</span></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000078">&#160;</span></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc. stockholders' equity:</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000094" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0000879407_20200930" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000095" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0000879407_20190930" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0000879407_20190930" decimals="INF" format="ixt:numdotdecimal">145,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:CommonStockSharesIssued" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal">102,376,303</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:CommonStockSharesIssued" contextRef="C_0000879407_20190930" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000101" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000879407_20190930" decimals="INF" format="ixt:numdotdecimal">95,506,271</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of September 30, 2020 and September 30, 2019, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:CommonStockValue" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">194,746</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:CommonStockValue" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">187,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">965,410,146</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">664,086,155</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income (loss)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">18,433</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0000879407_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">391,624</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000879407_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">503,844,193</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0000879407_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">419,290,967</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:StockholdersEquity" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">461,779,132</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:StockholdersEquity" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">244,591,440</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncontrolling interest</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:MinorityInterest" contextRef="C_0000879407_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">555,188</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">461,779,132</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">244,036,252</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:54.7pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">522,503,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.12%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">349,845,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-5</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Statements_of_Operations">Consolidated Statements of Operations and Comprehensive Income (Loss)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">REVENUE</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">87,992,066</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">168,795,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">16,142,321</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OPERATING EXPENSES</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">128,874,979</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">81,048,686</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">52,968,505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">52,275,890</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">26,556,257</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">19,110,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL OPERATING EXPENSES</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:OperatingExpenses" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">181,150,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:OperatingExpenses" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">107,604,943</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:OperatingExpenses" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">72,078,556</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OPERATING INCOME (LOSS)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">93,158,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">61,190,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">55,936,235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OTHER INCOME (EXPENSE)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income (expense), net</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">9,190,501</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">6,957,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">1,048,523</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value of derivatives</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">432,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other Income (expense)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">582,524</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">7,493</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TOTAL OTHER INCOME (EXPENSE)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">8,607,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">6,957,768</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:NonoperatingIncomeExpense" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">1,488,157</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INCOME (LOSS) BEFORE INCOME TAXES</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">84,550,826</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">68,148,402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">54,448,078</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">2,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">173,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">2,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCOME (LOSS)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:NetIncomeLoss" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">84,553,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:NetIncomeLoss" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">67,974,849</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:NetIncomeLoss" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">54,450,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCOME (LOSS) PER SHARE - BASIC</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000138" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20191001_20200930" decimals="2" sign="-">0.84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000139" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20181001_20190930" decimals="2">0.72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000140" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20171001_20180930" decimals="2" sign="-">0.65</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCOME (LOSS) PER SHARE - DILUTED</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000141" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20191001_20200930" decimals="2" sign="-">0.84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000142" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20181001_20190930" decimals="2">0.69</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000143" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20171001_20180930" decimals="2" sign="-">0.65</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding - basic</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000144" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">100,722,224</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000145" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">93,858,857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000146" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">83,638,469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding - diluted</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000147" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">100,722,224</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000148" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">98,607,815</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000149" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">83,638,469</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">410,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20181001_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">370,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">54,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COMPREHENSIVE INCOME (LOSS)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">84,143,169</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">67,604,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.92%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">54,505,274</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-6</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Statement_of_Stockholders">Consolidated Statement of Stockholders&#8217; Equity </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:7pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common&#160;Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2017</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000156" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170930" decimals="INF" format="ixt:numdotdecimal">74,785,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170930" decimals="0" format="ixt:numdotdecimal">167,155</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170930" decimals="0" format="ixt:numdotdecimal">514,037,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170930" decimals="0" format="ixt:numdotdecimal">33,232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170930" decimals="0" sign="-" format="ixt:numdotdecimal">432,815,338</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20170930" decimals="0" sign="-" format="ixt:numdotdecimal">555,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20170930" decimals="0" format="ixt:numdotdecimal">80,867,162</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930" decimals="0" format="ixt:numdotdecimal">8,454,607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">8,454,607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000165" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930" decimals="INF" format="ixt:numdotdecimal">604,611</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930" decimals="0">605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930" decimals="0" format="ixt:numdotdecimal">2,656,105</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">2,656,710</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000169" name="arwr:StockIssuedDuringPeriodSharesExerciseOfWarrants" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930" decimals="INF" format="ixt:numdotdecimal">288,473</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="arwr:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930" decimals="0">288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="arwr:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930" decimals="0" format="ixt:numdotdecimal">1,237,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="arwr:StockIssuedDuringPeriodValueExerciseOfWarrants" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">1,237,429</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - restricted stock units vesting</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000173" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930" decimals="INF" format="ixt:numdotdecimal">1,326,792</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930" decimals="0" format="ixt:numdotdecimal">1,327</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">55,995</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">54,668</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - issued for cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000177" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930" decimals="INF" format="ixt:numdotdecimal">11,500,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930" decimals="0" format="ixt:numdotdecimal">11,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930" decimals="0" format="ixt:numdotdecimal">56,573,535</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">56,585,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">54,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">54,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) for the twelve months ended September 30, 2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:ProfitLoss" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">54,450,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">54,450,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000185" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930" decimals="INF" format="ixt:numdotdecimal">88,505,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930" decimals="0" format="ixt:numdotdecimal">180,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180930" decimals="0" format="ixt:numdotdecimal">582,902,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">21,564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">487,265,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">555,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20180930" decimals="0" format="ixt:numdotdecimal">95,241,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000192" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930" decimals="INF" format="ixt:numdotdecimal">88,505,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930" decimals="0" format="ixt:numdotdecimal">180,875</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180930" decimals="0" format="ixt:numdotdecimal">582,902,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">21,564</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">487,265,816</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">555,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20180930" decimals="0" format="ixt:numdotdecimal">95,241,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">12,393,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">12,393,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000201" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="INF" format="ixt:numdotdecimal">1,542,795</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">1,543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">8,273,867</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">8,275,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - restricted stock units vesting</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000205" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="INF" format="ixt:numdotdecimal">2,197,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">2,197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">2,197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - issued for cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000208" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="INF" format="ixt:numdotdecimal">3,260,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">3,261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">60,518,468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">60,521,729</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181001_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">370,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20181001_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">370,060</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) for the twelve months ended September 30, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:ProfitLoss" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">67,974,849</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">67,974,849</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000216" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930" decimals="INF" format="ixt:numdotdecimal">95,506,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930" decimals="0" format="ixt:numdotdecimal">187,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930" decimals="0" format="ixt:numdotdecimal">664,086,155</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">391,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">419,290,967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">555,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">244,036,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Non-controlling</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Totals</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000223" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930" decimals="INF" format="ixt:numdotdecimal">95,506,271</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930" decimals="0" format="ixt:numdotdecimal">187,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930" decimals="0" format="ixt:numdotdecimal">664,086,155</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">391,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">419,290,967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">555,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">244,036,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">43,382,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">43,382,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000232" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">1,111,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">1,111</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">7,467,788</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">7,468,899</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - restricted stock units vesting</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000236" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">1,158,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">1,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">1,159</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock - issued for cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000239" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">4,600,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">4,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">250,474,374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">250,478,974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign currency translation adjustments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">410,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">410,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deconsolidation of Ablaris Therapeutics, Inc.</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">555,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">555,188</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss) for the twelve months ended September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:ProfitLoss" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">84,553,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">84,553,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000249" name="us-gaap:SharesOutstanding" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930" decimals="INF" format="ixt:numdotdecimal">102,376,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930" decimals="0" format="ixt:numdotdecimal">194,746</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930" decimals="0" format="ixt:numdotdecimal">965,410,146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200930" decimals="0" format="ixt:numdotdecimal">18,433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">503,844,193</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.26%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">461,779,132</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:7pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-7</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Statements_of_Cash_Flows">Consolidated Statements of Cash Flows </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years ended September 30,</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM OPERATING ACTIVITIES:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">84,553,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">67,974,849</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">54,450,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in value of derivatives</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">432,141</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:ShareBasedCompensation" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">43,382,988</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:ShareBasedCompensation" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">12,393,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:ShareBasedCompensation" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">8,454,607</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:DepreciationAndAmortization" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">5,942,264</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:DepreciationAndAmortization" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">4,439,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:DepreciationAndAmortization" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">4,699,275</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization/(accretion) of note premiums</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">525,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0000879407_20181001_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">1,069,070</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">383,075</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">184,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">333,986</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">259,578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">387,464</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">3,710,515</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">319,166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">63,513,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">82,804,171</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">5,269,140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">821,012</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">4,843,825</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">1,270,416</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">1,989,496</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">2,450,079</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">1,016,506</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">2,228,087</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">1,104,963</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">414,293</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">95,391,570</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">173,034,923</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">47,223,417</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM INVESTING ACTIVITIES:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">11,951,712</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">12,001,225</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">1,421,252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">278,964,290</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">90,266,001</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">52,083,131</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from sale of investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">50,138,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">54,521,219</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">46,069,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">240,777,764</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000879407_20181001_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">47,746,007</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">7,434,963</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH FLOWS FROM FINANCING ACTIVITIES:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principal payments on notes payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:RepaymentsOfNotesPayable" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">2,415,150</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:RepaymentsOfNotesPayable" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">208,506</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of taxes for net share settled restricted stock unit issuances</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">54,667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the exercises of&#160;&#160;stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">7,468,899</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">8,275,410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">3,631,164</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from the issuance of common stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">250,478,974</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">60,521,739</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">56,585,035</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">257,947,873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">66,381,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">59,953,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NET INCREASE (DECREASE) IN CASH</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000879407_20191001_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">78,221,461</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">191,670,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">5,294,646</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">221,804,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20180930" decimals="0" format="ixt:numdotdecimal">30,133,213</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20170930" decimals="0" format="ixt:numdotdecimal">24,838,567</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CASH AND CASH EQUIVALENTS AT END OF PERIOD</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">143,582,667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">221,804,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0000879407_20180930" decimals="0" format="ixt:numdotdecimal">30,133,213</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplementary disclosures:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest paid</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="us-gaap:InterestPaidNet" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">27,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="us-gaap:InterestPaidNet" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">173,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes (Paid) Refunded</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">103,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0000879407_20181001_20190930" decimals="0" sign="-" format="ixt:numdotdecimal">302,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0000879407_20171001_20180930" decimals="0" sign="-" format="ixt:numdotdecimal">2,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-8</p>
<hr style="page-break-after:always" />
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc.</span></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;" id="Notes_to_Consolidated">Notes to Consolidated Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Unless otherwise noted, (1)&#160;the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation and its Subsidiaries, (2)&#160;the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3)&#160;the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;), and Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), (4)&#160;the term &#8220;Common Stock&#8221; refers to Arrowhead&#8217;s Common Stock, (5) the term &#8220;Preferred Stock&#8221; refers to Arrowhead&#8217;s Preferred Stock&#160;and (6) the term &#8220;Stockholder(s)&#8221; refers to the holders of Arrowhead Common Stock. </p><ix:nonNumeric id="F_000327" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true" continuedAt="F_000327_dcnt_3b9a2095-0409-4404-ac74-b4384ba8a7e8">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1. <span style="font-style:italic;">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Nature of Business and Recent Developments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them.&#160;&#160;Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-LUNG2 as a candidate to treat chronic obstructive pulmonary disorder (&#8220;COPD&#8221;) and ARO-COV for treatment for the current novel coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.<span style="font-size:14pt;"> </span>ARO<span style="color:#000000;">-JNJ1, ARO-JNJ2 and ARO-JNJ3 are being developed for undisclosed liver-expressed targets under a collaboration agreement with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;).&#160;&#160;</span>ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) in October 2020. <span style="color:#000000;">ARO-HBV (JNJ-3989) for chronic hepatitis B virus was out-licensed to Janssen in October 2018.&#160;&#160;ARO-LPA (AMG 890)</span><span style="color:#000000;font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">&#160;</sub></span><span style="color:#000000;">for cardiovascular disease was out-licensed to Amgen Inc. (&#8220;Amgen&#8221;) in 2016.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead operates a lab facility in Madison, Wisconsin, where the Company&#8217;s research and development activities, including the development of RNAi therapeutics, are based. The Company&#8217;s principal executive offices are located in Pasadena, California. <span style="color:#000000;">In March 2020, the Company entered into a sublease for additional research and development facility space in San Diego, California as discussed further in Note 8 below.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal year 2020, the Company has continued to develop its pipeline and partnered candidates.&#160;&#160;Regarding the Company&#8217;s wholly-owned pipeline candidates, the Company dosed its first patients in three of its pipeline candidate studies: ARO-HSD1001, a phase 1/2 clinical study of ARO-HSD&#59; ARO-ENaC1001, a phase 1/2 clinical study of ARO-ENaC and ARO-HIF21001, a phase 1b study of ARO-HIF2. The Company also presented new clinical data on its two cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, at multiple medical meetings, including the European Society of Cardiology Congress and the American Heart Association Scientific Sessions.&#160;&#160;Finally, the Company is also progressing ARO-LUNG2 toward entering clinical trials and is continuing to perform discovery work to identify new candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s <span style="color:#000000;">partnered candidates under its collaboration agreements also continue to progress.&#160;&#160;Janssen began dosing patients in a phase 2b triple combination study called REEF-1,&#160;designed to enroll up to 450 patients with chronic hepatitis B infection, and in connection with the start of this study Arrowhead earned a&#160; $<ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="arwr:MilestonePaymentEarned" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930" decimals="-5" scale="6">25.0</ix:nonFraction> million&#160;milestone payment under the License Agreement (&#8220;Janssen License Agreement&#8221;).&#160;&#160;The Company is currently performing discovery, optimization and preclinical research and development for ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3 for Janssen as part of the Research Collaboration and Option Agreement (&#8220;Janssen Collaboration Agreement&#8221;).&#160;&#160;</span>Under the terms of the Janssen agreements taken together, the Company has received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="arwr:CashReceivedAsDueUnderAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003" decimals="-5" scale="6">175.0</ix:nonFraction> million as an upfront payment, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003" decimals="-5" scale="6">75.0</ix:nonFraction> million in the form of an equity investment by JJDC in Arrowhead Common Stock, two $<ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="arwr:MilestonePaymentEarned" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003" decimals="-5" scale="6">25.0</ix:nonFraction> million milestone payments and may receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003" decimals="INF" scale="9">1.6</ix:nonFraction> billion in development and sales milestones payments for the Janssen License Agreement, and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003" decimals="INF" scale="9">1.9</ix:nonFraction> billion in development and sales milestone payments for the <ix:nonFraction unitRef="U_arwrTarget" id="F_000376" name="arwr:NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003_20181003" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> additional targets covered under the Janssen Collaboration Agreement.&#160;&#160;The Company is further eligible to receive tiered royalties up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement on product sales.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s collaboration agreement with Amgen for <span style="color:#000000;">Olpasiran (previously referred to as AMG 890 or ARO-LPA), (the &#8220;Second Collaboration and License Agreement&#8221; or &#8220;Olpasiran Agreement&#8221;),</span> continues to progress. &#160;<span style="color:#000000;">In July 2020, Amgen initiated a Phase 2 clinical study, which resulted in a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="arwr:MilestonePaymentEarned" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20200731" decimals="-5" scale="6">20.0</ix:nonFraction> million milestone payment to the Company.</span>&#160;&#160;The Company has received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="arwr:CashReceivedAsDueUnderAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928" decimals="-5" scale="6">35.0</ix:nonFraction> million in upfront payments, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000379" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928" decimals="-5" scale="6">21.5</ix:nonFraction> million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="arwr:MilestonePaymentReceived" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20160928" decimals="-5" scale="6">30.0</ix:nonFraction> million in milestone payments, and may receive up to an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20200930" decimals="INF" scale="6">400.0</ix:nonFraction> million in remaining development, regulatory and sales milestone payments.&#160;&#160;The Company is eligible to receive up to&#160;low double-digit royalties for sales of products under the <span style="color:#000000;">Olpasiran</span> Agreement.&#160;&#160;<span style="color:#000000;">On October 7, 2020, the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda.&#160;&#160;Under the Takeda License Agreement, </span><span style="Background-color:#FFFFFF;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program. Within the United States, ARO-AAT, if approved, will be co-commercialized under a <ix:nonFraction unitRef="U_xbrlipure" id="F_000382" name="arwr:ProfitSharingStructureRatio" contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201007" decimals="INF" scale="-2">50</ix:nonFraction>/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to </span></p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-9</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000327_dcnt_3b9a2095-0409-4404-ac74-b4384ba8a7e8" continuedAt="F_000327_dcnt_d4f5e467-7589-4b6e-b797-a62eaf7ad71f">
<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">commercialize ARO-AAT with the Company eligible to receive tiered royalties of </span><ix:nonFraction unitRef="U_xbrlipure" id="F_000383" name="arwr:TieredRoyaltiesReceivedPercentage" contextRef="C_0000879407_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007" decimals="INF" scale="-2">20</ix:nonFraction><span style="Background-color:#FFFFFF;">%</span><span style="Background-color:#FFFFFF;"> to </span><span style="Background-color:#FFFFFF;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000384" name="arwr:TieredRoyaltiesReceivedPercentage" contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007" decimals="INF" scale="-2">25</ix:nonFraction></span><span style="Background-color:#FFFFFF;">% on net sales.&#160;&#160;The Company will receive $</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="arwr:CashReceivedAsDueUnderAgreement" contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007" decimals="-5" scale="6">300.0</ix:nonFraction><span style="Background-color:#FFFFFF;"> million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $</span><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="arwr:DevelopmentRegulatoryAndCommercialMilestonesPayments" contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201007" decimals="-5" scale="6">740.0</ix:nonFraction><span style="Background-color:#FFFFFF;"> million.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognition for these collaboration agreements is discussed further in Note 2 below.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the year ended September 30, 2020 were not significantly impacted by COVID-19. The Company temporarily paused enrollment in its two ARO-AAT studies, SEQUOIA and the ARO-AAT 2002 study, but resumed the process of screening and enrolling patients during the three months ended June 30, 2020. During the pause in enrollment, patients already enrolled in these studies continued to be dosed per protocol and continued to come in for their follow up visits. Additional delays have occurred in the Company&#8217;s earlier stage programs, but the Company does not expect a material impact to any program&#8217;s anticipated timelines. Several of the Company&#8217;s other clinical candidates are in the start-up stage (ARO-HSD, ARO-HIF2 and ARO-ENaC), during which significant clinical costs will continue to be incurred. Additionally, the Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued to operate with limited impact, other than for enhanced safety measures, including work from home policies. However, the Company cannot predict the impact of the progression of COVID-19 will have on future financial results due to a variety of factors including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees, and ultimately the length of the COVID-19 pandemic.<span style="color:#000000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Consolidated Financial Statements have been prepared in conformity with the accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), which contemplate the continuation of the Company as a going concern.&#160; Historically, the Company&#8217;s primary source of financing has been through the sale of its securities. Research and development activities have required significant capital investment since the Company&#8217;s inception. The Company expects its operations to continue to require cash investment to pursue its research and development goals, including clinical trials and related drug manufacturing.&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2020, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20200930" decimals="-5" scale="6">143.6</ix:nonFraction> million in cash and cash equivalents (including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20200930" decimals="-5" scale="6">1.8</ix:nonFraction> million in restricted cash), $<ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="C_0000879407_20200930" decimals="-5" scale="6">86.9</ix:nonFraction> million in short-term investments and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:MarketableSecurities" contextRef="C_0000879407_20200930" decimals="-5" scale="6">85.0</ix:nonFraction> million in marketable securities, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" contextRef="C_0000879407_20200930" decimals="-5" scale="6">137.5</ix:nonFraction> million in long-term investments to fund operations.&#160;&#160;During the year ended September 30, 2020, the Company&#8217;s cash and investments balance increased by $<ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="arwr:IncreaseDecreaseInCashAndInvestments" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">150.1</ix:nonFraction> million, which was primarily the result of purchases of investments and marketable securities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">279.0</ix:nonFraction> million and cash outflow primarily related to operations of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000394" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0000879407_20191001_20200930" decimals="-5" sign="-" scale="6">95.4</ix:nonFraction> million, partially offset by the December 2019 securities offering that generated $<ix:nonFraction unitRef="U_iso4217USD" id="F_000395" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_20191201_20191231" decimals="-5" scale="6">250.5</ix:nonFraction> million in net cash proceeds for the Company, as discussed further in Note 6 below, as well as maturities of investments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000396" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">50.1</ix:nonFraction> million. &#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Summary of Significant Accounting Policies </p><ix:nonNumeric id="F_000341" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation&#8212;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#8217;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. </p></ix:nonNumeric><ix:nonNumeric id="F_000342" name="arwr:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation and Use of Estimates&#8212;The <span style="color:#000000;">preparation of financial statements in conformity GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation</span>.&#160;&#160; </p></ix:nonNumeric><ix:nonNumeric id="F_000343" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents&#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000397" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20200930" decimals="-5" scale="6">1.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000398" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_0000879407_20190930" decimals="-5" scale="6">1.0</ix:nonFraction> restricted cash at September 30, 2020 and September 30, 2019, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#8217;s <span style="color:#000000;">lease for its corporate headquarters in Pasadena, California.</span>&#160;&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000344" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk&#8212;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000399" name="us-gaap:CashFDICInsuredAmount" contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_20200930" decimals="INF" format="ixt:numdotdecimal">250,000</ix:nonFraction> per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p></ix:nonNumeric>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-10</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000327_dcnt_d4f5e467-7589-4b6e-b797-a62eaf7ad71f" continuedAt="F_000327_dcnt_cb085187-f6f7-474b-ac07-4ceaf87254ae"><ix:nonNumeric id="F_000345" name="us-gaap:InvestmentPolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments&#8212;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 320, Investments &#8211; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-Maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2020, 2019 and 2018, all of the Company&#8217;s debt securities were classified as held-to-maturity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended September 30, 2020, the Company purchased shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#8217;s Consolidated Balance Sheet as &#8220;marketable securities&#8221; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). </p></ix:nonNumeric><ix:nonNumeric id="F_000346" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment&#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from <ix:nonNumeric id="F_000400" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000879407_srtRangeAxis_srtMinimumMember_20191001_20200930" format="ixt-sec:durwordsen" continuedAt="C_2ea78394-f04e-45e7-9d9b-12bd2603c624">three</ix:nonNumeric> to <ix:nonNumeric id="F_000401" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_20191001_20200930" format="ixt-sec:durwordsen">seven<ix:continuation id="C_2ea78394-f04e-45e7-9d9b-12bd2603c624"> years</ix:continuation></ix:nonNumeric>. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p></ix:nonNumeric><ix:nonNumeric id="F_000347" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000348" name="arwr:ContingentConsiderationPolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration&#8212;The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $<ix:nonFraction unitRef="U_iso4217USD" id="F_000402" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="C_0000879407_20200930" decimals="-6" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000403" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="C_0000879407_20190930" decimals="-6" scale="6">0</ix:nonFraction></ix:nonFraction> at September 30, 2020 and September 30, 2019. </p></ix:nonNumeric>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-11</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000327_dcnt_cb085187-f6f7-474b-ac07-4ceaf87254ae" continuedAt="F_000327_dcnt_23b86fb8-3f89-4150-848e-72043034ed90"><ix:nonNumeric id="F_000349" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true" continuedAt="F_000349_dcnt_30d693a5-7393-4ed3-b24c-4f17857f54c0">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212; <span style="color:#000000;">On October 1, 2018, the Company adopted FASB Topic 606 &#8211; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#8217;s adoption of the new revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#8217;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, and Takeda and the analysis of the impact of this guidance on those agreements is discussed further in Note 2 below.&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the new revenue standard, the Company performs the following five steps: (i) identify the contract&#59; (ii) identify the performance obligations&#59; (iii) determine the transaction price&#59; (iv) allocate the transaction price to the performance obligations in the contract&#59; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials&#59; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States&#59; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed&#160;&#160;are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the new revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</p>
</ix:nonNumeric></ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-12</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000327_dcnt_23b86fb8-3f89-4150-848e-72043034ed90" continuedAt="F_000327_dcnt_4f241b2a-0127-48be-a05e-3ce76b23dd5a"><ix:continuation id="F_000349_dcnt_30d693a5-7393-4ed3-b24c-4f17857f54c0">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">goods or services promised in a contract</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> should be accounted for as a </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combined performance obligation over time</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the proportional performance method</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Labor hours</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or costs incurred</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are typically used as the measure of performance.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company determines that</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the performance </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation is satisfied over time, any upfront</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payment </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received is initially recorded </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deferred</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> revenue </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the Company&#8217;s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Consolidated Balance Sheets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#8217;s current operating plan and, if the Company&#8217;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000350" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" contextRef="C_0000879407_20191001_20200930" escape="true">Allowance for Doubtful Accounts&#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed.</ix:nonNumeric> </p><ix:nonNumeric id="F_000351" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000352" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">Net Income (Loss) per Share&#8212;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees.&#160;&#160;During the years ended September 30, 2020, 2019 and 2018, the calculation of the effect of dilutive stock options and restricted stock units was <ix:nonFraction unitRef="U_xbrlishares" id="F_000404" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="C_0000879407_20191001_20200930" decimals="INF">0</ix:nonFraction> shares, <ix:nonFraction unitRef="U_xbrlishares" id="F_000405" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="C_0000879407_20181001_20190930" decimals="INF" format="ixt:numdotdecimal">4,748,958</ix:nonFraction> shares, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000406" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" contextRef="C_0000879407_20180101_20181231" decimals="INF">0</ix:nonFraction> shares, respectively.&#160;&#160;During the year ended September 30, 2020,<span style="color:#000000;"> the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2019, the calculation of the effect of dilutive stock options and restricted stock units excluded <ix:nonFraction unitRef="U_xbrlishares" id="F_000407" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">1,007,500</ix:nonFraction> stock options and <ix:nonFraction unitRef="U_xbrlishares" id="F_000408" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">11,500</ix:nonFraction> restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2018, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;&#160;&#160;&#160;&#160; </span></ix:nonNumeric> </p><ix:nonNumeric id="F_000353" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000354" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.</ix:nonNumeric><span style="font-size:12pt;">&#160;</span></p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-13</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000327_dcnt_4f241b2a-0127-48be-a05e-3ce76b23dd5a"><ix:nonNumeric id="F_000355" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases<span style="color:#000000;">&#8212;</span>The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term.&#160;Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </p></ix:nonNumeric><ix:nonNumeric id="F_000356" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and became effective for the Company in the first quarter of fiscal 2019. In April 2016, the FASB issued an amendment to ASU No. 2014-09 with update ASU 2016-10 which provided more specific guidance around the identification of performance obligations and licensing arrangements.&#160;&#160;On <ix:nonNumeric id="F_000410" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200930" format="ixt:datemonthdayyearen">October 1, 2018</ix:nonNumeric>, the Company adopted this standard using the modified retrospective method. The Company&#8217;s implementation approach included reviewing the status of each of its ongoing license agreements and collaboration agreements and designing appropriate internal controls to enable the preparation of financial information.&#160;&#160;The Company completed its assessment of the impact of the new revenue recognition guidance and determined that there will be no material impact.&#160;&#160;The Company&#8217;s existing performance obligations under its ongoing license and collaboration agreements as of October 1, 2018 and prior were substantially completed prior to September 30, 2018.&#160;&#160;For these agreements that were ongoing as of October 1, 2018, any future option, milestone or royalty payments received will be accounted for under the sales-based royalty exception provided for under this new revenue recognition guidance.&#160;&#160;Additionally, there will be no impact to cash from or used in operating, financing or investing activities on the Company&#8217;s Consolidated Statement of Cash Flows as a result of the adoption of the new standard.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842).&#160;&#160;Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&#160;&#160;The Company adopted this standard effective <ix:nonNumeric id="F_000415" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200930" format="ixt:datemonthdayyearen">October 1, 2019</ix:nonNumeric> and <span style="color:#000000;">elected the package of three practical expedients that permits an entity to i) not reassess whether expired or existing contracts contain leases, ii) not reassess lease classification for existing or expired leases, and iii) not consider whether previously capitalized initial direct costs would be appropriate under the new standard.&#160;&#160;At September 30, 2020, the Company has recorded right-of-use assets of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0000879407_20200930" decimals="-5" scale="6">16.1</ix:nonFraction> million and right-of-use liabilities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000413" name="us-gaap:OperatingLeaseLiability" contextRef="C_0000879407_20200930" decimals="-5" scale="6">21.1</ix:nonFraction> million on its Consolidated Balance Sheets for its research and development facility leases in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below.&#160;&#160;The adoption of this standard did not have a material impact on the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss) and the Company&#8217;s Consolidated Statements of Cash Flows.&#160;&#160; </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808).&#160;&#160;This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 becomes effective for the Company in the first quarter of fiscal 2021 with early adoption permitted.&#160;&#160;The Company does not expect the adoption of this update to have a material effect on its Consolidated Financial Statements. </p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-14</p>
<hr style="page-break-after:always" /><ix:nonNumeric id="F_000328" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true" continuedAt="F_000328_dcnt_3c6b97a3-e366-44cb-bb7b-c8d63544c8f3">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2. <span style="font-style:italic;">COLLABORATION AND LICENSE AGREEMENTS</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amgen Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000419" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928" format="ixt:datemonthdayyearen">September&#160;28, 2016</ix:nonNumeric>, the Company entered into <ix:nonFraction unitRef="U_arwrAgreement" id="F_000420" name="arwr:NumberOfAgreements" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160928" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> Collaboration and License Agreements, and a Common Stock Purchase Agreement with Amgen Inc., a Delaware corporation (&#8220;Amgen&#8221;). Under one of the collaboration and license agreements (the &#8220;Second Collaboration and License Agreement&#8221; or &#8220;Olpasiran Agreement&#8221;), Amgen has received a worldwide, exclusive license to Arrowhead&#8217;s novel, RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the other collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928" decimals="-5" scale="6">35.0</ix:nonFraction> million in upfront payments, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928" decimals="-5" scale="6">21.5</ix:nonFraction> million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="arwr:MilestonePaymentReceived" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20160928" decimals="INF" scale="6">30.0</ix:nonFraction> million in milestone payments, and may receive up to an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20200930" decimals="INF" scale="6">400.0</ix:nonFraction> million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement.&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement.&#160;&#160;Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study, which resulted in a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="arwr:MilestonePaymentReceived" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200731" decimals="-6" scale="6">20</ix:nonFraction> million milestone payment to the Company. During the years ended September 30, 2020, 2019 and 2018, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930" decimals="-5" scale="6">20.1</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930" decimals="-5" scale="6">0.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20180101_20181231" decimals="-5" scale="6">16.1</ix:nonFraction> million of Revenue associated with its agreements with Amgen, respectively.  As of September 30, 2020, there were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200930" decimals="-6" scale="6">0</ix:nonFraction> million in contract assets recorded as accounts receivable and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200930" decimals="-6" scale="6">0</ix:nonFraction> contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Janssen Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000434" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003_20181003" format="ixt:datemonthdayyearen"><ix:nonNumeric id="F_000435" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003" format="ixt:datemonthdayyearen"><ix:nonNumeric id="F_000436" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003" format="ixt:datemonthdayyearen">October 3, 2018</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric>, the Company entered into a License Agreement (&#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (&#8220;Janssen Collaboration Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) part of the Janssen Pharmaceutical Companies of Johnson &#38; Johnson.&#160;&#160;The Company also entered into a Stock Purchase Agreement (&#8220;JJDC Stock Purchase Agreement&#8221;) with Johnson &#38; Johnson Innovation-JJDC, Inc. (&#8220;JJDC&#8221;), a New Jersey corporation.&#160;&#160;Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), Janssen is also wholly responsible for clinical development and commercialization of JNJ-3989.&#160;&#160;Under the Janssen Collaboration Agreement, Janssen will be able to select three new targets against which Arrowhead will develop clinical candidates.&#160;&#160;These candidates are subject to certain restrictions and do not include candidates that already were in the Company&#8217;s pipeline.&#160;&#160;The Company will perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, is sufficient to allow the filing of a U.S. Investigational New Drug application or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned candidate.&#160;&#160;Under the terms of the agreements taken together, the Company has received $<ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003" decimals="-5" scale="6">175.0</ix:nonFraction> million as an upfront payment, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003" decimals="-5" scale="6">75.0</ix:nonFraction> million in the form of an equity investment <span style="color:#000000;">by JJDC in Arrowhead Common Stock under the JJDC </span>Stock Purchase Agreement, and two $<ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="arwr:MilestonePaymentEarned" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003" decimals="-5" scale="6">25.0</ix:nonFraction> million milestone payments, and may receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003" decimals="INF" scale="9">1.6</ix:nonFraction> billion in development and sales milestones payments for the Janssen License Agreement, and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003" decimals="INF" scale="9">1.9</ix:nonFraction> billion in development and sales milestone payments for the <ix:nonFraction unitRef="U_arwrTarget" id="F_000441" name="arwr:NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> additional targets covered under the Janssen Collaboration Agreement.&#160;&#160;The Company is further eligible to receive tiered royalties up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement on product sales.&#160;&#160; </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-15</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000328_dcnt_3c6b97a3-e366-44cb-bb7b-c8d63544c8f3" continuedAt="F_000328_dcnt_00b8e958-3de7-474e-b070-91e36fb8ca75">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated these agreements in accordance with the new revenue recognition standard that became effective for the Company on October 1, 2018.&#160;&#160;The adoption of the new revenue standard did not have a material impact on the balances reported when evaluated under the superseded revenue standard.&#160;&#160;At the inception of these agreements, the Company has identified <ix:nonFraction unitRef="U_arwrObligation" id="F_000443" name="arwr:NumberOfDistinctPerformanceObligations" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003_20181003" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> distinct performance obligation.&#160;&#160;Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&#38;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&#38;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Janssen R&#38;D Services, and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and thus, one performance obligation.&#160;&#160;The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for this option will be accounted for if and when it is exercised. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the transaction price totaled approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="arwr:InitialTransactionPrice" contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003" decimals="-5" scale="6">252.6</ix:nonFraction> million which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, the two $<ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="arwr:MilestonePaymentEarned" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003" decimals="-5" scale="6">25.0</ix:nonFraction> million milestone payments earned and estimated payments for reimbursable Janssen R&#38;D services to be performed.&#160;&#160;The Company has allocated the total $<ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="arwr:InitialTransactionPrice" contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003" decimals="-5" scale="6">252.6</ix:nonFraction> million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&#38;D Services.&#160;&#160;This revenue will be recognized using a proportional performance method (based on actual labor hours versus estimated total labor hours) beginning in October 2018 and ending as the Company&#8217;s efforts in overseeing the phase 1/2 clinical trial are completed.&#160;&#160;During the years ended September 30, 2020 and 2019, the Company recognized approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20191001_20200930" decimals="-5" scale="6">65.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181001_20190930" decimals="-5" scale="6">167.5</ix:nonFraction> million of Revenue associated with this performance obligation, respectively. As of September 30, 2020, there were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930" decimals="0">0</ix:nonFraction> in contract assets recorded as accounts receivable, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930" decimals="-5" scale="6">19.3</ix:nonFraction> million of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.&#160;&#160;The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930" decimals="-5" scale="6">19.3</ix:nonFraction> million of current deferred revenue is driven by the upfront payment, the premium paid by JJDC for its equity investment in the Company, and the two $<ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="arwr:MilestonePaymentEarned" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930" decimals="-5" scale="6">25.0</ix:nonFraction> million milestone payments earned, net of revenue recognized to date.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has begun to conduct its discovery, optimization and preclinical research and development of ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3 under the Janssen Collaboration Agreement.&#160;&#160;All costs and labor hours spent by the Company will be entirely funded by Janssen.&#160; During the years ended September 30, 2020 and 2019, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20191001_20200930" decimals="-5" scale="6">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20181001_20190930" decimals="-5" scale="6">1.0</ix:nonFraction> million of Revenue associated with these efforts, respectively. As of September 30, 2020, there were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20200930" decimals="-5" scale="6">0.8</ix:nonFraction> million of cont<span style="color:#000000;">ract assets recorded as accounts </span>receivable, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20200930" decimals="-6" scale="6">0</ix:nonFraction> of contract liabilities recorded as curren<span style="color:#000000;">t deferred revenue on the Company&#8217;s Consolidated Balance</span> Sheets.&#160; <span style="color:#000000;"> &#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Takeda Pharmaceuticals U.S.A., Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000457" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" format="ixt:datemonthdayyearen">October 7, 2020</ix:nonNumeric>, the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;).&#160;&#160;Under the Takeda License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a <ix:nonNumeric id="F_000458" name="arwr:RatioOfProfitSharingStructureForCommercialization" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">50/50 profit sharing</ix:nonNumeric> structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with the Company eligible to receive tiered royalties of <ix:nonFraction unitRef="U_xbrlipure" id="F_000459" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMinimumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="2" scale="-2">20</ix:nonFraction>% to <ix:nonFraction unitRef="U_xbrlipure" id="F_000460" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="2" scale="-2">25</ix:nonFraction>% on net sales.&#160;&#160;The Company will receive $<ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007" decimals="-5" scale="6">300.0</ix:nonFraction> million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007" decimals="-5" scale="6">740.0</ix:nonFraction> million.</span>&#160;&#160;</p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-16</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000328_dcnt_00b8e958-3de7-474e-b070-91e36fb8ca75">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the Takeda License Agreement in accordance with the new revenue recognition requirements that became effective for the Company on October 1, 2018. The adoption of the new revenue standard will not have a material impact on the balances reported when evaluated under the superseded revenue standard.&#160;&#160;At the inception of the Takeda License Agreement, the Company has identified <ix:nonFraction unitRef="U_arwrObligation" id="F_000464" name="arwr:NumberOfDistinctPerformanceObligations" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&#38;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&#38;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Takeda R&#38;D services, and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="U_arwrBundle" id="F_000463" name="arwr:NumberOfDistinctBundle" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> distinct bundle and thus, one performance obligation.&#160;&#160;Beyond the Takeda R&#38;D Services, Takeda will be responsible for managing future clinical development and commercialization.&#160;&#160;The Company will co-fund certain of the development and commercialization costs that Takeda manages, and these co-funding amounts will be offset against amounts owed to Arrowhead, either from milestones or royalties earned, or profits earned under the <ix:nonNumeric id="F_000465" name="arwr:RatioOfProfitSharingStructureForCommercialization" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">50/50 profit sharing</ix:nonNumeric> structure for U.S. commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the initial transaction price totaled approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="arwr:InitialTransactionPrice" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="-5" scale="6">300.0</ix:nonFraction> million which includes the upfront payment.&#160;&#160;The Company will exclude any future estimated milestones, royalties or profit-sharing payments from this transaction price to date.&#160;&#160;The Company will allocate the total $300.0 million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&#38;D Services.&#160;&#160;This revenue will be recognized using a proportional performance method (based on actual costs incurred versus estimated total estimated costs incurred for the Takeda R&#38;D Services) beginning in the Company&#8217;s first fiscal quarter of fiscal 2021 and ending as the Takeda R&#38;D Services are completed.&#160;&#160;<span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000329" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3. <span style="font-style:italic;">PROPERTY AND EQUIPMENT</span></p><ix:nonNumeric id="F_000357" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s major classes of property and equipment:<span style="font-size:11pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers, office equipment and furniture</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:FurnitureAndFixturesGross" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">661,927</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:FurnitureAndFixturesGross" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">637,577</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="arwr:ResearchEquipmentGross" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">20,654,323</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="arwr:ResearchEquipmentGross" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">12,932,304</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">631,204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:CapitalizedComputerSoftwareGross" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">147,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:LeaseholdImprovementsGross" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">25,237,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:LeaseholdImprovementsGross" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">21,579,415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross fixed assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">47,185,305</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">35,296,550</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">16,304,437</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">12,081,651</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">30,880,868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">23,214,899</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense for property and equipment for the years ended September 30, 2020, 2019, and 2018  was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">4,241,834</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">2,738,715</ix:nonFraction>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">2,998,846</ix:nonFraction> respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-17</p>
<hr style="page-break-after:always" /><ix:nonNumeric id="F_000330" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 4. <span style="font-style:italic;">INVESTMENTS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments at September 30, 2020 primarily consist of corporate bonds that have maturities of less than 36 months and marketable equity securities. The Company&#8217;s corporate bonds consists of both short-term and long-term bonds and are classified as &#8220;held-to-maturity&#8221; on the Company&#8217;s Consolidated Balance Sheets. The Company&#8217;s marketable equity securities consist of mutual funds that invests in U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities. Dividends from these three funds are automatically reinvested.&#160;&#160;The Company may also invest excess cash balances in certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper.&#160;&#160;The Company accounts for its held to maturity investments in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities and its marketable equity securities in accordance with ASC 321, Investments &#8211; Equity Securities.&#160;&#160;</p><ix:nonNumeric id="F_000358" name="arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s short-term, long-term investments and marketable securities as of September 30, 2020 and September 30, 2019 by measurement category. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Held to Maturity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930" decimals="0" format="ixt:numdotdecimal">86,889,751</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930" decimals="0" format="ixt:numdotdecimal">1,589,873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930" decimals="0" format="ixt:numdotdecimal">88,479,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930" decimals="0" format="ixt:numdotdecimal">137,486,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930" decimals="0" format="ixt:numdotdecimal">4,573,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930" decimals="0" format="ixt:numdotdecimal">79,471</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930" decimals="0" format="ixt:numdotdecimal">141,981,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">224,376,634</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">6,163,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">79,471</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">230,461,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20190930" decimals="0" format="ixt:numdotdecimal">36,899,894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20190930" decimals="0" format="ixt:numdotdecimal">222,584</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20190930" decimals="0" format="ixt:numdotdecimal">37,122,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20190930" decimals="0" format="ixt:numdotdecimal">44,175,993</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20190930" decimals="0" format="ixt:numdotdecimal">875,258</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20190930" decimals="0" format="ixt:numdotdecimal">45,051,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:HeldToMaturitySecurities" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">81,075,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">1,097,842</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">82,173,729</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized Gains/(Losses)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="us-gaap:EquitySecuritiesFvNiCost" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930" decimals="0" format="ixt:numdotdecimal">85,000,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="arwr:EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930" decimals="0" format="ixt:numdotdecimal">94,734</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930" decimals="0" format="ixt:numdotdecimal">75,015</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:EquitySecuritiesFvNi" contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930" decimals="0" format="ixt:numdotdecimal">85,019,719</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="us-gaap:EquitySecuritiesFvNiCost" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">85,000,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="arwr:EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">94,734</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">75,015</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="us-gaap:EquitySecuritiesFvNi" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">85,019,719</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><ix:nonNumeric id="F_000331" name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true" continuedAt="F_000331_dcnt_a5f45577-aa0f-472c-b66a-e8734c137bbb">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5. <span style="font-style:italic;">INTANGIBLE ASSETS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was <ix:nonNumeric id="F_000512" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191001_20200930" format="ixt-sec:duryear">21</ix:nonNumeric> years, and the accumulated amortization of the asset is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20200930" decimals="0" format="ixt:numdotdecimal">828,596</ix:nonFraction>.&#160;&#160;The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was <ix:nonNumeric id="F_000514" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191001_20200930" format="ixt-sec:duryear">14</ix:nonNumeric> years, and the accumulated amortization of the assets is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20200930" decimals="0" format="ixt:numdotdecimal">8,665,466</ix:nonFraction>.&#160;&#160;Amortization expense for the years ended September 30, 2020, 2019, and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">1,700,429</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">1,700,430</ix:nonFraction>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">1,700,429</ix:nonFraction>, respectively. Amortization expense is expected to be $<ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">1,700,429</ix:nonFraction> in 2021, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">1,700,429</ix:nonFraction> in 2022, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">1,700,429</ix:nonFraction> in 2023, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">1,700,429</ix:nonFraction> in 2024, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">1,700,429</ix:nonFraction> in 2025 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">6,861,006</ix:nonFraction> thereafter.</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-18</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000331_dcnt_a5f45577-aa0f-472c-b66a-e8734c137bbb"><ix:nonNumeric id="F_000359" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides details on the Company&#8217;s intangible asset balances: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">17,063,580</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">1,700,429</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">15,363,151</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000332" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6. <span style="font-style:italic;">STOCKHOLDERS&#8217; EQUITY</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2020, the Company had a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000528" name="us-gaap:CapitalUnitsAuthorized" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction> shares of capital stock authorized for issuance, consisting of <ix:nonFraction unitRef="U_xbrlishares" id="F_000529" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal">145,000,000</ix:nonFraction> shares of Common Stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000530" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0000879407_20200930" decimals="INF">0.001</ix:nonFraction> per share, and <ix:nonFraction unitRef="U_xbrlishares" id="F_000531" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction> shares of Preferred Stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000532" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0000879407_20200930" decimals="INF">0.001</ix:nonFraction> per share. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2020, <span style="color:#000000;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000533" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal">102,376,303</ix:nonFraction></span> shares of Common Stock were outstanding.&#160;&#160;At September 30, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000534" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_20200930" decimals="INF" format="ixt:numdotdecimal">8,462,148</ix:nonFraction> shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead&#8217;s 2004 Equity Incentive Plan and 2013 Incentive Plan, as well as for inducement grants made to new employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000535" name="us-gaap:SharesIssued" contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191231" decimals="INF" format="ixt:numdotdecimal">4,600,000</ix:nonFraction> shares of its Common Stock in a public offering at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000538" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191231" decimals="INF">58.00</ix:nonFraction> per share.&#160;&#160;The aggregate purchase price paid by the investors for the Common Stock was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000536" name="arwr:ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191201_20191231" decimals="-5" scale="6">266.8</ix:nonFraction> million, and the Company received net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191201_20191231" decimals="-5" scale="6">250.5</ix:nonFraction> million after deducting advisory fees and offering expenses.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="arwr:CommonStockCapitalSharesValueReservedForFutureIssuance" contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200831" decimals="INF" format="ixt:numdotdecimal">250,000,000</ix:nonFraction> in shares of the Company&#8217;s Common Stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000540" name="arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200801_20200831" decimals="3" scale="-2">3.0</ix:nonFraction>% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At September 30, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000541" name="us-gaap:SharesIssued" contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> shares have been issued under the ATM Agreement.</p></ix:nonNumeric><ix:nonNumeric id="F_000333" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7. <span style="font-style:italic;">COMMITMENTS AND CONTINGENCIES</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business.&#160;&#160;If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss.&#160;&#160;There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000542" name="us-gaap:LossContingencyAccrualAtCarryingValue" contextRef="C_0000879407_20200930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> contingent liabilities recorded as of the year ended September 30, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Purchase Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into various purchase commitments for the manufacture of drug components, for toxicology studies and for clinical studies. &#160;As of September 30, 2020, these future commitments were estimated at approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:PurchaseObligation" contextRef="C_0000879407_20200930" decimals="-5" scale="6">78.0</ix:nonFraction> million, of which approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" contextRef="C_0000879407_20200930" decimals="-5" scale="6">60.2</ix:nonFraction> million is expected to be incurred in fiscal 2021, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:PurchaseObligationDueInSecondYear" contextRef="C_0000879407_20200930" decimals="-5" scale="6">17.8</ix:nonFraction> million is expected to be incurred beyond fiscal 2021.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Technology License Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has licensed from third parties the rights to use certain technologies for its research and development&#160;activities,&#160;as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. &#160;Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and upon certain sales level milestones. &#160;These milestone payments could amount to the mid to upper double-digit millions of dollars. During the year ended September 30, 2020, the Company incurred $<ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="arwr:MilestonePayments" contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_us-gaapTypeOfArrangementAxis_arwrAROENacAndAROHIF2CandidatesMember_20191001_20200930" decimals="-5" scale="6">2.4</ix:nonFraction> million of milestone payments related to the progression of the ARO-ENaC and ARO-HIF2 candidates.  During the years ended September 30, 2019 and 2018, the Company did <ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="arwr:MilestonePayments" contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20181001_20190930" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="arwr:MilestonePayments" contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20171001_20180930" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t trigger any milestone payments.&#160;&#160;In certain agreements, the Company may be required to make mid to high single-digit percentage royalty payments based on a percentage of the sales of the relevant products.<span style="font-size:12pt;">&#160;</span>&#160;&#160;&#160;&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:4.54%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000334" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true" continuedAt="F_000334_dcnt_66524a76-ef0e-4a4e-8204-bc3fc7151fd5">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8. <span style="font-style:italic;">LEASES</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the Company entered into a lease for its corporate headquarters in Pasadena, California.&#160;&#160;The <ix:nonNumeric id="F_000549" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430" format="ixt-sec:durmonth">91</ix:nonNumeric> month office building lease between the Company and 177 Colorado Owner, LLC is for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000550" name="us-gaap:LandSubjectToGroundLeases" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430" decimals="0" format="ixt:numdotdecimal">24,000</ix:nonFraction> square feet of office space located at 177 E. Colorado Blvd, Pasadena, California. &#160;The increased capacity of this new office space compared to the Company&#8217;s prior corporate headquarters will accommodate increased personnel as the Company&#8217;s pipeline of drug candidates expands and moves closer to market. Lease payments began on <ix:nonNumeric id="F_000551" name="arwr:LeasePaymentsCommencementDate" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430" format="ixt:datemonthdayyearen">September 30, 2019</ix:nonNumeric> and are estimated to total approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430" decimals="-5" scale="6">8.7</ix:nonFraction> million over the term. <span style="font-size:12pt;color:#000000;">&#160;</span>The lease expires on <ix:nonNumeric id="F_000553" name="us-gaap:LeaseExpirationDate1" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430" format="ixt:datemonthdayyearen">April 30, 2027</ix:nonNumeric>.  The Company has paid approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430" decimals="-5" scale="6">3.5</ix:nonFraction> million for leasehold improvements, net of tenant improvement allowances.&#160;&#160;The lease contains an option to renew for <ix:nonFraction unitRef="U_arwrOption" id="F_000556" name="arwr:NumberOfOptionsToRenew" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> term of <ix:nonNumeric id="F_000555" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430" format="ixt-sec:durwordsen">five years</ix:nonNumeric>. The exercise of this option was not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#8217;s Consolidated Balance Sheet at September 30, 2020.&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the Company entered into a lease for its research facility in Madison, Wisconsin.&#160;&#160;The lease was for approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000557" name="us-gaap:LandSubjectToGroundLeases" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160131" decimals="0" format="ixt:numdotdecimal">60,000</ix:nonFraction> square feet of office and laboratory space and had an expiration date of <ix:nonNumeric id="F_000558" name="us-gaap:LeaseExpirationDate1" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160101_20160131" format="ixt:datemonthdayyearen">September 30, 2026</ix:nonNumeric>. The lease was amended in January 2019 to expand the rentable square feet by an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000559" name="arwr:AdditionalLandSubjectToLease" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20190131" decimals="INF" format="ixt:numdotdecimal">14,000</ix:nonFraction> square feet and to extend the lease expiration date to <ix:nonNumeric id="F_000560" name="arwr:LeaseExpirationMonthAndYear" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20190131" format="ixt:datemonthyearen">September 2029</ix:nonNumeric>. In May 2020, the Company further amended the lease to increase the rentable square feet by an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000561" name="arwr:AdditionalLandSubjectToLease" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200501_20200531" decimals="INF" format="ixt:numdotdecimal">26,000</ix:nonFraction> square feet and extended the lease expiration date to <ix:nonNumeric id="F_000562" name="us-gaap:LeaseExpirationDate1" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200501_20200531" format="ixt:datemonthdayyearen">September 30, 2031</ix:nonNumeric>.&#160;&#160;Lease payments are estimated to total approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000563" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200930" decimals="-5" scale="6">26.2</ix:nonFraction> million for the term.<span style="font-size:12pt;">&#160;</span><span style="color:#000000;">The lease contains <ix:nonFraction unitRef="U_arwrOption" id="F_000565" name="arwr:NumberOfOptionsToRenew" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200930" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> options to renew for two terms of <ix:nonNumeric id="F_000564" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200930" format="ixt-sec:durwordsen">five years</ix:nonNumeric>. The exercise of these options were not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#8217;s Consolidated Balance Sheet at September 30, 2020.&#160;</span> &#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with Halozyme, Inc. for additional research and development facility space in San Diego, California.&#160; The Sublease provides additional space needed to accommodate the recent growth of the Company&#8217;s personnel and discovery efforts. The sublease is for approximately <span style="Background-color:#FFFFFF;color:#000000;"><ix:nonFraction unitRef="U_utrsqft" id="F_000566" name="us-gaap:LandSubjectToGroundLeases" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331" decimals="0" format="ixt:numdotdecimal">21,000</ix:nonFraction></span> rentable square feet.&#160; The term of the Sublease commenced on <ix:nonNumeric id="F_000567" name="arwr:SubleaseCommencementDate" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331" format="ixt:datemonthdayyearen">April 1, 2020</ix:nonNumeric> and will end on <ix:nonNumeric id="F_000568" name="us-gaap:LeaseExpirationDate1" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331" format="ixt:datemonthdayyearen">January 14, 2023</ix:nonNumeric>.&#160;&#160;Sublease payments are estimated to total approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331" decimals="-5" scale="6">2.0</ix:nonFraction> million over the term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost during the years ended September 30, 2020, 2019, and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="us-gaap:OperatingLeaseCost" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">2.4</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="us-gaap:OperatingLeaseCost" contextRef="C_0000879407_20181001_20190930" decimals="-5" scale="6">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="us-gaap:OperatingLeaseCost" contextRef="C_0000879407_20171001_20180930" decimals="-5" scale="6">1.3</ix:nonFraction> million respectively.&#160;&#160;Variable lease costs during the year ended September 30, 2020 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000573" name="us-gaap:VariableLeaseCost" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">0.8</ix:nonFraction> million.&#160;&#160;There was <ix:nonFraction unitRef="U_iso4217USD" id="F_000574" name="us-gaap:ShortTermLeaseCost" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="us-gaap:ShortTermLeaseCost" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000576" name="us-gaap:ShortTermLeaseCost" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> short-term lease cost during the years ended September 30, 2020, 2019 and 2018. </p><ix:nonNumeric id="F_000360" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September 30, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">3,091,901</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">3,853,290</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">3,406,754</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000580" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">3,269,674</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000581" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">3,358,292</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000582" name="arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">15,331,296</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">32,311,207</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">11,173,252</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities (includes current portion)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:OperatingLeaseLiability" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">21,137,955</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for the amounts included in the measurement of the operating lease liabilities on the Company&#8217;s Consolidated Balance Sheet and included in Other changes in operating assets and liabilities within cash flows from operating activities on the Company&#8217;s Consolidated Statement of Cash Flow for the years ended September 30, 2020, 2019 and 2018 were  $<ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:OperatingLeasePayments" contextRef="C_0000879407_20191001_20200930" decimals="-5" scale="6">1.8</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:OperatingLeasePayments" contextRef="C_0000879407_20181001_20190930" decimals="-5" scale="6">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:OperatingLeasePayments" contextRef="C_0000879407_20171001_20180930" decimals="-5" scale="6">1.3</ix:nonFraction> million, respectively.&#160;The weighted-average remaining lease term and weighted-average discount rate for all leases as of September 30, 2020 was <span style="color:#000000;"><ix:nonNumeric id="F_000589" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0000879407_20200930" format="ixt-sec:duryear">9.4</ix:nonNumeric> years</span> and <ix:nonFraction unitRef="U_xbrlipure" id="F_000590" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0000879407_20200930" decimals="3" scale="-2">8.4</ix:nonFraction>%, respectively.</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-20</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000334_dcnt_66524a76-ef0e-4a4e-8204-bc3fc7151fd5"><ix:nonNumeric id="F_000361" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2019, future minimum lease payments due in fiscal years under operating leases were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000591" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">1,521,451</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000592" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">2,256,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000593" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">2,521,446</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000594" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">2,590,558</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">2,661,512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and thereafter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">10,834,206</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">22,385,552</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000335" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true" continuedAt="F_000335_dcnt_1cd84a24-cde0-4afd-9988-53a2637aa72d">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9. <span style="font-style:italic;">STOCK-BASED COMPENSATION</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has two plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and 2013 Incentive Plan, as of September 30, 2020, <ix:nonFraction unitRef="U_xbrlishares" id="F_000598" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20200930" decimals="INF" format="ixt:numdotdecimal">673,262</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000599" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930" decimals="INF" format="ixt:numdotdecimal">5,598,345</ix:nonFraction> shares, respectively, of Arrowhead&#8217;s Common Stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others. No further grants may be made under the 2004 Equity Incentive Plan.&#160;&#160;As of September 30, 2020, there were options granted and outstanding to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000600" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20200930" decimals="INF" format="ixt:numdotdecimal">673,262</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000601" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930" decimals="INF" format="ixt:numdotdecimal">2,611,625</ix:nonFraction> shares of Common Stock under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively, and there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000602" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930" decimals="INF" format="ixt:numdotdecimal">2,588,000</ix:nonFraction> restricted stock units granted and outstanding under the 2013 Incentive Plan. Also, as of September 30, 2020, there were <ix:nonFraction unitRef="U_xbrlishares" id="F_000603" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000879407_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20200930" decimals="INF" format="ixt:numdotdecimal">1,254,516</ix:nonFraction> shares reserved for options and <ix:nonFraction unitRef="U_xbrlishares" id="F_000604" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20200930" decimals="INF" format="ixt:numdotdecimal">936,025</ix:nonFraction>  shares reserved for restricted stock units issued as inducement grants to new employees outside of equity compensation plans. </p><ix:nonNumeric id="F_000362" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 2019</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000605" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000879407_20190930" decimals="INF" format="ixt:numdotdecimal">4,773,670</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000611" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0000879407_20190930" decimals="2">8.16</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000606" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0000879407_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">951,500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000612" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0000879407_20191001_20200930" decimals="2">48.19</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000607" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0000879407_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">74,639</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000613" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0000879407_20191001_20200930" decimals="2">22.38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000608" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0000879407_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">1,111,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000614" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0000879407_20191001_20200930" decimals="2">6.72</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September 30, 2020</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000609" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal">4,539,403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000615" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0000879407_20200930" decimals="2">16.67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000617" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:duryear">6.2</ix:nonNumeric> years</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">129,100,277</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable At September 30, 2020</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000610" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0000879407_20200930" decimals="INF" format="ixt:numdotdecimal">2,924,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000616" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0000879407_20200930" decimals="2">8.30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000618" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0000879407_20191001_20200930" format="ixt-sec:duryear">4.8</ix:nonNumeric> years</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">102,698,309</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to stock options for the years ended September 30, 2020, 2019, and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000621" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">9,719,116</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000622" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">3,955,216</ix:nonFraction>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000623" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171001_20180930" decimals="0" format="ixt:numdotdecimal">3,265,348</ix:nonFraction>, respectively.  For non-qualified stock options, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant date fair value of the options granted by the Company for the years ended September 30, 2020, 2019, and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">34,582,743</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000625" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">12,137,250</ix:nonFraction>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171001_20180930" decimals="0" format="ixt:numdotdecimal">4,141,318</ix:nonFraction>, respectively.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intrinsic value of the options exercised during the years ended September 30, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">44,082,294</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">24,561,189</ix:nonFraction>, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171001_20180930" decimals="0" format="ixt:numdotdecimal">5,805,317</ix:nonFraction>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200930" decimals="0" format="ixt:numdotdecimal">36,355,846</ix:nonFraction> will be recognized in the Company&#8217;s results of operations over a weighted average period of <span><span style="color:#000000;"><ix:nonNumeric id="F_000631" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930" format="ixt-sec:duryear">3.1</ix:nonNumeric> </span>years</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-21</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000335_dcnt_1cd84a24-cde0-4afd-9988-53a2637aa72d"><ix:nonNumeric id="F_000363" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;ended&#160;September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000632">0.4 &#8211; 1.8%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000633">1.50-3.11%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000634">2.05-2.99%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90-92%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000638" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0000879407_20181001_20190930" decimals="2" scale="-2">115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000639" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0000879407_20171001_20180930" decimals="2" scale="-2">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Expected life (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000642">6.25</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000643">6.25</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">6.25</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Weighted average grant date fair value per share of options granted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000645" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000879407_20191001_20200930" decimals="2">36.35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000646" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000879407_20181001_20190930" decimals="2">13.80</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000647" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000879407_20171001_20180930" decimals="2">5.04</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The dividend yield is <ix:nonFraction unitRef="U_xbrlipure" id="F_000648" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930" decimals="2" format="ixt-sec:numwordsen" scale="-2">zero</ix:nonFraction> as the Company currently does not pay a dividend. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk-free interest rate is based on that of the U.S. Treasury bond. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility is estimated based on volatility average of the Company&#8217;s Common Stock price. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units (&#8220;RSUs&#8221;), including time-based and performance-based awards, were granted under the Company&#8217;s 2013 Incentive Plan and as inducements grants granted outside of the Plan.&#160;During the year ended September 30, 2020, the Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000649" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">1,754,071</ix:nonFraction> RSUs under the 2013 Incentive Plan and <ix:nonFraction unitRef="U_xbrlishares" id="F_000650" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">933,025</ix:nonFraction> RSUs as inducement awards. <ix:nonNumeric id="F_000651" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" contextRef="C_0000879407_20191001_20200930">At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s Common Stock. RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee&#8217;s income taxes due upon vesting and withholds a number of shares of Common Stock of equal value.&#160;&#160;RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</ix:nonNumeric>&#160;&#160;</p><ix:nonNumeric id="F_000364" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity of the Company&#8217;s RSUs:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September&#160;30, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000652" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190930" decimals="INF" format="ixt:numdotdecimal">2,062,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000657" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190930" decimals="2">9.43</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">2,687,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000658" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" decimals="2">55.59</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000654" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">1,158,904</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000659" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" decimals="2">9.71</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000655" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" decimals="INF" format="ixt:numdotdecimal">67,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000660" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" decimals="2">31.78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September 30, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000656" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930" decimals="INF" format="ixt:numdotdecimal">3,524,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000661" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930" decimals="2">44.11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended September 30, 2020, 2019, and 2018, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" decimals="0" format="ixt:numdotdecimal">33,663,871</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930" decimals="0" format="ixt:numdotdecimal">8,438,107</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20171001_20180930" decimals="0" format="ixt:numdotdecimal">5,189,259</ix:nonFraction> of expense related to RSUs, respectively. Such expense is included in stock-based compensation expense in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). For RSUs, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.&#160;&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For RSUs, the grant date fair value of the award is based on the Company&#8217;s closing stock price at the grant date, with consideration given to the probability of achieving performance conditions for performance-based awards.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, the pre-tax compensation expense for all unvested RSUs in the amount of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930" decimals="0" format="ixt:numdotdecimal">88,548,649</ix:nonFraction> will be recognized in the Company&#8217;s results of operations over a weighted average period of <ix:nonNumeric id="F_000666" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" format="ixt-sec:duryear">3.1</ix:nonNumeric> years.  Unvested RSUs that we have deemed not probable of vesting as of September 30, 2020, have the potential of generating an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="arwr:EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930" decimals="-5" scale="6">38.0</ix:nonFraction> million of pre-tax compensation expense if we deem them probable of vesting in a future reporting period.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;</p></ix:continuation><ix:nonNumeric id="F_000336" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true" continuedAt="F_000336_dcnt_ea354e6d-78ab-489b-959d-71f56f520d59">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-22</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000336_dcnt_ea354e6d-78ab-489b-959d-71f56f520d59">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-style:italic;">FAIR VALUE MEASUREMENTS</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level&#160;1 provides the most reliable measure of fair value while Level&#160;3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#8217;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. </p><ix:nonNumeric id="F_000365" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes fair value measurements at September 30, 2020 and September&#160;30, 2019 for assets and liabilities measured at fair value on a recurring basis.&#160;&#160;Certain amounts have been reclassed to conform with current year presentation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:84.02%;">
<tr style="height:10.2pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="0" format="ixt:numdotdecimal">143,582,667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="0" format="ixt:numdotdecimal">143,582,667</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="0" format="ixt:numdotdecimal">85,019,719</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="0" format="ixt:numdotdecimal">85,019,719</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:13.45pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (held to maturity)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="0" format="ixt:numdotdecimal">88,479,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="0" format="ixt:numdotdecimal">88,479,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (held to maturity)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="0" format="ixt:numdotdecimal">141,981,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930" decimals="0" format="ixt:numdotdecimal">141,981,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, <span style="color:#000000;">2019</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:84.02%;">
<tr style="height:10.25pt;">
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.85pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000676" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930" decimals="0" format="ixt:numdotdecimal">221,804,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000677" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930" decimals="0" format="ixt:numdotdecimal">221,804,128</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.85pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000678" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930" decimals="0" format="ixt:numdotdecimal">37,122,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000679" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930" decimals="0" format="ixt:numdotdecimal">37,122,478</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:13.5pt;">
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000680" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930" decimals="0" format="ixt:numdotdecimal">45,051,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000681" name="arwr:HeldToMaturitySecuritiesFairValueNonCurrent" contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930" decimals="0" format="ixt:numdotdecimal">45,051,251</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.85pt;">
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a liability for contingent consideration related to its acquisition of the Roche RNAi business completed in 2011. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s assumptions and experience. Estimating timing to complete the development and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining FDA and other regulatory approvals. In determining the probability of regulatory approval and commercial success, the Company utilizes data regarding similar milestone events from several sources, including industry studies and its own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. In November 2016, the Company announced the discontinuation of its clinical trial efforts for ARC-520, ARC-AAT and ARC-521.&#160;&#160;Given this development, the Company assessed the fair value of its contingent consideration obligation to be $<ix:nonFraction unitRef="U_iso4217USD" id="F_000682" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="C_0000879407_20200930" decimals="0"><ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="C_0000879407_20190930" decimals="0">0</ix:nonFraction></ix:nonFraction> at September 30, 2020 and September 30, 2019.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000337" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true" continuedAt="F_000337_dcnt_0aad7f9d-9de0-4a37-98f9-d06b1354b511">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 11. <span style="font-style:italic;">INCOME TAXES</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes the guidance issued by the FASB for accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and </p>
</ix:nonNumeric><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-23</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000337_dcnt_0aad7f9d-9de0-4a37-98f9-d06b1354b511" continuedAt="F_000337_dcnt_fceed33b-2d73-403c-85e0-f9482f1568b1">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.</span></p><ix:nonNumeric id="F_000366" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of the net deferred tax asset (liability) at September 30, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued Compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000684" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">2,086,396</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000685" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">1,310,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000686" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">10,936,819</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000687" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">3,609,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized Research &#38; Development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">624,915</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">926,026</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">California Alternative Minimum Tax</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000690" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">178,652</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000691" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">173,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">438,882</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Operating Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000693" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">151,007,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">105,372,571</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">2,818,002</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">3,590,090</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">1,702,357</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of Use Assets/Lease Liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">1,015,626</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Rent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">821,317</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital Loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">709,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">709,779</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">171,079,659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">116,952,440</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">156,603,859</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">108,232,402</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">2,546,968</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="arwr:DeferredTaxLiabilitiesStateTaxes" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">11,928,832</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="arwr:DeferredTaxLiabilitiesStateTaxes" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">8,720,038</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0000879407_20200930" decimals="0" format="ixt:numdotdecimal">14,475,800</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0000879407_20190930" decimals="0" format="ixt:numdotdecimal">8,720,038</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, management has provided a <ix:nonFraction unitRef="U_xbrlipure" id="F_000711" name="arwr:PercentageOfValuationAllowance" contextRef="C_0000879407_20200930" decimals="INF" scale="-2">100</ix:nonFraction>% valuation allowance against its deferred tax assets until such time as management believes that its projections of future profits as well as expected future tax rates make the realization of these deferred tax assets more-likely-than-not. Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from our estimates could result in material differences in the realization of these assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax asset in accordance with FASB ASC 740-10, &#8220;Accounting for Income Taxes.&#8221; This assessment included the evaluation of scheduled reversals of deferred tax liabilities, the availability of carry forwards and estimates of projected future taxable income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2020, the Company had available gross federal net operating loss (&#8220;NOL&#8221;) carry forwards of approximately $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000712" name="arwr:FederalNetOperatingLossCarryForward" contextRef="C_0000879407_20200930" decimals="-5" scale="6">473.0</ix:nonFraction></span> million and gross state NOL carry forwards of $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000713" name="arwr:StateNetOperatingLossCarryForwards" contextRef="C_0000879407_20200930" decimals="-5" scale="6">497.0</ix:nonFraction>&#160;</span>million. The NOLs expire at various dates through 2040.</p><ix:nonNumeric id="F_000367" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions for income taxes for the years ended September 30, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Federal</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000714" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">2,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000715" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">173,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total State</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">2,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000717" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">173,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision from income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000718" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">2,400</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000719" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">173,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
</ix:continuation><p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-24</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000337_dcnt_fceed33b-2d73-403c-85e0-f9482f1568b1"><ix:nonNumeric id="F_000368" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended September 30, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At U.S. federal statutory rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000720" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0000879407_20191001_20200930" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000721" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0000879407_20181001_20190930" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal effect</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000722" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">7.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000723" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0000879407_20181001_20190930" decimals="3" scale="-2">7.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000724" name="arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" contextRef="C_0000879407_20191001_20200930" decimals="3" sign="-" format="ixt:numdotdecimal" scale="-2">29.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000725" name="arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" contextRef="C_0000879407_20181001_20190930" decimals="3" scale="-2">15.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark-to-market adjustments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000726" name="arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000727" name="arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" contextRef="C_0000879407_20181001_20190930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000728" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0000879407_20191001_20200930" decimals="3" sign="-" scale="-2">57.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000729" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0000879407_20181001_20190930" decimals="3" sign="-" scale="-2">13.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000730" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000731" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0000879407_20181001_20190930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">True-up on deferred taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000732" name="arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000733" name="arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" contextRef="C_0000879407_20181001_20190930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax rate change</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000734" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000735" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" contextRef="C_0000879407_20181001_20190930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000736" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0000879407_20191001_20200930" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000737" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0000879407_20181001_20190930" decimals="3" scale="-2">0.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense.&#160;&#160;The Company has not recognized any unrecognized tax benefits and does not have any interest or penalties related to uncertain tax positions as of September 30, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns with the Internal Revenue Service (&#8220;IRS&#8221;), the state of California and certain other taxing jurisdictions. The Company is subject to income tax examinations by the IRS and by state tax authorities until the net operating losses are settled.&#160;&#160;</p></ix:continuation><ix:nonNumeric id="F_000338" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 12. <span style="font-style:italic;">EMPLOYEE BENEFIT PLANS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2005, the Company adopted a defined contribution 401(k) retirement savings plan covering substantially all of its employees. The Plan is administered under the &#8220;safe harbor&#8221; provision of ERISA. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000738" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20191001_20200930" decimals="INF" scale="-2">100</ix:nonFraction>% of each participant&#8217;s first <ix:nonFraction unitRef="U_xbrlipure" id="F_000739" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20191001_20200930" decimals="2" scale="-2">3</ix:nonFraction>% of compensation contributed plus <ix:nonFraction unitRef="U_xbrlipure" id="F_000740" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20191001_20200930" decimals="INF" scale="-2">50</ix:nonFraction>% of each participant&#8217;s next <ix:nonFraction unitRef="U_xbrlipure" id="F_000741" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20191001_20200930" decimals="2" scale="-2">2</ix:nonFraction>% of compensation contributed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended September&#160;30, 2020, 2019, and 2018, the Company recorded expenses under this plan of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000742" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0000879407_20191001_20200930" decimals="0" format="ixt:numdotdecimal">863,080</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000743" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0000879407_20181001_20190930" decimals="0" format="ixt:numdotdecimal">545,698</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000744" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="C_0000879407_20171001_20180930" decimals="0" format="ixt:numdotdecimal">451,623</ix:nonFraction>, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the employee benefit plans described above, the Company provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000339" name="us-gaap:QuarterlyFinancialInformationTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 13. <span style="font-style:italic;">UNAUDITED QUARTERLY FINANCIAL DATA</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.11%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><ix:nonNumeric id="F_000369" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents selected unaudited quarterly financial data for each full quarterly period of the years ended September 30, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">First</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fourth</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended September 30, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000745" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20191001_20191231" decimals="0" format="ixt:numdotdecimal">29,454,579</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000746" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20200101_20200331" decimals="0" format="ixt:numdotdecimal">23,528,853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000747" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20200401_20200630" decimals="0" format="ixt:numdotdecimal">27,375,778</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20200701_20200930" decimals="0" format="ixt:numdotdecimal">7,632,856</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000753" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20191001_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">4,853,594</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20200101_20200331" decimals="0" sign="-" format="ixt:numdotdecimal">22,240,255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20200401_20200630" decimals="0" sign="-" format="ixt:numdotdecimal">15,945,862</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000756" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20200701_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">50,119,092</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000757" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20191001_20191231" decimals="0" sign="-" format="ixt:numdotdecimal">2,673,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000758" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20200101_20200331" decimals="0" sign="-" format="ixt:numdotdecimal">19,835,570</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000759" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20200401_20200630" decimals="0" sign="-" format="ixt:numdotdecimal">13,611,213</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000760" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20200701_20200930" decimals="0" sign="-" format="ixt:numdotdecimal">48,432,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Basic</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000761" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20191001_20191231" decimals="2" sign="-">0.03</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000762" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20200101_20200331" decimals="2" sign="-">0.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000763" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20200401_20200630" decimals="2" sign="-">0.13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000764" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20200701_20200930" decimals="2" sign="-">0.48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000765" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20191001_20191231" decimals="2" sign="-">0.03</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000766" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20200101_20200331" decimals="2" sign="-">0.20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000767" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20200401_20200630" decimals="2" sign="-">0.13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000768" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20200701_20200930" decimals="2" sign="-">0.48</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">First</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fourth</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended September 30, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000769" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20181001_20181231" decimals="0" format="ixt:numdotdecimal">34,657,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000770" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20190101_20190331" decimals="0" format="ixt:numdotdecimal">48,148,275</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000771" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20190401_20190630" decimals="0" format="ixt:numdotdecimal">42,696,636</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000772" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0000879407_20190701_20190930" decimals="0" format="ixt:numdotdecimal">43,292,770</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000777" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20181001_20181231" decimals="0" format="ixt:numdotdecimal">10,946,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000778" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20190101_20190331" decimals="0" format="ixt:numdotdecimal">22,010,692</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000779" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20190401_20190630" decimals="0" format="ixt:numdotdecimal">18,595,749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000780" name="us-gaap:OperatingIncomeLoss" contextRef="C_0000879407_20190701_20190930" decimals="0" format="ixt:numdotdecimal">9,638,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000781" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20181001_20181231" decimals="0" format="ixt:numdotdecimal">12,037,253</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000782" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20190101_20190331" decimals="0" format="ixt:numdotdecimal">23,896,982</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000783" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20190401_20190630" decimals="0" format="ixt:numdotdecimal">20,335,708</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000784" name="us-gaap:ProfitLoss" contextRef="C_0000879407_20190701_20190930" decimals="0" format="ixt:numdotdecimal">11,704,906</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Basic</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000785" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20181001_20181231" decimals="2">0.13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000786" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20190101_20190331" decimals="2">0.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000787" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20190401_20190630" decimals="2">0.21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000788" name="us-gaap:EarningsPerShareBasic" contextRef="C_0000879407_20190701_20190930" decimals="2">0.12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000789" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20181001_20181231" decimals="2">0.13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000790" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20190101_20190331" decimals="2">0.24</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000791" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20190401_20190630" decimals="2">0.21</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000792" name="us-gaap:EarningsPerShareDiluted" contextRef="C_0000879407_20190701_20190930" decimals="2">0.12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000340" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0000879407_20191001_20200930" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 14. <span style="font-style:italic;">SUBSEQUENT EVENTS</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive License and Co-Funding Agreement with Takeda Pharmaceuticals U.S.A., Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000793" name="arwr:AgreementDate" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" format="ixt:datemonthdayyearen">October 7, 2020</ix:nonNumeric>, the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda Pharmaceuticals U.S.A., Inc.&#160;&#160;(&#8220;Takeda&#8221;).&#160;&#160;Under the Takeda License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a <ix:nonNumeric id="F_000794" name="arwr:RatioOfProfitSharingStructureForCommercialization" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">50/50 profit sharing</ix:nonNumeric> structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with the Company eligible to receive tiered royalties of <ix:nonFraction unitRef="U_xbrlipure" id="F_000795" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMinimumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="2" scale="-2">20</ix:nonFraction>% to <ix:nonFraction unitRef="U_xbrlipure" id="F_000796" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="2" scale="-2">25</ix:nonFraction>% on net sales.&#160;&#160;The Company will receive $<ix:nonFraction unitRef="U_iso4217USD" id="F_000797" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007" decimals="-5" scale="6">300.0</ix:nonFraction> million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000798" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007" decimals="-5" scale="6">740.0</ix:nonFraction> million.</span>&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Headquarters Lease Expansion</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 23, 2020, the Company signed a lease expansion to add an additional <ix:nonFraction unitRef="U_utrsqft" id="F_000799" name="us-gaap:LandSubjectToGroundLeases" contextRef="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023" decimals="0" format="ixt:numdotdecimal">24,434</ix:nonFraction> square feet of office space for the Company&#8217;s corporate headquarters in Pasadena, CA.&#160;&#160;The lease commencement date is expected to be <ix:nonNumeric id="F_000800" name="arwr:LeaseCommencementMonthAndYear" contextRef="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023_20201023" format="ixt:datemonthyearen">July 2021</ix:nonNumeric>, after certain leasehold improvements are completed, and the lease expires in <ix:nonNumeric id="F_000801" name="arwr:LeaseExpirationMonthAndYear" contextRef="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023_20201023" format="ixt:datemonthyearen">April 2027</ix:nonNumeric>.&#160;&#160;The lease payments over the life of lease total $<ix:nonFraction unitRef="U_iso4217USD" id="F_000802" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023" decimals="-5" scale="6">7.3</ix:nonFraction> million.&#160;&#160;The Company anticipates paying approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000803" name="arwr:ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" contextRef="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023_20201023" decimals="-5" scale="6">4.0</ix:nonFraction> million of leasehold improvements, net of tenant improvement allowances.&#160;&#160;<span style="color:#000000;">The increased capacity of this additional office space compared to the Company&#8217;s current corporate headquarters will accommodate increased personnel as the Company&#8217;s pipeline of drug candidates expands and moves closer to market.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-26</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>2
<FILENAME>arwr-ex1023_125.htm
<DESCRIPTION>EX-10.23
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex1023_125.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:18pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p>
<p style="text-align:center;margin-bottom:13pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FIRST AMENDMENT TO LEASE AGREEMENT</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.33%;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIS FIRST AMENDMENT TO LEASE AGREEMENT <font style="font-weight:normal;">(the &#8220;First Amendment&#8221;) is made as </font><font style="font-size:12.5pt;font-weight:normal;">of </font><font style="font-weight:normal;">October 22, 2018 (the &#8220;Effective Date&#8221;), by and between </font>UNIVERSITY RESEARCH PARK, INCORPORATED, <font style="font-weight:normal;">a Wisconsin non-stock corporation (hereinafter referred to as &#8220;Landlord&#8221;) and </font>ARROWHEAD MADISON INC. <font style="font-weight:normal;">a Delaware corporation (hereinafter referred to as &#8220;Tenant&#8221;). </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11.5pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:11.5pt;">On January 8, 2016, Landlord and Tenant entered into that certain Lease Agreement (the &#8220;Lease&#8221;) for approximately 52,858 rentable square feet located in 502 Rosa Road and 7,759 rentable square feet located in 504 Rosa Road, Madison, Wisconsin (the &#8220;Leased Premises&#8221;). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:11.5pt;">Under the Lease, Landlord extended to Tenant's parent and affiliate corporation, Arrowhead Pharmaceuticals, Inc., f/k/a Arrowhead Research Corporation, an allowance for the construction </font><font style="font-size:12.5pt;">of </font><font style="font-size:11.5pt;">tenant improvements evidenced by a promissory note dated January 8, 2016, as amended on January 20, 2017, in the principal amount </font><font style="font-size:12.5pt;">of </font><font style="font-size:11.5pt;">$2,727,765.00 (together, the &#8220;Note&#8221;). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:11.5pt;">Prior to Tenant's occupancy </font><font style="font-size:12.5pt;">of </font><font style="font-size:11.5pt;">the Leased Premises, Tenant leased from Landlord the entire building located at 465 Science Drive, Madison, Wisconsin (the &#8220;465 Lease&#8221;). Under the terms </font><font style="font-size:12.5pt;">of </font><font style="font-size:11.5pt;">the 465 Lease, as amended, Landlord had granted a tenant improvement allowance equal to $2,216,130.00, which was amortized over 10 years in equal monthly installment (the &#8220;465 Allowance&#8221;). </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:11.5pt;">Tenant now desires to repay the obligations </font><font style="font-size:12pt;">of the </font><font style="font-size:11.5pt;">Note and 465 Allowance in full per the terms detailed below. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-size:11.5pt;">Landlord and Tenant now wish to amend the Lease as more particularly set forth herein. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.33%;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, <font style="font-weight:normal;">in consideration </font><font style="font-size:12.5pt;font-weight:normal;">of </font><font style="font-weight:normal;">the foregoing, and other good and valuable consideration, the receipt and sufficiency </font><font style="font-size:12.5pt;font-weight:normal;">of </font><font style="font-weight:normal;">which are acknowledged by each party, the following amendments to the Lease are hereby agreed to, effective as </font><font style="font-size:12.5pt;font-weight:normal;">of </font><font style="font-weight:normal;">the Effective Date. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;font-size:11.5pt;">Repayment </font><font style="text-decoration:underline;font-size:12.5pt;">of </font><font style="text-decoration:underline;font-size:11.5pt;">the Note.</font><font style="font-size:11.5pt;"> Tenant hereby agrees to cause Arrowhead Pharmaceuticals, Inc. to pay the remaining balance </font><font style="font-size:12.5pt;">of </font><font style="font-size:11.5pt;">the Note in full in accord with the letter agreement attached hereto as Exhibit A. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;font-size:11.5pt;">Repayment </font><font style="text-decoration:underline;font-size:12.5pt;">of the </font><font style="text-decoration:underline;font-size:11.5pt;">465 Allowance.</font><font style="font-size:11.5pt;"> On or before November 1, 2018, Tenant shall pay to Landlord Seventy-Six Thousand One Hundred Thirty-Nine and 84/100 Dollars ($76,139.84) as full reimbursement for the 465 Allowance. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;font-size:11.5pt;">Updated Base Rent.</font><font style="font-size:11.5pt;"> The Base Rent grid contained in Section 2.1 is hereby deleted in its entirety and replaced with the following: </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:366.9pt;;">
<tr>
<td style="width:155.25pt;"></td>
<td style="width:0.3pt;"></td>
<td style="width:113.2pt;"></td>
<td style="width:98.15pt;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:12.22%;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Base Rent per<br />Square Foot*</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total <br />Monthly Base<br />Rent Due</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2018 &#8211; 9/30/2019</p></td>
<td valign="bottom"  style="padding-left:22.45pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$16.81</p></td>
<td valign="bottom"  style="padding-left:12.5pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$84,914.32</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2019 &#8211; 9/30/2020</p></td>
<td valign="bottom"  style="padding-left:22.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.23</p></td>
<td valign="bottom"  style="padding-left:12.75pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$87,035.91</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2020 &#8211; 9/30/2021</p></td>
<td valign="bottom"  style="padding-left:22.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$17.66</p></td>
<td valign="bottom"  style="padding-left:12.5pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$89,208.02</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2021 &#8211; 9/30/2022</p></td>
<td valign="bottom"  style="padding-left:22.95pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18.10</p></td>
<td valign="bottom"  style="padding-left:12.75pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$91,430.64</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2022 &#8211; 9/30/2023</p></td>
<td valign="bottom"  style="padding-left:22.7pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18.55</p></td>
<td valign="bottom"  style="padding-left:12.75pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$93,703.78</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2023 &#8211; 9/30/2024</p></td>
<td valign="bottom"  style="padding-left:22.95pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.01</p></td>
<td valign="bottom"  style="padding-left:12.75pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$96,027.43</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2024 &#8211; 9/30/2025</p></td>
<td valign="bottom"  style="padding-left:22.95pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.49</p></td>
<td valign="bottom"  style="padding-left:12.95pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$98,452.11</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2025 &#8211; 9/30/2026</p></td>
<td valign="bottom"  style="padding-left:22.95pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:2.22%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.98</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$100,927.31</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:14.4pt;;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Extended Term 1</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2026 &#8211; 9/30/2027</p></td>
<td colspan="2" valign="bottom"  style="padding-left:12pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20.48</p></td>
<td valign="bottom"  style="padding-left:11.75pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$103,453.01</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2027 &#8211; 9/30/2028</p></td>
<td colspan="2" valign="bottom"  style="padding-left:12.2pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20.99</p></td>
<td valign="bottom"  style="padding-left:11.75pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$106,029.23</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2028 &#8211; 9/30/2029</p></td>
<td colspan="2" valign="bottom"  style="padding-left:12.2pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21.51</p></td>
<td valign="bottom"  style="padding-left:11.95pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$108,655.97</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2029 &#8211; 9/30/2030</p></td>
<td colspan="2" valign="bottom"  style="padding-left:12.2pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.05</p></td>
<td valign="bottom"  style="padding-left:11.95pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$111,383.74</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2030 &#8211; 9/30/2031</p></td>
<td colspan="2" valign="bottom"  style="padding-left:12.2pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.60</p></td>
<td valign="bottom"  style="padding-left:11.95pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$114,162.02</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:14.4pt;;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Extended Term 2</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2031 &#8211; 9/30/2032</p></td>
<td colspan="2" valign="bottom"  style="padding-left:11.95pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.17</p></td>
<td valign="bottom"  style="padding-left:11.85pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$117,041.32</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2032 &#8211; 9/30/2033</p></td>
<td colspan="2" valign="bottom"  style="padding-left:12.2pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.75</p></td>
<td valign="bottom"  style="padding-left:11.85pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$119,971.15</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2033 &#8211; 9/30/2034</p></td>
<td colspan="2" valign="bottom"  style="padding-left:12.2pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24.34</p></td>
<td valign="bottom"  style="padding-left:11.85pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$122,951.48</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2034 &#8211; 9/30/2035</p></td>
<td colspan="2" valign="bottom"  style="padding-left:12.2pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24.95</p></td>
<td valign="bottom"  style="padding-left:12.1pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$126,032.85</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/2035 &#8211; 6/30/2036</p></td>
<td colspan="2" valign="bottom"  style="padding-left:12.2pt;">
<p style="text-align:center;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.57</p></td>
<td valign="bottom"  style="padding-left:12.1pt;">
<p style="text-align:right;margin-bottom:0pt;margin-top:1pt;margin-left:0pt;;margin-right:3.89%;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$129,164.72</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:5.25%;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*The monthly Initial Space Rent listed above reflects increases of approximately two and one-half percent (2.5%) annually. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:underline;font-size:11.5pt;">General</font><font style="font-size:11.5pt;"> &#8211; All other terms and conditions of the Lease shall remain unchanged, and are hereby ratified and confirmed. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Except as otherwise defined herein, capitalized terms shall have the meanings set f01ih in the Lease. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.28%;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.83%;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties hereby cause this Amendment to be effective as of the Effective Date. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
<td colspan="2" valign="bottom"  style="padding-left:30.6pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gemzezolivjc000001.jpg" title="" alt="" style="width:288px;height:82px;"></p></td>
<td colspan="2" valign="bottom"  style="padding-left:30.7pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gemzezolivjc000002.jpg" title="" alt="" style="width:268px;height:77px;"></p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:29.7pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aaron Olver</p></td>
<td valign="bottom"  style="padding-left:30.75pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="bottom"  style="padding-Right:0.95pt;width:47.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kenneth A. Myszkowski</p></td>
</tr>
<tr>
<td valign="bottom"  style="padding-left:29.7pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assistant Secretary/Treasurer</p></td>
<td valign="bottom"  style="padding-left:31.1pt;width:12.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="bottom"  style="padding-Right:103.3pt;width:47.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CFO</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:13pt;margin-top:0pt;margin-left:0.06%;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely, </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UNIVERSITY RESEARCH PARK, INCORPORATED </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:355.6pt;;">
<tr>
<td style="width:35.35pt;"></td>
<td style="width:320.25pt;"></td>
</tr>
<tr style="height:13.95pt;">
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gemzezolivjc000003.jpg" title="" alt="" style="width:378px;height:74px;"></p></td>
</tr>
<tr style="height:13.95pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.1pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Aaron Olver</p></td>
</tr>
<tr style="height:13.95pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.65pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Assistant Secretary/Treasurer </p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.45pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: aaron.olver@wisc.edu</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:13pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acknowledged and agreed: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.05%;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD PHARMACEUTICALS, INC. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:355.6pt;;">
<tr>
<td style="width:35.35pt;"></td>
<td style="width:320.25pt;"></td>
</tr>
<tr style="height:13.95pt;">
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gemzezolivjc000004.jpg" title="" alt="" style="width:261px;height:52px;"></p></td>
</tr>
<tr style="height:13.95pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.1pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Kenneth A. Myszkowski</p></td>
</tr>
<tr style="height:13.95pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.65pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: CFO</p></td>
</tr>
<tr style="height:13.7pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:2.45pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: KMyszkowski@arrowheadpharma.com</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>3
<FILENAME>arwr-ex1024_124.htm
<DESCRIPTION>EX-10.24
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex1024_124.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:65pt;margin-top:0pt;margin-left:20%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">10.24</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECOND <font style="font-size:10pt;">AMENDMENT </font>TO <font style="font-size:10pt;">LEASE </font>AGREEMENT</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.6%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIS SECOND AMENDMENT TO LEASE AGREEMENT<font style="font-weight:normal;"> (the &#8220;Second Amendment&#8221;) is made as of </font><font style="text-decoration:underline;font-weight:normal;">January 10,</font><font style="font-weight:normal;"> 20l9 (the &#8220;Effective Date&#8221;), by and between </font>UNIVERSITY RESEARCH PARK, INCORPORATED,<font style="font-weight:normal;"> a Wisconsin non-stock corporation (hereinafter referred to as &#8220;Landlord&#8221;) and </font>ARROWHEAD MADISON INC.<font style="font-weight:normal;"> a Delaware corporation (hereinafter referred to as &#8220;Tenant&#8221;). </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.6%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:5.6%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Second Amendment is contingent upon the effective termination and surrender of<font style="font-size:11pt;"> </font>the Expansion Premises by the Vacating Tenant (defined below in this Second Amendment). In the event the effective termination and surrender of<font style="font-size:10.5pt;"> </font>the Expansion Premises by the Vacating Tenant does not occur by December 31, 2018, this Second Amendment shall be null and void and neither party shall have any further obligation hereunder, provided, however, that the parties shall agree that they shall promptly reach a separate agreement on the reconciliation discussed in Recital <font style="font-size:9.5pt;">D. </font>below. </p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On January 8, 2016, Landlord and Tenant entered into that certain Lease Agreement (the &#8220;Lease&#8221; or &#8220;original Lease&#8221;) which stated the Lease was for approximately 52,858 rentable square feet located in 502 South Rosa Road and 7,759 rentable square feet located in 504 South Rosa Road, Madison, Wisconsin (the &#8220;Leased Premises&#8221;). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Under the te1ms of<font style="font-size:11pt;"> </font>the Lease, Landlord provided a one-time allowance for Tenant Improvements (&#8220;Primary Tenant Allowance&#8221;) and an additional one-time allowance for Tenant Improvements (&#8220;Secondary Tenant Allowance&#8221;), which Secondary Tenant Allowance was in the form of<font style="font-size:10.5pt;"> </font>a loan from Landlord to Tenant, secured by a promissory note (&#8220;Note&#8221;). As of<font style="font-size:10.5pt;"> </font>the Effective Date of<font style="font-size:10.5pt;"> </font>this Second Amendment, Tenant has paid and satisfied the Note in full, as set forth in the First Amendment to Lease Agreement. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Tenant now desires to lease from Landlord and Landlord desires to lease to Tenant an additional 13,197 rentable square feet located at 502 South Rosa Road between the existing Leased Premises and 500 South Rosa Road (&#8220;Expansion Premises,&#8221; more specifically defined below). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Landlord and Tenant also reviewed the rentable square feet making up the original Leased Premises and agree to revise the Leased Premises as set forth in this Second Amendment. The Parties also agree to reconcile the area measurements retroactively. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Landlord and Tenant desire and agree to amend the existing Lease Agreement regarding the Expansion Premises and as a financial settlement for rent overpaid to date for the Leased Premises and for Tenant Improvement allowances and commissions overpaid to date. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.11%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:33.3%;"></td>
<td style="width:33.31%;"></td>
<td style="width:33.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second <font style="font-size:7.5pt;">Amendment </font><font style="font-size:6.5pt;">to Le</font><font style="font-size:7.5pt;">a</font>se<font style="font-size:7.5pt;">_</font>V5 <font style="font-size:7.5pt;">_</font>20181213 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1213181713</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:5.6%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE</font><font style="font-weight:normal;">, in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which are acknowledged by each party, the following amendments to the Lease are hereby agreed to, effective as of the Effective Date. </font><font style="font-weight:normal;margin-left:36pt;"></font><font style="font-weight:normal;margin-left:36pt;"></font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:9pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:normal;"></font>PREMISES AND TERM. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">Leased Premises.</font><font style="font-size:10pt;"> The description of the premises in Section 1.1 of the Lease is deleted in its entirety and replaced with the following:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,465 rentable square feet of space in that certain building identified as 502 South Rosa Road and 7,558 rentable square feet of space in that certain building identified as 504 South Rosa Road, Madison, Dane County, Wisconsin, (hereinafter referred to as the &#8220;Leased Premises&#8221;). In addition to the Leased Premises, Tenant shall have the right to the non-exclusive use of all Common Area (defined in the original Lease) situated upon the property described in Exhibit A attached to the original Lease (the Property described in Exhibit A is referred to herein as the &#8220;Landlord's Property&#8221;). The location of the Leased Premises on the Landlord's Property is indicated on the map attached to the original Lease as Exhibit B-1, and the floor plan attached to the original Lease as Exhibit B-2. The pro-rata share of the Leased Premises combined with the Expansion Premises (defined below) in proportion to the total building area located on Landlord's Property shall be calculated pursuant to the formula set forth in Section 5.6 of the original Lease. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">Expansion Premises.</font><font style="font-size:10pt;"> Section 1.1 of the Lease is also amended to add the following at the end of the section: </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord also hereby leases to Tenant and Tenant leases from Landlord on the terms and provisions and subject to the conditions hereinafter set forth in this Lease, as amended, the described Expansion Premises, consisting of 13,197 rentable square feet located at 502 South Rosa Road, and more specifically described in Exhibit 2A-A. This Expansion Premises shall be in addition to the original Leased Premises described above. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties acknowledge and accept the measurements for the Leased Premises and the Expansion Premises set forth above as being consistent with BOMA standards., and as more specifically detailed in Exhibit 2A-B. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">Term of Lease.</font><font style="font-size:10pt;"> Section 1.2 of the Lease is deleted in its entirety and replaced with the following: </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.2 Term of Lease.<font style="font-weight:normal;"> The term of this Lease (the &#8220;Term&#8221;) for the Leased Premises shall begin on January 1, 2016. The term of this Lease for the Expansion Premises (&#8220;Expansion Lease Term&#8221;) shall begin on the first day of the month following the occurrence of two events: (i) effective </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:33.3%;"></td>
<td style="width:33.31%;"></td>
<td style="width:33.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second <font style="font-size:7.5pt;">Amendment </font><font style="font-size:6.5pt;">to Le</font><font style="font-size:7.5pt;">a</font>se<font style="font-size:7.5pt;">_</font>V5 <font style="font-size:7.5pt;">_</font>20181213 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1213181713</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">term</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ination and surrender of the lease for the Expansion Premises by the Vacating Tenant; and (ii) full execution of this Second Amendment (</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expansion Lease Commencement</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">), provided, however, that in no event shall the Expansion Lease Commencement occur prior to January 1, 2019. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Term and Expansion Lease Term shall hereafter run concurrently and shall end at midnight on September 30, 2029. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">References throughout the Lease to the &#8220;original Term&#8221; of the Lease or &#8220;Term&#8221; shall hereafter be considered to include reference to the Expansion Lease Term and said terms shall run concurrently. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">Option to Extend. </font><font style="font-size:10pt;">Section 1.3 is revised to require Tenant to give Landlord written notice of its intention to exercise its option to extend the Lease Term no later than twelve (12) months prior to the expiration of the Expansion Lease Term. Base Rent and Expansion Base Rent for each year of any Extended Term shall increase by 2.5% annually over the prior year's Basic Rent and Expansion Base Rent. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">Condition of Expansion Premises. </font><font style="font-size:10pt;">Section 1.4 of the Lease is amended to add the following: </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord shall deliver, and Tenant shall accept the Expansion Premises as depicted on Exhibit 2A-A and in AS-IS, WHERE-IS condition, except as may be provided in this Second Amendment. Notwithstanding the foregoing, Landlord shall deliver the Expansion Premises broom-clean and free of all personal property of the Vacating Tenant. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">Security Deposit. </font><font style="font-size:10pt;">Section 1.5 of the Lease is amended to add the following at the end of the section: </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above paragraph is in reference to the Leased Premises. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regarding the Expansion Premises, Tenant shall pay to Landlord as and for a security deposit for the Expansion Premises (&#8220;Expansion Security Deposit&#8221;), the sum equal to one month of Expansion Base Rent and estimated Expansion Additional Rent (both terms defined below). Tenant shall pay the Expansion Security Deposit to Landlord upon the Expansion Lease Commencement. The Expansion Security Deposit shall be returned to Tenant within sixty (60) days following the termination of this Lease, as amended, less any amount appropriately applied by Landlord. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">Condition of Improvements. </font><font style="font-size:10pt;">Section 1.6 is amended to add the following at the end of the section: </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding any provisions above, Tenant may, with prior written approval by Landlord, choose a general contractor and architect for Tenant </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:33.3%;"></td>
<td style="width:33.31%;"></td>
<td style="width:33.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second <font style="font-size:7.5pt;">Amendment </font><font style="font-size:6.5pt;">to Le</font><font style="font-size:7.5pt;">a</font>se<font style="font-size:7.5pt;">_</font>V5 <font style="font-size:7.5pt;">_</font>20181213 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1213181713</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Improvements of the Expansion Premises. Tenant shall also submit to Landlord for prior written approval, detailed written plans for any and all Tenant Improvements to the Expansion Premises. Landlord's approval shall not be unreasonably conditioned, delayed, or withheld. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall be allowed an additional one-time Tenant Improvement allowance for approved Tenant Improvements in the Expansion Premises (&#8220;Expansion Premises Allowance&#8221;) in the total amount of Four Hundred Seven Thousand Two Hundred Seventeen Dollars and 00/100 ($407,217), which acknowledges the parties total agreement on allowances for the Expansion Premises (including penthouse) and settlements on past overpaid rent from Tenant and past overpaid allowances from Landlord. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Said Expansion Premises is being vacated by another unrelated tenant (&#8220;Vacating Tenant&#8221;). Landlord and Tenant agree that fifty percent (50%) of any base net rent (base rent, less costs incurred by Landlord including but not limited to Landlord's legal fees and broker commissions) collected from Vacating Tenant at the termination of Vacating Tenant's lease, and after the Expansion Lease Commencement, will be credited to Tenant as a one-time additional allowance for initial Tenant Improvements to the Expansion Premises. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the Expansion Premises Allowance, Landlord shall provide an allowance of up to Fifty Thousand and 00/100 ($50,000.00) specifically as and for replacement of approved boilers and related equipment selected and installed as part of Tenant Improvements. Tenant shall submit receipts for replacement of the boilers and related equipment to Landlord for prompt reimbursement to Tenant. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord reserves the right to review and approve plans for Tenant Improvements and to hire architects and/or engineers to review submitted plans prior to approval. While Landlord reserves the right to approve any specific Tenant Improvements, Landlord acknowledges Tenant Improvements will seek to connect Expansion Leased Premises and original Leased Premises. Landlord will work with Tenant to approve a mutually acceptable plan to connect the Expansion and Original Premises and modify both Premises as required. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord shall, at Landlord's expense, ensure that Tenant's name is included on the directories and standard interior directional signage of the Building. Tenant shall have the right to space on the multi-tenant monument sign located near the parking, at Tenant's cost. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to October 1,2019, Landlord will replace 26 UPS batteries at Landlord's sole expense, not to exceed Twenty Thousand and 00/100 Dollars ($20,000.00). </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:33.3%;"></td>
<td style="width:33.31%;"></td>
<td style="width:33.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second <font style="font-size:7.5pt;">Amendment </font><font style="font-size:6.5pt;">to Le</font><font style="font-size:7.5pt;">a</font>se<font style="font-size:7.5pt;">_</font>V5 <font style="font-size:7.5pt;">_</font>20181213 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1213181713</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as specifically revised above, all provisions of Section 1.6 remain unchanged and apply with equal force and effect to the condition of the improvements and Tenant Improvements for the Expansion Premises. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">New Section 1.7 is added as follows:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.7. <font style="margin-left:36pt;"></font>Tenant's Right of Opportunity to Expand.<font style="font-weight:normal;"> Landlord shall give Tenant notice (&#8220;Notice of Expansion Availability&#8221;) each time some or all of the suite adjacent to the Expansion Premises that is then contiguous to Tenant's Expansion Premises, consisting of approximately 25,965 rentable square feet located at 500 South Rosa Road (&#8220;Additional Premises&#8221;), is being vacated, the current tenant is given a lease expiration date, and the space is known to be available for lease. Tenant shall provide Landlord with notice that it desires to lease the Additional Premises within ten (10) days of receipt of the Notice of Expansion Availability. If Landlord and Tenant enter into a signed Letter of Intent within thirty (30) days of the Notice of Expansion Availability, Landlord will terminate discussions with and marketing to third parties and negotiate a lease or lease amendment exclusively with Tenant for the Additional Premises. If Landlord and Tenant have not entered into a lease for the Additional Premises, or an amendment to the current lease to include the Additional Premises, within sixty (60) days of Notice of Expansion Availability, Landlord may lease the Additional Premises to a third party, at its sole discretion, provided, however, Tenant shall continue to have a first right of opportunity to expand as set forth herein in the event some or all of the Additional Premises shall again become available during the Term of this Lease, provided Tenant is not then in default under the Lease. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:9pt;margin-left:6.67%;text-indent:-3.33%;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. <font style="font-size:10pt;">RENT </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">Base Rent.</font><font style="font-size:10pt;"> Section 2.1 of the Lease is deleted </font><font style="font-size:11pt;">in </font><font style="font-size:10pt;">its entirety and replaced with the following: </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.1 Base Rent and Expansion Base Rent.<font style="font-weight:normal;"> Beginning on the Expansion Lease Commencement, Tenant shall pay on or before the first day of each calendar month during the Term, to Landlord at its office in Madison, Wisconsin, or such other place as Landlord may designate in writing, and, without any deduction or offset except as provided in the Second Amendment, base rent for the Leased Premises and Expansion Premises as indicated in the table below. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:33.3%;"></td>
<td style="width:33.31%;"></td>
<td style="width:33.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second <font style="font-size:7.5pt;">Amendment </font><font style="font-size:6.5pt;">to Le</font><font style="font-size:7.5pt;">a</font>se<font style="font-size:7.5pt;">_</font>V5 <font style="font-size:7.5pt;">_</font>20181213 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1213181713</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:79.93%;">
<tr>
<td style="width:20.91%;"></td>
<td style="width:18.48%;"></td>
<td style="width:23.91%;"></td>
<td style="width:16.63%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:12.65pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-18.15pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Period</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Base</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent/Monthly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Original</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises</p></td>
<td valign="bottom"  style="padding-left:20.3pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-19.2pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Base</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-19.2pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent/Monthly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-19.2pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expansion Premises</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Base</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent/Monthly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Combined</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,023 RSF</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:18.85pt; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-52.95pt;;margin-right:6.85%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,197 RSF</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-19.2pt;;margin-right:5%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-9.45pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,220 RSF</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:-9.45pt;;margin-right:2.59%;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1/1/19 &#8211; 9/30/19</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$81,280.55</p></td>
<td valign="bottom"  style="padding-left:17.85pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,002.92</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$99,283.47</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/19 &#8211; 9/30/20</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$83,311.36</p></td>
<td valign="bottom"  style="padding-left:18.05pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,002.92</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$101,314.27</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/11/20 &#8211; 9/30/21</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$85,390.52</p></td>
<td valign="bottom"  style="padding-left:17.85pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,452.99</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$103,843.50</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/21 &#8211; 9/30/22</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$87,518.03</p></td>
<td valign="bottom"  style="padding-left:18.1pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,914.31</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$106,432.34</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/22 &#8211; 9/30/23</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$89,693.89</p></td>
<td valign="bottom"  style="padding-left:18.3pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19,387.17</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$109,081.06</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/23 &#8211; 9/30/24</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$91,918.10</p></td>
<td valign="bottom"  style="padding-left:18.05pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19,871.85</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$111,789.95</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/24 &#8211; 9/30/25</p></td>
<td valign="bottom"  style="padding-left:16.3pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$94,239.02</p></td>
<td valign="bottom"  style="padding-left:18.3pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20,368.65</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$114,607.67</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/25 &#8211; 9/30/26</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$96,608.30</p></td>
<td valign="bottom"  style="padding-left:18.3pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20,877.86</p></td>
<td valign="bottom"  style="padding-left:9.2pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$117,486.16</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/26 &#8211; 9/30/27</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$99,025.92</p></td>
<td valign="bottom"  style="padding-left:18.8pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21,399.81</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$120,425.73</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/27 &#8211; 9/30/28</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$101,491.90</p></td>
<td valign="bottom"  style="padding-left:18.8pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21,934.81</p></td>
<td valign="bottom"  style="padding-left:9.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$123,426.70</p></td>
</tr>
<tr>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/28 &#8211; 9/30/29</p></td>
<td valign="bottom"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:5%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$104,006.23</p></td>
<td valign="bottom"  style="padding-left:18.8pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:-7.05pt;;margin-right:7.04%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22,483.18</p></td>
<td valign="bottom"  style="padding-left:9.45pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:2.59%;text-indent:0pt;;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$126,489.40</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b. <font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:10pt;">Additional Rent. </font>Section 2.2 is revised to add the following sentence prior to the last sentence of Section <font style="font-style:italic;font-size:9pt;">2.2: </font>&#8220;The foregoing provisions of this Section 2.2 shall apply with equal force and effect to the Expansion Premises (&#8220;Expansion Additional Rent&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">RENT CONCESSION. </font><font style="font-size:10.5pt;">Landlord shall provide nine (9) monthly rent concessions in the amount of $23,000 per month, beginning on the Expansion Lease Commencement. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10.5pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">BUSINESS USE OF PREMISES. </font><font style="font-size:10.5pt;">Section 4.1 of the Lease is amended as follows: the first sentence is deleted in its entirety and replaced with the following: </font><font style="font-size:10pt;">&#8220;It </font><font style="font-size:10.5pt;">is understood and agreed that the Leased Premises and Expansion Leased Premises shall be used and occupied by Tenant as a general office, laboratory, research and development, manufacturing, assembly, warehousing, shipping and receiving and any other use permitted under all applicable laws and zoning laws. Landlord represents and warrants </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:33.3%;"></td>
<td style="width:33.31%;"></td>
<td style="width:33.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second <font style="font-size:7.5pt;">Amendment </font><font style="font-size:6.5pt;">to Le</font><font style="font-size:7.5pt;">a</font>se<font style="font-size:7.5pt;">_</font>V5 <font style="font-size:7.5pt;">_</font>20181213 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1213181713</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.08%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">that the foregoing are all permitted uses under applicable zoning laws.&#8221; The remainder of Section 4.1 remains the same and in full force and effect. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10.5pt;">BACK-UP GENERATOR. </font><font style="font-size:10pt;">Section 10.20 of the Lease is amended by adding the following at the end of the section: </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:8.51%;margin-right:7.96%;text-indent:0.04%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon Tenant's request, Landlord shall purchase a new generator to serve the property located at 504 Rosa Road and then dedicate the current generator exclusively to the Leased Premises and Expansion Premises for Tenant. Tenant shall pay to Landlord a fee equal to the purchase price for a new generator sized to serve the Expansion Leased Premises, up to a maximum of Two-Hundred Fifty Thousand Dollars ($250,000). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10.5pt;">MISCELLANEOUS. </font><font style="font-size:10pt;">Article 10 of the Lease is amended to add the following provisions: </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.21. <font style="margin-left:36pt;"></font>Fire Panel. <font style="font-size:10pt;font-weight:normal;">Landlord and Vacating Tenant, at their own expense and by separate agreement, are updating fire panels in the premises located at 500 and 504 Rosa Road to match Tenant's existing fire panel. Conditional on approval from the City of Madison, the fire panel for the Expansion Leased Premises shall be tied to the fire panel for the original Leased Premises at 502 Rosa Road. Landlord shall ensure that sprinkler flow switches will communicate and coordinate among and between the premises located at 500, 502 and 504 Rosa Road. Tenant and Landlord shall cooperate on coordinating issues to ensure seamless fire protection among the premises located at 500, 502, and 504 Rosa Road. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.22 <font style="margin-left:36pt;"></font>HVAC. <font style="font-size:10pt;font-weight:normal;">Extraordinary HVAC requirements must be handled by multiple units that include the option for a return air component. Tenant is obligated to minimize re-entrainment. Tenant is solely responsible to other of Landlord's tenants if its failure to minimize re-entrainment adversely affects other of Landlord's tenants. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.23. <font style="margin-left:36pt;"></font>Control Zones. <font style="font-size:10pt;font-weight:normal;">Landlord acknowledges that Tenant wishes to increase the number of fire code control zones. Such work shall be the responsibility of Tenant within Tenant Improvements, to be reviewed by an architect and/or engineer, and subject to Landlord's approval. Increasing the number of control zones shall be at Tenant's sole expense, subject to Section 1.6 of the Lease as amended by Section l.f. of this Amendment. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10.5pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-weight:bold;font-size:10.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.24. <font style="margin-left:36pt;"></font>Exterior Chemical Storage. <font style="font-size:10pt;font-weight:normal;">Landlord acknowledges Tenant's desire to increase exterior chemical storage. Landlord prefers to maximize use of existing chemical storage. To the extent Tenant requires additional chemical storage, such storage shall by sited and designed in a manner that is architecturally integrated with the buildings in which the Leased Premises and Expansion Premises are located, and with approval from Landlord, the Design Review Board, and any required regulatory bodies (such as the City of Madison). Landlord shall not charge any rent for exterior chemical storage constructed as part of Tenant Improvements outside of the building envelope. Upon vacation of the Leased Premises and Expansion Premises, Tenant shall </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:33.3%;"></td>
<td style="width:33.31%;"></td>
<td style="width:33.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second <font style="font-size:7.5pt;">Amendment </font><font style="font-size:6.5pt;">to Le</font><font style="font-size:7.5pt;">a</font>se<font style="font-size:7.5pt;">_</font>V5 <font style="font-size:7.5pt;">_</font>20181213 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1213181713</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18.8%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">restore and remove exterior chemical storage at Tenant's expense upon request by Landlord. Throughout the Term of the Lease, Tenant shall provide Landlord all reports showing compliance with City of Madison ordinances and any other applicable regulatory body immediately upon receipt. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">REFERENCES TO &#8220;PREMISES.&#8221; </font><font style="font-size:10pt;">Beginning on the Expansion Lease Commencement, references in the Lease Agreement to the &#8220;Premises&#8221; shall incorporate, include, and be deemed to include both the original Leased Premises and the Expansion Leased Premises. </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:12.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">BROKERAGE COMMISSION. </font><font style="font-size:10pt;">The Parties agree and acknowledge that the real estate broker, Cresa Global, Inc., shall receive a commission of four percent (4%) of the Expansion Premises Base Rent amount for the initial Term of the Lease for the Expansion Lease Premises only, less rent concessions. Additionally, Cresa Global, Inc. shall receive a commission of 2% of additional future net rent to be paid on Leased Premises due to this extension. The total commission will be reduced by Eighteen Thousand, Five Hundred Ninety-Seven and 00/100 Dollars ($18,597) in recognition of overpaid commission on the original Lease. The commission shall be paid by Landlord to Cresa Global, Inc. as follows: Fifty percent (50%) to be paid not later than thirty (30) days following full execution of this Second Amendment; fifty percent (50%) to be paid not later than ten (10) months following the Expansion Lease Commencement. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;font-size:10pt;">RATIFICATION; COUNTERPARTS. </font><font style="font-size:10pt;">All other terms and conditions of the Lease, as amended by the First Amendment, shall remain unchanged, and are hereby ratified and confirmed. This Second Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constih1te one and the same instrument. Except as otherwise defined herein, capitalized terms shall have the meanings set forth in the Lease. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:33.3%;"></td>
<td style="width:33.31%;"></td>
<td style="width:33.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second <font style="font-size:7.5pt;">Amendment </font><font style="font-size:6.5pt;">to Le</font><font style="font-size:7.5pt;">a</font>se<font style="font-size:7.5pt;">_</font>V5 <font style="font-size:7.5pt;">_</font>20181213 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1213181713</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The parties hereby cause this Second Amendment to be effective as of the Effective Date. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:45.83%;"></td>
<td style="width:54.17%;"></td>
</tr>
<tr style="height:6.95pt;">
<td valign="bottom" >
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
<td valign="bottom"  style="padding-left:23.65pt;">
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr style="height:35.8pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn51aow5g2rf000001.jpg" title="" alt="" style="width:240px;height:103px;"></p></td>
<td valign="bottom"  style="padding-left:23.75pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gn51aow5g2rf000002.jpg" title="" alt="" style="width:270px;height:104px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:73.68%;">
<tr>
<td style="width:12%;"></td>
<td style="width:61.68%;"></td>
</tr>
<tr style="height:6.85pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits:</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:23.55pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2A-A:</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specific Description of Expansion Premises</p></td>
</tr>
<tr style="height:12.05pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 2A-B:</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revised BOMA Rentable Area Measurement Summary</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:33.3%;"></td>
<td style="width:33.31%;"></td>
<td style="width:33.31%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second <font style="font-size:7.5pt;">Amendment </font><font style="font-size:6.5pt;">to Le</font><font style="font-size:7.5pt;">a</font>se<font style="font-size:7.5pt;">_</font>V5 <font style="font-size:7.5pt;">_</font>20181213 </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1213181713</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:-3.6pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>4
<FILENAME>arwr-ex1025_123.htm
<DESCRIPTION>EX-10.25
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex1025_123.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIRD AMENDMENT TO LEASE AGREEMENT</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:5.6%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THIS THIRD AMENDMENT TO LEASE AGREEMENT <font style="font-weight:normal;">(the &#8220;Third Amendment&#8221;) is made as of </font><font style="text-decoration:underline;font-weight:normal;">January 11</font><font style="font-weight:normal;">, 2019 (the &#8220;Effective Date&#8221;), by and between </font>UNIVERSITY RESEARCH PARK, INCORPORATED, <font style="font-weight:normal;">a Wisconsin non-stock corporation (hereinafter referred to as &#8220;Landlord&#8221;) and </font>ARROWHEAD MADISON INC., <font style="font-weight:normal;">a Delaware corporation (hereinafter referred to as &#8220;Tenant&#8221;). </font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">On January 8, 2016, Landlord and Tenant entered into that certain Lease Agreement (the &#8220;original lease&#8221;) for certain space located in 502 and 504 South Rosa Road, Madison, Wisconsin, as amended <font style="font-size:10.5pt;">by </font>that certain Second Amendment to Lease Agreement dated January 10, 2019, which expanded Tenant's leasehold interest to include an additional 13,197 rentable square feet (the &#8220;Expansion Leased Premises&#8221;) located in 502 South Rosa Road, Madison, Wisconsin (the &#8220;Second Amendment&#8221;; collectively, the original lease and Second Amendment shall <font style="font-size:10.5pt;">be </font>referred to herein as the &#8220;Lease&#8221;). </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Second Amendment contains a provision in second paragraph of the preamble conditioning the effectiveness of that amendment on the effective termination of the lease agreement between Landlord and the Vacating Tenant (as defined in the Second Amendment) and the effective surrender of the Expansion Leased Premises by the Vacating Tenant prior to December 31, 2018. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Landlord and Tenant desire and agree to amend the Lease to delete the second paragraph <font style="font-size:10.5pt;">of </font>the Second Amendment's preamble and to cause that amendment to be considered in full force and effect. </p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:5.6%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, <font style="font-weight:normal;">in consideration of the foregoing, and other good and valuable consideration, the receipt and sufficiency of which are acknowledged by each party, the following amendments to the Lease are hereby agreed to, effective as of the Effective Date. </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-weight:bold;"></font>The second paragraph of the preamble to the Second Amendment is hereby deleted in its entirety and is of no further force or effect. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Landlord and Tenant hereby agree that the Expansion Lease Commencement Date (as defined in the Second Amendment) is February 1, 2019. Prior to the Expansion Lease Commencement Date, but after the Vacating Tenant duly surrenders the Expansion Leased Premises, Tenant shall be permitted to access and occupy the Expansion Leased Premises for the purposes of commencing the Tenant Improvements (as defined in the Second Amendment), subject to all terms and conditions of the Lease as amended. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.67%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.06%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All other terms and conditions of the Lease shall remain unchanged, and are hereby ratified and confirmed. This Third Amendment may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Except as otherwise defined herein, capitalized terms shall have the meaning set forth in the Lease.</p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[Signatures on following page.]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The p</font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">art</font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ies hereby cause this Third Amendment to be effective as of the Effective Date. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:431.95pt;;">
<tr>
<td style="width:203.7pt;"></td>
<td style="width:228.25pt;"></td>
</tr>
<tr style="height:7.45pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
<td valign="bottom"  style="padding-left:27.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr style="height:11.3pt;">
<td rowspan="5" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghp5h1w3ypdd000001.jpg" title="" alt="" style="width:205px;height:89px;"></p></td>
<td valign="bottom"  style="padding-left:27.35pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD MADISON INC.</p></td>
</tr>
<tr style="height:11.3pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.3pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p></td>
</tr>
<tr style="height:17.1pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p></td>
</tr>
<tr style="height:17.55pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">parties</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hereby</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cause</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amendment</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:431.95pt;;">
<tr>
<td style="width:203.7pt;"></td>
<td style="width:228.25pt;"></td>
</tr>
<tr style="height:7.45pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
<td valign="bottom"  style="padding-left:27.25pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
</tr>
<tr style="height:11.3pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UNIVERSITY&#160;RESEARCH,</p></td>
<td valign="bottom"  style="padding-left:27.35pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARROWHEAD&#160;MADISON&#160;INC.</p></td>
</tr>
<tr style="height:11.3pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INCORPORATED</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:11.3pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td rowspan="4" valign="bottom"  style="padding-left:27.35pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghp5h1w3ypdd000002.jpg" title="" alt="" style="width:206px;height:67px;"></p></td>
</tr>
<tr style="height:11.3pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></p></td>
</tr>
<tr style="height:11.3pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:32.85pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aaron Olver</p></td>
</tr>
<tr style="height:11.3pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:32.85pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assistant Secretary/Treasurer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>5
<FILENAME>arwr-ex1026_121.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex1026_121.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:37pt;margin-top:0pt;text-indent:-2.12%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.26</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOURTH AMENDMENT TO LEASE AGREEMENT</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.64%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Fourth Amendment to Lease Agreement (this <font style="font-weight:bold;">&#8220;Amendment&#8221;) </font>is between University Research Park, Incorporated, a Wisconsin nonstock corporation <font style="font-weight:bold;">(&#8220;Landlord&#8221;) </font>and Arrowhead Madison Inc., a Delaware corporation <font style="font-weight:bold;">(&#8220;Tenant&#8217;) </font>and is dated as of <font style="text-decoration:underline;">September 19</font>, 2019.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.74%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:36pt;"></font>Landlord and Tenant are parties to that certain Lease Agreement dated as of January 8, 2016, as amended by that certain First Amendment to Lease Agreement dated October 22,2018, that certain Second Amendment to Lease Agreement dated January 10, 2019, and that certain Third Amendment to Lease Agreement dated January 11, 2019 (collectively, the <font style="font-weight:bold;font-size:11.5pt;">&#8220;Original Lease&#8221;). </font>The Original Lease and this Amendment are together referred to herein as the <font style="font-weight:bold;font-size:11.5pt;">&#8220;Lease.&#8221; </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.62%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:36pt;"></font>Pursuant to the Original Lease, Tenant leases from Landlord approximately 63,662 rentable square feet located at 502 South Rosa Road, Madison, Wisconsin and approximately 7,558 rentable square feet located at 504 South Rosa Road, Madison, Wisconsin, each as more particularly defined in the Original Lease (the <font style="font-weight:bold;font-size:11.5pt;">&#8220;Leased Premises&#8221;). </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.69%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="margin-left:36pt;"></font>Landlord and Tenant wish to amend the Lease to allow Tenant, at Tenant&#8217;s expense, to expand the Leased Premises as more particularly set forth in this Amendment. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AGREEMENTS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.66%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Landlord and Tenant hereby agree as follows: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.8%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:11.5pt;">Defined Terms. </font>Terms that are not defined in this Amendment but are defined in the Original Lease have the meanings given in the Original Lease. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.8%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:11.5pt;">Amendment of Lease. </font>The Lease is hereby amended as follows: </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:13.46%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:11.5pt;">Second Expansion Premises. </font>Subject to the provisions of this Amendment, effective as of the date hereof, the Leased Premises shall be expanded to include the approximately 2,971 rentable square feet of space (equal to 2,661 rsf for liquid storage and 310 rsf for vestibule enclosure) depicted on <font style="text-decoration:underline;">Exhibit A</font> attached hereto (the <font style="font-weight:bold;font-size:11.5pt;">&#8220;Second Expansion Premises&#8221;). </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:13.46%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:11.5pt;">Base Rent. </font>No Base Rent shall be payable on the Second Expansion Premises for the entire Term and any Extended Term. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:13.46%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:11.5pt;">Tenant&#8217;s Proportionate Share. </font>Effective January 1, 2020 (without regard to the status of completion of the Tenant Second Expansion Improvements, as defined below), Tenant&#8217;s Proportionate Share shall be increased to approximately 50.8% (resulting from 74,191 rsf divided by 146,036 rsf) as a result of the inclusion of the Second Expansion Premises within the Leased Premises and Tenant shall thereafter in accordance with Section 2.2 of the Original Lease pay, as additional rent, Tenant&#8217;s Proportionate Share of all amounts set forth in <font style="font-size:11.5pt;">the Original Lease, including, without limitation, Real Estate Taxes, Common Area/Operating Expenses and Landlord&#8217;s insurance and utilities based thereon. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:11.5pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42007883</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:13.46%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.</font><font style="font-weight:bold;margin-left:36pt;"></font><font style="font-weight:bold;"> Second Expansion Premises Condition; Tenant Second Expansion Improvements. </font><font style="font-size:11.5pt;">Tenant accepts the </font><font style="font-size:11pt;">Second Expansion</font><font style="font-size:11pt;"> Premises</font><font style="font-size:11.5pt;"> in as-is, where-is condition and acknowledges that Landlord has not made any representation or warranty related thereto and Landlord shall not be required to construct, modify or otherwise improve the Second Expansion Premises in any manner. Promptly following the date hereof, Tenant shall in a diligent, good and workmanlike manner in accordance with plans to be approved by Landlord and in compliance with all applicable federal, state and local laws, rules, regulations and ordinances, improve the Second Expansion Premises pursuant to the process as described on </font><font style="text-decoration:underline;font-size:11.5pt;">Exhibit B</font><font style="font-size:11.5pt;"> attached hereto, at Tenant</font><font style="font-size:11.5pt;">&#8217;</font><font style="font-size:11.5pt;">s sole expense (collectively, </font><font style="font-size:11.5pt;">&#8220;</font><font style="font-size:11.5pt;">Tenant Second Expansion Improvements</font><font style="font-size:11.5pt;">&#8221;</font><font style="font-size:11.5pt;">). Section 1.6 in the Original Lease shall not apply to construction of the Tenant Second Expansion Improvements, which shall be governed solely by this Amendment. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:13.46%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;">Review Fee. </font>Tenant shall pay to Landlord within 30 days of the date hereof a review fee in an amount not to exceed $7,500 to compensate Landlord for its actual and verifiable costs incurred prior to the execution of this Amendment in connection with outside counsel legal fees for the drafting and legal review of this Amendment and the architectural review by Strang of the Tenant Second Expansion Improvements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:13.46%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;">Maintenance and Repair of Second Expansion Premises. </font>Notwithstanding any provision in the Lease to the contrary (including the replacement reimbursement provisions set forth in Section 3.1 or with respect to Section 3.2), Landlord shall have no obligation to maintain, repair or replace the Second Expansion Premises or Tenant Second Expansion Improvements in any manner (including, without limitation, with respect to the foundations, exterior walls, roof or structural components thereof or to reimburse Tenant for any HVAC or elevator expenses related thereto). Tenant shall, in a good and workmanlike manner, at Tenant&#8217;s sole expense, keep the Second Expansion Premises and all components and systems thereof in good order, condition and repair, reasonable wear and tear and casualty excepted. To the extent that any warranties related to the Tenant Second Expansion Improvements remain in effect upon the expiration or earlier termination of this Lease, Tenant shall assign all such warranties to Landlord. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:13.46%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;">Insurance of Second Expansion Premises. </font>Tenant shall be responsible for obtaining Builder&#8217;s Risk Insurance with industry standard coverage during construction of the Tenant Second Expansion Improvements with commercially reasonable limits. Following Substantial Completion (as defined in Exhibit B), Landlord shall thereafter add that portion of the Tenant Second Expansion Improvements including the building and building systems (excluding any Tenant trade fixtures, furniture and equipment) to the property insurance policy maintained by Landlord pursuant to Section 6.1 of the Original Lease. Tenant shall provide to Landlord with its cost of construction of the Tenant Second Expansion Improvements, including reasonable supporting information so that Landlord can adjust its insurance policy appropriately. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:13.46%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;">Construction Liens. </font>Nothing contained herein shall imply any consent or agreement on the part of Landlord or any ground or underlying lessors or mortgagees having an interest in the Property to subject their respective estates or interests to liability under any mechanic&#8217;s or other lien law and, to the extent a lien arises out of any work performed by or at the direction of Tenant, such lien shall be limited to Tenant&#8217;s interest in this Lease. Nothing in this Section 2.h. shall be interpreted to limit Tenant&#8217;s indemnity and other obligations set forth in Section 3.6 of the Original Lease. Tenant shall, at the same time that Tenant makes payment to its contractors, subcontractors and material suppliers in connection with the Tenant Second Expansion Improvements, provide Landlord with copies of the draw requests and supporting information together with valid construction lien waivers from all parties paid in connection with such draw requests (such lien waivers may be partial waivers during construction and during construction, subcontractors and material suppliers may supply such lien waivers on a &#8220;draw delay&#8221; basis). Upon Substantial Completion, Tenant shall provide Landlord with full and final lien waivers from all contractors, subcontractors and material suppliers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.8%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Effect. </font>Except as amended by this Amendment, all of the terms, covenants, conditions, provisions, and agreements of the Original Lease remain in full force and effect. The provisions of this Amendment supersede and control over any conflicting provisions in the Original Lease. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42007883</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.8%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Estoppel. </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant and Landlord hereby represent and warrant that, as of the date hereof</font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(to the best of</font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">their actual knowledge with respect to items (b) and (c)), (a) the Lease is in full force and effect and has not been modified or amended, except as set forth herein, (b) neither Tenant nor Landlord is in default under the Lease nor does Tenant or Landlord have any knowledge of any event which with the giving of notice and passage of time would result in a default, and (c) Landlord and Tenant have performed all obligations on each of their respective parts under the Lease, and neither Party has any claims against the other Party, including any claims of offset against any rent or other sums payable by Tenant under the Lease. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.8%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Miscellaneous. </font>This Amendment and the Lease embodies the entire agreement between the parties as to its subject matter and supersedes any prior agreements with respect thereto. There are no agreements or understandings between the parties with respect to the subject matter of this Amendment not set forth in this Amendment or the Lease. This Amendment cannot be modified except by a writing signed by both parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.8%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Signing and Delivery. </font>This Amendment will be effective only when both Landlord and Tenant have signed and delivered it. Landlord&#8217;s submission of an unsigned copy this Amendment to Tenant for evaluation, negotiation, or signature by Tenant will not constitute signature of this Amendment by Landlord or otherwise bind Landlord, regardless of whether the cover letter or email transmitting that copy of this Amendment is signed or contains words of approval. This Amendment may be signed in counterparts and, when counterparts of this Amendment have been signed and delivered by the required parties as provided in this section, this Amendment will be fully binding and effective, just as if both of the parties had signed and delivered a single counterpart of this Amendment. Any counterpart transmitted by facsimile or email shall, in all cases, be deemed an original signature. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[signature page follows]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42007883</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.8%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, this Fourth Amendment to Lease is signed by the parties as of the date set forth above. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:40%;width:282.6pt;;">
<tr>
<td style="width:91.95pt;"></td>
<td style="width:70.7pt;"></td>
<td style="width:119.95pt;"></td>
</tr>
<tr style="height:7.9pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Landlord:</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:98pt;">
<td colspan="3" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gd14pbv45bwf000001.jpg" title="" alt="" style="width:326px;height:108px;"></p></td>
</tr>
<tr style="height:27.4pt;">
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tenant:</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:86.7pt;">
<td colspan="3" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gd14pbv45bwf000002.jpg" title="" alt="" style="width:330px;height:94px;"></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned Guarantor consents to the terms of this Fourth Amendment to Lease Agreement and agrees that except as limited by the First Amendment to Lease Agreement dated October 22, 2018, the Guaranty Agreement dated January 8, 2016 remains <font style="font-size:12pt;">in </font>full force and effect, including with respect to Tenant&#8217;s obligations pursuant to this Fourth Amendment to Lease Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:40.17%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gd14pbv45bwf000003.jpg" title="" alt="" style="width:358px;height:128px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42007883</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>6
<FILENAME>arwr-ex1027_122.htm
<DESCRIPTION>EX-10.27
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex1027_122.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DocuSign Envelope ID: 256996CC-2BE8-4440-9C25-54EC12980524 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.27</p>
<p style="text-align:center;margin-bottom:10pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FIFTH <font style="font-size:11pt;">AMENDMENT </font>TO <font style="font-size:11pt;">LEASE AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Fifth Amendment to Lease Agreement (this<font style="font-size:1pt;"> </font>&#8220;<font style="font-weight:bold;">Amendment</font>&#8221;) is between University Research Park, Incorporated, a Wisconsin nonstock corporation (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;) and Arrowhead Madison Inc., a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;) and is dated as <font style="font-size:12pt;">of </font>May 14, 2020. </p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">RECITALS</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:36pt;">Landlord and Tenant are parties to that certain Lease Agreement dated as </font><font style="font-size:11.5pt;">of </font>January <font style="font-size:10.5pt;">8, </font>2016, as amended by that certain First Amendment to Lease Agreement dated October 22, 2018, that certain Second Amendment to Lease Agreement dated January 10, 2019, that certain Third Amendment to Lease Agreement dated January 11, 2019 and that certain Fourth Amendment to Lease Agreement dated September 19,2019 (collectively, the &#8220;<font style="font-weight:bold;">Original Lease</font>&#8221;). The Original Lease and this Amendment are together referred to herein as the &#8220;<font style="font-weight:bold;">Lease</font>.&#8221; </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:36pt;">Pursuant to the Original Lease, Tenant leases from Landlord approximately 63,662 rentable square feet located at 502 South Rosa Road, Madison, Wisconsin (the &#8220;</font><font style="font-weight:bold;">502 Building</font>&#8221;), an additional2,971 rentable square feet <font style="font-size:10.5pt;">in </font>the 502 Building and approximately 7,558 rentable square feet located at 504 South Rosa Road, Madison, Wisconsin (the &#8220;<font style="font-weight:bold;">504 Building</font>&#8221;), each as more particularly defined in the Original Lease (the &#8220;<font style="font-weight:bold;">Leased Premises</font>&#8221;). </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="margin-left:36pt;"></font><font style="font-size:11pt;">Landlord and Tenant wish to amend the Lease to expand the Leased Premises, extend the term and make certain other adjustments as more particularly set forth in this Amendment. </font></p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">AGREEMENTS</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency <font style="font-size:12.5pt;">of </font>which <font style="font-size:10.5pt;">is </font>hereby acknowledged, Landlord and Tenant hereby agree as follows: </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Defined Terms</font>. Terms that are not defined in this Amendment but are defined in the Original Lease have the meanings given in the Original Lease. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:11pt;">Amendment </font><font style="font-weight:bold;font-size:11.5pt;">of </font><font style="font-weight:bold;font-size:11pt;">Lease</font><font style="font-size:11pt;">. The Original Lease is hereby amended as follows: </font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:11.5pt;">Third </font><font style="font-weight:bold;font-size:11pt;">Expansion Premises</font><font style="font-size:11pt;">. Subject to the provisions </font><font style="font-size:12pt;">of </font><font style="font-size:11pt;">this Amendment, effective as </font><font style="font-size:11.5pt;">of </font><font style="font-size:11pt;">the day following the date that the Third Expansion Premises (defined below) </font><font style="font-size:10.5pt;">is </font><font style="font-size:11pt;">vacated by both Nimble Therapeutics, Inc. or its affiliate (&#8220;</font><font style="font-weight:bold;font-size:11pt;">Nimble</font><font style="font-size:11pt;">&#8221;) and Roche Nimblegen, Inc. or its affiliate (&#8220;</font><font style="font-weight:bold;font-size:11pt;">Roche</font><font style="font-size:11pt;">&#8221;) as more particularly described in Section 2.b. below and delivered to Tenant in the condition described in Section 2.c. below (the &#8220;</font><font style="font-weight:bold;font-size:11pt;">Third Expansion Premises Commencement Date</font><font style="font-size:11pt;">&#8221;), the Leased Premises shall be expanded to include the 25,965 rentable square feet </font><font style="font-size:11.5pt;">of </font><font style="font-size:11pt;">space located at 500 South Rosa Road, Madison, Wisconsin (the &#8220;</font><font style="font-weight:bold;font-size:11pt;">500 Building</font><font style="font-size:11pt;">&#8221;) depicted on </font><font style="text-decoration:underline;font-size:11pt;">Exhibit A</font><font style="font-size:11pt;"> attached hereto (the </font><font style="font-size:11.5pt;">&#8220;</font><font style="font-weight:bold;font-size:11.5pt;">Third </font><font style="font-weight:bold;font-size:11pt;">Expansion Premises</font><font style="font-size:11pt;">&#8221;). Following the Third Expansion Premises Commencement Date, the Leased Premises shall include a total </font><font style="font-size:12pt;">of </font><font style="font-size:11pt;">100,156 rentable square feet. The 500 Building, 502 Building and 504 Building are collectively referred to hereinafter as the &#8220;</font><font style="font-weight:bold;font-size:11pt;">Buildings</font><font style="font-size:11pt;">.&#8221; Beginning July </font><font style="font-size:10.5pt;">1, </font><font style="font-size:11pt;">2020, Tenant and its employees, contractors and agents shall, upon reasonable prior written notice (but in no event less than 24 hours&#8217; prior written notice) be provided with reasonable access to the Third Expansion Premises during business hours in order to evaluate the space and plan for the Tenant Improvements provided that such right is exercised (i) in a manner so as to not interfere with the business operations of Nimble, Roche or any other occupant of the 500 Building and (ii) in compliance with any security, confidentiality or other reasonable protocols established by Landlord, Nimble or Roche (the </font><font style="font-weight:bold;font-size:11pt;">&#8220;Early Access</font><font style="font-size:11pt;">&#8221;). Early Access to that portion of the Third Expansion Premises occupied by Nimble and/or Roche may reasonably be withheld from time to time based upon the reasonable requirements of Nimble and/or Roche. Tenant&#8217;s Early Access shall not exceed twenty (20) cumulative (in total; not consecutive) hours in space actually occupied by Nimble and/or Roche. For the avoidance of doubt, that portion of the Third Expansion Premises which is not occupied by Nimble or Roche shall not be subject to the time limitation set forth in the immediately preceding sentence. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43149540v7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DocuSign Envelope ID: 256996CC-2BE8-4440-9C25-54EC12980524 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Existing Tenants. </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Third Expansion Premises is currently occupied by Nimble pursuant to a short term lease expiring September 30, 2020 and by Roche pursuant to a lease expiring June 30, 2020. In the event that the Third Expansion Premises is not vacated by Nimble or Roche on or before October I, 2020, Landlord agrees to, at Landlord&#8217;s expense, take commercially reasonable steps to cause Roche and/or Nimble, as applicable, to vacate the space promptly, including, without limitation, delivering any statutorily required notices, filing an eviction action and diligently prosecuting the same to completion as permitted by applicable law, if necessary. In the event of a hold over by Nimble beyond October </font><font style="font-weight:bold;font-size:10.5pt;">1, </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020, as Tenant&#8217;s sole remedy as a result of such delay, Tenant shall be entitled to a delivery delay penalty from Landlord in the amount of $27,334 per month, prorated on a daily basis for each day on or after October I, 2020 in which the Third Expansion Premises is not delivered to Tenant by Landlord in the condition required in this Amendment. Landlord represents and warrants that the base rent payable by Nimble pursua</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt to its short term lease is $1</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,667 per month. Further, in the event of a hold over by Roche or any other third party other than Nimble beyond October 1, 2020, as Tenant&#8217;s sole remedy as a result of such delay, Tenant shall be entitled to any holdover damages (including any base rent owed and any holdover penalties) actually paid by Roche or such third party other than Nimble to Landlord for the period beyond October 1, 2020, less Landlord&#8217;s cost of collection and expressly excluding additional rent (which has a meaning consistent with how that term is defined in Section 2.2 of the Lease) for such period, and Landlord shall take commercially reasonable steps to collect any holdover damages (including any base rent owed and any holdover penalties) or other amounts from Roche or such third party other than Nimble that may be due. </font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Third Expansion Premises Condition. </font>Subject to vacation of the Third Expansion Premises in broom clean condition and removal of all personal property therefrom, Tenant accepts the Third Expansion Premises in as-is, where-is condition and acknowledges that Landlord has not made any representation or warranty related thereto and Landlord shall not be required to construct, modify or otherwise improve the Third Expansion Premises in any manner except as explicitly set forth in Landlord&#8217;s Work to be completed following the Third Expansion Premises Commencement Date in accordance with <font style="text-decoration:underline;">Exhibit B</font> attached hereto. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Term. </font>The Term for the entire Leased Premises (including, without limitation, the Third Expansion Premises, following the Third Expansion Premises Commencement Date) is hereby extended through and shall expire at midnight on September 30, 2031. Section 1.3 of the Original Lease remains that Tenant is required to give Landlord written <font style="font-size:10.5pt;">notice of its intention to exercise its option to extend the Term no later than twelve (12) months prior to the expiration of the Term, as the same is extended, and Tenant has two (2) options to extend the term of the Lease for five (5) years each beyond the expiration of the Term during which Base Rent shall increase 2.5% annually. </font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Base Rent</font>. Effective as of the Third Expansion Premises Commencement Date, Tenant shall pay Base Rent for the entire Leased Premises as set forth in <font style="text-decoration:underline;">Exhibit C</font> attached hereto. As set forth in <font style="text-decoration:underline;">Exhibit C</font> and so long as Tenant is not in default beyond any applicable cure period, Base Rent and Additional Rent (totaling approximately $57,534.11 per month) related to the Third Expansion Premises shall be conditionally abated for the period beginning on the Third Expansion Premises Commencement Date and extending through the earlier of the following (the &#8220;Rent Abatement Period&#8221;) (i) Tenant&#8217;s use of the Third Expansion Premises for the operation of its business or (ii) the date that is eight (8) months following the Third Expansion Premises Commencement Date (without regard to the status of Tenant&#8217;s Improvements). In the event of Tenant&#8217;s default beyond any applicable cure period, the unamortized amount of abated rent shall become immediately due and payable. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>f.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Tenant&#8217;s Proportionate Share</font>. Effective as of the Third Expansion Premises Commencement Date, Tenant&#8217;s Proportionate Share of the Buildings shall be increased to 70.18% (100,156 square feet of Leased Premises divided by 142,714 square feet in the Buildings). Tenant shall thereafter in accordance with Section 2.2 of the Original Lease pay, as additional rent, Tenant&#8217;s Proportionate Share of all amounts set forth in the Lease, including, without limitation, Real Estate Taxes, Common Area/Operating Expenses and Landlord&#8217;s insurance and utilities based thereon. In the event that Tenant occupies the entire leasable premises in any one or more of the Buildings, Landlord may allocate all of the foregoing costs related to such Buildings to Tenant in which case (i) Tenant&#8217;s Proportionate Share would only apply to those Building(s) which are partially occupied by Tenant and (ii) Tenant&#8217;s Proportionate Share would instead be calculated based on Tenant&#8217;s percentage share of a multi-tenant Building. Notwithstanding the foregoing and anything to the contrary in the Original Lease: (i) for the eighteen (18) month period beginning on the Third Expansion Premises Commencement Date, Common Area costs related to the 500 Building shall not include any capital expenditure (as determined pursuant to generally accepted accounting principles consistently applied (&#8220;<font style="font-weight:bold;">GAAP</font>&#8221;)) related to the repair or replacement of the roof, building structure or building envelope (provided, however, that Tenant shall be responsible for any damage to the extent arising from or related to work </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43149540v7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DocuSign Envelope ID: 256996CC-2BE8-4440-9C25-54EC12980524 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">performed by or at the direction of Tenant); and (ii) following such eighteen (18) month period, such capital expenditures may be included in Common Area costs when amortized over such item&#8217;s useful life in accordance with GAAP subject, however, to the limitations and exclusions on Tenant&#8217;s obligations for payment of Common </font><font style="font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Area/Operating Expenses set forth</font><font style="font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in Lease (including, but not limited to, as set forth in Exhibit E to the Original Lease). </font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:12.37%;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Security Deposit</font>. On the date hereof, Tenant shall deposit an additional $57,534.11 with Landlord bringing the total Security Deposit to $199,183.62. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Utilities</font>. Commencing on the Third Expansion Premises Commencement Date, Tenant shall pay all utilities for the Third Expansion Premises (and the remainder of the Leased Premises).</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i.<font style="font-size:10.5pt;margin-left:36pt;"></font><font style="font-weight:bold;font-size:10.5pt;">Tenant Improvements</font><font style="font-size:10.5pt;">. Promptly following the Third Expansion Premises Commencement Date, Tenant shall in a diligent, good and workmanlike manner in accordance with plans to be approved by Landlord and in compliance with all applicable federal, state and local laws, rules, regulations and ordinances, improve the Third Expansion Premises pursuant to the process as described on </font><font style="text-decoration:underline;font-size:10.5pt;">Exhibit D</font><font style="font-size:10.5pt;"> attached hereto (collectively, &#8220;Tenant Improvements&#8221;). Section 1.6 in the Original Lease shall not apply to construction of the Tenant Improvements, which shall be governed solely by this Amendment. </font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">j.<font style="margin-left:36pt;"></font><font style="font-size:10.5pt;margin-left:36pt;"></font><font style="font-weight:bold;font-size:10.5pt;">Temporary Area</font><font style="font-size:10.5pt;">. Beginning on the date hereof and continuing during the Rent Abatement Period, Landlord will provide Tenant with up to 3,000 square feet of land area behind the Buildings in its as-is condition to enable Tenant, at Tenant&#8217;s sole expense, to place trailers for temporary office, laboratory and/or commercial space (the &#8220;</font><font style="font-weight:bold;font-size:10.5pt;">Temporary Space</font><font style="font-size:10.5pt;">&#8221;). The exact location of the Temporary Space will be determined by the parties in good faith, provided that it shall not restrict access to the loading dock or otherwise interfere with the use of the 500 Building. All utilities and other expenses attributable to the Temporary Space shall be paid by Tenant. No later than the expiration of the Rent Abatement Period, Tenant shall remove all temporary trailers and other improvements installed pursuant to this section and restore the area to its prior condition or as close thereto as reasonably possible, including, without limitation repairing damage to asphalt and landscaping. In the event that Tenant does not timely remove the temporary trailers and other improvements and repair any damage as set forth in the immediately preceding sentence, Landlord shall notify Tenant of the failure and if Tenant does not thereafter comply with its obligation in the preceding sentence within fifteen (15) days, Landlord may thereafter complete the same and Landlord&#8217;s costs shall be reimbursed by Tenant as set forth in Section3.1 of the Lease. </font></p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">k.<font style="font-size:11pt;margin-left:36pt;"></font><font style="font-weight:bold;font-size:10.5pt;">Generator at 502 Building</font><font style="font-size:10.5pt;">. Section 5 of the Second Amendment to Lease is hereby deleted in its entirety. Section 10.20 of the Lease is amended by adding the following at the end of the section: </font></p>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:13.33%;text-indent:0%;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord purchased a new generator to serve the property located at 504 Rosa Road and then dedicated the current generator exclusively to the Leased Premises and Expansion Premises for Tenant. Prior to the expiration of the Rent Abatement Period, Tenant shall pay to Landlord a one-time generator fee equal to $53,000.00, which amount may be paid from the TI Allowance. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l.<font style="font-size:11pt;margin-left:36pt;"></font><font style="font-weight:bold;font-size:10.5pt;">Generator at 500 Building</font><font style="font-size:10.5pt;">. To the extent that Roche and/or Nimble abandons its generator serving the 500 Building, Landlord will quit claim Landlord&#8217;s interest in such generator to Tenant, without representation or warranty of any kind, following which Landlord shall have no obligation to maintain, repair or replace the same and the generator shall be treated as part of Tenant&#8217;s Improvements, to be maintained, repaired, replaced and/or removed by Tenant. In the event that Roche and/or Nimble abandons its generator as set forth in the immediately preceding sentence, Landlord will use reasonable efforts to obtain and provide to Tenant historic preventative maintenance logs and reports regarding the generator. </font></p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:13.33%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">m.<font style="font-size:10.5pt;margin-left:36pt;"></font><font style="font-weight:bold;font-size:10.5pt;">Common Areas/Parking</font><font style="font-size:10.5pt;">. Without limiting Section 5.1 of the Original Lease, Tenant acknowledges that Landlord reserves the right to increase, decrease, alter, add to or eliminate the Common Area or portions thereof and to construct improvements thereon, </font><font style="font-size:11pt;">including the designation by Landlord of parking spaces or other Common Areas for the exclusive use by one or more tenant, occupant or user; provided, however, that reasonable access to and use of the Leased Premises is provided and Landlord uses reasonable measures to minimize disruption or interruption to the conduct of Tenant&#8217;s business operations at the Leased Premises. Landlord further reserves the right to implement a district parking management program which would assign employee parking to new locations or structures within reasonable walking distance to the Buildings, which program Tenant shall implement and abide by, provided, however, that any such program would not (i) reduce the overall parking available to Tenant or (ii) increase the Rent payable by Tenant, without Tenant&#8217;s written consent which may be withheld in Tenant&#8217;s sole discretion. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43149540v7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DocuSign Envelope ID: 256996CC-2BE8-4440-9C25-54EC12980524 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:12.41%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Installation, Repair and Maintenance. </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sections 3.1 and 3.2 of the Original Lease are amended and restated in their entirety as foll</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ows</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (but remain subject to Landlord&#8217;s obligations under this Fifth Amendment including but not limited to Landlord&#8217;s obligation to complete Landlord&#8217;s Work in accordance with </font><font style="text-decoration:underline;">Exhibit B</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">): </font></p>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:13.33%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;3.1. Maintenance by Tenant. Tenant shall at all times keep the Leased Premises and all partitions, doors, fixtures, equipment and appurtenances thereof (including but not limited to electrical, lighting, HVAC and plumbing equipment, lines and equipment or systems servicing only the Leased Premises), all Tenant Improvements and other alterations made by Tenant and those items set forth on Schedule 3.1 attached hereto in good order, condition and repair, reasonable wear and tear excepted. Tenant shall provide Landlord with evidence at such times as set forth on Schedule 3.1 and at such other times as may be reasonably requested by Landlord, including to the extent applicable, service contracts, invoices, payment records, preventative maintenance logs and reports and other records reasonably requested by Landlord, to evidence that Tenant is timely performing its obligations in a good and workmanlike manner. Landlord shall be provided with reasonable access to the Leased Premises from time to time to verify Tenant&#8217;s compliance with the maintenance, repair and replacement obligations. If Tenant refuses or neglects to repair as required hereunder and to the reasonable satisfaction of Landlord as soon as reasonably possible after written demand, Landlord may access the Leased Premises and may make such repairs without liability to Tenant for any loss or damage that may accrue to Tenant&#8217;s property or to Tenant&#8217;s business by reason thereof and upon completion thereof, Tenant shall pay Landlord&#8217;s costs for making such repairs plus twenty percent (20%) for overhead, upon presentation of a bill therefore, as additional rent. When used in this section, the term &#8220;repairs&#8221; shall include replacements and renewals when necessary and all such repairs shall be equal in quality and class of original work. For the avoidance of doubt, all repairs to be completed and paid for by Tenant as set forth above and in Schedule 3.1 will not be included in Common Area costs pursuant to Section 5.5. </p>
<p style="margin-bottom:10pt;margin-top:0pt;margin-left:13.33%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2. Maintenance by Landlord. Landlord shall keep the foundation, exterior and structural portions of exterior walls, roof, all other structural members of the Leased Premises and all Common Areas, including any electrical, HVAC and plumbing lines and equipment not exclusively servicing the Leased Premises (all of which shall be considered as part of Common Areas and included as a Common Area charge pursuant to Section 5.5) in good repair and shall have access to the Leased Premises for such purpose, but Landlord shall not be required to make any such repairs which become necessary or desirable by reason of the negligence of Tenant, its agents, servants, employees or customers or to the extent related to Tenant Improvements or other alterations.&#8221; </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:10.5pt;">Force Majeure. </font>The first sentence of Section 10.17 of the Original Lease is amended to clarify that force majeure shall include a pandemic, public health crisis or other health-related events that cause any government or health agency to declare a public health emergency, quarantine, travel restrictions or limitations on public gatherings or that cause governmental agencies or businesses to close or adopt restrictive practices in the area in which the Premises is located that materially interfere with the ability of a party to perform a particular obligation pursuant to the Lease. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:10.5pt;">Additional Expansion Opportunities (500 Building). </font>Subject to any and all necessary approvals, licensing, permitting, and an agreement to cost allocation and rental rates, Tenant and Landlord verbally agreed that they will jointly pursue the construction of approximately 3,700 square feet on the east side of the 500 Building, generally as shown herein in Exhibit E. Upon execution of this Fifth Lease Amendment, the Parties shall use commercially reasonable efforts, act in a commercially reasonable manner and negotiate in good faith to reach an agreement in the form of a new amendment to the Lease regarding the construction and lease of this additional space to Tenant, with the mutual understanding that Tenant desires to have such additional square footage constructed promptly. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43149540v7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DocuSign Envelope ID: 256996CC-2BE8-4440-9C25-54EC12980524 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:10.5pt;">Additional Expansion Opportunities (University Research Park). </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event Tenant seeks additional space, including in accordance with Landlord&#8217;s long-term expansion plan, Tenant may notify Landlord of its requirements (including programmatic requirements and timetable). Landlord and Tenant may negotiate for additional space subject to a separate and mutually agreeable lease or amendment. At Tenant&#8217;s request (including programmatic requirements and timetable), Landlord will provide Tenant with a proposal to construct additional contiguous space to the Leased Premises or an alternate location determined by Landlord. Such proposal will include construction of the exterior </font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">structure, fa&#231;</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ade, walls, structural support and roof and will be based on conditions at the time of the proposal, including market rents, current and projected interest rates, construction costs, the expansion size, availability/site control of nearby land, the required parking solution and the long term value of the expansion to Landlord. </font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:10.5pt;">Effect. </font>Except as amended by this Amendment, all of the terms, covenants, conditions, provisions, and agreements of the Original Lease remain in full force and effect. The provisions of this Amendment supersede and control over any conflicting provisions in the Original Lease. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:10.5pt;">Estoppel. </font>Tenant and Landlord hereby represent and warrant that, as of the date hereof (to the best of their actual knowledge with respect to items (b) and (c)), (a) the Lease is in full force and effect and has not been modified or amended, except as set forth herein, (b) neither Tenant nor Landlord is in default under the Lease nor does Tenant or Landlord have any knowledge of any event which with the giving of notice and passage of time would result in a default, and (c) Landlord and Tenant have performed all obligations on each of their respective parts under the Lease, and neither Party has any claims against the other Party, including any claims of offset against any rent or other sums payable by Tenant under the Lease. Without limiting the forgoing, Tenant hereby consents and waives and rights or claims against Landlord related to Nimble or Roche&#8217;s occupancy of the Third Expansion Premises as set forth above. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Miscellaneous. </font>This Amendment and the Original Lease embodies the entire agreement between the patties as to its subject matter and supersedes any prior agreements with respect thereto. There are no agreements or understandings between the parties with respect to the subject matter of this Amendment not set forth in this Amendment or the Original Lease. This Amendment cannot be modified except by a writing signed by both parties. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Signing and Delivery. </font>This Amendment will be effective only when both Landlord and Tenant have signed and delivered it. Landlord&#8217;s submission of an unsigned copy this Amendment to Tenant for evaluation, negotiation, or signature by Tenant will not constitute signature of this Amendment by Landlord or otherwise bind Landlord, regardless of whether the cover letter or email transmitting that copy of this Amendment is signed or contains words of approval. This Amendment may be signed in counterparts and, when counterparts of this Amendment have been signed and delivered by the required parties as provided in this section, this Amendment will be fully binding and effective, just as if both of the parties had signed and delivered a single counterpart of this Amendment. Any counterpart transmitted by facsimile or email shall, in all cases, be deemed an original signature. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">[signature page follows]</p>
<p style="margin-bottom:47pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7.5pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43149540v7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DocuSign Envelope ID: 256996CC-2BE8-4440-9C25-54EC12980524 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, this Fifth Amendment to Lease is signed by the pmties as of the date set fmth above. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:51.92%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Landlord: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:51.92%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:51.92%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gt1e50hnuuzf000001.jpg" title="" alt="" style="width:306px;height:107px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:51.92%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:51.92%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Tenant: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:51.92%;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:51.92%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gt1e50hnuuzf000002.jpg" title="" alt="" style="width:298px;height:84px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:51.92%;text-indent:0.03%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0.03%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned Guarantor consents to the terms of this Fifth Amendment to Lease Agreement and agrees that except as limited by the First Amendment to Lease Agreement dated October 22, 2018, the Guaranty Agreement dated January 8, 2016 remains in full force and effect, including with respect to Tenant&#8217;s obligations pursuant to this Fifth Amendment to Lease Agreement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:51.92%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gt1e50hnuuzf000003.jpg" title="" alt="" style="width:330px;height:123px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:7.5pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43149540v7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DocuSign Envelope ID: 256996CC-2BE8-4440-9C25-54EC12980524 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#161615;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="color:#161615;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.91%;">
<tr>
<td style="width:7.78%;"></td>
<td style="width:13.32%;"></td>
<td style="width:14.44%;"></td>
<td style="width:15.55%;"></td>
<td style="width:12.21%;"></td>
<td style="width:12.22%;"></td>
<td style="width:12.21%;"></td>
<td style="width:12.18%;"></td>
</tr>
<tr style="height:1pt;">
<td rowspan="4" valign="bottom"  style="padding-left:0pt; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td rowspan="4" valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Period</p></td>
<td valign="bottom"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Base</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent/Monthly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Original Premises</p></td>
<td rowspan="3" valign="bottom"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Base</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent/Monthly First</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">And Second</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expansion</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Premises</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td rowspan="4" valign="top"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third<font style="font-size:12pt;font-weight:normal;"> <br /></font>Expansion<font style="font-size:12pt;font-weight:normal;"> </font>Premises**</p></td>
<td rowspan="2" valign="bottom"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Base</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent/Monthly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expansion</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Premises</p></td>
<td rowspan="4" valign="top"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(-) <font style="font-size:8pt;">Monthly<br />Rent</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concession</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expansion</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Premises (up</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">to 8 initial</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">months)***</p></td>
<td rowspan="4" valign="top"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Base</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent/Monthly</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Combined</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Premises</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">97,185 RSF</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">chargeable*</p></td>
</tr>
<tr style="height:13.8pt;">
<td rowspan="3" valign="middle"  style="padding-left:0pt; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">58,023 RSF</p></td>
</tr>
<tr style="height:13.8pt;">
<td rowspan="2" valign="bottom"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">25,965 RSF**</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-left:0pt; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13,197 RSF<br />chargeable*</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr style="height:1pt;">
<td rowspan="12" valign="bottom"  style="padding-left:0pt; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/19 -<font style="font-size:12pt;"> </font>9/30/20</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$83,311.36</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,002.92</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$101,314.28</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/20 -<font style="font-size:12pt;"> </font>9/30/21</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$85,390.52</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,452.99</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21.75</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$47,061.56</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#FF0000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">($57,534.11)</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$93,370.96</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/21 -<font style="font-size:12pt;"> </font>9/30/22</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$87,518.03</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$18,914.31</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.29</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$48,238.10</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$154,670.44</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/22 -<font style="font-size:12pt;"> </font>9/30/23</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$89,693.89</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19,387.17</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22.85</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$49,444.05</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$158,525.11</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/23 -<font style="font-size:12pt;"> </font>9/30/24</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$91,918.10</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19,871.85</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23.42</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$50,680.16</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$162,470.11</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/24 -<font style="font-size:12pt;"> </font>9/30/25</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$94,239.02</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20,368.65</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24.01</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$51,947.16</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$166,554.83</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/25 -<font style="font-size:12pt;"> </font>9/30/26</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$96,608.30</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$20,877.86</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24.61</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$53,245.84</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$170,732.00</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/26 -<font style="font-size:12pt;"> </font>9/30/27</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$99,025.92</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21,399.81</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.22</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$54,576.98</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$175,002.71</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/27 -<font style="font-size:12pt;"> </font>9/30/28</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$101,491.90</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$21,934.81</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25.85</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$55,941.41</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$179,368.12</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/28 -<font style="font-size:12pt;"> </font>9/30/29</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$104,006.23</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$22,483.18</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$26.50</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$57,339.94</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$183,829.35</p></td>
</tr>
<tr style="height:1pt;">
<td valign="bottom"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/29 -<font style="font-size:12pt;"> </font>9/30/30</p></td>
<td valign="bottom"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$106,606.39</p></td>
<td valign="bottom"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23,045.26</p></td>
<td valign="bottom"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$27.16</p></td>
<td valign="bottom"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$58,773.44</p></td>
<td valign="bottom"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1.00</p></td>
<td valign="bottom"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$188,426.09</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/30 -<font style="font-size:12pt;"> </font>9/30/31</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$109,271.55</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$23,621.39</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$27.84</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$60,242.78</p></td>
<td valign="middle"  BGCOLOR="#FEFCE3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.00</p></td>
<td valign="middle"  style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$193,137.72</p></td>
</tr>
<tr style="height:1pt;">
<td rowspan="5" valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.65pt;;margin-right:0.93%;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Optional Extension #1 (5<br />years)</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/31 -<font style="font-size:12pt;"> </font>9/30/32</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$112,003.33</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24,211.93</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28.54</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$61,748.85</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$197,964.11</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/32 -<font style="font-size:12pt;"> </font>9/30/33</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$114,803.42</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$24,817.22</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.25</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$63,292.57</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$202,913.21</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/33 -<font style="font-size:12pt;"> </font>9/30/34</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$117,673.50</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$25,437.65</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29.98</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$64,874.88</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$207,986.04</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/34 -<font style="font-size:12pt;"> </font>9/30/35</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$120,615.34</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$26,073.60</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30.73</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$66,496.76</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$213,185.69</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/35 -<font style="font-size:12pt;"> </font>9/30/36</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$123,630.72</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$26,725.44</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$<font style="font-size:12pt;"> </font>31.50</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$68,159.17</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  BGCOLOR="#F0F0F0" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$218,515.33</p></td>
</tr>
<tr style="height:1pt;">
<td rowspan="5" valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.65pt;;margin-right:0.93%;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Optional Extension #2 (5<br />years)</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/36 -<font style="font-size:12pt;"> </font>9/30/37</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$126,721.49</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$27,393.57</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$32.29</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$69,863.15</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$223,978.22</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/37 -<font style="font-size:12pt;"> </font>9/30/38</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$129,889.53</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28,078.41</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$33.10</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$71,609.73</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$229,577.67</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/38 -<font style="font-size:12pt;"> </font>9/30/39</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$133,136.77</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$28,780.37</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$33.92</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$73,399.98</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$235,317.11</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/39 -<font style="font-size:12pt;"> </font>9/30/40</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$136,465.19</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$29,499.88</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$34.77</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$75,234.98</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$241,200.04</p></td>
</tr>
<tr style="height:1pt;">
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/1/40 -<font style="font-size:12pt;"> </font>9/30/41</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$139,876.82</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$30,237.38</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$35.64</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$77,115.85</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$0.00</p></td>
<td valign="middle"  BGCOLOR="#F3F3F3" style="padding-left:0pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$247,230.04</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:11.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">* <font style="font-size:8.5pt;">Per the Fourth Lease Amendment, 2,971 RSF (i.e., the Second Expansion Premises or chemical storage expansion area) is included for calculating Tenant&#8217;s proportionate share but not included for base rent calculations. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0.05%;font-size:12.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">** <font style="font-size:8.5pt;">Base </font><font style="font-size:8pt;">&amp; </font><font style="font-size:8.5pt;">Add I Rent is owed upon Third Expansion Rent Commencement Date, but offset by Rent Concession </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0.05%;font-size:12.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*** <font style="font-size:8.5pt;">See lease for details of 8 month rent concession; commencing upon delivery/rent commencement</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>7
<FILENAME>arwr-ex21_669.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex21_669.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiary </p></td>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Jurisdiction </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Madison Inc. </p></td>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delaware </p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Australia Pty Ltd</p></td>
<td valign="top"  style="width:50%; border-top:solid 1pt #000000; border-bottom:solid 1pt #000000; border-left:solid 1pt #000000; border-right:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.2pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Australia</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>8
<FILENAME>arwr-ex23_668.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex23_668.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We hereby consent to the incorporation by reference in the Registration Statements on Forms S-1 (Nos. 333-164039 and 333-161344), Forms S-3 (Nos. 333-235324, 333-228598, 333-214315, 333-214311, 333-213484, 333-202737, 333-191922, 333-188718, 333-178532, 333-178073, 333-178072, 333-144109, 333-137329, 333-132310, 333-124065, and 333-113065), and Forms S-8 (Nos. 333-238616, 333-230621, 333-223836, 333-210117, 333-202741, 333-198920, 333-194596, 333-190970, 333-180692, 333-170252, 333-136225, 333-124066, and 333-120072) of Arrowhead Pharmaceuticals, Inc. of our report dated November 23, 2020, with respect to the consolidated balance sheets of Arrowhead Pharmaceuticals, Inc. and Subsidiaries as of September 30, 2020 and September 30, 2019, and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the years in the three-year period ended September 30, 2020, and the effectiveness of internal control over financial reporting as of September 30, 2020, which reports appear in the September 30, 2020 annual report on Form 10-K of Arrowhead Pharmaceuticals, Inc.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rose, Snyder &amp; Jacobs LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Encino, California</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 23, 2020</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>arwr-ex311_7.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex311_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SECURITIES EXCHANGE ACT OF 1934 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc., certify that: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Annual Report on Form 10-K of Arrowhead Pharmaceuticals, Inc.; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 23, 2020</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>arwr-ex312_10.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex312_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF FINANCIAL OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SECURITIES EXCHANGE ACT OF 1934 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc., certify that: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. I have reviewed this Annual Report on Form 10-K of Arrowhead Pharmaceuticals, Inc.; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 23, 2020</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kenneth A. Myszkowski</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Kenneth A. Myszkowski,</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>arwr-ex321_6.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex321_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SECURITIES EXCHANGE ACT OF 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND 18 U.S.C. SECTION 1350 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section&#160;1350, that (i)&#160;the Annual Report on Form 10-K of the Company for the year ended September 30, 2020, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii)&#160;the information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 23, 2020</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Christopher Anzalone</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of these written statements required by 18 U.S.C. Section&#160;1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>arwr-ex322_9.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
arwr-ex322_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF FINANCIAL OFFICER </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PURSUANT TO RULE 13a-14(b) OR RULE 15d-14(b) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OF THE SECURITIES EXCHANGE ACT OF 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND 18 U.S.C. SECTION 1350 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Kenneth A. Myszkowski, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;), certify, pursuant to Rule 13(a)-14(b) or Rule 15(d)-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section&#160;1350, that (i)&#160;the Annual Report on Form 10-K of the Company for the year ended September 30, 2020, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and (ii)&#160;the information contained in such Annual Report on Form 10-K fairly presents in all material respects the financial condition and results of operations of the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 23, 2020</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:60%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kenneth A. Myszkowski</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Kenneth A. Myszkowski</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:40%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A signed original of these written statements required by 18 U.S.C. Section&#160;1350 has been provided to Arrowhead Pharmaceuticals, Inc. and will be retained by Arrowhead Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gemzezolivjc000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemzezolivjc000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U 08# 2(  A$! Q$!_\0
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M '&.:W:0$'H0: %HHHH 3 SG%4-7TH:M8_9?MMY9C>&\RSE\M^.V<=#WHHH
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M^$;LO^?C4_\ P9W/_P <H_X1NQ/6?4C_ -Q.X_\ BZ** $_X1G3_ /GKJ/\
FX,KC_P"+JWI^E6NF^8;<39D(+&6=Y22!ZN3110!=!R**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gei541vqjlbv000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gei541vqjlbv000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &W G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHI,T +129HS0 M%)NHW4 +12;J3=0 ZBF[J-U #J*3=1NH 6B
MDW49H 6BDS1F@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK
MQ_P[X@O[[]H#6(OM<YTMHI;:*$R$Q[X1&&(7ID'//N:J,7*_D)NQ[!1114C"
MBBB@ HHHH **** "BBB@ HI,T9H 6BDS1F@!:*3=1NH 6BDW4;J %HINZC=0
M ZBDW4;J %HI-U&: %HI,T9H 6BDS1F@!:*** "BBB@ HHHH **** "BBB@
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M"+6RC8.T+,#)+C^' Z#U[U[3T&!116%:M.J[R.BAAZ="/+!!4;QYIY( ))
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M  ,4?#"\FCN[_322;9HQ<Q+V0EBK8]CP?SKE8K&\NYA&+34+F3/^J2V=?S+
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M]DDXIW_"+QO_ *S4+UQZ&2NB"4NRCV\^Y/U6C_*8MMX;TRV;<+?S&]9#N_\
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M<<.VYO<X(R2032YF%D6(_$%I?7UK!IMU;RJUTUO.9(Y!DA7)2-L;2X*'()P
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M/=/5#-/9WUO:LI,-S+%A)...F2,]LBF^%O$FI:MJ,EKJ$%NFZV6ZC,.1L#'
M5L]3[U=I)7$Z+M=HWG@K!U/P[!=/Y\)-M=CE9H^.?<=_YUU94&J\D7%7"JXN
MZ.6K0C-6:.5TS5IUNO[-U10EXH^1_P"&4>HK>5JS->T@:A:?)\MS%\T+CJ#Z
M?0TS0]2.HZ>LDG$\9V2CT85O-*4>>)RPE*$O9R^1MJU2J:K*U3*:YVCJBRP#
M3P:B4T\5#-4R04ZF"G5):$-,/2G&FM4L9&QJ!S4S51OKR"QMVGN) D:]SW]A
M46;=D3)I*[%<U78\UB?VAK&L<Z= EK;'I--U;W _S]:=_P ([JDW,FNSAC_<
M3C^=:_4Y?;DE_7D<GUKF^"+?X?F-\/I]OUS4=0;D(WD1^P[_ *8KL88^*R?#
M^AC1K%K?SVG9I#(9&7!.<?X5NJN!6]:2O:.R*PM.487EN]6*!@4M%<+XC\23
MZC=2:-HTICC0[;R]7^'U1#_>]3VKBKUX48<\SNITY5)<L3M;>Z@NE=K>5)%1
MRC%3D!AU'X5Y7\31CQGI9];&0?\ C]=7\.5$7AR>!<[8KV9!GTR*P/B%HFJ:
MWXRT>WTJ(&0VL@DF<?)"NX?,?Z#O6%5NMA[KJ=N"E&CBDY/17.*B2[O]0CTW
M3(/M%_+R$_AC']YSV KV+PAX83PMI+6YG:XNIY/.N9B,!G( X'8#%2>&?"UA
MX7L#!:@R3R?-/<R??F;U/MZ#M6CI^IVFJ1S26<HE2&9X&8=-ZG# >N#3PV&5
M)7>X\?F$L3+E6D3E?$.K7&K7T^BV+M#:0G;>W"\,Q_YYK_4U0N[*(:+<6<,8
M2/R655';BIKI/L_C+5HL8$R13C\MI_45#--<WE[_ &7I:"2\8?O';[ENO]YO
M?T%>!C'6K8IPWL]#@6QV/ARY^V>&]-N.I>W3/U P?U%:=4-&TQ-&TBWT^.1I
M%A7&]NI).3^IJ/7->L] LOM%TQ9V.V&%.7E;T45].GRP3F))MV1<N[RVL81+
M=3)#&6"!G.,L3@#ZUPGQEM_-\#+<8YM;V&7/H,E?_9JP=??4=5M)]5U-RLT(
M\RWM4;Y( "#^+8ZFNY\9V4OB+X>:A;VL1EFN;420HO5F&& 'XBN6EBHXCG4=
MD=M*$L/6ISEW/!]/TN\\0:Q;Z+IW_'Q<'YY,<0Q_Q.:^DM(TNVT32+33+-=M
MO;1B-,]3CN?<GG\:YWP!X+C\):06N"LNJW0#74P['LB_[(_4\UU];T:?(M=S
MHS;,7BZMH_"MO\PKE/&OBT>'[1;2RVR:M= B"/J(QWD;V'ZG\:ZIL[3MQNQQ
MFO K:6:]EGU"]D::^GD832-U&#C:/0#'2IQ%5TXZ=3Y_%5G2CINSJOA<SVOB
M/5K-Y6E:>WCN&=SDNX8AC^;5ZF1D5X_X-G^S_$&P&?\ CXM9HB/IAA_*O8:,
M+*]-!A)<U)%2:/BN.U5/[/\ %5E=+PEVIAD]R.G\Q^5=RZY%<_X@T'^V8H%6
MY:W>&7S%=5R>F*]"E):QEL]"<33DXWBM59BK4@K$/A[5H>8M=F+?]-$X_G3#
MJ6JZ0P_M2W6>WS@W$/;ZBLEA)?9:9'UFWQQ:_KR.AQ1BF6T\5U L\#AXV'#"
MIL5,;K1F^C5T1%::5J<K2%:WBR&BL5I4CR:FV\U+%'S5N6@DM1T:)&C22,J(
MHW,S'  '4DUX1XK\3/XZUL2H2- L9"+*(]+AQP9F'IV4>GXUVWQ5UN5X[7PA
M8R%)M00RWTBGF.U!P1]7/'T!]:\Y2-(D6.-0J(-JJ.@ KHPU%O\ >2^1:J1Y
MG36ZM?Y_\,:UD<VH]F-6+.]U276%T3P^BOJMW$<ROREI'D9E?Z=AW./QQS?2
M6UO';VD#76HW4OEVML@R9&(Z_0=2:Z_PQX/\6^'8;AK;58(KJ\?S+J?["'=C
MV7<Q^Z.PQ59MC\-2PRH5M>9;6;V]#Q\#E56KF$\1M&+=O-L[_P .>&M/\)Z4
M+.T!EF=O,N;N49EN)#U=C_3M6F;A\\,?SKAGT7Q9-_K_ !==IG_GG%#&*Y:U
ML-;NX&.H>+)A,DC1R*FI< @X_A'Z5X^%Q5+$MQIWT[IK\SZ&I0G#<]BN;2#5
M=/GL;Z 3VMQ&8Y8W'#*>M?+OB;P[<>$_$5WH5PS21QCS+69O^6L#?=/U'0^X
MKT%O#EH__'SX@FE]<W4[_P A5+4O#_ANUTR[GDNV=HH7<'RWSD GJQKTJ//3
ME=?K_D8U**G&S.[^#=U]J^%>EJ3EH'FA/X2$C]"*[&1>:\V^ CS1^#=1L+A2
MLL%[YFT]0LD:,*].D7FL9:38I:HK;:,4_%(>!3N96&&F'/I6+/K-U?7#VNBQ
M+)M.'N7^XOTH7PW=7/S7VK74C'J(_E45KR6^)V.=U7)V@K_D1:VIO-3TS33]
MR63S)!ZJ/\FNN@C]JPM-\*6]CJ4=\+FZEE12JB5@1S^%=/&F!6=:<;*,37#4
MI7<IJS8Y%P*?117(=YSVO>$H-9O8]0@O+C3]0C3R_M%OCYTZ[6!X(KF=>T.+
MPKI#ZM]IFU'6Y9$MK:\O,$6Y<XW*HX7 R<^N*]'JIJ6FV>KZ?-8WT(FMY1AD
M/'N"#V(/>H<$]5N8U**DFUN>23:=?V%_I\5JMDEE8R^8AU"0K]KN3_&<<GGD
M5Z7X<\0KK>E2W$\/V2XM9&ANXF;(C=>3S_=P0<UR?BCP%IVG>%[R\L(+FZOH
M-DJ23RM*ZHK@L%ST^4'I7,W-S;3S7C'5DGTO49DG&GV>6N+J3:!Y9 Z+D<BN
M>+E2=F<JE*C+4]&'Q"\,M>+;KJ&X,^SSQ$_D[O3?C;^.<5E:KX"NS?W,^C7M
MK';W<GG2V=[!YD:R'JR>F?2N1U%-6MX]3T_5$ABBDT=KF.PA4;8/F( SW88R
M37=Z?X\\,VVF6,%SK=N9Q;QB0KEP&VC.2 0.?6NFAB9PD^@VX5ERUO\ +]3G
M?$/ANYT3PW<:AJ/B&\>Y0!+6WLD6"+S6.%&T9)Y_0&KW@47!\6ZJQZ"S@6]*
MC"FYY_7;G-:GC^SN+W0[*^L8C=?8;N.[:&/YC*@!!VXZX!S5?X;&8V.JM]FE
M2UDOFE@FFC*/+N )R#UP>,_X5Z+J.6';;N[F4:,88N*BK)+[S0M_!-G;^(VU
M875PZ>>UREJQ&Q96&"V>IZG ]ZW[\R+IUTT1(D$3E"/7!Q4LI=8G,:AG"DJI
M.,GM7ET=SKUZ6GN$\2?:5/[XVXV1Q-_=6,_> ]>:X:=-=#UJ5):VT'>&M,L]
M8O-/L;Y7>T72Q/'$KE0TA;#,<$9/-9JPW]Y9V'D*[K/:2VT]PS8"1>9_$WL%
MKK?"&BW4>I)?2VDUG:6MK]FMH[C_ %LF3EF8=NGZUI2>!=%ENGE=+CR7<R-:
MB=A"6/4[1_+I6SFDSH=1*3N<_H^B7.OI?:G::E+:1M/Y5NI0/%)$@ Y4]><\
M^U=5H'A_^QS<7$]T;N]N2/-F*!0 .BJ.P%;$,,=O"D,,:QQH-JH@P%'H!3ZR
ME-LQE4<M.@4C#(I:*DS*4T?%<E OV#QC<VZ\1W<0F _VAU_D?SKMW3(KG=9\
M-0:K=PW,D\\,D2%%,3 9!.>>*ZJ,TKJ6S.+$TI.TH+5,NKGTJ937-GPQ+!\U
MKJMY&XZ;FR/Z4B:OJ.CR+'J\8FMB<"ZB'3ZBK=)2^!W,E6<?XBL=6IJ457AD
M26-9(W#HPRK \$5.M<S1VQ9**<*8*>*AFB&FF-3S334,9"U<=$O_  DFKR7,
MWS:?;-LAC/1SZG^?Y#M72ZS(T.C7LBG#"%L'ZC%97AN)8]$M,#[R[S[DG-=.
M'7+%SZ['#B??J1IO;?\ R-F*(8'%6TB'I38A5D=*B4F=,(H15 IU%%9FIS'C
M?4KJRTNWM;-_*EOIQ;F<=8U())'O@8KF;6VALK9((%VQH./4^Y]ZW_B",:7I
MTO\ SSU"+]0PKG;Z\2RA#%6DE=MD42<M(QZ 5\[FSE*LHGKX#E5-R.A^'[8M
M-6B_N:@Y_-5-=?7/>$=#N-'T^:2]<->WDGG3*OW8SC 4?0=ZZ!B0I(&2!P*]
MO#1E&C&,M['F5I*51M'!_$WQBV@Z8NEZ?)C5;Y2%8=8(^C/]>P]^>U4O@K*/
M^$6O[/))M[YL9]&53_C7D]UJ-UK6I76JWS[[JYD.[T0 X"CV %>B?!BYV:EK
MUD?XUAG7_P >4_TJT[R/#HXMU<9R]%<ZGQ1INIW/BFS;2T >>U:*29A\L0#
M[C[\\"NDT71;70[$6]L"S,=TLK??E;N2:T:QO$_B6R\*Z-)J%X2QSLAA7[TS
MGHH_Q["E3P\54<TM6>P:IGB6=8#(@F92RIGYB!C)QZ<C\Z\[UJ/=X]OC.3(R
M6\36Y8Y\M2,,%].16#\/=9U'5_B?<7NJRAKBZT]]L:_=B4.I"+[#]3S72^-'
MBL/%EG>3.(X9;)T9CZHV?ZUAFU*4:#7H=6"DO:HIW@1K&X61@J&-@Q8X XKL
M?!UPUSX/TJ1\[OLZJ<_[/']*YC1/#L_B*2._U6)H=+4[H+1N&G]&?V]!_D^A
M*JHH55"JHP !@ 5RY7AITDYSZ]#7&UHS:C'H+4=Q<0VMO)/<2+'%&-SNQP *
M9>7EO86DMU=2K%!$NYW;L*X*ZNKGQ/<+<WB-#IB-NM[0\&3T>3^@KIQN.IX2
M'-+?HCBC%L[C2]3MM8T]+VT9C"Y8*6&#P2.GX5XEJ>S2M;UNV*L?+OW\J-1\
MS[_F4 >^:].\#.([?4[#I]FO&*CT5P&']:D3P;:GQQ<>)+@K(Q1!!%CA'"X+
MGWP!CTYHC_M5"$^YRXFBZB4?,J^!O";:-;MJ>HJ&U:Z7Y^X@3M&/ZGU^E=C1
M177&*BK(VA!0CRH*:R@TZBJ**SQ53FA!4@J"",$$<&M1AQ5645I"3,9P1QJ+
M_P (YK<:(2-.O&V[<\1O_G]/I74[:P?%<2OHLK'K&RNI]\X_K6[9L9K*WD;J
M\2L?Q K6NKI3ZG+A_=E*GTW0[;2;:EVT;:RBSI:(=O-3Q+2;:DC%4V$5J>)>
M(V:3XJ^)3(<F..UB3V3R\X_/-<S>745E;RW$QPB=<=2>P'N:ZCQ1E?BWX@7:
M1OMK5A[X3&:P/"U[X?G\8M?:]=;=/TN3-O (6D^T7&?O':#\J_SQ7K^T4,)"
M1YN&O_:%=?X?R.C\)?#_ ,7VTAUY_P"RK:]NXQY:W1D:2VC/.P!1@$]_R]:Z
M@^&/%[_Z[Q%IL?\ URLF;_T)JM3?%7PX?]5'J<W^Y9M_7%9UU\5].A3>-%U4
MID ,Z(@R>G4U\_5PE&O-U:L+OSU/85>I!<L'8G'@W6G_ -=XNN!_UQLXU_GF
MH(/A;9*7,FMZL_F.7?:Z)N8]3P*A?XEW)/[GPS-_VUNT7^0-1?\ "Q/$+_ZC
MP_8KZ;[IF_D**<,-1_A)+TT-'1Q<_B3-J'X6>'C_ *Z34YO]^];^F*X_XB^&
M/"^F_P!G>'=+L3_:FH2J\LC3N[06RGYVY. 3]T<>M2ZS\3O%VEP1EK+2XYYV
MV6\"Q2,\K>V2.!W-9-C;WANKC5=6G%SJ]ZP>XE'10.D:>BKTHJXB-.//UZ?U
MY')BYRP\>67Q,[GP0JV7Q#\6V"*%BE@L[B-1V 0H?Y"N]<5Y_P"&SN^+^HE?
MNG0H=WU\TX_2O0W%==7XQ4]::*V*P/$<\LC6^DVS;9;L_.W]U._]?RKHR*YI
MQN\<2;O^6=J-GZ?XFM*/Q7[&&(ORJ/=V-;3[&&SMDMX$VQH./4^Y]ZTXXJ@A
M%7HQ6523;.BE!)60JH!3ZK:C?P:7IUQ?73%8+>,R.0,G ]*\ZU?Q+J>HF-YI
MKG2K20@6]E:$-=W)]R.@]A^)KSL5C:>&2Y]WLENSKITW+8].J)KF!)EA>:-9
M6^ZA<!C]!7E]EXKU#28$%M-=ZC#J,!^PK<_.\,X(&&;^[@DG/]WWK-DL(3]K
MDFTQ]4CMF4:GJ)8F59&Y)3O\O!..@Q7#+-X.,?91<F[Z=5;<U5!WU9Z_>W]I
MIMJUS>W,5O O625@HINGZE9:K:BYL+J*YA)QOB8$ ^A]#7DPN9=0N+6(:BNO
MWD:^7IMNO(0?\]93Z@=6/I[U:TG5KS3)VU:SL'EFFA>UOK2$8V7*GY&(],Y!
M/H:F.<1=17BU!Z<STU!T--]3K-9\7S0:A-I^D6L-Q+;8^TW%Q+LAA)_AR.2W
MMVIOA?4=,N=3F@FT:STW6@OF$Q(N)T/\:. "1ZCJ*YO0-"35=3ATB[_?VMFA
MNM2])KASD*Q[]VQ["H]6TV7PY?0VDMR]O%%)YND:D_(C/>&0_ISU%91QV*M]
M::O3;VMJEW&Z5-^YU.R\3>%Y=8NK?4=/NUM-2MT:,-)'OCEC/5''I_\ 7K#7
MP%K5U:O;W>MV=I!("K0V-BH!!Z\L?Z5L^%/$UUK5W>V5Y%:^=:JC^;:2%HV#
M9XYZ'CI[UU%>O3]E7BJD=4SBJ8>/,^8KV=K#IVGP6D1*P6T2QJ6/15&!D_05
M0T;Q1HOB"6>+2[^.X>#EU (X/0C(Y'N.*P?B#J%P([#0X)7@74C)]HEC^^(8
MURZK[MD#Z9K(^&#:=>7U[J*W-O'>-$MO#IR'#VUNIXW \DDX)/TKO5)>S<V5
M>SLCNM3\0:3HTB1ZC?PV\D@RJN>2/7 [5G:^)/$_@Z]C\/W\32S)B.2.7 ;!
M!9-P^[D9'MFLOQQI1MDF\06MXT-UY26_E&)9%E.["#GIRW-4O"^J:9I?B/6$
MN;^TLU984,;N$#R@'<P!^H%>8\1*-?V<EHSNA2C[/VL'JCG=(U+6]*LIH_#D
M4\D-SFVDM+A][:9<@X+<_P /4XZ=*@M];?2KNZU#3M:U.\ETR=!J"W,QDCN8
MB<.P7MCG&*]'U;P3H>O7?]HMY\,\J@236=P8_.7MNQPW'>L7Q%X,%A%9W7A[
M34FB@@>TN;%7VF>!N<@GJX.3SUR:ZSLABL/-VE&SEN=;)XBT6*XCMY=6L4FE
M *1O.H8@].">]8_BSQ/=:5<6^EZ7% ^H7$;3-+<$B*WB7@NV.O/05P/_  C=
M[9:/-='PE#'I$( G@N,27DJ?Q2 C.-HYQ[57M;*[N[DYO(K[16TZ2TAO?-!=
M(B2Z!^<Y4Y'THN32P5)R34KI;FM9^.==1Y+BWUFPUM(%\R>S6V,#F,=3&W?'
MXUZEIU_;ZIIMM?VK;H+B-9(S[$9_.O+3.;KP]X#U29%0Y>QDD P"K(4'X$H#
M^-3^&O$VK:+X=M]'M_#\TTUF\B22W,P@C +L5"DYW'!% J^'56"E3C9WM_7]
M=3U2F,@-8WA?Q+'XELIY/LTEK<VTQAN('8-L; /##@@@CFMRF>9.#C)QDM45
M)(JHW-NDL;QR('1AAE(X(K5>J<PK:$F<U2*L<YH,CZ7J\VC2,6@<>;;%CT]1
M_/\ +WKJUKD]2^3Q'HLB_?,I4_3(_P :ZT5I7U:EW,,+HG#L_P#@CQ3Q3!3Q
M7,SM0AIAJ0TPU+&5+VW^UV-Q;_\ /6-D_,5S?A>YW:=]E?Y9K5S&ZGJ!GC_#
M\*ZQA7+ZUIES9WYUG3$WN1_I$'_/0>M;X>:U@^OYG'B8--58]-_3_@'1Q/5I
M6R*YK3-<M+]0(I-LO\43G##_ !_"MJ.:BI3:=F:4JL9*Z9=HJ-7S4F:Q-TSE
M/B)A?"C3'I#<0R'\'%5O"&AR7%Q_PD.I1%9'&+*!A_J8S_$?]IOY5U=]8VVH
MVWV>[C$D)97*'H2I!&?Q%6:YWAXRK>U?1&RJM4^1!111709'RS.@M;N_B8[5
MANIE/L YKUKX2>&;BQM)O$-YNCEU",)! 1C;"#D,?<]?I]:Y+3/"3>(_BGK-
ME-&?[,M+^2XNCV<%LK'^)_0&O>%4*H50 H&  .!4174\K!83EJRJR[NPM?/W
MC35;G6_&NH-<G$.G3-:VT.>$Q]YOJ3^F*^@:^=O$B>7XX\1)_P!/N[\U!KNP
M:3J:GIRV+7@FY^R?$319#TF\VW/_  )"1^H%>VZEH5AJUY97-[%YILV9HT/W
M23CJ.^,5XMX#T6[U[Q?:7-N-EGI4PFGG(X+XXC7U/KZ"O>ZG&J,IV'!M(***
M*YAG+^/4SX>CD(RL5W"[ ]"-V.?SJ@?O5M^,83/X1U-0,E8=X_X"0W]*Y*V-
MUXBF6PTQRD813=W@'$0(^ZOJQKYC.L-.MB81@KMHU@[(T_"4N_Q5JP@R\#0Q
M^8ZCY5D7(QGUP?TKMJJ:;IMKI-A'9V<0CA0?BQ[DGN35NO>P=!X>A&DW>QFW
M=W"BBBND0449J-Y,4[";L*S<54E>B2:L/5->M;$%"_FW!X6&,Y8GW]*VITVW
MH<]6M&*NV4O$\IFA@TZ+F:ZE4 >P/7\\5U,40BB2-?NHH4?@,5@Z%I-RUVVK
MZF +IQB*+_GDO^-=&!17FM(1Z?F1AX/6I+2_Y"8I=M. I<5BF=-B/;3U%+BE
M JFQ)'@/QAOFT?QY>3QG;+<Z-$L1_P!OS67/X#FH-'U7PWI>D6ME';/-)%&
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MC3ZW27VE]YU7FCUI1(*X>;7M;OD/]EZ<8D'/F7')/L!T_G6AI?B>WO"(9_\
M1;L<-#(<9/L3U_G2=!]!1QD&[?TS>L--M-/EO);>/;)>3F>9CU9B /RP!5ZJ
M"SU,LP]:R<&CIC-%FO O%.EWNJ?%?5=(TY/]*NY(F#D?+$GEKN<^P%>[><*S
MK;2K&TUJ_P!71,WMZ$620]E10 H]N]72DZ;;0VTR7P_H5GX;T6WTRQ7$40Y8
M_>D8]6;W)K3JL9Q0)Q4.+>K#G19HJ 3"CSA4\K'S(6[MTO+*>V<D+-&T9([
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M-\.)<W/_  DNIP*MT6(L[3JMFG]7]3V_EV.H)YFG7"]RA/Y<UG^&7W:;(O\
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M-6UB"[6\N0W$C%B,C.U6#8[\"KUI8RZ8^CW]IHFHRV]A#-;203A/M.^0HQN
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M:C)J(MIM2/\ H@G:."=/*BY*C[P)!!YP<8I<S#E1O6VJV=S<7,'F+$\%S]F
MD<#S7V*_R<\\.*N2S06YC$\\41D;:@D<+N/H,]37(3^&[6ZM?&MU<:8LUW/-
M)]G>2+<V%MX]GEYZ?-GE>X]J8BV,&HW4WBC2I[R6[@@^RRO9-<@Q^4H:( *=
MC^9O)!QG<#VX.8?*CM&F@CV[YXEW':-S@9/3 ]\T"YMBTBBYA+1KOD D&47K
MD^@]Z\Z\): RO;37>D3Q-;:3<) EU&6:%C=2$#)_CV[>>O/O5VP\(V$>G^"(
MSI"@J@^VYBY;_1V8B;U'F!3AN,@4KCY4=VLT#6_VA9HV@V[O-#C;CUSTQ3H9
MH;A%>":.56&5:-PP(]1BN#N=+%I/.LNF2OH-OK;336D4!93&UNFUQ&!\Z"4E
MB #SS@X-4KBQBO=5UNXT#1KR.RFL+82".!K8786<F98P0OS&/*YXR3^-%QV/
M2;>YMKK?]GN(IMAVOY;AMI]#CI3HKFWFFDBBGBDDB.)$1P2A]QVKCBNDZA;W
ML?A;29;35!I\T45TEBUHL3$#:C,P7YLXQP<8)X[U[*'2[C4-!3P[HMQ87EI*
M#=.]FT)AAV$/'(Y #EC@8RV3\W;-*X['50:[%=^'HM7MK>67SK<SPVVY5DDX
MSM&3C/XXJ_\ ;+=?*$LL<4DI"K&[@,6QG;UY//:O*M'TJ]LO"-_;ZKIMU/J=
MWH\J6-WY;,$C\L_Z-MQ^Z8>G\?7)/ WW\,VEU:>,;JZTL37<[,L#R1;FPMK'
MM\O/3YL\KW'J*0SN)[JVM=GVBXBB\P[4\QPNX^@SUJI=ZU:6>K6NF.<W5S%)
M)&@91G9MXY/4[N/H:\\OK2?^U)+O6VE/VBSMQ;>;H_VX,!&-\8X.QM^XD$#.
M1UQQLV>AM%>^&'GLYII;?3KE6FNH5,L9_=E%8C(!&2!R>AYZT ==#J47]F6]
MY>@6'G(I,=Q(H*$C[I()!/T)JP]Q!&T:O-&K2G$89@"Y]O6O.M*M[33DTV;Q
M+I<TUO\ V/:PVC/9O.D#!?WL90*2CDX.2.0,9XQ3M3MM/@GT6[T[1KE9401V
M^F7>GNZ-&9@3M;!$#C&X$D8&,CC@ ](HHHH **** "BBB@ I*6B@!N*,4ZDH
M ;BDQ3\48I6 9BDQ4F*-M%@(]M&VG[:-M%@(]M&VI-M&VBP#-M&*?MI=M%@(
M\4N*?MHQ18!N*,4[%&*+ )BEQ2T4P$I:** "BBB@ HHHH **** "BBB@"IJ>
MH0:3I=UJ%R2(+:)I7QUPHSQ[UY&F@WOCV Z]XAF9\@O;60;$=LAZ#'=B,9->
ME>,]-GU?P9J]A; F>:V81J/XF'('XXQ7B>F>.#!IJPEF0A0K+CH1QBM:<6UH
M>G@*+FFX?$OR*,LU[X&UQ;S0IC V<20Y)CF _A8=^_T[5]#:!K$.OZ#9:K;@
MK'=1!]IZJ>X_ Y'X5\QZMJ;7T[7$F1&G(SW-?0OP[TRXTCP%I-I=*4G\HR.A
MZKO8MC\ :NM&R5]SJS>A&G3A)_$SJ****YSP@HHHH **** "BBB@ HHHH *2
MEHH 2C%+10(;BDYIV*,4[A8;28I^*,47"PS%)BI,4;:+BL1XHQWJ3;1MHN%B
M/%+BG[:,47"PS%+3L48HN.PVEQ2XHQ0%@HI:*0!1110,**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KSSX@>!EU"&?5]+58[L(6N(NBR@#EO9A^OUZE%:4JDH3
M3B9U(1G&TBIX7\%7&KVEK>:XP2R"*8K.-O\ 6C'#.1V]A7I<44<$*10QK'&@
MVJB#  ] ***JM5E4E[Q-"E"G&T4/HHHK$V"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gei541vqjlbv000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gei541vqjlbv000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &I M # 2(  A$! Q$!_\0
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M))XKKJ* //$^$.C0Z'KVEP7=S&FL723O( N8E1]ZQKQC:#G\ZUM7\#"]UO\
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M+C#$!8BK$!AU();Z52M?%'B*.PM8I8K*6Y^R"Z>5D<!D$0?;@?QDY&>GMVH
M[^BN(OO%6HMJ;VD"Q(HN(T*(I,T:[X_F;/&UPQ X_$\XHW7C_4HD CBL"TC8
M#$-M@;YOW4F6'S# R<C /2@#T6BL/1]9N]0U6]L9H8E-C\LSIG#,QRFWV*8)
M^HK<H **** "BBB@ HIDSO'!(\<9D=5)5 <;CC@9]ZY[1]>UV_U%;>^\+S:?
M;E23<-<JX!'08 [U+DD[,F4U%I/J=)17"W7C#6(;NY2XL+?3#;@-%!<N9'O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"^S_A1F?\ YYQ_]]G_  J6B@"/,V?N1_\ ?9_PI,S_ //./_OL_P"%2T4
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M -ZBHM\V/]2O_??_ -:C?-G_ %2_]]__ %J ):*BWS?\\5[?Q_\ UJ-\^/\
M4K_WW_\ 6H EHJ+?-_SQ7_OO_P"M1OF_YXK_ -]__6H EHJ+?/C_ %*]/[__
M -:C?-_SQ7O_ !__ %J ):*BWS?\\5_[[_\ K4;Y\?ZE>G]__P"M0!+146^;
M_GBO?^/_ .M1OFS_ *I?^^__ *U $M%1;YO^>*_]]_\ UJ-\W_/%>_\ '_\
M6H EHJ+?-G_5+U_O_P#UJ-\W_/%?^^__ *U $M%1;YO^>*]_X_\ ZU&^;/\
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M>*_]]_\ UJ ):*BWSX_U*_\ ??\ ]:C?-_SQ7O\ Q_\ UJ ):*BWS9_U2_\
M??\ ]:C?-C_4K_WW_P#6H EHJ+?-_P \5[_Q_P#UJ-\V?]4O7^__ /6H EHJ
M+?/C_4K_ -]__6HWS?\ /%>_\?\ ]:@"6BHM\V?]4O7^_P#_ %J-\W_/%?\
MOO\ ^M0!+146^;_GBO\ WW_]:C?-G_5+U_O_ /UJ ):*BWS?\\5[?Q__ %J-
M\^/]2O\ WW_]:@"6BHM\V?\ 5+_WW_\ 6JKJ&J0Z58RWM^\-O;1+N>223 'Z
M?IWIQBY.R5V!?) &3P!7GNL>,]1\0:E+X?\  ZI-<(=MWJCC,%J.^T_Q-_GG
MM0>ZU[XHDI9+-I/A3=AYB=L]\!V7^ZI_SGI7?:/I-KH.FQ:?IEA%;VT7 56Z
M^Y..2?4UZ?LZ6"UJKFJ?R](_XN[_ +OW]B+N6VQG>%/!>G^%89)(V>ZU*X^:
MYOISF25N_/8>W\ZZ2HM\W_/%>W\?_P!:C?/C_4KT_O\ _P!:N"M6J5INI4=V
MRDDE9$M%1;YO^>*_]]__ %J-\W_/%?\ OO\ ^M60R6BHM\^/]2O3^_\ _6HW
MS?\ /%>_\?\ ]:@"6BHM\W_/%?\ OO\ ^M2JTI(W1 #N=^?Z4 24444 %%%(
M2 "3T% #$MX8XVC2) C,6*@<$DY)_.G[%W;MHR!C.*S1KEL;;S_*G$;2!(R8
M_P#69Z%?;K4DFKVT4TD;K*#%&))#LX0$9&??B@"\JA5VJ  .P%9%[_R,=C_N
MG^M:%I>1WB.4#JT;;'1UPRGKR/H16;=LK>)+(*P)52" >G6@#:HHHH ****
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M %@+-SU.#_A6[6/>_P#(QV/^Z?ZT :?V:'&-GMU-'V:'.=GZFI:* (OLT/\
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MV?\ "C,^?N1_]]'_  J6B@"+,_\ <C_[[/\ A1F?'W(_^^S_ (5+10!%F?\
MN1_]]'_"C,_]R/\ [Z/^%2T4 19GQ]R/_OL_X49G_N1_]]'_  J6B@"+,_\
M<C_[Z/\ A2J9LC<J =\,?\*DHH **** "D) &3T%+2')! .#ZT 44U>T:TFN
MBSI!$,EWC(##L5]0?:E.KV89AO?:L8E9_+;:JD9&3CCBJ,>@O)!,EQ<>67?*
MK; HBD9 ;;DC)!R>U%QX>%Q!#"TZJ(HU3S5B_>M@8Y;/(]L4 :MK=Q7:,T1;
MY&VLKJ593Z$'GN*S;P@^([( @X4@^W6K]E:/;><\LHDEFDWN57:.@& ,GL/6
MLRZ@C3Q);$+GS1N;/.3@C^E &[147V:#&/)3T^Z*7[/#_P \D_[YH DHJ+[/
M#_SR3_OD4?9H,8\E/3[HH EHJ/[/#_SR3_OD4?9X?^>2?]\B@"2BHOLT&,>2
MGI]T4OV>'_GDG_?(H DHJ/[/#_SR3_OFD^S08QY*>GW10!+147V>'_GDG_?(
MI?L\/_/)/^^: )**B^S0?\\4_P"^11]GA_YY)_WR* ):*C^SPYSY2>OW:3[/
M!_SQ3_OD4 2T5%]GA_YY)_WR*7[/#G/E)Z_=H DHJ+[/#_SR3_OD4?9X/^>2
M?]\B@"6BH_L\.?\ 5)Z_=I/L\/\ SR3_ +Y% $M%1?9H/^>*?]\BE^SPYSY2
M>OW: )**B^SP_P#/)/\ OD4?9H,8\E/3[HH EHJ/[/#_ ,\D_P"^12?9X?\
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M7O\ Q_\ UJ ):*BW39_U2]?[_P#]:C?/_P \E_[[_P#K4 2T5%OG_P">2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;-;33;.&U@7HD2 9^OJ?<U=HKGKXRM77+)VBMDM$ODOSW&HI!1117*4%%%%
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MZT9%1_9X?^>,?_?(H^SP_P#/&/\ [Y% $F:,U'Y$/_/)/7[HH^SP_P#/&/\
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M *U&Z;_GDG?^/_ZU $M%1;IL_P"J3_OO_P"M1NG_ .>2?]]__6H EHJ+=/\
M\\D_[[_^M1NFS_JD_P"^_P#ZU $M%1;I_P#GDG_??_UJ-T__ #R3_OO_ .M0
M!+146Z;/^J3_ +[_ /K4;I_^>2?]]_\ UJ ):*BW3_\ /)/^^_\ ZU&Z;/\
MJD_[[_\ K4 2T5%NF_YY)V_C_P#K4;I\?ZI/^^__ *U $M%1;IO^>2?]]_\
MUJ-TW_/)/^^__K4 2T5%NGQ_JD_[[_\ K4;IO^>2?]]__6H EHJ+=-_SR3_O
MO_ZU&Z?'^J3_ +[_ /K4 2T5%NF_YY)_WW_]:C=-_P \D_[[_P#K4 2T5%NG
MQ_JD_P"^_P#ZU&Z;_GDG?^/_ .M0!+146Z;/^J3_ +[_ /K4;I_^>2?]]_\
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MJ*/9QO<%2A>]BK9:;8Z;'LL;."V4]1%&%S]<5:HHJDDMBTDE9!1113&%%%%
M!1110 4444 %%%% !1110 4A!*D#N*6B@#"31[PZ?>0&:"(W'RA$0^6@R?F
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MYYK1]FAQCRUIZNKC*,&'L<TZI B^S0_\\U[_ *T?9H<Y\M>N:EHH B^S0_\
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MA';Z.K:E#:WNJPI.I%C NZ0H3T+%N<=,XKV^BAX_$:)3DEVYI?YB6&A:SO\
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M/BI:* (M\V?]3_X^*/,F_P">'I_&*EHH A\R;'^H[?WQ2^9-_P \?_'Q4M%
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M3/L\/_/&/_OD4>1#_P \H_\ OD4 /R/449'J*9Y$/_/)/^^11]GA_P">,?\
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MC(]13/L\/_/&/_OD4>1#_P \D_[Y% #\CU%&1ZBF>1#_ ,\H_P#OD4?9X?\
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M'_GE'_WR* 'Y'J*,CU%,^SP_\\8_^^11Y$/_ #R3_OD4 /R/449'J*9Y$/\
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MVYSWZU=ZC(KGCH^H.)9'>U\^>-XIFRQ!# <@8XQM  _6M^-!%$D8.0JA1^%
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ghp5h1w3ypdd000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ghp5h1w3ypdd000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !: ,X# 2(  A$! Q$!_\0
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M)(KLOIT:2W3) 66-&#%6XZCY&Z>E;4,T5S!'/"ZR12*'1U.0RD9!% #Z***
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M#UK"CT+7;%!!I_B4FV0 1I?V8N&11VWAD+?5LGU)K1_X1[3/^>$G_?\ D_\
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M@K4LM:COF4)9:A%N.,SVCQX^NX5!_96BXSN&-_EY^UO][T^]U]J>NBZ29#$
MQD'5/M+DCIVW>X_/WH 36=$;49K6]L[HV6I6A/DW(3>"I^]&ZY&Y#@<9'(!!
M!%4UUK7K(%=4\.22XZ3:7.LRM[[7V,/H U:'_"/Z;G/DR9_Z[R?_ !5'_"/Z
M;C'DR],#_2)/_BJ *+>+%"@KH6NNQ .T6+ C\20/UIDLVMZ_ 8(;&?1[.0$2
MSSR)]I([JB+N5<_WBV1_=]-'_A']-'_+*7\;B0_^S4?\(_IO_/&3_O\ R?\
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MN656(*QD+(00.=I(SCIWI(?$^CW%R]O%>;I4B><KY3C,:G#,..1R.G7(QUH
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(W-=?110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gn51aow5g2rf000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn51aow5g2rf000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !I 0\# 2(  A$! Q$!_\0
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M+1VP/3YCG=)QQS@<G*GC'51QI%&L<:JB( JJHP !T H =1110 4444 %%%%
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M33Z5:2/J"1 PPW&H7"H3QD,5?KC//K65HK6.JZ1;Z@/#FLB*Y1)$,.HM("&
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/J[110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gei541vqjlbv000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gei541vqjlbv000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %4 ?P# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(SYI"NHY]ZNQR++&KKT89%0XM;FBDGL.HHHI#"BBB@ HILDB1(7D=40=68X
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MEW*,_+\V_C_:J$6_BB'5((3>7WEI;Q-$[(TGFG8QE5R/E#%NA/3C%):6'B>
M03-=ZK)(D=A(4ED!5I&;%P".X"]N@ZB@#7\1^&FU6^NI&NK6*"^M([1EE7+;
MEDWC'J""01]*R_$7AR[M+FZO[&+[5+=-,B6XM?,15>)$Y^8;3F,<],$@U5A;
MQ3=7K.;6^CMS<0R^5*"WE,&D#@,W48V'(P/2GO;>)K32L&ZU61WLK6>0-EV>
MXRWF1 IR@(VY(X'YT 0IX7U&.]T_35A)B\Z"YN;@P8,12#RV"2YY' P,9R3V
MK5TOP&;);$7$EN[VEQ"Y?+OYJ1HZKD,<*<OGBG>)[G7RFFC3;*]BF\I)6:-R
MX#[EW1,!P?EW?,W'!QS6??6>I7VFS"]76FOH=2BFG2)F$?E+/QY.." F#QSQ
MSS0!MWOAV74=1U>2WN[5K74X?L\[E<RP,J%,(0<8YY![Y]:@M?!MPVIP:A?2
M6/F1NA,,$&(RJ1/&#@_Q?/GV  JHEMXF6]2*(W26U[>31RN"H^SQK,760?[\
M>4_$5>\'C7FNKJ36;B?>5Q);R1,%$FX_,C'C;MP,+QT/6@#+NO!-Y8VVDK8"
MVGDM_L4+JT6$_<N[%V&>GS?45/)X!N9()";Z))I/WI2-&6,2?:/.VC!R$[>O
M?VKNZ* .,M?!4MOJ>F:@DMO$UAG$*JSJ^]F,A9F.2><J?X3GUKLZ** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KS'6)K^+Q/J=RK3QPK=F$7"W#\#
M[)N$7E]-I;G=V->G4FT'J!^5 'E=IK6KZ3'#;SO=7%Q;Z*S6CL2?M1D:(1;N
MQ=6)4Y^O>M/PS?7]MJ&F:'>I<^=:7,\3-<R%I#&8M\;$J=K=2.<]/6O0<#C@
M<=.*,#.<#/K0!P6G:QKAU5K#^T8IFEUFYA<RP<P0HA=5 ![@#!/8]ZH6/C'4
MXK?3D#V\.YK2-;22-VDN%E(W.K$\8R0.O(.>U>F!%#%@HW'J<<FL^YT.RO-1
M@O;A9'> AHXS*WEAAT;9G&10!PO_  G6KK%(X>TF=K59GA6$JUDS3+&5<D\[
M 23G'(["KL7B/Q)-'/M?3$,%@9PSL-DK&1T4[PVU>%!(R>>,XKK;+0[&QO)[
MN-9)+B<;7DFE:0[<YVC)X&>U7O)B\OR_+39C&W:,8^E %#P_J']JZ#9WI=W,
MJ9+/'L)()!XR1U'8D>E:5(      . !2T %%%% !1110 5P_CV_U"TN;1+*2
M] %G=3LMK,L9!0)AVS]X+D_+W]#7<4QX8I&#/&C, 5!902 >H^AH \YN-5U(
MP75[-JDDMA9W;&X6VG6&1T\F)@T>>J@ECLR,[OPK=T"Y.KZC=7MUJMPEQ!>2
M0I8+($1$'"!DZL67#9/KQTKH)-)TV;R_-T^U?RVW)NA4[3P,CC@\#\A3VTZQ
M>]6]>SMVNT&%G,0+CZ-C- '$CQ3J%C<:I!&]O(T=Q>3[[V4JOEQ%!Y:8[_-^
M [&B?XB/'+(T5K') T#/$7)0QR*8PRN3V!DY('&#UKM9M-L+D 3V5M*%D\P!
MXE;#_P![D=?>C^S+ S2S&QMO-F!$K^4N7!&""<<\4 >>MXKU+3KK4YIY8;J2
M"XN"J13MY/[NVC8+WXR3QV)-:\OB[4X+QM-FBTZ*\6<H9WD80;!"LHZ\[B&Q
M^!/M751Z9I\,(ABL;9(@" BQ* ,C!XQZ<57U;1+;5K8P.[P!G#NT*KEL# SN
M![=^HH =H&I/K'A[3]2DC6-[J!)613D*2,X!K0;[IXS[5#9VD&GV4%G;)L@@
MC$<:YSA0,"IZ .<N499VW1^7D\"M/2I=T!C/53Q]*NRQ),FV1016>MJ]C<B5
M#NB/#>U:\RDK&*BX2OT-.BCJ,TTNH."P!]":R-AU%%% ',^*8?.O-/ -M,RB
M7%G-(H+L5P)%#<,5YX/J:SO[,\4W$:0O)"8CB3<DHV'(BPH7'12KD?7BM?7=
M"N-4OX9K9HH<Q-#/,6)9XSG,97&"#GKD$5B-X,U5=--O;75M#(5AC!#OB(1Q
M!1L]/G&[ISGK0!"^@>*3<2W"7#QRR*D<T@N=SR[3)\R=-BY93MSVQ]>ZLI4G
MLH9$G6=60?O5QA_?BN2;PCJ*D.EXDF]B]S$\L@6X/FLP!/8!6 X] .E='H.G
MR:3H-E82NKR6\01F3."1Z9YH T:*** "BBB@ HHK(NO$NF6SE!*TSC@B%=V/
MQZ?K0VEN!>O;^UT^'S;J41J3A1U+'T ZFLW_ (2:#[PL;XQ_W_*_^O6%%J4.
MH:]+=W*-M3"PQR?PK_\ 7.:Z07L;1Y5EV^F*Y98CWFD;QI>ZGW+5CJ-KJ,1>
MUE#[3AEQAE/N#R*M5Q%[<O:ZQ#<:<569SL8$9#+WR/UK3@\1W-NX&I6P$9_Y
M;0@_+]5_PK:E/VD;D3IN+.DHID<B31+)$ZNC#*LIR"*?6AF%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %!Z<UF:SJZ:5;*0OF3R'$
M4>>OJ3["N6N'FN@LNK7[J).8X$.-P]E';W-)7;Y8J[)G.,%>3-G5]0FEOTTJ
MRF\E=H::53R,]%![4H\/:4$_>1M*_=V;)_.N3O+JSTDBXCM-1\HHK-+%"'4
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MN]#T^YF;=+-;1R.P&,L5!)Q7,22>$M;NYX6MHW9+V:&Y=W,6'$>9,G(W*50
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!KR*Y@6%++[.LMK,))W:2:#R2,QHV.0><'CJ>*[^BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gemzezolivjc000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemzezolivjc000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !3 2(# 2(  A$! Q$!_\0
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MEQBIO#\=W#XVUZYFT^YBM[QH_*E=?E.T8- %2[U#4_#OC*U.J:A*^C7<1 )
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gei541vqjlbv000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gei541vqjlbv000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '; G # 2(  A$! Q$!_\0
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MJMJME96]S9S7;+,7;[J^9@*#G*C;@@]\_A0!R]%27"JMS,J_=61@OTR<5'0
M4444 %%%% $D,$UPQ6&*25@,D(I) ]>*4VUP&D4P2AHEW2 H<H/4^@]ZNZ4C
MRV^IQ1@M(]KA5'4_O$/%:EMA;);:])DN8[:4M%YV&V%X]D9(/7[Y /3- ',T
M5T\MC8H]PT4*R7#&-H[=803%&<YW(6P6! !()X(.!FJ\UK;!9#IUG#/*)]LL
M<KA_*7:O3#8VEMWS9., 9H P**ZJXT_2C<W49CCMK6*\ :8'>K1%E&U&SP1D
M]CD9/:L_58+:*T=A:^1+YP$14*H*\YX#,6'3YO\ &@#%HHHH **** "BBB@
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M*DU__GYT_P#[^/\ _$T?\*DU_P#Y^=/_ ._C_P#Q- '!45WO_"I-?_Y^=/\
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M_P#W\?\ ^)H X*BN]_X5)K__ #\Z?_W\?_XFC_A4FO\ _/SI_P#W\?\ ^)H
MX*BN]_X5)K__ #\Z?_W\?_XFC_A4FO\ _/SI_P#W\?\ ^)H X*C ]*[W_A4F
MO_\ /SI__?Q__B:/^%2:_P#\_.G_ /?Q_P#XF@#@NG2BN]_X5)K_ /S\Z?\
M]_'_ /B:0?"?7B[+]IL,K_TT;_XF@#@L ]0*6N]_X5)K_P#S\Z?_ -_'_P#B
M:/\ A4FO_P#/SI__ '\?_P")H X*BN]_X5)K_P#S\Z?_ -_'_P#B:/\ A4FO
M_P#/SI__ '\?_P")H X*BN]_X5)K_P#S\Z?_ -_'_P#B:/\ A4FO_P#/SI__
M '\?_P")H X*BN]_X5)K_P#S\Z?_ -_'_P#B:/\ A4FO_P#/SI__ '\?_P")
MH X' ]!1@>@KOO\ A4FO_P#/SI__ '\?_P")I/\ A4^O;POVFPR1G_6-_P#$
MT <$ !T&*6N]_P"%2:__ ,_.G_\ ?Q__ (FC_A4FO_\ /SI__?Q__B: ."HK
MO?\ A4FO_P#/SI__ '\?_P")H_X5)K__ #\Z?_W\?_XF@#@J*[W_ (5)K_\
MS\Z?_P!_'_\ B:/^%2:__P _.G_]_'_^)H X*BN]_P"%2:__ ,_.G_\ ?Q__
M (FC_A4FO_\ /SI__?Q__B: .!P/048'H*[[_A4FO_\ /SI__?Q__B:1OA/K
MRXS<V')Q_K&_^)H X+ '048&<X&:[[_A4FO_ //SI_\ W\?_ .)H_P"%2:__
M ,_.G_\ ?Q__ (F@#@J*[W_A4FO_ //SI_\ W\?_ .)H_P"%2:__ ,_.G_\
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M,W\ ?J$_WBH+?04VUO[^;6+BSELX(X80&\U;@LQ#9V_+M']WGG\Z -.BBB@
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MJ<7VVUN[:VA);R(7A+[U!P"[9&,XZ#I[T ;M%9^G:M!>P0!Y(HKJ13FW,@+
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M(0 QA6#1CH"&!''8^YJ&Z\.I</'*MY,LZQB-Y7CCD,B@DC.Y2 >3R,=:VJ*
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MI_SP3\JC2PM3-*/(3^'M[4?4H]P_U?H_SO\  \+_ +*OO^?67_O@T?V5??\
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M5]_SZR_]\&O>/[/M/^>"?E1_9]I_SP3\J/J4>X?ZOT?YW^!X/_95]_SZR_\
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M )]_C_P#Z!HKY^_M74/^?ZX_[^&C^U=0_P"?ZX_[^&CZZNP?ZP1_Y]_C_P
M^@:B3_7R_A7@?]JZA_S_ %Q_W\-)_:FH9S]MN.?^FAH^NKL'^L$?^??X_P#
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M'I4U% %?[#:X ^SQ\2^<..C_ -[ZU!<Z+IEY="YN+"WEF'\;("3]?7\:OT4
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MBTN](LK2XM-6C1;V21S<1RQ%FN"2<%>/G!&,8SCIQB@#J'=8T9W8*BC+,QP
M/6D::)&4-(BE\E06'S8Y.*YLIJ<7A66"2WC$ L9<F24F9/E;:NW&"0-H^]ZU
M#>6=S'=V/]HWLE[;/!.&C2W"L%,?.-O)..U '0G5]-%K]J.H6@M]VSS?.79N
M],YQFI[>ZM[R$2VT\4\9. \;AA^8KCTO[5(K6266W>TM]00?;1&$64>2X&[C
M&X<*3TZ=.@U]-EM+O7Y;K3%!M3;[9Y8UPDDFX;<=F(&[)'J!0!O4444 -:1$
M*AW52YVJ"<9/7 _(TU9XFF>%94,J %T##<H/0D=LX-9FNW,%H=.N+F58H4NP
M6=S@#]V_6JDMS-=WEY<:9*LFVW@GAV8VRX:3<N>^0,>W% '145R%_J&IRZ8F
MH1R/;6UW< ?O&,9A@"G!)"L5+'J<<9 XZTVQEU"_:P@;4I/L[S2_O;>0L714
M! +LBY^;/('([T =+<:MIUI.(+F_M89B,B.295;'T)JQ]HA\]8/.C\YDWB/<
M-Q7IG'I[USTM_I=GX@U2/4IH$$L<.U)1G>,-G [U1C,]M:!8Y#81&UN6@:5,
M&*/S4V \$K\I/T!Z<4 =G17#76JWC6]CMNWM[(Q,1-/<E#+('(_U@C;<, $<
M#<#GFKDE],5M!J^IS6436RNDL"E!-)DYR2N<@;?EP,Y/'' !UM%<78:G<EM'
M>XU"XE:7<ODX\N1R9& =DV\K@#(R-N,TFC:AJL^K0+/>1F=W/VFV,K,4 SQY
M?EC9CC!W<^IS0!VM%%% !1110 4444 %%%% !37=(T+NRJHY+,< 4ZO*/B-K
M%Q-K)TU79;:!5)0=&8C.3^>*RJU%3CS''CL6L+2]HU?H>D'7-)!P=4L@?^OA
M?\:3^W=(_P"@K9?^!"?XUX'D^IHR?4UR?79=CPO]8*G\B^\]\_MW2/\ H*V7
M_@0G^-1PZYI(CP=4LA\Q_P"7A?4^]>#Y/J:,GU-'UV78/]8*G\B^\]\_MW2/
M^@K9?^!"?XT?V[I'_05LO_ A/\:\#R?4T9/J:/KLNP?ZP5/Y%]Y[Y_;ND?\
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M6TYSM)^ZPYR*NGB^:2BUN=.$SMUJJISC:^AZW1117:?0!1110 4444 %%%%
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ME0:8K6Z+'EE.^1) XW!.,<8SUQ0!M6^LB>XCBDT^_MA+Q')-$ K'K@X)*_\
M @*TZS+:\U2>XC272A;1C_6R/.K#IT0+R>?7%:= %:^OX=/M_.FWG+!$1%+,
M['HJ@=34%KJJW$QAFM+JSDQN47" !AG'#*2,Y(XSGFDU6VN9/LUS9JDEQ:R^
M8L4C;1("I4C/8X/!]:@D-UJ=K<PWUB+&T,1R\DRLX;J& 7( &,YSG..* -22
M>&($R2HF,9W,!UZ52;6;;[9-:1K)+-#)''(L>T[=_0]>@[U@&PO=0T2._ELA
M<:A<N)PH*;$&PJ@(?@K@Y(ZC<<<U<?1KEKVXN/LT >2XM)"R8&0A4O[XX[T
M=!]HA\_R/.C\[&?+W#=CUQ5.^U3['=16T=E=74LB-)B )\J@@<[F'J*R[#3I
MK>XCBGT6"65)C(VHF1<MR3N_O[NV.GOBKFH:+#J>L02W< EMX[=U!WD88LOH
M?0&@"P-7@$PBFCE@)=UW2@ ?( 2V<].:M&ZMQ$LIGB$;#*N7&#]#7-76CW8O
MEN#IL=Y"E[+,86D494QJH(SP3D'@TZTT%Y-3M[FXTV&&V$TDJVI*L(2450<#
MC)()XX'UH Z43PF9H1*AE49*!AN ^E1/?1*\2QAIO,E\HM$01&<$_-SQTKG;
M;1[J.6UA.F1)-!<>:^I"1<RC))_VLL#@@\#)ZX%%CI%Y$L,8L%@MX;M9$5F3
MS-HC<'++U&2 "?FZYH ZB.6.92T4B. <$JP.#Z4^L7PY9W%C;30R6BVT(8"%
M3L,A 4#YBG!]CUQUK:H **** "BBB@ HHHH *H:AK.G:5M^W7<<)89"GEB/H
M.:O$X&:\%U>]GO\ 5;BXN&)D=SP>WH/PKNP.$6)D^9V2/,S/,'@X)Q5VSUO_
M (3;P[_T$1_WZ?\ PH_X3;P[_P!!$?\ ?I_\*\7HKU?[(H=W^'^1X?\ K!B?
MY8_C_F>T?\)MX=_Z"(_[]/\ X4R+QKX>6/!U 9R?^63^I]J\:HH_LBAW?X?Y
M!_K!B?Y8_C_F>T?\)MX=_P"@B/\ OT_^%'_";>'?^@B/^_3_ .%>+T4?V10[
MO\/\@_U@Q/\ +'\?\SVC_A-O#O\ T$1_WZ?_  H_X3;P[_T$1_WZ?_"O%Z*/
M[(H=W^'^0?ZP8G^6/X_YGM'_  FWAW_H(C_OT_\ A1_PFWAW_H(C_OT_^%>+
MT4?V10[O\/\ (/\ 6#$_RQ_'_,]H_P"$V\._]!$?]^G_ ,*/^$V\._\ 01'_
M 'Z?_"O%Z*/[(H=W^'^0?ZP8G^6/X_YGM'_";>'?^@B/^_3_ .%,7QIX>$TC
M'4!@XQ^Z?_"O&J*/[(H=W^'^0?ZP8G^6/X_YGM'_  FWAW_H(C_OT_\ A1_P
MFWAW_H(C_OT_^%>+T4?V10[O\/\ (/\ 6#$_RQ_'_,]H_P"$V\._]!$?]^G_
M ,*/^$V\._\ 01'_ 'Z?_"O%Z*/[(H=W^'^0?ZP8G^6/X_YGM'_";>'?^@B/
M^_3_ .%'_";>'?\ H(C_ +]/_A7B]%']D4.[_#_(/]8,3_+'\?\ ,]H_X3;P
M[_T$1_WZ?_"C_A-O#O\ T$1_WZ?_  KQ>BC^R*'=_A_D'^L&)_EC^/\ F>T?
M\)MX=_Z"(_[]/_A3#XU\/>>K?V@,!2/]4_J/:O&J*/[(H=W^'^0?ZP8G^6/X
M_P"9[1_PFWAW_H(C_OT_^%'_  FWAW_H(C_OT_\ A7B]%']D4.[_  _R#_6#
M$_RQ_'_,]H_X3;P[_P!!$?\ ?I_\*/\ A-O#O_01'_?I_P#"O%Z*/[(H=W^'
M^0?ZP8G^6/X_YGO6GZSIVJAOL-W',5&2HX(_ \U>KP;1;V>PUBUN+=B'60<#
M^(9Y'XU[S7E8["+#22B[IGN99CWC(-R5F@HHHKA/3"HIND?^^*EJ*;I'_OB@
M"6BBB@ HHHH **** "BBB@ IDO\ J9/]TT^F2_ZF3_=- #D^XOTI:1/N+]*6
M@ HHHH **** "BBB@ HHHH **** "BBB@ I" 1@C(/44M% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 (1D$>M>;^(? \TE_)<6> LC%BN.,UZ
M316U&O4HRYJ;L<^(PM+$PY*JNCQW_A"=2]!^O^%'_"$ZEZ#]?\*]BP/2C ]*
MZO[4Q/?\$</]B8/^5_>SQW_A"=2]!^O^%-7P7J3(&V@9SZ^N/2O9*B@_U7_
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M Y/N+]*6D3[B_2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *YKQ'X4@UMA*/EF QN'6NEH
MJH3E"7-%V9%2G"I%PFKH\T_X5Q+_ ,]W_2C_ (5Q+_SV?]*]&^TP#K/'_P!]
MBC[5;_\ />+_ +[%=7UW%?S,XO[-P7\B/.?^%;R_\]W_ $IJ?#J5T#><W4^G
MJ17I'VJW_P">\7_?8J.&Y@$?^OB^\W\8]31]=Q7\S#^SL%_(CSW_ (5Q+_SV
M?]*/^%<2_P#/9_TKT;[5;_\ />+_ +[%'VJW_P">\7_?8H^NXK^9A_9V"_D1
MYS_PKB7_ )[/^E'_  KB7_GL_P"E>C?:K?\ Y[Q?]]B@7,!.!/&?^!BCZ[BO
MYF']FX+^1'G/_"N)?^>S_I1_PKB7_GL_Z5Z712^O8C^=C_LS!_\ /M'FG_"N
M)?\ GL_Z4?\ "N)?^>S_ *5Z711]>Q'\[#^S,'_S[1YI_P *XES_ *]_TKJ?
M#?AN#1&FV_-(0N6/7I715$G^OE_"LZF*K5%RSDVC6C@L/1ES4X),EHHHK Z@
MHHHH **** "BBB@ J,_\?*_[A_F*DJ,_\?*_[A_F* )**** "BBB@ HHHH *
M*** "HIND?\ OBI:BFZ1_P"^* ):*** "BBB@ HHHH **** "F2_ZF3_ '33
MZ9+_ *F3_=- #D^XOTI:1/N+]*6@ HHHH *Y?_A)!_PE7V?[0OV/?]D\ORSG
MS.N_=C&,_)C/6NG/(QTJG_95I_97]F^6?LVS9C<<_7/7.><^O- '.PWUW-XD
MGMX9]1:=+K_5E5^S>0" W)&<@9Z'.<5H6D%[J]O_ &A_:UQ;,[-Y,4*KLC )
M # @[CQSD^W%:/\ 9-H)$D"L)$G,ZN&.0Q&#SZ$=1TJ";P_933R2!KF)96+2
MQ0SNB2$]25![]\=: *:^)HTT<RRE&OUMWD\M%;8Y7=R#T"G:3UZ5:M],OD:*
MX;6KB24D&12B>2P[@+C(]CG/UK32"*.!8$C18578(PORA>F,>E9T/AVQ@EC*
MFY,43!H[=KAS$A'3"DXX[#H* *MM!>ZQ$]\=5N+;,CK## %VQA6*_,"#N/&3
MGZ46NJ3JMI>W<R"VD62"8KQ&LB$X<>@;:W_CM6Y] LI[B28-<P^:=TR07#QI
M(?5@#U]QUJS<:7976F'39;=#9E0GE 87 Z#CZ4 0:)-<W=A]NN2P^U,98HB,
M>7&?N#ZXP3[DUI4  # & ** ,W5I[A3:6MM,()+J;RS-M!V *6. >-QVX&?6
MJUQ'=:'8W5VNH37<:1$B.ZP</GAMP (7U'\JT[RRM]0MC!<Q[XR01R05(Y!!
M'((]15:UT6UMFD=FGN9'0QL]S*TIV'JO/&/YT 4+NWO])LGU'^UY[B2(!I8Y
ME012#N% &5/I@]<9S2WFJ7.F+?6Y/FW3R+]A#?Q^8<!?HK9S_LXJU#X=L898
MVS<21Q$-%!+.[QQD="%)QQVST[5<GL+:YO+:[EB#3VI8PN?X=PP?TH YV\EO
M5NSI_P#:%P )+2(RI@.=P?<>G4X%7A<OH=^L-W?RW-G+"T@:90TD14J#RHY!
MW#MD8JY>:+:7SR/(9DDD9&+Q2%6!3.T@CIU-/L=)MK"1YD::6=P%::>4R.5'
M09/0>PH KRW)FU+29[>XD^SS[P4Z*XV$@D$9SD5EPWM__P )%';/->?:FG<R
M6S1#R!;#.&5L=?N\YSDD8KI);:.:>"9P2\!)0YZ$C!_0TD=I#%=37*J?.F #
M,3G@= /0=3CU)H GHHHH **** "BBB@ HHHH **** "O,?B#KUT=3.EPRM';
MQ*#(%.-[$9Y]L$5Z=7G?CGPW<7-]_:%LNXLH#K].]=V7SIPKIU/Z9YN;4ZU3
M#.-'?KZ'GF3ZFC<?4U>_L74?^?63\J/[%U'_ )]9/RKZ3ZS1_G7WH^-^IXC_
M )]O[F4=Q]31D^IJ]_8NH_\ /K)^5(-'U!AD6LA'TH^LT?YU]Z#ZGB/^?;^Y
ME+<?4T;CZFKW]BZC_P ^LGY4?V+J/_/K)^5'UFC_ #K[T'U/$?\ /M_<RCN/
MJ:-Q]35[^Q=1_P"?63\J/[%U'_GUD_*CZS1_G7WH/J>(_P"?;^YG8?#S7;IK
M\Z5/(TD+(6CW'.PCG ]L9KTFO/O GAR>SO#J%RNU@I5%],]:]!KYK,)TYUVZ
M>WZGV654ZU/#*-;?] HHHKB/2"HD_P!?+^%2U$G^OE_"@"6BBB@ HHHH ***
M* "BBB@ J,_\?*_[A_F*DJ,_\?*_[A_F* )**** "BBB@ HHHH **** "HIN
MD?\ OBI:BFZ1_P"^* ):*** "BBB@ HHHH **** "F2_ZF3_ '33Z9+_ *F3
M_=- #D^XOTI:1/N+]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&4,,, 1[TM% $/V6#_
M )XI^5'V2W_YXI^5(;RU!P;F$$=C(*/MUI_S]0?]_!3LQ70OV6#_ )XI^51P
MVL!B_P!4GWF[>YI_VZT_Y^H/^_@J.&]M!'@W4'WF_P"6@]319A=$OV2W_P">
M*?E1]DM_^>*?E2?;K3_GZ@_[^"C[=:?\_4'_ '\%'*PNA?LEO_SQ3\J/LL'_
M #Q3\J3[=:?\_4'_ '\%'VZT_P"?J#_OX*.5A=$P4*,  #VI:@^W6G_/U!_W
M\%'VZT_Y^H/^_@HY6%T3T5!]NM/^?J#_ +^"C[=:?\_4'_?P4<K"Z)ZB3_7R
M_A3?MUI_S]0?]_!4:7MKY\A^U0<X_P"6@HLPNBW14'VZT_Y^H/\ OX*/MUI_
MS]0?]_!1RL+HGHJ#[=:?\_4'_?P4?;K3_GZ@_P"_@HY6%T3T5!]NM/\ GZ@_
M[^"C[=:?\_4'_?P4<K"Z)Z*@^W6G_/U!_P!_!1]NM/\ GZ@_[^"CE871/49_
MX^5_W#_,4S[=:?\ /U!_W\%1F]M?M"G[5!]P_P#+0>HHY6%T6Z*@^W6G_/U!
M_P!_!1]NM/\ GZ@_[^"CE871/14'VZT_Y^H/^_@H^W6G_/U!_P!_!1RL+HGH
MJ..>&;/E2H^.NU@:DI#"BBB@ J*;I'_OBI:BFZ1_[XH EHHHH **** "BBB@
M HHHH *9+_J9/]TT^F2_ZF3_ '30 Y/N+]*6D3[B_2EH **** "N/_M*[_MO
M^V?(N?[-W_9_-WIY/D=/,QG=G?SG'W:[ @$8/0U'Y$7D>1Y2>3MV>7M&W;TQ
MCIB@#C(8#+XGD'V2VA9[YG2_,A\Q]A!:( #J1V)P1GCBKMI:Z/?6EQ=ZL\;7
MR2.+AYI=KVY!. IS\@ QC&,]><UTOV:# 'D1X#^8!L'WO7Z^]1S:=8W%PMQ/
M9V\LR?=D>)68?0D9H P6O;Q_"LJ36MRX:QE;[6Y4#&UMI89W9( )XZFJNI-J
M@DM?MQLQ']FN-GV<OG/E'KFNP=%D1D=0R,,,K#((]*8\$,FWS(D?:"!N4' (
MP?TH Y/2]/DNM8:Z6WL9!$(,RS*3*G[I#\IZ5;TFSM%UGS-.)\N!&CN+@R9-
MU(<9S_>VD'+>IP.]=$D,4>[9&B[L9VJ!G P/TXJM;Z3IMI-YUMI]I#+C&^.%
M5;\P* +E%%% &!XL1I+&T5+..];[4"+:1MJRX1SC.#65%?7ECIUC!IXC OI)
M95\G:P@48_=J)&49SG(.,8;CT[)D1RI=%8J=RY&<'U%0RV%G/"T,UI!)$[;V
M1XP5+>I![^] &!!J.L:@;&".6WM7E6<RR[%D)",H!4*Q4$[N1DXYI8M6O;\V
M\*WMK8O]G\YY'CW>80[*=H)  &W)Y)^85T4=O!$(Q'#&@C7:FU0-H]!Z#@?E
M44VGV5Q$D4UG;R1H<JCQ*0I]0".* ,/0;^;4;VUNIY(I)'M)<M#G8V)L CVP
M*5;;3M1U;4%U?RY9X9,10SM\L<6T890>.3G+>O':M^.W@AQY4,:8! VJ!@$Y
M(_/FF75A9WI4W=I!<;/N^;&&V_3- '-W6JSP/:6.C.TEMY!F6XW)(7 8C ,C
MKD#N<D\BHY[N:\47$RK'));6Q94<,O\ Q\=002,'ZFNHN+&TNXUCN;6":-.5
M62,,%^@-/-M W6&,\!>4'0'('X&@#'U-+6ZUV"TU-A]D: M#$[8263/S9[,0
M,8!]2>W$,D]IIL8M='N8(5FNA"[NQ>*V8J3@#. 3@ #(&3^!WKBVM[N(Q7,$
M<T9Y*2(&'Y&FBQM%M/L@M8!;$8\D1C9C_=Z4 <R-4U9[V33HM1LY9%NHX/M"
MPYPIB=VRN<;LJ.^*NP7]Y<3R3'4[.".&X,#6TD?S'#8^8[@0S=0 ,<CK6Q#8
M6=L%$%I!$%.5"1A<'!&>/8G\Z&L+-[I;I[2!KA>DQC!<?CUH YZUDOWN(['3
MI;>SC:2[>1O*WGY)@HP">IR<YIT>K7U^(52^M+!EM5G=I(]WF$E@< D84;>>
M_(Z=^C6"%&W)$BMSR% /)R?S/)J*;3K&XCCCGLK>5(SE%>)6"_0$<4 <Z-6U
M>]BDN+>:WMHX;".Z9&B+EV._(SD84A!SUYJ235]3L8#/<2VTHFM/M"#RRJP'
M<@.3G+* ^2>#\I]>.D,,1+DQ(2Z[7^4?,.>#ZCD_G1Y,7'[I/E78/E'"^GTX
M'% &)8WMXNOI83ZE:WD;VKS_ +N/8ZD,H&<$C;@G%;U5K;3[*S8M:V=O 3G)
MBB5>O7H/859H *\G^*OB6\AOH]%M97BA\H23%#@N3G ^@ _6O6*\V^)'A&XU
M:XCU*S7=,J;'4_Q =/QKKP,Z<:R=38QKJ3@U$\?R?4T9/J:UO^$8UK/_ !X2
M_I_C1_PC&L_\^$OZ?XU]']8I?SK[T>=[.?9F3D^IHR?4UK?\(QK/_/A+^G^-
M(/#.LD9%A(1]1_C1]8I?SK[T'LY]F963ZFC)]36M_P (QK/_ #X2_I_C1_PC
M&L_\^$OZ?XT?6*7\Z^]![.?9F3D^IHR?4UK?\(QK/_/A+^G^-'_",:S_ ,^$
MOZ?XT?6*7\Z^]![.?9F3D^IHR?4UK?\ ",:S_P ^$OZ?XT?\(QK/_/A+^G^-
M'UBE_.OO0>SGV9DY/J:,GU-:W_",:S_SX2_I_C1_PC&L_P#/A+^G^-'UBE_.
MOO0>SGV9DY/J:,GU-:W_  C&L_\ /A+^G^-)_P (SK.2/L$O&,\C_&CZQ2_G
M7WH/9S[,RLGU-&3ZFM;_ (1C6?\ GPE_3_&C_A&-9_Y\)?T_QH^L4OYU]Z#V
M<^S,G)]31D^IK6_X1C6?^?"7]/\ &C_A&-9_Y\)?T_QH^L4OYU]Z#V<^S,G)
M]31D^IK6_P"$8UG_ )\)?T_QH_X1C6?^?"7]/\:/K%+^=?>@]G/LS)R?4T9/
MJ:UO^$8UG_GPE_3_ !H_X1C6?^?"7]/\:/K%+^=?>@]G/LS)R?4T9/J:UO\
MA&-9_P"?"7]/\:3_ (1G6=V/L$F<9ZC_ !H^L4OYU]Z#V<^S,K)]31D^IK6_
MX1C6?^?"7]/\:/\ A&-9_P"?"7]/\:/K%+^=?>@]G/LS)R?4T9/J:UO^$8UG
M_GPE_3_&C_A&-9_Y\)?T_P :/K%+^=?>@]G/LS/M+VZL+E+BUGDAF0Y5T;!%
M?17A36'UWPU9ZA* )9%*R8& 64D$_CC->&V?@[6;NY6+[(T8)Y9R,"O=_#NE
MKHNAVM@G(B7!)[GJ3^=>5FE6E.*46F_T.O"QFF[[&I1117C'8%13=(_]\5+4
M4W2/_?% $M%%% !1110 4444 %%%% !3)?\ 4R?[II],E_U,G^Z: ')]Q?I2
MTB?<7Z4M !1110 4456N-1L[1F6XN$BV!&8N< !FVKSTY/% %FBHGN(H[B*!
MW EE#%%QUQC/\Q2Q7$4YE$;[C$^Q^.C8!Q^HH DHK.BUW3)I)42[3,2LS,P*
MJ0OWB&(PP'?!.*2+7M,FMYIUN<)#C>&1E8;ON_*1DY[8'/:@#2HK-.O::+5;
MC[0=C.8PHB<ON')&S&[('/3I5VVN8;NVCN+>19(9!N1U/!% $M%%% !14<D\
M4+Q)(^UI7V(,=3@G'Y TB7,,D\L".#)#CS%Q]W(R* ):*** "BHYYX[>,22M
MM4LJ9QGEB !^9%0+J5H[!1*<F5X0"C#+J"6'3T!YH MT5%;7$5W;1W$+%HI%
MW*2I7(^AYJK/K-A:WRV<TY28[?\ EFVT;CA<MC:,D=S0!?HHHH **** "BBB
M@ HHHH **** "D(##!&12UGZOK5CH=K]HO9=H)PJJ,LQ]A2;25V3.<81<I.R
M1;^RP?\ /)/RI/LL'_/)/RKC?^%G:;R5L;L@=\+_ (T'XFZ<%#&PNPIZ$A<'
M]:R^L4NYQ?VGA/Y_S.S^RP?\\D_*HH+: Q?ZI/O-V]S7(?\ "T-,_P"?*Z_\
M=_QID?Q-TQ$Q]BNNI/\ #Z_6CZQ2[A_:F$_G7XG;?98/^>2?E1]E@_YY)^5<
M9_PM#3/^?*Z_\=_QH_X6AIG_ #Y77_CO^-'UBEW#^U,)_.OQ.S^RP?\ /)/R
MH^RP?\\D_*N,'Q.TUC@6-V3[;?\ &C_A9VFD$BQN\#J?EX_6CZQ2[A_:>$_G
M_,[/[+!_SR3\J/LL'_/)/RKC/^%H:9_SY77_ ([_ (T#XG::QP+&[)]!M_QH
M^L4NX?VIA/YU^)V?V6#_ )Y)^5'V6#_GDGY5QG_"T-,_Y\KK_P =_P :/^%H
M:9_SY77_ ([_ (T?6*7</[4PG\Z_$[/[+!_SR3\J8EM"9Y1Y2?P]O:N/_P"%
MH:9_SY77_CO^-,7XFZ8)';[%=?-C^[_C1]8I=P_M3"?SK\3MOLL'_/)/RH^R
MP?\ /)/RKC/^%H:9_P ^5U_X[_C1_P +0TS_ )\KK_QW_&CZQ2[A_:F$_G7X
MG9_98/\ GDGY4?98/^>2?E7&?\+0TS_GRNO_ !W_ !H_X6AIG_/E=?\ CO\
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M]*EX:H^AS5,IQ4TDH)6\UY' 45W_ /PK:7_GLWZ4?\*VE_Y[-^E3]5J]C/\
ML7%]E]YP%%=__P *VE_Y[-^E'_"MI?\ GLWZ4?5:O8/[%Q?9?><!17?_ /"M
MI?\ GLWZ4?\ "MI?^>S?I1]5J]@_L7%]E]YP%%=__P *VE_Y[-^E-_X5Q+Y@
M7S6Y4GMZBCZK5[!_8N+[+[S@J*[_ /X5M+_SV;]*/^%;2_\ /9OTH^JU>P?V
M+B^R^\X"BN__ .%;2_\ /9OTH_X5M+_SV;]*/JM7L']BXOLOO. HKO\ _A6T
MO_/9OTH_X5M+_P ]F_2CZK5[!_8N+[+[S@**[_\ X5M+_P ]F_2C_A6TO_/9
MOTH^JU>P?V+B^R^\X"BN_P#^%;2_\]F_2D;X<2KM_?-RX4].]'U6KV#^Q<7V
M7WG T5W_ /PK:7_GLWZ4?\*VE_Y[-^E'U6KV#^Q<7V7WG 45W_\ PK:7_GLW
MZ4?\*VE_Y[-^E'U6KV#^Q<7V7WG 5[AX.>5_"E@9B2P3 S_=R=OZ8KE[+X<*
MEPK7$C,@/*GO7H%O EM D,8PJC KJPU"5-MR/7RG+JN&G*=7JK6):***ZSW
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MLCR;B<YW8_P_6O:O^$7TW_GBOY"C_A%]-S_J5_(4/"2?VOP)EDE22LZOX?\
M!.$^'6F7!UG[<R%8HT(!(^\3Q7JM06UG!9Q[(4"BIZZJ5-4X\J/8P>%CA:2I
MQ=PHHHK0Z@J)/]?+^%2U$G^OE_"@"6BBB@ HHHH **** "BBB@ J,_\ 'RO^
MX?YBI*C/_'RO^X?YB@"2BBB@ HHHH **** "BBB@ J*;I'_OBI:BFZ1_[XH
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M?+^%2U$G^OE_"@"6BBB@ HHHH **** "BBB@ J,_\?*_[A_F*DJ,_P#'RO\
MN'^8H DHHHH **** "BBB@ HHHH *BFZ1_[XJ6HIND?^^* ):*** "BBB@ H
MHHH **** "F2_P"ID_W33Z9+_J9/]TT .3[B_2EI$^XOTI: "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ,<8HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *YSQ+X6@UU5?[LRC 8=:Z.BDXJ2LR*E.-2+A-73/,/^%;R_\
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M% !1110 4444 %%%% !2.NY&7ID8I:* $ PH'H*6BB@ HHHH **** "BBB@
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M[>ZGN[RWEE-NQ>.".-LY+8Y8D]N@%==_PJ5?^?B;\U_PH_X5*O\ S\3?FO\
MA2^NX?:[MZ#]A4['G.M3QW6OZE<1.)(Y;J5T<=&!8D&NF^&FD37OB>&]VD06
MA+ENQ;& /US^%=-;?":!909II67N"P_H*[_2-&M=&M%@MHU11Z"LL1F,'2]G
M2ZZ%4\/+FYI&C1117C':%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gd14pbv45bwf000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gd14pbv45bwf000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !M 4<# 2(  A$! Q$!_\0
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MS5OQ'H1\0Z-)IK7DUM'+Q(T04EAZ<BMFB@#/@T^:#15L!>2&1(O+6X*KN'&
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MX4F'A6?4-'U4/$#=//;S&,E9$8YZCC-=Z5!IAA#'GI0!YUX\T:]\665E>Z9
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MPKHVK,7NK-3)C'F(Q1A^((I.5-O9K\1^\;*R!NA&#4E<YI?APZ3=*]OJE\T
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LC<W05/+ WRR$$$D\_=KU.C H I:4JC3;<BW,#&-=R,NT@X[CUHJ[BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gt1e50hnuuzf000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gt1e50hnuuzf000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !\ 4L# 2(  A$! Q$!_\0
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M!SR2L;9P#Z8R*D7Q$MMXMCU^"%#I]_;"U9E'WIE3<.?J2OX4 >E'5M/7[U[
M/FV<R#[WI]:>^HV<4RQ27,22.,JC, 6^@K@M=TUK#P_H*R1I+=2:I%+)P!N=
MMQ-7]3#R>/O#AN+2.,A+C;A@V>%]J .K&KZ<P8B^MR$)#8D'RD=<U9:>)(#.
MTBB(+N+D\ >N:\V\.I<B+Q0+;38;G.K3@[B.A(!&,>E;WB26.;3;/0H"1#?
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MTOV?6O\ G^M?^_!_QK4HH S/(UG_ )_;;_OR?\:#!K&!B]ML]_W)_P :TZ*
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MO)>26YGOV9+>:.6.,1 (-@88QZ$,:Z2B@#D_^$(B_LT6)OIO)ANA=66 ,VK
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D]:UJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gemzezolivjc000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemzezolivjc000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ 7L# 2(  A$! Q$!_\0
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M0]>L?$6GF]TZ0R0B1XB64J0RL5(P?I6G6+X8O=$OM+:70/*^Q":13Y4)C7S
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M+J"TA&>B0RKO.?=]WY5W7B;7+;PYH%WJ%Q,D>R-A$&/WY,':H]R:Y2+2Y/\
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M_B>Z-[?\2B3_ .2*Z*BBP'/?8O%^/^0[HW_@HD_^2*;]@\8?]##I'7_H#O\
M_)%='10!S?\ 9WC'!_XJ/2?_  3O_P#)%)_9WC'G_BI-*Y_Z@[\?^1ZZ6B@#
@$TJQ\16]]))JFMVM[;%<+#%8>25/KN\QLUMT44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>gd14pbv45bwf000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gd14pbv45bwf000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "! 6<# 2(  A$! Q$!_\0
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MKFVU%WEG24]9'Y9LCH<\^QJA=^)=>T;2(M8U&RM)]/,:23_96820J1R<,3N
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M;F4&V6+[49@!D,[').T *2>G3'I73N88^&2-5)_BP,_YXI8EA?E(X\>H48H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN[2ZNUN]55/,,;@%61=JE<]"!0!NZK+-%I%Y+;J6F2%FC7U8#@5ROPPBAD\
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IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>gn51aow5g2rf000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gn51aow5g2rf000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !H /$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V5?$<;>,'
M\."SG\]+479GROE^63M]<YW<8(]ZR[SQ]9Z=8:A?7EA<Q6NGWZV-U+N0A"=O
MS?>R1^\7/&>OI5;5S<Z%\14\02:=?7FG3Z4;-GL8&G>*02AAE%RV"">0.W-4
MS:WD&FWT\^FWC#4M>COHX$A9W6%3"#O ^Z<(3@_SH ZN\U[R-1TVUMK7[6FH
M*SPSQRKLPHW'GZ8QCK6)%\0[:2WTNZ;2[N*UU&^-C'+(\8"2!BIWX;@95@.N
M3CUJE;>&[[PYXULA9(\OALF>YCC4%C92F/!C4=HVZ@=CD=Q5?0- EUCX87NB
M7ME=V=V)YY8?/A*,LAE:6)USUP2OZB@#J;_Q*UE>:M"FG23KIEHEU(ZRJNX-
MN.T9Q@@(QY]O6D@\17<MS:PMH5VGVJ%Y(G\Q&7(7< VTG:#TR>,D#O67;6>I
MQ>!]4N[^TD;6M7B9Y;> ;C&[1B-$S_L@+D],[C5'2&&F:AI\MEX>UA98[0PW
MIG1RL:!03L)+;VW*H"KP<DD\"@#4TWQW#>W6AQ7&G36D>MI(UG(TBL"R+N*L
M!T)&<=?2B;QR$:>:+2Y9=/@U)-->Y65>)#((V8J,D*&.,]_05ROA+3-0T:WT
M75O[ U"X>"%K.[M[DL9K8DD^= )#C!SM95(XQC.W%2:MI.H7>J+J>CZ7J&F>
M(!J/[QX4V6UY;B; :;)*D^7SDC=D?2@#IQXSGD\2:AH<&CO-<V4L,;LDWR$2
MJ[JV=O'RQG.>Y &<YI-/\87^J6[36N@2.OVNXM!B?.)(MWWB%(56*$!CQDCU
MJ'0(+Z#XA^*[Z?3+F&SO([5;>8@;9?*5PW&<CEACUJQX M;RRTF_AOK*>UD?
M4KFX42@?,DDK,IX)YP1F@!L?C62YT+2;VUTP27VHW1M18-<;6B==Q?<=IQL"
M$MQQ[\9T/%/B&7PWIMM=QV(NVGNHK;R_.\O#2':#G!XSBL30](GM?BEX@U#^
MR9;>QN8(_*F( 1YAD2-C/!8;><#.WGFKOQ$MKN_\+?8K+3KF]EENK=L6Y4%%
M29)&)+$8^52!C/)% $UCXKGN[G7+"72_)U+28TE>+[0&BD5U++APO!^5N"O:
MI='\0WFIV&D7[Z?;Q6VIPI/&%NR\B*T>\$J4 .. <'C-8MC9:CH,NL0Q:-/=
M6&J;KF&:+9Y\3NO,4H9AD+GY2"<#CL*J>$=&OM,T_P .1-X?FM]3LH1;W=RY
MC$938 WW6RY^50..O7I0!M:3XPN]8BTN]MM*B.EZE,T44XNB9(P%8YDC\OY3
ME,8#'&>2*BL/%VL7L;3'1M-CACU V#@ZJ?,+J^UMBF$!N,D#<"0*Q]+T+4/[
M=T36K;1;G1]2;G68XY$6UG4QG<=BL<ONVX.!T.3Q3K31]3AM9I?^$9E_M(:K
M)?6<SR0!$WN<>80^XX5V) !] ?0 ZC7/%MAH.L:1IUR&+ZC-Y9=02(0>%9L
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M -LZJOR88E@<#=DYY% &WHWQ#TS6)]-C:QU"P74UD:RDNTC"3>6"7 *.VT@
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MOA'1)?#GA'2]'FF6:6TMUC>1<X)[XSVK:H **** "BBJ=]JNGZ:,WM[!!QN
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MQ7'E2G&>KH QZ^M#?#K3Y4,=QK7B2>,G.R769R,_]]5V%% ',Z5X%T?1 _\
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MI3DC:/[QYJRWA[1G:%FTNT9H8C#&3"OR1D$%1[8)X]ZX,:[J=TNBI/?)._\
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MKFZ?3+-[BYB,,\K0*6EC/56..5.!P?2K-M:V]E"(;6WB@B!)"1(%4$^PHHH
+FHHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>gd14pbv45bwf000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gd14pbv45bwf000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? 4L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BD) &36
M+;>);*^UR_TBW?\ TFR"F3(XY]* -NBN=OO$[VFNII":?--.\;2H4(PR@X[F
MFZ?XM@U+3[ZX@@E\RR++- V%=6 SCTH Z2BN&/Q(M8=(M]5N;&[BL;AMJS8#
M '..0.1T-;]_XFL;"PM[IF+BY($"1C<TA(X % &U17/KXE\O4K>SOK22T:YR
M(2^"K,/X<CH:KQ^+S)JNIZ8+";[3I\8D8$@>8",C'UY_*@#J**YBW\8177A9
MM?CM)/)"EO)+#?@''YT^+Q49-<@TEM/G6>:'SMW&U5Z'\<\4 =)17/)XH#Z]
M<Z.ME-]HMXA*SX&PJ3@8.>]5K3QG]NTV:_MM+NI(87=& QNRA(.!WZ4 =516
M<VJPQZ6=1E/EVZQ>:V\8(&,]*CTO6H=9T:'5++YX)DWH#P3[']* -6BN3M?&
MPO;>[GM]*O'CM)GBE( )RIP<#/-;6CZW9ZYIR7UE()(6!!XP5(Z@CL?K0!I4
M5@)XKM/^$L;PY-#)#>^3Y\98C;*F<97\C^52>(O$UEX<AMFN0SR75PEO#$A&
MYV;T&>E &W15&]U2'3=(GU*^_<Q01&60$C( &<?6BRU2'4=&AU*S4S1SPK-&
MJD98$ X^O- %ZBN6M/&L=[I3:E!I%_):H[H[*JDC:2&.,\@$$?A3K_QUI=EX
M:@U]$FN=/F95#PKDJ6( !!Z')Q^= '3T5BW?B%;>]@L(K*>>^FA,_D)C*(,
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MQX[8/TYJIXR9O#NMV'B.%6)E1K"8(.I(^0GWW<5V-GH.FV,YG@MHTF( +]6
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M_9R2ZA']G6 K<0F'YI).Q![8STH W:*:O0<YXIU '(>-0)[[P_9'I-J"N?\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ghp5h1w3ypdd000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ghp5h1w3ypdd000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ ,\# 2(  A$! Q$!_\0
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MD#&?-0A)!D_.K="#U^IK!Q;UO=FRE;R1V]%8'_"8Z(X(MKS[5(!D1VR-(Q_
M"JYU;Q!J<9&FZ3]B!.!-J)Q@>HC7D_B125.773U'SKH=*TB(I9F"@=23TK#G
M\6:8':&SD:_G4[3':*9,'T)' _&HAX72\'_$ZO+C4<\M&[;(L^FQ>,?7-;=I
M96MC L-I!'!$.B1J% _ 4>XO,/??D86E66MWNM)K6J3O9Q+$T46F1ON49(^=
MV'5N.F./6NEJM?7UOIMH]S=2B.%,98^YP/U-6%.1GUJ7KJ4NPM%%%(84449H
M Q/$G]@K;6[:_# ]N9A'&9X]Z*[<#/&!GIDU2N]/TV8_\(_IDS:6S#SY5M(
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(* %HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>gemzezolivjc000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gemzezolivjc000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. 0T# 2(  A$! Q$!_\0
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MCBNAA?7KB2(SV\%HB9+@2;]_' 'H* -NBJFFF^-C&=16);KG>(CE>O'Z5;H
M**** "BBB@ HHHH **** "BBB@ HHHH **BN+F&UB:6>58T49+,<5EV/BC2]
M1NTMK>5RTA81L4(5R.N#WH V:*** "BBB@ HHHH **** "BLK5]=M]*>& @R
MW<^?)@7JV.I]A[U'X9U>XUO2%O;BW$#-(RJH.1@'&: -FBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*UW7;?0[/S9 TDTAV0PI]
MZ1CT JUJ=_;Z9I\UY=2>7!$NYV]!6!X?L9M6O/\ A(=24[G!%G P_P!3&>_U
M- "V?AR?4;D:EKTOG3$9CM5/[J'\.Y]ZB3&H>/5MHT"6VDP;CM& 9'XQ^ KK
MJS-+TR/2VOI6DWO=3M,S-VST'T% &G12*ZN,J01ZBEH ***#P,T 9NO:HFC:
M%>7\AP(8R1[GL/SI="DNIM#LY;ULW$D0=SC')YKG/%\B:QK6C^'%?*SR?:+A
M1U\M.1^9KLU 50H& !@"@!:S=:UB'1[/S'^:9SLAB'61ST HUK68='M1(ZM)
M-(VR*%!EI&/85GZ5H\[W!U?6"LE\PS''U6W7T'OZF@#GKNUN+-8ENYA-K^KR
M>6,#/D1?Q!?0 =Z[RSM(;&SBM8%VQ1*%45RWAI_[>\0:CKTD8\J%C:6A/]U3
M\S?B:TO%>LRZ3I86T427]TXAMD]6/?Z#K0!D^(_%5S!J,-CI;1EA.D4C$9RQ
M/W![XYKLQT%<)H6EP3^(4@"F2/2T)FD/\=R_WC[X%=X!@8% !1110 4444 %
M%%% !1110 4444 %%%% !17,W?BB[@UY])ATB2>=4\T%95 *=,\_RJ_H?B*S
MURR>YB)B\N5H9$EX*N.HH UZ*B>X@C#%YHU"_>RPX^M2 @C(.0: %HHHH Y'
MQ._]J>(=)\/#'ER$W5P#T9$_A_$UUB[5C 4 *!Q[5R+.D/Q402X!ETXB(GOA
MN0*EUZ[N-6UF/PY83&,,GFWDJ]4C[*/<T 27&O7FJ7<UAH$<;F/Y9;QS^[C/
MH/4U-;^%8Y%5]5N[B^GSEBSE4S[**V+"PMM-M5MK6)8XEZ!15G- '*^)87T6
MP@U#3I7@%O,GF1@Y61"<$$?C74J=R@^HS7'>(9W\1:I9Z)IT@>&.99;Z5#D(
MJG(7/J379#@8H *BNIXK:UEGF8+'&I9B3T J6N \0:M_;GBR#PJ'$5F2'FF!
M_P!:1SY7UH I>%9_[4^(DNJ31N))[,O%OZK%NPOZ5Z6Q*HQ R0,@>M<:D2VO
MQ3C  2.33=D8 X^5NE=G0!SNBZ5<37DFKZNH:\9B(8SR($[ >Y]:G\6ZC_9?
MAF\G5L2LGEQ^[-P/YUMUR'C.%K[5/#NGC!22]\V0'^Z@S0!N^'].72="L[-1
M@QQC=[L>2?SKB?$NJO#XY:XVF8:;:A8( ,[YY?NX^@KT"\O+?3[.2YN9%CBC
M&2QK@] ,%]X_O=1U"%X9;B-'L4E&-R@8)^M '6^&]*.E:0D<AW7,I,L[GJ7;
MD_X5JNZQQL[D!5&23VJK?:E9Z9 9;J=8U[ GEOH.]<]J%KJOBJWFBW/8Z>T9
M"J1B24D=_04 +X5U#4-;U/4=5D=UTMF\JTB88R >7_&NLKE/#.LVNGZ/;:7J
M+I9WEJHBDC<;5.. 0>G-;S:QIBC)O[;C_IJO^- %VBL23Q7I2D+%++<,>BPQ
M,V?TJ$ZEKE]+MLM,%M#_ ,];ML$_\!% '0TUI$3[SJOU-8,NA:E>[3=ZW<H!
MU2U C!_'K3XO".DIS+%)<2?WYI68_P Z -&75M/ASYE[ N.N9!42:]I4DBHF
MH6[,W0"0<T0Z!I,#;H[" $]RF?YU#JGAS3M3TR>S:WBB\U"HDC0!E]P: -<'
M(R**HZ1;7-GI5O;7<HEFB4(9 /O < _E5Z@ HHHH X74#;O\12SWQMU&GE6=
M'V[3NZ9K$TG1C<^%]<M[<M+':7C7%G=."IF8?,<^OI7IKV-I(6+VT+%CDED!
MS5#7-&;5=/2SANY;*,."_D #<O=?H: .7LTTZ\\*WVNZU!*D.H%&D1,E@HP
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F3D0-_P!_&_QH U1(A. ZD_6G5GP:)86TRRQ0;74Y!W$UH4 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>gt1e50hnuuzf000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gt1e50hnuuzf000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L 3,# 2(  A$! Q$!_\0
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M(H [*BL+2[J_U*^>YCF4:6HVQDI\TQ[L#_=K=H **** "BBB@ HHHH ****
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M AD7ND%YEP/HR@'\ZT=,UFUU-6$>^*=/]9!,I61/J#V]^E.5.25^@7-*BD)
MHSFH&+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M7O+E+2TDG?)5%S@=3["IV8*"2< =:Y6YU&^\02M:Z,$CLU;$E_(NX9!Z(O\
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M[S;Y\SS3*85,;E@ 1LZ <9^N:2V\)Q6G]CB*X<)I;.T:[>&W@@_0<G KI**
M.8'A!9;E[B[O&GE:SDL]XC",R/C.XC[Q&./QJN?!+R?8VEU.1WM[)[(GRP T
M; #(_NM@=:Z^B@#D]+\%C2VM62_>1K?2_P"S%W1CE <AOK18^"UTZWT"*WOI
M VCQO"C[!F2-P,@^A^4<UUE% &;J>FRWS6;PW3V\EM-YH*C(;Y67!'<?-^E8
M]YX+@U07\FH7#R7-VD2>=$H0Q^6Q9"/<,<YKJJ* .6N?",M_IPBO]5GFO(Y$
MEANE4*8G3.TA>G<Y]<U)-X7FN8H?M.IRRSQW,5P9"@ /EG*J%[#-=+10!S=U
MX9G?6YM2LM3FL_M*!+F)5#!\=&&>AQQFJUUX)6>[U*2._FBCO[-+650,L-H(
M5@WKS76T4 <5_P ("66_#ZDY^VV,=G)B(# 3."!VX-3>*8EU&SC\._9IYKJ1
M%>*=4PD94CY]W8CKBNOHP* ,J/18DU.VN@?DM8#%#'C[N<9/UP,?C4.K:$^J
M:KIM[]J,0L)?-1 @.YL$<GZ&MNB@#%N-"-QXGL]:-R0UM"\(BV##!L9.?PJE
M;>%)+2ZG$6ISC3YI3,;3:,*Q.3ANN"><5T]% '(VW@Q[6>RE34I";2661,QC
M)$F<@GN>>M2MX.2:6YFN+DM+<6IMI'2,)O!/WFQU/%=310!R/_"&SN=\VJ.\
MGV$V61$ -G&#C/7BK5]X6:\TO3;=+^6"ZT_:8+I$&00,<KT((KI** .<;PU/
?)<V%Q-J4DDMK,9F+1C$A(QC&?E%=&*** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>gt1e50hnuuzf000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gt1e50hnuuzf000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !5 2L# 2(  A$! Q$!_\0
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M0:@=/TJ21&432$119/\ $W _QK&\#Z@]UIEUI5Y<"XO-/F:&63/^L'4-^(-
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M["3$M@%O[A0V"\8;&S\1N/\ P&@#N,T9&>M<;XWO_.\ -J=E,R,S0/%+&V"
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M;[2-59HM6M;3S(I@<?:%QQ(ON.XK0@FEU?Q.VEM/(EG86<4DB(V/-=\XR?0
M'\Z .P!![TM95AILMCJ=Q(MPSVDB*$A9B?+89SCV.?TK5H **** "BBB@ HH
MHH **** ,B^TJ>^UBUN)9(FL[<,?)*$EF/&<YQQ]*JQ^'9K;Q6^L6DT,4,L
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MGNSJ$EK/=7KEE^7!*@ !<$Y( Q7&_P#".^-UT58A?7!GW1.X^VD,3M(;#'.
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M;R2\P@_TB0@M)GG)*@#\J +E%%% !1110 4444 %%%% !1110 4444 %%%%
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MC5XC_P NM[^-J_\ A0!H45FG6HA_RZWW_@))_A2#6XB,_9+_ /\  23_  H
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,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>31
<FILENAME>arwr-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-11-20T13:52:30.4379849+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 998add94503b4928937c39d61a9ae7d1 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:arwr="http://www.arrowheadresearch.com/20200930" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20200930" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.arrowheadresearch.com/20200930/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity" id="Role_StatementConsolidatedStatementOfStockholdersEquity">
        <link:definition>100040 - Statement - Consolidated Statement of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies" id="Role_DisclosureOrganizationAndSignificantAccountingPolicies">
        <link:definition>100060 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100070 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100080 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestments" id="Role_DisclosureInvestments">
        <link:definition>100090 - Disclosure - Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssets" id="Role_DisclosureIntangibleAssets">
        <link:definition>100100 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100110 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100120 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100130 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100140 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100150 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlans" id="Role_DisclosureEmployeeBenefitPlans">
        <link:definition>100170 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialData" id="Role_DisclosureUnauditedQuarterlyFinancialData">
        <link:definition>100180 - Disclosure - Unaudited Quarterly Financial Data</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100190 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" id="Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100210 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsTables" id="Role_DisclosureInvestmentsTables">
        <link:definition>100220 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsTables" id="Role_DisclosureIntangibleAssetsTables">
        <link:definition>100230 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100240 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100250 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100270 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataTables" id="Role_DisclosureUnauditedQuarterlyFinancialDataTables">
        <link:definition>100280 - Disclosure - Unaudited Quarterly Financial Data (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail">
        <link:definition>100300 - Disclosure - Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail">
        <link:definition>100310 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" id="Role_DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail">
        <link:definition>100320 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" id="Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
        <link:definition>100330 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail">
        <link:definition>100340 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" id="Role_DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail">
        <link:definition>100350 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" id="Role_DisclosureIntangibleAssetsAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Intangible Assets - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail" id="Role_DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail">
        <link:definition>100370 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Stockholders&apos; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100390 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail" id="Role_DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail">
        <link:definition>100410 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2" id="Role_DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2">
        <link:definition>100420 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" id="Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
        <link:definition>100430 - Disclosure - Leases - Future Minimum Lease Payments Under Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" id="Role_DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail">
        <link:definition>100450 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" id="Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail">
        <link:definition>100460 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail" id="Role_DisclosureStockBasedCompensationSummaryOfRsusActivityDetail">
        <link:definition>100470 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" id="Role_DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
        <link:definition>100480 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Fair Value Measurements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail" id="Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail">
        <link:definition>100500 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100510 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail">
        <link:definition>100520 - Disclosure - Income Taxes - Provisions for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail" id="Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail">
        <link:definition>100530 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" id="Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
        <link:definition>100540 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail" id="Role_DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail">
        <link:definition>100550 - Disclosure - Unaudited Quarterly Financial Data - Summary of Unaudited Quarterly Financial Data (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="Role_DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100560 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_CollaborationAndLicenseAgreementsAbstract" name="CollaborationAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" name="BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_ContingentConsiderationPolicyTextBlock" name="ContingentConsiderationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" name="HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_CashReceivedAsDueUnderAgreement" name="CashReceivedAsDueUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_MilestonePaymentEarned" name="MilestonePaymentEarned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" name="DevelopmentRegulatoryAndSalesMilestonesPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" name="NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_ProfitSharingStructureRatio" name="ProfitSharingStructureRatio" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arwr_TieredRoyaltiesReceivedPercentage" name="TieredRoyaltiesReceivedPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments" name="DevelopmentRegulatoryAndCommercialMilestonesPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_MilestonePaymentReceived" name="MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" name="OrganizationAndSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_OrganizationAndSignificantAccountingPoliciesTable" name="OrganizationAndSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_JanssenPharmaceuticalsIncorporationMember" name="JanssenPharmaceuticalsIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" name="JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" name="JohnsonAndJohnsonInnovationJJDCIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_AmgenIncorporatedMember" name="AmgenIncorporatedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_JNJ3989AROHBVAgreementMember" name="JNJ3989AROHBVAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_LicenseAgreementMember" name="LicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CollaborationAgreementMember" name="CollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_OlpasiranAgreementMember" name="OlpasiranAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" name="LicenseCollaborationAndStockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" name="TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CommonStockPurchaseAgreementMember" name="CommonStockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_IncreaseDecreaseInCashAndInvestments" name="IncreaseDecreaseInCashAndInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_AgreementDate" name="AgreementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_NumberOfAgreements" name="NumberOfAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arwr_OlpasiranAndAROAMG1AgreementMember" name="OlpasiranAndAROAMG1AgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CashReceivedAsDueUnderCollaborationAgreement" name="CashReceivedAsDueUnderCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" name="AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" name="NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_ResearchCollaborationAndOptionAgreementMember" name="ResearchCollaborationAndOptionAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_AROJNJ1Member" name="AROJNJ1Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_NumberOfDistinctPerformanceObligations" name="NumberOfDistinctPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_InitialTransactionPrice" name="InitialTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_RatioOfProfitSharingStructureForCommercialization" name="RatioOfProfitSharingStructureForCommercialization" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" name="PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" name="CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_LicenseAndCoFundingAgreementMember" name="LicenseAndCoFundingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_NumberOfDistinctBundle" name="NumberOfDistinctBundle" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_ResearchEquipmentGross" name="ResearchEquipmentGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" name="EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" name="EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" name="EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CommercialNotesDueWithinOneYearMember" name="CommercialNotesDueWithinOneYearMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" name="CommercialNotesDueWithinOneThroughThreeYearsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_AssetAcquisitionAxis" name="AssetAcquisitionAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_AssetAcquisitionDomain" name="AssetAcquisitionDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_NovartisMember" name="NovartisMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" name="TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_AtTheMarketAgreementMember" name="AtTheMarketAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" name="ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" name="CommonStockCapitalSharesValueReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" name="PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_TechnologyLicenseCommitmentsMember" name="TechnologyLicenseCommitmentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_AROENacAndAROHIF2CandidatesMember" name="AROENacAndAROHIF2CandidatesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_LeasePaymentsCommencementDate" name="LeasePaymentsCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" name="PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_NumberOfOptionsToRenew" name="NumberOfOptionsToRenew" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arwr_ColoradoOwnerLLCMember" name="ColoradoOwnerLLCMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_CorporateHeadquartersInPasadenaMember" name="CorporateHeadquartersInPasadenaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_ResearchFacilityInMadisonMember" name="ResearchFacilityInMadisonMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_HalozymeIncMember" name="HalozymeIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_SubleaseAgreementMember" name="SubleaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_LeaseExpirationMonthAndYear" name="LeaseExpirationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_AdditionalLandSubjectToLease" name="AdditionalLandSubjectToLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_SubleaseCommencementDate" name="SubleaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_TwoThousandsFourEquityIncentivePlanMember" name="TwoThousandsFourEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_TwoThousandsThirteenIncentivePlanMember" name="TwoThousandsThirteenIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_OutsideOfEquityCompensationPlansMember" name="OutsideOfEquityCompensationPlansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" name="GrantDateFairValueOfOptionsGrantedDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" name="EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" name="HeldToMaturitySecuritiesFairValueNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" name="DeferredTaxAssetsInProcessResearchAndDevelopmentCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" name="DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_DeferredTaxLiabilitiesStateTaxes" name="DeferredTaxLiabilitiesStateTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="arwr_PercentageOfValuationAllowance" name="PercentageOfValuationAllowance" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="arwr_FederalNetOperatingLossCarryForward" name="FederalNetOperatingLossCarryForward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_StateNetOperatingLossCarryForwards" name="StateNetOperatingLossCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" name="EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" name="EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" name="EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_EmployeeContributionsUpToThreePercentMember" name="EmployeeContributionsUpToThreePercentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_EmployeeContributionNextTwoPercentMember" name="EmployeeContributionNextTwoPercentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="arwr_LeaseCommencementMonthAndYear" name="LeaseCommencementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" name="ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>32
<FILENAME>arwr-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-11-20T13:52:30.4379849+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 998add94503b4928937c39d61a9ae7d1 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="arwr-20200930.xsd#TemplateLink" roleURI="http://www.arrowheadresearch.com/20200930/role/TemplateLink" />
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="arwr-20200930.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_HeldToMaturitySecuritiesNoncurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10270.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10280.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10290.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10300.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10310.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" order="10320.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="arwr-20200930.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10130.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="arwr-20200930.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="10210.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:href="arwr-20200930.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ResearchEquipmentGross" xlink:type="locator" xlink:label="arwr_ResearchEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_FurnitureAndFixturesGross" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="arwr_ResearchEquipmentGross" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNi" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:type="locator" xlink:label="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2" xlink:href="arwr-20200930.xsd#Role_DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes" xlink:type="locator" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="arwr_DeferredTaxLiabilitiesStateTaxes" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="10160.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>33
<FILENAME>arwr-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-11-20T13:52:30.4379849+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 998add94503b4928937c39d61a9ae7d1 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="arwr-20200930.xsd#TemplateLink" roleURI="http://www.arrowheadresearch.com/20200930/role/TemplateLink" />
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity" xlink:href="arwr-20200930.xsd#Role_StatementConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator" xlink:label="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator" xlink:label="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="11500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="locator" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TieredRoyaltiesReceivedPercentage" xlink:type="locator" xlink:label="arwr_TieredRoyaltiesReceivedPercentage" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ProfitSharingStructureRatio" xlink:type="locator" xlink:label="arwr_ProfitSharingStructureRatio" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePaymentReceived" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceived" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" xlink:type="locator" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivedAsDueUnderAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderAgreement" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommonStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_CommonStockPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OlpasiranAgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JNJ3989AROHBVAgreementMember" xlink:type="locator" xlink:label="arwr_JNJ3989AROHBVAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AmgenIncorporatedMember" xlink:type="locator" xlink:label="arwr_AmgenIncorporatedMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_OrganizationAndSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsIncorporationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_AmgenIncorporatedMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_JNJ3989AROHBVAgreementMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAgreementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAgreementMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_OlpasiranAgreementMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_CommonStockPurchaseAgreementMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_MilestonePaymentEarned" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_CashReceivedAsDueUnderAgreement" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_MilestonePaymentReceived" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_ProfitSharingStructureRatio" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_TieredRoyaltiesReceivedPercentage" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments" order="11940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="12030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketableSecurities" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesNoncurrent" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_IncreaseDecreaseInCashAndInvestments" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="12310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="12360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="12450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="12580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="12730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="12750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="12770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="12820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="12840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="13010.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePaymentReceived" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceived" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfAgreements" xlink:type="locator" xlink:label="arwr_NumberOfAgreements" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OlpasiranAndAROAMG1AgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OlpasiranAgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AmgenIncorporatedMember" xlink:type="locator" xlink:label="arwr_AmgenIncorporatedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_AmgenIncorporatedMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_OlpasiranAgreementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_OlpasiranAndAROAMG1AgreementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfAgreements" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_MilestonePaymentReceived" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" xlink:type="locator" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AROJNJ1Member" xlink:type="locator" xlink:label="arwr_AROJNJ1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommonStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_CommonStockPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JNJ3989AROHBVAgreementMember" xlink:type="locator" xlink:label="arwr_JNJ3989AROHBVAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ResearchCollaborationAndOptionAgreementMember" xlink:type="locator" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsIncorporationMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAgreementMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_ResearchCollaborationAndOptionAgreementMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAgreementMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_JNJ3989AROHBVAgreementMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_CommonStockPurchaseAgreementMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_AROJNJ1Member" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_MilestonePaymentEarned" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctPerformanceObligations" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_InitialTransactionPrice" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11960.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfDistinctBundle" xlink:type="locator" xlink:label="arwr_NumberOfDistinctBundle" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="locator" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_RatioOfProfitSharingStructureForCommercialization" xlink:type="locator" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseAndCoFundingAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAndCoFundingAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAndCoFundingAgreementMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_RatioOfProfitSharingStructureForCommercialization" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctBundle" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctPerformanceObligations" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_InitialTransactionPrice" order="10940.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MarketableSecuritiesMember" xlink:type="locator" xlink:label="arwr_MarketableSecuritiesMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommercialNotesDueWithinOneYearMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneYearMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" order="10080.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_CommercialNotesDueWithinOneYearMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_MarketableSecuritiesMember" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiCost" order="12810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" order="13090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" order="13370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" order="13650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="13930.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NovartisMember" xlink:type="locator" xlink:label="arwr_NovartisMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AssetAcquisitionDomain" xlink:type="locator" xlink:label="arwr_AssetAcquisitionDomain" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AssetAcquisitionDomain" xlink:type="locator" xlink:label="arwr_AssetAcquisitionDomain_2" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AssetAcquisitionAxis" xlink:type="locator" xlink:label="arwr_AssetAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="arwr_AssetAcquisitionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="arwr_AssetAcquisitionAxis" xlink:to="arwr_AssetAcquisitionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="arwr_AssetAcquisitionAxis" xlink:to="arwr_AssetAcquisitionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="arwr_AssetAcquisitionDomain" xlink:to="arwr_NovartisMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="locator" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="locator" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" xlink:type="locator" xlink:label="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AtTheMarketAgreementMember" xlink:type="locator" xlink:label="arwr_AtTheMarketAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="arwr_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_UnderwrittenPublicOfferingMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_AtTheMarketAgreementMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" order="10790.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePayments" xlink:type="locator" xlink:label="arwr_MilestonePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AROENacAndAROHIF2CandidatesMember" xlink:type="locator" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TechnologyLicenseCommitmentsMember" xlink:type="locator" xlink:label="arwr_TechnologyLicenseCommitmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="arwr_TechnologyLicenseCommitmentsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_AROENacAndAROHIF2CandidatesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligation" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="arwr_MilestonePayments" order="10320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_SubleaseCommencementDate" xlink:type="locator" xlink:label="arwr_SubleaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AdditionalLandSubjectToLease" xlink:type="locator" xlink:label="arwr_AdditionalLandSubjectToLease" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfOptionsToRenew" xlink:type="locator" xlink:label="arwr_NumberOfOptionsToRenew" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeasePaymentsCommencementDate" xlink:type="locator" xlink:label="arwr_LeasePaymentsCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_SubleaseAgreementMember" xlink:type="locator" xlink:label="arwr_SubleaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_HalozymeIncMember" xlink:type="locator" xlink:label="arwr_HalozymeIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WI" xlink:type="locator" xlink:label="stpr_WI" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ResearchFacilityInMadisonMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInMadisonMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ColoradoOwnerLLCMember" xlink:type="locator" xlink:label="arwr_ColoradoOwnerLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arwr_ColoradoOwnerLLCMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_CorporateHeadquartersInPasadenaMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_ResearchFacilityInMadisonMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WI" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arwr_HalozymeIncMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_SubleaseAgreementMember" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_LeasePaymentsCommencementDate" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_NumberOfOptionsToRenew" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_AdditionalLandSubjectToLease" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_LeaseExpirationMonthAndYear" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_SubleaseCommencementDate" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11820.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:type="locator" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OutsideOfEquityCompensationPlansMember" xlink:type="locator" xlink:label="arwr_OutsideOfEquityCompensationPlansMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsFourEquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsThirteenIncentivePlanMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_OutsideOfEquityCompensationPlansMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11940.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureStockBasedCompensationSummaryOfRsusActivityDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10690.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EmployeeContributionNextTwoPercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionNextTwoPercentMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EmployeeContributionsUpToThreePercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="arwr_EmployeeContributionsUpToThreePercentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="arwr_EmployeeContributionNextTwoPercentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10290.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseCommencementMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="locator" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_RatioOfProfitSharingStructureForCommercialization" xlink:type="locator" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA" xlink:type="locator" xlink:label="country_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseAndCoFundingAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAndCoFundingAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAndCoFundingAgreementMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_CorporateHeadquartersInPasadenaMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_AgreementDate" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_RatioOfProfitSharingStructureForCommercialization" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_LeaseCommencementMonthAndYear" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_LeaseExpirationMonthAndYear" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" order="10730.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>34
<FILENAME>arwr-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-11-20T13:52:30.4390059+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 998add94503b4928937c39d61a9ae7d1 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:type="locator" xlink:label="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due year five and after year five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:to="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security12b Title</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL CURRENT ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="us-gaap_HeldToMaturitySecuritiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued payroll and benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LONG-TERM LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LONG-TERM LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrowhead Pharmaceuticals, Inc. stockholders&apos; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 145,000,000 shares authorized; 102,376,303 and 95,506,271 shares issued and outstanding as of September 30, 2020 and September 30, 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Arrowhead Pharmaceuticals, Inc. stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncontrolling interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MinorityInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minority Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Including Portion Attributable To Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">REVENUE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Revenue [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Revenue Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OPERATING EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Excluding Acquired In Process Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL OPERATING EXPENSES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OPERATING INCOME (LOSS)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OTHER INCOME (EXPENSE)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income (expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in value of derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain Loss On Derivatives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL OTHER INCOME (EXPENSE)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">INCOME (LOSS) BEFORE INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET INCOME (LOSS)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET INCOME (LOSS) PER SHARE - BASIC</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET INCOME (LOSS) PER SHARE - DILUTED</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding - basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average shares outstanding - diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Diluted Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign currency translation adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">COMPREHENSIVE INCOME (LOSS)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator" xlink:label="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares of stock issued during the period upon the exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator" xlink:label="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of stock issued during the period upon the exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-controlling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants, Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants, Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock - restricted stock units vesting, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock - restricted stock units vesting, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock - issued for cash, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock - issued for cash, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Foreign currency translation adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deconsolidation of Ablaris Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncontrolling Interest Decrease From Deconsolidation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in value of derivatives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization/(accretion) of note premiums</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net Amortization Of Discount And Premium</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sale of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Maturity And Collections Of Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Principal payments on notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of taxes for net share settled restricted stock unit issuances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the exercises of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">NET INCREASE (DECREASE) IN CASH</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplementary disclosures:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes (Paid) Refunded</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="arwr_CollaborationAndLicenseAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Classified [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unaudited Quarterly Financial Data</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:type="locator" xlink:label="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of presentation and use of estimates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:to="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Use Of Estimates Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets subject to amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="arwr_ContingentConsiderationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="arwr_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for contingent consideration obligations related to acquisitions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ContingentConsiderationPolicyTextBlock" xlink:to="arwr_ContingentConsiderationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for Doubtful Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trade And Other Accounts Receivable Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Held to maturity securities and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" xlink:to="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Short-term, Long-term Investments and Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities And Marketable Securities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Intangible Assets And Goodwill Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future Minimum Lease Payments Under Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summarized Information about Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions Used to Value Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share Activity Related to RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of the Net Deferred Tax (Liability)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions for Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Effective Income Tax Rate Reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unaudited Quarterly Financial Data</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Quarterly Financial Information Table [Text Block]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivedAsDueUnderAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderAgreement" />
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash received as due under agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CashReceivedAsDueUnderAgreement" xlink:to="arwr_CashReceivedAsDueUnderAgreement_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment earned.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MilestonePaymentEarned" xlink:to="arwr_MilestonePaymentEarned_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development regulatory and sales milestones payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" xlink:type="locator" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional targets for development and sales milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" xlink:to="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ProfitSharingStructureRatio" xlink:type="locator" xlink:label="arwr_ProfitSharingStructureRatio" />
    <link:label xml:lang="en-US" xlink:label="arwr_ProfitSharingStructureRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit sharing structure ratio.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ProfitSharingStructureRatio" xlink:to="arwr_ProfitSharingStructureRatio_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TieredRoyaltiesReceivedPercentage" xlink:type="locator" xlink:label="arwr_TieredRoyaltiesReceivedPercentage" />
    <link:label xml:lang="en-US" xlink:label="arwr_TieredRoyaltiesReceivedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tiered royalties received percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TieredRoyaltiesReceivedPercentage" xlink:to="arwr_TieredRoyaltiesReceivedPercentage_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development regulatory and commercial milestones payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:to="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePaymentReceived" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MilestonePaymentReceived" xlink:to="arwr_MilestonePaymentReceived_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="arwr_OrganizationAndSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Janssen Pharmaceuticals, Incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_JanssenPharmaceuticalsIncorporationMember" xlink:to="arwr_JanssenPharmaceuticalsIncorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Pharmaceuticals Incorporation [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Janssen Pharmaceuticals and Johnson And Johnson Innovation JJDC Incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen and JJDC</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Pharmaceuticals And Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Johnson and Johnson Innovation-JJDC, Incorporation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">JJDC</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AmgenIncorporatedMember" xlink:type="locator" xlink:label="arwr_AmgenIncorporatedMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_AmgenIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen Incorporated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AmgenIncorporatedMember" xlink:to="arwr_AmgenIncorporatedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AmgenIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Incorporated</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AmgenIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Incorporated [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JNJ3989AROHBVAgreementMember" xlink:type="locator" xlink:label="arwr_JNJ3989AROHBVAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_JNJ3989AROHBVAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">JNJ-3989 (ARO-HBV) Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_JNJ3989AROHBVAgreementMember" xlink:to="arwr_JNJ3989AROHBVAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_JNJ3989AROHBVAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">JNJ-3989 (ARO-HBV) Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_JNJ3989AROHBVAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">J N J3989 A R O H B V Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CollaborationAndLicenseAgreementMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LicenseAgreementMember" xlink:to="arwr_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CollaborationAgreementMember" xlink:to="arwr_CollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OlpasiranAgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Olpasiran agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OlpasiranAgreementMember" xlink:to="arwr_OlpasiranAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Olpasiran Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Olpasiran Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License collaboration and stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:to="arwr_LicenseCollaborationAndStockPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Collaboration and Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Collaboration And Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Takeda Pharmaceuticals United States of America Incorporated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Takeda License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Takeda Pharmaceuticals United States Of America Incorporated [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommonStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_CommonStockPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock purchase agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommonStockPurchaseAgreementMember" xlink:to="arwr_CommonStockPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2014-09</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201409 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2016-02</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2018-18</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201818Member" xlink:to="us-gaap_AccountingStandardsUpdate201818Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201818 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Earned</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received as due under agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received As Due Under Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development regulatory and sales milestones payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory And Sales Milestones Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional targets for development and sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Targets For Development And Sales Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ProfitSharingStructureRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit sharing structure ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ProfitSharingStructureRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Sharing Structure Ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TieredRoyaltiesReceivedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tiered royalties received percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TieredRoyaltiesReceivedPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tiered Royalties Received Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development regulatory and commercial milestones payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory And Commercial Milestones Payments</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="locator" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments" />
    <link:label xml:lang="en-US" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in cash and investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_IncreaseDecreaseInCashAndInvestments" xlink:to="arwr_IncreaseDecreaseInCashAndInvestments_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increase (decrease) in cash and investments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Cash And Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchases of investments and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Cash outflow primarily related to operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Maturity And Collection Of Longterm Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount insured in FDIC per account</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash F D I C Insured Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of contingent consideration obligation due to discontinuation of clinical trials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Calculation of effect of dilutive stock options and restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable To Share Based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive excluded for calculation of effect of dilutive stock options and restricted stock units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, early adoption [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Early Adoption</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:label xml:lang="en-US" xlink:label="arwr_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AgreementDate" xlink:to="arwr_AgreementDate_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfAgreements" xlink:type="locator" xlink:label="arwr_NumberOfAgreements" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfAgreements" xlink:to="arwr_NumberOfAgreements_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OlpasiranAndAROAMG1AgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Olpasiran and ARO-AMG1 agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OlpasiranAndAROAMG1AgreementMember" xlink:to="arwr_OlpasiranAndAROAMG1AgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Olpasiran and ARO-AMG1 Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Olpasiran And A R O A M G1 Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement date</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AgreementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Date</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Agreements</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash received as due under collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional remaining development regulatory and sales milestones payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received as due under collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Received As Due Under Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional remaining development regulatory and sales milestones payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Remaining Development Regulatory And Sales Milestones Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contract liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net Current</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" xlink:type="locator" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional targets for development, regulatory and sales milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" xlink:to="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ResearchCollaborationAndOptionAgreementMember" xlink:type="locator" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research collaboration and option agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ResearchCollaborationAndOptionAgreementMember" xlink:to="arwr_ResearchCollaborationAndOptionAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Collaboration and Option Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Collaboration And Option Agreement [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AROJNJ1Member" xlink:type="locator" xlink:label="arwr_AROJNJ1Member" />
    <link:label xml:lang="en-US" xlink:label="arwr_AROJNJ1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ARO-JNJ1.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AROJNJ1Member" xlink:to="arwr_AROJNJ1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AROJNJ1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ARO-JNJ1</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AROJNJ1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A R O J N J1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Development, regulatory and sales milestones payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional targets for development, regulatory and sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Targets For Development Regulatory And Sales Milestone Payments</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctPerformanceObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of distinct performance obligations.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfDistinctPerformanceObligations" xlink:to="arwr_NumberOfDistinctPerformanceObligations_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctPerformanceObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of distinct performance obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctPerformanceObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Distinct Performance Obligations</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:label xml:lang="en-US" xlink:label="arwr_InitialTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_InitialTransactionPrice" xlink:to="arwr_InitialTransactionPrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_InitialTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_InitialTransactionPrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Transaction Price</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_RatioOfProfitSharingStructureForCommercialization" xlink:type="locator" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization" />
    <link:label xml:lang="en-US" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ratio of profit sharing structure for commercialization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_RatioOfProfitSharingStructureForCommercialization" xlink:to="arwr_RatioOfProfitSharingStructureForCommercialization_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="locator" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" />
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of eligible to receive tiered royalties on net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:to="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash receivable as upfront payment due under collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:to="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseAndCoFundingAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAndCoFundingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAndCoFundingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and co-funding agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LicenseAndCoFundingAgreementMember" xlink:to="arwr_LicenseAndCoFundingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAndCoFundingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Co-Funding Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LicenseAndCoFundingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Co Funding Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratio of Profit Sharing Structure for United States Commercialization</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ratio Of Profit Sharing Structure For Commercialization</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eligible to receive tiered royalties on net sales</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Eligible To Receive Tiered Royalties On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received as due under collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Receivable As Upfront Payment Due Under Collaboration Agreement</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfDistinctBundle" xlink:type="locator" xlink:label="arwr_NumberOfDistinctBundle" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctBundle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of distinct bundle.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfDistinctBundle" xlink:to="arwr_NumberOfDistinctBundle_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctBundle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of distinct bundle</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfDistinctBundle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Distinct Bundle</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ResearchEquipmentGross" xlink:type="locator" xlink:label="arwr_ResearchEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research equipment gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ResearchEquipmentGross" xlink:to="arwr_ResearchEquipmentGross_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computers, office equipment and furniture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedComputerSoftwareGross" xlink:to="us-gaap_CapitalizedComputerSoftwareGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalizedComputerSoftwareGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Computer Software Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense for property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity securities FV NI accumulated gross realized gain loss before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity securities FV NI accumulated gross unrealized gain before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity securities FV NI accumulated gross unrealized loss before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommercialNotesDueWithinOneYearMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneYearMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial notes due within one year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommercialNotesDueWithinOneYearMember" xlink:to="arwr_CommercialNotesDueWithinOneYearMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Notes Due Within One Year</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneYearMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Notes Due Within One Year [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial notes due within one through three years.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" xlink:to="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Notes Due Within One Through Three Years</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Notes Due Within One Through Three Years [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MarketableSecuritiesMember" xlink:type="locator" xlink:label="arwr_MarketableSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MarketableSecuritiesMember" xlink:to="arwr_MarketableSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MarketableSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Held to Maturity, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecurities" xlink:to="us-gaap_HeldToMaturitySecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Held to Maturity, Gross Unrealized Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Accumulated Unrecognized Holding Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Held to Maturity, Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Accumulated Unrecognized Holding Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Held to Maturity, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Fv Ni Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Realized Gains/(Losses)</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities F V N I Accumulated Gross Realized Gain Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities F V N I Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketable Securities, Gross Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities F V N I Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Fv Ni</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AssetAcquisitionAxis" xlink:type="locator" xlink:label="arwr_AssetAcquisitionAxis" />
    <link:label xml:lang="en-US" xlink:label="arwr_AssetAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AssetAcquisitionAxis" xlink:to="arwr_AssetAcquisitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AssetAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AssetAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AssetAcquisitionDomain" xlink:type="locator" xlink:label="arwr_AssetAcquisitionDomain" />
    <link:label xml:lang="en-US" xlink:label="arwr_AssetAcquisitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Asset acquisition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AssetAcquisitionDomain" xlink:to="arwr_AssetAcquisitionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AssetAcquisitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AssetAcquisitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NovartisMember" xlink:type="locator" xlink:label="arwr_NovartisMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_NovartisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NovartisMember" xlink:to="arwr_NovartisMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_NovartisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NovartisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Novartis [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensing Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensingAgreementsMember" xlink:to="us-gaap_LicensingAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LicensingAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PatentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PatentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization period of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements remainder of fiscal year 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements in 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of license agreements, thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense After Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Intangible assets subject to amortization, beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets subject to amortization, Impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Finitelived</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets subject to amortization, Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Intangible assets subject to amortization, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand four equity incentive plan two thousand thirteen equity incentive plan and inducement grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" xlink:to="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, and Inducement Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan And Inducement Grants [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="arwr_UnderwrittenPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_UnderwrittenPublicOfferingMember" xlink:to="arwr_UnderwrittenPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AtTheMarketAgreementMember" xlink:type="locator" xlink:label="arwr_AtTheMarketAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_AtTheMarketAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-market agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AtTheMarketAgreementMember" xlink:to="arwr_AtTheMarketAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AtTheMarketAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AtTheMarketAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital stock authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsAuthorized" xlink:to="us-gaap_CapitalUnitsAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalUnitsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Share reserve for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" xlink:type="locator" xlink:label="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" />
    <link:label xml:lang="en-US" xlink:label="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash inflow from the issuance of common stock before deducting advisory fees and offering expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" xlink:to="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued to institutional investors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate purchase price paid by investors</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Before Deducting Fees And Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from common stock after deducting advisory fees and offering expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="locator" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock, capital shares value reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="locator" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of commission on aggregate gross proceeds from sale of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:to="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock shares value reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commission to sales agent</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Domain]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TechnologyLicenseCommitmentsMember" xlink:type="locator" xlink:label="arwr_TechnologyLicenseCommitmentsMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TechnologyLicenseCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Technology license commitments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TechnologyLicenseCommitmentsMember" xlink:to="arwr_TechnologyLicenseCommitmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TechnologyLicenseCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Technology License Commitments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TechnologyLicenseCommitmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Technology License Commitments [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AROENacAndAROHIF2CandidatesMember" xlink:type="locator" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ARO-ENac and ARO-HIF2 Candidates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AROENacAndAROHIF2CandidatesMember" xlink:to="arwr_AROENacAndAROHIF2CandidatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ARO-ENaC and ARO-HIF2 Candidates</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A R O E Nac And A R O H I F2 Candidates [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments expected to be incurred in fiscal 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation Due In Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments expected to be incurred beyond fiscal 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondYear" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation Due In Second Year</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePayments" xlink:type="locator" xlink:label="arwr_MilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_MilestonePayments" xlink:to="arwr_MilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeasePaymentsCommencementDate" xlink:type="locator" xlink:label="arwr_LeasePaymentsCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="arwr_LeasePaymentsCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease payments commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LeasePaymentsCommencementDate" xlink:to="arwr_LeasePaymentsCommencementDate_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:label xml:lang="en-US" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of leasehold improvements net of tenant improvement allowances.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:to="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfOptionsToRenew" xlink:type="locator" xlink:label="arwr_NumberOfOptionsToRenew" />
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfOptionsToRenew_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of options to renew.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_NumberOfOptionsToRenew" xlink:to="arwr_NumberOfOptionsToRenew_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ColoradoOwnerLLCMember" xlink:type="locator" xlink:label="arwr_ColoradoOwnerLLCMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_ColoradoOwnerLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Colorado Owner, LLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ColoradoOwnerLLCMember" xlink:to="arwr_ColoradoOwnerLLCMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ColoradoOwnerLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Colorado Owner, LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ColoradoOwnerLLCMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Colorado Owner L L C [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_CorporateHeadquartersInPasadenaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Corporate Headquarters in Pasadena</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_CorporateHeadquartersInPasadenaMember" xlink:to="arwr_CorporateHeadquartersInPasadenaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_CorporateHeadquartersInPasadenaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Headquarters In Pasadena</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_CorporateHeadquartersInPasadenaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Headquarters In Pasadena [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ResearchFacilityInMadisonMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInMadisonMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research facility in Madison.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ResearchFacilityInMadisonMember" xlink:to="arwr_ResearchFacilityInMadisonMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Facility in Madison</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ResearchFacilityInMadisonMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Facility In Madison [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WI" xlink:type="locator" xlink:label="stpr_WI" />
    <link:label xml:lang="en-US" xlink:label="stpr_WI_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Wisconsin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_WI" xlink:to="stpr_WI_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_WI_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">WISCONSIN</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_HalozymeIncMember" xlink:type="locator" xlink:label="arwr_HalozymeIncMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_HalozymeIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Halozyme, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_HalozymeIncMember" xlink:to="arwr_HalozymeIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_HalozymeIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Halozyme, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_HalozymeIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Halozyme Inc [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_SubleaseAgreementMember" xlink:type="locator" xlink:label="arwr_SubleaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_SubleaseAgreementMember" xlink:to="arwr_SubleaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office space leases, in square feet</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandSubjectToGroundLeases" xlink:to="us-gaap_LandSubjectToGroundLeases_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Land Subject To Ground Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeasePaymentsCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease payments, commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeasePaymentsCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Payments Commencement Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for leasehold improvements, net of tenant improvement allowances</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease renewal term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfOptionsToRenew_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options to renew</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_NumberOfOptionsToRenew_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Options To Renew</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpirationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease expiration month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LeaseExpirationMonthAndYear" xlink:to="arwr_LeaseExpirationMonthAndYear_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AdditionalLandSubjectToLease" xlink:type="locator" xlink:label="arwr_AdditionalLandSubjectToLease" />
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalLandSubjectToLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional land subject to lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_AdditionalLandSubjectToLease" xlink:to="arwr_AdditionalLandSubjectToLease_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalLandSubjectToLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional office space for lease</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_AdditionalLandSubjectToLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Land Subject To Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Month And Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_SubleaseCommencementDate" xlink:type="locator" xlink:label="arwr_SubleaseCommencementDate" />
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_SubleaseCommencementDate" xlink:to="arwr_SubleaseCommencementDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_SubleaseCommencementDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Commencement Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Lease Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five And After Year Five</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Total operating lease liabilities (includes current portion)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cash payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 and thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousands four equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:to="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2004 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands Four Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousands thirteen incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousands Thirteen Incentive Plan [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OutsideOfEquityCompensationPlansMember" xlink:type="locator" xlink:label="arwr_OutsideOfEquityCompensationPlansMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_OutsideOfEquityCompensationPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Outside of equity compensation plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_OutsideOfEquityCompensationPlansMember" xlink:to="arwr_OutsideOfEquityCompensationPlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_OutsideOfEquityCompensationPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outside Of Equity Compensation Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_OutsideOfEquityCompensationPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Outside Of Equity Compensation Plans [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserve for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted stock units outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options Outstanding, beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Options Outstanding, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options Outstanding, Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options Outstanding, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options Outstanding, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options Outstanding, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price Per Share, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price Per Share, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price Per Share, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:type="locator" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant date fair value of the options granted during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:to="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value of the options granted</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grant Date Fair Value Of Options Granted During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized pre-tax compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period to recognize pre-tax compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share of options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of restricted stock units outstanding, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSU awards vesting, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of RSUs, Unvested, beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of RSUs, Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of RSUs, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of RSUs, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of RSUs, Unvested, End of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value, beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value, ending balance</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee service share based compensation nonvested awards additional compensation cost not yet recognized share based awards other than options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized pre-tax compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional unrecognized pre-tax compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Additional Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" />
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Held to maturity securities fair value non current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:to="arwr_HeldToMaturitySecuritiesFairValueNonCurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurements, Recurring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Short-term investments (held to maturity)</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments (held to maturity)</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Held To Maturity Securities Fair Value Non Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent consideration obligations</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" />
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:to="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets right of use assets/ lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:to="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes" xlink:type="locator" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes" />
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_DeferredTaxLiabilitiesStateTaxes" xlink:to="arwr_DeferredTaxLiabilitiesStateTaxes_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Research &amp; Development</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Alternative Minimum Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of Use Assets/Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Right Of Use Assets Or Lease Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capital Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities State Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets (liabilities)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PercentageOfValuationAllowance" xlink:type="locator" xlink:label="arwr_PercentageOfValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of valuation allowance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_PercentageOfValuationAllowance" xlink:to="arwr_PercentageOfValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance against deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_PercentageOfValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Valuation Allowance</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_FederalNetOperatingLossCarryForward" xlink:type="locator" xlink:label="arwr_FederalNetOperatingLossCarryForward" />
    <link:label xml:lang="en-US" xlink:label="arwr_FederalNetOperatingLossCarryForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal net operating loss carry forward.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_FederalNetOperatingLossCarryForward" xlink:to="arwr_FederalNetOperatingLossCarryForward_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_StateNetOperatingLossCarryForwards" xlink:type="locator" xlink:label="arwr_StateNetOperatingLossCarryForwards" />
    <link:label xml:lang="en-US" xlink:label="arwr_StateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">State net operating loss carry forwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_StateNetOperatingLossCarryForwards" xlink:to="arwr_StateNetOperatingLossCarryForwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_FederalNetOperatingLossCarryForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross federal net operating loss carry forwards</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_FederalNetOperatingLossCarryForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Net Operating Loss Carry Forward</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_StateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross state net operating loss carry forwards</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_StateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State Net Operating Loss Carry Forwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Income Tax Expense Benefit Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Income Tax Expense Benefit Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision from income taxes</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" />
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" />
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to mark-to-market adjustments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" />
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation true-up on deferred tax rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At U.S. federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net of federal effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Deductions Stock Compensation Percent</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mark-to-market adjustments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Mark To Market Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">True-up on deferred taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation True Up On Deferred Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax rate change</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retirement Plan Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="us-gaap_RetirementPlanTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetirementPlanTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EmployeeContributionsUpToThreePercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee contributions up to three percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EmployeeContributionsUpToThreePercentMember" xlink:to="arwr_EmployeeContributionsUpToThreePercentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Contributions up to 3%</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Contributions Up To Three Percent [Member]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EmployeeContributionNextTwoPercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionNextTwoPercentMember" />
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionNextTwoPercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee contribution next two percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_EmployeeContributionNextTwoPercentMember" xlink:to="arwr_EmployeeContributionNextTwoPercentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionNextTwoPercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Contributions Next 2%</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_EmployeeContributionNextTwoPercentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Contribution Next Two Percent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discretionary match percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee benefits costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Income (Loss) per share-Basic</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Income (Loss) per share-Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA" xlink:type="locator" xlink:label="country_CA" />
    <link:label xml:lang="en-US" xlink:label="country_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CA" xlink:to="country_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CANADA</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseCommencementMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_LeaseCommencementMonthAndYear" xlink:to="arwr_LeaseCommencementMonthAndYear_lbl" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:label xml:lang="en-US" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected payments of leasehold improvements, net of tenant improvement allowances.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:to="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" />
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement period</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseCommencementMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_LeaseExpirationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease expiration month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected leasehold improvements, net of tenant improvement allowances</link:label>
    <link:label xml:lang="en-US" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Expected Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>35
<FILENAME>arwr-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-11-20T13:52:30.4390059+00:00 -->
<!-- Version            : 5.0.1.513 -->
<!-- Package ID         : 998add94503b4928937c39d61a9ae7d1 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/role/TemplateLink" xlink:href="arwr-20200930.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="arwr-20200930.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="arwr-20200930.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest" xlink:type="locator" xlink:label="us-gaap_MinorityInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_HeldToMaturitySecuritiesNoncurrent" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_MinorityInterest" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="arwr-20200930.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:href="arwr-20200930.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity" xlink:href="arwr-20200930.xsd#Role_StatementConsolidatedStatementOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="locator" xlink:label="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:type="locator" xlink:label="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_StockIssuedDuringPeriodValueExerciseOfWarrants" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_li0l2" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="arwr-20200930.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies" xlink:href="arwr-20200930.xsd#Role_DisclosureOrganizationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:href="arwr-20200930.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="arwr-20200930.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestments" xlink:href="arwr-20200930.xsd#Role_DisclosureInvestments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssets" xlink:href="arwr-20200930.xsd#Role_DisclosureIntangibleAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquity" xlink:href="arwr-20200930.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="arwr-20200930.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeases" xlink:href="arwr-20200930.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="arwr-20200930.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="arwr-20200930.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxes" xlink:href="arwr-20200930.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlans" xlink:href="arwr-20200930.xsd#Role_DisclosureEmployeeBenefitPlans" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlans">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialData" xlink:href="arwr-20200930.xsd#Role_DisclosureUnauditedQuarterlyFinancialData" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialData">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEvents" xlink:href="arwr-20200930.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" xlink:href="arwr-20200930.xsd#Role_DisclosureOrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="arwr_ContingentConsiderationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" xlink:type="locator" xlink:label="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arwr_ContingentConsiderationPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="arwr-20200930.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsTables" xlink:href="arwr-20200930.xsd#Role_DisclosureInvestmentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsTables">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsTables" xlink:href="arwr-20200930.xsd#Role_DisclosureIntangibleAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesTables" xlink:href="arwr-20200930.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="arwr-20200930.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="arwr-20200930.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="arwr-20200930.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataTables" xlink:href="arwr-20200930.xsd#Role_DisclosureUnauditedQuarterlyFinancialDataTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="locator" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:type="locator" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="locator" xlink:label="arwr_IncreaseDecreaseInCashAndInvestments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecurities" xlink:type="locator" xlink:label="us-gaap_MarketableSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TieredRoyaltiesReceivedPercentage" xlink:type="locator" xlink:label="arwr_TieredRoyaltiesReceivedPercentage" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ProfitSharingStructureRatio" xlink:type="locator" xlink:label="arwr_ProfitSharingStructureRatio" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePaymentReceived" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceived" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" xlink:type="locator" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivedAsDueUnderAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderAgreement" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommonStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_CommonStockPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OlpasiranAgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JNJ3989AROHBVAgreementMember" xlink:type="locator" xlink:label="arwr_JNJ3989AROHBVAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AmgenIncorporatedMember" xlink:type="locator" xlink:label="arwr_AmgenIncorporatedMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="arwr_OrganizationAndSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="arwr_OrganizationAndSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsIncorporationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_AmgenIncorporatedMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_JNJ3989AROHBVAgreementMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAgreementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAgreementMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_OlpasiranAgreementMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_CommonStockPurchaseAgreementMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_MilestonePaymentEarned" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_CashReceivedAsDueUnderAgreement" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_MilestonePaymentReceived" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_ProfitSharingStructureRatio" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_TieredRoyaltiesReceivedPercentage" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesCurrent" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_MarketableSecurities" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesNoncurrent" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="arwr_IncreaseDecreaseInCashAndInvestments" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="12760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="12810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption" order="13000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePaymentReceived" xlink:type="locator" xlink:label="arwr_MilestonePaymentReceived" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfAgreements" xlink:type="locator" xlink:label="arwr_NumberOfAgreements" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OlpasiranAndAROAMG1AgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAndAROAMG1AgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseCollaborationAndStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OlpasiranAgreementMember" xlink:type="locator" xlink:label="arwr_OlpasiranAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AmgenIncorporatedMember" xlink:type="locator" xlink:label="arwr_AmgenIncorporatedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_AmgenIncorporatedMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_OlpasiranAgreementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseCollaborationAndStockPurchaseAgreementMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_OlpasiranAndAROAMG1AgreementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfAgreements" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_MilestonePaymentReceived" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePaymentEarned" xlink:type="locator" xlink:label="arwr_MilestonePaymentEarned" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" xlink:type="locator" xlink:label="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AROJNJ1Member" xlink:type="locator" xlink:label="arwr_AROJNJ1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommonStockPurchaseAgreementMember" xlink:type="locator" xlink:label="arwr_CommonStockPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JNJ3989AROHBVAgreementMember" xlink:type="locator" xlink:label="arwr_JNJ3989AROHBVAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ResearchCollaborationAndOptionAgreementMember" xlink:type="locator" xlink:label="arwr_ResearchCollaborationAndOptionAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="locator" xlink:label="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="locator" xlink:label="arwr_JanssenPharmaceuticalsIncorporationMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsIncorporationMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAgreementMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_ResearchCollaborationAndOptionAgreementMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAndLicenseAgreementMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_CollaborationAgreementMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_JNJ3989AROHBVAgreementMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_CommonStockPurchaseAgreementMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_AROJNJ1Member" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_MilestonePaymentEarned" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctPerformanceObligations" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_InitialTransactionPrice" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_InitialTransactionPrice" xlink:type="locator" xlink:label="arwr_InitialTransactionPrice" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfDistinctPerformanceObligations" xlink:type="locator" xlink:label="arwr_NumberOfDistinctPerformanceObligations" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfDistinctBundle" xlink:type="locator" xlink:label="arwr_NumberOfDistinctBundle" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="locator" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_RatioOfProfitSharingStructureForCommercialization" xlink:type="locator" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseAndCoFundingAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAndCoFundingAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="locator" xlink:label="arwr_CollaborationAndLicenseAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAndCoFundingAgreementMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_AgreementDate" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_RatioOfProfitSharingStructureForCommercialization" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctBundle" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_NumberOfDistinctPerformanceObligations" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="arwr_InitialTransactionPrice" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:href="arwr-20200930.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizedComputerSoftwareGross" xlink:type="locator" xlink:label="us-gaap_CapitalizedComputerSoftwareGross" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ResearchEquipmentGross" xlink:type="locator" xlink:label="arwr_ResearchEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="arwr_ResearchEquipmentGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_CapitalizedComputerSoftwareGross" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNi" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" xlink:type="locator" xlink:label="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecurities" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MarketableSecuritiesMember" xlink:type="locator" xlink:label="arwr_MarketableSecuritiesMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommercialNotesDueWithinOneYearMember" xlink:type="locator" xlink:label="arwr_CommercialNotesDueWithinOneYearMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="locator" xlink:label="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HeldToMaturitySecuritiesClassifiedAbstract" xlink:to="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_CommercialNotesDueWithinOneYearMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_CommercialNotesDueWithinOneThroughThreeYearsMember" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="arwr_MarketableSecuritiesMember" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecurities" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiCost" order="12800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax" order="13360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax" order="13640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="13920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureIntangibleAssetsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember" xlink:type="locator" xlink:label="us-gaap_PatentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LicensingAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NovartisMember" xlink:type="locator" xlink:label="arwr_NovartisMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AssetAcquisitionDomain" xlink:type="locator" xlink:label="arwr_AssetAcquisitionDomain" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AssetAcquisitionAxis" xlink:type="locator" xlink:label="arwr_AssetAcquisitionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="arwr_AssetAcquisitionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_AssetAcquisitionAxis" xlink:to="arwr_AssetAcquisitionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="arwr_AssetAcquisitionDomain" xlink:to="arwr_NovartisMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LicensingAgreementsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="locator" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="locator" xlink:label="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="locator" xlink:label="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" xlink:type="locator" xlink:label="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:type="locator" xlink:label="us-gaap_CapitalUnitsAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AtTheMarketAgreementMember" xlink:type="locator" xlink:label="arwr_AtTheMarketAgreementMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="arwr_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" xlink:type="locator" xlink:label="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_UnderwrittenPublicOfferingMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="arwr_AtTheMarketAgreementMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CapitalUnitsAuthorized" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssued" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_MilestonePayments" xlink:type="locator" xlink:label="arwr_MilestonePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInSecondYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AROENacAndAROHIF2CandidatesMember" xlink:type="locator" xlink:label="arwr_AROENacAndAROHIF2CandidatesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TechnologyLicenseCommitmentsMember" xlink:type="locator" xlink:label="arwr_TechnologyLicenseCommitmentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherCommitmentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="arwr_TechnologyLicenseCommitmentsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_AROENacAndAROHIF2CandidatesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligation" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="arwr_MilestonePayments" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost" xlink:type="locator" xlink:label="us-gaap_VariableLeaseCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_SubleaseCommencementDate" xlink:type="locator" xlink:label="arwr_SubleaseCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AdditionalLandSubjectToLease" xlink:type="locator" xlink:label="arwr_AdditionalLandSubjectToLease" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_NumberOfOptionsToRenew" xlink:type="locator" xlink:label="arwr_NumberOfOptionsToRenew" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeasePaymentsCommencementDate" xlink:type="locator" xlink:label="arwr_LeasePaymentsCommencementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_SubleaseAgreementMember" xlink:type="locator" xlink:label="arwr_SubleaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_HalozymeIncMember" xlink:type="locator" xlink:label="arwr_HalozymeIncMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_WI" xlink:type="locator" xlink:label="stpr_WI" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ResearchFacilityInMadisonMember" xlink:type="locator" xlink:label="arwr_ResearchFacilityInMadisonMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ColoradoOwnerLLCMember" xlink:type="locator" xlink:label="arwr_ColoradoOwnerLLCMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arwr_ColoradoOwnerLLCMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_CorporateHeadquartersInPasadenaMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_ResearchFacilityInMadisonMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_WI" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="arwr_HalozymeIncMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_SubleaseAgreementMember" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_LeasePaymentsCommencementDate" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_NumberOfOptionsToRenew" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_AdditionalLandSubjectToLease" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_LeaseExpirationMonthAndYear" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="arwr_SubleaseCommencementDate" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_VariableLeaseCost" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:type="locator" xlink:label="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" xlink:type="locator" xlink:label="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_OutsideOfEquityCompensationPlansMember" xlink:type="locator" xlink:label="arwr_OutsideOfEquityCompensationPlansMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsThirteenIncentivePlanMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="locator" xlink:label="arwr_TwoThousandsFourEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsFourEquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_TwoThousandsThirteenIncentivePlanMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="arwr_OutsideOfEquityCompensationPlansMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureStockBasedCompensationSummaryOfRsusActivityDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_li0l2" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_HeldToMaturitySecuritiesFairValueNonCurrent" xlink:type="locator" xlink:label="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="locator" xlink:label="us-gaap_HeldToMaturitySecuritiesFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_HeldToMaturitySecuritiesFairValue" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="arwr_HeldToMaturitySecuritiesFairValueNonCurrent" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes" xlink:type="locator" xlink:label="arwr_DeferredTaxLiabilitiesStateTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:type="locator" xlink:label="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="arwr_DeferredTaxLiabilitiesStateTaxes" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_StateNetOperatingLossCarryForwards" xlink:type="locator" xlink:label="arwr_StateNetOperatingLossCarryForwards" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_FederalNetOperatingLossCarryForward" xlink:type="locator" xlink:label="arwr_FederalNetOperatingLossCarryForward" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PercentageOfValuationAllowance" xlink:type="locator" xlink:label="arwr_PercentageOfValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_PercentageOfValuationAllowance" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_FederalNetOperatingLossCarryForward" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_StateNetOperatingLossCarryForwards" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" xlink:type="locator" xlink:label="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureEmployeeBenefitPlansAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanDisclosureLineItems" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EmployeeContributionNextTwoPercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionNextTwoPercentMember" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_EmployeeContributionsUpToThreePercentMember" xlink:type="locator" xlink:label="arwr_EmployeeContributionsUpToThreePercentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:type="locator" xlink:label="us-gaap_RetirementPlanTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_RetirementPlanTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeAxis" xlink:to="us-gaap_RetirementPlanTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="arwr_EmployeeContributionsUpToThreePercentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanTypeDomain" xlink:to="arwr_EmployeeContributionNextTwoPercentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_DefinedBenefitPlanDisclosureLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ProfitLoss" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="arwr-20200930.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
    <link:loc xlink:href="arwr-20200930.xsd#arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" xlink:type="locator" xlink:label="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeaseExpirationMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseExpirationMonthAndYear" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LeaseCommencementMonthAndYear" xlink:type="locator" xlink:label="arwr_LeaseCommencementMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="locator" xlink:label="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="locator" xlink:label="arwr_CashReceivedAsDueUnderCollaborationAgreement" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="locator" xlink:label="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_RatioOfProfitSharingStructureForCommercialization" xlink:type="locator" xlink:label="arwr_RatioOfProfitSharingStructureForCommercialization" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_AgreementDate" xlink:type="locator" xlink:label="arwr_AgreementDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CA" xlink:type="locator" xlink:label="country_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_CorporateHeadquartersInPasadenaMember" xlink:type="locator" xlink:label="arwr_CorporateHeadquartersInPasadenaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_LicenseAndCoFundingAgreementMember" xlink:type="locator" xlink:label="arwr_LicenseAndCoFundingAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="arwr-20200930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="locator" xlink:label="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="dei_LegalEntityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="arwr_LicenseAndCoFundingAgreementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="arwr_CorporateHeadquartersInPasadenaMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementGeographicalAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CA" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_AgreementDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_RatioOfProfitSharingStructureForCommercialization" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_CashReceivedAsDueUnderCollaborationAgreement" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_LeaseCommencementMonthAndYear" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_LeaseExpirationMonthAndYear" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>arwr-10k_20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arwr="http://www.arrowheadresearch.com/20200930"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arwr-20200930.xsd" xlink:type="simple"/>
    <context id="C_0000879407_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="C_0000879407_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0000879407_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_20171001_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_20170930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171001_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171001_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseCollaborationAndStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-27</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-07</instant>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-06</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="C_0000879407_20191201_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMaximumMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMinimumMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMaximumMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-27</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAndAROAMG1AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:ResearchCollaborationAndOptionAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROJNJ1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMinimumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-07</instant>
        </period>
    </context>
    <context id="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-07</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesDueWithinOneThroughThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="arwr:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="arwr:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="arwr:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="arwr:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191201_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_us-gaapTypeOfArrangementAxis_arwrAROENacAndAROHIF2CandidatesMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20171001_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160101_20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200501_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HalozymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HalozymeIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:SubleaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171001_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20171001_20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionsUpToThreePercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20191001_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionNextTwoPercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_20191001_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_20200701_20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_20181001_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0000879407_20190401_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_20190701_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023_20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-23</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_arwrTarget">
        <measure>arwr:Target</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_arwrAgreement">
        <measure>arwr:Agreement</measure>
    </unit>
    <unit id="U_arwrObligation">
        <measure>arwr:Obligation</measure>
    </unit>
    <unit id="U_arwrBundle">
        <measure>arwr:Bundle</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_arwrOption">
        <measure>arwr:Option</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0000879407_20191001_20200930" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0000879407_20191001_20200930" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0000879407_20191001_20200930" id="F_000007">0000879407</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0000879407_20191001_20200930" id="F_000008">--09-30</dei:CurrentFiscalYearEndDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200930"
      id="F_000409">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200930"
      id="F_000411">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200930"
      id="F_000414">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200930"
      id="F_000416">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20200930"
      id="F_000417">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20200930"
      id="F_000418">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930"
      id="F_000429">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930"
      id="F_000430">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20180101_20181231"
      id="F_000431">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0000879407_20200930"
      id="F_000077"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0000879407_20190930"
      id="F_000078"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20191001_20200930" id="F_000105">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20181001_20190930" id="F_000106">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20171001_20180930" id="F_000107">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000632"
      unitRef="U_xbrlipure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000879407_20181001_20190930"
      decimals="INF"
      id="F_000633"
      unitRef="U_xbrlipure">0.0150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0000879407_20171001_20180930"
      decimals="INF"
      id="F_000634"
      unitRef="U_xbrlipure">0.0205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0000879407_20191001_20200930" id="F_000642">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0000879407_20181001_20190930" id="F_000643">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0000879407_20171001_20180930" id="F_000644">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000635"
      unitRef="U_xbrlipure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000879407_20181001_20190930"
      decimals="INF"
      id="F_000636"
      unitRef="U_xbrlipure">0.0311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0000879407_20171001_20180930"
      decimals="INF"
      id="F_000637"
      unitRef="U_xbrlipure">0.0299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000640"
      unitRef="U_xbrlipure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000641"
      unitRef="U_xbrlipure">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20191001_20191231" id="F_000749">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20200101_20200331" id="F_000750">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20200401_20200630" id="F_000751">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20200701_20200930" id="F_000752">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20181001_20181231" id="F_000773">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20190101_20190331" id="F_000774">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20190401_20190630" id="F_000775">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0000879407_20190701_20190930" id="F_000776">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember</us-gaap:TypeOfRevenueExtensibleList>
    <dei:DocumentType contextRef="C_0000879407_20191001_20200930" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0000879407_20191001_20200930" id="F_000031">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0000879407_20191001_20200930" id="F_000002">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0000879407_20191001_20200930" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0000879407_20191001_20200930" id="F_000032">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0000879407_20191001_20200930" id="F_000021">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0000879407_20191001_20200930" id="F_000006">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000879407_20191001_20200930" id="F_000022">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000879407_20191001_20200930" id="F_000023">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000879407_20191001_20200930" id="F_000024">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0000879407_20191001_20200930" id="F_000025">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0000879407_20191001_20200930" id="F_000026">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000879407_20191001_20200930" id="F_000027">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000879407_20191001_20200930" id="F_000028">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000879407_20191001_20200930" id="F_000029">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000879407_20191001_20200930" id="F_000030">304-3400</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0000879407_20191001_20200930" id="F_000019">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000879407_20191001_20200930" id="F_000005">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000879407_20191001_20200930" id="F_000020">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0000879407_20191001_20200930" id="F_000009">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0000879407_20191001_20200930" id="F_000011">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0000879407_20191001_20200930" id="F_000010">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0000879407_20191001_20200930" id="F_000018">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0000879407_20191001_20200930" id="F_000012">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0000879407_20191001_20200930" id="F_000013">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000879407_20191001_20200930" id="F_000014">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="C_0000879407_20191001_20200930" id="F_000015">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0000879407_20200331"
      decimals="-8"
      id="F_000017"
      unitRef="U_iso4217USD">2900000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0000879407_20201116"
      decimals="INF"
      id="F_000016"
      unitRef="U_xbrlishares">102756771</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000033">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#x2019;s 2021 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000034"
      unitRef="U_iso4217USD">143582667</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000035"
      unitRef="U_iso4217USD">221804128</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000036"
      unitRef="U_iso4217USD">845673</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000037"
      unitRef="U_iso4217USD">661361</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000038"
      unitRef="U_iso4217USD">4250896</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000039"
      unitRef="U_iso4217USD">3317999</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000040"
      unitRef="U_iso4217USD">1781691</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000041"
      unitRef="U_iso4217USD">2563435</us-gaap:OtherAssetsCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000042"
      unitRef="U_iso4217USD">85019719</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000043"
      unitRef="U_iso4217USD">86889751</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000044"
      unitRef="U_iso4217USD">36899894</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000045"
      unitRef="U_iso4217USD">322370397</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000046"
      unitRef="U_iso4217USD">265246817</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000047"
      unitRef="U_iso4217USD">30880868</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000048"
      unitRef="U_iso4217USD">23214899</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000049"
      unitRef="U_iso4217USD">15363151</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000050"
      unitRef="U_iso4217USD">17063580</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000051"
      unitRef="U_iso4217USD">137486883</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000052"
      unitRef="U_iso4217USD">44175993</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000053"
      unitRef="U_iso4217USD">16137085</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000054"
      unitRef="U_iso4217USD">265359</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000055"
      unitRef="U_iso4217USD">144148</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000056"
      unitRef="U_iso4217USD">522503743</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000057"
      unitRef="U_iso4217USD">349845437</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000058"
      unitRef="U_iso4217USD">6828909</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000059"
      unitRef="U_iso4217USD">7649921</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000060"
      unitRef="U_iso4217USD">5388556</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000061"
      unitRef="U_iso4217USD">6504729</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000062"
      unitRef="U_iso4217USD">8060854</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000063"
      unitRef="U_iso4217USD">4955887</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000064"
      unitRef="U_iso4217USD">1094777</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRentCreditCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000065"
      unitRef="U_iso4217USD">173952</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000066"
      unitRef="U_iso4217USD">19291075</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000067"
      unitRef="U_iso4217USD">77769629</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000068"
      unitRef="U_iso4217USD">17262</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000069"
      unitRef="U_iso4217USD">16561</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000070"
      unitRef="U_iso4217USD">40681433</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000071"
      unitRef="U_iso4217USD">97070679</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000072"
      unitRef="U_iso4217USD">20043178</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000073"
      unitRef="U_iso4217USD">3703364</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000074"
      unitRef="U_iso4217USD">5035142</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000075"
      unitRef="U_iso4217USD">20043178</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000076"
      unitRef="U_iso4217USD">8738506</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000094"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0000879407_20190930"
      decimals="INF"
      id="F_000095"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0000879407_20190930"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">102376303</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000100"
      unitRef="U_xbrlishares">102376303</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0000879407_20190930"
      decimals="INF"
      id="F_000099"
      unitRef="U_xbrlishares">95506271</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000879407_20190930"
      decimals="INF"
      id="F_000101"
      unitRef="U_xbrlishares">95506271</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000079"
      unitRef="U_iso4217USD">194746</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000080"
      unitRef="U_iso4217USD">187876</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000081"
      unitRef="U_iso4217USD">965410146</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000082"
      unitRef="U_iso4217USD">664086155</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000083"
      unitRef="U_iso4217USD">18433</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000084"
      unitRef="U_iso4217USD">-391624</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000085"
      unitRef="U_iso4217USD">-503844193</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000086"
      unitRef="U_iso4217USD">-419290967</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000087"
      unitRef="U_iso4217USD">461779132</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000088"
      unitRef="U_iso4217USD">244591440</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000089"
      unitRef="U_iso4217USD">-555188</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000090"
      unitRef="U_iso4217USD">461779132</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000091"
      unitRef="U_iso4217USD">244036252</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000092"
      unitRef="U_iso4217USD">522503743</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000093"
      unitRef="U_iso4217USD">349845437</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000102"
      unitRef="U_iso4217USD">87992066</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000103"
      unitRef="U_iso4217USD">168795577</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000104"
      unitRef="U_iso4217USD">16142321</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000108"
      unitRef="U_iso4217USD">128874979</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000109"
      unitRef="U_iso4217USD">81048686</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000110"
      unitRef="U_iso4217USD">52968505</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000111"
      unitRef="U_iso4217USD">52275890</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000112"
      unitRef="U_iso4217USD">26556257</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000113"
      unitRef="U_iso4217USD">19110051</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000114"
      unitRef="U_iso4217USD">181150869</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000115"
      unitRef="U_iso4217USD">107604943</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000116"
      unitRef="U_iso4217USD">72078556</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000117"
      unitRef="U_iso4217USD">-93158803</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000118"
      unitRef="U_iso4217USD">61190634</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000119"
      unitRef="U_iso4217USD">-55936235</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000120"
      unitRef="U_iso4217USD">9190501</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000121"
      unitRef="U_iso4217USD">6957768</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000122"
      unitRef="U_iso4217USD">1048523</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000123"
      unitRef="U_iso4217USD">432141</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000124"
      unitRef="U_iso4217USD">-582524</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000125"
      unitRef="U_iso4217USD">7493</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000126"
      unitRef="U_iso4217USD">8607977</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000127"
      unitRef="U_iso4217USD">6957768</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000128"
      unitRef="U_iso4217USD">1488157</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000129"
      unitRef="U_iso4217USD">-84550826</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000130"
      unitRef="U_iso4217USD">68148402</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000131"
      unitRef="U_iso4217USD">-54448078</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000132"
      unitRef="U_iso4217USD">2400</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000133"
      unitRef="U_iso4217USD">173553</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000134"
      unitRef="U_iso4217USD">2400</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000135"
      unitRef="U_iso4217USD">-84553226</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000136"
      unitRef="U_iso4217USD">67974849</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000137"
      unitRef="U_iso4217USD">-54450478</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000138"
      unitRef="U_iso4217USD_xbrlishares">-0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20181001_20190930"
      decimals="2"
      id="F_000139"
      unitRef="U_iso4217USD_xbrlishares">0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20171001_20180930"
      decimals="2"
      id="F_000140"
      unitRef="U_iso4217USD_xbrlishares">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000141"
      unitRef="U_iso4217USD_xbrlishares">-0.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20181001_20190930"
      decimals="2"
      id="F_000142"
      unitRef="U_iso4217USD_xbrlishares">0.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20171001_20180930"
      decimals="2"
      id="F_000143"
      unitRef="U_iso4217USD_xbrlishares">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000144"
      unitRef="U_xbrlishares">100722224</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000145"
      unitRef="U_xbrlishares">93858857</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000146"
      unitRef="U_xbrlishares">83638469</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000147"
      unitRef="U_xbrlishares">100722224</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000148"
      unitRef="U_xbrlishares">98607815</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000149"
      unitRef="U_xbrlishares">83638469</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000150"
      unitRef="U_iso4217USD">410057</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000151"
      unitRef="U_iso4217USD">-370060</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000152"
      unitRef="U_iso4217USD">-54796</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000153"
      unitRef="U_iso4217USD">-84143169</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000154"
      unitRef="U_iso4217USD">67604789</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000155"
      unitRef="U_iso4217USD">-54505274</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170930"
      decimals="INF"
      id="F_000156"
      unitRef="U_xbrlishares">74785426</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170930"
      decimals="0"
      id="F_000157"
      unitRef="U_iso4217USD">167155</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170930"
      decimals="0"
      id="F_000158"
      unitRef="U_iso4217USD">514037301</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170930"
      decimals="0"
      id="F_000159"
      unitRef="U_iso4217USD">33232</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170930"
      decimals="0"
      id="F_000160"
      unitRef="U_iso4217USD">-432815338</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20170930"
      decimals="0"
      id="F_000161"
      unitRef="U_iso4217USD">-555188</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20170930"
      decimals="0"
      id="F_000162"
      unitRef="U_iso4217USD">80867162</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930"
      decimals="0"
      id="F_000163"
      unitRef="U_iso4217USD">8454607</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000164"
      unitRef="U_iso4217USD">8454607</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930"
      decimals="INF"
      id="F_000165"
      unitRef="U_xbrlishares">604611</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930"
      decimals="0"
      id="F_000166"
      unitRef="U_iso4217USD">605</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930"
      decimals="0"
      id="F_000167"
      unitRef="U_iso4217USD">2656105</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000168"
      unitRef="U_iso4217USD">2656710</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <arwr:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930"
      decimals="INF"
      id="F_000169"
      unitRef="U_xbrlishares">288473</arwr:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <arwr:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930"
      decimals="0"
      id="F_000170"
      unitRef="U_iso4217USD">288</arwr:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <arwr:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930"
      decimals="0"
      id="F_000171"
      unitRef="U_iso4217USD">1237141</arwr:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <arwr:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000172"
      unitRef="U_iso4217USD">1237429</arwr:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930"
      decimals="INF"
      id="F_000173"
      unitRef="U_xbrlishares">1326792</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930"
      decimals="0"
      id="F_000174"
      unitRef="U_iso4217USD">1327</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930"
      decimals="0"
      id="F_000175"
      unitRef="U_iso4217USD">-55995</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000176"
      unitRef="U_iso4217USD">-54668</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930"
      decimals="INF"
      id="F_000177"
      unitRef="U_xbrlishares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171001_20180930"
      decimals="0"
      id="F_000178"
      unitRef="U_iso4217USD">11500</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171001_20180930"
      decimals="0"
      id="F_000179"
      unitRef="U_iso4217USD">56573535</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000180"
      unitRef="U_iso4217USD">56585035</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171001_20180930"
      decimals="0"
      id="F_000181"
      unitRef="U_iso4217USD">-54796</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000182"
      unitRef="U_iso4217USD">-54796</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171001_20180930"
      decimals="0"
      id="F_000183"
      unitRef="U_iso4217USD">-54450478</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000184"
      unitRef="U_iso4217USD">-54450478</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930"
      decimals="INF"
      id="F_000185"
      unitRef="U_xbrlishares">88505302</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930"
      decimals="0"
      id="F_000186"
      unitRef="U_iso4217USD">180875</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180930"
      decimals="0"
      id="F_000187"
      unitRef="U_iso4217USD">582902694</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180930"
      decimals="0"
      id="F_000188"
      unitRef="U_iso4217USD">-21564</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180930"
      decimals="0"
      id="F_000189"
      unitRef="U_iso4217USD">-487265816</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180930"
      decimals="0"
      id="F_000190"
      unitRef="U_iso4217USD">-555188</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20180930"
      decimals="0"
      id="F_000191"
      unitRef="U_iso4217USD">95241001</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930"
      decimals="INF"
      id="F_000192"
      unitRef="U_xbrlishares">88505302</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180930"
      decimals="0"
      id="F_000193"
      unitRef="U_iso4217USD">180875</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180930"
      decimals="0"
      id="F_000194"
      unitRef="U_iso4217USD">582902694</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180930"
      decimals="0"
      id="F_000195"
      unitRef="U_iso4217USD">-21564</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180930"
      decimals="0"
      id="F_000196"
      unitRef="U_iso4217USD">-487265816</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20180930"
      decimals="0"
      id="F_000197"
      unitRef="U_iso4217USD">-555188</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20180930"
      decimals="0"
      id="F_000198"
      unitRef="U_iso4217USD">95241001</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930"
      decimals="0"
      id="F_000199"
      unitRef="U_iso4217USD">12393323</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000200"
      unitRef="U_iso4217USD">12393323</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="INF"
      id="F_000201"
      unitRef="U_xbrlishares">1542795</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="0"
      id="F_000202"
      unitRef="U_iso4217USD">1543</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930"
      decimals="0"
      id="F_000203"
      unitRef="U_iso4217USD">8273867</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000204"
      unitRef="U_iso4217USD">8275410</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="INF"
      id="F_000205"
      unitRef="U_xbrlishares">2197305</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="0"
      id="F_000206"
      unitRef="U_iso4217USD">2197</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930"
      decimals="0"
      id="F_000207"
      unitRef="U_iso4217USD">-2197</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="INF"
      id="F_000208"
      unitRef="U_xbrlishares">3260869</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181001_20190930"
      decimals="0"
      id="F_000209"
      unitRef="U_iso4217USD">3261</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181001_20190930"
      decimals="0"
      id="F_000210"
      unitRef="U_iso4217USD">60518468</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000211"
      unitRef="U_iso4217USD">60521729</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181001_20190930"
      decimals="0"
      id="F_000212"
      unitRef="U_iso4217USD">-370060</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000213"
      unitRef="U_iso4217USD">-370060</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181001_20190930"
      decimals="0"
      id="F_000214"
      unitRef="U_iso4217USD">67974849</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000215"
      unitRef="U_iso4217USD">67974849</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930"
      decimals="INF"
      id="F_000216"
      unitRef="U_xbrlishares">95506271</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930"
      decimals="0"
      id="F_000217"
      unitRef="U_iso4217USD">187876</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930"
      decimals="0"
      id="F_000218"
      unitRef="U_iso4217USD">664086155</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930"
      decimals="0"
      id="F_000219"
      unitRef="U_iso4217USD">-391624</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930"
      decimals="0"
      id="F_000220"
      unitRef="U_iso4217USD">-419290967</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930"
      decimals="0"
      id="F_000221"
      unitRef="U_iso4217USD">-555188</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000222"
      unitRef="U_iso4217USD">244036252</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930"
      decimals="INF"
      id="F_000223"
      unitRef="U_xbrlishares">95506271</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190930"
      decimals="0"
      id="F_000224"
      unitRef="U_iso4217USD">187876</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190930"
      decimals="0"
      id="F_000225"
      unitRef="U_iso4217USD">664086155</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190930"
      decimals="0"
      id="F_000226"
      unitRef="U_iso4217USD">-391624</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190930"
      decimals="0"
      id="F_000227"
      unitRef="U_iso4217USD">-419290967</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20190930"
      decimals="0"
      id="F_000228"
      unitRef="U_iso4217USD">-555188</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000229"
      unitRef="U_iso4217USD">244036252</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930"
      decimals="0"
      id="F_000230"
      unitRef="U_iso4217USD">43382988</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000231"
      unitRef="U_iso4217USD">43382988</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="INF"
      id="F_000232"
      unitRef="U_xbrlishares">1111128</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="0"
      id="F_000233"
      unitRef="U_iso4217USD">1111</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930"
      decimals="0"
      id="F_000234"
      unitRef="U_iso4217USD">7467788</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000235"
      unitRef="U_iso4217USD">7468899</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="INF"
      id="F_000236"
      unitRef="U_xbrlishares">1158904</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="0"
      id="F_000237"
      unitRef="U_iso4217USD">1159</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930"
      decimals="0"
      id="F_000238"
      unitRef="U_iso4217USD">-1159</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="INF"
      id="F_000239"
      unitRef="U_xbrlishares">4600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191001_20200930"
      decimals="0"
      id="F_000240"
      unitRef="U_iso4217USD">4600</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191001_20200930"
      decimals="0"
      id="F_000241"
      unitRef="U_iso4217USD">250474374</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000242"
      unitRef="U_iso4217USD">250478974</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191001_20200930"
      decimals="0"
      id="F_000243"
      unitRef="U_iso4217USD">410057</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000244"
      unitRef="U_iso4217USD">410057</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapNoncontrollingInterestMember_20191001_20200930"
      decimals="0"
      id="F_000245"
      unitRef="U_iso4217USD">555188</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000246"
      unitRef="U_iso4217USD">555188</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191001_20200930"
      decimals="0"
      id="F_000247"
      unitRef="U_iso4217USD">-84553226</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000248"
      unitRef="U_iso4217USD">-84553226</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930"
      decimals="INF"
      id="F_000249"
      unitRef="U_xbrlishares">102376303</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200930"
      decimals="0"
      id="F_000250"
      unitRef="U_iso4217USD">194746</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200930"
      decimals="0"
      id="F_000251"
      unitRef="U_iso4217USD">965410146</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200930"
      decimals="0"
      id="F_000252"
      unitRef="U_iso4217USD">18433</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200930"
      decimals="0"
      id="F_000253"
      unitRef="U_iso4217USD">-503844193</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000254"
      unitRef="U_iso4217USD">461779132</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000255"
      unitRef="U_iso4217USD">-84553226</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000256"
      unitRef="U_iso4217USD">67974849</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000257"
      unitRef="U_iso4217USD">-54450478</us-gaap:ProfitLoss>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000258"
      unitRef="U_iso4217USD">432141</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000259"
      unitRef="U_iso4217USD">43382988</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000260"
      unitRef="U_iso4217USD">12393323</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000261"
      unitRef="U_iso4217USD">8454607</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000262"
      unitRef="U_iso4217USD">5942264</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000263"
      unitRef="U_iso4217USD">4439144</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000264"
      unitRef="U_iso4217USD">4699275</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000265"
      unitRef="U_iso4217USD">-525305</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000266"
      unitRef="U_iso4217USD">-1069070</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000267"
      unitRef="U_iso4217USD">-383075</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000268"
      unitRef="U_iso4217USD">184312</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000269"
      unitRef="U_iso4217USD">333986</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000270"
      unitRef="U_iso4217USD">259578</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000271"
      unitRef="U_iso4217USD">387464</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000272"
      unitRef="U_iso4217USD">3710515</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000273"
      unitRef="U_iso4217USD">-319166</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000274"
      unitRef="U_iso4217USD">-63513696</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000275"
      unitRef="U_iso4217USD">82804171</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000276"
      unitRef="U_iso4217USD">-5269140</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000277"
      unitRef="U_iso4217USD">-821012</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000278"
      unitRef="U_iso4217USD">4843825</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000279"
      unitRef="U_iso4217USD">-1270416</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000280"
      unitRef="U_iso4217USD">1989496</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000281"
      unitRef="U_iso4217USD">2450079</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000282"
      unitRef="U_iso4217USD">1016506</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000283"
      unitRef="U_iso4217USD">2228087</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000284"
      unitRef="U_iso4217USD">1104963</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000285"
      unitRef="U_iso4217USD">-414293</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000286"
      unitRef="U_iso4217USD">-95391570</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000287"
      unitRef="U_iso4217USD">173034923</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000288"
      unitRef="U_iso4217USD">-47223417</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000289"
      unitRef="U_iso4217USD">11951712</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000290"
      unitRef="U_iso4217USD">12001225</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000291"
      unitRef="U_iso4217USD">1421252</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000292"
      unitRef="U_iso4217USD">278964290</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000293"
      unitRef="U_iso4217USD">90266001</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000294"
      unitRef="U_iso4217USD">52083131</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000295"
      unitRef="U_iso4217USD">50138238</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000296"
      unitRef="U_iso4217USD">54521219</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000297"
      unitRef="U_iso4217USD">46069420</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000298"
      unitRef="U_iso4217USD">-240777764</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000299"
      unitRef="U_iso4217USD">-47746007</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000300"
      unitRef="U_iso4217USD">-7434963</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000301"
      unitRef="U_iso4217USD">2415150</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000302"
      unitRef="U_iso4217USD">208506</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000303"
      unitRef="U_iso4217USD">54667</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000304"
      unitRef="U_iso4217USD">7468899</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000305"
      unitRef="U_iso4217USD">8275410</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000306"
      unitRef="U_iso4217USD">3631164</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000307"
      unitRef="U_iso4217USD">250478974</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000308"
      unitRef="U_iso4217USD">60521739</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000309"
      unitRef="U_iso4217USD">56585035</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000310"
      unitRef="U_iso4217USD">257947873</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000311"
      unitRef="U_iso4217USD">66381999</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000312"
      unitRef="U_iso4217USD">59953026</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000313"
      unitRef="U_iso4217USD">-78221461</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000314"
      unitRef="U_iso4217USD">191670915</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000315"
      unitRef="U_iso4217USD">5294646</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000316"
      unitRef="U_iso4217USD">221804128</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20180930"
      decimals="0"
      id="F_000317"
      unitRef="U_iso4217USD">30133213</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20170930"
      decimals="0"
      id="F_000318"
      unitRef="U_iso4217USD">24838567</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000319"
      unitRef="U_iso4217USD">143582667</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000320"
      unitRef="U_iso4217USD">221804128</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0000879407_20180930"
      decimals="0"
      id="F_000321"
      unitRef="U_iso4217USD">30133213</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000322"
      unitRef="U_iso4217USD">27437</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000323"
      unitRef="U_iso4217USD">173381</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000324"
      unitRef="U_iso4217USD">103437</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000325"
      unitRef="U_iso4217USD">-302400</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000326"
      unitRef="U_iso4217USD">-2400</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000327">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 1. &lt;span style="font-style:italic;"&gt;ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Nature of Business and Recent Developments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them.&#160;&#160;Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#x2019;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-LUNG2 as a candidate to treat chronic obstructive pulmonary disorder (&#x201c;COPD&#x201d;) and ARO-COV for treatment for the current novel coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.&lt;span style="font-size:14pt;"&gt; &lt;/span&gt;ARO&lt;span style="color:#000000;"&gt;-JNJ1, ARO-JNJ2 and ARO-JNJ3 are being developed for undisclosed liver-expressed targets under a collaboration agreement with Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;).&#160;&#160;&lt;/span&gt;ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#x201c;AATD&#x201d;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#x201c;Takeda&#x201d;) in October 2020. &lt;span style="color:#000000;"&gt;ARO-HBV (JNJ-3989) for chronic hepatitis B virus was out-licensed to Janssen in October 2018.&#160;&#160;ARO-LPA (AMG 890)&lt;/span&gt;&lt;span style="color:#000000;font-size:8.5pt;"&gt;&lt;sub style="font-size:85%; vertical-align:bottom"&gt;&#160;&lt;/sub&gt;&lt;/span&gt;&lt;span style="color:#000000;"&gt;for cardiovascular disease was out-licensed to Amgen Inc. (&#x201c;Amgen&#x201d;) in 2016.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arrowhead operates a lab facility in Madison, Wisconsin, where the Company&#x2019;s research and development activities, including the development of RNAi therapeutics, are based. The Company&#x2019;s principal executive offices are located in Pasadena, California. &lt;span style="color:#000000;"&gt;In March 2020, the Company entered into a sublease for additional research and development facility space in San Diego, California as discussed further in Note 8 below.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During fiscal year 2020, the Company has continued to develop its pipeline and partnered candidates.&#160;&#160;Regarding the Company&#x2019;s wholly-owned pipeline candidates, the Company dosed its first patients in three of its pipeline candidate studies: ARO-HSD1001, a phase 1/2 clinical study of ARO-HSD; ARO-ENaC1001, a phase 1/2 clinical study of ARO-ENaC and ARO-HIF21001, a phase 1b study of ARO-HIF2. The Company also presented new clinical data on its two cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, at multiple medical meetings, including the European Society of Cardiology Congress and the American Heart Association Scientific Sessions.&#160;&#160;Finally, the Company is also progressing ARO-LUNG2 toward entering clinical trials and is continuing to perform discovery work to identify new candidates. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s &lt;span style="color:#000000;"&gt;partnered candidates under its collaboration agreements also continue to progress.&#160;&#160;Janssen began dosing patients in a phase 2b triple combination study called REEF-1,&#160;designed to enroll up to 450 patients with chronic hepatitis B infection, and in connection with the start of this study Arrowhead earned a&#160; $25.0 million&#160;milestone payment under the License Agreement (&#x201c;Janssen License Agreement&#x201d;).&#160;&#160;The Company is currently performing discovery, optimization and preclinical research and development for ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3 for Janssen as part of the Research Collaboration and Option Agreement (&#x201c;Janssen Collaboration Agreement&#x201d;).&#160;&#160;&lt;/span&gt;Under the terms of the Janssen agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead Common Stock, two $25.0 million milestone payments and may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement.&#160;&#160;The Company is further eligible to receive tiered royalties up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement on product sales.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s collaboration agreement with Amgen for &lt;span style="color:#000000;"&gt;Olpasiran (previously referred to as AMG 890 or ARO-LPA), (the &#x201c;Second Collaboration and License Agreement&#x201d; or &#x201c;Olpasiran Agreement&#x201d;),&lt;/span&gt; continues to progress. &#160;&lt;span style="color:#000000;"&gt;In July 2020, Amgen initiated a Phase 2 clinical study, which resulted in a $20.0 million milestone payment to the Company.&lt;/span&gt;&#160;&#160;The Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#x2019;s Common Stock, $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments.&#160;&#160;The Company is eligible to receive up to&#160;low double-digit royalties for sales of products under the &lt;span style="color:#000000;"&gt;Olpasiran&lt;/span&gt; Agreement.&#160;&#160;&lt;span style="color:#000000;"&gt;On October 7, 2020, the Company entered into an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;) with Takeda.&#160;&#160;Under the Takeda License Agreement, &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Takeda and the Company will co-develop the Company&#x2019;s ARO-AAT program. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to &lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;commercialize ARO-AAT with the Company eligible to receive tiered royalties of &lt;/span&gt;20&lt;span style="Background-color:#FFFFFF;"&gt;%&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt; to &lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;25&lt;/span&gt;&lt;span style="Background-color:#FFFFFF;"&gt;% on net sales.&#160;&#160;The Company will receive $&lt;/span&gt;300.0&lt;span style="Background-color:#FFFFFF;"&gt; million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $&lt;/span&gt;740.0&lt;span style="Background-color:#FFFFFF;"&gt; million.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The revenue recognition for these collaboration agreements is discussed further in Note 2 below.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the year ended September 30, 2020 were not significantly impacted by COVID-19. The Company temporarily paused enrollment in its two ARO-AAT studies, SEQUOIA and the ARO-AAT 2002 study, but resumed the process of screening and enrolling patients during the three months ended June 30, 2020. During the pause in enrollment, patients already enrolled in these studies continued to be dosed per protocol and continued to come in for their follow up visits. Additional delays have occurred in the Company&#x2019;s earlier stage programs, but the Company does not expect a material impact to any program&#x2019;s anticipated timelines. Several of the Company&#x2019;s other clinical candidates are in the start-up stage (ARO-HSD, ARO-HIF2 and ARO-ENaC), during which significant clinical costs will continue to be incurred. Additionally, the Company&#x2019;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued to operate with limited impact, other than for enhanced safety measures, including work from home policies. However, the Company cannot predict the impact of the progression of COVID-19 will have on future financial results due to a variety of factors including the ability of the Company&#x2019;s clinical sites to continue to enroll subjects, the ability of the Company&#x2019;s suppliers to continue to operate, the continued good health and safety of the Company&#x2019;s employees, and ultimately the length of the COVID-19 pandemic.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Liquidity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Consolidated Financial Statements have been prepared in conformity with the accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;), which contemplate the continuation of the Company as a going concern.&#160; Historically, the Company&#x2019;s primary source of financing has been through the sale of its securities. Research and development activities have required significant capital investment since the Company&#x2019;s inception. The Company expects its operations to continue to require cash investment to pursue its research and development goals, including clinical trials and related drug manufacturing.&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At September 30, 2020, the Company had $143.6 million in cash and cash equivalents (including $1.8 million in restricted cash), $86.9 million in short-term investments and $85.0 million in marketable securities, and $137.5 million in long-term investments to fund operations.&#160;&#160;During the year ended September 30, 2020, the Company&#x2019;s cash and investments balance increased by $150.1 million, which was primarily the result of purchases of investments and marketable securities of $279.0 million and cash outflow primarily related to operations of $95.4 million, partially offset by the December 2019 securities offering that generated $250.5 million in net cash proceeds for the Company, as discussed further in Note 6 below, as well as maturities of investments of $50.1 million. &#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Summary of Significant Accounting Policies &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&#x2014;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#x2019;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#x2019;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation and Use of Estimates&#x2014;The &lt;span style="color:#000000;"&gt;preparation of financial statements in conformity GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation&lt;/span&gt;.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&#x2014;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $1.8 million and $1.0 restricted cash at September 30, 2020 and September 30, 2019, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#x2019;s &lt;span style="color:#000000;"&gt;lease for its corporate headquarters in Pasadena, California.&lt;/span&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&#x2014;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments&#x2014;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 320, Investments &#x2013; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-Maturity&#x2014;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trading Securities&#x2014;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-Sale&#x2014;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&#x2019; equity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2020, 2019 and 2018, all of the Company&#x2019;s debt securities were classified as held-to-maturity.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-maturity investments are measured and recorded at amortized cost on the Company&#x2019;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended September 30, 2020, the Company purchased shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#x2019;s Consolidated Balance Sheet as &#x201c;marketable securities&#x201d; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#x2019;s Consolidated Statement of Operations and Comprehensive Income (Loss). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment&#x2014;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets Subject to Amortization&#x2014;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&#x2014;The consideration for the Company&#x2019;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $0 at September 30, 2020 and September 30, 2019. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&#x2014; &lt;span style="color:#000000;"&gt;On October 1, 2018, the Company adopted FASB Topic 606 &#x2013; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#x2019;s adoption of the new revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#x2019;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, and Takeda and the analysis of the impact of this guidance on those agreements is discussed further in Note 2 below.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The new revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the new revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Typically, the Company&#x2019;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#x201c;CTA&#x201d;) or a New Drug Application (&#x201c;NDA&#x201d;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#x2019;s Consolidated Statement of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#x2019;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#x2019;s performance obligations have been completed&#160;&#160;are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The new revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The new revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the new revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Whenever the Company determines that &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;goods or services promised in a contract&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; should be accounted for as a &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;combined performance obligation over time&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the proportional performance method&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Labor hours&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; or costs incurred&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; are typically used as the measure of performance.&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; If the &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company determines that&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; the performance &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;obligation is satisfied over time, any upfront&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; payment &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;received is initially recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;as &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;deferred&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;on the Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Consolidated Balance Sheets&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#x2019;s current operating plan and, if the Company&#x2019;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allowance for Doubtful Accounts&#x2014;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development&#x2014;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#x2019;s research and development operations, and costs to acquire technology licenses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per Share&#x2014;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees.&#160;&#160;During the years ended September 30, 2020, 2019 and 2018, the calculation of the effect of dilutive stock options and restricted stock units was 0 shares, 4,748,958 shares, and 0 shares, respectively.&#160;&#160;During the year ended September 30, 2020,&lt;span style="color:#000000;"&gt; the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2019, the calculation of the effect of dilutive stock options and restricted stock units excluded 1,007,500 stock options and 11,500 restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2018, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&#x2014;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#x2019;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#x2019;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#x2019;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income Taxes&#x2014;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;span style="color:#000000;"&gt;&#x2014;&lt;/span&gt;The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term.&#160;Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and became effective for the Company in the first quarter of fiscal 2019. In April 2016, the FASB issued an amendment to ASU No. 2014-09 with update ASU 2016-10 which provided more specific guidance around the identification of performance obligations and licensing arrangements.&#160;&#160;On October 1, 2018, the Company adopted this standard using the modified retrospective method. The Company&#x2019;s implementation approach included reviewing the status of each of its ongoing license agreements and collaboration agreements and designing appropriate internal controls to enable the preparation of financial information.&#160;&#160;The Company completed its assessment of the impact of the new revenue recognition guidance and determined that there will be no material impact.&#160;&#160;The Company&#x2019;s existing performance obligations under its ongoing license and collaboration agreements as of October 1, 2018 and prior were substantially completed prior to September 30, 2018.&#160;&#160;For these agreements that were ongoing as of October 1, 2018, any future option, milestone or royalty payments received will be accounted for under the sales-based royalty exception provided for under this new revenue recognition guidance.&#160;&#160;Additionally, there will be no impact to cash from or used in operating, financing or investing activities on the Company&#x2019;s Consolidated Statement of Cash Flows as a result of the adoption of the new standard.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842).&#160;&#160;Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&#160;&#160;The Company adopted this standard effective October 1, 2019 and &lt;span style="color:#000000;"&gt;elected the package of three practical expedients that permits an entity to i) not reassess whether expired or existing contracts contain leases, ii) not reassess lease classification for existing or expired leases, and iii) not consider whether previously capitalized initial direct costs would be appropriate under the new standard.&#160;&#160;At September 30, 2020, the Company has recorded right-of-use assets of $16.1 million and right-of-use liabilities of $21.1 million on its Consolidated Balance Sheets for its research and development facility leases in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below.&#160;&#160;The adoption of this standard did not have a material impact on the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Income (Loss) and the Company&#x2019;s Consolidated Statements of Cash Flows.&#160;&#160; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808).&#160;&#160;This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 becomes effective for the Company in the first quarter of fiscal 2021 with early adoption permitted.&#160;&#160;The Company does not expect the adoption of this update to have a material effect on its Consolidated Financial Statements. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <arwr:MilestonePaymentEarned
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930"
      decimals="-5"
      id="F_000370"
      unitRef="U_iso4217USD">25000000.0</arwr:MilestonePaymentEarned>
    <arwr:CashReceivedAsDueUnderAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003"
      decimals="-5"
      id="F_000371"
      unitRef="U_iso4217USD">175000000.0</arwr:CashReceivedAsDueUnderAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003"
      decimals="-5"
      id="F_000372"
      unitRef="U_iso4217USD">75000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentEarned
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003"
      decimals="-5"
      id="F_000373"
      unitRef="U_iso4217USD">25000000.0</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003"
      decimals="INF"
      id="F_000374"
      unitRef="U_iso4217USD">1600000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003"
      decimals="INF"
      id="F_000375"
      unitRef="U_iso4217USD">1900000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003_20181003"
      decimals="INF"
      id="F_000376"
      unitRef="U_arwrTarget">3</arwr:NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments>
    <arwr:MilestonePaymentEarned
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20200731"
      decimals="-5"
      id="F_000377"
      unitRef="U_iso4217USD">20000000.0</arwr:MilestonePaymentEarned>
    <arwr:CashReceivedAsDueUnderAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928"
      decimals="-5"
      id="F_000378"
      unitRef="U_iso4217USD">35000000.0</arwr:CashReceivedAsDueUnderAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928"
      decimals="-5"
      id="F_000379"
      unitRef="U_iso4217USD">21500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentReceived
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20160928"
      decimals="-5"
      id="F_000380"
      unitRef="U_iso4217USD">30000000.0</arwr:MilestonePaymentReceived>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20200930"
      decimals="INF"
      id="F_000381"
      unitRef="U_iso4217USD">400000000.0</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:ProfitSharingStructureRatio
      contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201007"
      decimals="INF"
      id="F_000382"
      unitRef="U_xbrlipure">0.50</arwr:ProfitSharingStructureRatio>
    <arwr:TieredRoyaltiesReceivedPercentage
      contextRef="C_0000879407_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007"
      decimals="INF"
      id="F_000383"
      unitRef="U_xbrlipure">0.20</arwr:TieredRoyaltiesReceivedPercentage>
    <arwr:TieredRoyaltiesReceivedPercentage
      contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007"
      decimals="INF"
      id="F_000384"
      unitRef="U_xbrlipure">0.25</arwr:TieredRoyaltiesReceivedPercentage>
    <arwr:CashReceivedAsDueUnderAgreement
      contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201006_20201007"
      decimals="-5"
      id="F_000385"
      unitRef="U_iso4217USD">300000000.0</arwr:CashReceivedAsDueUnderAgreement>
    <arwr:DevelopmentRegulatoryAndCommercialMilestonesPayments
      contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_20201007"
      decimals="-5"
      id="F_000386"
      unitRef="U_iso4217USD">740000000.0</arwr:DevelopmentRegulatoryAndCommercialMilestonesPayments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000387"
      unitRef="U_iso4217USD">143600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000388"
      unitRef="U_iso4217USD">1800000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000389"
      unitRef="U_iso4217USD">86900000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:MarketableSecurities
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000390"
      unitRef="U_iso4217USD">85000000.0</us-gaap:MarketableSecurities>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000391"
      unitRef="U_iso4217USD">137500000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:IncreaseDecreaseInCashAndInvestments
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000392"
      unitRef="U_iso4217USD">150100000</arwr:IncreaseDecreaseInCashAndInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000393"
      unitRef="U_iso4217USD">279000000.0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000394"
      unitRef="U_iso4217USD">-95400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_20191201_20191231"
      decimals="-5"
      id="F_000395"
      unitRef="U_iso4217USD">250500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000396"
      unitRef="U_iso4217USD">50100000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000341">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&#x2014;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#x2019;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#x2019;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. &lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <arwr:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000342">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basis of Presentation and Use of Estimates&#x2014;The &lt;span style="color:#000000;"&gt;preparation of financial statements in conformity GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation&lt;/span&gt;.&#160;&#160; &lt;/p&gt;</arwr:BasisOfPresentationAndUseOfEstimatesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_0000879407_20191001_20200930" id="F_000343">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&#x2014;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $1.8 million and $1.0 restricted cash at September 30, 2020 and September 30, 2019, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#x2019;s &lt;span style="color:#000000;"&gt;lease for its corporate headquarters in Pasadena, California.&lt;/span&gt;&#160;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000397"
      unitRef="U_iso4217USD">1800000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_0000879407_20190930"
      decimals="-5"
      id="F_000398"
      unitRef="U_iso4217USD">1000000.0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0000879407_20191001_20200930" id="F_000344">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&#x2014;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_20200930"
      decimals="INF"
      id="F_000399"
      unitRef="U_iso4217USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:InvestmentPolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000345">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments&#x2014;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 320, Investments &#x2013; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-Maturity&#x2014;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Trading Securities&#x2014;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-Sale&#x2014;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&#x2019; equity. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2020, 2019 and 2018, all of the Company&#x2019;s debt securities were classified as held-to-maturity.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Held-to-maturity investments are measured and recorded at amortized cost on the Company&#x2019;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the year ended September 30, 2020, the Company purchased shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#x2019;s Consolidated Balance Sheet as &#x201c;marketable securities&#x201d; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#x2019;s Consolidated Statement of Operations and Comprehensive Income (Loss). &lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000346">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and Equipment&#x2014;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000879407_srtRangeAxis_srtMinimumMember_20191001_20200930"
      id="F_000400">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_20191001_20200930"
      id="F_000401">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000347">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets Subject to Amortization&#x2014;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. &lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <arwr:ContingentConsiderationPolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000348">
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&#x2014;The consideration for the Company&#x2019;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $0 at September 30, 2020 and September 30, 2019. &lt;/p&gt;</arwr:ContingentConsiderationPolicyTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="-6"
      id="F_000402"
      unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0000879407_20190930"
      decimals="-6"
      id="F_000403"
      unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000349">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&#x2014; &lt;span style="color:#000000;"&gt;On October 1, 2018, the Company adopted FASB Topic 606 &#x2013; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#x2019;s adoption of the new revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#x2019;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, and Takeda and the analysis of the impact of this guidance on those agreements is discussed further in Note 2 below.&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The new revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the new revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Typically, the Company&#x2019;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#x201c;CTA&#x201d;) or a New Drug Application (&#x201c;NDA&#x201d;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#x2019;s Consolidated Statement of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#x2019;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#x2019;s performance obligations have been completed&#160;&#160;are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The new revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The new revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the new revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Whenever the Company determines that &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;goods or services promised in a contract&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; should be accounted for as a &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;combined performance obligation over time&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the proportional performance method&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. Labor hours&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; or costs incurred&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; are typically used as the measure of performance.&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; If the &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Company determines that&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; the performance &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;obligation is satisfied over time, any upfront&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; payment &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;received is initially recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;as &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;deferred&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; revenue &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;on the Company&#x2019;s&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Consolidated Balance Sheets&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#x2019;s current operating plan and, if the Company&#x2019;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="C_0000879407_20191001_20200930" id="F_000350">Allowance for Doubtful Accounts&#x2014;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0000879407_20191001_20200930" id="F_000351">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and Development&#x2014;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#x2019;s research and development operations, and costs to acquire technology licenses.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000352">Net Income (Loss) per Share&#x2014;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees.&#160;&#160;During the years ended September 30, 2020, 2019 and 2018, the calculation of the effect of dilutive stock options and restricted stock units was 0 shares, 4,748,958 shares, and 0 shares, respectively.&#160;&#160;During the year ended September 30, 2020,&lt;span style="color:#000000;"&gt; the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2019, the calculation of the effect of dilutive stock options and restricted stock units excluded 1,007,500 stock options and 11,500 restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2018, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000404"
      unitRef="U_xbrlishares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_0000879407_20181001_20190930"
      decimals="INF"
      id="F_000405"
      unitRef="U_xbrlishares">4748958</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_0000879407_20180101_20181231"
      decimals="INF"
      id="F_000406"
      unitRef="U_xbrlishares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20181001_20190930"
      decimals="0"
      id="F_000407"
      unitRef="U_xbrlishares">1007500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0000879407_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930"
      decimals="0"
      id="F_000408"
      unitRef="U_xbrlishares">11500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0000879407_20191001_20200930" id="F_000353">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&#x2014;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#x2019;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#x2019;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#x2019;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000354">Income Taxes&#x2014;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000355">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;span style="color:#000000;"&gt;&#x2014;&lt;/span&gt;The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term.&#160;Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. &lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000356">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and became effective for the Company in the first quarter of fiscal 2019. In April 2016, the FASB issued an amendment to ASU No. 2014-09 with update ASU 2016-10 which provided more specific guidance around the identification of performance obligations and licensing arrangements.&#160;&#160;On October 1, 2018, the Company adopted this standard using the modified retrospective method. The Company&#x2019;s implementation approach included reviewing the status of each of its ongoing license agreements and collaboration agreements and designing appropriate internal controls to enable the preparation of financial information.&#160;&#160;The Company completed its assessment of the impact of the new revenue recognition guidance and determined that there will be no material impact.&#160;&#160;The Company&#x2019;s existing performance obligations under its ongoing license and collaboration agreements as of October 1, 2018 and prior were substantially completed prior to September 30, 2018.&#160;&#160;For these agreements that were ongoing as of October 1, 2018, any future option, milestone or royalty payments received will be accounted for under the sales-based royalty exception provided for under this new revenue recognition guidance.&#160;&#160;Additionally, there will be no impact to cash from or used in operating, financing or investing activities on the Company&#x2019;s Consolidated Statement of Cash Flows as a result of the adoption of the new standard.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842).&#160;&#160;Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&#160;&#160;The Company adopted this standard effective October 1, 2019 and &lt;span style="color:#000000;"&gt;elected the package of three practical expedients that permits an entity to i) not reassess whether expired or existing contracts contain leases, ii) not reassess lease classification for existing or expired leases, and iii) not consider whether previously capitalized initial direct costs would be appropriate under the new standard.&#160;&#160;At September 30, 2020, the Company has recorded right-of-use assets of $16.1 million and right-of-use liabilities of $21.1 million on its Consolidated Balance Sheets for its research and development facility leases in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below.&#160;&#160;The adoption of this standard did not have a material impact on the Company&#x2019;s Consolidated Statements of Operations and Comprehensive Income (Loss) and the Company&#x2019;s Consolidated Statements of Cash Flows.&#160;&#160; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808).&#160;&#160;This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 becomes effective for the Company in the first quarter of fiscal 2021 with early adoption permitted.&#160;&#160;The Company does not expect the adoption of this update to have a material effect on its Consolidated Financial Statements. &lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20200930"
      id="F_000410">2018-10-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0000879407_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20200930"
      id="F_000415">2019-10-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000412"
      unitRef="U_iso4217USD">16100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000413"
      unitRef="U_iso4217USD">21100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000328">
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 2. &lt;span style="font-style:italic;"&gt;COLLABORATION AND LICENSE AGREEMENTS&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Amgen Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September&#160;28, 2016, the Company entered into two Collaboration and License Agreements, and a Common Stock Purchase Agreement with Amgen Inc., a Delaware corporation (&#x201c;Amgen&#x201d;). Under one of the collaboration and license agreements (the &#x201c;Second Collaboration and License Agreement&#x201d; or &#x201c;Olpasiran Agreement&#x201d;), Amgen has received a worldwide, exclusive license to Arrowhead&#x2019;s novel, RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the other collaboration and license agreement (the &#x201c;First Collaboration and License Agreement&#x201d; or the &#x201c;ARO-AMG1 Agreement&#x201d;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#x2019;s Common Stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement.&#160;&#160;&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement.&#160;&#160;Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study, which resulted in a $20 million milestone payment to the Company. During the years ended September 30, 2020, 2019 and 2018, the Company recognized $20.1 million, $0.3 million, and $16.1 million of Revenue associated with its agreements with Amgen, respectively.  As of September 30, 2020, there were $0 million in contract assets recorded as accounts receivable and $0 contract liabilities recorded as current deferred revenue on the Company&#x2019;s Consolidated Balance Sheets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Janssen Pharmaceuticals, Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 3, 2018, the Company entered into a License Agreement (&#x201c;Janssen License Agreement&#x201d;) and a Research Collaboration and Option Agreement (&#x201c;Janssen Collaboration Agreement&#x201d;) with Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;) part of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson.&#160;&#160;The Company also entered into a Stock Purchase Agreement (&#x201c;JJDC Stock Purchase Agreement&#x201d;) with Johnson &amp;amp; Johnson Innovation-JJDC, Inc. (&#x201c;JJDC&#x201d;), a New Jersey corporation.&#160;&#160;Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#x2019;s JNJ-3989 (ARO-HBV) program, the Company&#x2019;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#x2019;s Phase 1/2 study of JNJ-3989 (ARO-HBV), Janssen is also wholly responsible for clinical development and commercialization of JNJ-3989.&#160;&#160;Under the Janssen Collaboration Agreement, Janssen will be able to select three new targets against which Arrowhead will develop clinical candidates.&#160;&#160;These candidates are subject to certain restrictions and do not include candidates that already were in the Company&#x2019;s pipeline.&#160;&#160;The Company will perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, is sufficient to allow the filing of a U.S. Investigational New Drug application or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned candidate.&#160;&#160;Under the terms of the agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment &lt;span style="color:#000000;"&gt;by JJDC in Arrowhead Common Stock under the JJDC &lt;/span&gt;Stock Purchase Agreement, and two $25.0 million milestone payments, and may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement.&#160;&#160;The Company is further eligible to receive tiered royalties up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement on product sales.&#160;&#160; &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated these agreements in accordance with the new revenue recognition standard that became effective for the Company on October 1, 2018.&#160;&#160;The adoption of the new revenue standard did not have a material impact on the balances reported when evaluated under the superseded revenue standard.&#160;&#160;At the inception of these agreements, the Company has identified one distinct performance obligation.&#160;&#160;Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#x2019;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#x201c;Janssen R&amp;amp;D Services&#x201d;).&#160;&#160;Due to the specialized and unique nature of these Janssen R&amp;amp;D Services, and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and thus, one performance obligation.&#160;&#160;The Company also determined that Janssen&#x2019;s option to require the Company to develop up to three new targets is not a material right, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for this option will be accounted for if and when it is exercised. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined the transaction price totaled approximately $252.6 million which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, the two $25.0 million milestone payments earned and estimated payments for reimbursable Janssen R&amp;amp;D services to be performed.&#160;&#160;The Company has allocated the total $252.6 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;amp;D Services.&#160;&#160;This revenue will be recognized using a proportional performance method (based on actual labor hours versus estimated total labor hours) beginning in October 2018 and ending as the Company&#x2019;s efforts in overseeing the phase 1/2 clinical trial are completed.&#160;&#160;During the years ended September 30, 2020 and 2019, the Company recognized approximately $65.0 million and $167.5 million of Revenue associated with this performance obligation, respectively. As of September 30, 2020, there were $0 in contract assets recorded as accounts receivable, and $19.3 million of contract liabilities recorded as current deferred revenue on the Company&#x2019;s Consolidated Balance Sheets.&#160;&#160;The $19.3 million of current deferred revenue is driven by the upfront payment, the premium paid by JJDC for its equity investment in the Company, and the two $25.0 million milestone payments earned, net of revenue recognized to date.&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has begun to conduct its discovery, optimization and preclinical research and development of ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3 under the Janssen Collaboration Agreement.&#160;&#160;All costs and labor hours spent by the Company will be entirely funded by Janssen.&#160; During the years ended September 30, 2020 and 2019, the Company recognized $2.9 million and $1.0 million of Revenue associated with these efforts, respectively. As of September 30, 2020, there were $0.8 million of cont&lt;span style="color:#000000;"&gt;ract assets recorded as accounts &lt;/span&gt;receivable, and $0 of contract liabilities recorded as curren&lt;span style="color:#000000;"&gt;t deferred revenue on the Company&#x2019;s Consolidated Balance&lt;/span&gt; Sheets.&#160; &lt;span style="color:#000000;"&gt; &#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Takeda Pharmaceuticals U.S.A., Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 7, 2020, the Company entered into an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;) with Takeda Pharmaceuticals U.S.A., Inc. (&#x201c;Takeda&#x201d;).&#160;&#160;Under the Takeda License Agreement, &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Takeda and the Company will co-develop the Company&#x2019;s ARO-AAT program, the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with the Company eligible to receive tiered royalties of 20% to 25% on net sales.&#160;&#160;The Company will receive $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.&lt;/span&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has evaluated the Takeda License Agreement in accordance with the new revenue recognition requirements that became effective for the Company on October 1, 2018. The adoption of the new revenue standard will not have a material impact on the balances reported when evaluated under the superseded revenue standard.&#160;&#160;At the inception of the Takeda License Agreement, the Company has identified one distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#x201c;Takeda R&amp;amp;D Services&#x201d;).&#160;&#160;Due to the specialized and unique nature of these Takeda R&amp;amp;D services, and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and thus, one performance obligation.&#160;&#160;Beyond the Takeda R&amp;amp;D Services, Takeda will be responsible for managing future clinical development and commercialization.&#160;&#160;The Company will co-fund certain of the development and commercialization costs that Takeda manages, and these co-funding amounts will be offset against amounts owed to Arrowhead, either from milestones or royalties earned, or profits earned under the 50/50 profit sharing structure for U.S. commercialization. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined the initial transaction price totaled approximately $300.0 million which includes the upfront payment.&#160;&#160;The Company will exclude any future estimated milestones, royalties or profit-sharing payments from this transaction price to date.&#160;&#160;The Company will allocate the total $300.0 million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;amp;D Services.&#160;&#160;This revenue will be recognized using a proportional performance method (based on actual costs incurred versus estimated total estimated costs incurred for the Takeda R&amp;amp;D Services) beginning in the Company&#x2019;s first fiscal quarter of fiscal 2021 and ending as the Takeda R&amp;amp;D Services are completed.&#160;&#160;&lt;span style="font-size:12pt;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928"
      id="F_000419">2016-09-28</arwr:AgreementDate>
    <arwr:NumberOfAgreements
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160928"
      decimals="INF"
      id="F_000420"
      unitRef="U_arwrAgreement">2</arwr:NumberOfAgreements>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928"
      decimals="-5"
      id="F_000421"
      unitRef="U_iso4217USD">35000000.0</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrLicenseCollaborationAndStockPurchaseAgreementMember_20160927_20160928"
      decimals="-5"
      id="F_000422"
      unitRef="U_iso4217USD">21500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentReceived
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20160928"
      decimals="INF"
      id="F_000423"
      unitRef="U_iso4217USD">30000000.0</arwr:MilestonePaymentReceived>
    <arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAgreementMember_20200930"
      decimals="INF"
      id="F_000424"
      unitRef="U_iso4217USD">400000000.0</arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:MilestonePaymentReceived
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200731"
      decimals="-6"
      id="F_000425"
      unitRef="U_iso4217USD">20000000</arwr:MilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20191001_20200930"
      decimals="-5"
      id="F_000426"
      unitRef="U_iso4217USD">20100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20181001_20190930"
      decimals="-5"
      id="F_000427"
      unitRef="U_iso4217USD">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20180101_20181231"
      decimals="-5"
      id="F_000428"
      unitRef="U_iso4217USD">16100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200930"
      decimals="-6"
      id="F_000433"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrOlpasiranAndAROAMG1AgreementMember_20200930"
      decimals="-6"
      id="F_000432"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003_20181003"
      id="F_000434">2018-10-03</arwr:AgreementDate>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003"
      id="F_000435">2018-10-03</arwr:AgreementDate>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003"
      id="F_000436">2018-10-03</arwr:AgreementDate>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003"
      decimals="-5"
      id="F_000438"
      unitRef="U_iso4217USD">175000000.0</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJohnsonAndJohnsonInnovationJJDCIncorporationMember_us-gaapSubsidiarySaleOfStockAxis_arwrCommonStockPurchaseAgreementMember_20181003_20181003"
      decimals="-5"
      id="F_000437"
      unitRef="U_iso4217USD">75000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentEarned
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003"
      decimals="-5"
      id="F_000442"
      unitRef="U_iso4217USD">25000000.0</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrLicenseAgreementMember_20181003"
      decimals="INF"
      id="F_000439"
      unitRef="U_iso4217USD">1600000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAgreementMember_20181003"
      decimals="INF"
      id="F_000440"
      unitRef="U_iso4217USD">1900000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrResearchCollaborationAndOptionAgreementMember_20181003_20181003"
      decimals="INF"
      id="F_000441"
      unitRef="U_arwrTarget">3</arwr:NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003_20181003"
      decimals="INF"
      id="F_000443"
      unitRef="U_arwrObligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice
      contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003"
      decimals="-5"
      id="F_000444"
      unitRef="U_iso4217USD">252600000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181003"
      decimals="-5"
      id="F_000446"
      unitRef="U_iso4217USD">25000000.0</arwr:MilestonePaymentEarned>
    <arwr:InitialTransactionPrice
      contextRef="C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003"
      decimals="-5"
      id="F_000445"
      unitRef="U_iso4217USD">252600000</arwr:InitialTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20191001_20200930"
      decimals="-5"
      id="F_000447"
      unitRef="U_iso4217USD">65000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20181001_20190930"
      decimals="-5"
      id="F_000448"
      unitRef="U_iso4217USD">167500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930"
      decimals="0"
      id="F_000449"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930"
      decimals="-5"
      id="F_000450"
      unitRef="U_iso4217USD">19300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930"
      decimals="-5"
      id="F_000451"
      unitRef="U_iso4217USD">19300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:MilestonePaymentEarned
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrJNJ3989AROHBVAgreementMember_20200930"
      decimals="-5"
      id="F_000452"
      unitRef="U_iso4217USD">25000000.0</arwr:MilestonePaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20191001_20200930"
      decimals="-5"
      id="F_000453"
      unitRef="U_iso4217USD">2900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20181001_20190930"
      decimals="-5"
      id="F_000454"
      unitRef="U_iso4217USD">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20200930"
      decimals="-5"
      id="F_000455"
      unitRef="U_iso4217USD">800000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0000879407_deiLegalEntityAxis_arwrJanssenPharmaceuticalsIncorporationMember_us-gaapTypeOfArrangementAxis_arwrAROJNJ1Member_20200930"
      decimals="-6"
      id="F_000456"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      id="F_000457">2020-10-07</arwr:AgreementDate>
    <arwr:RatioOfProfitSharingStructureForCommercialization
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      id="F_000458">50/50 profit sharing</arwr:RatioOfProfitSharingStructureForCommercialization>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMinimumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="2"
      id="F_000459"
      unitRef="U_xbrlipure">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="2"
      id="F_000460"
      unitRef="U_xbrlipure">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007"
      decimals="-5"
      id="F_000461"
      unitRef="U_iso4217USD">300000000.0</arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007"
      decimals="-5"
      id="F_000462"
      unitRef="U_iso4217USD">740000000.0</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="INF"
      id="F_000464"
      unitRef="U_arwrObligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:NumberOfDistinctBundle
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="INF"
      id="F_000463"
      unitRef="U_arwrBundle">1</arwr:NumberOfDistinctBundle>
    <arwr:RatioOfProfitSharingStructureForCommercialization
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      id="F_000465">50/50 profit sharing</arwr:RatioOfProfitSharingStructureForCommercialization>
    <arwr:InitialTransactionPrice
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="-5"
      id="F_000466"
      unitRef="U_iso4217USD">300000000.0</arwr:InitialTransactionPrice>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000329">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 3. &lt;span style="font-style:italic;"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment:&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers, office equipment and furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;661,927&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;637,577&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,654,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,932,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;631,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;147,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,237,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,579,415&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,185,305&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,296,550&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,304,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,081,651&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,880,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,214,899&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expense for property and equipment for the years ended September 30, 2020, 2019, and 2018  was $4,241,834 and $2,738,715, and $2,998,846 respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000357">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment:&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computers, office equipment and furniture&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;661,927&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;637,577&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,654,323&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,932,304&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;631,204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;147,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,237,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,579,415&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,185,305&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;35,296,550&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,304,437&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,081,651&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,880,868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,214,899&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000467"
      unitRef="U_iso4217USD">661927</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000468"
      unitRef="U_iso4217USD">637577</us-gaap:FurnitureAndFixturesGross>
    <arwr:ResearchEquipmentGross
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000469"
      unitRef="U_iso4217USD">20654323</arwr:ResearchEquipmentGross>
    <arwr:ResearchEquipmentGross
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000470"
      unitRef="U_iso4217USD">12932304</arwr:ResearchEquipmentGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000471"
      unitRef="U_iso4217USD">631204</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:CapitalizedComputerSoftwareGross
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000472"
      unitRef="U_iso4217USD">147254</us-gaap:CapitalizedComputerSoftwareGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000473"
      unitRef="U_iso4217USD">25237851</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000474"
      unitRef="U_iso4217USD">21579415</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000475"
      unitRef="U_iso4217USD">47185305</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000476"
      unitRef="U_iso4217USD">35296550</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000477"
      unitRef="U_iso4217USD">16304437</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000478"
      unitRef="U_iso4217USD">12081651</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000479"
      unitRef="U_iso4217USD">30880868</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000480"
      unitRef="U_iso4217USD">23214899</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000481"
      unitRef="U_iso4217USD">4241834</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000482"
      unitRef="U_iso4217USD">2738715</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000483"
      unitRef="U_iso4217USD">2998846</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000330">
&lt;p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 4. &lt;span style="font-style:italic;"&gt;INVESTMENTS&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Investments at September 30, 2020 primarily consist of corporate bonds that have maturities of less than 36 months and marketable equity securities. The Company&#x2019;s corporate bonds consists of both short-term and long-term bonds and are classified as &#x201c;held-to-maturity&#x201d; on the Company&#x2019;s Consolidated Balance Sheets. The Company&#x2019;s marketable equity securities consist of mutual funds that invests in U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities. Dividends from these three funds are automatically reinvested.&#160;&#160;The Company may also invest excess cash balances in certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper.&#160;&#160;The Company accounts for its held to maturity investments in accordance with FASB ASC 320, Investments &#x2013; Debt and Equity Securities and its marketable equity securities in accordance with ASC 321, Investments &#x2013; Equity Securities.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the Company&#x2019;s short-term, long-term investments and marketable securities as of September 30, 2020 and September 30, 2019 by measurement category. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Held to Maturity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,889,751&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,589,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,479,624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one through three years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137,486,883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,573,964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,981,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224,376,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,163,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,461,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,899,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222,584&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,122,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one through three years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,175,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;875,258&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,051,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,075,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,097,842&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,173,729&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized Gains/(Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75,015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,019,719&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75,015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,019,719&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000358">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables summarize the Company&#x2019;s short-term, long-term investments and marketable securities as of September 30, 2020 and September 30, 2019 by measurement category. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Held to Maturity&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;86,889,751&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,589,873&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,479,624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one through three years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137,486,883&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,573,964&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,981,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;224,376,634&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,163,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(79,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,461,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one year)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36,899,894&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;222,584&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,122,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial notes (due within one through three years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,175,993&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;875,258&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,051,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,075,887&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,097,842&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;82,173,729&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realized Gains/(Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75,015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,019,719&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,000,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;94,734&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(75,015&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,019,719&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930"
      decimals="0"
      id="F_000484"
      unitRef="U_iso4217USD">86889751</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930"
      decimals="0"
      id="F_000487"
      unitRef="U_iso4217USD">1589873</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20200930"
      decimals="0"
      id="F_000492"
      unitRef="U_iso4217USD">88479624</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930"
      decimals="0"
      id="F_000485"
      unitRef="U_iso4217USD">137486883</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930"
      decimals="0"
      id="F_000488"
      unitRef="U_iso4217USD">4573964</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930"
      decimals="0"
      id="F_000490"
      unitRef="U_iso4217USD">79471</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20200930"
      decimals="0"
      id="F_000493"
      unitRef="U_iso4217USD">141981376</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000486"
      unitRef="U_iso4217USD">224376634</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000489"
      unitRef="U_iso4217USD">6163837</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000491"
      unitRef="U_iso4217USD">79471</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000494"
      unitRef="U_iso4217USD">230461000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20190930"
      decimals="0"
      id="F_000495"
      unitRef="U_iso4217USD">36899894</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20190930"
      decimals="0"
      id="F_000498"
      unitRef="U_iso4217USD">222584</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneYearMember_20190930"
      decimals="0"
      id="F_000501"
      unitRef="U_iso4217USD">37122478</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20190930"
      decimals="0"
      id="F_000496"
      unitRef="U_iso4217USD">44175993</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20190930"
      decimals="0"
      id="F_000499"
      unitRef="U_iso4217USD">875258</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrCommercialNotesDueWithinOneThroughThreeYearsMember_20190930"
      decimals="0"
      id="F_000502"
      unitRef="U_iso4217USD">45051251</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000497"
      unitRef="U_iso4217USD">81075887</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000500"
      unitRef="U_iso4217USD">1097842</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000503"
      unitRef="U_iso4217USD">82173729</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930"
      decimals="0"
      id="F_000504"
      unitRef="U_iso4217USD">85000000</us-gaap:EquitySecuritiesFvNiCost>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930"
      decimals="0"
      id="F_000506"
      unitRef="U_iso4217USD">94734</arwr:EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930"
      decimals="0"
      id="F_000508"
      unitRef="U_iso4217USD">75015</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_0000879407_us-gaapFinancialInstrumentAxis_arwrMarketableSecuritiesMember_20200930"
      decimals="0"
      id="F_000510"
      unitRef="U_iso4217USD">85019719</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000505"
      unitRef="U_iso4217USD">85000000</us-gaap:EquitySecuritiesFvNiCost>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000507"
      unitRef="U_iso4217USD">94734</arwr:EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax>
    <arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000509"
      unitRef="U_iso4217USD">75015</arwr:EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000511"
      unitRef="U_iso4217USD">85019719</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000331">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 5. &lt;span style="font-style:italic;"&gt;INTANGIBLE ASSETS&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was 21 years, and the accumulated amortization of the asset is $828,596.&#160;&#160;The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was 14 years, and the accumulated amortization of the assets is $8,665,466.&#160;&#160;Amortization expense for the years ended September 30, 2020, 2019, and 2018 was $1,700,429, $1,700,430, and $1,700,429, respectively. Amortization expense is expected to be $1,700,429 in 2021, $1,700,429 in 2022, $1,700,429 in 2023, $1,700,429 in 2024, $1,700,429 in 2025 and $6,861,006 thereafter.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides details on the Company&#x2019;s intangible asset balances: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;subject to&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September 30, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,063,580&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,700,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,363,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20191001_20200930"
      id="F_000512">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLicensingAgreementsMember_20200930"
      decimals="0"
      id="F_000513"
      unitRef="U_iso4217USD">828596</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20191001_20200930"
      id="F_000514">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0000879407_arwrAssetAcquisitionAxis_arwrNovartisMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapPatentsMember_20200930"
      decimals="0"
      id="F_000515"
      unitRef="U_iso4217USD">8665466</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000516"
      unitRef="U_iso4217USD">1700429</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000517"
      unitRef="U_iso4217USD">1700430</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000518"
      unitRef="U_iso4217USD">1700429</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000519"
      unitRef="U_iso4217USD">1700429</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000520"
      unitRef="U_iso4217USD">1700429</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000521"
      unitRef="U_iso4217USD">1700429</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000522"
      unitRef="U_iso4217USD">1700429</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000523"
      unitRef="U_iso4217USD">1700429</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000524"
      unitRef="U_iso4217USD">6861006</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000359">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides details on the Company&#x2019;s intangible asset balances: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;assets&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;subject to&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September 30, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,063,580&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Impairment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,700,429&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,363,151&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000525"
      unitRef="U_iso4217USD">17063580</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000526"
      unitRef="U_iso4217USD">1700429</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000527"
      unitRef="U_iso4217USD">15363151</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000332">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 6. &lt;span style="font-style:italic;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At September 30, 2020, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At September 30, 2020, &lt;span style="color:#000000;"&gt;102,376,303&lt;/span&gt; shares of Common Stock were outstanding.&#160;&#160;At September 30, 2020, 8,462,148 shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead&#x2019;s 2004 Equity Incentive Plan and 2013 Incentive Plan, as well as for inducement grants made to new employees. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Company sold 4,600,000 shares of its Common Stock in a public offering at a price of $58.00 per share.&#160;&#160;The aggregate purchase price paid by the investors for the Common Stock was $266.8 million, and the Company received net proceeds of $250.5 million after deducting advisory fees and offering expenses.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the Company entered into an Open Market Sale Agreement (the &#x201c;ATM Agreement&#x201d;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#x2019;s Common Stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#x201c;ATM Offering&#x201d;). The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At September 30, 2020, no shares have been issued under the ATM Agreement.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CapitalUnitsAuthorized
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000528"
      unitRef="U_xbrlishares">150000000</us-gaap:CapitalUnitsAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000529"
      unitRef="U_xbrlishares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000530"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000531"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000532"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000533"
      unitRef="U_xbrlishares">102376303</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember_20200930"
      decimals="INF"
      id="F_000534"
      unitRef="U_xbrlishares">8462148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharesIssued
      contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191231"
      decimals="INF"
      id="F_000535"
      unitRef="U_xbrlishares">4600000</us-gaap:SharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191231"
      decimals="INF"
      id="F_000538"
      unitRef="U_iso4217USD_xbrlishares">58.00</us-gaap:SharesIssuedPricePerShare>
    <arwr:ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses
      contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191201_20191231"
      decimals="-5"
      id="F_000536"
      unitRef="U_iso4217USD">266800000</arwr:ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrUnderwrittenPublicOfferingMember_20191201_20191231"
      decimals="-5"
      id="F_000537"
      unitRef="U_iso4217USD">250500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:CommonStockCapitalSharesValueReservedForFutureIssuance
      contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200831"
      decimals="INF"
      id="F_000539"
      unitRef="U_iso4217USD">250000000</arwr:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock
      contextRef="C_0000879407_srtRangeAxis_srtMaximumMember_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200801_20200831"
      decimals="3"
      id="F_000540"
      unitRef="U_xbrlipure">0.030</arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="C_0000879407_us-gaapSubsidiarySaleOfStockAxis_arwrAtTheMarketAgreementMember_20200930"
      decimals="INF"
      id="F_000541"
      unitRef="U_xbrlishares">0</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000333">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 7. &lt;span style="font-style:italic;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Litigation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business.&#160;&#160;If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss.&#160;&#160;There were no contingent liabilities recorded as of the year ended September 30, 2020. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Purchase Commitments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the normal course of business, the Company enters into various purchase commitments for the manufacture of drug components, for toxicology studies and for clinical studies. &#160;As of September 30, 2020, these future commitments were estimated at approximately $78.0 million, of which approximately $60.2 million is expected to be incurred in fiscal 2021, and $17.8 million is expected to be incurred beyond fiscal 2021.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Technology License Commitments&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has licensed from third parties the rights to use certain technologies for its research and development&#160;activities,&#160;as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. &#160;Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and upon certain sales level milestones. &#160;These milestone payments could amount to the mid to upper double-digit millions of dollars. During the year ended September 30, 2020, the Company incurred $2.4 million of milestone payments related to the progression of the ARO-ENaC and ARO-HIF2 candidates.  During the years ended September 30, 2019 and 2018, the Company did not trigger any milestone payments.&#160;&#160;In certain agreements, the Company may be required to make mid to high single-digit percentage royalty payments based on a percentage of the sales of the relevant products.&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000542"
      unitRef="U_iso4217USD">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PurchaseObligation
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000543"
      unitRef="U_iso4217USD">78000000.0</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000544"
      unitRef="U_iso4217USD">60200000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000545"
      unitRef="U_iso4217USD">17800000</us-gaap:PurchaseObligationDueInSecondYear>
    <arwr:MilestonePayments
      contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_us-gaapTypeOfArrangementAxis_arwrAROENacAndAROHIF2CandidatesMember_20191001_20200930"
      decimals="-5"
      id="F_000546"
      unitRef="U_iso4217USD">2400000</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20181001_20190930"
      decimals="INF"
      id="F_000547"
      unitRef="U_iso4217USD">0</arwr:MilestonePayments>
    <arwr:MilestonePayments
      contextRef="C_0000879407_us-gaapOtherCommitmentsAxis_arwrTechnologyLicenseCommitmentsMember_20171001_20180930"
      decimals="INF"
      id="F_000548"
      unitRef="U_iso4217USD">0</arwr:MilestonePayments>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000334">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 8. &lt;span style="font-style:italic;"&gt;LEASES&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2019, the Company entered into a lease for its corporate headquarters in Pasadena, California.&#160;&#160;The 91 month office building lease between the Company and 177 Colorado Owner, LLC is for approximately 24,000 square feet of office space located at 177 E. Colorado Blvd, Pasadena, California. &#160;The increased capacity of this new office space compared to the Company&#x2019;s prior corporate headquarters will accommodate increased personnel as the Company&#x2019;s pipeline of drug candidates expands and moves closer to market. Lease payments began on September 30, 2019 and are estimated to total approximately $8.7 million over the term. &lt;span style="font-size:12pt;color:#000000;"&gt;&#160;&lt;/span&gt;The lease expires on April 30, 2027.  The Company has paid approximately $3.5 million for leasehold improvements, net of tenant improvement allowances.&#160;&#160;The lease contains an option to renew for one term of five years. The exercise of this option was not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#x2019;s Consolidated Balance Sheet at September 30, 2020.&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2016, the Company entered into a lease for its research facility in Madison, Wisconsin.&#160;&#160;The lease was for approximately 60,000 square feet of office and laboratory space and had an expiration date of September 30, 2026. The lease was amended in January 2019 to expand the rentable square feet by an additional 14,000 square feet and to extend the lease expiration date to September 2029. In May 2020, the Company further amended the lease to increase the rentable square feet by an additional 26,000 square feet and extended the lease expiration date to September 30, 2031.&#160;&#160;Lease payments are estimated to total approximately $26.2 million for the term.&lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;"&gt;The lease contains two options to renew for two terms of five years. The exercise of these options were not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#x2019;s Consolidated Balance Sheet at September 30, 2020.&#160;&lt;/span&gt; &#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2020, the Company entered into a sublease agreement (the &#x201c;Sublease&#x201d;) with Halozyme, Inc. for additional research and development facility space in San Diego, California.&#160; The Sublease provides additional space needed to accommodate the recent growth of the Company&#x2019;s personnel and discovery efforts. The sublease is for approximately &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;21,000&lt;/span&gt; rentable square feet.&#160; The term of the Sublease commenced on April 1, 2020 and will end on January 14, 2023.&#160;&#160;Sublease payments are estimated to total approximately $2.0 million over the term.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease cost during the years ended September 30, 2020, 2019, and 2018 was $2.4 million, $1.3 million and $1.3 million respectively.&#160;&#160;Variable lease costs during the year ended September 30, 2020 were $0.8 million.&#160;&#160;There was no short-term lease cost during the years ended September 30, 2020, 2019 and 2018. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of September 30, 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,091,901&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,853,290&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,406,754&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,269,674&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,358,292&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025 and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,331,296&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,311,207&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,173,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities (includes current portion)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,137,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for the amounts included in the measurement of the operating lease liabilities on the Company&#x2019;s Consolidated Balance Sheet and included in Other changes in operating assets and liabilities within cash flows from operating activities on the Company&#x2019;s Consolidated Statement of Cash Flow for the years ended September 30, 2020, 2019 and 2018 were  $1.8 million, $1.3 million and $1.3 million, respectively.&#160;The weighted-average remaining lease term and weighted-average discount rate for all leases as of September 30, 2020 was &lt;span style="color:#000000;"&gt;9.4 years&lt;/span&gt; and 8.4%, respectively.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2019, future minimum lease payments due in fiscal years under operating leases were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,521,451&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,256,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,521,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,590,558&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,661,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025 and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,834,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,385,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430"
      id="F_000549">P91M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430"
      decimals="0"
      id="F_000550"
      unitRef="U_utrsqft">24000</us-gaap:LandSubjectToGroundLeases>
    <arwr:LeasePaymentsCommencementDate
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430"
      id="F_000551">2019-09-30</arwr:LeasePaymentsCommencementDate>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430"
      decimals="-5"
      id="F_000552"
      unitRef="U_iso4217USD">8700000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430"
      id="F_000553">2027-04-30</us-gaap:LeaseExpirationDate1>
    <arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190401_20190430"
      decimals="-5"
      id="F_000554"
      unitRef="U_iso4217USD">3500000</arwr:PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
    <arwr:NumberOfOptionsToRenew
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430"
      decimals="INF"
      id="F_000556"
      unitRef="U_arwrOption">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrColoradoOwnerLLCMember_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_20190430"
      id="F_000555">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160131"
      decimals="0"
      id="F_000557"
      unitRef="U_utrsqft">60000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20160101_20160131"
      id="F_000558">2026-09-30</us-gaap:LeaseExpirationDate1>
    <arwr:AdditionalLandSubjectToLease
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20190131"
      decimals="INF"
      id="F_000559"
      unitRef="U_utrsqft">14000</arwr:AdditionalLandSubjectToLease>
    <arwr:LeaseExpirationMonthAndYear
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20190101_20190131"
      id="F_000560">2029-09</arwr:LeaseExpirationMonthAndYear>
    <arwr:AdditionalLandSubjectToLease
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200501_20200531"
      decimals="INF"
      id="F_000561"
      unitRef="U_utrsqft">26000</arwr:AdditionalLandSubjectToLease>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200501_20200531"
      id="F_000562">2031-09-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200930"
      decimals="-5"
      id="F_000563"
      unitRef="U_iso4217USD">26200000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <arwr:NumberOfOptionsToRenew
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200930"
      decimals="INF"
      id="F_000565"
      unitRef="U_arwrOption">2</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0000879407_srtStatementGeographicalAxis_stprWI_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrResearchFacilityInMadisonMember_20200930"
      id="F_000564">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331"
      decimals="0"
      id="F_000566"
      unitRef="U_utrsqft">21000</us-gaap:LandSubjectToGroundLeases>
    <arwr:SubleaseCommencementDate
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331"
      id="F_000567">2020-04-01</arwr:SubleaseCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200301_20200331"
      id="F_000568">2023-01-14</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000879407_srtCounterpartyNameAxis_arwrHalozymeIncMember_srtStatementGeographicalAxis_stprCA_us-gaapTypeOfArrangementAxis_arwrSubleaseAgreementMember_20200331"
      decimals="-5"
      id="F_000569"
      unitRef="U_iso4217USD">2000000.0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000570"
      unitRef="U_iso4217USD">2400000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000879407_20181001_20190930"
      decimals="-5"
      id="F_000571"
      unitRef="U_iso4217USD">1300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_0000879407_20171001_20180930"
      decimals="-5"
      id="F_000572"
      unitRef="U_iso4217USD">1300000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000573"
      unitRef="U_iso4217USD">800000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000574"
      unitRef="U_iso4217USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000575"
      unitRef="U_iso4217USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000576"
      unitRef="U_iso4217USD">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000360">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of September 30, 2020:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,091,901&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,853,290&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,406,754&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,269,674&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,358,292&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025 and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,331,296&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,311,207&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,173,252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities (includes current portion)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,137,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000577"
      unitRef="U_iso4217USD">3091901</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000578"
      unitRef="U_iso4217USD">3853290</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000579"
      unitRef="U_iso4217USD">3406754</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000580"
      unitRef="U_iso4217USD">3269674</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000581"
      unitRef="U_iso4217USD">3358292</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000582"
      unitRef="U_iso4217USD">15331296</arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000583"
      unitRef="U_iso4217USD">32311207</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000584"
      unitRef="U_iso4217USD">11173252</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000585"
      unitRef="U_iso4217USD">21137955</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000879407_20191001_20200930"
      decimals="-5"
      id="F_000586"
      unitRef="U_iso4217USD">1800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000879407_20181001_20190930"
      decimals="-5"
      id="F_000587"
      unitRef="U_iso4217USD">1300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0000879407_20171001_20180930"
      decimals="-5"
      id="F_000588"
      unitRef="U_iso4217USD">1300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0000879407_20200930" id="F_000589">P9Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0000879407_20200930"
      decimals="3"
      id="F_000590"
      unitRef="U_xbrlipure">0.084</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000361">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2019, future minimum lease payments due in fiscal years under operating leases were as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,521,451&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,256,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,521,446&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,590,558&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,661,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025 and thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,834,206&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,385,552&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000591"
      unitRef="U_iso4217USD">1521451</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000592"
      unitRef="U_iso4217USD">2256379</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000593"
      unitRef="U_iso4217USD">2521446</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000594"
      unitRef="U_iso4217USD">2590558</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000595"
      unitRef="U_iso4217USD">2661512</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000596"
      unitRef="U_iso4217USD">10834206</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000597"
      unitRef="U_iso4217USD">22385552</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000335">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 9. &lt;span style="font-style:italic;"&gt;STOCK-BASED COMPENSATION&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Arrowhead has two plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and 2013 Incentive Plan, as of September 30, 2020, 673,262 and 5,598,345 shares, respectively, of Arrowhead&#x2019;s Common Stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others. No further grants may be made under the 2004 Equity Incentive Plan.&#160;&#160;As of September 30, 2020, there were options granted and outstanding to purchase 673,262 and 2,611,625 shares of Common Stock under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively, and there were 2,588,000 restricted stock units granted and outstanding under the 2013 Incentive Plan. Also, as of September 30, 2020, there were 1,254,516 shares reserved for options and 936,025  shares reserved for restricted stock units issued as inducement grants to new employees outside of equity compensation plans. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about stock options:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September&#160;30, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,773,670&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;951,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(74,639&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.38&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,111,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,539,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;129,100,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable At September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,924,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,698,309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense related to stock options for the years ended September 30, 2020, 2019, and 2018 was $9,719,116, $3,955,216, and $3,265,348, respectively.  For non-qualified stock options, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The grant date fair value of the options granted by the Company for the years ended September 30, 2020, 2019, and 2018 was $34,582,743, $12,137,250, and $4,141,318, respectively.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The intrinsic value of the options exercised during the years ended September 30, 2020, 2019 and 2018 was $44,082,294, $24,561,189, and $5,805,317, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2020, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $36,355,846 will be recognized in the Company&#x2019;s results of operations over a weighted average period of &lt;span&gt;&lt;span style="color:#000000;"&gt;3.1 &lt;/span&gt;years&lt;/span&gt;. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#x2019;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. &lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to value stock options are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years&#160;ended&#160;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000632"&gt;0.4 &#x2013; 1.8%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000633"&gt;1.50-3.11%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000634"&gt;2.05-2.99%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90-92%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000642"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000643"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000644"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Weighted average grant date fair value per share of options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The dividend yield is zero as the Company currently does not pay a dividend. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The risk-free interest rate is based on that of the U.S. Treasury bond. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility is estimated based on volatility average of the Company&#x2019;s Common Stock price. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted stock units (&#x201c;RSUs&#x201d;), including time-based and performance-based awards, were granted under the Company&#x2019;s 2013 Incentive Plan and as inducements grants granted outside of the Plan.&#160;During the year ended September 30, 2020, the Company issued 1,754,071 RSUs under the 2013 Incentive Plan and 933,025 RSUs as inducement awards. At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s Common Stock. RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee&#x2019;s income taxes due upon vesting and withholds a number of shares of Common Stock of equal value.&#160;&#160;RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at September&#160;30, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,062,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,687,096&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,158,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.71&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(67,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31.78&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,524,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended September 30, 2020, 2019, and 2018, the Company recorded $33,663,871, $8,438,107 and $5,189,259 of expense related to RSUs, respectively. Such expense is included in stock-based compensation expense in the Company&#x2019;s Consolidated Statement of Operations and Comprehensive Income (Loss). For RSUs, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.&#160;&#160; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For RSUs, the grant date fair value of the award is based on the Company&#x2019;s closing stock price at the grant date, with consideration given to the probability of achieving performance conditions for performance-based awards.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September 30, 2020, the pre-tax compensation expense for all unvested RSUs in the amount of $88,548,649 will be recognized in the Company&#x2019;s results of operations over a weighted average period of 3.1 years.  Unvested RSUs that we have deemed not probable of vesting as of September 30, 2020, have the potential of generating an additional $38.0 million of pre-tax compensation expense if we deem them probable of vesting in a future reporting period.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20200930"
      decimals="INF"
      id="F_000598"
      unitRef="U_xbrlishares">673262</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930"
      decimals="INF"
      id="F_000599"
      unitRef="U_xbrlishares">5598345</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsFourEquityIncentivePlanMember_20200930"
      decimals="INF"
      id="F_000600"
      unitRef="U_xbrlishares">673262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930"
      decimals="INF"
      id="F_000601"
      unitRef="U_xbrlishares">2611625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20200930"
      decimals="INF"
      id="F_000602"
      unitRef="U_xbrlishares">2588000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000879407_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20200930"
      decimals="INF"
      id="F_000603"
      unitRef="U_xbrlishares">1254516</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20200930"
      decimals="INF"
      id="F_000604"
      unitRef="U_xbrlishares">936025</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000362">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information about stock options:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September&#160;30, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,773,670&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.16&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;951,500&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48.19&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(74,639&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22.38&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,111,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.72&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance At September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,539,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.67&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;129,100,277&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable At September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,924,744&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;102,698,309&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000879407_20190930"
      decimals="INF"
      id="F_000605"
      unitRef="U_xbrlishares">4773670</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0000879407_20190930"
      decimals="2"
      id="F_000611"
      unitRef="U_iso4217USD_xbrlishares">8.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000606"
      unitRef="U_xbrlishares">951500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000612"
      unitRef="U_iso4217USD_xbrlishares">48.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000607"
      unitRef="U_xbrlishares">74639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000613"
      unitRef="U_iso4217USD_xbrlishares">22.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000608"
      unitRef="U_xbrlishares">1111128</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000614"
      unitRef="U_iso4217USD_xbrlishares">6.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000609"
      unitRef="U_xbrlishares">4539403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0000879407_20200930"
      decimals="2"
      id="F_000615"
      unitRef="U_iso4217USD_xbrlishares">16.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0000879407_20191001_20200930" id="F_000617">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000619"
      unitRef="U_iso4217USD">129100277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000610"
      unitRef="U_xbrlishares">2924744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0000879407_20200930"
      decimals="2"
      id="F_000616"
      unitRef="U_iso4217USD_xbrlishares">8.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0000879407_20191001_20200930" id="F_000618">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000620"
      unitRef="U_iso4217USD">102698309</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930"
      decimals="0"
      id="F_000621"
      unitRef="U_iso4217USD">9719116</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930"
      decimals="0"
      id="F_000622"
      unitRef="U_iso4217USD">3955216</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171001_20180930"
      decimals="0"
      id="F_000623"
      unitRef="U_iso4217USD">3265348</us-gaap:AllocatedShareBasedCompensationExpense>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930"
      decimals="0"
      id="F_000624"
      unitRef="U_iso4217USD">34582743</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930"
      decimals="0"
      id="F_000625"
      unitRef="U_iso4217USD">12137250</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171001_20180930"
      decimals="0"
      id="F_000626"
      unitRef="U_iso4217USD">4141318</arwr:GrantDateFairValueOfOptionsGrantedDuringPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930"
      decimals="0"
      id="F_000627"
      unitRef="U_iso4217USD">44082294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20181001_20190930"
      decimals="0"
      id="F_000628"
      unitRef="U_iso4217USD">24561189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20171001_20180930"
      decimals="0"
      id="F_000629"
      unitRef="U_iso4217USD">5805317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200930"
      decimals="0"
      id="F_000630"
      unitRef="U_iso4217USD">36355846</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930"
      id="F_000631">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000363">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The assumptions used to value stock options are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years&#160;ended&#160;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000632"&gt;0.4 &#x2013; 1.8%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000633"&gt;1.50-3.11%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000634"&gt;2.05-2.99%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90-92%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Expected life (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000642"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000643"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000644"&gt;6.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Weighted average grant date fair value per share of options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.80&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0000879407_20181001_20190930"
      decimals="2"
      id="F_000638"
      unitRef="U_xbrlipure">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0000879407_20171001_20180930"
      decimals="2"
      id="F_000639"
      unitRef="U_xbrlipure">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_20191001_20200930"
      decimals="2"
      id="F_000645"
      unitRef="U_iso4217USD_xbrlishares">36.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_20181001_20190930"
      decimals="2"
      id="F_000646"
      unitRef="U_iso4217USD_xbrlishares">13.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_20171001_20180930"
      decimals="2"
      id="F_000647"
      unitRef="U_iso4217USD_xbrlishares">5.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191001_20200930"
      decimals="2"
      id="F_000648"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrTwoThousandsThirteenIncentivePlanMember_20191001_20200930"
      decimals="INF"
      id="F_000649"
      unitRef="U_xbrlishares">1754071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapPlanNameAxis_arwrOutsideOfEquityCompensationPlansMember_20191001_20200930"
      decimals="INF"
      id="F_000650"
      unitRef="U_xbrlishares">933025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="C_0000879407_20191001_20200930" id="F_000651">At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s Common Stock. RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee&#x2019;s income taxes due upon vesting and withholds a number of shares of Common Stock of equal value.&#160;&#160;RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000364">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Date&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at September&#160;30, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,062,833&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.43&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,687,096&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;55.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Vested&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,158,904&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.71&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(67,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31.78&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unvested at September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,524,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190930"
      decimals="INF"
      id="F_000652"
      unitRef="U_xbrlishares">2062833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190930"
      decimals="2"
      id="F_000657"
      unitRef="U_iso4217USD_xbrlishares">9.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      decimals="INF"
      id="F_000653"
      unitRef="U_xbrlishares">2687096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      decimals="2"
      id="F_000658"
      unitRef="U_iso4217USD_xbrlishares">55.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      decimals="INF"
      id="F_000654"
      unitRef="U_xbrlishares">1158904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      decimals="2"
      id="F_000659"
      unitRef="U_iso4217USD_xbrlishares">9.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      decimals="INF"
      id="F_000655"
      unitRef="U_xbrlishares">67000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      decimals="2"
      id="F_000660"
      unitRef="U_iso4217USD_xbrlishares">31.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930"
      decimals="INF"
      id="F_000656"
      unitRef="U_xbrlishares">3524025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930"
      decimals="2"
      id="F_000661"
      unitRef="U_iso4217USD_xbrlishares">44.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      decimals="0"
      id="F_000662"
      unitRef="U_iso4217USD">33663871</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20181001_20190930"
      decimals="0"
      id="F_000663"
      unitRef="U_iso4217USD">8438107</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20171001_20180930"
      decimals="0"
      id="F_000664"
      unitRef="U_iso4217USD">5189259</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20200930"
      decimals="0"
      id="F_000665"
      unitRef="U_iso4217USD">88548649</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      id="F_000666">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <arwr:EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20191001_20200930"
      decimals="-5"
      id="F_000667"
      unitRef="U_iso4217USD">38000000.0</arwr:EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000336">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE &lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/span&gt;&lt;span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="font-style:italic;"&gt;FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level&#160;1 provides the most reliable measure of fair value while Level&#160;3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;1&#x2014;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;2&#x2014;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level&#160;3&#x2014;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#x2019;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes fair value measurements at September 30, 2020 and September&#160;30, 2019 for assets and liabilities measured at fair value on a recurring basis.&#160;&#160;Certain amounts have been reclassed to conform with current year presentation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.02%;"&gt;
&lt;tr style="height:10.2pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.75pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143,582,667&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143,582,667&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.75pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,019,719&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,019,719&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.45pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,479,624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,479,624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.75pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,981,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,981,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.75pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30, &lt;span style="color:#000000;"&gt;2019&lt;/span&gt;: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.02%;"&gt;
&lt;tr style="height:10.25pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.85pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;221,804,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;221,804,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.85pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,122,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,122,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.5pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,051,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,051,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.85pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had a liability for contingent consideration related to its acquisition of the Roche RNAi business completed in 2011. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#x2019;s assumptions and experience. Estimating timing to complete the development and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining FDA and other regulatory approvals. In determining the probability of regulatory approval and commercial success, the Company utilizes data regarding similar milestone events from several sources, including industry studies and its own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. In November 2016, the Company announced the discontinuation of its clinical trial efforts for ARC-520, ARC-AAT and ARC-521.&#160;&#160;Given this development, the Company assessed the fair value of its contingent consideration obligation to be $0 at September 30, 2020 and September 30, 2019.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000365">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes fair value measurements at September 30, 2020 and September&#160;30, 2019 for assets and liabilities measured at fair value on a recurring basis.&#160;&#160;Certain amounts have been reclassed to conform with current year presentation. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30, 2020: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.02%;"&gt;
&lt;tr style="height:10.2pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.75pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143,582,667&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143,582,667&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.75pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,019,719&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85,019,719&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.45pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,479,624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;88,479,624&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.75pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments (held to maturity)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,981,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,981,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.75pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;September&#160;30, &lt;span style="color:#000000;"&gt;2019&lt;/span&gt;: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.02%;"&gt;
&lt;tr style="height:10.25pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.85pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;221,804,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;221,804,128&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.85pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,122,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,122,478&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:13.5pt;"&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,051,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45,051,251&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="height:12.85pt;"&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contingent Consideration&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="0"
      id="F_000668"
      unitRef="U_iso4217USD">143582667</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="0"
      id="F_000669"
      unitRef="U_iso4217USD">143582667</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="0"
      id="F_000670"
      unitRef="U_iso4217USD">85019719</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="0"
      id="F_000671"
      unitRef="U_iso4217USD">85019719</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="0"
      id="F_000672"
      unitRef="U_iso4217USD">88479624</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="0"
      id="F_000673"
      unitRef="U_iso4217USD">88479624</us-gaap:HeldToMaturitySecuritiesFairValue>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="0"
      id="F_000674"
      unitRef="U_iso4217USD">141981376</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930"
      decimals="0"
      id="F_000675"
      unitRef="U_iso4217USD">141981376</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930"
      decimals="0"
      id="F_000676"
      unitRef="U_iso4217USD">221804128</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930"
      decimals="0"
      id="F_000677"
      unitRef="U_iso4217USD">221804128</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930"
      decimals="0"
      id="F_000678"
      unitRef="U_iso4217USD">37122478</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930"
      decimals="0"
      id="F_000679"
      unitRef="U_iso4217USD">37122478</us-gaap:HeldToMaturitySecuritiesFairValue>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="C_0000879407_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930"
      decimals="0"
      id="F_000680"
      unitRef="U_iso4217USD">45051251</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <arwr:HeldToMaturitySecuritiesFairValueNonCurrent
      contextRef="C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20190930"
      decimals="0"
      id="F_000681"
      unitRef="U_iso4217USD">45051251</arwr:HeldToMaturitySecuritiesFairValueNonCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000682"
      unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000683"
      unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000337">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 11. &lt;span style="font-style:italic;"&gt;INCOME TAXES&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company utilizes the guidance issued by the FASB for accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and &lt;/p&gt;

&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Components of the net deferred tax asset (liability) at September 30, 2020 and 2019 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,086,396&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,310,466&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,936,819&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,609,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized Research &amp;amp; Development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;624,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;926,026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;California Alternative Minimum Tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178,652&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,553&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;438,882&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Operating Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151,007,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,372,571&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,818,002&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,590,090&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,702,357&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of Use Assets/Lease Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,015,626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;821,317&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capital Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;709,779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;709,779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171,079,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116,952,440&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(156,603,859&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(108,232,402&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,546,968&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,928,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,720,038&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,475,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,720,038&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, management has provided a 100% valuation allowance against its deferred tax assets until such time as management believes that its projections of future profits as well as expected future tax rates make the realization of these deferred tax assets more-likely-than-not. Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from our estimates could result in material differences in the realization of these assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax asset in accordance with FASB ASC 740-10, &#x201c;Accounting for Income Taxes.&#x201d; This assessment included the evaluation of scheduled reversals of deferred tax liabilities, the availability of carry forwards and estimates of projected future taxable income.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of September&#160;30, 2020, the Company had available gross federal net operating loss (&#x201c;NOL&#x201d;) carry forwards of approximately $&lt;span style="color:#000000;"&gt;473.0&lt;/span&gt; million and gross state NOL carry forwards of $&lt;span style="color:#000000;"&gt;497.0&#160;&lt;/span&gt;million. The NOLs expire at various dates through 2040.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The provisions for income taxes for the years ended September 30, 2020 and 2019 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,553&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,553&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision from income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,553&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended September 30, 2020 and 2019: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal effect&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-7.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-29.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-15.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mark-to-market adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-13.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;True-up on deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax rate change&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. The Company&#x2019;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense.&#160;&#160;The Company has not recognized any unrecognized tax benefits and does not have any interest or penalties related to uncertain tax positions as of September 30, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns with the Internal Revenue Service (&#x201c;IRS&#x201d;), the state of California and certain other taxing jurisdictions. The Company is subject to income tax examinations by the IRS and by state tax authorities until the net operating losses are settled.&#160;&#160;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000366">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Components of the net deferred tax asset (liability) at September 30, 2020 and 2019 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Tax Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,086,396&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,310,466&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,936,819&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,609,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capitalized Research &amp;amp; Development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;624,915&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;926,026&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;California Alternative Minimum Tax&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178,652&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,553&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;438,882&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Operating Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151,007,113&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105,372,571&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,818,002&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,590,090&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,702,357&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right of Use Assets/Lease Liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,015,626&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred Rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;821,317&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Capital Loss&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;709,779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;709,779&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;171,079,659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116,952,440&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(156,603,859&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(108,232,402&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,546,968&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,928,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,720,038&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,475,800&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,720,038&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets (liabilities)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000684"
      unitRef="U_iso4217USD">2086396</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000685"
      unitRef="U_iso4217USD">1310466</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000686"
      unitRef="U_iso4217USD">10936819</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000687"
      unitRef="U_iso4217USD">3609756</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000688"
      unitRef="U_iso4217USD">624915</arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost>
    <arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000689"
      unitRef="U_iso4217USD">926026</arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000690"
      unitRef="U_iso4217USD">178652</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000691"
      unitRef="U_iso4217USD">173553</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000692"
      unitRef="U_iso4217USD">438882</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000693"
      unitRef="U_iso4217USD">151007113</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000694"
      unitRef="U_iso4217USD">105372571</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000695"
      unitRef="U_iso4217USD">2818002</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000696"
      unitRef="U_iso4217USD">3590090</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000697"
      unitRef="U_iso4217USD">1702357</us-gaap:DeferredTaxAssetsDeferredIncome>
    <arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000698"
      unitRef="U_iso4217USD">1015626</arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000699"
      unitRef="U_iso4217USD">821317</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000700"
      unitRef="U_iso4217USD">709779</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000701"
      unitRef="U_iso4217USD">709779</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000702"
      unitRef="U_iso4217USD">171079659</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000703"
      unitRef="U_iso4217USD">116952440</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000704"
      unitRef="U_iso4217USD">156603859</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000705"
      unitRef="U_iso4217USD">108232402</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000706"
      unitRef="U_iso4217USD">2546968</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <arwr:DeferredTaxLiabilitiesStateTaxes
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000707"
      unitRef="U_iso4217USD">11928832</arwr:DeferredTaxLiabilitiesStateTaxes>
    <arwr:DeferredTaxLiabilitiesStateTaxes
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000708"
      unitRef="U_iso4217USD">8720038</arwr:DeferredTaxLiabilitiesStateTaxes>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0000879407_20200930"
      decimals="0"
      id="F_000709"
      unitRef="U_iso4217USD">14475800</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0000879407_20190930"
      decimals="0"
      id="F_000710"
      unitRef="U_iso4217USD">8720038</us-gaap:DeferredIncomeTaxLiabilities>
    <arwr:PercentageOfValuationAllowance
      contextRef="C_0000879407_20200930"
      decimals="INF"
      id="F_000711"
      unitRef="U_xbrlipure">1</arwr:PercentageOfValuationAllowance>
    <arwr:FederalNetOperatingLossCarryForward
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000712"
      unitRef="U_iso4217USD">473000000.0</arwr:FederalNetOperatingLossCarryForward>
    <arwr:StateNetOperatingLossCarryForwards
      contextRef="C_0000879407_20200930"
      decimals="-5"
      id="F_000713"
      unitRef="U_iso4217USD">497000000.0</arwr:StateNetOperatingLossCarryForwards>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000367">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The provisions for income taxes for the years ended September 30, 2020 and 2019 are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,553&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,553&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision from income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,400&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;173,553&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000714"
      unitRef="U_iso4217USD">2400</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000715"
      unitRef="U_iso4217USD">173553</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000716"
      unitRef="U_iso4217USD">2400</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000717"
      unitRef="U_iso4217USD">173553</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000718"
      unitRef="U_iso4217USD">2400</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000719"
      unitRef="U_iso4217USD">173553</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000368">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended September 30, 2020 and 2019: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;September 30,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At U.S. federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net of federal effect&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-7.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-29.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-15.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Mark-to-market adjustments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-13.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;True-up on deferred taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax rate change&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0000879407_20191001_20200930"
      decimals="INF"
      id="F_000720"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0000879407_20181001_20190930"
      decimals="INF"
      id="F_000721"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000722"
      unitRef="U_xbrlipure">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0000879407_20181001_20190930"
      decimals="3"
      id="F_000723"
      unitRef="U_xbrlipure">0.073</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000724"
      unitRef="U_xbrlipure">-0.294</arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent
      contextRef="C_0000879407_20181001_20190930"
      decimals="3"
      id="F_000725"
      unitRef="U_xbrlipure">0.150</arwr:EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000726"
      unitRef="U_xbrlipure">0.000</arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments>
    <arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments
      contextRef="C_0000879407_20181001_20190930"
      decimals="3"
      id="F_000727"
      unitRef="U_xbrlipure">0.000</arwr:EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000728"
      unitRef="U_xbrlipure">-0.574</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0000879407_20181001_20190930"
      decimals="3"
      id="F_000729"
      unitRef="U_xbrlipure">-0.130</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000730"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0000879407_20181001_20190930"
      decimals="3"
      id="F_000731"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000732"
      unitRef="U_xbrlipure">0.000</arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate>
    <arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate
      contextRef="C_0000879407_20181001_20190930"
      decimals="3"
      id="F_000733"
      unitRef="U_xbrlipure">0.000</arwr:EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000734"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_0000879407_20181001_20190930"
      decimals="3"
      id="F_000735"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0000879407_20191001_20200930"
      decimals="3"
      id="F_000736"
      unitRef="U_xbrlipure">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0000879407_20181001_20190930"
      decimals="3"
      id="F_000737"
      unitRef="U_xbrlipure">0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000338">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 12. &lt;span style="font-style:italic;"&gt;EMPLOYEE BENEFIT PLANS&lt;/span&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2005, the Company adopted a defined contribution 401(k) retirement savings plan covering substantially all of its employees. The Plan is administered under the &#x201c;safe harbor&#x201d; provision of ERISA. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participant&#x2019;s first 3% of compensation contributed plus 50% of each participant&#x2019;s next 2% of compensation contributed. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended September&#160;30, 2020, 2019, and 2018, the Company recorded expenses under this plan of $863,080, $545,698 and $451,623, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition to the employee benefit plans described above, the Company provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20191001_20200930"
      decimals="INF"
      id="F_000738"
      unitRef="U_xbrlipure">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionsUpToThreePercentMember_20191001_20200930"
      decimals="2"
      id="F_000739"
      unitRef="U_xbrlipure">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20191001_20200930"
      decimals="INF"
      id="F_000740"
      unitRef="U_xbrlipure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="C_0000879407_us-gaapRetirementPlanTypeAxis_arwrEmployeeContributionNextTwoPercentMember_20191001_20200930"
      decimals="2"
      id="F_000741"
      unitRef="U_xbrlipure">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0000879407_20191001_20200930"
      decimals="0"
      id="F_000742"
      unitRef="U_iso4217USD">863080</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0000879407_20181001_20190930"
      decimals="0"
      id="F_000743"
      unitRef="U_iso4217USD">545698</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="C_0000879407_20171001_20180930"
      decimals="0"
      id="F_000744"
      unitRef="U_iso4217USD">451623</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000339">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 13. &lt;span style="font-style:italic;"&gt;UNAUDITED QUARTERLY FINANCIAL DATA&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.11%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents selected unaudited quarterly financial data for each full quarterly period of the years ended September 30, 2020 and 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;First&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Second&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fourth&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,454,579&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,528,853&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,375,778&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,632,856&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Income (Loss)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,853,594&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,240,255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,945,862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(50,119,092&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,673,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,835,570&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,611,213&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(48,432,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per share-Basic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.03&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per share-Diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.03&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;F-25&lt;/p&gt;
&lt;hr style="page-break-after:always"/&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;First&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Second&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fourth&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended September 30, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,657,896&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,148,275&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,696,636&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,292,770&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Income (Loss)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,946,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,010,692&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,595,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,638,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,037,253&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,896,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,335,708&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,704,906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per share-Basic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per share-Diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000369">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents selected unaudited quarterly financial data for each full quarterly period of the years ended September 30, 2020 and 2019:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;First&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Second&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fourth&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended September 30, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,454,579&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,528,853&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,375,778&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,632,856&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Income (Loss)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,853,594&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22,240,255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,945,862&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(50,119,092&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,673,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,835,570&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,611,213&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(48,432,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per share-Basic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.03&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per share-Diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.03&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.48&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;F-25&lt;/p&gt;
&lt;hr style="page-break-after:always"/&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;First&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Second&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Third&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fourth&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year ended September 30, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Quarter&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,657,896&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,148,275&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;42,696,636&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;43,292,770&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating Income (Loss)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,946,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,010,692&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,595,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,638,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,037,253&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,896,982&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,335,708&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,704,906&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per share-Basic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net Income (Loss) per share-Diluted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.24&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.21&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20191001_20191231"
      decimals="0"
      id="F_000745"
      unitRef="U_iso4217USD">29454579</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20200101_20200331"
      decimals="0"
      id="F_000746"
      unitRef="U_iso4217USD">23528853</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20200401_20200630"
      decimals="0"
      id="F_000747"
      unitRef="U_iso4217USD">27375778</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20200701_20200930"
      decimals="0"
      id="F_000748"
      unitRef="U_iso4217USD">7632856</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20191001_20191231"
      decimals="0"
      id="F_000753"
      unitRef="U_iso4217USD">-4853594</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20200101_20200331"
      decimals="0"
      id="F_000754"
      unitRef="U_iso4217USD">-22240255</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20200401_20200630"
      decimals="0"
      id="F_000755"
      unitRef="U_iso4217USD">-15945862</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20200701_20200930"
      decimals="0"
      id="F_000756"
      unitRef="U_iso4217USD">-50119092</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20191001_20191231"
      decimals="0"
      id="F_000757"
      unitRef="U_iso4217USD">-2673728</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20200101_20200331"
      decimals="0"
      id="F_000758"
      unitRef="U_iso4217USD">-19835570</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20200401_20200630"
      decimals="0"
      id="F_000759"
      unitRef="U_iso4217USD">-13611213</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20200701_20200930"
      decimals="0"
      id="F_000760"
      unitRef="U_iso4217USD">-48432715</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20191001_20191231"
      decimals="2"
      id="F_000761"
      unitRef="U_iso4217USD_xbrlishares">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20200101_20200331"
      decimals="2"
      id="F_000762"
      unitRef="U_iso4217USD_xbrlishares">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20200401_20200630"
      decimals="2"
      id="F_000763"
      unitRef="U_iso4217USD_xbrlishares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20200701_20200930"
      decimals="2"
      id="F_000764"
      unitRef="U_iso4217USD_xbrlishares">-0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20191001_20191231"
      decimals="2"
      id="F_000765"
      unitRef="U_iso4217USD_xbrlishares">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20200101_20200331"
      decimals="2"
      id="F_000766"
      unitRef="U_iso4217USD_xbrlishares">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20200401_20200630"
      decimals="2"
      id="F_000767"
      unitRef="U_iso4217USD_xbrlishares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20200701_20200930"
      decimals="2"
      id="F_000768"
      unitRef="U_iso4217USD_xbrlishares">-0.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20181001_20181231"
      decimals="0"
      id="F_000769"
      unitRef="U_iso4217USD">34657896</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20190101_20190331"
      decimals="0"
      id="F_000770"
      unitRef="U_iso4217USD">48148275</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20190401_20190630"
      decimals="0"
      id="F_000771"
      unitRef="U_iso4217USD">42696636</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0000879407_20190701_20190930"
      decimals="0"
      id="F_000772"
      unitRef="U_iso4217USD">43292770</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20181001_20181231"
      decimals="0"
      id="F_000777"
      unitRef="U_iso4217USD">10946144</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20190101_20190331"
      decimals="0"
      id="F_000778"
      unitRef="U_iso4217USD">22010692</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20190401_20190630"
      decimals="0"
      id="F_000779"
      unitRef="U_iso4217USD">18595749</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0000879407_20190701_20190930"
      decimals="0"
      id="F_000780"
      unitRef="U_iso4217USD">9638049</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20181001_20181231"
      decimals="0"
      id="F_000781"
      unitRef="U_iso4217USD">12037253</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20190101_20190331"
      decimals="0"
      id="F_000782"
      unitRef="U_iso4217USD">23896982</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20190401_20190630"
      decimals="0"
      id="F_000783"
      unitRef="U_iso4217USD">20335708</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0000879407_20190701_20190930"
      decimals="0"
      id="F_000784"
      unitRef="U_iso4217USD">11704906</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20181001_20181231"
      decimals="2"
      id="F_000785"
      unitRef="U_iso4217USD_xbrlishares">0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20190101_20190331"
      decimals="2"
      id="F_000786"
      unitRef="U_iso4217USD_xbrlishares">0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20190401_20190630"
      decimals="2"
      id="F_000787"
      unitRef="U_iso4217USD_xbrlishares">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_0000879407_20190701_20190930"
      decimals="2"
      id="F_000788"
      unitRef="U_iso4217USD_xbrlishares">0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20181001_20181231"
      decimals="2"
      id="F_000789"
      unitRef="U_iso4217USD_xbrlishares">0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20190101_20190331"
      decimals="2"
      id="F_000790"
      unitRef="U_iso4217USD_xbrlishares">0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20190401_20190630"
      decimals="2"
      id="F_000791"
      unitRef="U_iso4217USD_xbrlishares">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_0000879407_20190701_20190930"
      decimals="2"
      id="F_000792"
      unitRef="U_iso4217USD_xbrlishares">0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0000879407_20191001_20200930" id="F_000340">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 14. &lt;span style="font-style:italic;"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Exclusive License and Co-Funding Agreement with Takeda Pharmaceuticals U.S.A., Inc.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 7, 2020, the Company entered into an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;) with Takeda Pharmaceuticals U.S.A., Inc.&#160;&#160;(&#x201c;Takeda&#x201d;).&#160;&#160;Under the Takeda License Agreement, &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;Takeda and the Company will co-develop the Company&#x2019;s ARO-AAT program, the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with the Company eligible to receive tiered royalties of 20% to 25% on net sales.&#160;&#160;The Company will receive $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.&lt;/span&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Corporate Headquarters Lease Expansion&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 23, 2020, the Company signed a lease expansion to add an additional 24,434 square feet of office space for the Company&#x2019;s corporate headquarters in Pasadena, CA.&#160;&#160;The lease commencement date is expected to be July 2021, after certain leasehold improvements are completed, and the lease expires in April 2027.&#160;&#160;The lease payments over the life of lease total $7.3 million.&#160;&#160;The Company anticipates paying approximately $4.0 million of leasehold improvements, net of tenant improvement allowances.&#160;&#160;&lt;span style="color:#000000;"&gt;The increased capacity of this additional office space compared to the Company&#x2019;s current corporate headquarters will accommodate increased personnel as the Company&#x2019;s pipeline of drug candidates expands and moves closer to market.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <arwr:AgreementDate
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      id="F_000793">2020-10-07</arwr:AgreementDate>
    <arwr:RatioOfProfitSharingStructureForCommercialization
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      id="F_000794">50/50 profit sharing</arwr:RatioOfProfitSharingStructureForCommercialization>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMinimumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="2"
      id="F_000795"
      unitRef="U_xbrlipure">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_srtRangeAxis_srtMaximumMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="2"
      id="F_000796"
      unitRef="U_xbrlipure">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007"
      decimals="-5"
      id="F_000797"
      unitRef="U_iso4217USD">300000000.0</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments
      contextRef="C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007"
      decimals="-5"
      id="F_000798"
      unitRef="U_iso4217USD">740000000.0</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023"
      decimals="0"
      id="F_000799"
      unitRef="U_utrsqft">24434</us-gaap:LandSubjectToGroundLeases>
    <arwr:LeaseCommencementMonthAndYear
      contextRef="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023_20201023"
      id="F_000800">2021-07</arwr:LeaseCommencementMonthAndYear>
    <arwr:LeaseExpirationMonthAndYear
      contextRef="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023_20201023"
      id="F_000801">2027-04</arwr:LeaseExpirationMonthAndYear>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023"
      decimals="-5"
      id="F_000802"
      unitRef="U_iso4217USD">7300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <arwr:ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances
      contextRef="C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023_20201023"
      decimals="-5"
      id="F_000803"
      unitRef="U_iso4217USD">4000000.0</arwr:ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246456030120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 16, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,756,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#8217;s 2021 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246451994248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 143,582,667<span></span>
</td>
<td class="nump">$ 221,804,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">845,673<span></span>
</td>
<td class="nump">661,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">4,250,896<span></span>
</td>
<td class="nump">3,317,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,781,691<span></span>
</td>
<td class="nump">2,563,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">85,019,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments</a></td>
<td class="nump">86,889,751<span></span>
</td>
<td class="nump">36,899,894<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">TOTAL CURRENT ASSETS</a></td>
<td class="nump">322,370,397<span></span>
</td>
<td class="nump">265,246,817<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">30,880,868<span></span>
</td>
<td class="nump">23,214,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">15,363,151<span></span>
</td>
<td class="nump">17,063,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long term investments</a></td>
<td class="nump">137,486,883<span></span>
</td>
<td class="nump">44,175,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">16,137,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">265,359<span></span>
</td>
<td class="nump">144,148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">522,503,743<span></span>
</td>
<td class="nump">349,845,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,828,909<span></span>
</td>
<td class="nump">7,649,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,388,556<span></span>
</td>
<td class="nump">6,504,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">8,060,854<span></span>
</td>
<td class="nump">4,955,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">1,094,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">19,291,075<span></span>
</td>
<td class="nump">77,769,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">17,262<span></span>
</td>
<td class="nump">16,561<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">TOTAL CURRENT LIABILITIES</a></td>
<td class="nump">40,681,433<span></span>
</td>
<td class="nump">97,070,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">20,043,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,703,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,035,142<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">TOTAL LONG-TERM LIABILITIES</a></td>
<td class="nump">20,043,178<span></span>
</td>
<td class="nump">8,738,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Arrowhead Pharmaceuticals, Inc. stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 145,000,000 shares authorized; 102,376,303 and 95,506,271 shares issued and outstanding as of September 30, 2020 and September 30, 2019, respectively</a></td>
<td class="nump">194,746<span></span>
</td>
<td class="nump">187,876<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">965,410,146<span></span>
</td>
<td class="nump">664,086,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">18,433<span></span>
</td>
<td class="num">(391,624)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(503,844,193)<span></span>
</td>
<td class="num">(419,290,967)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</a></td>
<td class="nump">461,779,132<span></span>
</td>
<td class="nump">244,591,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(555,188)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">461,779,132<span></span>
</td>
<td class="nump">244,036,252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 522,503,743<span></span>
</td>
<td class="nump">$ 349,845,437<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549951&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246532220696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">102,376,303<span></span>
</td>
<td class="nump">95,506,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">102,376,303<span></span>
</td>
<td class="nump">95,506,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246533835960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">REVENUE</a></td>
<td class="nump">$ 87,992,066<span></span>
</td>
<td class="nump">$ 168,795,577<span></span>
</td>
<td class="nump">$ 16,142,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 128,874,979<span></span>
</td>
<td class="nump">$ 81,048,686<span></span>
</td>
<td class="nump">$ 52,968,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">52,275,890<span></span>
</td>
<td class="nump">26,556,257<span></span>
</td>
<td class="nump">19,110,051<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">181,150,869<span></span>
</td>
<td class="nump">107,604,943<span></span>
</td>
<td class="nump">72,078,556<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="num">(93,158,803)<span></span>
</td>
<td class="nump">61,190,634<span></span>
</td>
<td class="num">(55,936,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">9,190,501<span></span>
</td>
<td class="nump">6,957,768<span></span>
</td>
<td class="nump">1,048,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other Income (expense)</a></td>
<td class="num">(582,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,493<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER INCOME (EXPENSE)</a></td>
<td class="nump">8,607,977<span></span>
</td>
<td class="nump">6,957,768<span></span>
</td>
<td class="nump">1,488,157<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="num">(84,550,826)<span></span>
</td>
<td class="nump">68,148,402<span></span>
</td>
<td class="num">(54,448,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(2,400)<span></span>
</td>
<td class="num">(173,553)<span></span>
</td>
<td class="num">(2,400)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="num">$ (84,553,226)<span></span>
</td>
<td class="nump">$ 67,974,849<span></span>
</td>
<td class="num">$ (54,450,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">NET INCOME (LOSS) PER SHARE - BASIC</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">NET INCOME (LOSS) PER SHARE - DILUTED</a></td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic</a></td>
<td class="nump">100,722,224<span></span>
</td>
<td class="nump">93,858,857<span></span>
</td>
<td class="nump">83,638,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted</a></td>
<td class="nump">100,722,224<span></span>
</td>
<td class="nump">98,607,815<span></span>
</td>
<td class="nump">83,638,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">$ 410,057<span></span>
</td>
<td class="num">$ (370,060)<span></span>
</td>
<td class="num">$ (54,796)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">COMPREHENSIVE INCOME (LOSS)</a></td>
<td class="num">$ (84,143,169)<span></span>
</td>
<td class="nump">$ 67,604,789<span></span>
</td>
<td class="num">$ (54,505,274)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246450773208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statement of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance, Amount at Sep. 30, 2017</a></td>
<td class="nump">$ 80,867,162<span></span>
</td>
<td class="nump">$ 167,155<span></span>
</td>
<td class="nump">$ 514,037,301<span></span>
</td>
<td class="nump">$ 33,232<span></span>
</td>
<td class="num">$ (432,815,338)<span></span>
</td>
<td class="num">$ (555,188)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Sep. 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,785,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,454,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,454,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, Amount</a></td>
<td class="nump">2,656,710<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">2,656,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">604,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants, Amount</a></td>
<td class="nump">1,237,429<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
<td class="nump">1,237,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Amount</a></td>
<td class="num">(54,668)<span></span>
</td>
<td class="nump">$ 1,327<span></span>
</td>
<td class="num">(55,995)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,326,792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock - issued for cash, Amount</a></td>
<td class="nump">56,585,035<span></span>
</td>
<td class="nump">$ 11,500<span></span>
</td>
<td class="nump">56,573,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock - issued for cash, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(54,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(54,450,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,450,478)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, Amount at Sep. 30, 2018</a></td>
<td class="nump">95,241,001<span></span>
</td>
<td class="nump">$ 180,875<span></span>
</td>
<td class="nump">582,902,694<span></span>
</td>
<td class="num">(21,564)<span></span>
</td>
<td class="num">(487,265,816)<span></span>
</td>
<td class="num">(555,188)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Sep. 30, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,505,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">12,393,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,393,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, Amount</a></td>
<td class="nump">8,275,410<span></span>
</td>
<td class="nump">$ 1,543<span></span>
</td>
<td class="nump">8,273,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,197<span></span>
</td>
<td class="num">(2,197)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,197,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock - issued for cash, Amount</a></td>
<td class="nump">60,521,729<span></span>
</td>
<td class="nump">$ 3,261<span></span>
</td>
<td class="nump">60,518,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock - issued for cash, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,260,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(370,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(370,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">67,974,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,974,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, Amount at Sep. 30, 2019</a></td>
<td class="nump">244,036,252<span></span>
</td>
<td class="nump">$ 187,876<span></span>
</td>
<td class="nump">664,086,155<span></span>
</td>
<td class="num">(391,624)<span></span>
</td>
<td class="num">(419,290,967)<span></span>
</td>
<td class="num">(555,188)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,506,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">43,382,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,382,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, Amount</a></td>
<td class="nump">$ 7,468,899<span></span>
</td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="nump">7,467,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="nump">1,111,128<span></span>
</td>
<td class="nump">1,111,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,159<span></span>
</td>
<td class="num">(1,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,158,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock - issued for cash, Amount</a></td>
<td class="nump">$ 250,478,974<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">250,474,374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock - issued for cash, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">410,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">410,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of Ablaris Therapeutics, Inc.</a></td>
<td class="nump">555,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(84,553,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,553,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance, Amount at Sep. 30, 2020</a></td>
<td class="nump">$ 461,779,132<span></span>
</td>
<td class="nump">$ 194,746<span></span>
</td>
<td class="nump">$ 965,410,146<span></span>
</td>
<td class="nump">$ 18,433<span></span>
</td>
<td class="num">$ (503,844,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,376,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued during the period upon the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246533787272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">$ (84,553,226)<span></span>
</td>
<td class="nump">$ 67,974,849<span></span>
</td>
<td class="num">$ (54,450,478)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in value of derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(432,141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">43,382,988<span></span>
</td>
<td class="nump">12,393,323<span></span>
</td>
<td class="nump">8,454,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,942,264<span></span>
</td>
<td class="nump">4,439,144<span></span>
</td>
<td class="nump">4,699,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization/(accretion) of note premiums</a></td>
<td class="nump">525,305<span></span>
</td>
<td class="nump">1,069,070<span></span>
</td>
<td class="nump">383,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(184,312)<span></span>
</td>
<td class="num">(333,986)<span></span>
</td>
<td class="num">(259,578)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(387,464)<span></span>
</td>
<td class="num">(3,710,515)<span></span>
</td>
<td class="nump">319,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(63,513,696)<span></span>
</td>
<td class="nump">82,804,171<span></span>
</td>
<td class="num">(5,269,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(821,012)<span></span>
</td>
<td class="nump">4,843,825<span></span>
</td>
<td class="num">(1,270,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,989,496<span></span>
</td>
<td class="nump">2,450,079<span></span>
</td>
<td class="nump">1,016,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other</a></td>
<td class="nump">2,228,087<span></span>
</td>
<td class="nump">1,104,963<span></span>
</td>
<td class="num">(414,293)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES</a></td>
<td class="num">(95,391,570)<span></span>
</td>
<td class="nump">173,034,923<span></span>
</td>
<td class="num">(47,223,417)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(11,951,712)<span></span>
</td>
<td class="num">(12,001,225)<span></span>
</td>
<td class="num">(1,421,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(278,964,290)<span></span>
</td>
<td class="num">(90,266,001)<span></span>
</td>
<td class="num">(52,083,131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sale of investments</a></td>
<td class="nump">50,138,238<span></span>
</td>
<td class="nump">54,521,219<span></span>
</td>
<td class="nump">46,069,420<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES</a></td>
<td class="num">(240,777,764)<span></span>
</td>
<td class="num">(47,746,007)<span></span>
</td>
<td class="num">(7,434,963)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,415,150)<span></span>
</td>
<td class="num">(208,506)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payment of taxes for net share settled restricted stock unit issuances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercises of stock options</a></td>
<td class="nump">7,468,899<span></span>
</td>
<td class="nump">8,275,410<span></span>
</td>
<td class="nump">3,631,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">250,478,974<span></span>
</td>
<td class="nump">60,521,739<span></span>
</td>
<td class="nump">56,585,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES</a></td>
<td class="nump">257,947,873<span></span>
</td>
<td class="nump">66,381,999<span></span>
</td>
<td class="nump">59,953,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH</a></td>
<td class="num">(78,221,461)<span></span>
</td>
<td class="nump">191,670,915<span></span>
</td>
<td class="nump">5,294,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">221,804,128<span></span>
</td>
<td class="nump">30,133,213<span></span>
</td>
<td class="nump">24,838,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">143,582,667<span></span>
</td>
<td class="nump">221,804,128<span></span>
</td>
<td class="nump">30,133,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,437)<span></span>
</td>
<td class="num">(173,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income Taxes (Paid) Refunded</a></td>
<td class="nump">$ 103,437<span></span>
</td>
<td class="num">$ (302,400)<span></span>
</td>
<td class="num">$ (2,400)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447918440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1. <span style="font-style:italic;">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Nature of Business and Recent Developments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them.&#160;&#160;Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-LUNG2 as a candidate to treat chronic obstructive pulmonary disorder (&#8220;COPD&#8221;) and ARO-COV for treatment for the current novel coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.<span style="font-size:14pt;"> </span>ARO<span style="color:#000000;">-JNJ1, ARO-JNJ2 and ARO-JNJ3 are being developed for undisclosed liver-expressed targets under a collaboration agreement with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;).&#160;&#160;</span>ARO-AAT for liver disease associated with alpha-1 antitrypsin deficiency (&#8220;AATD&#8221;) was out-licensed to Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;) in October 2020. <span style="color:#000000;">ARO-HBV (JNJ-3989) for chronic hepatitis B virus was out-licensed to Janssen in October 2018.&#160;&#160;ARO-LPA (AMG 890)</span><span style="color:#000000;font-size:8.5pt;"><sub style="font-size:85%; vertical-align:bottom">&#160;</sub></span><span style="color:#000000;">for cardiovascular disease was out-licensed to Amgen Inc. (&#8220;Amgen&#8221;) in 2016.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead operates a lab facility in Madison, Wisconsin, where the Company&#8217;s research and development activities, including the development of RNAi therapeutics, are based. The Company&#8217;s principal executive offices are located in Pasadena, California. <span style="color:#000000;">In March 2020, the Company entered into a sublease for additional research and development facility space in San Diego, California as discussed further in Note 8 below.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During fiscal year 2020, the Company has continued to develop its pipeline and partnered candidates.&#160;&#160;Regarding the Company&#8217;s wholly-owned pipeline candidates, the Company dosed its first patients in three of its pipeline candidate studies: ARO-HSD1001, a phase 1/2 clinical study of ARO-HSD; ARO-ENaC1001, a phase 1/2 clinical study of ARO-ENaC and ARO-HIF21001, a phase 1b study of ARO-HIF2. The Company also presented new clinical data on its two cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, at multiple medical meetings, including the European Society of Cardiology Congress and the American Heart Association Scientific Sessions.&#160;&#160;Finally, the Company is also progressing ARO-LUNG2 toward entering clinical trials and is continuing to perform discovery work to identify new candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s <span style="color:#000000;">partnered candidates under its collaboration agreements also continue to progress.&#160;&#160;Janssen began dosing patients in a phase 2b triple combination study called REEF-1,&#160;designed to enroll up to 450 patients with chronic hepatitis B infection, and in connection with the start of this study Arrowhead earned a&#160; $25.0 million&#160;milestone payment under the License Agreement (&#8220;Janssen License Agreement&#8221;).&#160;&#160;The Company is currently performing discovery, optimization and preclinical research and development for ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3 for Janssen as part of the Research Collaboration and Option Agreement (&#8220;Janssen Collaboration Agreement&#8221;).&#160;&#160;</span>Under the terms of the Janssen agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in Arrowhead Common Stock, two $25.0 million milestone payments and may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement.&#160;&#160;The Company is further eligible to receive tiered royalties up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement on product sales.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s collaboration agreement with Amgen for <span style="color:#000000;">Olpasiran (previously referred to as AMG 890 or ARO-LPA), (the &#8220;Second Collaboration and License Agreement&#8221; or &#8220;Olpasiran Agreement&#8221;),</span> continues to progress. &#160;<span style="color:#000000;">In July 2020, Amgen initiated a Phase 2 clinical study, which resulted in a $20.0 million milestone payment to the Company.</span>&#160;&#160;The Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments.&#160;&#160;The Company is eligible to receive up to&#160;low double-digit royalties for sales of products under the <span style="color:#000000;">Olpasiran</span> Agreement.&#160;&#160;<span style="color:#000000;">On October 7, 2020, the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda.&#160;&#160;Under the Takeda License Agreement, </span><span style="Background-color:#FFFFFF;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to </span></p>

<p style="margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">commercialize ARO-AAT with the Company eligible to receive tiered royalties of </span>20<span style="Background-color:#FFFFFF;">%</span><span style="Background-color:#FFFFFF;"> to </span><span style="Background-color:#FFFFFF;">25</span><span style="Background-color:#FFFFFF;">% on net sales.&#160;&#160;The Company will receive $</span>300.0<span style="Background-color:#FFFFFF;"> million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $</span>740.0<span style="Background-color:#FFFFFF;"> million.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The revenue recognition for these collaboration agreements is discussed further in Note 2 below.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is actively monitoring the ongoing COVID-19 pandemic. The financial results for the year ended September 30, 2020 were not significantly impacted by COVID-19. The Company temporarily paused enrollment in its two ARO-AAT studies, SEQUOIA and the ARO-AAT 2002 study, but resumed the process of screening and enrolling patients during the three months ended June 30, 2020. During the pause in enrollment, patients already enrolled in these studies continued to be dosed per protocol and continued to come in for their follow up visits. Additional delays have occurred in the Company&#8217;s earlier stage programs, but the Company does not expect a material impact to any program&#8217;s anticipated timelines. Several of the Company&#8217;s other clinical candidates are in the start-up stage (ARO-HSD, ARO-HIF2 and ARO-ENaC), during which significant clinical costs will continue to be incurred. Additionally, the Company&#8217;s operations at its research and development facilities in Madison, Wisconsin and San Diego, California, and its corporate headquarters in Pasadena, California have continued to operate with limited impact, other than for enhanced safety measures, including work from home policies. However, the Company cannot predict the impact of the progression of COVID-19 will have on future financial results due to a variety of factors including the ability of the Company&#8217;s clinical sites to continue to enroll subjects, the ability of the Company&#8217;s suppliers to continue to operate, the continued good health and safety of the Company&#8217;s employees, and ultimately the length of the COVID-19 pandemic.<span style="color:#000000;"> </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Consolidated Financial Statements have been prepared in conformity with the accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;), which contemplate the continuation of the Company as a going concern.&#160; Historically, the Company&#8217;s primary source of financing has been through the sale of its securities. Research and development activities have required significant capital investment since the Company&#8217;s inception. The Company expects its operations to continue to require cash investment to pursue its research and development goals, including clinical trials and related drug manufacturing.&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2020, the Company had $143.6 million in cash and cash equivalents (including $1.8 million in restricted cash), $86.9 million in short-term investments and $85.0 million in marketable securities, and $137.5 million in long-term investments to fund operations.&#160;&#160;During the year ended September 30, 2020, the Company&#8217;s cash and investments balance increased by $150.1 million, which was primarily the result of purchases of investments and marketable securities of $279.0 million and cash outflow primarily related to operations of $95.4 million, partially offset by the December 2019 securities offering that generated $250.5 million in net cash proceeds for the Company, as discussed further in Note 6 below, as well as maturities of investments of $50.1 million. &#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Summary of Significant Accounting Policies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation&#8212;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#8217;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation and Use of Estimates&#8212;The <span style="color:#000000;">preparation of financial statements in conformity GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation</span>.&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents&#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $1.8 million and $1.0 restricted cash at September 30, 2020 and September 30, 2019, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#8217;s <span style="color:#000000;">lease for its corporate headquarters in Pasadena, California.</span>&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk&#8212;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments&#8212;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 320, Investments &#8211; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-Maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2020, 2019 and 2018, all of the Company&#8217;s debt securities were classified as held-to-maturity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended September 30, 2020, the Company purchased shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#8217;s Consolidated Balance Sheet as &#8220;marketable securities&#8221; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment&#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration&#8212;The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $0 at September 30, 2020 and September 30, 2019. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212; <span style="color:#000000;">On October 1, 2018, the Company adopted FASB Topic 606 &#8211; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#8217;s adoption of the new revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#8217;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, and Takeda and the analysis of the impact of this guidance on those agreements is discussed further in Note 2 below.&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the new revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed&#160;&#160;are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the new revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">goods or services promised in a contract</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> should be accounted for as a </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combined performance obligation over time</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the proportional performance method</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Labor hours</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or costs incurred</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are typically used as the measure of performance.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company determines that</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the performance </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation is satisfied over time, any upfront</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payment </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received is initially recorded </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deferred</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> revenue </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the Company&#8217;s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Consolidated Balance Sheets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#8217;s current operating plan and, if the Company&#8217;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Doubtful Accounts&#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per Share&#8212;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees.&#160;&#160;During the years ended September 30, 2020, 2019 and 2018, the calculation of the effect of dilutive stock options and restricted stock units was 0 shares, 4,748,958 shares, and 0 shares, respectively.&#160;&#160;During the year ended September 30, 2020,<span style="color:#000000;"> the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2019, the calculation of the effect of dilutive stock options and restricted stock units excluded 1,007,500 stock options and 11,500 restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2018, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;&#160;&#160;&#160;&#160; </span> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.<span style="font-size:12pt;">&#160;</span></p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases<span style="color:#000000;">&#8212;</span>The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term.&#160;Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and became effective for the Company in the first quarter of fiscal 2019. In April 2016, the FASB issued an amendment to ASU No. 2014-09 with update ASU 2016-10 which provided more specific guidance around the identification of performance obligations and licensing arrangements.&#160;&#160;On October 1, 2018, the Company adopted this standard using the modified retrospective method. The Company&#8217;s implementation approach included reviewing the status of each of its ongoing license agreements and collaboration agreements and designing appropriate internal controls to enable the preparation of financial information.&#160;&#160;The Company completed its assessment of the impact of the new revenue recognition guidance and determined that there will be no material impact.&#160;&#160;The Company&#8217;s existing performance obligations under its ongoing license and collaboration agreements as of October 1, 2018 and prior were substantially completed prior to September 30, 2018.&#160;&#160;For these agreements that were ongoing as of October 1, 2018, any future option, milestone or royalty payments received will be accounted for under the sales-based royalty exception provided for under this new revenue recognition guidance.&#160;&#160;Additionally, there will be no impact to cash from or used in operating, financing or investing activities on the Company&#8217;s Consolidated Statement of Cash Flows as a result of the adoption of the new standard.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842).&#160;&#160;Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&#160;&#160;The Company adopted this standard effective October 1, 2019 and <span style="color:#000000;">elected the package of three practical expedients that permits an entity to i) not reassess whether expired or existing contracts contain leases, ii) not reassess lease classification for existing or expired leases, and iii) not consider whether previously capitalized initial direct costs would be appropriate under the new standard.&#160;&#160;At September 30, 2020, the Company has recorded right-of-use assets of $16.1 million and right-of-use liabilities of $21.1 million on its Consolidated Balance Sheets for its research and development facility leases in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below.&#160;&#160;The adoption of this standard did not have a material impact on the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss) and the Company&#8217;s Consolidated Statements of Cash Flows.&#160;&#160; </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808).&#160;&#160;This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 becomes effective for the Company in the first quarter of fiscal 2021 with early adoption permitted.&#160;&#160;The Company does not expect the adoption of this update to have a material effect on its Consolidated Financial Statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447923752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">
<p style="text-align:justify;margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2. <span style="font-style:italic;">COLLABORATION AND LICENSE AGREEMENTS</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Amgen Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September&#160;28, 2016, the Company entered into two Collaboration and License Agreements, and a Common Stock Purchase Agreement with Amgen Inc., a Delaware corporation (&#8220;Amgen&#8221;). Under one of the collaboration and license agreements (the &#8220;Second Collaboration and License Agreement&#8221; or &#8220;Olpasiran Agreement&#8221;), Amgen has received a worldwide, exclusive license to Arrowhead&#8217;s novel, RNAi Olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the other collaboration and license agreement (the &#8220;First Collaboration and License Agreement&#8221; or the &#8220;ARO-AMG1 Agreement&#8221;), Amgen received an option to a worldwide, exclusive license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target. In both agreements, Amgen is wholly responsible for clinical development and commercialization. Under the terms of the agreements taken together, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s Common Stock, and $30.0 million in milestone payments, and may receive up to an additional $400.0 million in remaining development, regulatory and sales milestone payments. The Company is further eligible to receive up to low double-digit royalties for sales of products under the Olpasiran Agreement. In July 2019, Amgen informed the Company that it would not be exercising its option for an exclusive license for ARO-AMG1, and as such, there will be no further milestone or royalty payments under the ARO-AMG1 Agreement.&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company substantially completed its performance obligations under the Olpasiran Agreement and the ARO-AMG1 Agreement.&#160;&#160;Future milestones and royalties achieved will be recognized in their entirety when earned. In July 2020, Amgen initiated a Phase 2 clinical study, which resulted in a $20 million milestone payment to the Company. During the years ended September 30, 2020, 2019 and 2018, the Company recognized $20.1 million, $0.3 million, and $16.1 million of Revenue associated with its agreements with Amgen, respectively.  As of September 30, 2020, there were $0 million in contract assets recorded as accounts receivable and $0 contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Janssen Pharmaceuticals, Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 3, 2018, the Company entered into a License Agreement (&#8220;Janssen License Agreement&#8221;) and a Research Collaboration and Option Agreement (&#8220;Janssen Collaboration Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson.&#160;&#160;The Company also entered into a Stock Purchase Agreement (&#8220;JJDC Stock Purchase Agreement&#8221;) with Johnson &amp; Johnson Innovation-JJDC, Inc. (&#8220;JJDC&#8221;), a New Jersey corporation.&#160;&#160;Under the Janssen License Agreement, Janssen has received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989 (ARO-HBV), Janssen is also wholly responsible for clinical development and commercialization of JNJ-3989.&#160;&#160;Under the Janssen Collaboration Agreement, Janssen will be able to select three new targets against which Arrowhead will develop clinical candidates.&#160;&#160;These candidates are subject to certain restrictions and do not include candidates that already were in the Company&#8217;s pipeline.&#160;&#160;The Company will perform discovery, optimization and preclinical research and development, entirely funded by Janssen, which on its own or in combination with Janssen development work, is sufficient to allow the filing of a U.S. Investigational New Drug application or equivalent, at which time Janssen will have the option to take an exclusive license. If the option is exercised, Janssen will be wholly responsible for clinical development and commercialization of each optioned candidate.&#160;&#160;Under the terms of the agreements taken together, the Company has received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment <span style="color:#000000;">by JJDC in Arrowhead Common Stock under the JJDC </span>Stock Purchase Agreement, and two $25.0 million milestone payments, and may receive up to $1.6 billion in development and sales milestones payments for the Janssen License Agreement, and up to $1.9 billion in development and sales milestone payments for the three additional targets covered under the Janssen Collaboration Agreement.&#160;&#160;The Company is further eligible to receive tiered royalties up to mid-teens under the Janssen License Agreement and up to low teens under the Janssen Collaboration Agreement on product sales.&#160;&#160; </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated these agreements in accordance with the new revenue recognition standard that became effective for the Company on October 1, 2018.&#160;&#160;The adoption of the new revenue standard did not have a material impact on the balances reported when evaluated under the superseded revenue standard.&#160;&#160;At the inception of these agreements, the Company has identified one distinct performance obligation.&#160;&#160;Regarding the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 (ARO-HBV) and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 (ARO-HBV) drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Janssen R&amp;D Services, and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and thus, one performance obligation.&#160;&#160;The Company also determined that Janssen&#8217;s option to require the Company to develop up to three new targets is not a material right, and thus, not a performance obligation at the onset of the agreement.&#160;&#160;The consideration for this option will be accounted for if and when it is exercised. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the transaction price totaled approximately $252.6 million which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, the two $25.0 million milestone payments earned and estimated payments for reimbursable Janssen R&amp;D services to be performed.&#160;&#160;The Company has allocated the total $252.6 million initial transaction price to its one distinct performance obligation for the JNJ-3989 (ARO-HBV) license and the associated Janssen R&amp;D Services.&#160;&#160;This revenue will be recognized using a proportional performance method (based on actual labor hours versus estimated total labor hours) beginning in October 2018 and ending as the Company&#8217;s efforts in overseeing the phase 1/2 clinical trial are completed.&#160;&#160;During the years ended September 30, 2020 and 2019, the Company recognized approximately $65.0 million and $167.5 million of Revenue associated with this performance obligation, respectively. As of September 30, 2020, there were $0 in contract assets recorded as accounts receivable, and $19.3 million of contract liabilities recorded as current deferred revenue on the Company&#8217;s Consolidated Balance Sheets.&#160;&#160;The $19.3 million of current deferred revenue is driven by the upfront payment, the premium paid by JJDC for its equity investment in the Company, and the two $25.0 million milestone payments earned, net of revenue recognized to date.<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has begun to conduct its discovery, optimization and preclinical research and development of ARO-JNJ1, ARO-JNJ2 and ARO-JNJ3 under the Janssen Collaboration Agreement.&#160;&#160;All costs and labor hours spent by the Company will be entirely funded by Janssen.&#160; During the years ended September 30, 2020 and 2019, the Company recognized $2.9 million and $1.0 million of Revenue associated with these efforts, respectively. As of September 30, 2020, there were $0.8 million of cont<span style="color:#000000;">ract assets recorded as accounts </span>receivable, and $0 of contract liabilities recorded as curren<span style="color:#000000;">t deferred revenue on the Company&#8217;s Consolidated Balance</span> Sheets.&#160; <span style="color:#000000;"> &#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Takeda Pharmaceuticals U.S.A., Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 7, 2020, the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda Pharmaceuticals U.S.A., Inc. (&#8220;Takeda&#8221;).&#160;&#160;Under the Takeda License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with the Company eligible to receive tiered royalties of 20% to 25% on net sales.&#160;&#160;The Company will receive $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.</span>&#160;&#160;</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has evaluated the Takeda License Agreement in accordance with the new revenue recognition requirements that became effective for the Company on October 1, 2018. The adoption of the new revenue standard will not have a material impact on the balances reported when evaluated under the superseded revenue standard.&#160;&#160;At the inception of the Takeda License Agreement, the Company has identified one distinct performance obligation.&#160;&#160;The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing phase 2 AROAAT2002 study and to ensure certain manufacturing of ARO-AAT drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;).&#160;&#160;Due to the specialized and unique nature of these Takeda R&amp;D services, and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and thus, one performance obligation.&#160;&#160;Beyond the Takeda R&amp;D Services, Takeda will be responsible for managing future clinical development and commercialization.&#160;&#160;The Company will co-fund certain of the development and commercialization costs that Takeda manages, and these co-funding amounts will be offset against amounts owed to Arrowhead, either from milestones or royalties earned, or profits earned under the 50/50 profit sharing structure for U.S. commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined the initial transaction price totaled approximately $300.0 million which includes the upfront payment.&#160;&#160;The Company will exclude any future estimated milestones, royalties or profit-sharing payments from this transaction price to date.&#160;&#160;The Company will allocate the total $300.0 million initial transaction price to its one distinct performance obligation for the ARO-AAT license and the associated Takeda R&amp;D Services.&#160;&#160;This revenue will be recognized using a proportional performance method (based on actual costs incurred versus estimated total estimated costs incurred for the Takeda R&amp;D Services) beginning in the Company&#8217;s first fiscal quarter of fiscal 2021 and ending as the Takeda R&amp;D Services are completed.&#160;&#160;<span style="font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447555928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3. <span style="font-style:italic;">PROPERTY AND EQUIPMENT</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s major classes of property and equipment:<span style="font-size:11pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers, office equipment and furniture</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661,927</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">637,577</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,654,323</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,932,304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">631,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,237,851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,579,415</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross fixed assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,185,305</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,296,550</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,304,437</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,081,651</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,880,868</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,214,899</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense for property and equipment for the years ended September 30, 2020, 2019, and 2018  was $4,241,834 and $2,738,715, and $2,998,846 respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246641753048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Held To Maturity Securities Classified [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 4. <span style="font-style:italic;">INVESTMENTS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments at September 30, 2020 primarily consist of corporate bonds that have maturities of less than 36 months and marketable equity securities. The Company&#8217;s corporate bonds consists of both short-term and long-term bonds and are classified as &#8220;held-to-maturity&#8221; on the Company&#8217;s Consolidated Balance Sheets. The Company&#8217;s marketable equity securities consist of mutual funds that invests in U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities. Dividends from these three funds are automatically reinvested.&#160;&#160;The Company may also invest excess cash balances in certificates of deposits, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper.&#160;&#160;The Company accounts for its held to maturity investments in accordance with FASB ASC 320, Investments &#8211; Debt and Equity Securities and its marketable equity securities in accordance with ASC 321, Investments &#8211; Equity Securities.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s short-term, long-term investments and marketable securities as of September 30, 2020 and September 30, 2019 by measurement category. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Held to Maturity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,889,751</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589,873</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,479,624</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,486,883</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,573,964</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,471</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,981,376</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,376,634</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,163,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,471</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,461,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,899,894</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,584</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,122,478</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,175,993</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">875,258</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,051,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,075,887</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097,842</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,173,729</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized Gains/(Losses)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,000,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,734</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,015</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,019,719</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,000,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,734</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,015</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,019,719</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246538088792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5. <span style="font-style:italic;">INTANGIBLE ASSETS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The license agreement associated with the Novartis RNAi asset acquisition is being amortized over the estimated life remaining at the time of acquisition, which was 21 years, and the accumulated amortization of the asset is $828,596.&#160;&#160;The patents associated with the Novartis RNAi asset acquisition are being amortized over the estimated life remaining at the time of acquisition, which was 14 years, and the accumulated amortization of the assets is $8,665,466.&#160;&#160;Amortization expense for the years ended September 30, 2020, 2019, and 2018 was $1,700,429, $1,700,430, and $1,700,429, respectively. Amortization expense is expected to be $1,700,429 in 2021, $1,700,429 in 2022, $1,700,429 in 2023, $1,700,429 in 2024, $1,700,429 in 2025 and $6,861,006 thereafter.</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides details on the Company&#8217;s intangible asset balances: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,063,580</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,700,429</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,363,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246449317144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6. <span style="font-style:italic;">STOCKHOLDERS&#8217; EQUITY</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2020, the Company had a total of 150,000,000 shares of capital stock authorized for issuance, consisting of 145,000,000 shares of Common Stock, par value $0.001 per share, and 5,000,000 shares of Preferred Stock, par value $0.001 per share. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At September 30, 2020, <span style="color:#000000;">102,376,303</span> shares of Common Stock were outstanding.&#160;&#160;At September 30, 2020, 8,462,148 shares of Common Stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under Arrowhead&#8217;s 2004 Equity Incentive Plan and 2013 Incentive Plan, as well as for inducement grants made to new employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company sold 4,600,000 shares of its Common Stock in a public offering at a price of $58.00 per share.&#160;&#160;The aggregate purchase price paid by the investors for the Common Stock was $266.8 million, and the Company received net proceeds of $250.5 million after deducting advisory fees and offering expenses.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the Company entered into an Open Market Sale Agreement (the &#8220;ATM Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s Common Stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the ATM Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the ATM Agreement. Unless otherwise terminated, the ATM Agreement continues until the earlier of selling all shares available under the ATM Agreement or December 2, 2022. At September 30, 2020, no shares have been issued under the ATM Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447844872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7. <span style="font-style:italic;">COMMITMENTS AND CONTINGENCIES</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Litigation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business.&#160;&#160;If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss.&#160;&#160;There were no contingent liabilities recorded as of the year ended September 30, 2020. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Purchase Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into various purchase commitments for the manufacture of drug components, for toxicology studies and for clinical studies. &#160;As of September 30, 2020, these future commitments were estimated at approximately $78.0 million, of which approximately $60.2 million is expected to be incurred in fiscal 2021, and $17.8 million is expected to be incurred beyond fiscal 2021.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Technology License Commitments</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has licensed from third parties the rights to use certain technologies for its research and development&#160;activities,&#160;as well as in any products the Company may develop using these licensed technologies. These agreements and other similar agreements often require milestone and royalty payments. &#160;Milestone payments, for example, may be required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and upon certain sales level milestones. &#160;These milestone payments could amount to the mid to upper double-digit millions of dollars. During the year ended September 30, 2020, the Company incurred $2.4 million of milestone payments related to the progression of the ARO-ENaC and ARO-HIF2 candidates.  During the years ended September 30, 2019 and 2018, the Company did not trigger any milestone payments.&#160;&#160;In certain agreements, the Company may be required to make mid to high single-digit percentage royalty payments based on a percentage of the sales of the relevant products.<span style="font-size:12pt;">&#160;</span>&#160;&#160;&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246537203320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8. <span style="font-style:italic;">LEASES</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the Company entered into a lease for its corporate headquarters in Pasadena, California.&#160;&#160;The 91 month office building lease between the Company and 177 Colorado Owner, LLC is for approximately 24,000 square feet of office space located at 177 E. Colorado Blvd, Pasadena, California. &#160;The increased capacity of this new office space compared to the Company&#8217;s prior corporate headquarters will accommodate increased personnel as the Company&#8217;s pipeline of drug candidates expands and moves closer to market. Lease payments began on September 30, 2019 and are estimated to total approximately $8.7 million over the term. <span style="font-size:12pt;color:#000000;">&#160;</span>The lease expires on April 30, 2027.  The Company has paid approximately $3.5 million for leasehold improvements, net of tenant improvement allowances.&#160;&#160;The lease contains an option to renew for one term of five years. The exercise of this option was not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#8217;s Consolidated Balance Sheet at September 30, 2020.&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the Company entered into a lease for its research facility in Madison, Wisconsin.&#160;&#160;The lease was for approximately 60,000 square feet of office and laboratory space and had an expiration date of September 30, 2026. The lease was amended in January 2019 to expand the rentable square feet by an additional 14,000 square feet and to extend the lease expiration date to September 2029. In May 2020, the Company further amended the lease to increase the rentable square feet by an additional 26,000 square feet and extended the lease expiration date to September 30, 2031.&#160;&#160;Lease payments are estimated to total approximately $26.2 million for the term.<span style="font-size:12pt;">&#160;</span><span style="color:#000000;">The lease contains two options to renew for two terms of five years. The exercise of these options were not determined to be reasonably certain and thus was not included in lease liabilities on the Company&#8217;s Consolidated Balance Sheet at September 30, 2020.&#160;</span> &#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.67%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, the Company entered into a sublease agreement (the &#8220;Sublease&#8221;) with Halozyme, Inc. for additional research and development facility space in San Diego, California.&#160; The Sublease provides additional space needed to accommodate the recent growth of the Company&#8217;s personnel and discovery efforts. The sublease is for approximately <span style="Background-color:#FFFFFF;color:#000000;">21,000</span> rentable square feet.&#160; The term of the Sublease commenced on April 1, 2020 and will end on January 14, 2023.&#160;&#160;Sublease payments are estimated to total approximately $2.0 million over the term.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost during the years ended September 30, 2020, 2019, and 2018 was $2.4 million, $1.3 million and $1.3 million respectively.&#160;&#160;Variable lease costs during the year ended September 30, 2020 were $0.8 million.&#160;&#160;There was no short-term lease cost during the years ended September 30, 2020, 2019 and 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September 30, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,091,901</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,853,290</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,406,754</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,269,674</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,358,292</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,331,296</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,311,207</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,173,252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities (includes current portion)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,137,955</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for the amounts included in the measurement of the operating lease liabilities on the Company&#8217;s Consolidated Balance Sheet and included in Other changes in operating assets and liabilities within cash flows from operating activities on the Company&#8217;s Consolidated Statement of Cash Flow for the years ended September 30, 2020, 2019 and 2018 were  $1.8 million, $1.3 million and $1.3 million, respectively.&#160;The weighted-average remaining lease term and weighted-average discount rate for all leases as of September 30, 2020 was <span style="color:#000000;">9.4 years</span> and 8.4%, respectively.</p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2019, future minimum lease payments due in fiscal years under operating leases were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,521,451</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,256,379</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,521,446</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,590,558</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,661,512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,834,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,385,552</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447868424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9. <span style="font-style:italic;">STOCK-BASED COMPENSATION</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arrowhead has two plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan and 2013 Incentive Plan, as of September 30, 2020, 673,262 and 5,598,345 shares, respectively, of Arrowhead&#8217;s Common Stock are reserved for the grant of stock options, stock appreciation rights, restricted stock awards and performance unit/share awards to employees, consultants and others. No further grants may be made under the 2004 Equity Incentive Plan.&#160;&#160;As of September 30, 2020, there were options granted and outstanding to purchase 673,262 and 2,611,625 shares of Common Stock under the 2004 Equity Incentive Plan and the 2013 Incentive Plan, respectively, and there were 2,588,000 restricted stock units granted and outstanding under the 2013 Incentive Plan. Also, as of September 30, 2020, there were 1,254,516 shares reserved for options and 936,025  shares reserved for restricted stock units issued as inducement grants to new employees outside of equity compensation plans. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,773,670</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.16</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">951,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,639</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.38</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,111,128</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September 30, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,539,403</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.67</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,100,277</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable At September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,924,744</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,698,309</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense related to stock options for the years ended September 30, 2020, 2019, and 2018 was $9,719,116, $3,955,216, and $3,265,348, respectively.  For non-qualified stock options, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The grant date fair value of the options granted by the Company for the years ended September 30, 2020, 2019, and 2018 was $34,582,743, $12,137,250, and $4,141,318, respectively.  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The intrinsic value of the options exercised during the years ended September 30, 2020, 2019 and 2018 was $44,082,294, $24,561,189, and $5,805,317, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $36,355,846 will be recognized in the Company&#8217;s results of operations over a weighted average period of <span><span style="color:#000000;">3.1 </span>years</span>. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </p>

<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;ended&#160;September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000632">0.4 &#8211; 1.8%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000633">1.50-3.11%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000634">2.05-2.99%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90-92%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Expected life (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000642">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000643">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Weighted average grant date fair value per share of options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36.35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The dividend yield is zero as the Company currently does not pay a dividend. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The risk-free interest rate is based on that of the U.S. Treasury bond. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility is estimated based on volatility average of the Company&#8217;s Common Stock price. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Restricted Stock Units</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted stock units (&#8220;RSUs&#8221;), including time-based and performance-based awards, were granted under the Company&#8217;s 2013 Incentive Plan and as inducements grants granted outside of the Plan.&#160;During the year ended September 30, 2020, the Company issued 1,754,071 RSUs under the 2013 Incentive Plan and 933,025 RSUs as inducement awards. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s Common Stock. RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee&#8217;s income taxes due upon vesting and withholds a number of shares of Common Stock of equal value.&#160;&#160;RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity of the Company&#8217;s RSUs:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September&#160;30, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,062,833</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.43</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,687,096</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.59</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,158,904</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.71</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.78</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September 30, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,524,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended September 30, 2020, 2019, and 2018, the Company recorded $33,663,871, $8,438,107 and $5,189,259 of expense related to RSUs, respectively. Such expense is included in stock-based compensation expense in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). For RSUs, the expense creates a timing difference, resulting in a deferred tax asset, which is fully reserved by a valuation allowance.&#160;&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For RSUs, the grant date fair value of the award is based on the Company&#8217;s closing stock price at the grant date, with consideration given to the probability of achieving performance conditions for performance-based awards.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020, the pre-tax compensation expense for all unvested RSUs in the amount of $88,548,649 will be recognized in the Company&#8217;s results of operations over a weighted average period of 3.1 years.  Unvested RSUs that we have deemed not probable of vesting as of September 30, 2020, have the potential of generating an additional $38.0 million of pre-tax compensation expense if we deem them probable of vesting in a future reporting period.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246449327992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-style:italic;">FAIR VALUE MEASUREMENTS</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its financial assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., exit price) in an orderly transaction between market participants at the measurement date. Additionally, the Company is required to provide disclosure and categorize assets and liabilities measured at fair value into one of three different levels depending on the assumptions (i.e., inputs) used in the valuation. Level&#160;1 provides the most reliable measure of fair value while Level&#160;3 generally requires significant management judgment. Financial assets and liabilities are classified in their entirety based on the lowest level of input significant to the fair value measurement. The fair value hierarchy is defined as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;1&#8212;Valuations are based on unadjusted quoted prices in active markets for identical assets or liabilities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;2&#8212;Valuations are based on quoted prices for similar assets or liabilities in active markets, or quoted prices in markets that are not active for which significant inputs are observable, either directly or indirectly. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level&#160;3&#8212;Valuations are based on prices or valuation techniques that require inputs that are both unobservable and significant to the overall fair value measurement. Inputs reflect management&#8217;s best estimate of what market participants would use in valuing the asset or liability at the measurement date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes fair value measurements at September 30, 2020 and September&#160;30, 2019 for assets and liabilities measured at fair value on a recurring basis.&#160;&#160;Certain amounts have been reclassed to conform with current year presentation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.02%;">
<tr style="height:10.2pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,582,667</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,582,667</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,019,719</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,019,719</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:13.45pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (held to maturity)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,479,624</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,479,624</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (held to maturity)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,981,376</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,981,376</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, <span style="color:#000000;">2019</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.02%;">
<tr style="height:10.25pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.85pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,804,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,804,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.85pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,122,478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,122,478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:13.5pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,051,251</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,051,251</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.85pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a liability for contingent consideration related to its acquisition of the Roche RNAi business completed in 2011. The fair value measurement of the contingent consideration obligations is determined using Level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on the Company&#8217;s assumptions and experience. Estimating timing to complete the development and obtain approval of products is difficult, and there are inherent uncertainties in developing a product candidate, such as obtaining FDA and other regulatory approvals. In determining the probability of regulatory approval and commercial success, the Company utilizes data regarding similar milestone events from several sources, including industry studies and its own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period. In November 2016, the Company announced the discontinuation of its clinical trial efforts for ARC-520, ARC-AAT and ARC-521.&#160;&#160;Given this development, the Company assessed the fair value of its contingent consideration obligation to be $0 at September 30, 2020 and September 30, 2019.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447531592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 11. <span style="font-style:italic;">INCOME TAXES</span> </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company utilizes the guidance issued by the FASB for accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and </p>

<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of the net deferred tax asset (liability) at September 30, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued Compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,086,396</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,310,466</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,936,819</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,609,756</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized Research &amp; Development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">926,026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">California Alternative Minimum Tax</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,652</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,553</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">438,882</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Operating Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,007,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,372,571</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,818,002</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,590,090</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702,357</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of Use Assets/Lease Liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,015,626</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Rent</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">821,317</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital Loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,079,659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,952,440</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(156,603,859</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(108,232,402</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,546,968</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,928,832</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,720,038</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,475,800</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,720,038</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has concluded, in accordance with the applicable accounting standards, that it is more likely than not that the Company may not realize the benefit of all of its deferred tax assets. Accordingly, management has provided a 100% valuation allowance against its deferred tax assets until such time as management believes that its projections of future profits as well as expected future tax rates make the realization of these deferred tax assets more-likely-than-not. Significant judgment is required in the evaluation of deferred tax benefits and differences in future results from our estimates could result in material differences in the realization of these assets. The Company has performed an assessment of positive and negative evidence regarding the realization of the net deferred tax asset in accordance with FASB ASC 740-10, &#8220;Accounting for Income Taxes.&#8221; This assessment included the evaluation of scheduled reversals of deferred tax liabilities, the availability of carry forwards and estimates of projected future taxable income.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September&#160;30, 2020, the Company had available gross federal net operating loss (&#8220;NOL&#8221;) carry forwards of approximately $<span style="color:#000000;">473.0</span> million and gross state NOL carry forwards of $<span style="color:#000000;">497.0&#160;</span>million. The NOLs expire at various dates through 2040.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions for income taxes for the years ended September 30, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Federal</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,553</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,553</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision from income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,553</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended September 30, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At U.S. federal statutory rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal effect</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-7.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-29.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-15.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark-to-market adjustments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-13.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">True-up on deferred taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax rate change</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits in income tax expense.&#160;&#160;The Company has not recognized any unrecognized tax benefits and does not have any interest or penalties related to uncertain tax positions as of September 30, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns with the Internal Revenue Service (&#8220;IRS&#8221;), the state of California and certain other taxing jurisdictions. The Company is subject to income tax examinations by the IRS and by state tax authorities until the net operating losses are settled.&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447848488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 12. <span style="font-style:italic;">EMPLOYEE BENEFIT PLANS</span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2005, the Company adopted a defined contribution 401(k) retirement savings plan covering substantially all of its employees. The Plan is administered under the &#8220;safe harbor&#8221; provision of ERISA. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participant&#8217;s first 3% of compensation contributed plus 50% of each participant&#8217;s next 2% of compensation contributed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended September&#160;30, 2020, 2019, and 2018, the Company recorded expenses under this plan of $863,080, $545,698 and $451,623, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the employee benefit plans described above, the Company provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246450715224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Quarterly Financial Data<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Unaudited Quarterly Financial Data</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 13. <span style="font-style:italic;">UNAUDITED QUARTERLY FINANCIAL DATA</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.11%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents selected unaudited quarterly financial data for each full quarterly period of the years ended September 30, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">First</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fourth</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,454,579</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,528,853</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,375,778</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,632,856</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Income (Loss)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,853,594</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,240,255</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,945,862</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,119,092</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,673,728</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,835,570</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,611,213</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,432,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Basic</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.03</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.48</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.03</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.48</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always"/>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">First</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fourth</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended September 30, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,657,896</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,148,275</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,696,636</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,292,770</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Income (Loss)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,946,144</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,010,692</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,595,749</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,638,049</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,037,253</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,896,982</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,335,708</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,704,906</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Basic</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.24</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246451730184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NOTE 14. <span style="font-style:italic;">SUBSEQUENT EVENTS</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive License and Co-Funding Agreement with Takeda Pharmaceuticals U.S.A., Inc.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 7, 2020, the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;) with Takeda Pharmaceuticals U.S.A., Inc.&#160;&#160;(&#8220;Takeda&#8221;).&#160;&#160;Under the Takeda License Agreement, <span style="Background-color:#FFFFFF;color:#000000;">Takeda and the Company will co-develop the Company&#8217;s ARO-AAT program, the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate&#160;being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, ARO-AAT, if approved, will be co-commercialized under a 50/50 profit sharing structure.&#160;&#160;Outside the United States, Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with the Company eligible to receive tiered royalties of 20% to 25% on net sales.&#160;&#160;The Company will receive $300.0 million as an upfront payment and is eligible to receive potential development, regulatory and commercial milestones of up to $740.0 million.</span>&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Corporate Headquarters Lease Expansion</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 23, 2020, the Company signed a lease expansion to add an additional 24,434 square feet of office space for the Company&#8217;s corporate headquarters in Pasadena, CA.&#160;&#160;The lease commencement date is expected to be July 2021, after certain leasehold improvements are completed, and the lease expires in April 2027.&#160;&#160;The lease payments over the life of lease total $7.3 million.&#160;&#160;The Company anticipates paying approximately $4.0 million of leasehold improvements, net of tenant improvement allowances.&#160;&#160;<span style="color:#000000;">The increased capacity of this additional office space compared to the Company&#8217;s current corporate headquarters will accommodate increased personnel as the Company&#8217;s pipeline of drug candidates expands and moves closer to market.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246452320392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Principles of Consolidation&#8212;The Consolidated Financial Statements include the accounts of Arrowhead and its Subsidiaries.&#160;&#160;Arrowhead&#8217;s primary operating subsidiary is Arrowhead Madison, which is located in Madison, Wisconsin, where the Company&#8217;s research and development facility is located.&#160;&#160;All significant intercompany accounts and transactions are eliminated in consolidation. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basis of Presentation and Use of Estimates&#8212;The <span style="color:#000000;">preparation of financial statements in conformity GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;&#160;Actual results could materially differ from those estimates. Additionally, certain reclassifications have been made to prior period financial statements to conform to the current period presentation</span>.&#160;&#160; </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and Cash Equivalents&#8212;The Company considers all liquid debt instruments purchased with a maturity of three months or less to be cash equivalents.&#160;&#160;Included within Cash and cash equivalents on the Consolidated Balance Sheets is $1.8 million and $1.0 restricted cash at September 30, 2020 and September 30, 2019, respectively.&#160;&#160;Amounts included in restricted cash are primarily held as collateral associated with a letter of credit for the Company&#8217;s <span style="color:#000000;">lease for its corporate headquarters in Pasadena, California.</span>&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk&#8212;The Company maintains several bank accounts primarily at two financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments&#8212;The Company may invest excess cash balances in short-term and long-term marketable debt and equity securities. Investments may consist of certificates of deposit, money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper. The Company accounts for its investment in marketable securities in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 320, Investments &#8211; Debt and Equity Securities and ASC 321, Investments in Equity Securities.&#160;ASC 320-Investments-Debt and Equity Securities requires debt securities to be classified into three categories: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-Maturity&#8212;Debt securities that the entity has the positive intent and ability to hold to maturity are reported at amortized cost. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Securities&#8212;Debt securities that are bought and held primarily for the purpose of selling in the near term are reported at fair value, with unrealized gains and losses included in earnings. </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-Sale&#8212;Debt securities not classified as either securities held-to-maturity or trading securities are reported at fair value with unrealized gains or losses excluded from earnings and reported as a separate component of shareholders&#8217; equity. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies its investments in marketable debt securities based on the facts and circumstances present at the time of purchase of the securities. During the years ended September 30, 2020, 2019 and 2018, all of the Company&#8217;s debt securities were classified as held-to-maturity.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Held-to-maturity investments are measured and recorded at amortized cost on the Company&#8217;s Consolidated Balance Sheet. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security. No gains or losses on investment securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended September 30, 2020, the Company purchased shares of mutual funds that invest in marketable debt securities such as U.S. government bonds, U.S. government agency bonds, corporate bonds, and other asset backed debt securities.&#160;&#160;The Company accounts for these securities using the guidance from FASB ASC 321, Investments-Equity Securities. These securities are recorded on the Company&#8217;s Consolidated Balance Sheet as &#8220;marketable securities&#8221; and recorded at fair value. All unrealized gains/losses associated with these securities are recorded in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and Equipment&#8212;Property and equipment are recorded at cost, which may equal fair market value in the case of property and equipment acquired in conjunction with a business acquisition. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from three to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. Long-lived assets, including property and equipment are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets subject to amortization</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets Subject to Amortization&#8212;Intangible assets subject to amortization include certain patents and license agreements. Intangible assets subject to amortization are reviewed for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable and are also reviewed annually to determine whether any impairment is necessary. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration&#8212;The consideration for the Company&#8217;s acquisitions may include future payments that are contingent upon the occurrence of a particular event.&#160;&#160;For example, milestone payments might be based on the achievement of various regulatory approvals or future sales milestones, and royalty payments might be based on drug product sales levels. The Company records a contingent consideration obligation for such contingent payments at fair value on the acquisition date. The Company estimates the fair value of contingent consideration obligations through valuation models designed to estimate the probability of such contingent payments based on various assumptions and incorporating estimated success rates.&#160;&#160;Estimated payments are discounted using present value techniques to arrive at an estimated fair value at the balance sheet date. Changes in the fair value of the contingent consideration obligations are recognized within the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss). Changes in the fair value of the contingent consideration obligations can result from changes to one or multiple inputs, including adjustments to the discount rates, changes in the amount or timing of expected expenditures associated with product development, changes in the amount or timing of cash flows from products upon commercialization, changes in the assumed achievement or timing of any development milestones, changes in the probability of certain clinical events and changes in the assumed probability associated with regulatory approval. These fair value measurements are based on significant inputs not observable in the market. Substantial judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense the Company records in any given period.&#160;&#160;The Company determined the fair value of its contingent consideration obligation to be $0 at September 30, 2020 and September 30, 2019. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue Recognition&#8212; <span style="color:#000000;">On October 1, 2018, the Company adopted FASB Topic 606 &#8211; Revenue for Contracts from Customers which amended revenue recognition principles and provides a single, comprehensive set of criteria for revenue recognition within and across all industries. The Company&#8217;s adoption of the new revenue standard did not have a material impact on its Consolidated Financial Statements.&#160;&#160;The Company has not yet achieved commercial sales of its drug candidates to date, however, the new standard is applicable to the Company&#8217;s ongoing licensing and collaboration agreements, including those with Amgen, Janssen, and Takeda and the analysis of the impact of this guidance on those agreements is discussed further in Note 2 below.&#160;&#160;&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of the new revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&#160;&#160;At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified.&#160;&#160;The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that the Company determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved.&#160;&#160;The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license&#160;to the customer and resulting ability of the customer to use and benefit from the license,&#160;if the license is determined to be distinct from the other performance obligations identified in the contract.&#160;&#160;These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing.&#160;&#160;If the license is not considered to be distinct from other performance obligations,&#160;the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time.&#160;&#160;If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas.&#160;The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold.&#160;At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for our milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price.&#160;&#160;Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s Consolidated Statement of Operations and Comprehensive Income (Loss).&#160; Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or pre-clinical program.&#160;&#160;Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed&#160;&#160;are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price.&#160;&#160;The Company performs this assessment at the onset of its licensing or collaboration agreements.&#160;&#160;Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment.&#160;&#160;Additionally, future royalty payments are not substantially within the control of the Company or the customer.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The new revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the new revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Whenever the Company determines that </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">goods or services promised in a contract</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> should be accounted for as a </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">combined performance obligation over time</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the proportional performance method</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Labor hours</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or costs incurred</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are typically used as the measure of performance.</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> If the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company determines that</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the performance </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation is satisfied over time, any upfront</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> payment </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">received is initially recorded </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">deferred</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> revenue </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on the Company&#8217;s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Consolidated Balance Sheets</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term and long-term deferred revenue based on its best estimate of when such revenue will be recognized. Short-term deferred revenue consists of amounts that are expected to be recognized as revenue in the next 12&#160;months, and long-term deferred revenue consists of amounts that the Company does not expect will be recognized in the next 12 months. This estimate is based on the Company&#8217;s current operating plan and, if the Company&#8217;s operating plan should change in the future, the Company may recognize a different amount of deferred revenue over the next 12-month period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Allowance for Doubtful Accounts</a></td>
<td class="text">Allowance for Doubtful Accounts&#8212;The Company accrues an allowance for doubtful accounts based on estimates of uncollectible revenues by analyzing historical collections, accounts receivable aging and other factors. Accounts receivable are written off when all collection attempts have failed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and Development&#8212;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred in accordance with FASB ASC 730-10.&#160;&#160;Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) per Share</a></td>
<td class="text">Net Income (Loss) per Share&#8212;Basic net income (loss) per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per share are computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units issued to employees.&#160;&#160;During the years ended September 30, 2020, 2019 and 2018, the calculation of the effect of dilutive stock options and restricted stock units was 0 shares, 4,748,958 shares, and 0 shares, respectively.&#160;&#160;During the year ended September 30, 2020,<span style="color:#000000;"> the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2019, the calculation of the effect of dilutive stock options and restricted stock units excluded 1,007,500 stock options and 11,500 restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;During the year ended September 30, 2018, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units granted and outstanding during the period due to their anti-dilutive effect.&#160;&#160;&#160;&#160;&#160;&#160; </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-Based Compensation&#8212;The Company accounts for share-based compensation arrangements in accordance with FASB ASC 718, which requires the measurement and recognition of compensation expense for all share-based payment awards to be based on estimated fair values. The Company uses the Black-Scholes option valuation model to estimate the fair value of its stock options at the date of grant. The Black-Scholes option valuation model requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date.&#160;&#160;For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved.&#160;&#160;The Company uses historical data and other information to estimate the expected price volatility for stock option awards and the expected forfeiture rate for all awards.&#160;&#160;Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes&#8212;The Company accounts for income taxes under the liability method, which requires the recognition of deferred income tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred income tax assets to the amount expected to be realized. The provision for income taxes, if any, represents the tax payable for the period and the change in deferred income tax assets and liabilities during the period.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leases<span style="color:#000000;">&#8212;</span>The Company determines whether a contract is, or contains, a lease at inception. The Company classifies each of its&#160;&#160;leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Consolidated Balance Sheets as Right-of-use assets and Lease liabilities and are measured at the present value of the fixed payments due over the expected lease term minus the present value of any incentives, rebates or abatements expected to be received from the lessor. Options to extend a lease are typically excluded from the expected lease term as the exercise of the option is typically not reasonably certain.&#160;&#160;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term.&#160;Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the FASB issued ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), which will supersede nearly all existing revenue recognition guidance under GAAP. ASU No. 2014-09 provides that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This update also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU No. 2014-09 allows for either full retrospective or modified retrospective adoption and became effective for the Company in the first quarter of fiscal 2019. In April 2016, the FASB issued an amendment to ASU No. 2014-09 with update ASU 2016-10 which provided more specific guidance around the identification of performance obligations and licensing arrangements.&#160;&#160;On October 1, 2018, the Company adopted this standard using the modified retrospective method. The Company&#8217;s implementation approach included reviewing the status of each of its ongoing license agreements and collaboration agreements and designing appropriate internal controls to enable the preparation of financial information.&#160;&#160;The Company completed its assessment of the impact of the new revenue recognition guidance and determined that there will be no material impact.&#160;&#160;The Company&#8217;s existing performance obligations under its ongoing license and collaboration agreements as of October 1, 2018 and prior were substantially completed prior to September 30, 2018.&#160;&#160;For these agreements that were ongoing as of October 1, 2018, any future option, milestone or royalty payments received will be accounted for under the sales-based royalty exception provided for under this new revenue recognition guidance.&#160;&#160;Additionally, there will be no impact to cash from or used in operating, financing or investing activities on the Company&#8217;s Consolidated Statement of Cash Flows as a result of the adoption of the new standard.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, the FASB issued ASU No. 2016-02, Leases (Topic ASC 842).&#160;&#160;Under ASC 842, lessees are required to recognize a right-of-use asset and a right-of-use lease liability for virtually all leases other than those that meet the definition of a short-term lease. For income statement purposes, a dual model was retained, requiring leases to be classified as either operating or finance. Operating leases will result in straight-line expense while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&#160;&#160;The Company adopted this standard effective October 1, 2019 and <span style="color:#000000;">elected the package of three practical expedients that permits an entity to i) not reassess whether expired or existing contracts contain leases, ii) not reassess lease classification for existing or expired leases, and iii) not consider whether previously capitalized initial direct costs would be appropriate under the new standard.&#160;&#160;At September 30, 2020, the Company has recorded right-of-use assets of $16.1 million and right-of-use liabilities of $21.1 million on its Consolidated Balance Sheets for its research and development facility leases in Madison, Wisconsin and San Diego, California, as well as its corporate headquarters lease in Pasadena, California, as discussed further in Note 8 below.&#160;&#160;The adoption of this standard did not have a material impact on the Company&#8217;s Consolidated Statements of Operations and Comprehensive Income (Loss) and the Company&#8217;s Consolidated Statements of Cash Flows.&#160;&#160; </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued ASU No. 2018-18 Collaborative Arrangements (Topic 808).&#160;&#160;This update provides clarification on the interaction between Revenue Recognition (Topic 606) and Collaborative Arrangements (Topic 808) including the alignment of unit of account guidance between the two topics. ASU 2018-18 becomes effective for the Company in the first quarter of fiscal 2021 with early adoption permitted.&#160;&#160;The Company does not expect the adoption of this update to have a material effect on its Consolidated Financial Statements. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and use of estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contingent consideration obligations related to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246456557624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the Company&#8217;s major classes of property and equipment:<span style="font-size:11pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers, office equipment and furniture</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">661,927</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">637,577</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research equipment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,654,323</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,932,304</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">631,204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147,254</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,237,851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,579,415</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross fixed assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,185,305</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,296,550</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: Accumulated depreciation and amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,304,437</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,081,651</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,880,868</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,214,899</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447906856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract', window );"><strong>Held To Maturity Securities Classified [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock', window );">Summary of Short-term, Long-term Investments and Marketable Securities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables summarize the Company&#8217;s short-term, long-term investments and marketable securities as of September 30, 2020 and September 30, 2019 by measurement category. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Held to Maturity</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,889,751</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,589,873</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,479,624</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,486,883</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,573,964</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,471</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,981,376</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224,376,634</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,163,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(79,471</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,461,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one year)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,899,894</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,584</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,122,478</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial notes (due within one through three years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,175,993</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">875,258</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,051,251</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,075,887</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,097,842</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,173,729</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.86%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.54%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:9pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Realized Gains/(Losses)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,000,000</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,734</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,015</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,019,719</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.54%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,000,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94,734</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,015</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,019,719</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesClassifiedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesClassifiedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447899304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides details on the Company&#8217;s intangible asset balances: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intangible</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">assets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,063,580</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.02%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impairment</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,700,429</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.02%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,363,151</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246536502520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September 30, 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,091,901</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,853,290</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,406,754</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,269,674</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,358,292</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,331,296</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,311,207</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,173,252</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities (includes current portion)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="middle">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,137,955</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Minimum Lease Payments Under Operating Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of September 30, 2019, future minimum lease payments due in fiscal years under operating leases were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,521,451</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,256,379</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,521,446</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,590,558</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:79.88%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.24%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,661,512</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and thereafter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,834,206</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:79.88%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,385,552</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246452036440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information about Stock Options</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information about stock options:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September&#160;30, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,773,670</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.16</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">951,500</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48.19</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,639</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.38</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.18%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,111,128</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.72</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance At September 30, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,539,403</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.67</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129,100,277</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable At September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,924,744</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.30</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.18%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8 years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,698,309</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The assumptions used to value stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years&#160;ended&#160;September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000632">0.4 &#8211; 1.8%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000633">1.50-3.11%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000634">2.05-2.99%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90-92%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Expected life (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000642">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000643">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000644">6.25</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Weighted average grant date fair value per share of options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36.35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.80</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Share Activity Related to RSUs</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity of the Company&#8217;s RSUs:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RSUs</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September&#160;30, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,062,833</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.43</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,687,096</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.59</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,158,904</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.71</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(67,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.78</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unvested at September 30, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,524,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.11</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246536864776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes fair value measurements at September 30, 2020 and September&#160;30, 2019 for assets and liabilities measured at fair value on a recurring basis.&#160;&#160;Certain amounts have been reclassed to conform with current year presentation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2020: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.02%;">
<tr style="height:10.2pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,582,667</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143,582,667</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,019,719</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,019,719</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:13.45pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments (held to maturity)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,479,624</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88,479,624</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments (held to maturity)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,981,376</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,981,376</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.75pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September&#160;30, <span style="color:#000000;">2019</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:84.02%;">
<tr style="height:10.25pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.85pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,804,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221,804,128</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.85pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,122,478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,122,478</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:13.5pt;">
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,051,251</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,051,251</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:12.85pt;">
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.04%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contingent Consideration</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246594698488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Net Deferred Tax (Liability)</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of the net deferred tax asset (liability) at September 30, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Tax Assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued Compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,086,396</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,310,466</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,936,819</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,609,756</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized Research &amp; Development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624,915</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">926,026</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">California Alternative Minimum Tax</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,652</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,553</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">438,882</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Operating Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151,007,113</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105,372,571</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,818,002</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,590,090</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702,357</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of Use Assets/Lease Liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,015,626</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Rent</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">821,317</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capital Loss</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709,779</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">171,079,659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,952,440</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(156,603,859</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(108,232,402</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,546,968</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,928,832</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,720,038</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,475,800</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,720,038</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets (liabilities)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provisions for Income Taxes</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The provisions for income taxes for the years ended September 30, 2020 and 2019 are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Federal</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,553</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,553</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision from income taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,400</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">173,553</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Effective Income Tax Rate Reconciliation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s effective income tax rate differs from the statutory federal income tax rate as follows for the years ended September 30, 2020 and 2019: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.54%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At U.S. federal statutory rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal effect</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-7.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-29.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-15.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mark-to-market adjustments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-13.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.7%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">True-up on deferred taxes</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax rate change</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.7%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246449102744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Quarterly Financial Data (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Unaudited Quarterly Financial Data</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents selected unaudited quarterly financial data for each full quarterly period of the years ended September 30, 2020 and 2019:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">First</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fourth</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended September 30, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,454,579</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,528,853</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,375,778</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,632,856</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Income (Loss)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,853,594</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,240,255</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,945,862</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,119,092</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,673,728</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,835,570</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,611,213</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(48,432,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Basic</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.03</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.48</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.03</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.20</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.48</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-25</p>
<hr style="page-break-after:always"/>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">First</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Second</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Third</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fourth</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended September 30, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.02%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Quarter</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,657,896</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,148,275</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,696,636</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,292,770</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating Income (Loss)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,946,144</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,010,692</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,595,749</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,638,049</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,037,253</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,896,982</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,335,708</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,704,906</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Basic</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.21</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.12</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.82%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Income (Loss) per share-Diluted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.24</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.21</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246441081448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 07, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2018 </div>
<div>USD ($) </div>
<div>Target</div>
</th>
<th class="th">
<div>Sep. 28, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,500,000<span></span>
</td>
<td class="nump">$ 250,478,974<span></span>
</td>
<td class="nump">$ 60,521,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,585,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,582,667<span></span>
</td>
<td class="nump">221,804,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,889,751<span></span>
</td>
<td class="nump">36,899,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,486,883<span></span>
</td>
<td class="nump">44,175,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_IncreaseDecreaseInCashAndInvestments', window );">Net increase (decrease) in cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278,964,290<span></span>
</td>
<td class="nump">90,266,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,083,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash outflow primarily related to operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,391,570<span></span>
</td>
<td class="num">(173,034,923)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,223,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments', window );">Maturities of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Fair value of contingent consideration obligation due to discontinuation of clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Calculation of effect of dilutive stock options and restricted stock units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,748,958<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,137,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Right-of-use liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,137,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">ASU No. 2014-09</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASU No. 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member', window );">ASU No. 2018-18</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption', window );">Change in accounting principle, accounting standards update, early adoption [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded for calculation of effect of dilutive stock options and restricted stock units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,007,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded for calculation of effect of dilutive stock options and restricted stock units | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderAgreement', window );">Cash received as due under agreement</a></td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ProfitSharingStructureRatio', window );">Profit sharing structure ratio</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments', window );">Development regulatory and commercial milestones payments</a></td>
<td class="nump">$ 740,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-3989 (ARO-HBV) Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments', window );">Number of additional targets for development and sales milestone payments | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">Janssen and JJDC | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderAgreement', window );">Cash received as due under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen Incorporated | Olpasiran Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember', window );">Amgen Incorporated | License Collaboration and Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderAgreement', window );">Cash received as due under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Amount insured in FDIC per account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Takeda License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_TieredRoyaltiesReceivedPercentage', window );">Tiered royalties received percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Janssen | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Janssen | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Amgen Incorporated | Olpasiran Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Takeda License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_TieredRoyaltiesReceivedPercentage', window );">Tiered royalties received percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and commercial milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseDecreaseInCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_IncreaseDecreaseInCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional targets for development and sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProfitSharingStructureRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit sharing structure ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProfitSharingStructureRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TieredRoyaltiesReceivedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tiered royalties received percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_TieredRoyaltiesReceivedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was early adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520240&amp;loc=SL120174030-210619<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246450935112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 28, 2016 </div>
<div>USD ($) </div>
<div>Agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,478,974<span></span>
</td>
<td class="nump">$ 60,521,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,585,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,632,856<span></span>
</td>
<td class="nump">$ 27,375,778<span></span>
</td>
<td class="nump">$ 23,528,853<span></span>
</td>
<td class="nump">$ 29,454,579<span></span>
</td>
<td class="nump">$ 43,292,770<span></span>
</td>
<td class="nump">$ 42,696,636<span></span>
</td>
<td class="nump">$ 48,148,275<span></span>
</td>
<td class="nump">$ 34,657,896<span></span>
</td>
<td class="nump">$ 87,992,066<span></span>
</td>
<td class="nump">$ 168,795,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,142,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,291,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,769,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,291,075<span></span>
</td>
<td class="nump">$ 77,769,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements | Amgen Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Sep. 28,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfAgreements', window );">Number of agreements | Agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember', window );">Olpasiran Agreement | Amgen Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember', window );">Olpasiran Agreement | Amgen Incorporated | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments', window );">Additional remaining development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember', window );">License Collaboration and Stock Purchase Agreement | Amgen Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember', window );">Olpasiran and ARO-AMG1 Agreement | Amgen Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,100,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional remaining development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseCollaborationAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAndAROAMG1AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246445700440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 03, 2018 </div>
<div>USD ($) </div>
<div>Target </div>
<div>Obligation</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,478,974<span></span>
</td>
<td class="nump">$ 60,521,739<span></span>
</td>
<td class="nump">$ 56,585,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,632,856<span></span>
</td>
<td class="nump">$ 27,375,778<span></span>
</td>
<td class="nump">$ 23,528,853<span></span>
</td>
<td class="nump">$ 29,454,579<span></span>
</td>
<td class="nump">$ 43,292,770<span></span>
</td>
<td class="nump">$ 42,696,636<span></span>
</td>
<td class="nump">$ 48,148,275<span></span>
</td>
<td class="nump">$ 34,657,896<span></span>
</td>
<td class="nump">87,992,066<span></span>
</td>
<td class="nump">168,795,577<span></span>
</td>
<td class="nump">$ 16,142,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,291,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,769,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,291,075<span></span>
</td>
<td class="nump">77,769,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 252,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Oct.  03,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Research Collaboration and Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Oct.  03,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments', window );">Number of additional targets for development, regulatory and sales milestone payments | Target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">$ 1,900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-3989 (ARO-HBV) Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | Obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000,000.0<span></span>
</td>
<td class="nump">167,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | ARO-JNJ1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Oct.  03,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">Janssen and JJDC | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional targets for development, regulatory and sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_ResearchCollaborationAndOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_ResearchCollaborationAndOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROJNJ1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROJNJ1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246451858056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail) - Takeda License Agreement - License and Co-Funding Agreement - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th">
<div>Oct. 07, 2020 </div>
<div>USD ($) </div>
<div>Obligation </div>
<div>Bundle</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">Oct.  07,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RatioOfProfitSharingStructureForCommercialization', window );">Ratio of Profit Sharing Structure for United States Commercialization</a></td>
<td class="text">50/50 profit sharing<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="nump">$ 300.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="nump">$ 740.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | Bundle</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | Obligation</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 300.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="nump">$ 740.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash receivable as upfront payment due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RatioOfProfitSharingStructureForCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of profit sharing structure for commercialization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RatioOfProfitSharingStructureForCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447784264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Computers, office equipment and furniture</a></td>
<td class="nump">$ 661,927<span></span>
</td>
<td class="nump">$ 637,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ResearchEquipmentGross', window );">Research equipment</a></td>
<td class="nump">20,654,323<span></span>
</td>
<td class="nump">12,932,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareGross', window );">Software</a></td>
<td class="nump">631,204<span></span>
</td>
<td class="nump">147,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">25,237,851<span></span>
</td>
<td class="nump">21,579,415<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total gross fixed assets</a></td>
<td class="nump">47,185,305<span></span>
</td>
<td class="nump">35,296,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(16,304,437)<span></span>
</td>
<td class="num">(12,081,651)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 30,880,868<span></span>
</td>
<td class="nump">$ 23,214,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research equipment gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246537203320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense for property and equipment</a></td>
<td class="nump">$ 4,241,834<span></span>
</td>
<td class="nump">$ 2,738,715<span></span>
</td>
<td class="nump">$ 2,998,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246451840504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Amortized Cost</a></td>
<td class="nump">$ 224,376,634<span></span>
</td>
<td class="nump">$ 81,075,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held to Maturity, Gross Unrealized Gains</a></td>
<td class="nump">6,163,837<span></span>
</td>
<td class="nump">1,097,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held to Maturity, Gross Unrealized Losses</a></td>
<td class="num">(79,471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="nump">230,461,000<span></span>
</td>
<td class="nump">82,173,729<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Marketable Securities, Amortized Cost</a></td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax', window );">Marketable Securities, Realized Gains/(Losses)</a></td>
<td class="nump">94,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Gross Unrealized Losses</a></td>
<td class="num">(75,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable Securities, Fair Value</a></td>
<td class="nump">85,019,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneYearMember', window );">Commercial Notes Due Within One Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Amortized Cost</a></td>
<td class="nump">86,889,751<span></span>
</td>
<td class="nump">36,899,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held to Maturity, Gross Unrealized Gains</a></td>
<td class="nump">1,589,873<span></span>
</td>
<td class="nump">222,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="nump">88,479,624<span></span>
</td>
<td class="nump">37,122,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneThroughThreeYearsMember', window );">Commercial Notes Due Within One Through Three Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held to Maturity, Amortized Cost</a></td>
<td class="nump">137,486,883<span></span>
</td>
<td class="nump">44,175,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held to Maturity, Gross Unrealized Gains</a></td>
<td class="nump">4,573,964<span></span>
</td>
<td class="nump">875,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held to Maturity, Gross Unrealized Losses</a></td>
<td class="num">(79,471)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held to Maturity, Fair Value</a></td>
<td class="nump">141,981,376<span></span>
</td>
<td class="nump">$ 45,051,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=arwr_MarketableSecuritiesMember', window );">Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Marketable Securities, Amortized Cost</a></td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax', window );">Marketable Securities, Realized Gains/(Losses)</a></td>
<td class="nump">94,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax', window );">Marketable Securities, Gross Unrealized Losses</a></td>
<td class="num">(75,015)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable Securities, Fair Value</a></td>
<td class="nump">$ 85,019,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities FV NI accumulated gross realized gain loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity securities FV NI accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneThroughThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesDueWithinOneThroughThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246456497512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 1,700,429<span></span>
</td>
<td class="nump">$ 1,700,430<span></span>
</td>
<td class="nump">$ 1,700,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Amortization of license agreements remainder of fiscal year 2021</a></td>
<td class="nump">1,700,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Amortization of license agreements in 2022</a></td>
<td class="nump">1,700,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Amortization of license agreements in 2023</a></td>
<td class="nump">1,700,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Amortization of license agreements in 2024</a></td>
<td class="nump">1,700,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Amortization of license agreements in 2025</a></td>
<td class="nump">1,700,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Amortization of license agreements, thereafter</a></td>
<td class="nump">$ 6,861,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Licensing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible assets</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">$ 828,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period of intangible assets</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="nump">$ 8,665,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AssetAcquisitionAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AssetAcquisitionAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246451973592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Net Excluding Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, beginning balance</a></td>
<td class="nump">$ 17,063,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Intangible assets subject to amortization, Amortization</a></td>
<td class="num">(1,700,429)<span></span>
</td>
<td class="num">$ (1,700,430)<span></span>
</td>
<td class="num">$ (1,700,429)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, ending balance</a></td>
<td class="nump">$ 15,363,151<span></span>
</td>
<td class="nump">$ 17,063,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246450812440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Capital stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,376,303<span></span>
</td>
<td class="nump">95,506,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock after deducting advisory fees and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,500,000<span></span>
</td>
<td class="nump">$ 250,478,974<span></span>
</td>
<td class="nump">$ 60,521,739<span></span>
</td>
<td class="nump">$ 56,585,035<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwrittenPublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued to institutional investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses', window );">Aggregate purchase price paid by investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 266,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock after deducting advisory fees and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Stock issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued to institutional investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock shares value reserved for future issuance</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission to sales agent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember', window );">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, and Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common Stock, Share reserve for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,462,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on aggregate gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from the issuance of common stock before deducting advisory fees and offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246532264632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Future commitments</a></td>
<td class="nump">78,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Commitments expected to be incurred in fiscal 2021</a></td>
<td class="nump">60,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Commitments expected to be incurred beyond fiscal 2021</a></td>
<td class="nump">17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember', window );">Technology License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember', window );">Technology License Commitments | ARO-ENaC and ARO-HIF2 Candidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROENacAndAROHIF2CandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROENacAndAROHIF2CandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246449959592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2020 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>Option</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,385,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,311,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember', window );">Research Facility in Madison | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases, in square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Sep. 30,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AdditionalLandSubjectToLease', window );">Additional office space for lease | ft&#178;</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_LeaseExpirationMonthAndYear', window );">Operating lease expiration month and year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember', window );">Colorado Owner, LLC | Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">91 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases, in square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_LeasePaymentsCommencementDate', window );">Lease payments, commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Payments for leasehold improvements, net of tenant improvement allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_HalozymeIncMember', window );">Halozyme, Inc. | California | Sublease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases, in square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 14,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_SubleaseCommencementDate', window );">Sublease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalLandSubjectToLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional land subject to lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalLandSubjectToLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LeasePaymentsCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease payments commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LeasePaymentsCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of leasehold improvements net of tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SubleaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublease commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SubleaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_HalozymeIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_HalozymeIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_SubleaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_SubleaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246447707384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 3,091,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">3,853,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">3,406,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">3,269,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">3,358,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive', window );">2025 and thereafter</a></td>
<td class="nump">15,331,296<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">32,311,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(11,173,252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities (includes current portion)</a></td>
<td class="nump">$ 21,137,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year five and after year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246452120152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments Under Operating Leases (Detail)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2020</a></td>
<td class="nump">$ 1,521,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2021</a></td>
<td class="nump">2,256,379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2022</a></td>
<td class="nump">2,521,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2023</a></td>
<td class="nump">2,590,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2024</a></td>
<td class="nump">2,661,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">2025 and thereafter</a></td>
<td class="nump">10,834,206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 22,385,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246451018536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">4,539,403<span></span>
</td>
<td class="nump">4,773,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">RSU awards vesting, description</a></td>
<td class="text">At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s Common Stock. RSU recipients may elect to net share settle upon vesting, in which case the Company pays the employee&#8217;s income taxes due upon vesting and withholds a number of shares of Common Stock of equal value.&#160;&#160;RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,719,116<span></span>
</td>
<td class="nump">$ 3,955,216<span></span>
</td>
<td class="nump">$ 3,265,348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod', window );">Grant date fair value of the options granted</a></td>
<td class="nump">34,582,743<span></span>
</td>
<td class="nump">12,137,250<span></span>
</td>
<td class="nump">4,141,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">44,082,294<span></span>
</td>
<td class="nump">24,561,189<span></span>
</td>
<td class="nump">5,805,317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 36,355,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 33,663,871<span></span>
</td>
<td class="nump">$ 8,438,107<span></span>
</td>
<td class="nump">$ 5,189,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stock units outstanding, granted</a></td>
<td class="nump">2,687,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 88,548,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Additional unrecognized pre-tax compensation expense</a></td>
<td class="nump">$ 38,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
<td class="nump">673,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">673,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
<td class="nump">5,598,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding</a></td>
<td class="nump">2,611,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of restricted stock units outstanding</a></td>
<td class="nump">2,588,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stock units outstanding, granted</a></td>
<td class="nump">1,754,071<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember', window );">Outside Of Equity Compensation Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
<td class="nump">1,254,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember', window );">Outside Of Equity Compensation Plans | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance</a></td>
<td class="nump">936,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted stock units outstanding, granted</a></td>
<td class="nump">933,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards additional compensation cost not yet recognized share based awards other than options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant date fair value of the options granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246450063064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summarize Information about Stock Options (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, beginning balance | shares</a></td>
<td class="nump">4,773,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Outstanding, Granted | shares</a></td>
<td class="nump">951,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options Outstanding, Cancelled | shares</a></td>
<td class="num">(74,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options Outstanding, Exercised | shares</a></td>
<td class="num">(1,111,128)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, ending balance | shares</a></td>
<td class="nump">4,539,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable | shares</a></td>
<td class="nump">2,924,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, beginning balance | $ / shares</a></td>
<td class="nump">$ 8.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted | $ / shares</a></td>
<td class="nump">48.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Cancelled | $ / shares</a></td>
<td class="nump">22.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercised | $ / shares</a></td>
<td class="nump">6.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, ending balance | $ / shares</a></td>
<td class="nump">16.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable | $ / shares</a></td>
<td class="nump">$ 8.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 129,100,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 102,698,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246532281832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">3.11%<span></span>
</td>
<td class="nump">2.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of options granted</a></td>
<td class="nump">$ 36.35<span></span>
</td>
<td class="nump">$ 13.80<span></span>
</td>
<td class="nump">$ 5.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246456537384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSUs Activity (Detail) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Unvested, beginning of period | shares</a></td>
<td class="nump">2,062,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted | shares</a></td>
<td class="nump">2,687,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of RSUs, Vested | shares</a></td>
<td class="num">(1,158,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of RSUs, Forfeited | shares</a></td>
<td class="num">(67,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of RSUs, Unvested, End of period | shares</a></td>
<td class="nump">3,524,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, beginning balance | $ / shares</a></td>
<td class="nump">$ 9.43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">55.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">9.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, Forfeited | $ / shares</a></td>
<td class="nump">31.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value, ending balance | $ / shares</a></td>
<td class="nump">$ 44.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246455936392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments (held to maturity)</a></td>
<td class="nump">$ 230,461,000<span></span>
</td>
<td class="nump">$ 82,173,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent Consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">143,582,667<span></span>
</td>
<td class="nump">221,804,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">85,019,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments (held to maturity)</a></td>
<td class="nump">88,479,624<span></span>
</td>
<td class="nump">37,122,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent', window );">Long-term investments (held to maturity)</a></td>
<td class="nump">141,981,376<span></span>
</td>
<td class="nump">45,051,251<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">143,582,667<span></span>
</td>
<td class="nump">221,804,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">85,019,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Short-term investments (held to maturity)</a></td>
<td class="nump">88,479,624<span></span>
</td>
<td class="nump">37,122,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent', window );">Long-term investments (held to maturity)</a></td>
<td class="nump">$ 141,981,376<span></span>
</td>
<td class="nump">$ 45,051,251<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesFairValueNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities fair value non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesFairValueNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246532373400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246533799448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued Compensation</a></td>
<td class="nump">$ 2,086,396<span></span>
</td>
<td class="nump">$ 1,310,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock Compensation</a></td>
<td class="nump">10,936,819<span></span>
</td>
<td class="nump">3,609,756<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost', window );">Capitalized Research &amp; Development</a></td>
<td class="nump">624,915<span></span>
</td>
<td class="nump">926,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax', window );">California Alternative Minimum Tax</a></td>
<td class="nump">178,652<span></span>
</td>
<td class="nump">173,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438,882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Losses</a></td>
<td class="nump">151,007,113<span></span>
</td>
<td class="nump">105,372,571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible Assets</a></td>
<td class="nump">2,818,002<span></span>
</td>
<td class="nump">3,590,090<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred Revenue</a></td>
<td class="nump">1,702,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities', window );">Right of Use Assets/Lease Liabilities</a></td>
<td class="nump">1,015,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">821,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital Loss</a></td>
<td class="nump">709,779<span></span>
</td>
<td class="nump">709,779<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">171,079,659<span></span>
</td>
<td class="nump">116,952,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(156,603,859)<span></span>
</td>
<td class="num">(108,232,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed Assets</a></td>
<td class="num">(2,546,968)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DeferredTaxLiabilitiesStateTaxes', window );">State taxes</a></td>
<td class="num">(11,928,832)<span></span>
</td>
<td class="num">(8,720,038)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liability</a></td>
<td class="num">$ (14,475,800)<span></span>
</td>
<td class="num">$ (8,720,038)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use assets/ lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxLiabilitiesStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxLiabilitiesStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246451149240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfValuationAllowance', window );">Valuation allowance against deferred tax assets</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_FederalNetOperatingLossCarryForward', window );">Gross federal net operating loss carry forwards</a></td>
<td class="nump">$ 473.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_StateNetOperatingLossCarryForwards', window );">Gross state net operating loss carry forwards</a></td>
<td class="nump">$ 497.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FederalNetOperatingLossCarryForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal net operating loss carry forward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FederalNetOperatingLossCarryForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_StateNetOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State net operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_StateNetOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246532427832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provisions for Income Taxes (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>State:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Current</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 173,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">Total State</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">173,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision from income taxes</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 173,553<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246532521160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">At U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal effect</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent', window );">Stock compensation</a></td>
<td class="nump">29.40%<span></span>
</td>
<td class="num">(15.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments', window );">Mark-to-market adjustments</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(57.40%)<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate', window );">True-up on deferred taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to mark-to-market adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation true-up on deferred tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246452296744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee benefits costs</a></td>
<td class="nump">$ 863,080<span></span>
</td>
<td class="nump">$ 545,698<span></span>
</td>
<td class="nump">$ 451,623<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember', window );">Employee Contributions up to 3%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary match percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember', window );">Employee Contributions Next 2%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary match percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of compensation</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246450551656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unaudited Quarterly Financial Data - Summary of Unaudited Quarterly Financial Data (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 7,632,856<span></span>
</td>
<td class="nump">$ 27,375,778<span></span>
</td>
<td class="nump">$ 23,528,853<span></span>
</td>
<td class="nump">$ 29,454,579<span></span>
</td>
<td class="nump">$ 43,292,770<span></span>
</td>
<td class="nump">$ 42,696,636<span></span>
</td>
<td class="nump">$ 48,148,275<span></span>
</td>
<td class="nump">$ 34,657,896<span></span>
</td>
<td class="nump">$ 87,992,066<span></span>
</td>
<td class="nump">$ 168,795,577<span></span>
</td>
<td class="nump">$ 16,142,321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
<td class="text">arwr:TechnologyLicensesCollaborativeResearchAndDevelopmentArrangementsResearchGrantsAndProductSalesMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="num">$ (50,119,092)<span></span>
</td>
<td class="num">$ (15,945,862)<span></span>
</td>
<td class="num">$ (22,240,255)<span></span>
</td>
<td class="num">$ (4,853,594)<span></span>
</td>
<td class="nump">$ 9,638,049<span></span>
</td>
<td class="nump">$ 18,595,749<span></span>
</td>
<td class="nump">$ 22,010,692<span></span>
</td>
<td class="nump">$ 10,946,144<span></span>
</td>
<td class="num">$ (93,158,803)<span></span>
</td>
<td class="nump">$ 61,190,634<span></span>
</td>
<td class="num">$ (55,936,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (48,432,715)<span></span>
</td>
<td class="num">$ (13,611,213)<span></span>
</td>
<td class="num">$ (19,835,570)<span></span>
</td>
<td class="num">$ (2,673,728)<span></span>
</td>
<td class="nump">$ 11,704,906<span></span>
</td>
<td class="nump">$ 20,335,708<span></span>
</td>
<td class="nump">$ 23,896,982<span></span>
</td>
<td class="nump">$ 12,037,253<span></span>
</td>
<td class="num">$ (84,553,226)<span></span>
</td>
<td class="nump">$ 67,974,849<span></span>
</td>
<td class="num">$ (54,450,478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Income (Loss) per share-Basic</a></td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Income (Loss) per share-Diluted</a></td>
<td class="num">$ (0.48)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
<td class="num">$ (0.84)<span></span>
</td>
<td class="nump">$ 0.69<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140246445783368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Oct. 23, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Oct. 07, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Estimated lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,385,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases, in square feet | ft&#178;</a></td>
<td class="nump">24,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_LeaseCommencementMonthAndYear', window );">Lease commencement period</a></td>
<td class="text">2021-07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_LeaseExpirationMonthAndYear', window );">Lease expiration month and year</a></td>
<td class="text">2027-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Estimated lease payments</a></td>
<td class="nump">$ 7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances', window );">Expected leasehold improvements, net of tenant improvement allowances</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | License and Co-Funding Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_AgreementDate', window );">Agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  07,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_RatioOfProfitSharingStructureForCommercialization', window );">Ratio of Profit Sharing Structure for United States Commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">50/50 profit sharing<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Cash received as due under collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | Minimum | License and Co-Funding Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda License Agreement | Maximum | License and Co-Funding Agreement | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected payments of leasehold improvements, net of tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LeaseCommencementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LeaseCommencementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LeaseExpirationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease expiration month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LeaseExpirationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RatioOfProfitSharingStructureForCommercialization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio of profit sharing structure for commercialization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RatioOfProfitSharingStructureForCommercialization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>93
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MV1@#^'VA0,EW#^9%S_[%WMG_ %!+ P04    " !,A'=1Q:5?L&P"  "5!@
M&    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)5576^;,!3]*Q;:PR9UP8%
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M!TAZ'%#C@&P'W.. &P=L.: ^2*1Q()8#83T.M'&@]AE CP-K')CM0'L<>./
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MJ;ZTF%7,>>3NLAC9UZDO%HVBGG:&H)4<X&<FV[\6S7EH-PW&(]0#<4\5P==
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M*3KX&XXK)C"KWM&*1=?0SCY7=?ZYJ&\K7+-5S1ID+>UI=C#O)*L;_*.99 ;
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MJ."7AYF"L4N-9"2L#M2 P'6 ")N7-5('(7TJ=(G40CQ@\1V !+!6EZ6"945
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MRQ [W&BRBR3>[B(>L-ZF+@LV-41W(/D'S=VB\@9*PSP'AMW@S!M%GEC8XC&
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MQ]QH%V<M7&8.2PT'N"B842E0XV858 $])^_* !JW!K!*EJIR%.0U7KHWA"P
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MDR94Q2''Z'V9V8;W5?2^#SNZ, OFDRL?2)+*(5]3D4#RE9G_)5#'IC/2$Y9
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M'L'4T5V.B%32;_Z"'L:=2*T1(AT,!-YE8$S=9#YD.[#0* ?%B=)&(MCPB\?
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M5(X'#[R/GTW&H?&ZE=X.I#3&9^[6(WGN*YLE;"=/8T? 90JE&%#T9K#K,;J
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M]UYDA73:RGQCT=U!=2@<%T"6*. 0F0-XE:5(=S40ZG.2E0[7:PUAWHE%B"V
MM"3GZ.%C)W)SK;*!N#R?:-'L=P>>O]:F=-F*<%)9<A#NQVZ3M[^*DT<C4G-R
M>7'PYMWDKBBLF5NY'(KW"P1,$+8T@,DR4TZ0K5/E]#P/0B"K3)0 C%Y+K\B"
MA8$$KW1^1^)D-PN=+(3&C0)'5%XG,H,>US+3*=TP0*BD"C4D)0];[3Z*&3(*
M"J&B" GC6^.2#']QJTBD3;6YE@[*2"M2[11")+J6/&7HCB_Q;,>Q+[5U_BO]
MVKJ=; =3'FUW;>/67)B"Y9,'=OMX5KF%1%..!%_0 66Q"O;)19G#"DEF'(3W
M6GC=:%[:N?)#I)"8PEJM6(_*PELW"Y-QN+C"H,).LZ!- GPA^0@!1)HIV)!D
MJ 2IJVRBL>F?;+ZV3P )2Q>3KI5:7GY49 >H@S-U@:23"_O']X<CE+<L(\-I
M'+J861004<A5I?G^^&AXO[V$A!$IH7UA)O6IU'Z%'ZZ5\ZSV=!6/F[=WKI.I
MC48!H?:/1UTU\!'2"%$:16CA4JZB\E"5/8UX2E--EH'U]N^-UB1910Q)Y_.V
M90>X/(?/D TKENLDI>#FKIRKM>G@OEEI.0]4IN?L/,[4MD)@6R(U)7X[2+$&
MJ6=6,O,:\LG182>8#KF,!(>SRMJ=/4C&T?2Z1,2@)#RJXR@G!Q!.M+3S"^D%
M]KLQ998"L> (P,=G"AY'Y]?8J\J0*L)O3XR4L,R5R8)C" AU \N2W-S4IFBL
MAIO#85>U 5NGV\SEKG5=B:(O<Z\YRQ#W1:8HRTCO0EGFP3D0T4QA>TZ%6VS'
M^F_;^67I2YRG5M[QZL97,EEH12D23PPOFWFN_^0:3&*UI:*LK<)Q42U@3FF!
MW6V/C4>-QQ"B#!I2O./J.VYRWODR745$!S* V(9=)+*OB>:-\*1P:T7 4+PH
M+7F:KJV@C1.$_FF+6T0BQPSC$1\9'TZZ"-$Z*;8?'D4%@ 6CX7'SC3/WZ$&S
M@,+Z$D;+2Z"1<R8))V9V05YL(53#. :,A8J;A QGF'!V]*E<12#]V>_D.+@#
MLT7:5'F&-V/IX)+\F)@R]Q'S).4L*SYJ;LNTG.I,L]_;]R8E*CK,G,;:;JO#
MF6W ECL3B\.IS#A<KZA% )"\ECFTR\G[".1$E5Q/@&N1 5Z@./.!!ST^Z= _
MN5D^:VH6M]E68.]6E/ 2%$2""/;4YHL $MMEKW'XC1W8N;O/NR:ROK60UL>"
MUB^A,HD.*/K:+&#S7/PLE\7C^*V+*]C4K-MO*Q.N]7K]XOG656L'[5,!IP1G
M9 ,=D*SU8^-2PV2D.$<7_5I9IU9MOMTN]5O].JA_^DJ6VQ?!K\]?'QP_.GDD
M[A!F_G;Z>\U:![WK_4+;](#8414, /&D!(JKP(IEBM99NV#[%LEB7X(_@6)1
MM@!?6Q6Z2EQ1@.QR.>@PLP(;-1"2+$!7(&JAZ+I'A3X5U]J6CFID&$ ,Q:E:
MF3SM/4# XJ/#<0!A#JD-&S0F)KI-X?3-+*Z]49^;MZ18HTDL2[(B(6'> AE8
M*7*$4V"C!+K@/^#@H;K4K4T04.G9*%Z[Q,4VI;G"+0H<_!_>R(A$62^98J%9
MUTFHR'3:U##]T#FB+NU(8(XB,YIBK0*2;^&(A2X4M=S=5&:=*RY /4J"MLRB
M<A*M64;+D@9HS.HCV8ATK%J;!(;R#3_.2JZ3(*Z5>6,QIOI"M.DF)W+#I68Y
MU7G8J -S;8_3/&Q L>+*V4PGNBK5X#7@ADR?46T0[T2@Q8?A%5$&8L\5K8'.
MA <O;#D7LBB0LE7(6";;Z#]8>QE]BK.K;EPL)%*=F[:Z(Z*6H)?S8?-9>RW4
MKD@C]9#KX?9= E]),BUOQUU4%1[?M[,Y>MAN;0A0-KH;$)J':_W/ES0W7!NP
MMLFESGREX:2\\/V:AFCGLY(9@N?\:AV.&%]"](.) X<7B:%LCLRCXF8!:X&S
M*5K0D%53E4C$@9K- I=BO[3-8QJ*<10H1D@NF5:>KZS=WJ[> A[BG.;(DNC#
MX"!"9@W90(.*$$T#YR$WH(8Q]V-B7!^YL8TK"ZIW:8M5Q<W  3VO 8"HMFH=
M:VWZ7M.D0\\T1!))!CYX2/!;FH<A*-"<&OB*,.\HL.V-4D6AJ7E(0V:GWSXJ
MNI[!Z);@V$7D"R6G'I!0.E20><EDX86@N:%.ZCNB+NMH6*<;L=058V_5'O'R
M+RIB=3=TNW"H2[U15!:6*VET%)J+?N$I@575TA*$-.U;0%TV3AAL14.WQT3Q
M6K3+56679L;XHJQ)"W4+#"B5]#+7G_ K4)FTKD-EF\Q!M(2F.9>E8H8B$!K*
MA2Z:O*L<=ZO_G>IZ'\%/-2?WW3"<(OBKYL,O2JC!G=R6V-P@L.O[MH@S>[%!
M>DN@955W-F#J4A^F%)L\03M.\%9N6WJP,F@I''[O5UE4N0 C*K\!W.% "859
M&JEBP"==JUXSFM"QX:"T0L]8 <81[3O5J6NECH%P>@L#R? $J@ [H>CQJ)PI
ME51K/FLZ)BK9_OC^>/B@+@'55#7DKV-)&T6#+L+#2UTN<5&G=4U@?6'*S:K1
M93E!! WQL?MP1X/OJID"FX (PI)1M/Z5-K1*+Z>E=4P$UV.^QA>X?%I'V[KI
M"#R)G"2Q+ 5;K=LFS#"R7M,&FG0[ZM95J0=#VD#)T=.,$+;E,IU#N[J"],QJ
M2IY]2<(F*DF!7K5U6X))F%3<H4>,5#CH>66)-4R_Q<+ M *I[=!2-!X(]FDM
MN8MMYSKG0:-N"BU5V>"\G,%=NEX(1M&&;DP B-$ZI6(E*&IHKRF6Y^0,CV8J
MD/V*R4^<^3S:.O-9RX\''1H51CX/6Q/A'3,?SN[^./BK4Y^OG_;$.=6C9G1%
M6_UOAS^4;9LJ;-L!5DLM#),3LOPH"(I9]A4PA H0L'V-C?X9"GO@\.O @KPH
M\T!9\L .(.];>S=2@G #* (N6WT:\ZKJRW&;A^]NJA%]@(W$.!_:UW;F(T8#
MZ6\G2X29[?WC=TW(_?'PT5H&MKRU,_^(FU3@\A<S;GBRGC7BUN3[QJ1YCQXO
ME>N#0VZ4)\/->>G#EMY;YJ6Y.*O;WC>M*O/<'+PL S)/>A]?5JIL'Z:RG;]$
MX3L=B>O/SFG+;7L-XB]K!#Z$86(.(K/K,S _^IB\WSW%<_ST_4>-\;Q5,D 0
M@1/SY/A\>2-B98:"=W DZ#&0MZL"Q9MBB6<H"8+V#RRJ@.P#V @EE*?!TB >
M=,"$D2K8->%5S%18J3V)J#M1*>Z/#N^/R#PSL$L'#]()G+<E]3N LXO2$V?M
MV[)R"^^1T1B ULPS,Z4YVL;<@UYH\6H>GC?&1X:]#^%">]<H6SNQ[DSJ*.]Y
M"HE"QHE7/\E"VHY'/]&2\?V?*!$)Q/DQ9,]P+4K9/^X\2.T=G_!)B)#W:-',
M;G<]=FV.V7X0!X5#D[+_\%Y+B<W2TAFE;,V?KQVK5/U3-6_Z\:,5MOO?/EO9
M 3_?.F?9VJ7]+>,3';JAS@ E=C95AQ!-<G7VSP\7KR;Q^>SZ72:?&]JRJ)[G
M(DV1I>/1*,YA&+!O'Z?$]/Z*&4KEK)Y2]3TG*&LBW?_3 *7US&>+9;H SEUC
M=Z@-H7)./IJ%=P6^YAV=#6!%!2*66$=!%6*WS\L#+V535?JR7BTW.!6E<XNY
M#"0LGLK,9C21B8^!XL_F)D12/<0>"*6IJ@M@_+(#Q[953&(C0 _BN&;6(XH&
M?G:75#8M/_2XQ6QK YU=TX?>P4ZW@MT^V.EQ&M?FE$)N%8.@F0$T)AJTJVTT
MS$$\>3.M(<-R3]P[0=ELGUB'.)AISV6.U]YR^HYSF0A&.X8Q6_+I!\YB0@Y
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M6U-P96.;\F 4G99D9V9+1?U5YAE$D\/B<U>V5'$S\0QA6PTO.^!<#SC\%9R
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MD*E_F<0NJ&$9#XR1;;\ -]+0.NW)';U?J*P"G1=2FB-C'9Q>Q-D_4$L#!!0
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M!:#;GMM.K*I]GULK2UW3#TOZ3$'M#&A_HY0]3%R [L-G^@]02P,$%     @
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M]Y!A(6J G9B<I/?43V:92H"4T'.>]167.F(JDXJ&1]7!IFMB]]?.9+,\O,%
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M3F)IF@&D;?_B8)?'(TCM"%^>NQWMT+S1%S"5HZAJE3-5:6I6,G>*(#ZR=0U
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M-.F_&T=@#X_18>)-'1Z S'AZ3L*00J [X0.TOS;&'R?LH/M',/L'4$L#!!0
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MP;53@/N-4O9)< Z&KY7I=U!+ P04    " !,A'=1UF',=4,%  #/"P  &0
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M>_KU)X- L+PXD W$60V1/@,Q2N&S-6'M86XRS)X"#(A/2RK=D3I+7T1<8)G
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M,!:75ZS/!T5C"I(G!Y..T':P__*B'V5+RZ0K@NRN4=>@<4U0U!I%*R,=@Y#
M!.5'A6TT7%,H.WE]DD&.CW!UB/=FLG*.CWHFH[%VA.3LV3IK+862UJTQJ+F(
M]D&7JD2^8IECYJK\L9_Z6IJ9CSDKR%TBHJWG/%@:K-PMA@3V#06#SI!%%9;'
M49+U6)E0SUOMUW9:G=5#VN/V>M3]+%RNC*>TK,ATF!P?]<#5XV/]$FP91[:E
M#30 QD>.#3K>0.LK2[V@>>$#VAE^^C=02P,$%     @ 3(1W47?SC7BY'P
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MG#DLXE<<Z.! '6\?R+%\RPS;K)0\$F5O(YI=N%2=-Y+CPC;EP2@\Y>AG-K>
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M-:254KS<DB737)\ZDZ>CN<D!/0NL0 MB[-$V9<A_HN>-];9WWHINL!@(YMY
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M +<C$B241(F//M6&U0L!7=,!48@G!5D*,4691[S,VY!W Q'4*PZT)!XE092
M73<';4*_Z@YD<LEAT."N5H1U@'A^1&*(=+0-!TR,4$HMS4E'G?,9)9;/).N?
M=])NO2P6@$X /,F FPSY?DRRB)(P]- W5JY8.SIM<; ZYVCH1S&D*B I"!_!
MIY<2&H \Q'NT<<RBEQOOCW>Y'@)W(=B)4] 9064PPZT*A#GT?9)12$1@\88I
M22A0&%C!/0'T90YZ(0F3B*2>]Z/>Y[T]HC=- @X>0:F.[-^!*1#U4R ZV*77
M2CX(>V;9KE)X>\#N:_G#8'?0Y,TNH&@!'5]NP0Z"9^@3C;F=O?]+NW_D!71
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M_:RM?8,Z9XFWI&F9S :1<\H31GF:CG*4TC)):9'Q44X9C:*2LM++O^ ;]5^
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MVPDL>]]@LX75CF=9-BS#'H,5?YK60,+F=?CVXMQIG=5VO'ZY*1XU]41Z29A
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MMC0<?!]+9G M2,)_:/PR"[_,S"^KQ:\IHP$A(0>/C"9 + B(.%_A-"" /H*
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MW4#]<$UW?M1N [U?*F4/$W<-K?Y%3+X#4$L#!!0    ( $R$=U%^@[]$%0,
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M05H'<[X40F\W-D _W?,_4$L#!!0    ( $R$=U%@ATU,5P0  &D3   9
M>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;,V8;6^;.A3'OXH5W1>=U!9L'FRF
M-%*7:ENE[JYJUDW3U7WA!B>@ LXU3K/=3S\;&) 8:)/<*[4O&A[..?QLGW/^
MAO&&B\<\8DR"'VF2Y1>C2,K56\O*YQ%+:7[.5RQ3=Q9<I%2J4[&T\I5@-"R<
MTL1"MNU;*8VST61<7+L5DS%?RR3.V*T ^3I-J?CYCB5\<S&"H]\7[N)E)/4%
M:S)>T26;,7F_NA7JS*JCA''*LCSF&1!L<3&ZA&^G"&N'PN)KS#9YZQCHH3QP
M_JA/KL.+D:V)6,+F4H>@ZN>)35F2Z$B*XY\JZ*A^IG9L'_^._KX8O!K, \W9
ME"??XE!&%R,R B%;T'4B[_CF(ZL&Y.EX<Y[DQ7^PJ6SM$9BO<\G3RED1I'%6
M_M(?U42T'*#;XX J!_12!Z=R<(J!EF3%L*ZHI).QX!L@M+6*I@^*N2F\U6CB
M3"_C3 IU-U9^<G*=/;%<JG61.3@#LW(Q 5^ 6<2%/)-,I*?@AF?+XA"TS6D6
M@D]4/#))'Q(&9FR^%K&,60Y.KM2U.'FC(M[/KL#)'V_&EE2P^I'6O )[5X*A
M'K 96YT#QSX%R$9VA_OTQ>XPV':WU!35\X3J>4)%/*<OGJJ?<*V&^7D!/K(D
M!%^X&KS4(_[9'OIE[Z3\=:-"@FO)TOSO 2"G!G(*(+<'J("0#<0IN$S5BL7_
MLA!,>2Z[9KR,B(N(NKZ?)@BY#O9]QQU;3^W)-2T)M+%'"*X-MZC=FMK=D_J#
MX'D.[C/5@Y("_H/J/7D7?1G9:S'YT'>(@W?833MH!YBXJ!O=J]&]8]%OU#GK
M9/<,IC,<N!AV(_DUDK\GTGL:"_"5)FO61>$;%,BQ71_:MKTSAZ8E01 [& 7=
MQ+@FQH/$G:7QDM3%)I!G%W_=0*0&(H< W6UEHW52KFQG&R,&F5K85D%M804U
M5G (UAX9%W1DG&=#KYL+VHU>V(>0#2=>%7-G^6" 84\^P99^P4&>*4]3)N8Q
M3<"?7*H^>[5FX%LLHS@#GU7#_<ZH&&BWL!$ ^$H4 #82 /][#:A";BV%3TB
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M?"6GTG[1ROEF9QXJ.ZEXVX-U!BUA[H\?^WW8 (39#D#4 Z+G@&0'(.X!\;Z
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MG5I9E:9G5-/)6(H-DF8V2#,/E;DJ-"B8%\:SYEK"5PXX/9EK$3\N198PJ7Y
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M.;S6%KPKDX(B]03]OL MY-Q IO_L(&A7!&U'T-Z:^S+7AG!&YXQCID$W);+
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MF)_0C*3RSI2R! MYRF9MGC&"0VV4Q&WD.+UV@J.T-1SH:P]L.* +$4<I>6"
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MSN7&BC U0-Z?4BI6)\I!^?5L^"]02P,$%     @ 3(1W46 J%O/% @  PP<
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M+(PO!GQQ$O]=&L)#P")PN@E"&.9A((+_?06>1-Y1K0&KF]:9 K/6H*@V03N
M!QHN$4)Y@M,CAX[VS V=[QO(P<&X=S"^YV 73)2\K>RH;)6BPH!&*G=?A*T+
M'7S:&*$D+]+TG=1XSY+=]79/U(8);16L;2H<Y;9?U=T876!DXUUZ)8WU?#_<
MVEN6*K?!KJ^E-&^!,_[AWI[_ U!+ P04    " !,A'=1R=6YDF0"  !Y!@
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M5*C31X?TS;D2J"<J5TKQ:B:@\ RZWJ!MN5N^<8^OUESEZ%]_!Y7HHQ&E_G<
M$.L ,0>(#0#ZQ[)\$ K5CZA>6" : 8=HPZM<5K.^^#?J8J?.<L_JDL5TRB)Z
M/EYMAZ5'+DGH)(DZN1V\<8<W#N+]?'>/N'6$1BNA#8!\ VR@,R4=_#[$8857
MQBL2/)MOVX_L;FM9%.A!(/&4S6V(<@0E@VH(@G9! M>9N7#1Y-7FIQ]2@I.?
MM;TO(:ZN#,^<(B4RN9 020UUOD&.(9&I405-H%&EA3&%0,L%+.Q R0JMYQ*
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M,W&%GDPMI&35!NECU+ \P+'=#3O8Y<6>R10^,R[;#![G=E&E<(TZ%ZDHQ.8
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M(U;"5NP4/IKN.PS]7'J^PB@7OJSK8Z\HN-@Y-,T I@H:J?M5O XZ' &F%R<
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MV1BD^0MF32\$6!] YUMC\.#X(1S?G/PO4$L#!!0    ( $R$=U&+.^)A*@0
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MH95YRXV?GMZ+5.8,_*#OK 178"[S0@HF= GD"N@- W^:5KIC*Z846UHS</'
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MF ,<4]; O%])J0\W]HC0' FG_P%02P,$%     @ 3(1W41ATD&!' @  . 4
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M0\>8QEL Z;@Z)^P8J0\A)(E<72@:9>\(0.) %^?8*,W';:#CA-H9ME&D3MI
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M^]>=LL!O-=9WD]CFL,SM.*PD3Q'+<B7790*AK@04DUP@ WT""=W[A@B'E9E
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M90? ]X649O=@SY#-/QE&_P%02P,$%     @ 3(1W49W]U59# @  ?@L   T
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 3(1W47;^B2"P!   524   \
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M@FN;-X5'3\K-6T? 13'TIQI.^$G9@O-!7L"Q,[J$IY?B7!II"R7:X 8$F!"
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M"^(M!'HKZJT$>BOJK01ZZ^AAFT!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " !,A'=1F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M $R$=U%2/3ZA3P8  (T9   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " !,A'=1I,)SH$0'  #D&P  &
M            @(&2#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ 3(1W4<6E7[!L @  E08  !@              ("!#!8  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $R$=U'ZQUSO/@8  &D7
M   8              " @:X8  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " !,A'=1.VYSJT0'  "Y(@  &               @($B'P
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 3(1W45Q\28R9
M!P  >1P  !@              ("!G"8  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( $R$=U&AR<@FER@  .^$   8              "
M@6LN  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !,A'=1
MDR68CU4.  #$,   &               @($X5P  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ 3(1W4>C).8%Y P  '0<  !@
M     ("!PV4  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M $R$=U%K'PE1*P4  ,8,   9              " @7)I  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ 3(1W4;/06OZT P  ! D  !D
M             ("!U&X  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " !,A'=1:68$#&T$  #V"0  &0              @(&_<@  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( $R$=U'(ZY]<6 4
M 'P,   9              " @6-W  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ 3(1W4<W 1]7Z!@  BQ$  !D              ("!
M\GP  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !,A'=1
M=A" *^X*  #''   &0              @($CA   >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( $R$=U%R"5U4[P<  $@4   9
M      " @4B/  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ 3(1W42+N+5FJ"0  +A@  !D              ("!;I<  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !,A'=1=0F]M]T#   ="
M&0              @(%/H0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( $R$=U&J.?P0O0,  +D(   9              " @6.E  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 3(1W4=9AS'5#
M!0  SPL  !D              ("!5ZD  'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " !,A'=1=_.->+D?  #%;P  &0
M@('1K@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( $R$
M=U%3-I9]$@,  $@&   9              " @<'.  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ 3(1W48-2X'2K P  \@@  !D
M         ("!"M(  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4
M    " !,A'=1)'LD.8H"  !J!0  &0              @('LU0  >&PO=V]R
M:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $R$=U%[OFD_3@,  '('
M   9              " @:W8  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL
M4$L! A0#%     @ 3(1W44%/C1>.!   +PH  !D              ("!,MP
M 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !,A'=1'1(B
M4D8#   ,"   &0              @('WX   >&PO=V]R:W-H965T<R]S:&5E
M=#(W+GAM;%!+ 0(4 Q0    ( $R$=U$'[#XI(04  %X,   9
M  " @73D  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
M3(1W4;@>.<.D P  H@@  !D              ("!S.D  'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " !,A'=1*<'P>+ )  "8-@  &0
M            @(&G[0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( $R$=U$VSKPU*@8  ' B   9              " @8[W  !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ 3(1W45C@V$QY!@
M=R$  !D              ("![_T  'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " !,A'=1RH1O'\\#  !1#   &0              @(&?
M! $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( $R$=U%^
M@[]$%0,  *P(   9              " @:4( 0!X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ 3(1W49,>X"-N @  Z04  !D
M     ("!\0L! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M" !,A'=18(=-3%<$  !I$P  &0              @(&6#@$ >&PO=V]R:W-H
M965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( $R$=U$28>XM?0,  (T-   9
M              " @203 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L!
M A0#%     @ 3(1W46J5T-BE @  9P<  !D              ("!V!8! 'AL
M+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !,A'=1);&ALNP$
M   *$P  &0              @(&T&0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y
M+GAM;%!+ 0(4 Q0    ( $R$=U&J=CS_( ,  .X)   9              "
M@=<> 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 3(1W
M49Y>'L(-!@  21L  !D              ("!+B(! 'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " !,A'=18"H6\\4"  ##!P  &0
M        @(%R* $ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( $R$=U')U;F29 (  'D&   9              " @6XK 0!X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 3(1W4;60_C.X!@  =!X
M !D              ("!"2X! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " !,A'=1< '!C@ $  # #@  &0              @('X- $
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( $R$=U&/D3&I
M9@,  %@+   9              " @2\Y 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ 3(1W4::'06-/ P  BPH  !D
M ("!S#P! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !,
MA'=1.A+<78X#  !(#@  &0              @(%20 $ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( $R$=U'B@)$:"@(  '\$   9
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M970U,RYX;6Q02P$"% ,4    " !,A'=1;M5D(_ "  #'"0  &0
M    @(%,4P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M $R$=U'G#=X'3P4  &4:   9              " @7-6 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ 3(1W45@*$:1_!   <!   !D
M             ("!^5L! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    " !,A'=1G?W55D,"  !^"P  #0              @ &O8 $ >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( $R$=U&7BKL<P    !,"   +
M      "  1UC 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $R$=U%V_HD@L 0
M %4E   /              "  09D 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " !,A'=1##^0_.4!  !_(0  &@              @ 'C: $ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !,A'=1C^&W:=,!   V
M(0  $P              @ $ :P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    0 !  '<1   $;0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>150</ContextCount>
  <ElementCount>410</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statement of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity</Role>
      <ShortName>Consolidated Statement of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Unaudited Quarterly Financial Data</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialData</Role>
      <ShortName>Unaudited Quarterly Financial Data</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Unaudited Quarterly Financial Data (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataTables</Role>
      <ShortName>Unaudited Quarterly Financial Data (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialData</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail</Role>
      <ShortName>Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail</Role>
      <ShortName>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Intangible Assets - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail</Role>
      <ShortName>Intangible Assets - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Leases - Future Minimum Lease Payments Under Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail</Role>
      <ShortName>Leases - Future Minimum Lease Payments Under Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Summarize Information about Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail</Role>
      <ShortName>Stock-Based Compensation - Summary of RSUs Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Fair Value Measurements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurements - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail</Role>
      <ShortName>Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Income Taxes - Provisions for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Provisions for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail</Role>
      <ShortName>Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Employee Benefit Plans - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Unaudited Quarterly Financial Data - Summary of Unaudited Quarterly Financial Data (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail</Role>
      <ShortName>Unaudited Quarterly Financial Data - Summary of Unaudited Quarterly Financial Data (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arwr-10k_20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="arwr-10k_20200930.htm">arwr-10k_20200930.htm</File>
    <File>arwr-20200930.xsd</File>
    <File>arwr-20200930_cal.xml</File>
    <File>arwr-20200930_def.xml</File>
    <File>arwr-20200930_lab.xml</File>
    <File>arwr-20200930_pre.xml</File>
    <File>arwr-ex1023_125.htm</File>
    <File>arwr-ex1024_124.htm</File>
    <File>arwr-ex1025_123.htm</File>
    <File>arwr-ex1026_121.htm</File>
    <File>arwr-ex1027_122.htm</File>
    <File>arwr-ex21_669.htm</File>
    <File>arwr-ex23_668.htm</File>
    <File>arwr-ex311_7.htm</File>
    <File>arwr-ex312_10.htm</File>
    <File>arwr-ex321_6.htm</File>
    <File>arwr-ex322_9.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gei541vqjlbv000001.jpg</File>
    <File>gei541vqjlbv000002.jpg</File>
    <File>gei541vqjlbv000003.jpg</File>
    <File>gei541vqjlbv000004.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "arwr-10k_20200930.htm": {
   "axisCustom": 1,
   "axisStandard": 19,
   "contextCount": 150,
   "dts": {
    "calculationLink": {
     "local": [
      "arwr-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arwr-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "arwr-10k_20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "arwr-20200930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 517,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 33,
    "http://xbrl.sec.gov/dei/2019-01-31": 4,
    "total": 37
   },
   "keyCustom": 53,
   "keyStandard": 357,
   "memberCustom": 35,
   "memberStandard": 21,
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Investments",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Intangible Assets",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Stockholders' Equity",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Commitments and Contingencies",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Leases",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Stock-Based Compensation",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Fair Value Measurements",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Income Taxes",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Employee Benefit Plans",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Unaudited Quarterly Financial Data",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialData",
     "shortName": "Unaudited Quarterly Financial Data",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Subsequent Events",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Investments (Tables)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Intangible Assets (Tables)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsTables",
     "shortName": "Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Leases (Tables)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Unaudited Quarterly Financial Data (Tables)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataTables",
     "shortName": "Unaudited Quarterly Financial Data (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191201_20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Organization and Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191201_20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Amgen, Inc - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_deiLegalEntityAxis_arwrAmgenIncorporatedMember_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20160927_20160928",
      "decimals": null,
      "lang": "en-US",
      "name": "arwr:AgreementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191201_20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_us-gaapTypeOfArrangementAxis_arwrCollaborationAndLicenseAgreementMember_20181003_20181003",
      "decimals": "-5",
      "lang": null,
      "name": "arwr:InitialTransactionPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007_20201007",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "arwr:AgreementDate",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
     "shortName": "Collaboration and License Agreements - Takeda Pharmaceuticals U.S.A., Inc - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_deiLegalEntityAxis_arwrTakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_arwrLicenseAndCoFundingAgreementMember_20201007",
      "decimals": "-5",
      "lang": null,
      "name": "arwr:CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FurnitureAndFixturesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FurnitureAndFixturesGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Property and Equipment - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail",
     "shortName": "Property and Equipment - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail",
     "shortName": "Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Intangible Assets - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
     "shortName": "Intangible Assets - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Leases - Future Minimum Lease Payments Under Operating Leases (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail",
     "shortName": "Leases - Future Minimum Lease Payments Under Operating Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail",
     "shortName": "Stock-Based Compensation - Summarize Information about Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20181001_20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail",
     "shortName": "Stock-Based Compensation - Assumptions Used to Value Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20181001_20190930",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail",
     "shortName": "Stock-Based Compensation - Summary of RSUs Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20190930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:HeldToMaturitySecuritiesFairValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
     "shortName": "Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20200930",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Fair Value Measurements - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
     "shortName": "Fair Value Measurements - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20170930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statement of Stockholders' Equity",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity",
     "shortName": "Consolidated Statement of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20170930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail",
     "shortName": "Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "arwr:PercentageOfValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "arwr:PercentageOfValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Income Taxes - Provisions for Income Taxes (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail",
     "shortName": "Income Taxes - Provisions for Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail",
     "shortName": "Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Employee Benefit Plans - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail",
     "shortName": "Employee Benefit Plans - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200701_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Unaudited Quarterly Financial Data - Summary of Unaudited Quarterly Financial Data (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail",
     "shortName": "Unaudited Quarterly Financial Data - Summary of Unaudited Quarterly Financial Data (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20200701_20200930",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20190930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_srtStatementGeographicalAxis_countryCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_arwrCorporateHeadquartersInPasadenaMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20201023",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LandSubjectToGroundLeases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_utrsqft",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Organization and Significant Accounting Policies",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Property and Equipment",
     "role": "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "arwr-10k_20200930.htm",
      "contextRef": "C_0000879407_20191001_20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "arwr_AROENacAndAROHIF2CandidatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ARO-ENac and ARO-HIF2 Candidates.",
        "label": "A R O E Nac And A R O H I F2 Candidates [Member]",
        "terseLabel": "ARO-ENaC and ARO-HIF2 Candidates"
       }
      }
     },
     "localname": "AROENacAndAROHIF2CandidatesMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AROJNJ1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ARO-JNJ1.",
        "label": "A R O J N J1 [Member]",
        "terseLabel": "ARO-JNJ1"
       }
      }
     },
     "localname": "AROJNJ1Member",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AdditionalLandSubjectToLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional land subject to lease.",
        "label": "Additional Land Subject To Lease",
        "terseLabel": "Additional office space for lease"
       }
      }
     },
     "localname": "AdditionalLandSubjectToLease",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional remaining development regulatory and sales milestones payments.",
        "label": "Additional Remaining Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Additional remaining development regulatory and sales milestones payments"
       }
      }
     },
     "localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_AgreementDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement date.",
        "label": "Agreement Date",
        "terseLabel": "Agreement date"
       }
      }
     },
     "localname": "AgreementDate",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "arwr_AmgenIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amgen Incorporated.",
        "label": "Amgen Incorporated [Member]",
        "terseLabel": "Amgen Incorporated"
       }
      }
     },
     "localname": "AmgenIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AssetAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_AssetAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_AtTheMarketAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "At-the-market agreement.",
        "label": "At The Market Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "AtTheMarketAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Basis of presentation and use of estimates.",
        "label": "Basis Of Presentation And Use Of Estimates Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Use of Estimates"
       }
      }
     },
     "localname": "BasisOfPresentationAndUseOfEstimatesPolicyTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash receivable as upfront payment due under collaboration agreement.",
        "label": "Cash Receivable As Upfront Payment Due Under Collaboration Agreement",
        "terseLabel": "Cash received as due under collaboration agreement"
       }
      }
     },
     "localname": "CashReceivableAsUpfrontPaymentDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashReceivedAsDueUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received as due under agreement.",
        "label": "Cash Received As Due Under Agreement",
        "terseLabel": "Cash received as due under agreement"
       }
      }
     },
     "localname": "CashReceivedAsDueUnderAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CashReceivedAsDueUnderCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received as due under collaboration agreement.",
        "label": "Cash Received As Due Under Collaboration Agreement",
        "terseLabel": "Cash received as due under collaboration agreement"
       }
      }
     },
     "localname": "CashReceivedAsDueUnderCollaborationAgreement",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License agreements"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration and license agreements.",
        "label": "Collaboration And License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "xbrltype": "stringItemType"
    },
    "arwr_ColoradoOwnerLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Colorado Owner, LLC.",
        "label": "Colorado Owner L L C [Member]",
        "terseLabel": "Colorado Owner, LLC"
       }
      }
     },
     "localname": "ColoradoOwnerLLCMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommercialNotesDueWithinOneThroughThreeYearsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercial notes due within one through three years.",
        "label": "Commercial Notes Due Within One Through Three Years [Member]",
        "terseLabel": "Commercial Notes Due Within One Through Three Years"
       }
      }
     },
     "localname": "CommercialNotesDueWithinOneThroughThreeYearsMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommercialNotesDueWithinOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commercial notes due within one year.",
        "label": "Commercial Notes Due Within One Year [Member]",
        "terseLabel": "Commercial Notes Due Within One Year"
       }
      }
     },
     "localname": "CommercialNotesDueWithinOneYearMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock, capital shares value reserved for future issuance.",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "terseLabel": "Common stock shares value reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_CommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common stock purchase agreement.",
        "label": "Common Stock Purchase Agreement [Member]",
        "terseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for contingent consideration obligations related to acquisitions.",
        "label": "Contingent Consideration Policy [Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_CorporateHeadquartersInPasadenaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate Headquarters in Pasadena",
        "label": "Corporate Headquarters In Pasadena [Member]",
        "terseLabel": "Corporate Headquarters In Pasadena"
       }
      }
     },
     "localname": "CorporateHeadquartersInPasadenaMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.",
        "label": "Deferred Tax Assets In Process Research And Development Cost",
        "terseLabel": "Capitalized Research &amp; Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopmentCost",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10140.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred tax assets right of use assets/ lease liabilities.",
        "label": "Deferred Tax Assets Right Of Use Assets Or Lease Liabilities",
        "terseLabel": "Right of Use Assets/Lease Liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DeferredTaxLiabilitiesStateTaxes": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.",
        "label": "Deferred Tax Liabilities State Taxes",
        "negatedLabel": "State taxes"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesStateTaxes",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DevelopmentRegulatoryAndCommercialMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development regulatory and commercial milestones payments.",
        "label": "Development Regulatory And Commercial Milestones Payments",
        "terseLabel": "Development regulatory and commercial milestones payments"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndCommercialMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development regulatory and sales milestones payments.",
        "label": "Development Regulatory And Sales Milestones Payments",
        "terseLabel": "Development regulatory and sales milestones payments",
        "verboseLabel": "Development, regulatory and sales milestones payments"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to stock compensation.",
        "label": "Effective Income Tax Rate Reconciliation Deductions Stock Compensation Percent",
        "negatedLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsStockCompensationPercent",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to mark-to-market adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Mark To Market Adjustments",
        "terseLabel": "Mark-to-market adjustments"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationMarkToMarketAdjustments",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective income tax rate reconciliation true-up on deferred tax rate.",
        "label": "Effective Income Tax Rate Reconciliation True Up On Deferred Tax Rate",
        "terseLabel": "True-up on deferred taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTrueUpOnDeferredTaxRate",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_EmployeeContributionNextTwoPercentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee contribution next two percent.",
        "label": "Employee Contribution Next Two Percent [Member]",
        "terseLabel": "Employee Contributions Next 2%"
       }
      }
     },
     "localname": "EmployeeContributionNextTwoPercentMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_EmployeeContributionsUpToThreePercentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee contributions up to three percent.",
        "label": "Employee Contributions Up To Three Percent [Member]",
        "terseLabel": "Employee Contributions up to 3%"
       }
      }
     },
     "localname": "EmployeeContributionsUpToThreePercentMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards additional compensation cost not yet recognized share based awards other than options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Additional Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Additional unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsAdditionalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity securities FV NI accumulated gross realized gain loss before tax.",
        "label": "Equity Securities F V N I Accumulated Gross Realized Gain Loss Before Tax",
        "terseLabel": "Marketable Securities, Realized Gains/(Losses)"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAccumulatedGrossRealizedGainLossBeforeTax",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity securities FV NI accumulated gross unrealized gain before tax.",
        "label": "Equity Securities F V N I Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Marketable Securities, Gross Unrealized Gains"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity securities FV NI accumulated gross unrealized loss before tax.",
        "label": "Equity Securities F V N I Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Marketable Securities, Gross Unrealized Losses"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected payments of leasehold improvements, net of tenant improvement allowances.",
        "label": "Expected Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances",
        "terseLabel": "Expected leasehold improvements, net of tenant improvement allowances"
       }
      }
     },
     "localname": "ExpectedPaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_FederalNetOperatingLossCarryForward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Federal net operating loss carry forward.",
        "label": "Federal Net Operating Loss Carry Forward",
        "terseLabel": "Gross federal net operating loss carry forwards"
       }
      }
     },
     "localname": "FederalNetOperatingLossCarryForward",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_GrantDateFairValueOfOptionsGrantedDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Grant date fair value of the options granted during the period.",
        "label": "Grant Date Fair Value Of Options Granted During Period",
        "terseLabel": "Grant date fair value of the options granted"
       }
      }
     },
     "localname": "GrantDateFairValueOfOptionsGrantedDuringPeriod",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_HalozymeIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Halozyme, Inc.",
        "label": "Halozyme Inc [Member]",
        "terseLabel": "Halozyme, Inc."
       }
      }
     },
     "localname": "HalozymeIncMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Held to maturity securities and marketable securities.",
        "label": "Held To Maturity Securities And Marketable Securities Table [Text Block]",
        "terseLabel": "Summary of Short-term, Long-term Investments and Marketable Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "arwr_HeldToMaturitySecuritiesFairValueNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Held to maturity securities fair value non current.",
        "label": "Held To Maturity Securities Fair Value Non Current",
        "terseLabel": "Long-term investments (held to maturity)"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValueNonCurrent",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_IncreaseDecreaseInCashAndInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase decrease in cash and investments.",
        "label": "Increase Decrease In Cash And Investments",
        "terseLabel": "Net increase (decrease) in cash and investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndInvestments",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_InitialTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial transaction price.",
        "label": "Initial Transaction Price",
        "terseLabel": "Initial transaction price"
       }
      }
     },
     "localname": "InitialTransactionPrice",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_JNJ3989AROHBVAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "JNJ-3989 (ARO-HBV) Agreement.",
        "label": "J N J3989 A R O H B V Agreement [Member]",
        "terseLabel": "JNJ-3989 (ARO-HBV) Agreement"
       }
      }
     },
     "localname": "JNJ3989AROHBVAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Janssen Pharmaceuticals and Johnson And Johnson Innovation JJDC Incorporation.",
        "label": "Janssen Pharmaceuticals And Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "terseLabel": "Janssen and JJDC"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsAndJohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JanssenPharmaceuticalsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Janssen Pharmaceuticals, Incorporation.",
        "label": "Janssen Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Janssen"
       }
      }
     },
     "localname": "JanssenPharmaceuticalsIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Johnson and Johnson Innovation-JJDC, Incorporation.",
        "label": "Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "terseLabel": "JJDC"
       }
      }
     },
     "localname": "JohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LeaseCommencementMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease commencement month and year.",
        "label": "Lease Commencement Month And Year",
        "terseLabel": "Lease commencement period"
       }
      }
     },
     "localname": "LeaseCommencementMonthAndYear",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "arwr_LeaseExpirationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease expiration month and year.",
        "label": "Lease Expiration Month And Year",
        "terseLabel": "Operating lease expiration month and year",
        "verboseLabel": "Lease expiration month and year"
       }
      }
     },
     "localname": "LeaseExpirationMonthAndYear",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "arwr_LeasePaymentsCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease payments commencement date.",
        "label": "Lease Payments Commencement Date",
        "terseLabel": "Lease payments, commencement date"
       }
      }
     },
     "localname": "LeasePaymentsCommencementDate",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee operating lease liability payments due year five and after year five.",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And After Year Five",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LicenseAndCoFundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License and co-funding agreement.",
        "label": "License And Co Funding Agreement [Member]",
        "terseLabel": "License and Co-Funding Agreement"
       }
      }
     },
     "localname": "LicenseAndCoFundingAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_LicenseCollaborationAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License collaboration and stock purchase agreement.",
        "label": "License Collaboration And Stock Purchase Agreement [Member]",
        "terseLabel": "License Collaboration and Stock Purchase Agreement"
       }
      }
     },
     "localname": "LicenseCollaborationAndStockPurchaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_MilestonePaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payment earned.",
        "label": "Milestone Payment Earned",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePaymentEarned",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payment received.",
        "label": "Milestone Payment Received",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "verboseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_NovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Novartis.",
        "label": "Novartis [Member]",
        "terseLabel": "Novartis"
       }
      }
     },
     "localname": "NovartisMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional targets for development and sales milestone payments.",
        "label": "Number Of Additional Targets For Development And Sales Milestone Payments",
        "terseLabel": "Number of additional targets for development and sales milestone payments"
       }
      }
     },
     "localname": "NumberOfAdditionalTargetsForDevelopmentAndSalesMilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional targets for development, regulatory and sales milestone payments.",
        "label": "Number Of Additional Targets For Development Regulatory And Sales Milestone Payments",
        "terseLabel": "Number of additional targets for development, regulatory and sales milestone payments"
       }
      }
     },
     "localname": "NumberOfAdditionalTargetsForDevelopmentRegulatoryAndSalesMilestonePayments",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of agreements.",
        "label": "Number Of Agreements",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfAgreements",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctBundle": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of distinct bundle.",
        "label": "Number Of Distinct Bundle",
        "terseLabel": "Number of distinct bundle"
       }
      }
     },
     "localname": "NumberOfDistinctBundle",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfDistinctPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of distinct performance obligations.",
        "label": "Number Of Distinct Performance Obligations",
        "terseLabel": "Number of distinct performance obligations"
       }
      }
     },
     "localname": "NumberOfDistinctPerformanceObligations",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_NumberOfOptionsToRenew": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options to renew.",
        "label": "Number Of Options To Renew",
        "terseLabel": "Number of options to renew"
       }
      }
     },
     "localname": "NumberOfOptionsToRenew",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "arwr_OlpasiranAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Olpasiran agreement.",
        "label": "Olpasiran Agreement [Member]",
        "terseLabel": "Olpasiran Agreement"
       }
      }
     },
     "localname": "OlpasiranAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OlpasiranAndAROAMG1AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Olpasiran and ARO-AMG1 agreement.",
        "label": "Olpasiran And A R O A M G1 Agreement [Member]",
        "terseLabel": "Olpasiran and ARO-AMG1 Agreement"
       }
      }
     },
     "localname": "OlpasiranAndAROAMG1AgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization and significant accounting policies.",
        "label": "Organization And Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSignificantAccountingPoliciesTable",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_OutsideOfEquityCompensationPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outside of equity compensation plans.",
        "label": "Outside Of Equity Compensation Plans [Member]",
        "terseLabel": "Outside Of Equity Compensation Plans"
       }
      }
     },
     "localname": "OutsideOfEquityCompensationPlansMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments of leasehold improvements net of tenant improvement allowances.",
        "label": "Payments Of Leasehold Improvements Net Of Tenant Improvement Allowances",
        "terseLabel": "Payments for leasehold improvements, net of tenant improvement allowances"
       }
      }
     },
     "localname": "PaymentsOfLeaseholdImprovementsNetOfTenantImprovementAllowances",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock.",
        "label": "Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock",
        "terseLabel": "Percentage of commission to sales agent"
       }
      }
     },
     "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of eligible to receive tiered royalties on net sales.",
        "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales",
        "terseLabel": "Percentage of eligible to receive tiered royalties on net sales"
       }
      }
     },
     "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_PercentageOfValuationAllowance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of valuation allowance.",
        "label": "Percentage Of Valuation Allowance",
        "terseLabel": "Valuation allowance against deferred tax assets"
       }
      }
     },
     "localname": "PercentageOfValuationAllowance",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash inflow from the issuance of common stock before deducting advisory fees and offering expenses.",
        "label": "Proceeds From Issuance Of Common Stock Before Deducting Fees And Offering Expenses",
        "verboseLabel": "Aggregate purchase price paid by investors"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockBeforeDeductingFeesAndOfferingExpenses",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ProfitSharingStructureRatio": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profit sharing structure ratio.",
        "label": "Profit Sharing Structure Ratio",
        "terseLabel": "Profit sharing structure ratio"
       }
      }
     },
     "localname": "ProfitSharingStructureRatio",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_RatioOfProfitSharingStructureForCommercialization": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ratio of profit sharing structure for commercialization.",
        "label": "Ratio Of Profit Sharing Structure For Commercialization",
        "terseLabel": "Ratio of Profit Sharing Structure for United States Commercialization"
       }
      }
     },
     "localname": "RatioOfProfitSharingStructureForCommercialization",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ResearchCollaborationAndOptionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research collaboration and option agreement.",
        "label": "Research Collaboration And Option Agreement [Member]",
        "terseLabel": "Research Collaboration and Option Agreement"
       }
      }
     },
     "localname": "ResearchCollaborationAndOptionAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ResearchEquipmentGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research equipment gross.",
        "label": "Research Equipment Gross",
        "terseLabel": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentGross",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_ResearchFacilityInMadisonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research facility in Madison.",
        "label": "Research Facility In Madison [Member]",
        "terseLabel": "Research Facility in Madison"
       }
      }
     },
     "localname": "ResearchFacilityInMadisonMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of held to maturity securities and marketable securities.",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "arwr_StateNetOperatingLossCarryForwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "State net operating loss carry forwards.",
        "label": "State Net Operating Loss Carry Forwards",
        "terseLabel": "Gross state net operating loss carry forwards"
       }
      }
     },
     "localname": "StateNetOperatingLossCarryForwards",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of stock issued during the period upon the exercise of warrants.",
        "label": "Stock Issued During Period Shares Exercise Of Warrants",
        "terseLabel": "Exercise of warrants, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "arwr_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued during the period upon the exercise of warrants.",
        "label": "Stock Issued During Period Value Exercise Of Warrants",
        "terseLabel": "Exercise of warrants, Amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "arwr_SubleaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sublease Agreement.",
        "label": "Sublease Agreement [Member]",
        "terseLabel": "Sublease Agreement"
       }
      }
     },
     "localname": "SubleaseAgreementMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_SubleaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sublease commencement date.",
        "label": "Sublease Commencement Date",
        "terseLabel": "Sublease commencement date"
       }
      }
     },
     "localname": "SubleaseCommencementDate",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Takeda Pharmaceuticals United States of America Incorporated.",
        "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]",
        "terseLabel": "Takeda License Agreement"
       }
      }
     },
     "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TechnologyLicenseCommitmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Technology license commitments.",
        "label": "Technology License Commitments [Member]",
        "terseLabel": "Technology License Commitments"
       }
      }
     },
     "localname": "TechnologyLicenseCommitmentsMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TieredRoyaltiesReceivedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tiered royalties received percentage.",
        "label": "Tiered Royalties Received Percentage",
        "terseLabel": "Tiered royalties received percentage"
       }
      }
     },
     "localname": "TieredRoyaltiesReceivedPercentage",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousand four equity incentive plan two thousand thirteen equity incentive plan and inducement grants.",
        "label": "Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan And Inducement Grants [Member]",
        "terseLabel": "2004 Equity Incentive Plan, 2013 Equity Incentive Plan, and Inducement Grants"
       }
      }
     },
     "localname": "TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanAndInducementGrantsMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsFourEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousands four equity incentive plan.",
        "label": "Two Thousands Four Equity Incentive Plan [Member]",
        "terseLabel": "2004 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandsFourEquityIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_TwoThousandsThirteenIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two thousands thirteen incentive plan.",
        "label": "Two Thousands Thirteen Incentive Plan [Member]",
        "terseLabel": "2013 Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandsThirteenIncentivePlanMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "arwr_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.arrowheadresearch.com/20200930",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CANADA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Security12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r48",
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r326",
      "r331",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r513",
      "r551",
      "r553"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r326",
      "r331",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r513",
      "r551",
      "r553"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r278",
      "r326",
      "r331",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r513",
      "r551",
      "r553"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r278",
      "r326",
      "r331",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r513",
      "r551",
      "r553"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r247",
      "r249",
      "r552",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r247",
      "r249",
      "r552",
      "r568",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WI": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "WISCONSIN",
        "terseLabel": "Wisconsin"
       }
      }
     },
     "localname": "WI",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update201409 [Member]",
        "terseLabel": "ASU No. 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASU No. 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201818Member": {
     "auth_ref": [
      "r420",
      "r421"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.",
        "label": "Accounting Standards Update201818 [Member]",
        "terseLabel": "ASU No. 2018-18"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201818Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r24",
      "r153",
      "r154"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10280.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r214"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r51",
      "r52",
      "r53",
      "r539",
      "r561",
      "r565"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r50",
      "r53",
      "r54",
      "r97",
      "r98",
      "r99",
      "r432",
      "r556",
      "r557"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid In Capital Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r104",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r399",
      "r400",
      "r401",
      "r402",
      "r516",
      "r517",
      "r518",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r333",
      "r335",
      "r376",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r335",
      "r362",
      "r375"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r81",
      "r201",
      "r207"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Assets",
        "negatedLabel": "Intangible assets subject to amortization, Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive excluded for calculation of effect of dilutive stock options and restricted stock units"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r139",
      "r142",
      "r147",
      "r176",
      "r426",
      "r433",
      "r449",
      "r523",
      "r538"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r47",
      "r91",
      "r176",
      "r426",
      "r433",
      "r449"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "TOTAL CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "CURRENT ASSETS"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r162",
      "r164",
      "r193",
      "r527"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "verboseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r336",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination Contingent Consideration Liability Noncurrent",
        "positiveLabel": "Contingent Consideration",
        "terseLabel": "Fair value of contingent consideration obligation due to discontinuation of clinical trials",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitsAuthorized": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.",
        "label": "Capital Units Authorized",
        "terseLabel": "Capital stock authorized for issuance"
       }
      }
     },
     "localname": "CapitalUnitsAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareGross": {
     "auth_ref": [
      "r583"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.",
        "label": "Capitalized Computer Software Gross",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r31",
      "r83"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10270.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r15",
      "r84",
      "r87",
      "r522"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r77",
      "r83",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r451"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash F D I C Insured Amount",
        "terseLabel": "Amount insured in FDIC per account"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r100",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r366",
      "r367",
      "r368",
      "r399",
      "r439",
      "r450",
      "r464",
      "r516",
      "r517",
      "r554",
      "r555"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r107",
      "r177",
      "r178",
      "r179",
      "r181",
      "r182",
      "r366",
      "r367",
      "r368",
      "r399",
      "r439",
      "r450",
      "r464",
      "r516",
      "r517",
      "r554",
      "r555"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in CCYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption": {
     "auth_ref": [
      "r100",
      "r177",
      "r180",
      "r183",
      "r369",
      "r400",
      "r439",
      "r450",
      "r464",
      "r518",
      "r554",
      "r555",
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was early adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Early Adoption",
        "terseLabel": "Change in accounting principle, accounting standards update, early adoption [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateEarlyAdoption",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r101",
      "r113",
      "r185",
      "r373",
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r417",
      "r418",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r220",
      "r528",
      "r544"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r217",
      "r218",
      "r219",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Shares reserve for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value; 145,000,000 shares authorized; 102,376,303 and 95,506,271 shares issued and outstanding as of September 30, 2020 and September 30, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r252",
      "r255",
      "r332",
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation And Employee Benefit Plans [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59",
      "r63",
      "r532",
      "r546"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "COMPREHENSIVE INCOME (LOSS)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Comprehensive Income Net Of Tax [Abstract]",
        "terseLabel": "OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r133",
      "r536"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r235",
      "r237",
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract With Customer Asset Net Current",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r235",
      "r236",
      "r248"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r235",
      "r236",
      "r248"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r396",
      "r406"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense Benefit",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r396",
      "r406"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State And Local Tax Expense Benefit",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r397",
      "r406"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense Benefit",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r20",
      "r21",
      "r387",
      "r524",
      "r537"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedTotalLabel": "Total deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditCurrent": {
     "auth_ref": [
      "r38",
      "r460"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.",
        "label": "Deferred Rent Credit Current",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r41",
      "r460"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.",
        "label": "Deferred Rent Credit Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r397",
      "r406"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State And Local Income Tax Expense Benefit",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10160.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets Capital Loss Carryforwards",
        "terseLabel": "Capital Loss"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10130.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10120.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets Goodwill And Intangible Assets",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax assets (liabilities)"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net Operating Losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets Property Plant And Equipment",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax": {
     "auth_ref": [
      "r393",
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible alternative minimum tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax",
        "terseLabel": "California Alternative Minimum Tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits",
        "terseLabel": "Accrued Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock Compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10150.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent",
        "terseLabel": "Deferred Rent"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r389"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Liabilities Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities Property Plant And Equipment",
        "negatedLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesComponentsOfNetDeferredTaxLiabilityAndAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan Cost Recognized",
        "terseLabel": "Employee benefits costs"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent",
        "terseLabel": "Percentage of compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match",
        "terseLabel": "Discretionary match percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r81",
      "r212"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r81",
      "r137"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization expense for property and equipment"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r64",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r114",
      "r116",
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r533",
      "r547"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share Basic",
        "terseLabel": "NET INCOME (LOSS) PER SHARE - BASIC",
        "verboseLabel": "Net Income (Loss) per share-Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r64",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r116",
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r533",
      "r547"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Diluted",
        "terseLabel": "NET INCOME (LOSS) PER SHARE - DILUTED",
        "verboseLabel": "Net Income (Loss) per share-Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r124",
      "r125"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Income (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r383",
      "r407"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "At U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r383",
      "r407"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r383",
      "r407"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10080.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate",
        "terseLabel": "Tax rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r383",
      "r407"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r383",
      "r407"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State taxes, net of federal effect"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesSummaryOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Accrued payroll and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Weighted average period to recognize pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r363"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized pre-tax compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r102",
      "r110",
      "r112",
      "r130",
      "r184",
      "r225",
      "r232",
      "r370",
      "r371",
      "r372",
      "r401",
      "r402",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities Fv Ni",
        "terseLabel": "Marketable Securities, Fair Value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities Fv Ni Cost",
        "totalLabel": "Marketable Securities, Amortized Cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r446"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r318",
      "r441",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r440",
      "r441",
      "r443",
      "r444",
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r279",
      "r280",
      "r285",
      "r318",
      "r441",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r279",
      "r280",
      "r285",
      "r318",
      "r441",
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r318",
      "r441",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r318",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r445",
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r93",
      "r382"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current and deferred federal income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Federal Income Tax Expense Benefit Continuing Operations",
        "totalLabel": "Total Federal"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Federal Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "Federal:"
       }
      }
     },
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r169",
      "r173",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r194",
      "r195",
      "r196",
      "r197",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Asset Useful Life",
        "terseLabel": "Amortization period of intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "terseLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense After Year Five",
        "terseLabel": "Amortization of license agreements, thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months",
        "terseLabel": "Amortization of license agreements remainder of fiscal year 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Five",
        "terseLabel": "Amortization of license agreements in 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Four",
        "terseLabel": "Amortization of license agreements in 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Three",
        "terseLabel": "Amortization of license agreements in 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Two",
        "terseLabel": "Amortization of license agreements in 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r202",
      "r203",
      "r206",
      "r209",
      "r515",
      "r519"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r202",
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r206",
      "r515"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "periodEndLabel": "Intangible assets subject to amortization, ending balance",
        "periodStartLabel": "Intangible assets subject to amortization, beginning balance",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r213"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures Gross",
        "terseLabel": "Computers, office equipment and furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10130.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill And Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r200",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets Policy [Text Block]",
        "terseLabel": "Intangible Assets subject to amortization"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r162",
      "r165",
      "r527"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities",
        "totalLabel": "Held to Maturity, Amortized Cost"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r167",
      "r171"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities Accumulated Unrecognized Holding Gain",
        "terseLabel": "Held to Maturity, Gross Unrealized Gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r168",
      "r172"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities Accumulated Unrecognized Holding Loss",
        "negatedLabel": "Held to Maturity, Gross Unrealized Losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesClassifiedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Held To Maturity Securities Classified [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesClassifiedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10320.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Held To Maturity Securities Current",
        "terseLabel": "Short term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r166",
      "r170",
      "r527"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Held To Maturity Securities Fair Value",
        "terseLabel": "Held to Maturity, Fair Value",
        "verboseLabel": "Short-term investments (held to maturity)"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsFairValueMeasurementsForAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Held To Maturity Securities Noncurrent",
        "terseLabel": "Long term investments"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r81",
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment Of Intangible Assets Finitelived",
        "terseLabel": "Intangible assets subject to amortization, Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsScheduleOfIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r61",
      "r139",
      "r141",
      "r143",
      "r146",
      "r148",
      "r520",
      "r530",
      "r534",
      "r549"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10030.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r384",
      "r385",
      "r392",
      "r404",
      "r408",
      "r410",
      "r411",
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r94",
      "r111",
      "r112",
      "r138",
      "r382",
      "r405",
      "r409",
      "r550"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Provision from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r87",
      "r380",
      "r381",
      "r385",
      "r386",
      "r391",
      "r398",
      "r569"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Income Taxes (Paid) Refunded"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase Decrease In Other Operating Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Share Based Payment Arrangements",
        "terseLabel": "Calculation of effect of dilutive stock options and restricted stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Intangible Assets Net Excluding Goodwill [Abstract]"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10070.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "terseLabel": "Interest income (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r75",
      "r78",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "negatedLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income Net Amortization Of Discount And Premium",
        "negatedLabel": "Amortization/(accretion) of note premiums"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r175",
      "r548"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment Policy [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r174",
      "r521",
      "r535",
      "r567"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject To Ground Leases",
        "terseLabel": "Office space leases, in square feet"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r9",
      "r213"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "terseLabel": "Estimated lease payments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r30",
      "r91",
      "r176",
      "r449",
      "r526",
      "r542"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r91",
      "r176",
      "r427",
      "r433",
      "r434",
      "r449"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "TOTAL CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r18",
      "r19",
      "r91",
      "r176",
      "r427",
      "r433",
      "r434",
      "r449"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities Noncurrent",
        "totalLabel": "TOTAL LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities Noncurrent [Abstract]",
        "terseLabel": "LONG-TERM LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreement"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r220"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual At Carrying Value",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r529"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r4",
      "r37"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10310.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r45",
      "r91",
      "r176",
      "r449",
      "r525",
      "r541"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Minority Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r79",
      "r82"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "negatedTerseLabel": "Cash outflow primarily related to operations",
        "totalLabel": "NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r55",
      "r57",
      "r62",
      "r82",
      "r91",
      "r101",
      "r105",
      "r106",
      "r107",
      "r108",
      "r111",
      "r112",
      "r120",
      "r139",
      "r141",
      "r143",
      "r146",
      "r148",
      "r176",
      "r449",
      "r531",
      "r545"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "totalLabel": "NET INCOME (LOSS)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r233",
      "r431"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest Decrease From Deconsolidation",
        "terseLabel": "Deconsolidation of Ablaris Therapeutics, Inc."
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r232",
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "TOTAL OTHER INCOME (EXPENSE)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "OTHER INCOME (EXPENSE)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "TOTAL OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "OPERATING EXPENSES"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r139",
      "r141",
      "r143",
      "r146",
      "r148"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10050.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "terseLabel": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r471",
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "positiveLabel": "Total operating lease liabilities (includes current portion)",
        "terseLabel": "Right-of-use liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesOnUndiscountedBasisDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r467",
      "r474"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating lease cash payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r465"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10250.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r476",
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r475",
      "r478"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r459",
      "r461"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases Future Minimum Payments Due",
        "terseLabel": "Estimated lease payments",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r459",
      "r461"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due Current",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r459",
      "r461"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Five Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r459",
      "r461"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Four Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r459",
      "r461"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Three Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r459",
      "r461"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Two Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r459",
      "r461"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due Thereafter",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesFutureMinimumLeasePaymentsUnderOperatingLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r96",
      "r134",
      "r438"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10300.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10260.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax",
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r38"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10090.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other Income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payments Related To Tax Withholding For Share Based Compensation",
        "negatedLabel": "Payment of taxes for net share settled restricted stock unit issuances"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments To Acquire Investments",
        "negatedLabel": "Purchases of investments",
        "verboseLabel": "Purchases of investments and marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r336",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r198",
      "r199"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10290.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock",
        "verboseLabel": "Net proceeds from common stock after deducting advisory fees and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds From Sale Maturity And Collection Of Longterm Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds From Sale Maturity And Collections Of Investments",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r365"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from the exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r55",
      "r57",
      "r76",
      "r91",
      "r101",
      "r111",
      "r112",
      "r139",
      "r141",
      "r143",
      "r146",
      "r148",
      "r176",
      "r425",
      "r429",
      "r430",
      "r436",
      "r437",
      "r449",
      "r534"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Net Income (Loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r216",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r213"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "totalLabel": "Total gross fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r215",
      "r543"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r87",
      "r215",
      "r571",
      "r572"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Summary of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Future commitments"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation Due In Next Twelve Months",
        "terseLabel": "Commitments expected to be incurred in fiscal 2021"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation Due In Second Year",
        "terseLabel": "Commitments expected to be incurred beyond fiscal 2021"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Unaudited Quarterly Financial Data"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialData"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments Of Notes Payable",
        "negatedLabel": "Principal payments on notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r87",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r15",
      "r83",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r232",
      "r373",
      "r540",
      "r560",
      "r565"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r102",
      "r110",
      "r112",
      "r184",
      "r370",
      "r371",
      "r372",
      "r401",
      "r402",
      "r556",
      "r558"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r253",
      "r254",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r328",
      "r329",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r135",
      "r136",
      "r140",
      "r144",
      "r145",
      "r149",
      "r150",
      "r152",
      "r246",
      "r247",
      "r514"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Provisions for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of the Net Deferred Tax (Liability)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Summary of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r440",
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r202",
      "r205",
      "r515"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule Of Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
        "terseLabel": "Future Minimum Lease Payments Under Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule Of Intangible Assets And Goodwill Table [Text Block]",
        "terseLabel": "Schedule of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Schedule Of Quarterly Financial Information Table [Text Block]",
        "terseLabel": "Schedule of Unaudited Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r336",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]",
        "terseLabel": "Summary of Share Activity Related to RSUs"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r340",
      "r352",
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summarized Information about Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Assumptions Used to Value Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r89",
      "r131",
      "r132",
      "r222",
      "r223",
      "r224",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r334",
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Description",
        "terseLabel": "RSU awards vesting, description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Number of RSUs, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Number of restricted stock units outstanding, granted",
        "verboseLabel": "Number of RSUs, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of RSUs, Unvested, End of period",
        "periodStartLabel": "Number of RSUs, Unvested, beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value, ending balance",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of RSUs, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r341",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number",
        "terseLabel": "Number of restricted stock units outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Common Stock, Share reserve for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Options Outstanding, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
        "negatedLabel": "Number of Options Outstanding, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "verboseLabel": "Number of Options Outstanding, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r342",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options Outstanding, ending balance",
        "periodStartLabel": "Number of Options Outstanding, beginning balance",
        "terseLabel": "Number of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, ending balance",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r334",
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRsusActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r87",
      "r336",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r358",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedToValueStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued",
        "verboseLabel": "Shares issued to institutional investors"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "verboseLabel": "Stock issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Ending Balance, Shares",
        "periodStartLabel": "Beginning Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r472",
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short Term Lease Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r92",
      "r382",
      "r405"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of state and local current and deferred income tax expense (benefit) attributable to continuing operations.",
        "label": "State And Local Income Tax Expense Benefit Continuing Operations",
        "totalLabel": "Total State"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "State And Local Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "State:"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureIncomeTaxesProvisionsForIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r97",
      "r98",
      "r99",
      "r102",
      "r110",
      "r112",
      "r130",
      "r184",
      "r225",
      "r232",
      "r370",
      "r371",
      "r372",
      "r401",
      "r402",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r556",
      "r557",
      "r558"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r130",
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r225",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Common stock - issued for cash, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r225",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "terseLabel": "Common stock - restricted stock units vesting, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r225",
      "r232",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Options Outstanding, Exercised",
        "terseLabel": "Exercise of stock options, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockBasedCompensationSummarizeInformationAboutStockOptionsDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r225",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Common stock - issued for cash, Amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r22",
      "r23",
      "r225",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Gross",
        "terseLabel": "Common stock - restricted stock units vesting, Amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r225",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options, Amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r28",
      "r29",
      "r91",
      "r160",
      "r176",
      "r449"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "totalLabel": "Total Arrowhead Pharmaceuticals, Inc. stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Arrowhead Pharmaceuticals, Inc. stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r91",
      "r97",
      "r98",
      "r99",
      "r102",
      "r110",
      "r176",
      "r184",
      "r232",
      "r370",
      "r371",
      "r372",
      "r401",
      "r402",
      "r423",
      "r424",
      "r435",
      "r449",
      "r452",
      "r453",
      "r457",
      "r557",
      "r558"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest",
        "periodEndLabel": "Ending Balance, Amount",
        "periodStartLabel": "Beginning Balance, Amount",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r232",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r458",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r458",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r458",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r458",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r480",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade And Other Accounts Receivable Policy",
        "terseLabel": "Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r169",
      "r173",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureInvestmentsSummaryOfShortTermLongTermInvestmentsAndMarketableSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r104",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r187",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r399",
      "r400",
      "r401",
      "r402",
      "r516",
      "r517",
      "r518",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsJanssenPharmaceuticalsIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTakedaPharmaceuticalsUSAIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureOrganizationAndSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Type Of Revenue Extensible List",
        "terseLabel": "Type of Revenue [Extensible List]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAmgenIncAdditionalInformationDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureUnauditedQuarterlyFinancialDataSummaryOfUnauditedQuarterlyFinancialDataDetail",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss": {
       "order": 10080.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain Loss On Derivatives",
        "negatedLabel": "Change in value of derivatives",
        "terseLabel": "Change in value of derivatives"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r473",
      "r478"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number Of Diluted Shares Outstanding",
        "terseLabel": "Weighted average shares outstanding - diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r114",
      "r123"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number Of Shares Outstanding Basic",
        "terseLabel": "Weighted average shares outstanding - basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.arrowheadresearch.com/20200930/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31010-122693"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e39927-112707"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120520240&loc=SL120174030-210619"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r584": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r585": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r586": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r587": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r588": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r589": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r590": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001564590-20-054893-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-054893-xbrl.zip
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M@ 8^=TRT?M*MI5@LGQ9KY50+.2B?A@O1"OE#H\>=KF@Z=8/$']A^MYX%ELS
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M<=.]>72$=W75&%4U4$8]A2N%V_7XH(?9]LJG\0=>HQX%F3T75N@/,<SI@[[
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ML-/7)+#]K]S[P6X<\2Y$..CU<!,*VXB#CVCG_N1SU(,*[3_O ?$9PK;E@!N
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MI=.08L(%?6(=R[9Q91V.<BT8P)_()H;M2B73<,,#H*XDN(U!!?[XBF-.=1O
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M@(U - !\B-P**.D?!1 8)Q$8"2O$/-&C*:0!R%!@5%+%=$%<*$6/P@D(3]$
M\"FI3OP738!)58T[C-1UP^WW+8(."4D;V3G423$"F\45L!KD4+A &QJ3I!;G
MN FF+M -]"5A!]Y*1!:_1<,.20OT+*A(>#8\ *#$X1.2.;Q;7=H9LH#D*/$8
M00AP)UTG9G>$7(2J$Q_(C1XJ1E-9*IY&&!(S< $^5:AW(T?;X,7 YLT UV%;
M**41X8GV3&P+)80UVA1<AK:#)_X*+! 0N&2;/Q80?\@F-K?ZM'I2;_16)!4@
MDB3()IHX6ES2G?<V&E$S]0MZ!O1@$Y[#1FHW=B_^ZAI*W.)N[V'_(Z/!U,].
MJ8L6\2.><75>TX7)O:Q11&0J,K.)56 J*8CZ6'AF>\T>,%9_WKMV?2'O7% Y
MTK4MY#Z3%-$H_K;WZ9MC@RI48NP1)0!((113^Y5WBAR1-=$J#FWMNN>YCST0
M8*&Q30:M1&Z.?F*W8(?V08R!: .W!K1.TS%*(/O8F0 Y1&+/!2?*BQE((#K:
M04=:I@5[02MHOSJQ@LA%P>:#(+VFW)0I[R*0T3?X#OTM&#N%L<6'_I_KD&,4
MF=;,C70RBJ31]I(7#+\I(QQ4?& HW]%S@VXO=B=J#70[U6W#L<?"EFLS@!Y_
MT3RX?^4@W@&B"&ZV/XFQ\&?]A'=*&8U^K@?21V>1LUOP%Z]\,^$1T36CA^P?
MS%@UJGQ83-MWC1]S5AT94/'KX;&'[]CD$V_I=M1H"S]TZI91G!%WOW\T_1:Z
ML >B1WC[\MWT2_!Z]?,$7<0WD-9Q.IDM038@#$E^-._.OWZO?/_\K=V\/F^W
M]S[A%]I6+HW)[+&SB -29F$O*WUS.F@<I0'&"^5K"LUP1C;QP-?&8^A K&Q/
MFSF'&-&M"?:5[0[ ;D1G$O>F3%D?8V!H)&)0@?Q:D!\"O%V)%J4$3P"<FEBD
M2=^F'#OXLE]BWR1>P%G'<^%%Z+S<@RYR$8RMZSHSX"(+)$KH+@AT="VT2?LN
M>")XF0DV\(/PAH48HZ&<Y0.\"6[M=K5]B0]$B];3KB-L!YT/2_8I?(-2&6QB
MN ]$K2G$@-YH!BKR\\,!IC7=1\*P#V@3OMI3:?JYH5C$7ZQ0$#(+?871*[7/
M@/X*; "A8(#?I4$$W@QE.=*ZM1NMJ0OTPT 8Z [1^PMA!!(,Z7N,%VEX#SP7
MM<ST3?"##Z9Y"71M+'((=!!Z6WU7^A1%\'QRN 2:B^07N !GY6O!DN_!+T-4
M&#'G;N"BOX!^+(K!D,HBLE&.5O@D+1X11N!X@,Y'S4].%;MV.\(&T0QTCR^K
MELM'% J%VRT/XY(@/J=%.3ZIJ((MB@#(OI#,!O+UP$A6GC*ECF#LC/L]L)-Q
M"0C'$;F67E$PO[XLNK4& H]!V0UL&MW[71%"@+I[UPAT*$V+).7C.NZ#"N2:
M7M"51"F1("+:Y(1B( :,Q5E@B_G# 5J>]C >$E6.,%EZ +MQ!B+^\%3<2'.0
M9E45!J;PG:G>IM]=8AA;-,'E[I$D@6=B0^PPV(XQ-:)]'T0"A921M82#TD9B
M! %]_9"?,&QGFB@%R'RTE-$)K/%@>1B6H[#>,$[VN"Y.[QT$G@PBT:QE5VSQ
M&%<8V??Z-23S4(CW,=K8=\$-QT-X>F#'HM4:,L:$B!X;_@W%S[TE; H1=3SX
M*B:4^OB2D.UAB^&V(H2Y@0^V;"2-2+@K2Q0A-@C)VW$?PSB.G-J;C@'I>^T
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MJL!%@HGDQ5+81XTCJ+;@09VR&)2ICW?9U./-C5'H5E/5&PRY:3DQPQ09#[,
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MU]KDGK2N0[#/,:]Q&.*<_'C5R^E-X6<1D[MV?'A8V7*3&XN8TR7F9T[G1=M
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MZV1[J=9;J",^@P5];ZE24RK]OXLU0=MN=X2V0QT.^@)'=.&85PP9Z@YAMO5
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M/4XK]M6HW]RE^XC<4M"-6O#%T3%&_/W1F*[XM '%^=@U6P<P\7;-E6I<M3[
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MCUY/]29YLNA$QYU8;7#,PHI%WB!U0]+% TG^]$2EI0DZV<$?E6_Q(,8>JC/
M9]C6RI' [&[R4EQ@E)XVCP0MWPO;(A'L%!5&(2U5VS"5N!U.B ?S?N ': QZ
MO"_(A0Z+&,<71(:DZ [5SF6X=7+%$6X4Y^?^1*T1.-:>$$YHN8Y<JW#>O2I
M#QTU&=+WZ'3!PS0&F[I+V>X89R@CARHA 52I79!,:9&P22<"Z2P66[G@AJH1
MW6[%,J<MZ43K0Y"XPM-81N\#9#5LS*(*!$5>0 A?P6J7KE-@OV.8!FQV)QP1
MZ+ S2W3= FL MF!9CL5+V-Q#8G<!B_@3RZ"UC)EL\LBEI'ZJZ/7HMPF+"I55
M6A[X1?<*(:0/Z6LWP#HC;X"-507#/?X58*,TU3_YEDL.*(!%U)D,^GWD8'@Y
MWC03 O #_$XG:Q2@>* F\> 3N8\?\B*#_ PL/P/;^3.PRFF5M:A9S9D^Y7)
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MHZ$B#0NM= D223R!V()/AC+8(W\$//6N2\WD7#IZ"UV3$EM,I&RK4W8;>.B
M^DI"@S,2,P0+VJCD$DN5E!0?F;$60A.@"HZ:IPSY /8$OI/PR &+W*VHQ^$'
MT@':"R"H-U!*@NA4SE>]"]JECYY!1_B/V,51OQ^NK-O.T 9LWO8XK-P@6YG;
M4MO#^]K&U5>%5BY3G?Q^"<#Y.$%#O'S,]G$-XY>'2PIO4]H$KQOS8$*W)=S
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MRWRD#I1!-5(K2%9*,6YW6^NF@SV%443&NIQ&TGL\ZAA: A@4UO8+,0+2&VE
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M9$VU6=<DW3G@,M\<3_X%7Q(#[9>" &]O&@Q&376VTTFV%$!Y2A!##DS 4D6
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M-WA&N[/AU+5(9$S/8K/?M$)>VM^R.:ZJ?4MN":T!!_DU((]PFMZ]0!:5>5;
M4A7T($Z/H+V1%6TJN1,<+NX%'W&R<!>V04D+$BE1+A>.'M4N?/3H!!9N4\NC
M"/2R;J* >5OD>(TEY,'6$&9]=)6J)*N)WHU8KVK<@O]K<;YXJ1QW7A*\[$[(
M1+9IGK*PX#^6+G1P5>8+8H[A128A,;5YZQG44X^#HO.(*>"<8$IPKML&+Q#=
M9ANJS2GM#@G%(87(J&-=(N=YZIU@.Q7<QZYLY$L:QJ83I-0@W2B(@J1@('L?
M^']A!"@Z)37RDNZR"H*-EBTD:W']:/_]#W#/)T0LC@<.?PU;T?DX(S 7]?"A
M[%IDJ^A-UN/!U'GPJJ&#&"6,)OQM3IPQQU5Q6;)@<E_#\6B2K3^NL;1@6>2;
MB-C=?HKUFJ2!X!41GILDSPOB]TC0;YLB]$*YI)'!J9R7EO+C=;>_9C7W"L M
M$C993+X2T/ J _G)TD^_S\'A!4R^/)[\5+)/"%M0= 0%@G "#6MOVZKAA0E;
MSI6TW+$NVJ5D<E.A!$-D(8KN2(7.DCH+B'B6"N'T14TY[SPBLGO\YN,"T";A
M=5YY(8L#QP(Y6%!N@A =+W43^T^3%6<[Q6:/O-W\JT6*VD+K>:D^P/1?:.LG
M)UO?-R\K[-*EB7=#G&;4*C.]SA@+.Z=<FF8C;Y!8A2,!&_TE797AP:,4U,'O
MN>'_(P6CGW9M?Y#5;]JUHLC@&^!<_DF\@*>]P/PU:<MFE'DKZ^2VC$B[E%B_
M6-@>45.W:X3 J/2C$(?T7=6'44/6?E8 P_L=@UP8ZMC:WH9XM!_QR4X(#RSU
M#C9()WZR2NX<56\7->>,2!3A-0EV0B9R9)ZM>6EPX&!>Q'KN>-)=7&Z,2QZ*
MB785=%:0)A(8Q$&2,4YR;(:2Z+L.[3KH(?PA1NU7*<%*&+?8UDSQ! _+8+4)
M+1X2(@2MBY(B\PI-Z"R1GXLK0T9E4"R6'!DPYG!%T&-!7<8 (/X-#*M8,*A(
MDIG!8ATQO$W_O0Q49R2T7[[^?B!-YQ)]?J,* Q=TLW5L)QK&3B% M(Z@?H1?
MLKO!>B*RQFR>FG' 291L#(%/'"Z]3/U4,>(9)VKOKU(_ CX9\,@\3;"E W4<
MSC>L2.R)_>&/'YSXK GPM'?P@_;A$V Z"*TB>H)>(O8S="3:7'( 24">@O>@
M7[JW@-O<-L;GT4M7]X[*#9=4F V$_L@2#[UU7_KIY8_,:\-HO 78!FFD8>$(
MZAU]2Z\YOBRO)S?I#/.[>V^2_SB8>D4A%) T01S1U<#J0KFP>,")2-%$+ME$
MX)SFR9J9D86!)%W\;=^72KB*_J9([A@'/B%F<TSEYT0(WF@*@JJ^&+.VZ6J_
M'I\2>;7<>D6KB)ANGN49"PFV^IG\$(7S%#DNL;=#4^9PK:AU4C(#TV\ML'A0
M$]0!;-4%S*>_S:M4'TS516"L$[4)A3<NB24>2Z,KFI/EMD'<4GM KPSV_BH(
M >>6_8W*Q2A0H<SDLHNP?&L%2\'GTCQ^8ZL: C>T<G7$N)C5[SBJ!*HJ)]Q?
M!=,VI:KJ%_9@OG%P! ,@!"%'!RA=Z!&R/)6Z#VGOP#"L%,F),#Y&'WXF^_GH
M??:3?$GN8M;?T>F$"PGQ?H.FO4P1>[J^$B$):[W&K>W%K%!-4(BX!WL9"/5(
MJ2)L=$&= 2A42;H473$-S@T?"7>6!D['9P:F^.KW U,<H!/?!9!]#R"%RIV\
M)!!71S,XKEA:2@#K/.V<NZG*'?6?+./M#4<-TFC-5^<AQY\)(O="VD>A*U)6
MC7/>AM(@MUNV/5L_<HNHBT>%[6/84$/UO02KK<)@3S=]4,[G+?;78?MFJDS4
MO'TB10>AH1@O9 L/,2+4H&..Y1K+-I?Z$7%Z136A6"4N8*[G('?[>/*""2-P
MO"'L)X?"LD94Z\%15OQ(HF!I/W#LRTW@=.%&X)2Y'CU*U6'KK6)AI'"^ C)8
M:&@)<^$WEA#6IB?:(H&IKKF=/%MW="6.)V] =>=H,)GS.2>3;VCP#J\P-)&,
M:FJ<C\@M#+SKBGS8ZMO69,$-^*X2VN5Y1-;\$,!2\*W<E<B7]S#PR2 [&."<
M85?B;IU[6U@YI)XX3$!*0UVR=CL1SN!K"*(H0AI%B%J* &&J"&XBFC #2E3@
M.#W$#X:)U,M&ML#+RN4QX^R@2X_M>3CS33</]5-(>+SXTX0PS^%(K"B<91*J
M VTS#$LW81L5POH8XRW9:TK*]A+)<3*;=4"ZB!2B;^$T! B;7Z4K].(VG?KK
M "XC7E%)7(52ZJ%(CQ"E;@VLR9F1?--(K4X7R,<%SNX2!^^QUM8;BJW(DQN)
M.45G=56"=H,WUVRJAQZ('I^1%!'EJ(+%IHKO@V__Y>SXFZ^?&*\#L05G->[*
M!H0]\K6 SJ/HG>_UQGL=96055!"G<WB%E)6#E@K'BSS<G7&2HM::M=XH'SUZ
M,OWJT=G@^+H$%M@8+DT51OAK2P$!"_KMN:7$A\-B?%DU;U<,::D[:<&;)-,T
MA#L#L#)F5'(+$(ZZ++K\M!SQG]0KM&=G;8UUC%2EN:3&P505.C>F$.Q#QB@E
M>-;CDY-)"N*CW*1QAW?[(YV+)1+G<KTQWS+.27(<EB*B]A4\--&;=4!<C"PM
MR:X2QAA(</0J6PL*4+AN>K_*&+3;_;/*"C(I\*&,O;I)*P8<"(,#&?PD,#H/
M8%-DPOSC*"CN_$AB#=#ZZFZ[E2AN'VU5* I$(8OMP)FR-Y(YMD1&3%I6:]PN
M;FZ4*,DO&D/^;@X\4@6)@EJZATQ22[74#_FB#Y6P"><1*NJN-!3,"Q4B)CUO
MN-LY#?:]4ZD[=Y/5QA.3L^:5EMB6A^*+BA&/X8D ""3*J%"CD(*H(P$LZ>ZO
MOT*%BJ@-GX9WEBP_1;-@48U*"(S=7*6R?9W]]N38N>'B";R]QM\V@6;B.K4;
MKBO A(RD0#TS7Z3VDW!NV+?096&-@$J<DENP1C6[;M/>,-5/1+O$YT D5SOT
M8AZD_T%GWEU5ID5Q 1)%!@,-N4:'Q(_W9S2_.PN.SZ1O2Q1[*3E,?13!J>1F
M'2W@>U=;UY9D(E*1<=;)NYI6@7992D49&VTT >$6P!.!5L;QY%5)T,3Y56P)
MX/U=I=)X=J8_#\DES,R":=5<U:%6G2*,\&"=&COD=:>?+$Y>@-9K\)/('>&G
M"^;:L9_<,H@Z^TT'8:_5G8UF*U6'Q SDP"(OY)SUR"/EH2S"D2&LHC)L?W()
M,0F77WN&]I HH=H;I>UB07$0!$LYJ%T@0M.P>=8=G>^>!8MU297QX5SM?<#Z
M>[Y1@7^"[W^X&,%-)O-'?>4FE)QT"VVX>LG'@K,Z @UW''%"@$E>N6M:LR+,
M @I)VR0TO;*?P'-$)>2N\*<:S/EB@4T<:Z <M2N0,9\>SF#="%; ^"GB<+=<
M"?/H-#&BWD?<3WUVVZJ_?X1B>PQB[\^IGAA2#*K9LJKKOR43K!YA< 3:;UQH
MPB!;=\45]QC%BR@9QF<S/&1>M@B9U/;1J5E=ERT\#SE.",6>T5=7J[8P>83(
M[JF4&3#3C/P%RWQS9;NW7<,L"EJ  :NMG4/2191!#=5=FBZJ0'?51,DU-2P=
M=\#$5).U_FA*L)0_FX.0N1(@,A"6C-V-O#)R&*B7*9NZVI2P6W+)[>E@@S!C
M=K7A+>#&I@A]950E'+L%EG/HK9R./(OPM># I11C]87^&**LXMH-OL59$I&?
MU63Q45[5?D)2C_4J4M5(-LX"+ZC[V$UCR,]"L"MTQ,8,S/J*3O<L#:$$(BAF
M !AW+1''P45/-;*+P6U5EO%K:PU0#-2VPB%F8!(K]EK7.OX],NU(1/\*39WD
M'>OK.6'U!D[QGJ<6'_\^J<6=BPS?4KSUAXWC;<=3>R8G:T*P%,+9#E!^?[ZQ
MZI\+!V$7T\:O3[]@["=)^6$VA\)5O=*HF":T$[4.5=Q;B[@S'W]#M4^%%"'X
M2?RE2#_&L2'SD*5A4BJ?<MBK\POAE?QW6D<$N9X,LFOA^<(&BM[,.K..03%1
M_/E\='0.XP'>22Y&;@<U+WZD,W="TP6SA(QRTC/Q2P"]K**!9EJ:HF%+*4I!
M22P^5T==4.<JHE)!D<Q$@-$0J:,69^?8WXK"^X$A6VO]%:&L@0"SXN1\=<SA
ML:V/O7)5-8L0-I <S%7T'E[1FY)LP>#(LK*F]>(%1\8[UN-^[<@<!$?F^74J
M/<ZZ,XCR!_'%T%G!?<C@;TB42W4M<&H6KJ+?:^I%F4H(D<LCY$H9!Y^!HB6G
M0.NS][;>2Q-$:J!P.$^0'EE#ZT9X.%TQMF+<Q:,5:>L0GK>?!_;61&D W>^F
MRH+(B$GD-&R%KR^U ] AE'6)K^CAPQ7L,P^ZQ[)?:6+A*I/1:'7WAE'Q'4I*
M>Y-+'8)'<9W"G2$GT)K)H$/$(/MHT/S  1K=4BJI4B.%5F/0"_?(-XFZ'79\
MD:1(A!YQE2(Q<U:OH@>ATZ607H0OX-6H&-J:$'11HOM:K.T8^YAL,8FKA$,U
M<&?%O#Y!*D#!/UX+PP>?)]V-2!_8X:/ZJ(7*"*?;:*ME9+K1Y&T.;(@4[!JG
MIK!5J\RTTVPGUG@5%K1@'!-S)W:0_%K"&B:*#/,T)V;(:;=QI4Y<SU,O1,)@
M^0ZJ_S.0-AZRB4>#0@VS:&U*BL;C(E)!+8*ATBG%2"-(CPMV55U'51MT:JY1
MBJVE%Q0^MV-WA&(.>A*]DV/8_N996TD7<[MUX+VQ^D+YFJHY:VL@";_L0@D2
M?52HV0"7\H:!3G6[6F'&1:8#"I$T%2;9PROU4QQ6(""VVY3D>=\\3*O0BY@6
M3Y8TW$<9JE[T."62A91?;S- PBTSU--&4(F/A,?1:&HNKY?HN.P+KX!:N?35
M_MZ\R"3P%QDT6FSCB!D,#.9*T\GLVT(1Y].1^Q_?"9U??N8\*E.WS9M8;H,
M)6G-J5;\BL^W4H)56%LEYX +B7U3B*]C)#MJ-7RUAUT/)U(YD2^0^F5ZHVFT
MLY.3Z<G)"0GFZVS1NAQ0APU< [FW_@PY@846->1NJY0#,5B458-@1TP@0^ <
MT(! 9I@"PF/"I-=J(DA()5!51&_CQ6.3"5ZC1O#@2FA+&/0<N-D7I:2X9YA_
MZE(+D?'AQ[J_O<VC1'V>1OEO3N. K9 67%BHJI#/P5*:&#4E&&V+NMM.#Y<
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M-_FZFVZS(E=DU*>/'"; M(_#_H2Z'*S2Z6LLO*TM=GQ]6TIM?*=_DQ^(;V"
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M)9H\F6Z*(-5MQ9]/R$[:$!!__XW>@(N=4G,B=)YOS.]"K">:#LU$$\YIW72
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MD::0;6=L&LY)"Y#\Q.KB:H6XXPG7)G><B../W2OJTR1XQW3(1:AHW._(EJD
M\3,G+^=I3L5Z/Y45=3^#/_\S P,?0>I-"M]XT)27::/]<,S8? Z*LERA&032
M!<^CVIK/79IQ+$2,Z %J1#D;;FXL!:V.>V14O0>5[H+G =D!5O%Y0,-*N4HG
MG>P0"Q(=[:1V*?1A72%)/7$D11!BF/@E? ,%-V"CX8I2J([4HO^#,^WV^R!1
M5'MH8OU*3\[3<B""0X5C\7BU#G1[R)IGPT##_TR)MI1BZ%X:BHXR'QYS<B+T
ML-*X2,R0N]4X%-&*'\?-@,VT&#ST$MH?7(2,T&WK%F1NQ5Y3+6T*[H>>"SX[
MY37,X>-OL(&E[;AF64FI 8:J!&06J@:[B5K3C-'"6HM@[P?P6UQ+Q(I:=]T'
M&LJNPGU^3^X"YYZD6Z)DZ.>ID=P%]B<KD?!=S199G5*/J ?G+Y^]F:(PF*-M
M6Z1P*A8I-1=CR!E\DZ"Q!&1,9BGC5]NF/,I6JU;"@-=919D:?NA#CK+?9XJ]
M+E>]B:(?M4D;WY^WFWV(I;D8 :] 2I^=3!'G\Y7HBZTKQA%LG=KT7K.2-C(%
M-W-+HPZ&3>@)-_7N,X[)0E/2C)$S=E6'V\2)I#%9Y&/EPW><X9ZS-*2-0>P(
MQ0,'0;7S'4>2)=X1@X9@B:_+'%M]5UF^<5JFET[Y\)'NNZYQ\)2AZ4G9TH^O
M+D+)#8JSQD=,A.'0J@LE)JH!-P9UY3Z#UBVAP><C/P*;T?'3-"_+<.5H=_#>
M8*TEV%-T&>EVDN,:.-<H'AR]>54NC.*,SJ]5#=921&F)^I%C$:%ZQI<-,\G+
M"JGLK)@R2G6)O1/\=JOZE 7AE&4%BBFCV-+9Z0G3.U+,*F)V9-T-CXO )!C.
M@D%0GH0JZ]%VF.?E_!UF'-94FY]&]!!*E8 PJHJN>DA2&'8N!,8V/MY>]/@N
M0[PLJ=^%[^/T8(<X\%#2]@9L<XB_-<D[ E10PS=!TQU/SJTT+TH=,G+8T4:X
M=Q%2D%H]\22M+V%Q+X0Z+@AQ:/Q*E6(BH4(I;YGQ@2.P=%]PL9/@,M+V2_R!
M_=I)9"=XL10X)G^@B:(U#2YH*Y 5 F7S$83=.'TLQR?KDM>:75FWB') J3_A
MZ$2WV,PM?KA5[A93NDHCW /X00XOJFCP@IA\%A@9B.A5FJ+R%2-!(JK3#@$8
M57=TF'-B'-6 J8LQ*B9<2@S$B5.C0Z.C>F6D%D^^]G2J[L+9@LN\X%CFV/M4
M5(74V?P//'$!>\HXJF4S@$I W^P?2=%B"O'1*=H#:!5T$9,,."M&U91C!7*E
M)K&#2,]@0 I3\3C2QF(1$EB@-3)7N^^R 7.#KWC@2HXU[;UGX3S _A(HG,(U
MA04!5KRY,MP.9\+GY=K*E+Q,C6L?R#@0J8X5W^9&2*!:L:GU5;9V")Q92OB]
M]+)D>'%$"M#9+$TBQOMT;W3]V2=W*4>\9:M8#2$MHHA ,FSKEO[J/$9SLM4T
M$F#;&E&&_<;A(<"UYV'6&2)FDB+E3IT@#)BX>_@UVO&!KB7&V-SMB*HU-B.@
M8T$Y1IYE2*QO@^'A:Y<)!_%<<L^A!,:.LS,<M^Y)U )69S/;1,!RJ4(I';)E
MVE]488"*C:_8!H83@">(E2;2<GA/W;NQ77T_I3;/A=[(T'2Q!^YPM0#.2HKL
M=65UZ@S.DF_A- J85TG.<AH;UD/ULN]H98+P]B@-2T;!WH+!"+\!&3&7M!I_
M&PY FFO^C2L!4Q#@R3)/FZD>[]'):H)O%*WS=NNOUQ46(I#APZ-Q6\=0EC!2
M$W^]1=!C>7IV,J+"U&:,P%;_XE]]*S\B?@&\73TRY.ZP V')X&@'-HD2M.-H
M)4IO841I04AS#I*61JK4,>NWO>K^+MJGE=TO*6_707+Y7N'OL18:"KX$M[9@
MQJW **&%!Y@_-O2MVJMLE"RR>MT2PAC-4V,)4P12HE] +P!<;[;,4U3_6;T2
M?PW,!^269T3"3,Y4%>H1!NPV-$(0<!B(HFO+6I?%8+CR,X0^G6-W!W@9>'D"
M3=)<:S)YC7OV*N3\HW3RZU<NG2SI,[O1^$,'%I ",FO*806X9-BWY.(Q)IZD
MD-0P<,/<I"83E#@>:8])58&!O-*Z)'P;R8ARSH:80337VOR$I>-@F2Z>'8H1
M8(UUG8:XKX>0)XS!+]BEM3(-<(QA&5AE7)!EB[S.[%'\LB8VJ-?"C&=9^#>_
MO ZU*M2VN80C7:01 (].;58MV)-+C9*/],><(;3NBBC\$@Z\E/7LN6DYDCRJ
M+0>J\1]0^1;Z" QDX#EIKPKLLFQ_%T;#R,T1]P$44'H3TEI@(+ CCG#D/IB8
MT# S^,D2/,M90F 9])[G]J"I>GUQ#@0)V(R@C7G,7')YR+N4*(]E1_H6\$94
M6DVDMN)BIPN3QY[3M0?QF0I[ZCS5BX/6H O>X.H=4;2$9D:%<UVK73XQ^ CA
M2ATB)$%<$+IT!0:-A"G4%>F%=\B:<'N!K:?X;NGILT];?XQ8'10.?)X]S?L(
M-\F'LAON.1#F]",!879<K.T*#N;<REDZY"V9D4JNT1T25:2Y>;V=QO%+9_M+
MRIKC21]@&7X^RK;S:69^-R:@3S,VMH\X2\7EF5>IJSZ3JC*UL5*B>:#BKH##
M8".*"WA(3R#]BKE1E/K$'-S59E9QH[)95M:@CC!2K#[L [2R-)R[)4RB'&$6
M*J'4PT-E%+\"<U#PIA%5;=%HIL&Z"8FFY'Y8-EI559(-1T7U6V;_&<-8Z?AE
M12"36]IK7YU;IF3=5FCB,?:+BVQX@-Y?G3H4"X,9<5%UU8T#R:-?0G.]'3E)
M+X=KU?HM@-"T%'H[1AQ3PH/I0Y'1O7NKJ;W 6,"8*MJBQ ]2(-C#1&1T"+M#
MK@9LFL@&V+$UA9.[8R,B[E_EJ"9'>97\EJU:0N!CH!^N,:]^MISZ^I)E5H$M
MUMEK9@UJ]#=3=[[[6\U7U3B:DJ+S.36B<E'%@AM;N)Q3Z)Q"J8!H? XBX$QO
M3PR;55UN+?2DKM*<%F+&D/@(@V"B0JUV8F]%+J>L5NY62]'R4#-V^#\*!]P.
M1.J[=UFNV2R]S J+X2B#L9-U)I#YV*!+,R1>U.=RQPK1=:)S K&ZB\**J1'J
M':E 17X0,@?<IX3I+H=5!;/LNX+%[ELEN)4G;3&_TL22"2>,9U63!Y1^"#3*
M)_)I:'O86X!?=*DDAUJ:%F6(/:/5MKWD]%XO42UM*V(W4K1>CY&5J2JVW0N7
M>J"M9)D\<GI\7Y%\,S6EBW4G[:H5 F&,_GO)/J19M!)VL0A!N]NT$9.%]$ML
MR?T<G#[_$?GLCCSTQ*!7TP!#X!ZO;J7657IDJ^6KM!5&?H.CF2=5A<YWV39#
MO#;Q>)"#AA>,X0@#<Y0[,K8N4UT$28=RY7H"MKMEV;?4H[GVI0%JUHV =->
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MK#^(M*F[B?=3Z8P^S:6+%76EUQ"#!'$Q)T'JA]RZ0O[=VMR46CW@ LI&CR;
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MWP[3"P5ZVH8ZJ\-H<$\"9.9C](QA-5DND8DC*Y9YFVH9\_@-)SQL;>&V>P9
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MYF;CRNY;+?L;-N""PL)^_QXJ/0[47\AG.9\-<]-$=51BHPP.RB!?I-KOVI/
M@"J8IY)'6HP,00LZD^%Y[K2.*)AZL1_$GLI\GU)F%(F/XTA(2-7'WH92<>H
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MA/0R_[#7:LF^9E&X&*+P#O3W/G/@Q373$!,;WB".H?.I#1&TMN-@C&V;:N>
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M]=S "T8M<@Q;/VJ148O<6,@BIKS12L:(JE"A<_-YK\F;RQ":CNFY4&/%4'^
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M%FXOCWPE7%=\BD2<^(7 C=]K%:L2RK$T&\CK'V ZEZ2DN& [)1CP12W>T U
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MV1%Q'+[E[#J;[892O<DEI_JOK>85%"H)7P@='[+D=+SAT5X6PCE.DCD+ERW
M0ZS]&_O)W0%?4/L3$V0:>FFR568.A6R%+@2K^K(/^U/3Z<@TFJN*W7;\4(PS
M+IU*8)T:-8<UTGF%>.717\%\V'SE+&+&G)W6.A!G%E;0G8P9TX^E1\SHG 08
MHDS?U/DY#F+T*PG/Z6T34;0W)TE"E:2TJK__EX?\OZM=D]:&;45^]R#5Q^SP
M%ZS+9W_U68I GSY,'1^!&EB[#7\0Q.Z]C-NA0O5IWVNW:W[OMO-@4%ZM1)>?
M%7\NJCW.['@:7.C#/SNK[F&3NB =<RB1>\<+*;Z]]VA$??'M775]\S3]*YMP
M136/C%.ME(RLN8'H3%^J2$*K/=&J(/?SNLLYG!7U16K&V8Q!.BCD#Y8NS6O^
MJ'5M>^P+ES.^DTHL4!+* XGYKG78Y5GD(V(P9SFZ*\ KR]6_9OC$:<]^XX35
M7_FDNUC-5CV<[YD.6":SJCD^56DH4*\,+90"]SB2M!H?TU"RYE7#_:*W/OU5
M/*R+-//=:7UD]>E7=*>0AM:[$M!-TPA )O"'(!_7LK!,KT>L>$YSSIE^G#_
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M&65)%+!T$F?GI10@@(K !M.F#[;\=QN#EMX&A+(4^$K*CC#$.)>OMUX *S'
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M&\D+=^:B0@5]W>=7.#=?@*",3DQ_7'[?Y<6Q1>.K+NQ/C2NUIG_?EY1$@F)
MFL.*TIBH?$%<4:G7M\1&Z"PP?QUI#+6@-C0X7"!A6??D1 KS8AR%Q.^=.<GA
M>M/*1S%GSHN#+&:X(N]P1<*O3(B(< I.B<@<74I%5BNEW8*DB$:Y:.PZOS@D
M<.?4H/1DT?Q]_;QQ^0UTVG1E89UMDDW7[+R1?J)LALQE-JRXT$K,*U_=PO6J
M3M/U57E60=@$')6]!6@C*>Z*H4!09RZE.!PS6]:9I3*5;K KE0F<<X*!WQG'
M1(N&,$.E:PT[J@>@1%!35'[2D'5WI?KE,JZCX]C= LXPKO6LV"& K5+/L6\T
M)Q@DE(1@D8VJNMX^X#E+H?D1&T+-7;AH:Q26Z":30YC5TB9E"DLYTX)$3:,4
MCF@>=8]5MQ?=VFGS% "I;B:6?HLGC:579V>EB-H&FJAG92+/RR5Y4)Q@T_+'
M!+/+-DD.@.TMLZW[7?<[;5N\OZ,GDZ=V:4^Y0:S.SN+0I]F"D?0L!E]!9S D
M#OW1XVN2HR!QA7!""6%VES2BT3SSM+9/0]M9F??9>"U#ZX<ME44Z(FV#\7[J
M96NDIT'D>.Z2Q8CL,/%";1^32+&(LG<VK>01V3SZZER69MEOHV$S*0QB6Y[1
MLUV<WJQU4&W\R,H#$7#A4+-_FI*C,_C>)GJSE%#R8K-=VM7)BG5\]I=97K"1
MX55&K"EB:U4B0C6D:E_ I24(L1]8#Z'ET/Q["<[[;M78WV;[2.J_^_/%;9 J
M#[W(>0%>B/W*QIJ4W(<>B6G<8I#V#<#=EAB4/WNZ8(--LKTQ]4MTDU0V78G0
M&9R#7-)M U,=^3"N8L=MZKL6N/RZ^LV'Z7K*@ ?T.0S@F.,YEQN/*^/(SB\7
M%10UAW7D%M3T4K_4QXL&NRMFE\J2FQ- ZYNU?MN&U+A\*UB9,;&R[DD2T$H/
M43*HNWL'1Z7#T/2;CO8KLZ2@!,P&_;BD#B-T:^,;'.NR/TW*CLNV4"(AYGZ\
M69'[4+& \8<VQ<6$W7?@(O7!P[V5XTNH::6JS&L#+=6_('TXA<%GP="69\.R
M&%T3M06J6?NVJQQEDGA#?.&%>P$YZ+JT#4&+ &\#N=ODQLV,,3LZ1WH3[%\H
MO4YZ])$KFL1! >+[FC1:V^G=9\:[OYO(S#\[XS0ZE\D-F&C) \N*U'5YAH@V
MC;=9RE6<WM01N@4$]JPC"YN/.1<2J4P'U *&*U"9/#"-W[M\_DY3VKA?(JIZ
M+M9"[T5C&9FX;\$6[A_BJVQ=#\ 4<U1_!5^W+'KP&>*6@-A@398\ONZ#HEMG
MO^&B+,!\I\:P17=M:Z,1WK-T\N-C2B<?1P+YXT6,D[,BPH6PFXD>PE7)@6&[
MCHV+K(%=<,YUK5H'K$9X7%!"!C&W:47AT! .% ?/(@2#?2Q& "7VZ<D5PO1W
MX.[YT<GEJCK%Q:U7I "#[\3-_!'"8)P67M)H*\YSPXU9.R!T< 5@ $%E&%,H
M+U6<&GFFN^8I+:U8D#"NM\YB&FPK7J6(Q1<]^YWV(I-*3 )S$W]>*F9;EUAU
MVBH<4&<4M8#]+;5<$M0#C5/&<IC$7EXJQBL9S*7,1%'7_*NX3%17QAX?4FV1
M?<WK%/*XYC2;EYKTVJEYSXNDV4[>D,A:G^U\E)WA432"JT5/(X7/AQRQ:YSM
MD;/L]L9Q[SC+3LNR0H6-KY>,T6%C\O0X>C92EQ[#UHU:8-0"-R1*O>YD=L'@
M#%;2(<KIP;0(>H.(SC3!JM=?!6"#_)_19Z/BN8Q,/%4X7+8-_'KZZU_X70K\
MIKCZHZHY"OD85<VH:CZ*P1$2INI)MIT'YD1*HBA"^QJ=P%EE3G85P*CC0I24
M <P<]%&)',/.CTID5"(W)$H_::P'O<F<L33[P4>R&]0<LED25$P:AAF5PC'L
MY*@41J7PL4(9UFV$JN,KMVUR^]6+JI+*Z&<(9Y\NUF15,*@ZHQ:,>N/V-WO4
M&Z/>^,@>21()U5S7ZY]/)4FN!??<JI97<7(G=X44V"K RJ@OCF&31WTQZHN/
MK"^&8P\!+-/B%5K9"FX^Y$\5!2GEUAKUQ:@O1GUQ/_3%P6!%=D"1Q.VG*#F,
M:O:\#O%EXZ[@UL74" G8;@B%;-R<BUOP<]^ &;7-,8C(J&U&;7-#HL2T!$W3
M95H\9I8&2NY0!*:(YHN\81BR3)T8@S5G0X4_IKV\0O4Y:HA10XP:XOYH"&L0
M9%4 +IY6:TG?.<#QN'D'A1'S_([G?SS_X_F_#^?_?_!EWZ(SB--T<M^9>*M6
M>K0]Z R:1+AAV_>!6GD[V'QZO08[1<S13O5^)V@/,W6H07GFF^!<@!V+VN+Z
M[57<6* F&A?%U%PA-TCE>G<;1]\$Q V#%?<=:;IJ0]2VPEL'R,$(B%:_KI;P
MAP++W[KD,J5?H'H28I\8!%X3FO^4%L7$!7CTY1#LT!XVSM"'?O$80&\4NZ(4
M614^3@:(:^4W+-P,,CR,J:2-^8+KY@359%G!!V&B7[2*-M+:TG3K-4 FK;\W
M3$8Q)>DY 9-RF3=S;:29",7+/HG)]V-KRLU<+GML]T=EJ5QUD#=]. ^R O_I
M(V$PKZ]_B'H.C]Q:N8) 79ES^;._/IX^_H94V)/'A_3<IJNA2EHC/2%7IY[G
M@F2KL".;T,7)#=9."M+I T8J[A'1@.62H!*/+M*H>D;5\TFJGB^G7U]L8C&>
MC1)[DIECYCMTC">B8LZM&+\,8+UTZJ^F8NZH:=MCGCO [_KHX>/IDV^^GCYY
M^.30"MOB,H%&R[@<M'9B:<;V<.0FQ)RKI8$PP;",T<J%UYE1]VH&8.G?''9G
M , XJ\%=KXW4XI_(YU-_Q@?;?<=3BBE*'OF*='GJ[TP',8;X)<IYRR!=8('!
MC0)VPEE5O0L@(9D:U /M\>CE MT(AM)MJAB[(^*@9*O?D[:W420Q\Y@FF9?S
MZP)]'#>&LT SORQ7@I]-J_U*:%H8+>SNPC _ZT$V $Z(X2;1[-^M&=)7>%WR
M<Q$&4/_<>3@E95Z(B8U# CUJ?-;N1(#9U=4Y_6X#5BNR%NC0P?&<0\V R;<Y
M(7=9D!K"[Q2_>+-A'K2Z6@N7H!Y5P='8"#I6VGP=JI(YN)&OE?]!OK+JUJ &
M32J.@(6W;%WIX>IJE^DAC="XL@@]2T#F0P'T".$PQO/'>/Z1F:F7BM+3X;I#
M#9AV939'W9%023!2HL+(;6IWJ&11H1=%68TE0L>PRZ/"&!7&#8G2R](!CC";
M[ZP2$18-  *9+U0H'=CN8#-#P&'9 AF+DX]B T==,.J"&RP&*AT 0I%QBQHD
M9]7B^KV14X^;1QX/O"6I)_3<WX9D)Q0&3IDGR*?J@!P#-<,@>&/9T;&(QZAI
M1DUS8VT098>:&LG<"S^P\JX@>.G=%>,2RHK[6H64 %NC;D7(-E&@#3I[\\G,
M&_/QG\839R2?8\S4;-UXW3L#9O>FX$*1A3?C0K2H:;L%DR.^-3:C\'T0)8)K
M8%EU0@G$>])D2Q?LP1Z\/PC#A?=Q42&.!58;"9UE\Q53'$+5+US#=*,*\5\M
M[QL(]).; ($>GN4MRNJ5,V ?>1SFL8!#LZF$C<0?&XAGN_,'AJ%X$;DH'(OD
M ?D_?%XDV2'?T@_'(%-K$-9N[.'^-/DXC ! 1R<4'PG#XZAS;5C&9& UW!<&
M>X7.#$U])Q'BA#\62:B&^:5(:=)HUF!]PN%W=5.5I2NFL?$6_1:86L@PS?-,
MJQIX=IY?1$+&3-Y'OV.&!6%@5>*^QK-?^.G$N8*J3E UV.K+Y'SOF7WQ&DG$
MFDE_ ,\AM9<"RFVD[@[$QS%K+JNJN9,J2%E3:)4S,CO#4N? 9V:2 ^VT4]J0
M>=WERL.S1(<+EK(98+>G 2'94>=<V1D!0^L:"54A#R]I^O5RHK0MS"XPKX5>
M9H5D2M-&(7[A0V2T;)\LD$K0556W3C-YR,)( J$TBWKAC6A5U_1CZRE2M,-'
MB&\,CCO*1D#VF!XE(04XD$W8^EI5.IYS4>GS#FQ\7(":S>BYH)E5@KX$"U+O
M%!Z(@G5?MJ3@'U+2R&B!&?MM?Y&-.QR\:R2;>N3#DV6YSUU==V6/2R=B$XKH
M:^;9!EDVR +]:%2*50J,:7)II(IV]*] Q7K<E;=P U<N*]K5G#DC=DWKUD(P
MAV+<>&4#4Q$34:!OI/7<C5CVWG+K7S;9SI/8UBY?ST @+@!=+)DP;2"M%U(J
MWH&TXENI$3!BJ&U5%^(NIY1(0\SM[4UN0L(E]#;FX4CSE\*W.W.D<C)ZQB:?
M2]>@X+RS%\VT5W.8Z_.N >VE$G,*GY7+6#'(X[6>O@D$K_S[!WRO2)4#MOL,
MUR^KJQTJ@_EQ Y2R3,8I:+!7%![_WBU*,];9.[LY]E%I!U:":5-(=2US]C3,
M0+: :"+/L.$QJY*KL5,U0;=V5Y=:=F%LDBB.T/*..\P:^CI<]A'Q#=/,,+,#
M:TGA]!7B#7KSU#8B;U,FG&Q.UPFM'W+@0F.I# KO:&E7B#/1)DGNFN]+M2XD
MB[5=N;T[2R@VA:+'E8M-E9?M75<H!U<<";JN.,OTZC<>IS.L>\F' ^:7)QL<
MWJ19IL4//38',S:7./@1$-+4M$& ,V!S#"4A4IZTJ4!!CSUAJ\$4T<0H1/I;
M)@8H&X%#]A^7HS35V@D_%=G\#9O*3*+AUX,U")=2Q:T!I(TBR 52NC0P?_BS
M/F!+M"AN";9 ?D3ZF;SQ8UN([7N>NZUL0+3PWB3VLT]\?C6L=#S[2R(F7^W4
MO!7+BPS#+8VL=$O06],<(EXN-AH?H#HKB/V4.Y?@JJSEB+&;\WO'7OC>\^A"
M$JHK>0I=7S3/R,+Y=856)>S#H("Q\H8;=M;Q?OC +J.)\_T4"2_POQ=290:W
MAO[;&!])6+F)\KJ@E,^U@SN&)2*E4.3T--WVR!F1O3&? 59CNV*'+0PSX&1L
MT)82;QSK)WJV\K_7^5E5XWB%:6R9V";ZQHRT%L(="R;W!8E0$V+K)@BG<L2,
M%T=93\N*Z1=K+E%4ML^!8^\%@U7AIF;IN7R=U!H/O6\SQ[N;SBPZ. ,NG?>]
M0@FB=_ *<VXY5B56/0HQ[:O<9%QB)*D^UY8E/I(G=Z3TZ-'#D\??7#G&'5TJ
M_3O^P!5^]>#5S85T;F,4+]\^_TF.Q*,?]UHHKA;FOO[B?O0H]R1?_,=G+\EL
M?_3C__ZCA"]9D,M.]OUR^53(;)O/_OJ/GU\_?_/J[__S_-GDS=O3%R\F3U_]
M]-/SG]^^N0QFXVH+\/5A"^9V0J,_5Q&+]7B^/[7S/7E\#\_WX__]I4;;/*R?
MS_[ZR^M7OSQ__?;E\_MZA-]&'->+"DD>LB*JK;1=UT[, RS'KM_8*X=:6GI]
M=[(^2J$/X7BS&T(^"'SH7-N(EP.=O%>A2!Y>TXO318__Y 5-)J"R\;[Z3R;Y
M/9E3U0\?H MEV8)6S>;OSFJD ?&TJO[^7U[P_W[0$3R XN95M5^\YM5Y>/+-
M5]$OWV+IY5=:(_#UR3??_ML/.D_;++HH\\5$/BC=-YL,;18_?':U'.'A/=<?
M_6A3(< O;M.[O[# XD_:D4<GC[]\WPVY@>7?T^4ZN8?\OV@#OOV8]]7M;H3]
MZL>PCKHWCTZ>7'):;*'^A)-R'%OU"B%$=^7R@;L_X3<P0T<=<>O[,*@C:"0P
M;O_CL\>?'8.^>#CJB_ZV_42_7A5['9KW>,;/N5W3-;>L,X;<Z$]*-XQ*^E/;
MB-&0N\96_5+G /J2'?M'<Q0FSG@JQE-QNUOU=P3#/BUC)9?VH?'\C^=_//]\
M_K5NS]7K>,_^HD';:X=NG[YX\?#%TX^P@1K-O?%3,[#RMQ.@_25K,AI6-IT\
MI<6FCY=Y]K['Z*/MPD=274>S"1^FO3[>LJ?:"PM[/=7%%!LWH;F.9J<>?PD,
M/-FOYG?-UBW;D^/;N_'(W,JR7^&X_!E!HZ/9IW\]NBWZ[FI*[=)=NM=Z[NNO
MIM\\^?KH]NY/"KD>S38<JY8;+Y<[:8_=G"MY-%OUM*HW:H;]I\L6O[=U,QIC
MXWD9S\N!K3K=U'DA^_7XX>-OCF_/QJ-R)X_*_3.!OSGY2C:+V_9N)$SYT>+,
M]SY,^5.VR!L L/V:-]R\?6O)E%%S'=FRB^;ZA!33(R'BN+D@Y'@D[MF1^,2B
M).\=8_QH.R QQD\[A/CHX:/IDT=?'=W>?&JGXUB5U'@W'*.Y= ]#'J]=0Q[<
M?"4[\D*:,'?'MS/C@1@/Q)^R$STNNL</GSPZOFT93\,QGH9[:*;>>)1O+$9\
M;\64E9-GN3NKQFK$.ZN:/G:*XA-238\?#<;YCF]GQ@,Q%D,=<9CO(Y<2?MIA
MOJ\?3A\^?F__83P<]UQ'C5?#,=I*]S"H<;-1OO% C ?BCN_$?V5EY]$''C]\
M_.3X-F4\"\=X%NZ?C?KXY,G%0;[W@S'%C\FD]R W]X$P[STX\->]_?NDL8&?
MW"@T\ 5+^UXCO<:)#,C 3_[W[^XL*WX!7+Z#-#:?_?7OS_]V^O?)+Z]?/7W^
M_-G+G_]V;9C@.\)5PC.?1%,7UA''C+_MBKGUNOK_L??MS6TCQ[Y?!>5X<^TJ
MB,LWJ76R55I)WFAC6SZ2-CGYZQ0(C$1D08 !0,G*I[_=/0-@ #Y$R9(P)/K6
MN1M+ @8S_?QU3T^/=GL1WDXG+_))W*GP%H&@JRB^.G$J!>3L'[;Z!]Z%U!E@
M5^!TZB?640C>.[ NQ!Q&SB\X\4,WBN$W="D*7K#@TQ43L;B&?X>N:%F70EA?
MHE18(XO:#W<_6"ON?*7UJXMT\ S-;"8OCY/7'QS#,[ ZO*\,YJLD&":&X]+%
M$<=XHT5 =ZYYUL=\M9?9:JFY\?I%MAZ>TNFWJ3_QU7Q6?,&ZS.BIIL?W*S35
MQO;WL/UZ__\^^Z&XI'L_3_S$#2*\8P8L[>>S+Z?6Y=''TZM_62=GE\>?SB]_
MO]C;MNQ?Y$WK>'4IW5>V9U?J]I]ZI>X3 M=5RVZN]?AZ='%EG9U5+K9LA._H
MLN_0[NX8/*_SV$#<UW,>@__[3'=0?8SB"W&#E] [="_/YZ.+OY]>61_/+ZR+
MTU_/+J\NCKY<J3LJ+NF2GO,OUNG__'YV]2\;GOAT=$4W^)P?__UOYY].3B^L
MST=75Z<7E];1EQ/K[/+R=_C5U]\OCO]V= D>Z/RC>M>Z/#W^_>)LCV\+.0>,
MCY@Y"@&01NX?>!$:O.G)FP;Q?I O3N(Y_[%^#:()HE:ZK]F27%&WG>(U(<G]
M# 2$<'JW_>'HXI\7],_.AY4 64LJ9';K* 5,?BMO$.D,Y0TBMM5I=^W18&B/
M1AUY+6<BHXKE>TE*B[C#^]K\)%D(3]T-G-+-;&#1Y,V']$!T%\KK $LS+&=Z
ML/9_J*8(3\#@ZF)0NDE10 CCV<7-C'Z(!)?W%N*%:KXG/[!JPI(_L%KPDV'Z
M],M2]%M(*8'5)<NZ$AOH@<GW"=TC1.S$1SJ$7K*$>79+5?2+=? BWE#@K:ES
MQ_<L+U\B"D%:D484N/PF'AC3=WV\_%M>$>BG\JX_+Z)K".5EPWBG92($.>KK
M10IX>1DP[K907 IW$<O[@X[4W8)XJU 46V>@MG2WXN^Y<3G]SP*OZT7BBS"1
MZO4U@,_L@41Y>4A47/F9F56PQ3ZF&>CZ4'5#IR2%JY-B3J3 A_64BIY+D9>N
MHT-5]_AULZP&(,>S-8D:&!G<[@QL\,'?]T[\G$"Z$KSY#W&%0+IK0KG;@G4$
M!D7W19I 4=XJOT=\CC>O1HN$K@5%KDL_AIF_XT6,O>>5-"2Y.(SW3QI@B8O8
M!:)(F5#F9F^DX9]H93SR/G&^4KH.KH!4414':E?,_F<!AD+0-=VD)$L7O>V9
M.'P5,:D.&LY?(22=[O:MY.5+_N;:XFYP<2@$^5W#EB?$#)BL<#QFQEV?;@#&
MFZGQAF(%Z_&B8'!'\(9Z]-H/A)?]\<Y/IR0Z$#_9.!/U$;JQ7#=,$['!:?DA
M7NP,8BHAD 6?P)D408<.(ERZ3[ESV.OAU+2_G'Y35X47C_1M2SCR[G1G1E(-
MO_B&]X_CFG!DH"[:/D)H=Q#=S(6+]ZO3_<G:A!&]+4^95BDG6X+UR A)<G3?
MI'ET;_EBMI#7@UN# ]S5A4F Q,.HL.I0WO\-#^=Q1[BLK-G]XMGTM2'UL?+@
M2<5T"*BB!""&=09$^$9 5?OS+WZ4"G<:0D!T<R\?:5G_Q$TBC '%0\_BU=5T
MC?R=R._;QC=\^B/0#$>1))C)<-*-($23]]2C!"DP#,\O(/!'PEMW4Q]H"P/.
MZ3X*T"8+[[($5LC++"5AL;T*+56G(X5GMR*AS2$;!/W:Q_#/44R0,@*?0 X<
M@%#(: \_!'R=!XO$PBTJ'$!H@-\FS$K2I&@+T_$CO#H=<.Q,J(O WW;:;>O.
M2:Q\!.1=R9+N64)X\-2$\(/&M493NIS*J*D(I-W)<GV&S&A@V'QL5.5,+:OV
MTOX^(VA+_U98$TM.7&HUOCMQ$I^,;6;8G#F!F/^2UVN54_6K)'\+_38"5Q3V
M-BER%QG4D+X.]_KS!!E$("G$^N!(+<])G;P8 -$'^$Z),,&)80+$=9)46M0H
M2?PB%5*","NXVWHI2UJ3S?%G-U82NW]]<R/\0;]S^Y]_!Y-;RD[V6_^>W[RQ
M4C_%9;ZQG"#%_REMM(PZA_-O'Z9R/OUN'WY B_LL]S%OF<W_^0E9S5W_9 W[
M;X?CUF!4W8$K;[IU6E2DJFT.E?[>;@VZF_X.)F?PP/N=37_OMD8;WQ^WNN/O
M>?][OS\BDUK?]\>MSJC>[_=[]=+_^];_\/CC[YI?NS74_YR?JL^>4E:V,VH-
MYYFRU]L)X?&W-3U#K?32KG$M=S-1R*5A-#]4$1W$:Q2"UM6PHK9+/[^+#<:<
M)3!"2U[DN(T9>G/ENW^(> UW9K[G!8*5XY65PY2+RUE15K6>4ALA]?6'Y*N[
MV3BQ<6+CM,DX/?D"+#9.NX%K&R/:;(1VA5-+1NC)=_2\EN=F8U6'L7I%A(2]
M&">QS\B(C5)FE,9LE$SA3;U&R?CPCHT7&Z^*\3KDL([C#=:.U=K1;9ON2AJN
M17L5;ZQRTJ_9D&U=.4)WJ-'@,>GRX^/3XQ<R5^EVE[(^BE'#UGA@=/;\*(ZC
MNZEP/.OKU('?N6*18BED8EMGH;ONRL,ZV-2L#8P=4HC7:O-9CWY<_//"(-:P
M$ABC!#6U/Z^%.^NN!MA-QKQ2+]9:.-5IMUOM=2%&'>QJDIH89\1>3>X_?F32
ML_]@_['SG.IT1ZTA^P\V8J_K/YCT[#_8?^P!IT:#UMJ**G8?#;-A3.G=,4I[
MQ!WV%KO"J5ZOVQJON]R2W47#C!A3>G>LTAYQA]W%KG"J/SYL=?L&L:M):L)&
MS&3NL!';%4Z-^J/6@%,D;,1>#?.:<COOLQ>#OD#M^C[7>GXYNCPY^I]5W4/K
M:E[!0: QE-[K*LX__^FP_^'++V?&4G^O:&V8G#<)WSPY#*B#[ON,\K^O#I.U
M8+],$-=ALMRS]6^.]3\<M ;=76+&'M'>. O4'+$WCO1-DGLV_H8PHH/WR+/U
M9Q/$>1X6<S;V>V[LNYU6N[=+W-@CXAMG@IC2+.9L[/?6V!^.6\-US0V-9,8>
MT9XM$%L@MD"=7K_5X]P"FZ!7@YL[4#S8-J639 .*!RLWDS>LDG8'S<YK=@79
MT\+!L_\].S:6_'M%;,,$O4G@QJ0#1,V&^-S!D4T05P[63_HFR3U;?T,8T>GT
M6X=\.I1-T.M:?R9]D^6>K;\AC.CTV]Q]ETT0)WI8S-G8[[VQ'_5;G>$N<6./
MB&^<"6)*LYBSL=]C8]]K=;AU(9N@QA&?39 AC.CV.ZT1-]MF$_1J>-.PVL$?
M4V<2"/BMY]\^;O6EQ?[PF,7IT^%/OL(GUY:CX2<[W?DJD[YJ%A7Y?*T.UT.U
MGFE>YSIW;L3!)!;.'P?.-:SG)R>X<^Z3-]:/^!R(<O:@7#1JJ"J&16E7O7C_
M^J;]QG)%$*"U!4N0_ZPL _V<F1_9O1?T.7#FB?@I^\<'Z\[WTBD0!6@DOQ!7
M#!G0.!]&/GS8:@]_6&'I'VE^=#I/HL![-(^>RI"_P*3#;)JUS>+LZO2S%'=K
MV/K+CSBGG]?X$F3!L]#V25-]C );OO?7-V>IF W_[U($PDV%]]$/G=#UG< 4
MPF>T-F(REZ>?3H^O3D^LCV=?CHR:V9?CLZ-/ULG1U9%5E4YROD]TO<.*;>ZW
M!OU:S?/55%C78 ZC.["95J*DUKK.Q-;RG-2QIDYB380(+3"C_BW^/8YF5K2(
M+6?A^?B"&X74&-TIOYVD\(L9K#2QG-"SDFFT"#P8R@+K[UE^B._]>Q&ZJ1^%
M8(S3J97"A!X<S*;'8A'0$V&4 HW@-[%((_H._A4I/!=$9CG+*$[^_*=QMS/Z
M &_.HSB5KT2A3>_@W[KM#Y^=$-P3?D4]G%@G?N(ND@2GB \>A4YPG_B)%5U;
MN7I;QU$(W\B>N1#)(DCID?.YB!W\0V+3)SK@=::^.[6<&"?I!@L/UB""1-SA
M=) HZ11&_P@LDA:RTS[X.XT*?YK'XM:/%DEP#X0)!,XF7,#G+VA%\,&P^B),
MX2B.(Q@<*/YUZ@#C7;%(?=<)@(YGH=NRG@7D2/GMUA:%2.CP/3!!+O(G9Y%&
M'[X#,KSXN2DY@UZO!:8CNYE \:IT.0%1< YB%KY <&14./3ZU!^TQL.G4O]%
MSI<L><KORA,\*VM@)NA!__JF.WI3[]%.R;K#UJB[F7<9U1K#MW\))TZLTQ!=
MT:68@YN=B-CJU=;N5QG9[37L-3)O9K!JPT'21CJB_<B'UN^5]IT5N1?JF>"$
MP >-?WCX7BEV4OIV3[M;OT-JLJ.I@>"M;G\+-6$.O!@'VJW#;3C D= N^J#!
MD'W08WU0I[9^:1P4&6TIV5?5S8$M?55CC!7[H+UD*_B@,?L@X]AB@@7<T@?5
MNVO$G'KIN&J_.<4>;-?9"A[LR1U!.).WD_:NT^IOHR;,@<9Z'-X]VMKGC%M=
M=CF/=CE//IG.0=,N5#.<C$]//QZ_@+;) H?Z&'#XD@PHE5O3>YYP(UFQ^A-0
M5\2!#V^_^?G\Z^G%T=79EU^MR]\_?SZZ^-?FJOWZV"6+(%[-/6W%'6/J3%Z,
MZIW6T&Q\]Z):9"I3MN"(4;ZFB4P:M9Z%3?5BMR8RSK0<0B-Y0 EOIOEKTEPF
M$MCZU"WYAB?4&LD4!ESF,XD!UXXRC@&7 3Q@P&4$X.*,%@.L!JH" ZP=8!(#
MK!UE' ,L WC  (L!%@,L!E@,L)A)#+#VBW$,L S@ ;D=ICD#K/T'6%R391Y3
M&&"9SZ1!:[!-A3TC+.,XUW"$55LOP&96SU^<_N/TR^^G=1TLX1IXHZ@N\=:>
MBOJ3;[UZ.7(WV]0;P0/*1-5R"9D9;!F/[,/#KMT>UG:XD-7#8/7@S;S7I_D+
MY9J8YDW-J3+R89%GY+-T__-P;(\.!_9@5%LK']8/@_6#H0]#GR;0G*$/F_:&
MB3Q#'[O3[]J][I/OGF?UV&/U8.3#R*<)--]KY&,JS9MDW\U#GTU'/KV.W6^/
M[%&[MDMP6#-,MD[L$?8%^7"I#Y?Z&$1N-NZU\T#61#<8_'0&8[O7ZQG'F(8K
M!S<,?U4&%'W 3__WZ^F7R]-+X\X </5S?:?-F.I[>=Z%N? ,>2'F VM#([CP
M,AM@3'5.!!E']1=*>3+5V<X;SP5&/6;P@;E@!!<8]3#J:0C5&?6PG6\J%QCU
MF,$'YH(17&#4PZBG(51GU,-VOJE<8-1C!A^8"T9P@3T!HYZ&4)WK>MC.-Y4+
M6]8\,R-8'5Z8"WO8V+G3:XV,YL*%2(03NU/+"3W+$[<BB.8SF*5Q)P"XX'F/
MSH QU=D3&,^%^@["F\*83G=LCT=]^W#4V+/PIK#"4!WAK3$^#]\4JG-"E.U\
M4[G 6&C<L=O]L3T<-_86#%,X8:B*,!1B*-04JC,48CO?5"XP%!IT[</AV!ZT
M!\8QAU7$""XP%&(HU!"J,Q1B.]]4+C 4&K3MPW;?[C?W;E13.&&HBK![8"C4
M%*ISL1#;^:9RH<;.T:9P9MBU.YV1/>Z,C>-.XW5D#QM(&U]:_:L(1>P$5%GM
M>#,_]!-X,?5OA26^S468B,2X,PA<9<W'SQI#]:8[!2.XP#FD0=?NC@;V^+!M
M''-818S@ F^G\4G\AE"=\Z5LYYO*!89"W:$]& SM[F!D''-818S@ D,AAD(-
MH3I#(;;S3>4"0Z'.H=WIM.WVH&,<<UA%C. "0R&&0@VA.D,AMO--Y0)#H<[(
M[A\"'!ITC6,.JX@17&#WP%"H(53G6B&V\TWE A=9_]SMV8/#OCT>/[G(FG7$
MN")K[E_]9"Z<S>:.'V/'ZJRHVKC#!UQ3S8?17H?J,#FPO4#V[AL#.##&Q$5S
M//.!>2K0=(=L!A=XGX9/@#>$ZDU,Q+'39:?+3M<T+K#39:?;$*JSTZV; ^QT
MZU8!=KHF<(&=+CO=AE"=G6[='&"G6[<*L-,U@0L--$3U4YV=+N_I-H;J;.<-
MX +7OOW<M=N#MCWN/+DY!*N(<:5OWUN-J->Y69,H]D2<D3B) M^SY',6+6SN
MQ$#+O:Z'.X9? XFP'LZ-PL0'>CBI'X76@77M^#$R9B$LQ_OW(DFQ:JZV%J1Z
M;=PK,&[7%.KU62'!%;/BV3(?+U9H39F/38S*J-@<:/#D[,@SZ4[3_7\=YJK[
M.BZ?6?$0*V0RA%EA "MD-I!9P4Y\![G&3KQV':G%B3.)V3DW@17LG-DY[RS7
MZG?.VRH..W%VXGM&8BXW8.?,SIF=,SOG7>(*FS5F!3OQU]_#9A*_>N.O;=PQ
MF_[:.26+")^%6?L,I]X-[/&P:_>'?<95!K+GO1%-]UZY\K [:O4&1K/EZOSJ
MZ)-U_O7TXNCJ[,NOUNG_?CW]<GEZ:;USWM=5L<M5AL94MG.5H3&LV ;)(4U7
M(@.&>CO!RE'KU9BYSU"P,^[8'3QU,CRLV7 R%C1/^[@4U3!6<+6+,:S@S+,!
MK&"DM_^L9*3W/$BO/;*'[;Y]V.\QTC.0/V;X-$9ZAK""D9XQK&"D9P K&.GM
M/RL9Z3T+=T==NST:VX/!D(&>@>PQPZ4QT#.$%0STC&$% ST#6,% ;_]9R4#O
M6;@['-O]=L\>=IY\62X#O;U5/G9IAK&"@9XQK. J/0-8P4!O_UE9/I#!2.^I
M[!UW[,-VQVX/N$K/1/8TMV'T:K[H])U$@?=]C'HJ5XJC&F=?CL\_GUKO/IU?
M7C[YK 9WA#;&7^U%1V@SE,30DYR[A &9D?N;ZC.#M^\.>W9G,+;'[2?7[NWE
MB5TSN%,SHJAY+]<,'IB )VI.\#$C#$EZ,R,8V.T_(QG8/0-OAQV[<]BVASWN
MQ&(><\QP90SNC& $@SM#&,'@KG9&,+C;=T8RN'N.K-U@8!_VAG:W-V!T9QQW
M.&M7/P],P!,,[ QA! .[VAG!P&[?&<G [CF '8"ZPT, =^TGE^,QL-M?8,=N
MS @\P<#.$$9PG5WMC&!@M^^,W/63%F8P]]VX8X_Z77O4?7+O%$9VKX/L:KL8
M8ZT*RD,7>TK[+Z=7SW.,X@7/FHU?XG(L,\AOZ/F^%[J0C&G^G9"M.3[!4"9M
MEV=K--+JVX-!S^X^'6F]I(8U1X',<^0O=.&Z&>0VU%Z]T.6M3/.-<MYG\,3@
MB9G$X.FQQP9&]N&H;X_[M;4#8>QDL/XP@&( U02:,X!B ,5,8@#UE-+\OMT?
MM.W^J+;6N8R@./O$]HK!$X.G!M&<P9/Y3&+P]&#Y>]_NC=MV]_#)YQH9/.TK
M>&*GPN!I_VG.=4\,GIA)3R]#;S)ZPA+S;L]NM[O&<:^YZ*FV?OU<34[5Y-;7
MTPOK\F]'%Z<_&7BTA@O+7_U<&@.L.LX"-L?Z&\H#2CXQ%U@3F >\#_?J-.=4
M4AURSBE3MN_-XP$C'1.XP#PP@ >,=!CI-(#FC'38OC>1!XQT3. "\\  'C#2
M8:33 )HSTF'[WD0>,-(Q@0O, P-XP!Z D4X#:,YU.FS?F\@#6>?,;&!5J),'
MM?7 UDN4*WW*O6@Q"835;0V>[V*'3J\U6LF8[^*#8JBB[W>QYHM(K;/0C6;"
M>O<I2I+WUE<16Y=36+EU8/WB)+Y;5[&_7L/\"JS:+04RX]3%JOM12KS)Z+2G
M?'EK'DNVXT>3?8\1?"J=U?\N3NWQ@;-V:]ROU_L\P"2^S:0.GJRZ@)@1P>LS
M8N4]=<P((_S+RLL<FPS-8!(@B<"3[AL#V#/>UOTWQ=<#P6H[5<X9&?;C368$
M^_':&<%^G%,L.\LB0U6'4RQ;I5B&M?5";"#NXM1)_3Q@R,6,8,C%D(M9Q&CK
MU=%6?\1HJSEHZR%'PDZ>T58S&,$U1+OCRAEM&<^B<K=JAENKX5:GU:N_?J@Y
M:F)&7VJN\'Y,A?>)'RQ2X=5U/H)KO(T_J%+"9TC4E6Z& 9Q)/'LFAC7'=1FJ
M?$LWNKT<*_<8!GY/&?GS.#@N(W_.[-PS\83W0NNV>YR=,X016^Z%,OI[H3KS
M%^/?^-D 1%/00KLU/*P=+#0'!)C@@!@)&,((1@*U,X*1 .>!. ]D&B,Y#U1W
MK3M#.\[O[" /&-4Q(QC5,:IK-JHSCX<,Z.HNIV= MWN CLOI&= Q([A<:\_
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MUNFWN0@3^(BWB/'G%-ZY%TYL"; AGG4IYJF8341L]=JVU6UWVY:?6//8!Q+
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M)L5T2M%AB @*!BJ&2XKQLH3:6B&4^I)_YO 1GUG^BO386#B"W$5KK;)9)*Y
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M?ZT@9%N[M89R?F 0W#^$5_WHVC,?)?"L#CP44UTD^953"U\"9C+CB($M0+2
M9#LE)'NP!%RSD'5)3)6>/EHKM4-,*PMA]!OW=&M0R'K+PE1\U6?]F%5M5G(J
M2T0I37]MK9@V_>)@)0C-N7;,@-JXS,"L3+%X"W#HF:S3??<)IO*>:L?VJ0YD
MT'ZYAI%&F9BOV!0]5L6KJ!'SK%L)P+32'T7VQ[)4X>U4X+*RH \C<'@2;0T*
ML0JQE=T.U6:X]./S-:.[%#9FVT?_7H1:4VNGN'&2GI/YF!9FD&!&?I[U6C.V
MGQ03+PP&UF8C00_(U\Q$.HV\PM<5:5$LQ[A>!'3U0UX?JK8O@-@W="F!W W
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M6KY!O_Q$A272HU)I!_4S<THA!8I0G% =:15A+V88N*!&592=(FE<*KZP"%7
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M345(EB_W:8NFJ[E_R[?D*OME>O/_6+_B(=2OYM6>0NM?'!O-BN__6Z[)!_>
MY?CKLMK%^Z6M/'7M;=Z*YYOOTM$-U:,VBJL]H&6PH:6MM_A(LI@ W$\(DE_[
M5*4=Q7F^6QHH/0T>Y <OL](VQ\J;G%]1[NI(.S2_\E8H8^1KPX5,QLSQ^.K(
MZ/FI$CRCY_A>%L/B]Z@_/DOHLW9M/6$)_7X)7=5HH,@>D?,YD);[ :L^$T*V
MQY@+%W,%Y(,2+)N3O=<IXX^[I&JW]$9@/_#Y%)YTL*E/:Q/"S!"ZGY;3%'E
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M^F3P'CO-3>\7W1"U9JH)7287:8>[M1[0\H^+D#K"092M=#B[&O9[FK3)VM'
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M#+@2P,!2ZX%7"S!D(A"W9 @"?Q[!"*GPPW?.^TRCP34[%LP9?!PX![ ;F%]
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M+;TT<I$&KWEOS;(LVJ6A[(2DIMIK;>UKB([*)\!*+>1N"SD436\Q3'4Q3*(
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MEU7UJC^FSB00\%O/OWW<PO5U]EL#4!UM^MUL^FM6JMN Y_MJ^X&O/C=!+YT
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M&%"ZL4:30KJ;\TE2V!V-'F$_UT\;Q7)"$US,(RG1$.HLG$S8$GHSFN//TK*
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M*4"+K4#SLO]8$@8MO>/""")>$H9E<2GE#6J5C<%0K6<:9PN:.S?B8 )L_^/
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MXK,=!V"V+!IP]LS-@''HD,WN^"CBPQX/6*VJ,:.J=UCDLU]U76NU]=G[K#A
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MUHE6RW[T32<0V@$IP07),Y*=\K$5&6.03PRS35TE+C-*>S,MKN*G)-E3!:2
M,R<+S#CO*M]M=(QLQM+9W&N;^BOH2R99F.H *,O%JP>^"[G"$-!!FM\DE5D1
MF#?4;7L)V4VTU8,F9'7E0%KE6)OH?N,,X,*#F,;9.W:>N.E&'6JJ9JNR4T[:
MJ2QH)U^"NG]M:IU&2VLUV^N;'T9^,Y#FDWE2&PA12^NT6JML\@+".L;\],:!
M;$WB&DE^,7V3B*TQ]N01;A31$.T3WA#"[8\86_PG;T?)Z?I6N;Y.MU7@I?/O
MV+&=2*9-9QA.;GD(HD"26FS;[ :@,XP>P@ @'054AY31A=C4=SR$-C &"#N8
MG9HR6X@&@1\_#(2!A*8K; XOX2 D$%'(P6H$6:R@E,"  0E1;C9 J.N/A-V8
M5N0\BHNDY01X,UIRZ#QX#J2EB(Z6.<)@D[6WT,&2PR+8PQ]&$S0(9%YKC9D8
M5C<D:";OFGE5"A&@YC@8)]C]&#_-1]1,?=OBZ$ES:#EO!LL+BH=6>J.5]&<0
MI!T:F0^0Q(#W_S@U^]"?]Z;[9#Z')^Q=D;.$OX=@(VG;\_2R""P(VZ),B[)H
MHEC3$-P,@+B,ET.0L*6/@G\/)'=EY@C2HI^0244<HM6OBO5"K]<J3<7:!!S$
M=46(#*=RAU\-0Z^T)[]&"Y*-&;JO5+_.%&L/&JH$+9E*A0-([4\AJ@X!5'^*
M[T3.-8%*Q3H@,!0B^P\NAL\4;B@FT<JY?DNO=!1K4]:Y%6O:.-8HUJXD]"$4
M307+6K/2>2%6JB9BIGJ$='WO866 E(ZN*]:-6JO24$W7Y.B[<O1ZO6(4-RFZ
MSZ3/IAOZ3/#4=.@1FG@-;)=]%2#/[I#'=Q\"+HO<;S#W1FIM5#]T[[^*O_0/
MS$PO>*NQ41R$,5)G>-C3P+$&4_GZT'S69$U5U)ZQ5 W_:N#0KLOBD4PZ&V(D
M3Q1/19($@@_3,O4LO<?!+-]+BMMI!>(OWN]S,4?E\O)L2A?=\8-65-!0X9Z?
MOEC4(7H<9.*$88PC)W!3()X!(ICTO2@Z[W$7!RU"49M)"WFRIN.8+H[W) 4L
MK)6$,8X%.ESJLQ][2ZL^X =8F98#"QXTC45/W'W$<6TO&H05Q20RCH'%'N[H
M@H:&T$(QZ"R(<-_UG^1H0&KEX0HSQV EQ^K@KS;RO[[OXA/>OVJ2VOR\N)FY
M;\FL.\DBY)S%WT^J)\R".("S$AWO8?PYF>\H/D\UYKT91_Z'9,:C!>TV1R%_
MG_[Q@<E9D6UHS$D^NU0NG7';J%6:]=]V/^7R1=,KW=SFVAZDK,S$UH4RA]9A
M9/O]I'VB@/SK1J5FS.I@:97\U;:?'05ZG9JVU<G_+HNXRKF&_MM!IH$KHI=Y
M7\EY\^($ UZ]T.FP'B2TT=[GH*H*:]!J.>XJK; 6QM!BJ  MNE&IM]?;3+\T
MSH-9?>Z+D%1!%?(2U$>]TB$OF?42!1:@DY>HY"5&I;WFP2QE\I)V[EZBTH)6
M-=2R/I&!GN5QQ-&^BEO*E%W$1,\OKO\D1C+>*W?&5/EJ7OG+?)W],$JUZ%Y5
M/>E3I'%[71WU3A:J*N\P63.I@6+=4>BI-D7]25<JZXI"FR)J('<I@I[TJ7H-
MI7&%4E[I8]UV%9O"34=21@/7<KZB]\"ZXP6FRLW'*&_99NC8MLN/> Z,,FI8
MMJUVCAJ0!9ER _6;3D.K=72MT5HV>D\N<BA=O"4-4)!:7$DI=Y#26S6M6JMK
M':.FGH)*YB*43BFA!@4CE2R,E#M2O:FW-,.H:75]V8[LY"*YI%,T4^6PPK\0
M2^EW4_>@Z2I4@B4U4/%C]VAMU*M:JX5[7-;5TU#)'&59]8,T4/90124022Q:
M==R*?>NCGLA/*%(=B094C514 H%(U1*'['2:RVJUY"8%JH HL./ ,6GDB]SM
M2HGI(/EO.*",6A3=0NB%58@T+50A5>EK;PE1[O3 :+2T#I"9=FOK_. HE_@J
MHR!5'8QB86%455M[XX]RQ\)F4ZNU=:W3R7]/$ J%!?(O"H6%496^]NXNY0Z%
MC8[6:=2TJM&D4*BB?FCOE[PU<,4C/(92'MGYQN;RK[>X4;W8?EL<>RL.C?MW
M[( R\&Q.Y2JP-..&5A:3GM8J(='*XB7#2WBVN:[5F[IZ&BSS^)(J&J!85X18
MMZL-8HXZUND=76NVJEI';ZBGP9+%.E4=B0)>,?1$V\:L4P72C$Y=:]:W+@)1
MN%.LWD/SAW:_ ?"B2@^>@M?CT T/)Q?Y?3;B@>/;2_SH$#JCB44*#TO0"%)A
M5$43B]:<6&3H6KM:UW2#S@Y04D&J.AC%PL*HBB86K7D*?%73:S7-T&F.I9+Z
M4=6_*!061E4TL6C-M+"NM6MMK='<>MTLA<(B%)I>6_E;56BR_1A/BS<JY2E<
MK"PT<?C^I1+3WDNURZI,)526JF,>:XQWK%(>Y1L*Z7+-R4D[T>=1)R1ZO:8U
MVH;6W#XCV4WHG,](EH9.\D %/)"BZ?'H<LWI3Q1-#U#UIVA:1@^D:'H\NEQS
M;A5%T_V/&Y0EF$H=I"I8I:U#U,K>129(![ZUG<?-.I_M:[W2 #?*=,]XH7_9
M%KWRK4M%7#VPC#_' <Z@B@:</7,SP%H7M]D='T5\V.,! Q=A1M6 _^(E9_YP
M9'K/+ [AHE\[C4J=02M=Q_?&Z_+PI';FCX\!,\?[/FD,;-<:L"<S9*/  1%!
M_UC 73."AT6^>('O/?AX&_\YXEX(/??[V1?_[9>VH;<^A'!;"*VU9,W.YH_<
M]4=#$"\\V7\(S&$H?GC@'K3#%7^;]M#QG##"=CWR\0LJ4J7ROZ(**/KF8(?2
M+;TG?1"-_]6H5ROMM.-K=6L40UMQ(2-T1SYW*(J+\/%7H]6I5,=BQ*9"'T!^
MT;/X@+5(V36\6#<FUVH,8D+DF"Z\S^_W0QZQWC,;FA&H5#06;N@[/[D-IF?Y
M0\Y";F5^^K51K>CIL^;% (UX=- 6X)G]\39>&5&(MC=:E<ZX[2@".P#I>G@3
M]COSQLDS0+:?N27-RZCJG52"4ELH-7ANM=+(FI8'G;.29EF<VV!-\+(G[KKX
M[Z^MZ:O%E0&\ ]IB2XL,(]_Z 789X27\)P\L![7/-O)E$2%6AI"<W/?O  A>
MVH7IV'+R\07?1@5D?3NC!KU5RYCF;CP<'MK(/#0>P>/0;\UG8>1H\GA9].2C
M&62NA'_!;T 6Z;7AC(K_ H&%'-PB?<8HX$,GAA_^^GP&-T&&!(]9%$W .X:^
ME]B(/8F(LN(_Y1OW X@\((J^ZS^A 09\H1>:(S#4GR""B,/WOS:;&0,%Q['&
M@08T7)S 5V]56FO'O33FS<>AV0C8J59J8^EL&--FG]6H3R2]95 #9=57Q#0,
MR!";)R^>\IX9DT3+FS.HO[]#=_U8.8[8\U)X:2]*'<"2C!T&EE\;V>?-.-;I
MO&<YT0X]2<M8JHQP*X+6N%W=KW^P=J?*WG1OKT\O;[IO6?<AX%Q<\^1$ ]8=
MPKNW\=+6Q'Q?%-P&GE5O3M*%3(^7N_ELNF&\.MUH5C-X,.^9OS::E>9<F)W@
MF; OO! (' ^>H&T1W#P"IN58V",>).D)($EL!L_">C?TTO:,EU9_F_*[GN_:
M&_OLUH/:\'4 (HS!?J^ADP\F9C_A1AUJJA9U+B2$"P;(>N"T3V#D:&S"M<!O
M_!A#$?QM<7$->J[+'P2D]* 78L'(1!KB]WX,;L!%'N D)F]&"UC0V'LM,*@'
M/T### ?^DS>5CF:?GO$U*U%'B"86QN"6F:=$ W@A] -8/G.='Y@U)+<X7LPK
M[ X]*LD)^LX#M'9R#_B;&]OX+WSEA(EL\$D]$Z,%QB'3,Q]$<!EG$A@],#^1
M$C##,!Z.$HGT_%B@&A*625^TY$5)T'<"1#;QDXSP(S\,G9[C(CI"2P/PNR?3
MQ70L<BQG),2 #HVO$![K!+:$^Z0-/CPE8'VXQ@\@-?_$+1.B7=*0%<V%CGH
MNV$HPUL8]_Z/8^#@LEU9=8"TGAS4DO *N!C",LHM,0")SR&(ZYD]8@1(0H8/
M#0AXWX7'RN@[-L$*NT>-^"X8HLC$9YPK4S^S0/H\F,/T>?=;%#_R<;9&.^G/
M($@[- ([.NT%W/QQ:O:A/^]-]\E\#D_8N\V"2HZ]FF)+.;9#^JGMPTL\/QJ[
M,69)B3UF35=X.QIF#[Y_ C,4* 99B"/3   Q3$>8F:81DB.+:,6#R'0\Z9>F
M-7#X8YJY07SBC]"L2::2QA4_=B%L!<[# P\2'QP3+P@R@.U8D 07BKT?'H3
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MV"G3:^:IWGC#WXJWZ@U;?GJ+C#,ABQS[)_\$VN?X0/>QJ)#)LI8G3]/-2"0
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M;4XX0->5!7;P(/A_\=F&2(HE[[6=BLU'DW!I.%D,H15VO8D;8Z=LCF5F"4.
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M3JN9V.)D"9!_8@#"?6)+$G01EJ>M@,]:P3K4<7E[>R;6"WR9HXPGGP 6H'3
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M-R;HXT;)!T*VB=,P KG"Y"\3GA@\,Z,M\C]]6:USA0DKI:A_)8MD3-N70V/
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MJ$+@M$T1$Z_\1SF@@H,IE=<I,E^7_PRIFOT^VR$Y0L0VZM3+9>=#]FEU@3O
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ME/,--=1 H+<-Z!FSH#=QNLG)OGN9<MG0 #&UEDZ53.7,2%47)U9'UE]>-1#
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M;0-O<[N7O1+>-N5X];JFMQI:IT/HIIPUT?B= DH0PCGU^Z=QR%]Y& ,5/Y2
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M%GIW!O\ZT3X&A?163>LT#!H24LV":$A(!2UD.- C]^*M]]^@TH 2H$>%,[5
M;^[$JS-X,M[^+R<:G,4AR(0'^QT7ZFA&1]>JK08-#*EF3ZKZ.I$ZLOFRJ8'P
M;1M\FSMEZM7XMO$V'2VMU>QH35K<I9X]J3+,M>J,Y:4'8A\W[Q,GHK/D)/1=
M3 D\Q.$@BU1&9TXHI*KI\T%>I2X"VBF@G=O-43CPGA>+Z2W-:*I3.ETK'ASZ
M:$=E;"K?F+#B(.5](.P1,DP"T-(X"P'HX0%T;@O);0!TX\''IM9HJK.!) %H
MR0<DZWJEJC@QO;^^[UZR@APD]N*Y]B5W(#7T-']J)2'JZQ&U-;=!Y9[9:+VJ
M-=NZ5J_5J-*KFO6HZOHTDDEX2$Y!>'@(/)S;W'+/Y++3T@"$M6:+1CZ5LQY5
M1C[WR"75/XWZ\OKJC]/[\]NONZ"1-.];"53,?54'J8(\HB1J(/)$-E\V-1 *
M**.*TJOAZ(:?"C O<FZ+1(UY/&)^?SQ7<N0'R+&)8BOG+VJH@182;%,\F]L6
M?\G6B5>^9^UA;,FH:M5Z3=-;;:JEJ69,JCHZT2.R^;*I@<"-MD_,7P,E&%TI
M %6:VCYQUS2)R@I*($GNA39"$O*.$GH'<0NR^;*I@1!AF\+9W)E;\]LJKEDS
MVW3^64UK56M:K4E'22IG1JJ,)='&&R]NN%BD\25:1ERH,ATM(U:VE$<K<=5U
M*]K*(F\-$ 8=@:H(@_9%^>:.F5RYZ>*>V%]#J]8:FE[?W?90A*E%H(0*CYD5
M9G>+PBQ,HO6\Q2F<TGK>'</LW($UF?6\Q9F&2#75(_=^&BHD2"2G($@\!"3.
M'6>S.21NRC/;6JO6UAK5)B&B:O:CRBCC'BFE^IM<G/G#H1,-H6$A,SU;N!X(
M@WL6^"1[<^5'G+7>JE<>++VOJ*&&$JYW_COTTTL[=AIRZ]3Y>3H %7#O?8)S
MK8G"\&): Y:WSE1U'R)?9/-E4P-!QB+(:!-DJ*6S$@QXJ<].[NZOS_[QY_7E
MY_/;N[_]TC;TU@=V_L]O%_?_2^Q=.?]00PTEA!=554%J4$(-1#+(YLNF!D(!
M9511>C4<W:@&>%=+;25T@\!_&G#39C<#$[ZS>!PYENF&&KOPK KTVK=^#'S7
MYD'X_S'^[]B)GM\3Y5;.==10 X&),JH@-2BA!J(49/-E4P.A@#*J*+T:CFXH
MH@ [+^!,*=^3U$%COZXU^_'[SU[@.B%P$!YF9T)V%JS!PZ??X<-OS. ZN(O,
MB-O_;;HQO^'!'3YAPZ4"%U=?UIRCN;25<TL87MO*^=F;HI752K6ZZ)CKF2_8
MR S0U&/^MU\:G0]L1>>6]6AN!FJF1Z+Y83>.!GX 5F1O(>]5,U&W:&UK5ZU=
M+/>51X_7&QH\ ?]_#<7(MC-SW)JM%=1^L<L781CGKQR].G=^[5Q+K^,HC$P/
M8^:.FZM7#:W6:FJUZJ+#;&>U@_,ZMU#%W)'WVZAB<\O;0A5S1R=NK8K-F]MI
MX.QRS6BM$\ 2/W&$W(1>_$G#F!GB1CYW?!3Q88\'K%;5&%J'N'#V:[VC,7C6
MB,.C'[G[O"1+D_!+A=^<D^4<U4#[XFVS5&55\!/YSDX7;NJ=NM:JK[U&A9Q:
M":>F,?UR1%"R>2740$"V!9"U5]&4EX%LT^66>KNEM5L$9,H93@FF)12@AMB%
MSJ,_F"X;F8X-C626.7(BTZ4BNW(.HH8:"/6V0;VYBM#$\V[ \2Z\,^EV&3#<
M*:'K-!M:7:]J^OJDCER][*Y>/E)'-E]VFR=XVP;>YHZ[?26\;4KSFLVZ5FTW
M-;W1('A3S9QHNH@*6NA:5CR,79P?P?QHP /PO^$HX /NA<XC9XX'GSE[X_IA
MN/7^.E0>40(>J>:I%CS.'6J5<<9K],6SK"M>"$^\!#^\XM%U_][\N=NQO;96
MKRV:IJ&:K9'+*Z$&8H%D\V53 \'<R<<WF^/<W"SB7>+<0DX8"DLY77VP8T?7
MF@8=ZZB<A;W-?_B/3G1<211MWG<L)U*QA$('9Q6JHDH'9^T!;^?6P]SRR'0\
M;I^;@0?:"#.^_%FZ\N94<AV(;51K6KM>U_3.[H@EG9]U,.REXRB+Q#X)50E5
M"57WAZIS:S)?B:I;$]>ZWM&,3E7K-%N$JH6PMATP6H5'.6OUBJ&V_._]R'39
M-KMMJ5@,HK.YBE,KIK.Y=CQF.K?7P%W&:\^%S^YT6+3>U+56JZ/IM=T= 4V5
MXB/W?1H;)4 DIR! / 0@SNU$LR$@;CJGUJC7M49'U^KU13ONJ&9TI0?$<HR?
MJK_5,YX;"[\$ONN"K)@#_ACPD(90B^E5:JB*BKWKZ>^4JJ(JJB5?MZ(!Q[PU
M0!AT!*HB#-K;@./<WFY?'7@<\+F+)'G<S_!BH]'0]':;AA8+85<*#"T>FNS5
M]4I5\<FR]]?WW4M6K&-!7ZS,$28?5Z650'OGU=C.W#9V\]78"\]R8]3<C1_@
M4[M1%#B].#)[+K_WI^M$:R'],0QI$LBK&VB(*>>M 8+M,NB28#LWV)[;A^\
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M4;PZ&C,_LH2"'*H^\IV=&SI '+:$^]!F"3ALY,0<Q$>A@\T9.5B@'D1P #M
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M#^8Z #ONK9I!5]NMMMH E1*45Z*V!%0*\:\Q#J#275*2H!XGKAY@!XA_C7%
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MRU)\V3TD7^Y6I[ N?-Y66YVFVFI65Z(  W+B!@3\"?&O,0YHG4H&"J@$$1S
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M#1S .L<!%%CGB,$#ZR"!G0@.-/0![$\#!]@E$C@DY [NIH@-=(0(#N ,&CA
M'TC@ ,Z@BPUTA @.X P:.$ ?2.  SJ"+#72$" [@#!HX0!](X #.H(L-=(0(
M#N ,&CA 'TC@(/.R01D4H8&*$,$!E$$#!^@#"1RPS:"+#72$" [@#!HX0!](
MX #.H(L-=&1ERO/>0<GG-R^T5Y^;"K#7L1N4D7E_,):-0-D0BYSYLIF8#E"%
M_<JO,:U.]QP;_BQ\*3@X^@<"EJPS5WFS#+MLU6J$VT4P&@6^(F=='%BSWH=H
MJ"P\C-F180-C1AZWWHBO?:Q\_*[TG#28LF,V9342=9BHX\2MQQ=+S.NR/(%=
M;5[[SG*=L[ZO7%AC-T[>_:#F>5.G!V8<9AQF'&:\8,9M>S*:>%;,G%K9\=MX
MR,):O;&8QAVR(?,C]X75ZLW[OAV,F/+Q2Q!%A]]0@;$),S9B2,?)[%T0.XA=
MOO<E>W)M-SZXF8?YAODFBPTU\XV-60&WF\#G"^_'8>!Y?-5J9</[XH58!"-^
M<$.!J!F,,XQS ;?'(+:\Z.#F":&$O39ZO;B^UJXO]J!3.S=ZI0W!9\NS?)LI
M5JP\L'',1@,6*DU-572M8995FKV!L81S3@B+W5A]?XL^WSE\*9_4VVJ1@*G8
MX[T<4OLH>* "W7^YW\3?KT/+%OD0RL1WXWOV],\/O_WQ;1!Z;C3D)!Q]4%SG
MGQ^N_^"/UNARQ\ZW1GQ=)M'9LV6-?WB0G[F=Q%%L^0**#XK8^_&'D%>Z$%_3
MS$[7T#I_I-]YB"UN6?EJ7/T]<>-7<;K#']*/H]XW-\H^E"3%RIS87Z49_D.8
M8*W;U#XH#K-=_@;1/S_T;ZX_*.(]K?B?']QO\0_^9.0$<?J!#S^9IMK26FI3
MT__K^_F7_8F<Q&+31@(%<"HX]= P?4<.(=#I3G3J1H&A-SJ_/5S.L6FSP*:"
M[X;\'5@8)>S8]VUO(C"Y"T)QU5X<A^Y@$EL#CST&-X&?B[1FP<=WI6!M+0'S
MSZMFIP7V)2:K5(D [ OV/31,8-]C1&U[]C5(L^^L2D$D[O?]-&V_-!.W3%WM
M:KK:[AI@8V*R2Y48P,9@XT/#!#8^1M0^;D_'+=IT/$M*E048<S4)29K^>FJ.
MI-2>K>5HO:&VVJ!G:L)<NO("S QF/EV8*#)S%\1<.3&W21/S/8LMUV?.E17Z
M_.K1[BQLF!U5;[=4L]$&%1,37U QJ!A4?!14C$WR'KBX0YJ+EU]\=T9NM5IJ
MPS3!QL0$&&P,-@8;@XU/ K7MR=A\=S+>_MBWVU)UHZ'RQP5[$A.X"NN]]E9#
MN7.]5_O<;"U%@4Y/>ZFU9P,K8J*"=31F?F0)!:$W!V(OS@T=(#!^ SB\Z<34
M?$3-&3E8H!Y$<  [0/SKBP/8 >Q  0*BZ@%V@/C7& >P0ZD(9W<QPMES_IQ$
ML3@'C!Z#%24JLB6$#*=<Y*(I]^SOB1OQ]7]@X8MKLSL6NH%SS^S@V9=7^=WR
M)NS=BF<:_/7$#]TMZUEUM=EMJDV]65DX%;;GQ&T/J!?B7V,<0+W8F%& @*AZ
M@!T@_C7&099L@!R(H0+M(((#R 'B7U\<L'4 .U" @*AZ@!T@_C7& >Q0XDQ'
MUS1"9SHXB:F+Q3C!429'D-I^]8V%MALQ)7CBKQC8?RG!6*A(Z0% 1U:X1P<)
MNJ5[=;=,)'" +U-F'@GW&I:6X/6C:,*<RTG(USKQ29(Q)?*/MXD%S$RCL]=N
MZ2N=F[<FES34EJ&KG2Y:I].34Z(V!!0*\:\Q#J#04N& XD2OY0PJM_*$"/2-
MZ "GS^H" [ =)VX[0)T0_QKC .HL19W+QW<=@#KW5NY@JGJGJ9KM#JB4G+P2
MM26@4HA_C7$ E>Z2L@3U.''U #M _&N, ZH=0 X$(""J'2 'B'^-<<#6 >Q
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M5462<W;* 7G:#$"THNP-M+*5JY=I)(I5XDE5 M=IZ]K!ZL<WTJF\!81>@:
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MV!AL?&B8P,;'B-K'[>FX39N.9TFIL@!CKB8A2=-?3\V1E-JSM1S=[#;4MFZ
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M4UQ?K/>$B<8B#@O=%RMV7UA$[_P$C@>.K>H+ [R/ [8+AG80UPYP Z2_OC"
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MAXZQ];I+>PZ<F)_846W-3!%5&."3E/))EHP&6%7&=9<8OCV'H4V]H6H5-NF
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M'1,4Z!H/<"X=+,"Y)P 5.'=?G%OHU5\YYY8-MK<,M26RVAI=<.Y1"!\X%UB
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M2)H.%B#I$X *)+TODBZTE:-#TMMVZ=741K.IZ@TZU6S@:+K&!AQ-!PMP] E
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M)/"\L$;GRA=QH"6# ^Y(]J>:>7,SGVDJAN( .#E$DQ$(69HCI3@5R2>F!)G
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M_W@)W2OK.KS9.3N1UL#1F+L<CM3#+(K/,DS7>+ 6IF&+HW35Z68^!MS)ZG6
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MMKD\G.;'5LZ<:53]9"%._'E._&?"^V;AO7AH6 PX'RR<_8!PC+<3%_V'@6.
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M;)*,1)%@*)("0PJ,!H%;<B.A\2-=4L*C2 J,4X-?PEJ2>A/ ?])I;1(#C3X
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MX-3@E["6I-X$\,L@^:DQT-P#<+(@>=G@D^.-T4H">.Y81A*\I@^PT N1-MW
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M;VEM(&)1-;AO.@(3H9H'WG>(I=PAJ24-]RBZ'C$5SE,2%Z7]7 \O:W*W2*0
MQ#Z.[W?7MYH^LPWXZV\WGWM7$:J+!XT41A3:@V+&#UC(0:E+V- 1CLV0J!*C
M1V!=+5CB%:4B_("K3%!D6]E$:M&,C.XT&HZ11B\\J88%,SXE8DOG4&PU>ZIO
M=G+BS18/IZACXV6^P,QQ\_$12(4*B R=INWYF)'%C#_7L9#TQ:^T/R-NM001
MJ*#DB9C5.G*&9Z2$,L=$'6Q8K24OX\<CY1:&TT2>-"8 J-QKYSBRHASN.$^;
MNJN26]S4N\J&'IY]Z_=IE=;O.^MIFPKH]D&3A6[<C-7R!64ZN0-JT-!5\84
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M#Q&3W6]*:T>=] =JK[._*(_L8GT.RI!L$22[6%\F*D3U$\B>U1=4QB-[5I]
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MFN<G!?D9,'\IR&O@\FRG*T@9?MC(U2''&]4.6>5&JKJC]F@L9?A9T*24X>>
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M<8'+]U-^-[T_6PN7T!IN@I4UBJOY1+B^R(T4^D(&R1HD)%)EF%ANV#)_MI;
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MWUQ=R1L.(11EOM#QW8CAB5,L<T&4MZ;-YCC\(IZ772HK,KC17#1(9667@.$
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MSGV2!*AYVGO_>T@@#/01= -;,_X54$/JWX&#_Z&'CCH:-.I7Y(>+^6E,W"!
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M6/O:H"8X>JDCS]]N#3/J@D'/;N*L>*'.LU JK>4[>L[P^7,R$=L3<.UV[G:
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M63#EOCC[P /+4&\I  4=M !#W:"#5EI5'W3\\3CV;4LZL2 3@+2>!R"7W'=
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MW;?R>IA.>F-+\6O)<M=M)J[QRG=G%_ 0;.E_K7!Z$04@'N%?/AIVA!"-@D#
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M(R@87  TWL0'^3&/SV6,@7[>"E;Z:,\-X1O@W1<12AR8^>(^LGGH^C%)/)$
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MO%"37K/6Q) 5GO136OK69>)J)A!79WHO'N'8->=R/< TG-GPQ_\'4$L#!!0
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MDJ5V?EX0'0V%QCI_5I?W)=)7VV+7F91GC3 ]H=XI7E.)'?\,J#X.J;(!XI&
M$Q#^'<YAMQ3L'6A4NROSF#ISOF164W_@PU6C[82-%_".+&#.IJ=L2?"HM&8*
M.$4)TM:L.I@MG1%KR;C#%R_1KJ+H0RB9D:4&91==S7@Z.;_!EK^2_^7RXO 4
M1CZJ]E2XN44K$V$7]2M=<C6LG'9^12=UO;V>+3$KMVW&0-2];32AK).Y%EU]
MF.IRM1;\T=\Y<T/D9#XC#'QBXO'8<?B3ZKEXQ-N436>@4&.D"[/TP8W-:F&*
MD:=L#C];VL4M2*?@0 6V^>2)$7%U=9K;DUM8VD6W<QKNI?Q"L/V'?X..>\EN
ML8MMP%U6L5K$7=0S7%:YP):^AN2276.;NMD#&4:R+NKV!3O\3_ C,/-+:U-0
MT$7Y[V &1\JWQY86=U$7[<9A(D*#0SN<2;7+5:7_4F-=&4G2VRUTUE05O_YX
M%V_XNH)P"DSR+V+)&=>ZY+?7%=%T<BTVQ%997%)>WKV0))$1<DN21J5))E.%
M+KYJ2?'#%%A-;2O)NZCKQ)/JFIC)W+=1\K,'^L+%S+[GFM1=U%0G*=4K%M_4
M'X:$NBA]9U2H<=-:;REL#J_8O"/B$:;L.K^3^\3&#=?G*(@]?L+"3MRQER0Z
MY:Z\X?*?1!W.YPNFUK=C=G[-B5P2,5MB%G1?M&K^RE*\)8N5+01'X(1^.O6$
M2&Q5:U2E*\F[&EV1N.3>_^0%3!=4=DUMWO%#;0A]$CO'%3C"/FE7]RUWSI0N
MEC#COW>##ZA/1/:3DZ5]4Z?JV^R:A KZ**"^D[J@'TKHNJ)TTTRW>NO]+:EA
MNJ<HB5U$M<W\]';R)1=$77'GJ'16="LH=]U3+,3+!1?*Y8?*U2+MBDWK[,)2
M4*S2)G$MIIGR#2E>[WIZO9(' [R_@I4,5'WH1N''EKAU<.VFCFIJ35B%!WIE
MV/Z7ESE=NQ&+-]HE,V![OYZPQ @P3<S<-V+1Q2X)XF]U=:B@#[I]]WX]XWI[
M68#O]#2P494NS@6+%+@ASQ*F\K45+J;OHK97V413:?*PG*BKZ4.U-<.">>&6
MELVVQJZ+LTK_QG;76I(5_O7_ %!+ P04    " !-A'=1=]=I.KH1   [%@$
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MOH!-]T=L!1$*2"$:*[0<L%L$[TXXJ:G8Y&"Q@HT2+<AI(@)]3\*@Z"X@=_W
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M.<]B?;WX'U?6Q<?PN(.#KQ8I?,'>E<\NB^)B^2%%KBHH= 5<V2R=,75!15_
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M]''T#4S2./1IG1+ZJ06A)_@4*]8#U02P,]YJ!;1V[HYWOL<@SI'%K_9D\I2
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M5P(46DAG*LGV?XG(*!B%_X3!)R^,Z)AB%9V1+NR1 #\.7G!H?-_T](%H!<G
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M$9H"%T .R#M*S.K^\?,GJ>A!70U8)6?H#&%Y"F9&O$289VZ0J0&$'FP4S,M
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MF6.'?GK)PK(&=(Z8^KO-.1-DJ,I@)CK/D\V+;R![P7N-U]X3/;1':Q^1&+[
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M_&I]"Q9K<'+^:7EU14=^JPMP?7ZS7)V]@(2LZ[FFTK$6\Z_)2XVFXB+C9DT
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MP]+!6<-=/R]WRCU9_L#L*8[2V//3O8?H([/OE1/NV.H-]/)QU1TA$1=/!9?
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MEI S9G-65J$,$\:';$=V],\PWQV^P<='G.L8O7F;4PMA]3'\%+YR?%;OW0B
M3AE4=Y<@ \HJ(8*H;IW ,IFJZ;4P*H:YALZK 3K__ <'*=ZY>Y=(._:0044
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M?;B+_C<RO&O7(LY4YJMB[O?U+0P8SS.<6]=";_^!.#?9WL>UL3E"4]N'L=R
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ME^9O0'QP%2,E7_>WZ78@R:;-2C>A$';F("A(WRD_0;.NZR>:OPYQ8U><@9;
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MBE*QBTQ*BIWN[JD\["3=1KI24EW>(DQC)O_$P %Y1]<"LWPG!LV DZ?YSF,
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MZ4L@@;L@$C"AA7,7F.#3")O/T+]8Q0"*M%H8<&<R.S7>!VF\C5=CO%]>$O-
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M852*2GI2 6U&.2.+A*G^9()@&+;S%PIH%8'J'P!:42?U!!J/$FA8ADO+4 7
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M(N7K:9S]%(SCJ(MF!]YUMUF@9=8/'\\"3T.V=Y_;IY&C9RX]U9L7XV_L9\.
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M'%BG3ICI4.<C )3/W"DL&M 4HW #O$>FR<8$R""<(V?EBQT3E8AF_H>C8,J
M94ST4722RA)-TCCGQY4"Z%K-KF2TDM%>'*,UGC6CW0MZ"HKAOM;=WD1;ZQE#
M"CEW4A >9^"C25 Q#P>,@IM G5*_6^$*@X(0.$DH -6T!,'W;JQ4@E,)3B\.
MG)K/&IPVA=O+88R.<#>D]>0\G 'T.+K(@)',;@4$P*!?V%CH(K:N89OD*JL
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M<39SX[HHY 8<T$Q\RT6*V@ICX3.O/U\QNUW8&M0'-@;Z0N*N^QV4RA\("I1
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M-_C!9^X+.!(B5]W+=2U8NP6BM76 ZX&^R[X*D=_!:L+%<6-CU!><:R.2:I-
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M4KF()8BD\PD<I<_G)*N?^]':WV0OUF&0ST$@PKQ/'F;1.I^M23[;_3U.CW-
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M[$5;36?:+B)5XH2J$](R+BO*"/%TRN=CA3L^A\'!(O!%;N:NU19,2>9[<J)
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M1L00<:W;$\ L(+X9O'%*3I<#K2DY3T9:8 ^VCHK(-Q3?I5YE*[2[N/0D*XE
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M%]1(&@+'<XI6/\^2* P,VQH"A1L_D*2TBT<$?56>(?I=^AAFK_+K>_ 158?
MWZMDBQ_<DW#+'=ZU18LP"")VQ!;A/!MO4/T9>NN=3]R!Q'?:X=U)0$<I#_=V
M%J'*^_6BJ+T+Y/VOJ]38^) >I,"OHJX.G7,5P!J"#Z?7M)>8KNDZNU=/_,A@
M_\^+7^%O\VCSE-=9Y-#(7*X],LN[AUC_MAQ#<X+'IIV_'B?@#L"GO-K+.!!7
ML3SE518IK$]YD2I'?W16>1_C"(8'*?/JY]?O?WG_\1\G/[R]>OOZRCO1MI*6
M34=$B\(TV'>]@;O;WW_RD_%RDAH7/Q5E29)+-'\/?X,\@G__^QYJ=W>H5=^
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M*?'\7YN!7_U5#?SJ]^U74$L#!!0    ( $V$=U%&.OU=Z@<   PH   0
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M<$-*9&X=*BM686$]M!1"<>?F*C2O7-6LP@X-2H0(Z&*TDA&W3M&)D9$$"F2
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M^Q]V>[E/(5+]9NXHJ'Z;]P=02P,$%     @ 381W46J\W(7Q!P  $B@  !$
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M>%;\@#KNYU?M-ZVC$VZA<@.P?(S\LB?K&+X36MC=IV <C3EXI=PI1&9=&%@
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M%_H,54[&M+:*".4<0TY(+TE@EJ/%TJ/:E!)HX%;_V!RXU3]0_P%02P,$%
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MY)\F;,H,M)I.$WIN]NEZ5"'&2=5Z6(WF"\+E^>-@.!AZ_6!X.(+# 7C[0W\
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MS%Z^_3=I%5+)A.=UC##*Z:'_!_!;/IDJ;^-O<0_] SY)L,A W2UHX\2DXI&
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M"7DY^3&![L1#09J'CN:LOI--^Z]-U+"3V(6)#WLW$-RSYI4>?7+ONSWN+W
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MF3F8&*S  !P-"CU+Z(<#Z.4OP:NW0#N#<,"?:O>#JPO,EQ8&!9VJO>F7.I;
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MEB5C-2:OFF=&MBU)B47T>6  ^6SM'Y0&3,LK(C8/=JX*L 2_\!4CZ9$P;O0
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MF(==R WB<OR?ZKXS+*JE6[,1$ 4%B1(E2@Z2)-.@DG/.H 1)DC,(C0110**
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M$.*<<;A/\X$4"FKM&;P&P!/@5Y=F*/;HO]:BL;-Q2K!#S8)$REG(N"SL54"
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M-9]MS;ZI'G(@)=Q"T8TC^-7*EKO<;N+0SBM6&;%$=-N3B=S\\<Z/=HNT*;@
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MSRRS&JLRDA80(GNDX+&:_)7L@)\#T%-\JQ,AA-DB J<>LX\F-N8PZG!PHCZ
M,-B:"J3(GS-A4]U+75-3YXTZPA@9TH_=/#T=EDTDTRCB9!/8<M\.];*^!:"
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MV_7BS3RI#A?'2-^Q0M8;>2=6Z6M.+.L&#<<.4/K](#>$L*#IBM0(=UZ<K</
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MYVM3&H=K$,"W/&<CBO4V9H[&O0-J=GS> ;$G^M38:4I.C>/<[<QEM*M9<^\
M7,-#ZZD'3>6X8.Y1C&K_H)979_TP')%QBCUI'K]/T.BKZZN?A)HVB6@7BG&$
MN\+L=IP6.$9<8[?\X%XB#/LA5N57#*=BT"7J   ;X$S^[VH$LL+<Y@!Q")+)
M]0NX=5FSHZ4,.LRU2:I93&&&Q$>2]/6%9ND%)=Z(3C?F-(.V>*5<CX7I+<)H
M/X-9I*\J(HW2E=)'H\&9L0]S1Z*JW!&Y$$G-AC;YGSL1))):%<M-^Z5%52%
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MF5G53(G"2XJ.$"NWGA?$]_ "XXA:KM/GT4/)W1!T2O0K$GK'LW3WH,F&OYW
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MA@O$I(%3714I',_PP9=:]6HA#.,2@S4]?9GIJ.^<V&:J'P?CBZ1S2;7(G](
MD7[N=N:=/Y84P;I"1#B#\.9Q_<CHGXO$\/V%;>65+HEYWSYU36NL2SS3P=%2
MV:<3\QG>RP)>;44"X9;6I4JY;R;<278]LYSZ7[M5Y++O=$<.W@&5WZS?4&MG
MW)$5/G\P?[93XE1B/W'>!VNQ'=W7>+T=YJ"!@9+FSHE&O_D&^0O_55U^%H--
M"!)(T#M; /*.&\V08T&4N,>Q_IP'M",I%#83"82]"-CGZRF H7K*;DU\H+0Q
M)JH-JS.)=)=Z XX3US<B1;>T-'6F#86DCH\LK[(9XHKPJ,XF9F@)A+XM]#LO
M#^T=X_+R3%:)94>(AR^-\Q-/E\K5^3 &!'IL%QM$)\YT[=V?VBJ5;"SF2Y9_
M09W+"*J(Q=P,$R*N_LP@TTZ9/V*,C>; 4IG$HP6[@+)%Z0YCD]7\"_^F3V66
M&Z>E=@-*.S>P=2KS5UJY::$\3H4C:F_-*(*:"_^;>B:!HD*IFP MXI*<L$)4
M-KQU<B3FFKPO)Y4]AF>S_7C8=WL3@>@@&^L7VH()ZMD\ HJT_3V6+*T"AAXU
M? W2S'< IZJU3LR(Z!(W("1PTWUG] G4WWABJ_5KIZH=&:.U#M0WO]R/A2PG
M-(0"]E;J$"=87KWGIZ2MQM^8OI'7)RG$C>4#?DD,*V"*OY)%$D1)F_ZO50&Q
M^ZDX4Q&R:RV6IHEC4)8@\+_"BQ(>5)HUS-@GV1:KK8M(#L(&SSY#G>@[5!?'
M*"F"-SP6!JT6[XRGFR-E&MO? 0JUDFWJ5]>LY%7L_5X4Q6NJ[7<<Y1..;AW^
MI0;==C,Z1Q^<(IL'J5+Z/Y>=C\L,D%]JO0-6TB1G$!USLJ4Z^9:3Y4.IHJ/Y
M=G(KO6XMD;#CL%%SG?N%V8]DW;G#7LST=?/),KX'2>T#<+LW,U!@EF-MY>2F
M?U16@2&W5\=:,PVS;EA\UUHW[OP(1\ .YK'&] JTX9GXJU_%^R^2KBK:1QK)
M3$T)$Y;$XP/#(1[*6!: ?I_S_8KNU\QBB4ILJQE 6)%#X:Q1C;#WA-PZ$MC@
MO/R<ZZ!:Q5#RU6TR( >U.IGM'1";2S&\2_SR2!P  [Q@C)EV>VS4'3PWE]+E
M6PG0,AVCS"%=NM!/E(!P)?_U @RR?[^HIZ]Y?J1==&1JOG81B)5]ZP=D_+A]
M-_C4W[G/^=[3)S/Q]6P^F[F[L16\9-8%IL#/":M9_=2O"\CL2K*=+LE!%WI;
MN/R[V9*$8@XF-+9),V7)7K5WH]TD<F1\"N"WRX@/!H9?]W92VMKZ-I]5V^^W
M! H0>7S?TYJ+1['CP=1Z.1O2@T:SG;9)*BY;.6*39MJ6MC;#D,26T=]U30@C
M$U/:$B/&>0?\\)-U]+GLIAXQY&NG&3H3BX%FP_AIW^(8=[Z9D3W<P-+5<*L$
MR^>;W2BW\.<1LX^ I38R;B]8?8CXN@$%O5*IP":)MY,]L6&,B\G>\B[R/ OW
MFB"J+J5?:?C+I\$!*E^+@KK+L\J^#%X(3_WR;RKJEZ3HAI9KB2_XFR$R]SDH
M*YFNAC.FK2#/MI]4GI,K,LR\7'6E7SY\TB0@;^(#;&<\Q0*WK1UR.<?[M[<1
MSP@789=K\*0&"<8OHP\0^"J;VUWS^>*&'>SGN>)3BX/C+#A@BD5["T#"#V/R
MYCNH+&_GR],;$[ZIJ;-]>]>XJV80XUFW"1W ;L,2M_7M?M+PT^MV>]HT?S5U
M/6(?+K]\"9P8OAW*3O1.FG]GV[9&DW<UBPXL9W]R.4D;5Y-1FP,#DJD#=.S.
M26L'#1!PG8VR=NS!ZZ->WS&SHJ?@HD-&.9+ S!4J3Z-)A#@ *(4%H=E.E?P5
MX?Z>?3.KQU>'.K"8:VO!31IBZL9&/N=W1T<*LUN7_HG)*\SVS.=%I-96QBGE
M12]F)4+L^'RDMZNP8GL]=*:SP4/%&L[?%88/),IFIJ20"R\JS^X#=5<WC2ZC
M2:EJLI64.*9/:,?#S1FI9!")M-R9!IX[RLX2TW^1H(C7_W3@0#=A--7Z,YY>
M,9C,*5;JB_=4_O-17\G!%[CK3J2O.$Q3#[Q"U+62L&T($/'?#?\63@5ZF6V8
M:8\L1>)TWO6X",@^> @H6.#0/KHVW@Y';&&IK?J@%[16X^MD^WE=BUN!XFEW
M!3\?J+0J5SX:M;+ /$1LF7"B5S@>+_PZO'HB4-/*T =>GV=EH::Z\CY(F_,]
MB<S5TK[$C&;R>A0;>G0^:MCY@X-4D.X@H<A%_R4)[6)$HKU]F- _,<6[ZB9J
M?^;\)QZ8KINNMT;]"Y&G\%MC^_WR9-SO?:VJ"3Z"3]%[T;J>[GP(^Z^,S%1U
M>'20CU)+9+Y\QJ",F2I[+FMM U=WAG+."B4W#P?'=B>!_59CC?*8&\>)-\3/
M,1]L/9*37^"[OEBMKO1G']8)CP:%\TIV7E#BDQY<BLJ=,H*G&I8<S<,U(+C+
M?JB=?"%GUT2U \5^68WSDZM9=9XFX%"WD,F_4OW#?ZGT$NAKQ9)_=1!&K73>
M&O)/C1"N(=*1HDN\+-ZK:USPHYIICT" =])11&[R"YRC*G&<&-]]X7 ;7+P4
M*IX")"Q/G@\(65]OB_*7+8R5FOGD=&3J@.\FB("C,[\M,8OT=7?W;+_QN)!4
MU93%[*\EI_BW!%&)3:N:3H5R1)*6.>2G LID'"DO(#HZ!!TV!/'0YA4;*J'0
MRV-$.K.HB9.K^F/,LO2JX8$E4^ RTZEL&;L7XU<@W\XU2ZK)-IL9&<5CGG*'
M #S)L[,^-3;4Q)H7KVR'M&SO:-4])L9^('8O[MEB<*R<X8/$F986$X1SD.G@
M>M(NAI>/'S9167HK&M12^?1/UN0S'935OUH?>G ?\:"JUKR$L'JXI @0,)C\
M6^!K0;SM7L([0&BU^HH;X85B^:NIKW=?X')JK8XFQ(3I<\1][,!T@O+K>G:#
M+Y+-A^5=?F:_D/G?BL"U7 @D8EC4RQY!5.^VE'*FPMC_4GLEWZ?"B#!*#K]A
M7*#1(+=<$ ?/W>G?"H;^,RB@8D@R^>NMLN:P/9/J<KS.C=W):\R=Q&%*7^B@
M;>BCF!SZU.=2 #((5#"3,X> O)+5XSN-5([1'(8D6B$ (D)6AF6\7M]%KS\U
M\A=;EP2]>(H*)_J4" 3D>R_RV>N!<JYBN4)I&V?'R2/WJ/Z&VOCM5)-$J<T^
MWC#2"LX,CXD.WL_>YC.XWEH)C)S18"_:)E]-0=SDP.VHE/-&1.KZ6C0JM9_;
M'JKPAR#1O51*/J$%B[*28#4X=7P &B"79R/>_1.A;=)]LB'K XUBZ0=9#?>+
MA1,=W/JH*/> 5_3Y;"YY+@4B-XHZ9FI;QB:@(G8&V65E<@>1!]]&"^.-Q1JV
M.P&VAD7N?Y2/4;MPU%CSJ.8@74]TJ>.6C<^0*$,&%1//B>O'JRP+X%1ZRON%
M@63MTCK*FRAB_!6MF;GN@3)%3,(+T[FS*Z/M6@-&<+;Y2>$:-FC[8<#3^FB?
MZ+DT&Y9>]1O\8@WFM?1"<Z/_RA!NK?0L[^BT-N4R@64_2FNS9,9'?8#YX]4-
M+_J\7]85[(X#_(;RQ[^,SQSW&D*T-,W-<)R#6L#("O-<7.F#@PTU;+5..MOP
M#OC85,HTB=T<_9M+CE]"&5;+<;L?O7B#NZU<O[(HDQ,<!HPK.__F62,<8U#%
MV/?4E0W7&!/::9?L\BA+&-3SE2Q]32[^:=[=<@1^JI)0L6)6\X4W>\1Y\D%>
M\9+):>.$47C4WZ0)K$JY$S.*1Y2R4WH&/&)J6&.4^2%M;FUKE6.$F*_^IFXR
MO:BK]<5^F:_'^91=^QVPI-H&O@)P#OBTNFTG%<Q7\IPV<8FLV+\#A),2SIHV
MKI=L<J9FVHNO"M\&%*<A>SK+)*.LWVJ]+<-:98HORUK#<K)$.43T_06!5<M?
MT%OH[@9+QC)/B7-IR=:XIF77.,QVY])H9ZI]Q.F[B>E%AQM.TI)'KY%E$!V+
M&!4'E%$Z]<;"2?#O\YR.0S*>..6 (>O'@IDKZ&M\I2<\%39IOG#8FFC+V5&D
MRQI>3J3LH:"YQ-GFGTXNWOH_? +QIN/&MX'7RD*Z]LAU_BWKZQ]2<U#&ZZ#C
M-QEYJ;N9?@LC&D]#N.1C7-\P*:E/>0V7[C&\V2^$*/L1QC4)]'>[:*MP@P2.
MZ4JJ6'(:HD:;4RF4+@0!=- ZP(/Q9Z8-RY6#4T=63X7%'9&E,I63)S40AF/N
MJB+\3NSL;%I'3==4564M9T4M3B\:SGA@JQ+!TY1O6(6+AN?R7+35Y-%R:#8%
M42D-.F5#&/%'[ PCOF\_=^!SDG;Z>#$0S9M:?\ARJ08<4WAF3B6KNE[1$;6Z
M'US66N9[ ?FG@L%+Q&+1-7(E482"YT3\2*.%G!!0<P%HI)\S,G4_:94.+&.J
M/=7I1S-+FU&U^99!.@O5ME4^9G'F *HEE-@:2/[XN:+#1< XN0AQ8AY2GCC9
M<&8ABJGD7QI!OM*@.UJFG,WKM)@?U^:\T.&N!E"15&_OD#?[M?]E\ILLQ(QF
M6M/$T #9Z@_Z!;KXD=K-R1?*USR5?A?.U1EF>[/VGV/L@IQ#PB=F@!P &X*X
MQC*PCE-V[%HX**Y,]A#>%G>6*%-FT >FM?KXF[=&G_AC=K#*D?)IT*!/R\Z1
MA%N4,:N/+.'?G<;"YO_VJ.,_A(R4.,% !\#T>/G4Q^?MP@Z$Y@'RW-R*,WWX
M=6J;$(CYT'.F(TB&:@-KG&B9;D;^\JBQO!J;',*P$;J5K'7)4EJQ1OG(-K2[
MG*20>]D=^-G_]:2U(I]>D7?Q),,T(IL)G##]FO B$F#Y,?YA0LU#/IU(GHZ8
MSY%C=U#,SC3LO'D;PI6-NF)]/WW\#;+<R-\UK\<!-X#?4[(5F%K9RC#K>VS.
M<+813[?A:VC84?-7YD=__M=-%;[=FOQWB?$Y(^'3E$G"/=W#Q0 .1%+-; HS
M!,S?YKV^;+1S2=HX^9MA[*.;$*%=TN3(_<ZW"R!04*F>WTKK3%BE55U.3J*?
M(S;7!@BT_5&Y[4UM7_9#ORT#K1A'\]E@9A2Y_6J/USDX=%UI!B=M;G$V(.5T
M?A34ET9OP*&UF\$^< 1LT7[R^[&0'* +#])/R"7YS<+Y#@ MB%8>+^!!ZK1T
M!J=6^E=(?FZV>1*<(IS(J<KJ?Y]QS6^9YSKA61'>I?O]X&GV]KFEDGMK[H+T
M[;6]G^I1!2)A\ NI["Y)P#U?@;^G9/<I6_Q"Z\)-PIXEJP[7Z#0H.X$!BO%8
M$=520-WF2ZI5LG^8$I8BUJ[O2E'U[(4EI"X),]81MT>8$6E /5VJ%3Q.E[:_
M&#-5](+_N(MR=U>E^X;9H3A7^%UUYH=6ZL\)N[Z!D6BPP*9EI:.5I@:>-?6I
M9ZW"U=Z? '.R\]O2PHBRXM'YS(47F$![.?FDISL!ZDMLS6![YN]? MF7XX<%
MT,X.Q=X!2(M-$'E=MW"A,Y79#+!OPKEM=!LDM'<!3T+2G0:)Y93+1N20-*)%
MI''*BO<BT&)E3_LK$X7E2L@H BW9CZIDW,11W5A>!N[2#P"S#"AUA^KI): ]
MTUMBAL&%LAW XPD-4)2S7A&I)B^ATSK;LT>^U]6AHK,H='&@9XF005I4J7,T
MU1T>^-?>BVM:MU 7R"J[>,8!<]48HJ$FD708DO+==W_OE3YNW.!\T%^<:L1Q
MB1E)7]DB])]T8C3_2,' *L;&$)YL7RNT3\;I]J01H[8A(<E]EZW\-]!0_[-'
M>_\  ( '_/J?I\GC<^[I_E2Z%?%*0@LLJOCD"N.[T ,PH""L^2 NJQ+,J[5"
M+;]=[6'O+'DV-+S9:AT[@;#$?J&H$6^7%:DA]3KOG>\+WQ^5X=(8FCL;6 F1
M2Y"'D:7RQ)-A2DD;YF8K#.C-=5<L0&2W(&I5K&/7@1TQW)(2S*=I64J08 FA
M+-9HC(:8?/5]T+GP(?AJGL"OU,%8%BEY<1QJ62##QW<2]D;=\(P1O9Y[8L6^
M/=2^DC6M3?R&EF^,YT*MH5YC@X,K3Y3M,P@ENC/',EZ,^+QQZ]738#Y$*1"G
M*OI[&&0B[94#/]MPN,+@ 4^F?4:D%W46!6%$B+-N$(W]1LB#$L=3X9(GNVQ]
M77>%C]YFM)H^GJ?V6_BOM3; /3G2;,@V<HF&K7=^&LWA98VYZ(\2M>UTC[E,
M=!R50NS39'N1MX.,X&U'N(WTJ#]/3=D-I1W!HM[1QGZS-P8!9]\B].JO61PH
MDL<C#61Y<XYS#OB$.=-N?;KG7LCR;3&R><;Y]L;]!G_2B^JYD^FDBB\/T@JH
MJ^YKV):=7%WL9P_N.KY(.^3HY,@6^%7-\3,X7T&N[\MQE[5;0S0[X^.+":RV
M[0N<HW?=^$X9S/XH]"?M+NHN-[]=^<4\O0-BR(SF/VXN*CT8O0,HM4H4[Y.*
M7#/(*R7]UM\!+!OSQ<RE7JZJ,R1[TXV1#L:.MTG+$>/X9IB\(.\^^;LN 8MD
MC4DJ2"N%K,B40UMB2O4@3G(.PGQK2@.SP660EP2B3WL%WPN"3H,09^FO/#H'
MYC5L(TZ';P\@6QLYE3E!/,)A9Z=*[(75=T"UFO/E!';]!#%/,B:E_6A5!#Y[
MT [SX1+WAM?G:1FWIN9$CX9=>X+C,C;\IX39[$*>F9[=ULY\)QK P5#TQXAC
M)=HC_8__U,NB 7#*VSP==L?5SD84>20XEG]SY<GB4:&H#>=*80.$X9BQST?M
M0H#TX.&X?OUQ0 $[!*NP77+U%:'2;*7W_EY*5N207W1+IE]?[@ FE"RG\H>Q
M# 7B]V =/^31@9V +[\ 1DY_WZ%AT?W?=-((I95%.UT\SS5E"]>14=GVJ4I_
MLM?Y=S[=H%% MLY*7A ?[Q^2W05>BQWEZ[%>:?NE^"2)N!X*6B-\RM)C@>Q*
M<<NM3'WWMJBPIAGF*N:BQBRJ:(YN.JV"F(BO(;SN SGW90*6/[B';IJKDG94
MVV4K!]L<R:685X=Q"!"_Q$.<^5!_(0#K;7F!+&^]T\@IM(E&X;:)C5!W_GEB
M _L&',%*E-$'V%"F7_^0C%7.%23H=;L26^.[U EXNTCI)@*(HR&?I0/^BM<'
M,0?FL]. $6K0LZZMUSIN](\J4EK3ZYW:M>[=$#B-^'8%0H-TC7:(KE=5%85,
MY0*6' N1D2@KO^+O*E>-FS--31'6VL:.K#/2;=MJD;DM:!P)LE:ZQ8.0#_Q"
M"1G*<"5^E$Y^LJ^%+L;L@E1M)IF3*ZT#]38 -LWF<8$LANH?[?0^IEWI2B(F
M0\6RCN1@J23;A,80^K7)$)_O8+XRYZ'2HPMWV.2T7H_*TC6"?1F_I8^DQA^N
MLN/K9V$&8:+GDW)9(ZNX*HDP]9;7A'].K[UF4=..:76+N2 2.&RHB&$["!%Y
M344M%<Z<45V;B)I%+M-I,=FE,D=?"'8(0DWHU+\#$-U[>7PR0UF-[WR;L3\4
M6ECG]#"$#I%Q^+7 QGD+:;CW)?]PYZ^HK/IVIFL1OF7PMN F,V%/<VNNYY?[
M!R&7.YDFJKPOWU!_26L]5;2N\G2_*5[66CD?'OEX<)%RA;(Y!PU\\*MNC+AV
MP-T*W-SJ>!OH)<\ADUL[9)A@_;1@7-0GQ,->V(L[*<>9<B9[-3!#'LBPG0.9
M_]9_>=+?]]8_\PZPQ$JZ%@IJ1JW'1]X/69KX8A#\KZ6G&E+9WJ43Y6M]WE;&
M$$G2+VA?7%QD;X_Z8.IM#A?R<K7UJ]99F7Y,B:_[)BP&X'!3G3/^?>XK-%#*
MJ$P;!#BVQ54P4&H038X)-79].2IT,><F&=.-2CE+8/$^%4P;>GTK%,U#'_RV
M69=V]K(TA.3ODS8/XHJ$IMA$:BNQ;\%UW3"N$4NZ#!6_%6G\.ZD\6\HT_KO_
M4:4,0:S,U3**I(B$Q\%P0IA4^_F7MEJ$? VD,^F.2$;UV/$V 98H_;+<[?\Z
M+;7O\4[=J6=R1UVY#*P2$QBC=TA\YH:*0+#HC*&JGT-\$W[A&*JV-\W8[7<V
M,W3JD*7#.-^1%B\G:$[A$#%K\R<:QP@]*K/C#^TX#_#AJ-_*:\Q0MVNG?M*+
MY<HE^X%0LM\R9>DP_PY8T0%5,_>UF#6'I7YNQ<%GP'9[$694,FB;/IBQ5WVC
M+X2TD0_4>HUS</A:<I-.,1L,SJOI3T=UC92Z] A_1M8VR3HG*NT>_2HE8K T
ML",%6DXO')KM8?0>&$9D@S8RJ;V5X?(7N9 &;15#KB+.\WYPX@Y\DD>3F1 ?
MLS[2%(A^BCELO0KK_/(Y."(5C\P]Z-QGLBH-H2QAILN>U?X#15>[O8NM5%WZ
M::X+!!:0LU/<:2L3ET^UB32:H-\8:Q K:QJ9B6SVA[,?<$ME>57) 8/R$?&^
M' C1356:[E?86=T@8UCGP? T[;?ANY%51!XLO_DKA*M,3V<\S9SZ32)5,EI@
M"+BIL56Y_K_Z[YTS:_FR,31QE&,)*E%#3^@K/ >ZWTSU106Y><BYK]>>.S/A
MN-.'HXW55YM7Y=:FF49^$^W1;]P5658*O\Z,5X&93<=6:0EZ*RS]Q'AUR-9<
M*[OU4:IV!;C;0OT V(O;92<75W6+K%<[NPN4>534W&OS[P%[!Z'J_3[1]A=I
M+<XE2S8:O[_5U&E?;">,R!0\ZD7'N2"8<$;/8BTMK^@N:Q\M?[?FM>N1#JU9
M:_PQ?-;_X500.,[3D?^JM\:UMF=K:,CH"$E9$_&EJWQ;HP*/>#(*'VL/>]35
M"LH<- N9WA0T;A -;//6I=XB1[Y$&L-8)F4"!BX_L@^=I-5[6I:M=9P635.G
MT(S0DP31H2,(O9X_/LV=H>LT=Z3IBSS-Y75"\!,34A8O)Y^NT.@B>J9/]MZ,
M59Y73ZXOIM<E0YOC;\- NG 2/&]&<57:NGS]TB0,9XV#+1KF0#/ SOT/3=&O
M<\A>M\%5;7IC1%J(@Y(Q'B]+)-Y4:7,6:JJCW>I2LK0 I#F:U F:-&EVYYUT
M1)8B""YA="4VN)>03QQMRI7\6];O+.>LU4MMCH>[W1.\C\NO("OL; ;F*BKV
MUPR%_:2C(!DXG_G&PN((1[.6-%[*H?8L'L]DI.G1[P$S6>(H[*J!/;Q;#UNV
M)%L>K<-#=[&I,E'#MX-$?$7BF44/1^>?M%DKMR%67$<.U7'L-/Q8QCT)<]J&
M3B*AZC&<?75K#RSW&LVX4^O:CMKSF&8Q6D;11KLQA4HZ=6^$?_;.IN/WVOO'
MF.4*7H:0^(SP80:'@[._ HT@?_9VG\[ .#+[X90^@ULFY.'*X@B +:> D"!N
MKDJ7#<VL*T:W.'^P$H.T$X#IKSNAO(01KM=QGQ"P)H3/>\J 8(YX!DR)M16@
M>"3WA!'[Y4 ,;'/_TTK]?PNEJP8ZVJNZW2RX\D5T032>I(^B.YH,]/:YF3O>
MIBA3/+NTM04OP)CJ$GQ3+6U<-CQK_1+V@9PJ3SF)S+<-;U.GV.)<F2HS0,/(
M]Q?*#."A@RE8YJ?$LY8 1,\,^@-9HH!E/(4%D)7]F<4YNS]\K3T"-ZEI+N,N
MUM:YY!A&LP.2->X.1[@VKM+5^LMC\^:VLEF?,LLKK%[*=1\7N3?U.*!S#B=L
M;O7>,UZOYT<\-D9=^&,=A[>P]TWY+;N&IJ1ZXE[9.R!(>=JQBAO9FR9KK/*G
MC ;;&/A8\%E-A&IZ?]Z-_C3'39LX'XK&0V0>M;;VA3F:S%2G09WY1X+"&B.I
M-VLPZSXS4Z0%IFWD+GCXPU?GLN':Z/#E ..:Z^#[YCZ5EC\=>_/5+,F.2!S?
MO<8"J5@J(TT8<E>C>9"AKA+B.FH-\B4Y%)'> =V$,6LO\G!]E949&(].^.(:
M,5]1"?1S7#QY3I..^AG('L1O>61ID(M71)XM<)LJ-/B%"MT%4ZK]?\7^W($1
M:3QT4T8 =,*W _?API@ZQ^N61ZDREV5SKF1&K19W29V\CKVJWOX+=;__+P+F
M?>G_ %!+ P04    " !-A'=1O\DAX4V=  #"H0  %@   &=E:34T,79Q:FQB
M=C P,# P,RYJ<&?LNW50'$$;/K@$ H0@P0D>-'APAQ""!S;8XA""LP&"NR7!
M%@L>%@\NN[@ME@!!@^[B%AP6=UO@^+Z[^UW5W=75W=7]>3WU3O5,=T_W\_8[
M3_=3-7,_??\/\$Q=64T9@(6%!?CP< #NYP"* 'Q<7#S<Q_AX>'A/GN 3$%(0
M$3Y]2OB<C)R$@H&6B9&!EIZ>F8V?DYF%EY6>_J4X%^\K01$1$29.25D)(1E^
M81&A_SP$Z\F3)X1/"6F(B&B$7M"_$/I_G.Y_ 4CQL1H??<;&8@$\(L7")L6Z
M[P8P 0!8C['^FP#_2\)ZA(WS&!</_PG!TX<*]<\ C["PL1_A8#]^C(/S4!KX
M4 [ (7U,]D)0 9=<VQ*/Q95"*#0A#Y_U3?5O2IVQ0S;ACVY?GA!04=,\IV7G
MX'S)Q2TB*B8N(2FE^%9)645535U73Q]D8&AD;&5M8VMG[^#H[N'IY>WCZ_?U
M6UAX1&04)#$I.24U[4<Z]&=^06%1<4EI64UM77U#8U,SHK.K^T]/;U__P#@2
M-3$Y-3TSN[RRNK:^L;FUC3XZ/CD].[^XO+K^#RXL #;6_YK^3W&1/N!ZA(.#
MC8/W'UQ8C[S_4X$4Y_$+05PR!6T\2U=R%J%0?(HW"7G5OY^P"NL<4GYT&R.@
M8A-99C_Z#[3_(ON_!^S+_RMD_P/8_X9K%D"(C?4P>=BD 'G Q?7+GR$$_[_]
M?V %0P ^BO1\$4"=CG.^YT,^HU3\/79)T?[#A11$$^6<^_AGDN?S_YQ%;$.H
M("]S'_U?&D\O1GKEZ<W!++9A])Y[%M_/U-F7[[[UMI/2?*0N4AB1VR@3=.OX
MGE&]2Z&MI-KY?VC^;@P*,.825K;'LB]84$8_Y,6U$0_=.J/_,ZK_<>M_JS3T
MGZ%!7@+^STT=\'*(PT'XW>.'<TMI84E5E+#FPKL%-416F)LF*J.,#Y6Q/<VO
M@8B=($:+:W]H%D.+ZTEO+2F%N3FA6LJ(3EM*JO8U$6F>"H@L1/3C_EH-:(2G
MA"@/\5ISOB@CVLO!$&\C-1UJ.DZ#YA+6>/V80OM_9R"O9KC#(OTXYX2H1MB7
M2=+$WG+&@?QFV; GI@3FKX[8Y"@.)R:+F4E>,9K5R6ZD-[W%;@=N$?FFA=>E
M!\BO"CSZ[78#WX1<+G1<%'F0B>_T+AOPAN>M++@)D(-'ZT@5<W;;1!$FI?>
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MHTOGXJ,>1#MG.\A,:#YE;(_>P_RDZN[$ZY0IR^RR$B:7'PS^MV/'\S2W!;4
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M1P8QHA%/?/?T#SZE)8BP7I3(SVG= [2-9L4AE:=?C_O8&F6$<M*!**]*@WM
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M2[ELD'W'[+3"F:U9#S&J9Y&P91I]/'D=H!O0K]E\Z&63@M*I#"U2MV0M)8G
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M5FM\3F&<N3>I8+HW?G^.^2YEE5'V2+\C*D 37.1@;G$NEN)6H\;[X7%3$QZ
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MOCQ4ZR=D3?I-#481II)KG[2$.$CX_/W/HAH)04?.-A15R7$$:G2%7Q;W5X<
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M]G5*SW%)QBE)V,^UD^A;S@=YKD#%(>QU"=;A[_7.G@]4/=2]]#:I1P8XV7!
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MV%.E61XX;8II-/AZ1XN(I6?^*V7!Z[AO<.".P5N/J]+>98.SQQ'E G&@TWN
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M?'VIKIUT+2;2[FXAA?RE<[I)6!P&X!P,9KZ LFP17A<]A<6_C_Q<UI=M;/\
MVBVX; RLK9;H>_-9>SJU%*G1^)H=>K3HT_:U'9+_ (8[26P\6S_\?7BF[7U
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MX8U(ZWX-T?4F.7N+.-W/^UM ;]0:M2+S1!VT-JB( *>!2@4[%6V9 *6BFFD
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MVMY4D5'*,5.0&'4?A7E?Q-&/&>EGUL9!_P"/UU?PY41>')X%SMBO9D&?3(K
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M/)=S(UJ)V$)8]3M'\NE;.:3.AU$I.YS^CZ)<Z^E]J=IJ4MI&T_E6ZE \4D2
M#E3UYSS[5U6@>'_['-Q<3W1N[VY(\V8H%  Z*H[ 5L0PQV\*0PQK'&@VJB#
M4>@%/K*4VS&51RTZ!2,,BEHJ3,I31\5R4"_8/&-S;KQ'=Q"8#_:'7^1_.NW=
M,BN=UGPU!JMW#<R3SPR1(44Q,!D$YYXKJHS2NI;,XL32D[2@M4RZN?2IE-<V
M?#$L'S6NJWD;CIN;(_I2)J^HZ/(L>KQB:V)P+J(=/J*MTE+X'<R59Q_B*QU:
MFI15>&1)8UDC<.C#*L#P14ZUS-';%DHIPI@IXJ&:(::8U/---0QD+5QT2_\
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MO[10PD)'FX:_]H5U_A_(Z/PE\/\ Q?;2'7G_ +*MKV[C'EK=&1I+:,\[ %&
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M\(AG_P!%NQPT,AQD^Q/7^=)T'T%'&0;M_3-ZPTVTT^6\EMX]LEY.9YF/5F(
M_+ %7JH+/4RS#UK)P:.F,T6:\"\4Z7>ZI\5]5TC3D_TJ[DB8.1\L2>6NYS[
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M8G8P,# P,#0N:G!GS+P%7%1KU_>_*5%$0:1KE) 2$*2D46EI!"15&D1$NC$
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MU=0DQLK<[_*86XD:1/O3=+J,RHBOC9?&T6M!.$39G,)E(W_&UW>W],L\N/2
MXMF@1+USXOD6_]4<_YCUX5?#-%KV 4&LW0M;=8XVUN2.%^9;@4Q/UI\<Y<;C
M7$N5JVJ^&J61C-VJ_36J.O;WLMD#[L>]K;=]+4!1![AZDTQIGLV47=I4[;)R
MDQYW-?\=:0Z9Y0N]Q685<EGN+73*=7VNV;@UP\E7=@GDO1ZR);.8G6WO+O7-
M9#5,F$[@X:]BE6\3.<)XP 8EV[/N@GG%@?&W'>_+C'+A572QK&)@!L=0>_75
MVS[3-:A9I)C3+LP;*WZP3#*<9>-(G9/9-ZB3D?H%?][^2>8(S9E$@J?P?KVS
M#'Z5V+XG97].,H6?T$ V59=8^4'DT%L>]VL>>H'7?UEVEU^WY]WTYG$MB\8/
M;S7$_W(#Y!R-P;3*@Y$N2:R,\?_XA<LY3G!*^I.E1O]09)ICRNS2[?MD&M]T
MW(RF+=DP3[?R:L. KV>=[)IZU^?E:*R5I(-XQ5520K7"&F<US:F7N.H<>)1Q
M+\( O.YO>R)9,ZNS9%%DI=TCA;/<\]R5@U: (8!_'V %[[$-<4(O&BTKQ7+V
M=[?^'M8_-3C?-^59D3]>.LN,%=#I07W/O-"#HE!^-TH/T]G$^RV',><[GXG"
MA:[4<3%<+:<TU8[IKC/Q'=]2PG]S/$N*[G-XOCU7],[=,BG)2T ^P=N%2W#0
MQ2TH3=MBP]**-RO?(C==+?02^>Y0%65;^-=(4RUHA\^*DU&XO*!Q]4?R."YO
M$QA@YM*C*0G8,(VMM9MI"(J$^*T+"<F[*N4VAGXRNO-N\G6C0Q&#D>J@&W^N
MWUI3$(%J1?NBW9R**4E=90\G@5XV->'@ZGIVMS\P3C46'S-,#K'SK2P/<Y<;
M%XIMVI8Q_V!G;Q-_#;<I$*/>XN>TU]IN%8V6TR==)9+FC+VV#\(EL8:73#;Q
M:FU^L64F>=UHO>ATDX!P2&L$[&Z?9A&)$U3P,U>OD<I'E9RPT?V<J>325-M,
MS*1F3-S/A>0L\?NE$*:!J4?UF!E>).)KF&5RS)@?(N[':(08ITG]GC&WIL:;
M[WK^45FIBN3'T!8NE*FH_T-(SJRVD 4V[V^- 0K&^US%UFH%N8.:AO#\=]*\
MH%U9LIDS+AO)*<.#XH6;JA*Y>^LJW@P" @_VQQ0+MUQ3>\%CWS]-Q3/GLZ3$
M,#)P1;\CK&M-9XAGRT[R$EX6)?S5]LME(PIGZ(?Y)SV&Q4MGWT: 7.K+#<UN
M[,WI:"Y=J^B& 85VS18P0 9".ZBCQ/Y9ZJ*4H+$NX>EUDNYV<6K>GAJV4TO#
MX<DS.T$_0SLY10=(V@880OB;(ZUJL,-JU]+)QIKC-K)(D\<M>Y;Q7P]0.77L
M#%\+B!K4L?#BMZ, 2^AE$6/4#[@)=G[*%[M@UAW%_2UMCO&MN/][*WF.[A5P
MFJ)(QG#J:*:>_*VVM1*.:9FU@ #G"7LL;G(IP#JGP&Y-&?=RYIY(IWT(E993
MO/FT;)8#69&NLRWW8^;FA;(J"=G,+;KQS;JG3@&*RR13$<[L&?W%/N0I^/[R
MGI3Q,*"Q#(\9$W0YINGW2F,'5XBAC#A.\3=A&]V*JIHA%E&0Y.A<M&GQEZ G
M>42DXHY1^*='"17L(<JX-&E.9QN[']F+F.I#[-/SER3#]+#57X8^[U7FYQ.*
MZ7Q10SBP5::Z3.RH&A PIUYHML27J!@H,N?B#ZPN;JE5DGOBRZ;*/_YB($->
MF-'.V2\?R5[F(#@Y,:-)]5739BM8X7%3[>9&U/5O^/R7[_O55G,%QC7:Q,N"
MLQSRE4_1EHU]Y!V2EZR(&=>*E2O=5;?P>M#"]6)>=W^Z>I<MB%.],Q&RD&5E
M;4\,,93IDBEZ0QT737/FV[>U[!5_8-IPJ6MRF!JR%J1I4 ;Q&+I8-]V ;];.
MQC&,R8S;$_-\]6NI.PQX_MN-5Z0.'/4PUSU^YO0]51EPXT2@Z=*BG@(Q1H.Y
M!XZ\@M2B.J0@8$A3K3B?[^'4*-VV"JU#QD? ML7B+,B75-!.E()TL^>L32+I
M!27O(1ZKN/:JW-8QO51BC!J]O6N=G,*7^7V'5W[>760H#YYYPN WY'=?R!!?
M\Y=E3N=5PXZU6!'1*R;!W=C/*$I?9Q!?7*S3_@>7O?_NQ9J=;&-CGJ:KJ]W/
M.U1K$QD\I,OR.C@@_&NSC<%2C%,KU*^K!XI/#P/&+3_X$*7:#;*G.4MZ6)UI
MH*]**N]UFJBKZL=_41V\.K^=_WDKC'&>Y6W0RXOU;4+N%CU[5^*OPX D>WL8
M\.(T#-B*Z;YA[VS5! .>27I80S&$?RW^RN:\MWPE\UQA!)WYID,/E6B?JQ71
MIP\"$"^5V$1<]N_3/S,U=C9R;!Q2+Q>XFNS>\<\(J4CV>_Z1>L+65'1XO8ZY
MN##A9DN&_^C[Y?J4MC/GLK*J9;V#94@V_/#.X)OFL+[_)EKF1,-JLBSU.7R_
M@EU5A^DY&6F93K/H@_#''0(->"4M+ALIN-:23TBA@I!HGF3V"C_+LE"J;=53
MJMZA'JK48_50S?!G\3CF3JX&E5V+O&0Q6C>ES:E2N"[OUT2&,T^NVQ1(@*GM
MB#&ZV_7MS3.</C2V]"_<$_X^610V6>=TMR_BPEE;<O(&,6:1&RTN=^<(R&9=
M(O8V(I>TLSDZF(>Z*M6MKPM!N"[[1K6%;C[[.NXEY,+F_V59L7!5I\'1TG3#
M_"8I88J/. V-#[?S)7!K]J@ ^)IY/']EI0_DQU7VO8;)6VR8JGI)W/1WN#"E
M5@EL@]("E\5I?I)\U=G:V#(_Y^YJ97S:Z$T]J56M0"#W[6^R-=/TN-@3B9ED
M^E>ZKBXL[K72V3Y:>?.<P9CU.:,Q9T.KZE.NMC:$'&25UZO(E RM>>.^6K(P
MD/%]E%[$O'Y*_%X1)WD+5_SU>+;W[;Q359"<WX^-"XF^<?2&T8<US>H(%V6,
MDNR;8;GX3SPJOY7IGDT>+V!4>#'E:5[F&8+HJZ^X@@'EY!R#[H)R_JRXA]_E
M19JCXQK$3%]<'J,VIB92_-E"@#4C3O5&11(@/GAI)C1/&% RK-"Y"939:5S6
MV97B*C;-D6LH7>[QH]T9%Y'#7BJ*L&#PH0J*.C7FY_9Z\ G?L^#R[B_) MFF
MUA6>;[-="D@BQK)N;MY=&DYP_]@7*U0RIAF)^75>S#='UZ'YP:Q+U:O'^0.U
M(4I1TL4AJC[#W:9V;Y0H0B4>8:RD4]..4@9KYKQNJ?=?K1EO5I6Y%,]LK13E
M>+5(1?HQ>8K,&+[5N_ON>Q=:&V[OS%?'OF7L3I6!CA!&KC I<3#'O7M$83#T
MN1_C7'PMK87XFB!;Z[R;?*9[8>W#A?'NJS571TPPKG!HW5YP8GU"+XSO!@/D
M*L:"C+/M7V4IYO>L*!A/#]VZI&PUA8^A#."X?.Y_*M6^Y>6@KAGKY%C;GYX;
M+#L=KNP01O: ^MF2-LM9*1D)GT;\#^>Y;]S(9)D0T2K](98W7:CCG$ H!0-F
MB%CI7[5%COEHT5808"4":WAL09W"=SW=;4QQFF8BI\R&-J69WG)<J\5YE4E(
M;G\I<N<NFP&QD[_06:U4_T:=A"]GTR)"OQI=P!UXMF<T:9I69 ' =R[=;IUV
M@(6U.6:M/P?]S5<IS92+(5./E@MJ" 7VE 22[2?VY1@P!3Z=E>G%OV7UK-)Z
M2#82=.UKP_>O(LQ8[6:?1$#WRB"\.@,4[_T40IJN?WCR \Q2U/OAS([_8"*F
M/S/Z9=2R_(T>3!':):N.2Q4L0+&9[2K=4S"P+VFU6,[)E_!8/?Q)#^OHA;;[
MY]<Y9(6XC7E)PV?MWFB>M9\X]Y"J[$WQYZ+.<\7GB,DXC%R_:H6\SL'Z(/0N
MM#\_V^W6^&E[J4+?:LV+.F<P Y[9>9% -[AVU'>U8(!LZ'SR_A5[8@U<?PY>
M ;([E.HO[_0X.VT\OR(9U%LO.Q-7W)K-]N[+LG[RC?8%Z0':MJ!-1?;Z0;G?
MZ57O]1)91MTM;ZFU?<P14'CJ4%3X?+7VXD!BF=-TE=\$R^45>>!E&I:(<N"+
M>@513N*Y'_5J5O;A1FT?^:K*=I5#/!9UPR,&MI1QDU1T3:(^?6_Z5)<Z.WV/
M;\-26.%*]P.6<RM[B49/TFCR@M?QXQG=A>2>Z]!HB]R^<R]F?,GX;O6I%9^O
M5==IO=:F<^2 !;-LCH':G<D>LY6^?FF+3L"0%6J17GSM?GQL*9_+$VDW_XUX
M_HJ2W'C;#0"KOO+)><."(7H6HE4(#FZ@/4@;6&3.IARH*PWZ'7 6C*U*6L#Z
M^F<PK:3J#]N5%^^\+Q%=LY4*'Q_2']^5^1+'LWVN]D$VX[F?Q@'<$9(F#<;]
M_!CQ%1^Q2I+\F8%__Y(:DVT16&L&V$F^[Q>.:C72E<1HK$;934E=*,*E%_CA
M?DH<]]WYM:;8_3OB6=1%!A9G:;\WND^RK>:2UTNT3C)CY2;EV3G3RBR(N3)\
MOMKK(RL8\;559+N9?I;L@D5U^Y@:]8O-V[3N#?"3DJ)_@%LO#% 56RSE;TY8
MIX?N)IXQ^UC4# .$I:TGDI%C@IX>7HQ)22/\>\N@S2&J*1@0?V@7LDZ?MOD+
M,40# X)/F(%W0CMWUS#824BWJZ9?+>[96<>*S4KO;XH3M:M8QT*=0G87@E8]
M6R^,;/W"U&9E7S7=EYG;W^%'+GUD%0P#P%+;>= 4>^@^("\I66F]/8X,]K@9
MW*_!8CMB2,B3!FGUR#,=&43K3B@,<&_#+J!X?B6.B2L]@CBCA-K+YK5H,2CB
M"B*N>41<H%EII<4V['QU'?2$/WW1B%5)(:QA0"4J6'C<2#/4V%^"]1RQ0R:>
M"TVQ@^ZC)*M:/KD"*L2#G(1@  TRW!Z$9EQ)02FR%,2EII87&J>S"2P>'RR.
M5A<5%PQ(I_%$!09/XT!II!F?)R2X:B3QC$7\^Y1>B_;ZJ(W<P:M6);>"?=*0
MQ:H*#EHUW)=!V +^_>244OX,4A%%-U2"P( 1%""H3D7WP/[F"??'\_DO6@7W
M"SUW'FM8&JO,C.+?-PT\7F0_H&,ZT!C>&P>IX#K;;"?I!4SA](.H)SI%W^P$
MN(VLUL*%/A!>G BBL;'4KY-"NGQ5Y5)U4B#&0=_\-5Y$6B=["E[LDV;(S9",
M6,,!*@A$_L-]4H0N.OA86\$K?:R3[SK+4B4!CD)YXD0JDL2 BN3E2YA*$N*8
M&1^KO4[)CCJ*F%N*BNA36,6,72KA>O'M@OM8X (M)""K[S.#<YG&Y>M<@6/J
M@8%0=8QDK<VJ%2YX(*6>66;:^I).P>V^JD&Y[3V6+'/?=R[<ZPG,&I>_=)I1
M_3G&3+<7GUF2/\#\_^M7GGV0HV+;^V"]FQ.-1(40#'FN=0'JT?.ROW $ZAKZ
M,%(E^6X0:77+#.E1G])0>RWQ2R)-%4BY<<G+9E%>$C"L299A7TB.G&0IOB3@
MQY?=YB[X^ &DLX#FO(AD_0PI,^2!6[&7S3,O?A?7AP4?$_$*-8(LKI@SKAI'
M;Y99]5_W$@")LW$OG.ZIC4SAW/E64C+[Q+.ZR))V$RHE!-I46D\\QYEW*]!J
M8];<HYG48W'60IL9DS-/<G]$<;J J>]]/9\#6$U-1?R">PSG O1#"')D*C7)
MZ_(NCT!]2R]B&MFFNVM,I#\0\+O=TW&=)\'$EWQ@ .0$@2AC&Y@$[%96M+J(
M-I/:%HVDIYLEGO9H)M@44Y/?,/,LFQO<1!RI1 Q6NL2(PD<\U53;$8N!%G8V
M>=QCKDY;NZWSLA-CD/6]AR[.FNWRB WM*\!5D=PPRXNK6(6T(_S,#&Z@_" \
M2_<EM3CLHB<E01?3;/O#?[=-4 D9IJ=_1"[F@71D,+2VX*J>KXPM!H^W;X!&
M@1-A?90_I,,]AMK0])$]+R_:4X[M,#S_A+(=1+*^:)^I"$_K"ZZ0?&2V-P86
MD3&5[* 4:8,!CCTEB\B@-EL/DT,H>6M_1!^A)-TNS[V6X6U4<FL+J #@@P@_
MR!Q1KGUW*^-:+93@Q7JTKZ" 4F#3?0>N&EQ_H?@N>+X$B'IM@(=YJN"R5Z6C
M-$&,QB"GS0=_^(!<#A$P4@&DE+<VS&R"XG(A'?OP$N]LBLRB%$#DJ81J#0L+
M=$CZTQ4@1(XC(N@:>);M(,MVV "F0J[3Z<G(M$_6#9GB86Z*4\C\(7^H=E!)
MC^;S7$4#"&WOM1P:'>9O=2R1?040<J3YKXGPLMOJLRU_2!@S2_;K6EAG>U'8
M7TT0<T^I\_,FU#Z+DI=-0>U#=F^LK%Z,8'URRB_*1S$^:8(Z ^ &$\,P5T H
MX8&^XP,8<(;SU;IK#I&6F1]I+(^LM>6YWW7&QMC0)=.%M!ML(]0F!?F>IRPH
MH<EDKX2?-(A4QW67:J_B?)P/W5. .L__TCN%XRAG]R3T29IY\\(.)^-(\_Q
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M6]W_!5!+ 0(4 Q0    ( $V$=U'9'S*6'$T# .+F-0 5              "
M 0    !A<G=R+3$P:U\R,#(P,#DS,"YH=&U02P$"% ,4    " !-A'=1# 2*
MO0(5  !YZ   $0              @ %/30, 87)W<BTR,#(P,#DS,"YX<V10
M2P$"% ,4    " !-A'=1=]=I.KH1   [%@$ %0              @ & 8@,
M87)W<BTR,#(P,#DS,%]C86PN>&UL4$L! A0#%     @ 381W40#R]S!$*P
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M=W(M97@Q,#(S7S$R-2YH=&U02P$"% ,4    " !-A'=1_?>1ZZHG  "'I $
M$P              @ &+? 0 87)W<BUE>#$P,C1?,3(T+FAT;5!+ 0(4 Q0
M   ( $V$=U$J_Z=F.0H  )E>   3              "  6:D! !A<G=R+65X
M,3 R-5\Q,C,N:'1M4$L! A0#%     @ 381W48O'#7'_$@  H5X  !,
M         ( !T*X$ &%R=W(M97@Q,#(V7S$R,2YH=&U02P$"% ,4    " !-
MA'=1L_=6<+TO   3_@$ $P              @ $ P@0 87)W<BUE>#$P,C=?
M,3(R+FAT;5!+ 0(4 Q0    ( $V$=U$O/,4%00(  &<,   1
M  "  >[Q! !A<G=R+65X,C%?-C8Y+FAT;5!+ 0(4 Q0    ( $V$=U'"A:/"
M_0,  "\.   1              "  5[T! !A<G=R+65X,C-?-C8X+FAT;5!+
M 0(4 Q0    ( $V$=U%&.OU=Z@<   PH   0              "  8KX! !A
M<G=R+65X,S$Q7S<N:'1M4$L! A0#%     @ 381W46J\W(7Q!P  $B@  !$
M             ( !H@ % &%R=W(M97@S,3)?,3 N:'1M4$L! A0#%     @
M381W48SEA1;)!   L14  !               ( !P@@% &%R=W(M97@S,C%?
M-BYH=&U02P$"% ,4    " !-A'=1.QX$%,T$  "U%0  $
M@ &Y#04 87)W<BUE>#,R,E\Y+FAT;5!+ 0(4 Q0    ( $V$=U&%6G2-$'0
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M!@!G96DU-#%V<6IL8G8P,# P,#0N:G!G4$L%!@     5 !4 6@4  'G !@
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
